<SEC-DOCUMENT>0000950123-21-007613.txt : 20210702
<SEC-HEADER>0000950123-21-007613.hdr.sgml : 20210702
<ACCEPTANCE-DATETIME>20210607172102
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-21-007613
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20210607
<PUBLIC-REL-DATE>20210702
DATE AS OF CHANGE:		20210607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rallybio Holdings, LLC
		CENTRAL INDEX KEY:			0001739410
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				823919910
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-04734
		FILM NUMBER:		211000421

	BUSINESS ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203- 859-3820

	MAIL ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rallybio Holdings, LLC
		DATE OF NAME CHANGE:	20180502
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As confidentially submitted with the Securities and Exchange Commission on June 7, 2021, as Amendment
No. 1 to the draft registration statement confidentially submitted on April 27, 2021. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains
confidential. </B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE SECURITIES ACT OF&nbsp;1933 </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>Rallybio Holdings, LLC </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">(to be succeeded by
Rallybio Corporation in the reorganization) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">(Exact name of registrant as specified in its charter) </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">82-4956058</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">(State or other jurisdiction of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">incorporation or organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">(Primary Standard Industrial&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">Classification Code Number)&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">(I.R.S. Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">Identification No.)</P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>234 Church Street, Suite 1020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>New Haven, CT 06510 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>(203) <FONT
STYLE="white-space:nowrap">859-3820</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal
executive offices) </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Martin W. Mackay, Ph.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Chief Executive
Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>234 Church Street, Suite 1020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>New Haven, CT 06510 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>(203) <FONT
STYLE="white-space:nowrap">859-3820</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service)
</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Copies to:</B></P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Marc Rubenstein<BR>Zachary Blume<BR>Ropes&nbsp;&amp; Gray&nbsp;LLP<BR>Prudential Tower<BR>800 Boylston Street<BR>Boston, MA
<FONT STYLE="white-space:nowrap">02199-3600</FONT><BR><FONT STYLE="white-space:nowrap">(617)&nbsp;951-7000</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Michael Greco<BR>General Counsel<BR>234 Church Street, Suite 1020<BR>New Haven, CT 06510<BR>(203) <FONT STYLE="white-space:nowrap">859-3820</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Lisa Firenze<BR>Molly W. Fox<BR>Wilmer Cutler Pickering Hale&nbsp;&amp; Dorr LLP<BR>7 World Trade Center<BR>250 Greenwich Street<BR>New York, NY 10007<BR>(212)
<FONT STYLE="white-space:nowrap">230-8880</FONT><BR></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>As soon as practicable after the effective date of this Registration Statement. </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933,
check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If this Form is filed to register additional securities for an
offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If this Form is a <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment filed pursuant to
Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If this Form is a <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment
filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and
&#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top">Large&nbsp;accelerated&nbsp;filer&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer&nbsp;&nbsp;</FONT><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="right">Smaller&nbsp;reporting&nbsp;company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:ARIAL" ALIGN="right">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>PROPOSED<BR>MAXIMUM<BR>AGGREGATE<BR>OFFERING<BR>PRICE<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>AMOUNT OF<BR>REGISTRATION<BR>FEE&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL">Common Stock, par value
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Includes the offering price of shares that the underwriters may purchase
pursuant to an option to purchase additional shares. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><B>The Registrant hereby amends this
Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently operate as Rallybio Holdings, LLC, a Delaware limited liability company, or the LLC Entity. Prior to the completion of this offering, we intend to
complete a series of transactions pursuant to which (i)&nbsp;Rallybio IPD, LLC, a direct subsidiary of the LLC Entity, will be converted from a Delaware limited liability company to a Delaware corporation and change its name to Rallybio Corporation,
or the Corporation, (ii)&nbsp;the Corporation will form four direct subsidiaries, each a Delaware limited liability company, or collectively the Merger Subs, (iii)&nbsp;each of the Merger Subs will consummate a separate merger with one of the LLC
Entity&#146;s direct subsidiaries, other than Rallybio IPD, LLC, or collectively the Asset Subsidiaries, with the Asset Subsidiaries surviving the mergers and the LLC Entity receiving common stock of the Corporation in exchange for its interest in
each Asset Subsidiary, which will result in the Asset Subsidiaries becoming subsidiaries of the Corporation and the Corporation becoming the only direct subsidiary of the LLC Entity, and (iv)&nbsp;following this series of mergers, the LLC Entity
will liquidate and distribute 100% of the capital stock of the Corporation, consisting solely of common stock, to the unitholders of the LLC Entity. We refer to these transactions throughout the prospectus included in this registration statement
collectively as the &#147;Reorganization.&#148; As a result of the Reorganization, the unitholders of the LLC Entity will become the holders of common stock of the Corporation, and the Corporation will become the registrant for purposes of this
offering, and our consolidated financial statements will be reported from the Corporation. See &#147;The Reorganization&#148; for further detail regarding these transactions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares of the common stock of the Corporation are being offered by the prospectus included in this registration statement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FINANCIAL STATEMENT PRESENTATION </B></P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as disclosed in
this prospectus, the audited consolidated financial statements for the years ended December&nbsp;31, 2020 and 2019 and the notes thereto, the unaudited condensed consolidated financial statements for the three months ended March 31, 2021 and 2020
and the notes thereto, and selected historical consolidated financial data and other financial information included in this registration statement are those of the LLC Entity and do not give effect to the Reorganization. </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#c21128"><B>The information in this preliminary prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT
 COLOR="#c21128">SUBJECT TO COMPLETION, DATED&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g01k65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>Rallybio Holdings,&nbsp;LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are
offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. This is an initial public offering, and no public market currently exists for our common stock. We expect the initial
public offering price to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. We
intend to apply for listing of our common stock on the Nasdaq Global Market under the symbol &#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; under federal securities laws and are subject to reduced public company
reporting requirements. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; for additional disclosure regarding underwriting compensation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our common
stock involves a high degree of risk. See &#147;<A HREF="#toc99471_2">Risk Factors</A>&#148; beginning on page&nbsp;12 of this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Delivery of the shares of common stock is expected to be made on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. We have granted the underwriters an option for a period of 30 days to purchase an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us
will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before expenses, will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021.
</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_">PROSPECTUS SUMMARY </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_3">SPECIAL NOTE REGARDING <FONT STYLE="white-space:nowrap">FORWARD-LOOKING</FONT> STATEMENTS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_5">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_6">THE REORGANIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_9">SELECTED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_10">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_11">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_12">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_13">EXECUTIVE AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_15">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_16">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_17">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_18">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT STYLE="white-space:nowrap">NON-U.S.
</FONT> HOLDERS OF OUR COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_19">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_20">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_21">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_22">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_23">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide any information other than that contained in this
prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We
and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front
cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For investors outside of the United States: Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this
prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions
relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through and
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021 (the 25th&nbsp;day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not
participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or
subscriptions. </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TRADEMARKS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
use Rallybio as a trademark in the United States and/or in other countries. This prospectus contains references to our trademark and to those belonging to other entities, including
Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B>. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;or TM symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable
licensor to these trademarks and trade names. We do not intend our use or display of other entities&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>MARKET AND INDUSTRY DATA </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise indicated,
information contained in this prospectus concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is based on our management&#146;s estimates and research, as well as
industry and general publications and research and studies conducted by third parties. We believe that the information from these <FONT STYLE="white-space:nowrap">third-party</FONT> publications, research and studies included in this prospectus is
reliable. Management&#146;s estimates are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of
assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors.&#148; These and other factors could cause our future performance to
differ materially from our assumptions and estimates. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>REORGANIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the completion of this offering, we intend to complete a series of transactions pursuant to which (i)&nbsp;Rallybio IPD, LLC, a direct subsidiary of the LLC
Entity, will be converted from a Delaware limited liability company to a Delaware corporation and change its name to Rallybio Corporation, or the Corporation, (ii)&nbsp;the Corporation will form four direct subsidiaries, each a Delaware limited
liability company, or collectively the Merger Subs, (iii)&nbsp;each of the Merger Subs will consummate a separate merger with one of the LLC Entity&#146;s direct subsidiaries, other than Rallybio IPD, LLC, or collectively the Asset Subsidiaries,
with the Asset Subsidiaries surviving the mergers and the LLC Entity receiving common stock of the Corporation in exchange for its interest in each Asset Subsidiary, which will result in the Asset Subsidiaries becoming subsidiaries of the
Corporation and the Corporation becoming the only direct subsidiary of the LLC Entity, and (iv)&nbsp;following this series of mergers, the LLC Entity will liquidate and distribute 100% of the capital stock of the Corporation, consisting solely of
common stock, to the unitholders of the LLC Entity. We refer to these transactions throughout the prospectus included in this registration statement collectively as the &#147;Reorganization.&#148; As a result of the Reorganization, the unitholders
of the LLC Entity will become the holders of common stock of the Corporation, and the Corporation will become the registrant for purposes of this offering, and our consolidated financial statements will be reported from the Corporation. See
&#147;The Reorganization&#148; for further detail regarding these transactions. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares of the common stock of the Corporation are being offered by the
prospectus included in this registration statement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FINANCIAL STATEMENT PRESENTATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as disclosed in this prospectus, the audited consolidated financial statements for the years ended December&nbsp;31, 2020 and 2019 and the notes thereto, the
unaudited condensed consolidated financial statements for the three months ended March 31, 2021 and 2020 and the notes thereto, and selected historical consolidated financial data and other financial information included in this prospectus are those
of the LLC Entity and do not give effect to the Reorganization. </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights information included elsewhere in this prospectus. This summary does not contain all the information you should consider before investing in
our common stock. You should read and consider this entire prospectus carefully, including the sections titled &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements&#148; and &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes included elsewhere in the prospectus, before making any investment decision. Except where the context otherwise requires or where
otherwise indicated, the terms &#147;Rallybio,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our company,&#148; &#147;the company,&#148; and &#147;our business&#148; refer, prior to the Reorganization discussed below, to Rallybio
Holdings, LLC and its consolidated subsidiaries and, after the Reorganization, to Rallybio Corporation and its consolidated subsidiaries. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering,
developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Our mission at Rallybio is aligned with our expertise, and we believe we have assembled the best people,
partners and science to forge new paths to life-changing therapies. Since our launch in January 2018, we have acquired a portfolio of promising product candidates that consists of five programs, and we are focused on further expanding our portfolio
with the goal of making a profound impact on the lives of even more patients. We are drawing on our decades of knowledge and experience with a determination to tackle the undone, the too difficult, the inaccessible &#150; and change the odds for
rare disease patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, or FNAIT, a potentially life-threatening
rare hematological disease that impacts fetuses and newborns. We are evaluating RLYB211, a polyclonal anti-HPA-1a antibody, in a Phase 1/2 clinical trial, which we believe has established proof of concept for RLYB211 and provides support for our
proposed mechanism of action. We plan to move this program forward with our lead product candidate, RLYB212, a monoclonal anti-HPA-1a antibody, and submit an Investigational New Drug application, or IND, for RLYB212
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We are also focused on developing therapies that address diseases of complement dysregulation, including paroxysmal nocturnal hemoglobinuria, or PNH,
generalized myasthenia gravis, or gMG, and ophthalmic disorders. RLYB116 is a novel, potentially long-acting, subcutaneously administered inhibitor of complement factor 5, or C5, in development for the treatment of patients with PNH and gMG. We
expect to submit a clinical trial application, or CTA, for RLYB116 in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. RLYB114 is a pegylated C5 inhibitor in preclinical development for the treatment
of complement-mediated ophthalmic diseases, and we expect to submit a CTA for this product candidate in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Additionally, in collaboration with Exscientia
Limited, or Exscientia, we have two discovery-stage programs focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Approach </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At Rallybio, we do not accept that millions of patients
suffering from devastating rare diseases should have to live without transformative treatments. There are an estimated 25 to 30&nbsp;million people affected by as many as 7,000 rare diseases in the United States alone, with a significantly greater
number of affected people globally. We are building a diversified pipeline of product candidates that we believe have the potential to transform the lives of patients in need. Our goal is to deliver therapeutics that provide meaningful clinical
benefits to patients so they can become unbound and undefined by the diseases from which they suffer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe the success of our company is built on three key
strengths: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Our extensive knowledge of rare diseases and our scientific expertise positions us to identify therapies with the
potential for transformative impact.</B> We seek to acquire and develop product candidates that possess a clear mechanism of action and that aim to address diseases with a well-understood pathophysiology for which there is a significant unmet
medical need. We believe that a product candidate&#146;s mechanism of action should target the causal biology of the disease to provide the highest </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
probability of dramatically improving the lives of patients. We believe that our team&#146;s extensive experience in rare diseases and our scientific expertise position us to identify
opportunities where these links can be made, which may go unnoticed by others. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Our ability to source, to identify and to evaluate potential high-quality product candidates</B>. We apply decades of
experience across drug discovery, research, development, regulatory strategy and manufacturing to source, to identify and to evaluate therapeutic targets and product candidates that we believe have a high probability of success. Our ability to
source these product candidates is facilitated by our extensive network of relationships with leaders in industry and in academic clinical centers worldwide. We view ourselves as partners of choice given our team&#146;s track record of success in
developing and delivering new therapies to patients. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Our team&#146;s proven execution capability to drive product candidates through clinical development to regulatory
approvals. </B>We have assembled a team with a proven history of successfully advancing product candidates from discovery to clinical development and through regulatory approval. Members of our team have played critical roles in the approval of more
than 30 drugs, including seven approvals for rare disease therapeutics since 2013, and secured approvals from regulatory authorities in the Americas, Europe, Australia, and Asia. In doing so, our employees previously developed and implemented novel
clinical trial designs and successfully conducted clinical trials in never-before treated patient populations. We believe this collective prior experience positions us to efficiently and expertly execute at each step in the research and development
process and enhances the value we can bring to product candidates and to patients. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Company </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were founded in January 2018 by Martin W. Mackay, Ph.D., Stephen Uden, M.D., and Jeffrey M. Fryer, CPA to identify and accelerate the development of
life-transforming therapies for patients with severe and rare disorders. Our founders were previously executives at Alexion Pharmaceuticals, Inc., where Dr.&nbsp;Mackay was Global Head of Research&nbsp;&amp; Development, Dr.&nbsp;Uden served as Head
of Research, and Mr.&nbsp;Fryer was Chief Tax Officer. We believe our team&#146;s prior industry contributions have made a significant positive impact on the lives of thousands of patients around the world. As a strong and experienced team, we
believe we can transform the lives of thousands more. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
pipeline is illustrated in the chart below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g09q91.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:8pt; font-family:ARIAL"><B>FNAIT: Fetal and neonatal alloimmune
thrombocytopenia; <FONT STYLE="white-space:nowrap">HPA-1a:</FONT> Human platelet antigen 1a; PNH: Paroxysmal nocturnal hemoglobinuria; gMG: Generalized myasthenia gravis; ABD: Albumin binding domain; HPP: Hypophosphatasia; ENPP1: Ectonucleotide
pyrophosphatase/phosphodiesterase 1; PoC: Proof of concept; IND: Investigational new drug; CTA: Clinical trial application; HV: Healthy volunteer </B></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>RLYB211 and RLYB212 for the Prevention of FNAIT </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FNAIT is a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. FNAIT can arise during pregnancy due to an immune
incompatibility between an expectant mother and her fetus in a specific platelet antigen called human platelet antigen 1, or <FONT STYLE="white-space:nowrap">HPA-1.</FONT> We estimate that there are over 22,000 pregnancies at high risk of developing
FNAIT each year in the United States, Canada, United Kingdom, other major European countries and Australia. There is currently no approved therapy for the prevention or treatment of FNAIT. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The lead product candidate in our FNAIT prevention program is RLYB212, a preclinical-stage monoclonal
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody. We are evaluating RLYB211, a polyclonal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody, in a
Phase 1/2 clinical trial, which we believe has established proof of concept for RLYB211 and provides support for our proposed mechanism of action. Data generated from the first cohort of healthy participants in this trial demonstrated the ability of
an <FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT> antibody to rapidly eliminate transfused <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive platelets from the circulation of healthy HPA-1a negative participants. Based on these results,
we believe that targeting <FONT STYLE="white-space:nowrap">HPA-1a</FONT> with an anti-HPA-1a antibody has the potential to prevent maternal alloimmunization and therefore the occurrence of FNAIT. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to submit an IND for RLYB212 in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and to initiate a Phase 1
clinical trial in healthy participants by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We anticipate reporting additional data from our Phase 1/2 clinical trial for RLYB211
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>RLYB116 and RLYB114 for the Treatment of Diseases Related
to Complement Pathway Dysregulation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our next two programs target diseases related to complement pathway dysregulation. The complement system plays a
central role in innate immunity, as well as shaping adaptive immune response. Dysregulation of the complement pathway has been implicated in the pathogenesis of a growing number of diseases, making it an attractive target for therapeutic
intervention. Antibody inhibitors of C5 have been successfully developed to treat diseases caused by complement pathway dysregulation, including PNH, refractory gMG, atypical hemolytic uremic syndrome, and relapsing neuromyelitis optica spectrum
disorder. Despite the approval of antibody-based C5 inhibitors for patients with these diseases, we believe there remains significant need in the market for safe, effective, patient-friendly and accessible therapies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team has a track record of success and significant expertise in designing, developing and securing approval for complement inhibitors, including Soliris and
Ultomiris, for patients with severe and rare diseases around the world. We believe our internal knowledge and expertise positions us to successfully advance our programs and deliver transformative benefits to patients in need. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced product candidate in this therapeutic area is RLYB116, an inhibitor of complement factor C5, which is a central component of the complement pathway.
RLYB116 is an Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> molecule attached to an albumin binding domain that has the potential to drive the rapid, complete and sustained inhibition of C5 with a subcutaneous injection.
We plan to pursue PNH and gMG as our lead indications for RLYB116. We also plan to evaluate the development of RLYB116 for the treatment of additional rare complement-mediated diseases. We expect to submit a CTA for RLYB116
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and to initiate a Phase 1 clinical trial by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our second C5 inhibitor, RLYB114, is a pegylated <FONT STYLE="white-space:nowrap">C5-targeted</FONT> Affibody<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
molecule with pharmacokinetic properties designed for the treatment of complement-mediated ophthalmic diseases. Preclinical data generated with RLYB114 demonstrate that it is well-tolerated in animal models with no serious adverse effects. RLYB114
is in preclinical development, and we expect to submit a CTA for RLYB114 in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Artificial Intelligence Drug Discovery Collaboration with Exscientia </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have established a partnership with Exscientia, an Oxford, <FONT STYLE="white-space:nowrap">UK-based</FONT> artificial intelligence-driven pharmatech company that is
a leader in the use of computational tools and machine learning capabilities to rapidly and efficiently discover novel small molecule drug candidates. Our partnership consists of two joint ventures that each focus on the discovery and development of
small molecule therapeutics for the treatment of patients with rare metabolic diseases. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our mission
at Rallybio is aligned with our expertise: to identify and accelerate the development of life-transforming therapies for patients with severe and rare disorders. To achieve this mission, our strategy includes the following key components: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Establish a leading rare disease company through a team that delivers transformative medicines to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Advance RLYB212 into and through clinical development for the prevention of FNAIT; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Advance RLYB116 and RLYB114 into and through clinical development for the treatment of diseases of complement
dysregulation; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Identify and advance pipeline product candidates for rare metabolic diseases through our joint ventures with Exscientia;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Expand our pipeline through partnering, acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> additional
product candidates that target validated biology; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Maximize the value of pipeline product candidates through commercial independence in key markets and select partnerships.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary of Risks Associated with Our Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the &#147;Risk Factors&#148; section of this prospectus immediately following this prospectus
summary. These risks include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the
foreseeable future.&nbsp;We have not commercialized any products and have never generated revenue from the commercialization of any product.&nbsp;We are not currently profitable, and we may never achieve or sustain profitability;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Even if this offering is successful, we will require significant additional capital to fund our operations, and if we fail
to obtain necessary financing, we may not be able to complete the development and commercialization of RLYB212, RLYB116 or any additional product candidates we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering,
restrict our operations or require us to relinquish rights to our technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in the United States and other countries has
resulted in and may further result in disruptions to our preclinical studies, clinical trials, manufacturing and other business operations, which could adversely affect our business and the market price of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We are heavily dependent on the success of RLYB212 and RLYB116, which are in preclinical
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities.&nbsp;If we are not able to develop, obtain regulatory approval for, or successfully commercialize our product candidates, or if we experience significant delays in doing so, our
business will be materially harmed; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may not be successful in our efforts to identify additional product candidates.&nbsp;Due to our limited resources and
access to capital, we must prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Preclinical studies and clinical trials are expensive, time consuming, and difficult to design and implement, and involve
uncertain outcomes.&nbsp;Any product candidates that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.&nbsp;We may incur additional costs or experience delays in
completing, or ultimately be unable to complete, the development and commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more
difficult or rendered impossible by multiple factors outside our control, including our focus on rare diseases; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Results of preclinical studies, clinical trials, or analyses that we may announce or publish from time to time, may not be
indicative of results obtained in later trials, and any interim results we may publish could be different than final results; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any product candidates that we develop or the administration thereof, may cause serious adverse events or undesirable side
effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The regulatory approval processes of the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA,
and comparable foreign regulatory authorities are lengthy, time- consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for RLYB212, RLYB116 or any of our other product candidates, our business will be
substantially harmed; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our product candidates target rare diseases and conditions, and the market opportunities for RLYB212 and RLYB116, if
approved, may be smaller than we anticipate. As a result, our commercial opportunity may be limited and because the target populations of our product candidates are for rare diseases, we must be able to successfully identify patients and capture a
significant market share to achieve profitability and growth; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The FDA, EMA or other comparable foreign regulatory authorities could require the clearance or approval of an in vitro
diagnostic or companion diagnostic device as a condition of approval for any product candidate that requires or would commercially benefit from such tests.&nbsp;Failure to successfully validate, develop and obtain regulatory clearance or approval
for companion diagnostics on a timely basis or at all could harm our drug development strategy and we may not realize the commercial potential of any such product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We face significant competition from biotechnology and pharmaceutical companies, and our operating results will suffer if
we fail to compete effectively; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We intend to continue to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> rights to additional product
candidates or collaborate with third parties for the development and commercialization of our product candidates.&nbsp;We may not succeed in identifying and acquiring businesses or assets, <FONT STYLE="white-space:nowrap">in-licensing</FONT>
intellectual property rights or establishing and maintaining collaborations, which may significantly limit our ability to successfully develop and commercialize our other product candidates, if at all, and these transactions could disrupt our
business, cause dilution to our stockholders or reduce our financial resources; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates, or if the
scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and
product candidates may be adversely affected. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foregoing is only a summary of some of our risks. For a more detailed discussion of these and
other risks you should consider before making an investment in our common stock, see &#147;Risk Factors.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth Company
and a Smaller Reporting Company </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS
Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure about our executive compensation arrangements,
exemption from the requirements to hold <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive compensation and golden parachute payments and exemption from the auditor attestation requirement in the assessment of our
internal control over financial reporting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may take advantage of these exemptions until the last day of the fiscal year following the fifth anniversary of this
offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company earlier if we have more than $1.07&nbsp;billion in annual revenue, we have more than
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
$700.0&nbsp;million in market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> (and we have been a public company for at least 12&nbsp;months and have filed one
Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K)</FONT> or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities over a <FONT STYLE="white-space:nowrap">three-year</FONT>
period. For so long as we remain an emerging growth company, we are permitted, and intend, to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. We may choose
to take advantage of some, but not all, of the available exemptions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have elected to take advantage of certain of the reduced disclosure obligations in the
registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. In particular, in this prospectus, we have provided only two years of audited financial statements
and have not included all of the executive compensation related information that would be required if we were not an emerging growth company. As a result, the information that we provide to our stockholders may be different than you might receive
from other public reporting companies in which you hold equity interests. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the JOBS Act provides that an emerging growth company can take advantage of
an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We
have elected not to &#147;opt out&#148; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at
the time private companies adopt the new or revised standard and will do so until such time that we either (i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer qualify as an emerging growth
company. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. Therefore, the reported results of operations contained in our financial statements may not be directly
comparable to those of other public companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue is less than $100.0&nbsp;million during the most
recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or
(ii)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are
a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting
company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and, similar to emerging growth companies, smaller reporting
companies have reduced disclosure obligations regarding executive compensation. We may continue to be a smaller reporting company until the fiscal year following the determination that we no longer meet the requirements necessary to be considered a
smaller reporting company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Corporate Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio
Holdings, LLC, or the LLC Entity, was formed in Delaware in March 2018. Rallybio IPD, LLC was formed in Delaware in May 2020. Prior to the completion of this offering, Rallybio IPD, LLC will be converted into a Delaware corporation and change its
name to Rallybio Corporation, or the Corporation. The Corporation will be the issuer of the shares of common stock being offered by this prospectus. See &#147;The Reorganization.&#148; Our principal executive offices are located at 234 Church
Street, Suite 1020, New Haven, CT 06510 and our telephone number is (203) <FONT STYLE="white-space:nowrap">859-3820.</FONT> Our corporate website address is https://www.rallybio.com. Information contained on or accessible through our website is not
a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Reorganization </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to
the completion of this offering, we intend to complete a series of transactions pursuant to which (i)&nbsp;Rallybio IPD, LLC, a direct subsidiary of the LLC Entity, will be converted from a Delaware limited liability company to a Delaware
corporation and change its name to Rallybio Corporation, (ii)&nbsp;the Corporation will form four direct subsidiaries, each a Delaware limited liability company, or collectively the Merger Subs, (iii)&nbsp;each of the Merger Subs will consummate a
separate merger with one of the LLC Entity&#146;s direct subsidiaries, other than Rallybio IPD, LLC, or collectively the Asset Subsidiaries, with the Asset Subsidiaries surviving the mergers and the LLC Entity receiving common stock of the
Corporation in exchange for its interest in each Asset Subsidiary, which will result in the Asset Subsidiaries becoming subsidiaries of the Corporation and the Corporation becoming the only direct subsidiary of the LLC Entity, and
(iv)&nbsp;following this series of mergers, the LLC Entity will liquidate and distribute 100% of the capital stock of the Corporation, consisting solely of common stock, to the unitholders of the LLC Entity. See &#147;The Reorganization&#148; and
&#147;Description of Capital Stock&#148; for additional information, including a description of the terms of our capital stock following the Reorganization and the terms of our amended and restated certificate of incorporation and amended and
restated bylaws that will be in effect prior to the consummation of this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of common stock that holders of incentive units will
receive in the Reorganization will be based on the fair value per common unit, as determined by our board of managers, immediately prior to the Reorganization. In this prospectus, we have assumed a fair value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common unit, which is the midpoint of the price range per share set forth on the cover page of this prospectus. Based on an assumed fair value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common unit, the incentive units will convert into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. At a fair value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
common unit, which is the high end of the price range per share set forth on the cover page of this prospectus, the incentive units would convert into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. At a fair value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
common unit, which is the low end of the price range set forth on the cover page of this prospectus, the incentive units would convert into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the Reorganization,
based on an assumed fair value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common unit, which is the midpoint of the price range per share set forth on the cover page of this prospectus,
the holders of existing units in the LLC Entity will collectively own an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock of the Corporation as of immediately prior
to the consummation of this offering. See &#147;The Reorganization.&#148; </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock to be outstanding after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>shares (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise their option to purchase additional shares in full).
</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Underwriters&#146; option to purchase additional shares of common stock from us </P></TD>
<TD><BR>We have granted the underwriters an option to purchase up to an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock from us at the initial public offering price, less the
estimated underwriting discounts and commissions, for a period of 30&nbsp;days after the date of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that our net proceeds from the sale of our common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>We intend to use the net proceeds from this offering, together with cash on hand, as follows: (i)&nbsp;to advance our FNAIT prevention program, including completion of our Phase 1/2 clinical trial for RLYB211 and completion of our Phase&nbsp;1
and Phase&nbsp;1b clinical trials for RLYB212, (ii)&nbsp;to advance our complement program, including completion of our Phase&nbsp;1a clinical trial and initiation of our Phase&nbsp;1b clinical trial for RLYB116, and initiation of our Phase 1
clinical trial for RLYB114, (iii)&nbsp;to advance our joint ventures with Exscientia, including the initiation of our Phase&nbsp;1 clinical trial for our ENPP1 inhibitor, and (iv)&nbsp;any remaining proceeds for business development activities and
other general corporate purposes. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Dividend policy </P></TD>
<TD>We do not anticipate declaring or paying any cash dividends on our capital stock in the foreseeable future. See &#147;Dividend Policy.&#148; </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Risk factors </P></TD>
<TD>You should carefully read the &#147;Risk Factors&#148; section of this prospectus and the other information included in this prospectus for a discussion of factors that you should consider before deciding to invest in our common stock.
</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Proposed Nasdaq Global Market symbol </P></TD>
<TD><BR>&#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#148; </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of our common stock to be outstanding immediately following the completion of this offering is
based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding as of March&nbsp;31, 2021, after giving effect to the Reorganization, including the issuance by the Corporation of an
aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of its common stock and the subsequent distribution of those shares to members of the LLC Entity, assuming an initial public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus. These amounts exclude: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">shares of our common stock reserved for issuance under the Rallybio Corporation 2021 Equity Incentive Plan, or the 2021
Plan, which will become effective in connection with this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">shares of common stock reserved for issuance under the Rallybio Corporation 2021 Employee Stock Purchase Plan, or the
ESPP, which will become effective in connection with this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as otherwise noted, all information in this prospectus assumes or
gives effect to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the completion of the Reorganization, including the distribution to the members of the LLC Entity of all outstanding units
of the Corporation as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 for an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock of the Corporation, prior to the completion of this offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the
midpoint of the price range set forth on the cover page of this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no exercise by the underwriters of their option to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock from us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our amended and
restated bylaws prior to the consummation of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no issuance of stock options on or
after&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, under the Rallybio Holdings, LLC 2018 Share Plan, or the 2018 Plan, or the 2021 Plan. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should read the following summary financial data together with the sections titled &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; of this prospectus and our financial statements and the related notes included elsewhere in this prospectus. The statements of operations and comprehensive loss data for the years ended
December&nbsp;31, 2020 and 2019 and the balance sheet data as of December&nbsp;31, 2020 and 2019 have been derived from our audited financial statements included elsewhere in this prospectus. The statements of operations and comprehensive loss data
for the three months ended March&nbsp;31, 2021 and 2020 and our balance sheet as of March&nbsp;31, 2021 have been derived from our unaudited financial statements included elsewhere in this prospectus. In the opinion of management, the unaudited
financial data reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of such financial information in those statements. Our historical results are not necessarily indicative of the results that may
be expected in the future. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED<BR>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statement of Operations and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing right
obligation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common unit, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">
(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average common units outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,659,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,715,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,228,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,968,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted average common stock outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO FORMA<BR>AS&nbsp;ADJUSTED<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Condensed Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total members&#146; deficit, actual; total unitholders&#146; equity, pro forma and pro forma as
adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 11 to our audited consolidated financial statements and Note 8 to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for details on the calculation of basic and
diluted net loss per common unit attributable to common unitholders. </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets, less current liabilities. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma balance sheet data gives effect to (i)&nbsp;the Reorganization, including the issuance by the Corporation of an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of its common stock and the subsequent distribution of those shares to members of the LLC Entity, prior to the completion of this offering, as
if the Reorganization had occurred as of March&nbsp;31, 2021, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price
range set forth on the cover page of this prospectus, and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation and amended and restated bylaws. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted balance sheet data give further effect to our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in
this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:8pt; font-family:ARIAL">The pro
forma as adjusted information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro
forma as adjusted amount of each of cash, working capital, total assets and total unitholders&#146; equity (deficit) by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming
that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease)
of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, working capital, total assets and total unitholders&#146;
equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the
other information contained in this prospectus, including our financial statements and related notes appearing at the end of this prospectus and the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations,&#148; before deciding to invest in our common stock. Some of the following risks and uncertainties are, and will be, exacerbated by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic (including any
resurgences thereof) and any worsening of the global business and economic environment as a result. Negative consequences from these risks could harm our business, prospects, operating results and financial condition or cause the trading price of
our common stock to decline, which could result in the loss of all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we
currently believe to be immaterial may also adversely affect our business. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related
to Our Financial Position and Need for Additional Capital </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have incurred significant losses since our inception and anticipate that we will continue to
incur losses in the foreseeable future. We have not commercialized any products and have never generated revenue from the commercialization of any product. We are not currently profitable, and we may never achieve or sustain profitability.
</I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company with a limited operating history. As a result, we are not profitable and have incurred significant losses
since our formation. We had net losses of $26.4&nbsp;million and $17.6&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively, and net losses of $13.3 million and $3.9 million for the three months ended March&nbsp;31, 2021
and 2020, respectively. As of March&nbsp;31, 2021, we had an accumulated deficit of $60.3 million. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant
risk that any potential product candidate will fail to gain regulatory approval and become commercially viable. Since inception, we have devoted substantially all of our resources to raising capital, organizing and staffing our company, business
planning, conducting discovery and research activities, acquiring or discovering product candidates, establishing and protecting our intellectual property portfolio, developing and progressing our product candidates and preparing for clinical trials
and establishing arrangements with third parties for the manufacture of our product candidates and component materials, including activities relating to our preclinical development and manufacturing activities for each of our five programs and our
Phase 1/2 clinical trial for RLYB211. We do not have any product candidates approved for sale and have not generated any revenue from product sales. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect
to incur significant additional operating losses in the foreseeable future as we advance our programs through preclinical and clinical development, expand our research and development activities, acquire and develop new product candidates, complete
preclinical studies and clinical trials, finance our business development strategy, seek regulatory approval for the commercialization of our product candidates and commercialize our products, if approved. The costs of advancing product candidates
through each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any product candidate to marketing approval in even a single jurisdiction are substantial.
Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the
commercialization of any product candidates or achieve or maintain profitability. Our expenses will increase substantially if and as we: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">file an Investigational New Drug application, or IND, and initiate a Phase 1 clinical trial for RLYB212, our lead product
candidate for our fetal and neonatal alloimmune thrombocytopenia, or FNAIT, program; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">file an IND or a clinical trial application, or CTA, and initiate our clinical trials for RLYB116 and other product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate a natural history alloimmunization study of FNAIT, or our FNAIT Natural History Alloimmunization Study, to
support our development program and related regulatory submissions for RLYB212; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue to develop and conduct clinical trials with respect to RLYB211; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seek regulatory approvals for RLYB212, RLYB116 and any other product candidates, as well as for any related companion
diagnostic, if required; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue and expand upon our discovery and development joint ventures with Exscientia Limited, or Exscientia;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue to discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">hire additional clinical, scientific, and commercial personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">add operational, financial, and management personnel, including personnel to support our product development and planned
future commercialization efforts and to support our transition to a public company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates or technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">secure a commercial manufacturing source and supply chain capacity sufficient to produce commercial quantities of any
product candidate for which we obtain regulatory approval; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish a sales, marketing, and distribution infrastructure to commercialize our programs, if approved, and for any
other product candidates for which we may obtain marketing approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not know when or whether we will become profitable. Our ability to
generate revenue and become profitable depends upon our ability to successfully complete the development of our product candidates and to obtain the necessary regulatory approvals for their commercialization, which is subject to substantial
additional risks and uncertainties, as described under &#147;&#151; Risks Related to Discovery, Development, Clinical Testing, Manufacturing, and Regulatory Approval.&#148; Each of our product candidates will require additional preclinical and/or
clinical development, regulatory approval in multiple jurisdictions, the securing of manufacturing supply, capacity, distribution channels and expertise, the use of external vendors, the building of a commercial organization, substantial investment
and significant marketing efforts before we generate any revenue from product sales. As a result, we expect to continue to incur net losses and negative cash flows in the foreseeable future. These net losses and negative cash flows have had, and
will continue to have, an adverse effect on our stockholders&#146; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are
unable to develop and commercialize one or more product candidates, either alone or through current or future collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even
if we successfully commercialize RLYB212, RLYB116 or any of our other product candidates, we may continue to incur substantial research and development and other expenses to identify and develop other product candidates. Even if we do achieve
profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis or meet outside expectations for our profitability. Our failure to become and remain profitable would decrease the value of our company and could
impair our ability to raise capital, maintain our research and development efforts, expand our business, execute our business plan or continue our operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if this offering is successful, we will require significant additional capital to fund our operations, and if we fail to obtain necessary financing, we may
not be able to complete the development and commercialization of RLYB212, RLYB116 or any additional product candidates we may develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to spend
significant amounts of capital to complete the development of, seek regulatory approvals for and, if approved, commercialize RLYB212 and RLYB116. These expenditures will include costs related to our ongoing Phase 1/2 clinical trial for RLYB211. We
expect similar expenditures as we initiate our planned clinical trials for RLYB212 and for RLYB116, and our FNAIT Natural History Alloimmunization Study. In addition, we are obligated to make certain milestone and royalty payments in connection with
achievement of certain development and commercial milestones as well as the sale of resulting products under our agreements with Prophylix AS, or Prophylix, Swedish Orphan Biovitrum AB (Publ), or Sobi, and Affibody AB, or Affibody. We may also spend
significant capital to develop laboratory tests, and if required by the U.S. Food and Drug Administration, or the FDA, or other healthcare agencies, one or more companion diagnostics, to identify patients for inclusion in our clinical trials or who
are likely to respond to our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based upon our current operating plan, we believe that the anticipated net proceeds from this offering, together
with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital expenditure requirements for more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from
the date of this prospectus. This estimate and our expectation regarding the sufficiency of the net proceeds from this offering to advance the preclinical and clinical development of RLYB212, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
RLYB116 and any other product candidates are based on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect, or our clinical trials
may be more expensive, time consuming or difficult to design or implement than we currently anticipate. Changing circumstances, including any unanticipated expenses, could cause us to consume capital significantly faster than we currently
anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because of the numerous risks and uncertainties, the length of time and scope of activities associated with development of RLYB212,
RLYB116 or any product candidate we may develop is highly uncertain, we are unable to estimate the actual amount of funds we will require for development, approval and any approved marketing and commercialization activities. Our future capital
requirements, both near and long-term, will depend on many factors, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, progress, timing, costs and results of our clinical trials through all phases of development, including
our ongoing Phase 1/2 clinical trial for RLYB211, the planned clinical trials for RLYB212 and RLYB116 and the development of any other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the identification, assessment, acquisition and/or development of additional research programs and additional product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the European Medicines Agency, or
the EMA, and other comparable foreign regulatory authorities, including any additional clinical trials required by the FDA, EMA or other comparable foreign regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of the FDA, EMA and other comparable foreign regulatory authorities to accept our clinical trial designs,
as well as data from our completed and planned preclinical studies and clinical trials, as the basis for review and approval of RLYB212, RLYB116 and any other product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress, timing and costs of the development by us or third parties of companion diagnostics, if required, for
RLYB212 or any other product candidates, including design, manufacturing and regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of filing, prosecuting, and enforcing our patent claims and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third
parties against us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with potential clinical trial liability or product liability claims, including the costs associated
with obtaining insurance against such claims and with defending against such claims; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to develop and commercialize products that are considered medically and/or financially differentiated to
competitive products by physicians, patients and payers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost and timing of completion of commercial-scale manufacturing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of making royalty, milestone or other payments under any future
<FONT STYLE="white-space:nowrap">in-license</FONT> agreements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to maintain our collaboration with Exscientia on favorable terms and establish new collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional product candidates or
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the severity, duration and impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which may adversely
impact our business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of establishing sales, marketing and distribution capabilities for our product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, progress and timing of our commercialization of RLYB212, RLYB116, if approved, or any other product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of third-party coverage and reimbursement for and pricing of any approved products; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even with the net proceeds from this offering, we will require significant additional capital to advance the development and potential commercialization of our product
candidates, which we may raise through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. Depending on our business performance, the
economic climate and market conditions, we may be unable to raise additional funds when needed on acceptable terms, or at all. Moreover, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic is impacting the global economy, and the U.S.
economy in particular, with the potential for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
economic downturn to be severe and prolonged. A severe or prolonged economic downturn as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could result in a variety of
challenges for our business, including disruptions in the financial markets, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. If we do not succeed in raising additional funds on
acceptable terms, we may need to significantly delay, scale back or discontinue the development of one or more of our product candidates or the commercialization of any product that may be approved for marketing, and we could be forced to
discontinue operations. In addition, attempting to secure additional financing may divert the time and attention of our management from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and harm
our product candidate development efforts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this
offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time, if ever, as we generate
significant revenue from product sales, we expect to finance our operations through the sale of equity, debt financings, marketing and distribution arrangements and collaborations, strategic alliances and licensing arrangements or other sources. We
do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future
operating plans. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that we raise additional capital through the future sale of equity or convertible debt securities, your ownership interest will be
diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. In addition, debt financing and preferred equity financing, if available, may involve agreements that
include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through debt financing, we may be subject to
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and we may need to dedicate a substantial additional portion of any operating cash flows
to the payment of principal and interest on such indebtedness. Any future indebtedness, combined with our other financial obligations, could increase our vulnerability to adverse changes in general economic, industry and market conditions, limit our
flexibility in planning for, or reacting to, changes in our business and the industry and impose a competitive disadvantage compared to our competitors that have less debt or better debt servicing options. If we raise additional funds through
collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or
grant licenses on terms that may not be favorable to us. Furthermore, any capital raising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may
adversely affect our ability to advance research programs, product development activities or product candidates. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate product candidate
development or future commercialization efforts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have a limited operating history and no history of commercializing pharmaceutical products, which may
make it difficult to evaluate the prospects for our future viability. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were formed in January 2018, and our operations to date have been limited to
financing and staffing our company, identifying, evaluating and acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> product candidates and technologies, conducting preclinical studies and our clinical trial for RLYB211 and preclinical
studies for RLYB212 and RLYB116, and developing a pipeline of other preclinical and research programs. We have not yet demonstrated the ability to complete successfully a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a
commercial-scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be
as accurate as they could be if we had a longer operating history or a history of successfully developing, obtaining marketing approval for and commercializing pharmaceutical products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown
challenges. We will eventually need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition and, as a result, our business may be
adversely affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our quarterly and annual financial results may fluctuate, which makes our results difficult to predict and may cause our results to fall short
of expectations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our financial condition and operating results have varied in the past and will continue to fluctuate from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> in the future due to a variety of factors, many of which
are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this prospectus: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">variations in the level of expense related to the ongoing development of our product candidates or research pipeline;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays or failures in advancement of existing or future product candidates into the clinic or in clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the feasibility of developing, manufacturing and commercializing our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our relationships, and any associated exclusivity terms, with strategic collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make
or receive under existing or future arrangements, or the termination or modification of any such existing or future arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our operation in a net loss position in the foreseeable future; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability, ourselves or with collaborators, to develop a companion diagnostic, if required, and obtain marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to consistently manufacture our product candidates, including in sufficient quantities for clinical or
commercial purposes; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our dependence on, and the need to attract and retain, key management and other personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments or disputes concerning patents or other proprietary rights, litigation matters and our ability to obtain and
maintain patent protection for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic
investments or changes in business strategy; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand
for such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">business interruptions such as power outages, strikes, civil unrest, wars, acts of terrorism or natural disasters;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential advantages that our competitors and potential competitors may have in developing and commercializing competing
technologies or products, securing funding for or obtaining the rights to critical intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory developments affecting our product candidates or those of our competitors; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to use our net operating loss, or NOL, and income tax credit carryforwards to offset income tax.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to these and other factors, the results of any of our prior quarterly or annual periods should not be relied upon as indications of our
future operating performance, and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a meaningful indication of our future performance. In any
particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ability to use our net operating loss and income tax credit carryforwards to offset future income tax liabilities may be subject to certain limitations.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred substantial NOLs during our history. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset
future taxable income, if any, until such unused losses expire. NOLs generated in taxable years beginning after December&nbsp;31, 2017 are not subject to expiration. Federal NOLs generated in taxable years beginning after December 31, 2017 generally
may not be carried back to prior taxable years except that, under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, federal NOLs generated in taxable years beginning after December 31, 2017 and before January 1, 2021 may be
carried back to each of the five taxable years preceding the taxable year in which the loss arises. Additionally, the deduction for NOLs arising in taxable years beginning after December 31, 2017 is generally limited to 80% of current year taxable
income, however, as a result of the CARES Act, for taxable years beginning before January 1, 2021, the deductibility of federal NOLs generated in taxable years beginning after December&nbsp;31, 2017 is not so limited. We also have substantial
federal and state research and development and other tax credit carryforwards that expire at various dates. These tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
In addition, in general, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#147;ownership change&#148; is subject to
limitations on its ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and tax credit carryforwards to offset future taxable income. For these purposes, an ownership change generally occurs where the aggregate stock ownership
of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#146;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. We may
experience such ownership changes in the future as a result of this offering and/or future transactions in our stock, some of which may be outside our control. If we undergo an ownership change in connection with or after this offering, our ability
to use our NOLs and income tax credit carryforwards could be further limited. For these reasons, we may not be able to use a material portion of our NOLs or tax credit carryforwards, even if we attain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Discovery, Development, Clinical Testing, Manufacturing, and Regulatory Approval </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in the United States and other countries has resulted in and may further result in
disruptions to our preclinical studies, clinical trials, manufacturing and other business operations, which could adversely affect our business and the market price of our common stock. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ongoing global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic is impacting worldwide economic activity, particularly economic activity in the United
States, and poses the risk that we or our employees, contractors, suppliers, or other partners may be prevented from or delayed in conducting business activities for an indefinite period of time, including due to shutdowns, quarantines and other
public health measures that may be requested or mandated by governmental authorities. The continued prevalence of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the measures taken by the governments of countries affected could disrupt the
supply chain and the manufacture or shipment of both drug substance and finished drug product for our product candidates for preclinical testing or clinical trials, cause diversion of healthcare resources away from the conduct of preclinical and
clinical trial matters to focus on pandemic concerns, limit travel in a manner that interrupts key trial activities, such as trial site initiations and monitoring, delay regulatory filings with regulatory agencies in affected areas or adversely
affect our ability to obtain or timing to obtain regulatory approvals. These actions have in the past, continue to and could in the future negatively affect our preclinical studies, clinical trials, manufacturing and other business operations,
including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Preclinical studies and clinical trials:</B> The impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> may cause
delays and disruptions to some of our preclinical studies and clinical trials. The response to <FONT STYLE="white-space:nowrap">COVID-19</FONT> by healthcare providers may delay site initiation, may slow down enrollment and make the ongoing
collection of data for patients enrolled in trials more difficult or intermittent. In addition, some participants and clinical investigators may be unable or unwilling to comply with clinical trial protocols. For example, quarantines or other travel
limitations have been implemented in many countries and across the United States that may impede participant movement, affect sponsor access to study sites, and/or interrupt healthcare services, which may negatively impact the execution of clinical
trials. We are initiating a global natural history study for FNAIT in 2021 that requires screening a large number of potential participants, and we could experience delays in screening due to <FONT STYLE="white-space:nowrap">COVID-19.</FONT>
Significant delays or disruptions to our preclinical studies or clinical trials could adversely affect our ability to timely initiate studies, conduct successful studies, generate scientifically robust clinical data, obtain regulatory approvals or
commercialize our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Manufacturing and supply:</B> We have encountered only limited disruptions to our manufacturing and supply chain as a
result of <FONT STYLE="white-space:nowrap">COVID-19</FONT> to date, which have not had a material adverse impact on our business, but significant or prolonged disruptions could materially impact our business, operations or financial results. Even if
our manufacturing operations are not materially disrupted, pandemic-related disruptions in other businesses, such as shipping and logistics companies, could affect the availability of our product candidates for our preclinical studies and clinical
trials. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Operations:</B> In accordance with direction from state and local government authorities to protect the health of our
employees, their families, and our communities, we made several changes to our operations in response to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> This response included performing all office-based work outside of the office. Our increased
reliance on personnel working from home may negatively impact productivity or disrupt, delay or otherwise adversely impact our business. In addition, remote working could increase our cyber security risk. Government authorities could impose further
restrictions, including mandated shutdown of businesses, which may negatively affect our operations. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Stock Price:</B> The extent and duration of the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
on our stock price following this offering is uncertain. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may cause our stock price to be more volatile, and our ability to raise capital could be impaired. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory agencies may redirect resources in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in a way that would adversely impact our ability
to progress and achieve regulatory approvals. In addition, measures intended to limit <FONT STYLE="white-space:nowrap">in-person</FONT> interactions with regulatory agencies may interfere with our ability to hold required regulatory meetings and
restrict the feedback necessary to advance filings. If global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly
impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are
monitoring the potential impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business and financial statements. To date, we have not incurred impairment losses in the carrying values of our assets as a result of the
pandemic and we are not aware of any specific related event or circumstance that would require us to revise our estimates reflected in our financial statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
cannot be certain what the overall impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will be on our business and prospects. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will directly or
indirectly impact our business, results of operations, financial condition and liquidity, including planned and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a
result of new information that may emerge concerning <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the actions taken to contain or treat it, including the availability and administration of vaccines, and the duration and intensity of the related
effects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are heavily dependent on the success of RLYB212 and RLYB116, which are in preclinical <FONT STYLE="white-space:nowrap">IND-enabling</FONT>
activities. If we are not able to develop, obtain regulatory approval for, or successfully commercialize our product candidates, or if we experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead programs are in early-stage clinical development or preclinical <FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities, and we do not currently have
any commercial products that generate revenues or any other sources of revenue. To date, we have invested a significant portion of our efforts and financial resources in the development of RLYB211 and RLYB212 for the prevention of FNAIT and the
development of RLYB116. Our future success is substantially dependent on our ability to successfully complete preclinical and clinical development for, obtain regulatory approval for, and successfully commercialize, our product candidates, which may
never occur. We currently have no products that are approved for commercial sale and may never be able to develop a marketable product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before obtaining regulatory
approvals for the commercial sale of our product candidates, we must demonstrate the safety and efficacy of our investigational product candidates for use in each target indication through lengthy, complex and expensive preclinical studies and
clinical trials. Failure can occur at any time during the preclinical study and clinical trial processes, and, because our product candidates are in an early stage of development, there is a high risk of failure, and we may never succeed in
developing marketable products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to generate product revenue will depend heavily on the successful development and eventual commercialization of our
product candidates, which may never occur. Ongoing and future preclinical studies and clinical trials of our product candidates may not show sufficient safety or efficacy or be of sufficient quality to obtain or maintain regulatory approvals. There
can be no assurance that any of our product candidates, even if approved, will prove to be commercially viable therapeutics. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB212 and RLYB116 are designed for
subcutaneous self-administration. The formulation or physical properties of RLYB212 and RLYB116 may ultimately be determined to be inadequate to support this route of administration. If subcutaneous administration is not feasible, then we may need
to identify additional formulations or routes of administration, which could delay initiation of our clinical trials or commercialization and result in significant additional costs. Further, alternative formulations and routes of administration may
be required to differentiate our product candidates from competitors and/or secure access to support successful commercialization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Commercialization of product
candidates we may develop will require additional preclinical and clinical development; regulatory and marketing approval in multiple jurisdictions, including by the FDA and the EMA; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
obtaining manufacturing supply, capacity and expertise; building of a commercial organization; and significant marketing efforts. The success of our most advanced product candidates and other
product candidates will depend on several factors, including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successful and timely initiation of preclinical studies, and successful and timely initiation of, enrollment in, and
completion of our clinical trials with results that support a finding of safety and effectiveness and an acceptable risk-benefit profile of our product candidates in the intended populations within the timeframes we have projected;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory grants of authorization to proceed under INDs or CTAs such that we can commence planned or future clinical
trials of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">receipt of regulatory approvals from applicable regulatory authorities for our product candidates, and if required, in
vitro diagnostic devices including companion diagnostics; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to successfully utilize certain delivery systems, such as <FONT STYLE="white-space:nowrap">pre-filled</FONT>
syringes, or PFSs, <FONT STYLE="white-space:nowrap">pen-injectors</FONT> and/or autoinjectors, for certain of our product candidates and to obtain regulatory approval of any such drug/device combination product; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the outcome, timing, and cost of meeting regulatory requirements, including any post-marketing commitments, established by
the FDA, EMA and other comparable foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing commercially viable arrangements with third-party manufacturers for clinical supply and commercial
manufacturing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing sales, marketing and distribution capabilities, whether alone or through a collaboration, to support
commercialization of our product candidates, if and when approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">effectively differentiating and competing with other therapies approved and/or used for the same indications as our
product candidates, particularly RLYB116; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing appropriate prices for any product candidates that receive regulatory approval that reflect the value that
the product candidates offer in the indications for which they are approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining third-party coverage and reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enforcing and defending intellectual property rights and claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintaining an acceptable safety profile of the product candidates following approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to commercialize our product
candidates successfully, which would materially harm our business. Due to the uncertain and time-consuming clinical development and regulatory approval process, we may not successfully develop any of our product candidates and may choose to
discontinue the development of any of our product candidates. If we discontinue development of a product candidate, we will not receive anticipated revenues from that product candidate and we may not receive any return on our investment in that
product candidate. We may discontinue a product candidate for clinical reasons if it does not prove to be safe and effective for its targeted indications. During clinical development, companies in our field often need to discontinue the development
of product candidates if such product candidates do not achieve the necessary efficacy at tolerated doses required for patient benefit. In addition, there may be important facts about the safety, efficacy and risk versus benefit of our product
candidates that are not known to us at this time. Any unexpected safety events or our failure to generate sufficient data in our clinical trials to demonstrate efficacy may cause a product candidate to fail clinical development. Furthermore, even if
that product candidate meets its safety and efficacy endpoints, we may discontinue its development for various reasons, such as changes in the competitive environment or the standard of care and the prioritization of our resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and
access to capital, we must prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An important component of our strategy is expanding our pipeline through partnering, acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> additional
product candidates that target validated biology. We also seek to identify and develop product candidates under our joint ventures with Exscientia Limited, or Exscientia. If we fail to identify additional potential product candidates, or fail to
partner, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates, our business could be materially harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research programs to
develop additional product candidates require substantial technical, financial, and human resources whether or not they are ultimately successful. Our efforts may initially show promise in identifying potential indications or product candidates, yet
fail to yield results for clinical development for several reasons, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the research methodology used may not be successful in identifying potential indications or product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential product candidates may, after further study, be shown to have harmful or unexpected adverse effects or other
characteristics that indicate they are unlikely to be effective drugs; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it may take greater human and financial resources than we possess to identify additional therapeutic opportunities for our
product candidates or to develop suitable potential product candidates through research programs, thereby limiting our ability to develop, diversify, and expand our product portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because we have limited financial and human resources, we intend to focus initially on research programs and product candidates for a limited set of indications. As a
result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that could have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to
capitalize on viable commercial products or profitable market opportunities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, there can be no assurance that we will ever be able to identify
additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical studies and clinical trials are expensive, time consuming and difficult to design and implement, and involve uncertain outcomes. Any product
candidates that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval. We may incur additional costs or experience delays in completing, or ultimately be unable to complete,
the development and commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before obtaining marketing approval from the FDA, EMA or other comparable regulatory
authorities for the sale of our product candidates, we must complete preclinical studies and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. To initiate clinical trials for any future product candidates,
we must submit the results of preclinical studies to the FDA, EMA or other comparable foreign regulatory authorities, along with other information, including information about chemistry, manufacturing and controls, or CMC, and our proposed clinical
trial protocol, as part of an IND or similar regulatory filing that must be accepted by the FDA, EMA or other applicable regulatory authorities before we may proceed with clinical development. In the event that regulators require us to complete
additional preclinical studies or we are required to satisfy other regulator requests, such as obtaining alignment on the device regulatory pathway for our FNAIT prevention program, the start of our clinical trials may be delayed or prevented. Even
after we receive and incorporate guidance from these regulatory authorities, the FDA, EMA or other regulatory authorities could (i)&nbsp;disagree that we have satisfied their requirements to commence our clinical trial, (ii)&nbsp;change their
position on the acceptability of our data, trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials or (iii)&nbsp;impose stricter requirements for approval than we currently
expect. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether planned preclinical studies
or clinical trials, will begin on time, need to be redesigned, enroll an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
adequate number of patients on time, or be completed on schedule, or at all. We may experience numerous unforeseen events that could delay or prevent our ability to complete current clinical
trials or initiate and complete new trials, any of which may delay or prevent us from receiving marketing approval or commercializing our product candidates. These events include, but are not limited to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities requiring us to submit additional data or imposing other
requirements before permitting us to commence a trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in receiving or denial by regulatory agencies of permission to proceed with our planned clinical trials or any
other clinical trials we may initiate, or placement of a clinical trial on hold; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">negative results from our <FONT STYLE="white-space:nowrap">non-clinical</FONT> trials or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">challenges, delays and cost involved in identifying, recruiting and retaining suitable patients and clinical trial sites
in sufficient numbers to participate in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and
clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in obtaining Institutional Review Board, or IRB, approval at each site within the United States, or Independent
Ethics Committee, or IEC, approval at sites outside the United States; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays or problems in analyzing data, or the need for additional analysis or data or the need to enroll additional
patients; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure by us, our CROs, trial sites or investigators to adhere to clinical trial, regulatory, legal or contractual
requirements and perform trials in accordance with the FDA&#146;s good clinical practices, or GCP, requirements and trial protocol; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inadequate quantity or quality of product candidate or other materials necessary to conduct clinical trials, for example
as a result of delays in defining and implementing the manufacturing process for materials used in clinical trials or for the manufacture of larger quantities or other delays or issues arising in the manufacturing of sufficient supply of finished
drug product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">with respect to RLYB211, our inability to source a sustained, dependable long-term supply, including due to the scarcity
of potential donors who maintain an adequate level of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibodies and because supply will decrease if RLYB211 becomes clinically successful in preventing
FNAIT; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">problems with designing and readiness of in vitro diagnostic devices, including companion diagnostic testing, if required,
and our inability, or that of our collaborators, to develop any required laboratory diagnostic tests or companion diagnostics for RLYB212 or any other product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">lack of adequate funding to continue a clinical trial, including as a result of unanticipated costs or increases in costs
of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">occurrence of serious adverse events including unexpected serious adverse events, associated with the product candidate or
reports from <FONT STYLE="white-space:nowrap">non-clinical</FONT> or clinical testing of our own or competing therapies that raise safety or efficacy concerns, or delays or failures in addressing patient safety concerns that arise during the course
of a trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in regulatory requirements and guidance that require changes to planned or ongoing preclinical and clinical
studies, or the conduct of additional studies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulties recruiting and retaining employees, consultants or contractors with the required level of expertise.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may increase the likelihood that we encounter
such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in
which such trials are being conducted, the FDA, EMA or other regulatory authorities, or recommended for termination by a Data and Safety Monitoring Board, or DSMB, for such trial. Such authorities may impose a suspension or termination or recommend
an alteration to clinical trials due to several factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, the identification of safety issues or adverse side effects, failure to
demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions. Furthermore, we rely and will rely on CROs and clinical trial sites to ensure the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in the
section titled &#147;&#151; Risks Related to Our Dependence on Third Parties.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead product candidates, RLYB212 and RLYB116, are still in development and
will require the successful completion of one or more registrational clinical trials before we are prepared to submit a Biologics License Application, or BLA, for regulatory approval by the FDA. We cannot predict with any certainty if or when we
might complete the development of RLYB212 or RLYB116, submit a BLA for regulatory approval or whether any such BLA will be approved by the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Principal
investigators for our clinical trials could serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these
relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of a clinical trial. The FDA may therefore question the
integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may
ultimately lead to the denial of marketing approval of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we experience delays in the completion, or termination, of any clinical trial of
our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed or prevented. Moreover, any delays in completing our
clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. In addition, many of the factors that cause, or lead to,
termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any delays to our clinical trials that occur as a result could
shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be
significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Enrollment and retention of patients
in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including our focus on rare diseases. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timely completion of clinical trials in
accordance with their protocols depends, among other things, on the speed at which we can recruit eligible patients to participate in testing our product candidates and our ability to enroll a sufficient number of patients who remain in the study
until its conclusion. Clinical trial recruitment delays often result in increased costs, delays in advancing product development, delays in testing the effectiveness of technologies, delays in obtaining regulatory approval or termination of clinical
trials. We may be unable to enroll a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patient enrollment and retention in clinical trials depends on many factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the design of the clinical trial, including the patient eligibility criteria defined in the protocol;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the size and nature of the patient population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the existing body of safety and efficacy data with respect to the product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the proximity of patients to clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product candidate being studied in
relation to other available therapies, including any new drugs or medical devices that may be approved for the indications we are investigating; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">competing clinical trials being conducted by other companies or institutions, particularly for RLYB116;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain patient consents; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">other factors we may not be able to control, such as the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
that may limit patients, principal investigators or staff, or clinical site availability. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we may have difficulty identifying and
enrolling patients for our planned clinical trials because the conditions for which we plan to evaluate our current product candidates are rare diseases and we anticipate that there will be limited patient pools from which to draw for clinical
trials. Further, because screening for many of these diseases is not widely adopted, and because it can be difficult to diagnose these diseases in the absence of screening, we may have difficulty finding patients who are eligible to participate in
our studies or trials. For example, participants in clinical trials for RLYB211 and RLYB212 have rare HPA-1b genotype and we may have difficulty identifying and receiving consent from a sufficient amount of participants for such clinical trials. In
addition, our clinical trials for RLYB116 will compete with other clinical trials for product candidates that are currently being tested in clinical trials for paroxysmal nocturnal hemoglobinuria, or PNH, and generalized myasthenia gravis, or gMG,
and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Furthermore, any
negative results we may report in clinical trials of any of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same or a similar product candidate. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Outside of the United States, our ability to initiate, enroll and complete a clinical trial successfully is subject to numerous additional risks, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulty in establishing or managing relationships with CROs and physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">different standards for the conduct of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our inability to locate qualified local consultants, physicians and partners; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including
the regulation of pharmaceutical and biotechnology products and treatment. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not be able to initiate or continue clinical trials required by
the FDA, the EMA or other regulatory authorities if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials. If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as
planned, we may need to delay, limit or terminate ongoing or planned clinical trials. Delays or failures in planned patient enrollment or retention may result in increased costs or program delays, which could have a harmful effect on our ability to
develop our product candidates or could render further development impossible. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Results of preclinical studies, clinical trials or analyses that we may
announce or publish from time to time, may not be indicative of results obtained in later trials, and any interim results we may publish could be different than final results. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The results of preclinical studies, clinical trials or analyses of the results from such trials, may not be predictive of the results of later clinical trials. Product
candidates in later clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and prior clinical trials or having shown promising results based on analyses of data from earlier
trials. Late-stage clinical trials may include a larger number of patients and could differ in other significant ways from early-stage clinical trials, including changes to inclusion and exclusion criteria, patient population, efficacy endpoints,
dosing regimen and statistical design. Our Phase 1/2 clinical trial for RLYB211 is single blinded, making it difficult to predict how rapid platelet clearance will lead to prevention of alloimmunization in pregnant women at higher risk for FNAIT and
whether any favorable results that we may observe in such trial will be repeated in larger and more advanced clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials
due to lack of efficacy or adverse safety profiles, notwithstanding earlier promising results. In addition, conclusions based on promising data from analyses of clinical results, such as the prospective and post hoc analysis of results may be shown
to be incorrect in subsequent clinical trials that have <FONT STYLE="white-space:nowrap">pre-specified</FONT> end points or may not be considered adequate by regulatory authorities. We believe data from our Phase 1/2 clinical trial of RLYB211 has
demonstrated proof of concept of our proposed mechanism of action and supports advancing RLYB212 into clinical trials, however, we cannot guarantee that clinical trial results will be similar for RLYB212. Even if we complete later clinical trials as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
planned, we cannot be certain that their results will support the safety and efficacy requirements sufficient to obtain regulatory approval, and, as a result, our clinical development plans may
be materially harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, interim, <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our clinical trials that we
announce or publish may change as more patient data become available or as additional analyses are conducted. The data obtained in such clinical trial are subject to additional audit and verification procedures and following such procedures, such
interim data could be materially different from the final data. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Any product candidates that we develop or the administration thereof, may cause serious
adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Adverse events or undesirable side effects caused by any product candidates we develop could cause us or regulatory authorities or IRBs, IECs or DSMBs,
where applicable, to interrupt, delay, or halt clinical trials and, if we seek approval of any such product candidate, could result in a more restrictive label, imposition of a Risk Evaluation and Mitigation Strategy, or REMS, program by the FDA or
the delay or denial of regulatory approval by the FDA, EMA or other comparable foreign regulatory authorities. Additionally, the administration process or related procedures associated with our product candidates also may cause adverse side effects.
Even if we determine that serious adverse events are unrelated to study treatment, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Results of any clinical trial we conduct could reveal a
high and unacceptable severity and prevalence of side effects. For example, complement inhibitors have, by design, immunosuppressive effects and, in some cases, may be administered to patients with significantly compromised health. As a result,
administration of RLYB116 could make patients more susceptible to infection. The chronic dosing of patients with RLYB116 could lead to an immune response that causes adverse reactions or impairs the activity and/or efficacy. Patients may develop an
allergic reaction to the drug and/or develop antibodies directed at RLYB116, or may require immunization with a meningococcal vaccine and prophylactic antibiotics. An immune response that causes adverse reactions or impairs the activity of RLYB116
could cause a delay in or termination of our development plans. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some potential therapeutics that initially showed therapeutic promise in early-stage trials have
later been found to cause side effects that prevented their further development. In addition, side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential clinical trial or product
liability claims. Inadequate training or failures by clinical trial personnel in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Furthermore, clinical trials by their nature
utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates or those of our competitors may only be uncovered when a significantly
larger number of patients have been exposed to the drug. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we or others later identify undesirable side effects caused by any product candidate that we develop
after the product is approved, several negative consequences could result, which could materially harm our business, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory authorities may suspend or withdraw approvals of such product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory authorities may require additional warnings on the label, limit the approved use of such product candidate, or
otherwise restrict distribution or marketing such as through requiring adoption of a REMS program; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be required to conduct additional clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we could be sued and held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on
preclinical studies or early-stage clinical trials. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its
tolerability versus other therapies. Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, time-
consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for RLYB212, RLYB116 or any of our other product candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, we are not permitted to market a product candidate until we receive approval of a BLA or a New Drug Application, or NDA, from the FDA. The process
of obtaining BLA and NDA approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved. Approval policies or regulations may change, and the FDA and other regulatory
authorities have substantial discretion in the approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. In addition, the FDA may require post-approval clinical trials or studies as a condition
of approval, which also may be costly. The FDA approval for a limited indication or approval with required warning language, such as a boxed warning, could significantly impact our ability to successfully market our product candidates. The FDA also
may require adoption of a REMS requiring prescriber training, post-market registries, or otherwise restricting the marketing and dissemination of these products. The FDA may inform us that an approved device, including a companion diagnostic, is
required to obtain marketing approval of RLYB212. Companion diagnostics are subject to regulation as medical devices and must be separately approved for marketing by the FDA. Certain of our product candidates will rely on delivery systems, such as
PFSs, <FONT STYLE="white-space:nowrap">pen-injectors</FONT> and/or autoinjectors, and may ultimately be regulated as a drug/device combination product. Although the FDA and similar foreign regulatory agencies have systems in place for the review and
approval of combination products, we may experience delays in the development and commercialization of our product candidates due to regulatory timing constraints and uncertainties in the product development and approval process. Despite the time
and expense invested in the clinical development of product candidates, regulatory approval is never guaranteed for our product candidates or a companion diagnostic, if required. Assuming successful clinical development, we intend to seek product
approvals in countries outside the United States, including in Europe. As a result, we would be subject to regulation by the EMA, as well as the other regulatory agencies in these countries. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy
approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates and we may be forced to abandon our development efforts for our product
candidate, which would significantly harm our business, results of operations, and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The time required to obtain approval by the FDA, EMA and other
comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of
clinical data necessary to gain approval may change during a product candidate&#146;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that we will never
obtain regulatory approval for any product candidate. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must
demonstrate to the satisfaction of the FDA, EMA or other comparable foreign regulatory authority, that such product candidates are safe and effective for their intended uses. Data obtained from preclinical studies and clinical trials are susceptible
to varying interpretations, and regulatory authorities may not interpret our data as favorably as we do, which may further delay, limit, or prevent development efforts, clinical trials, or marketing approval. Even if we believe the preclinical or
clinical data for our product candidates are sufficient to support approval, such data may not be considered sufficient to support approval by the FDA, EMA and other comparable regulatory authorities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, we have proposed to use real-world data from our FNAIT Natural History Alloimmunization Study to support our development program and related regulatory
submissions for RLYB212. Specifically, the natural history study data would assist us in assessing the frequency of women at higher risk of FNAIT among women of different racial and ethnic characteristics and the occurrence of <FONT
STYLE="white-space:nowrap">HPA-1a</FONT> alloimmunization in these women. The natural history studies and other real-world evidence we may submit to support applications for marketing approval may not be accepted by the FDA, EMA, or other comparable
foreign regulatory authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA, EMA or other comparable foreign regulatory authority can delay, limit, or deny approval of RLYB212, RLYB116 or
any of our other product candidates that we develop or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including, but not limited to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be unable to demonstrate to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities
that our product candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals
using drugs similar to our product candidates, or other products containing an active ingredient in our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance
required by the FDA, EMA or other comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety and efficacy
in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities may not accept clinical data from trials which are
conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States or the applicable foreign jurisdiction; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be unable to demonstrate that our product candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the
submission of a BLA or NDA or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA&#146;s or the applicable foreign regulatory authority&#146;s disagreement regarding the formulation, the labeling,
and/or the specifications of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA, or other comparable foreign regulatory authorities may require us to obtain clearance or approval of a
companion diagnostic test; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additional time may be required to obtain regulatory approval for our product candidates because they are combination
products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve or find deficiencies with the
manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never obtained marketing approval for a product candidate. It
is possible that the FDA may refuse to accept for substantive review any BLAs or NDAs that we submit for our product candidates or may conclude after review of our data that our applications are insufficient to obtain marketing approval of our
product candidates. If the FDA does not accept or approve our BLAs or NDAs for our product candidates, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit that data before it will
reconsider our applications. Depending on the extent of these or any other <FONT STYLE="white-space:nowrap">FDA-required</FONT> studies, approval of any BLA or NDA that we submit may be delayed or prevented, or may require us to expend more
resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our BLA or NDA. Any delay in obtaining, or an inability to obtain, marketing approvals
would prevent us from commercializing our product candidates, generating revenues, and achieving and sustaining profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our product candidates target rare diseases and conditions, and the market opportunities for RLYB212 and RLYB116, if
approved, may be smaller than we anticipate. As a result, our commercial opportunity may be limited and because the target populations of our product candidates are for rare diseases, we must be able to successfully identify patients and capture a
significant market share to achieve profitability and growth. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates target rare diseases and conditions. We are developing RLYB212 for the
potential prevention of FNAIT, and we estimate that each year greater than 22,000 pregnancies are at high risk for FNAIT in the United States, Canada, United Kingdom, other major European countries and Australia, based on the presence of HLA
DRB3*01:01 positive and <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative antibody in mothers and <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive in the fetus. With respect to RLYB116, we estimate that there are approximately 4,700
patients with PNH and up to 60,000 patients with gMG in the United States. Our projections of the number of eligible patients are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific
literature, population statistics and market research, and may prove to be incorrect. Further, new sources may reveal a change in the estimated number of eligible patients, and the number of patients may turn out to be lower than expected.
Additionally, the potentially addressable patient population for our current programs or future product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to
identify or gain access to. For example, even if we obtain FDA approval for RLYB212 or RLYB116, the drug may be approved for a target population that is more limited than what we currently anticipate. Furthermore, even if we obtain significant
market share for any product candidate, if approved, the potential target populations for our product candidates are for rare diseases, and we may never achieve profitability. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, in many cases there are either no or limited screening or diagnostic tests for the indications our product candidates are being developed to potentially treat.
For example, the successful prevention of FNAIT in mothers at risk for developing this rare disorder will require identifying expectant mothers who are HPA-1 negative and HLA DRB3*01:01 positive and HPA-1a positive in the fetus. In collaboration
with partners, we may develop screening and diagnostics tests to help us to identify individuals at risk, and the FDA, EMA or other comparable foreign regulatory authorities may require us to do so. The lack of screening and diagnostic tests,
coupled with the fact that there is frequently limited awareness among certain health care providers concerning the rare diseases we may seek to treat, often means that a proper diagnosis can, and frequently does, take years to identify (or an
appropriate diagnosis may never be made for certain patients). As a result, even if one of our product candidates is approved for commercial sale, we may not be able to grow our revenues due to difficulty in identifying eligible patients. There can
be no guarantee that any of our programs will be effective at identifying patients that will benefit from our product candidates, and even if we can identify patients that our product candidates can help, the number of patients that our product
candidates may ultimately treat may turn out to be lower than we expect, they may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify, all of which may adversely affect
our ability to grow and generate revenue and adversely affect our results of operations and our business. In addition, even in instances where we are able to expand the number of patients being treated, the number may be offset by the number of
patients that discontinue use of the applicable product in a given period resulting in a net loss of patients and potentially decreased revenue. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The FDA, EMA
or other comparable foreign regulatory authorities could require the clearance or approval of an in vitro diagnostic or companion diagnostic device as a condition of approval for any product candidate that requires or would commercially benefit from
such tests. Failure to successfully validate, develop and obtain regulatory clearance or approval for companion diagnostics on a timely basis or at all could harm our drug development strategy and we may not realize the commercial potential of any
such product candidate. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If safe and effective use of RLYB212 or any of our other product candidates depends on an in vitro diagnostic, then the FDA
generally will require approval or clearance of that test, known as a companion diagnostic, at the same time that the FDA approves our product candidates. The process of development and approval of such diagnostic is time consuming and costly.
Companion diagnostics, which provide information that is essential for the safe and effective use of a corresponding therapeutic product, are subject to regulation by the FDA, EMA and other comparable foreign regulatory authorities as medical
devices and require separate regulatory approval from therapeutic approval prior to commercialization. The FDA previously has required in vitro diagnostic tests intended to select the patients who will respond to a product candidate to obtain <FONT
STYLE="white-space:nowrap">pre-market</FONT> approval, or PMA, simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of preclinical and clinical data and the submission and review by the FDA, can take
several years or longer. It involves a rigorous <FONT STYLE="white-space:nowrap">pre-market</FONT> review during which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
applicant must prepare and provide FDA with reasonable assurance of the device&#146;s safety and effectiveness and information about the device and its components regarding, among other things,
device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion,
labeling, import, export, record-keeping, and adverse event reporting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given our limited experience in developing and commercializing in vitro diagnostic devices,
including companion diagnostic tests, we do not plan to develop such tests internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in developing and obtaining approval for these in vitro diagnostic
tests. We may not be able to enter into arrangements with a provider to develop screening and/or diagnostic tests for use in connection with a registrational trial for RLYB212 or for commercialization of RLYB212, or do so on commercially reasonable
terms, which could adversely affect and/or delay the development or commercialization of RLYB212. We and our future collaborators may encounter difficulties in developing and obtaining approval for the such tests, including issues relating to
selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our collaborators to develop or obtain regulatory approval of in vitro diagnostic tests could delay or prevent approval of RLYB212 or
any of our other product candidates. In addition, we, our collaborators or third parties may encounter production difficulties that could constrain the supply of such tests, and both they and we may have difficulties gaining acceptance of the use of
such tests by physicians. We believe that adoption of screening and treatment into clinical practice guidelines is important for market access, third-party payer reimbursement, utilization in medical practice and commercial success. Both our
collaborators and we may have difficulty gaining acceptance of such screening and/or diagnostic tests into clinical practice guidelines. If such tests fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues
from sales, if any, of RLYB212 if it is approved for commercial sale, or any other approved products that require an in vitro diagnostic test. In addition, any collaborator or third-party with whom we contract may decide not to commercialize or to
discontinue selling or manufacturing the test that we anticipate using in connection with development and commercialization of our product candidates, or our relationship with such collaborator or third-party may otherwise terminate. We may not be
able to enter into arrangements with another provider to obtain supplies of an alternative in vitro diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms,
which could adversely affect and/or delay the development or commercialization of our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We face significant competition from biotechnology
and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology and pharmaceutical industries are
highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them
successfully. If a product candidate we develop is approved, we will face intense competition. There are many public and private biopharmaceutical companies, universities, government agencies and other research organizations actively engaged in the
research and development of products that may be like our product candidates or address similar markets. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated
among a smaller number of our competitors. These competitors also compete with us in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our
programs. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, the number of companies seeking to develop and commercialize
products and therapies competing with our product candidates is likely to increase. However, we seek to build our portfolio with key differentiating attributes to provide a competitive advantage in the markets we target. We believe RLYB212 could be
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody for the prevention of FNAIT, and no direct mechanistic based clinical competition currently exists. Our second product candidate, RLYB116 faces
competition from a number of companies for the treatment of patients with PNH and gMG, including Soliris and Ultomiris marketed by Alexion Pharmaceuticals, Inc., or Alexion. If we successfully develop and, if approved, commercialize RLYB116, this
therapy may compete, or potentially be used in conjunction, with currently marketed treatments, including Soliris and Ultomiris, and any new therapies that may become available in the future. See &#147;Business&#151;Competition.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competition could render any product candidate we develop obsolete, less competitive, or uneconomical. In addition,
product candidates developed by our competitors may prove to be more safe or more effective than our product candidates. Our competitors may, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">have significantly greater name recognition and financial, manufacturing, marketing, product development, technical,
commercial infrastructure, and human resources than we do; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">more effectively recruit and retain qualified scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">more effectively establish clinical trial sites and patient registration; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to
administer, or have fewer or less severe side effects; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtain quicker regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">better protect their patents and intellectual property or acquire technologies that are complementary to, or necessary
for, our programs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">implement more effective approaches to sales, marketing, pricing, coverage, market access, and reimbursement; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">form more advantageous strategic alliances or collaborations. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are not able to effectively compete for any of the foregoing reasons, our business will be materially harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Disruptions in the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key
leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and
retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes and other events that may otherwise affect the FDA&#146;s ability to perform routine functions. Average review times at the agency have
fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would
adversely affect our business. For example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to
furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse
effect on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020, the FDA announced its intention to
postpone most inspections of foreign manufacturing facilities, and on March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&nbsp;10, 2020, the FDA announced
its intention to resume certain <FONT STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the
categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. In April 2021, the FDA released additional guidance on its handling of inspections
during the COVID-19 pandemic, addressing situations where FDA may request to conduct a remote interactive evaluation. While participation in a remote interactive evaluation is voluntary, declining FDA&#146;s guidance could impede the FDA&#146;s
ability to make a timely regulatory decision (e.g., regarding adequacy of a clinical trial used in support of a pending application or adequacy of a drug manufacturing operation described in the application). Regulatory authorities outside the
United States may also impose similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the
FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory
submissions, which could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we obtain FDA approval for a product candidate in the United States, we or our current or future
collaborators may never obtain approval for or commercialize the product candidate in any other jurisdiction, which would limit our ability to realize its full market potential. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to market any product in a particular jurisdiction, we or our current or future collaborators must establish and comply with numerous and varying regulatory
requirements regarding safety and efficacy on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. Approval by the FDA in the United States does not ensure approval by comparable regulatory
authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our or our collaborators&#146; ability to obtain approval elsewhere. In addition, clinical trials conducted in one
country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign
regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time- consuming. Regulatory requirements can vary widely from country to country and
could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory
approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our
target market will be reduced and we will be unable to realize the full market potential of any product we develop. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we obtain regulatory approval for
any of our product candidates, we will still face extensive and ongoing regulatory requirements and obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to
comply with regulatory requirements or experience unanticipated problems with any product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any product candidate for which we obtain marketing
approval, along with the manufacturing processes, post-approval preclinical and clinical testing, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, and advertising and promotional activities for such
product, among other things, will be subject to extensive and ongoing requirements of the FDA and other regulatory authorities. These requirements include submissions of safety and other post- marketing information and reports, establishment
registration and drug listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements regarding the distribution of samples to physicians and recordkeeping and Good Laboratory Practice, or GLP, and GCP
requirements for <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and any clinical trials that we conduct post-approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may also require
costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. Additionally, the FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the
approved indications and in a manner that is consistent with the provisions of the approved labeling. If we market our products for uses beyond their approved indications or otherwise inconsistent with the
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling, we may be subject to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing by the FDA and other federal and state enforcement agencies, including the
Department of Justice. Violation of the Federal Food, Drug, and Cosmetic Act, or FDCA, and other statutes, including the False Claims Act, and equivalent legislation in other countries relating to the promotion and advertising of prescription
products may also lead to investigations or allegations of violations of federal and state and other countries&#146; health care fraud and abuse laws and state consumer protection laws. Even if it is later determined we were not in violation of
these laws, we may be faced with negative publicity, incur significant expenses defending our actions and have to divert significant management resources from other matters. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes or failure to comply
with regulatory requirements, may yield various results, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on manufacturing such products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions in the labeling or on the marketing of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">requirements to conduct post-marketing studies or additional post-marketing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issuance of warning letters or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal to approve pending applications or supplements to approved applications that we submit, or delays in such
approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recalls or market withdrawals of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, restitution, or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">suspension or termination of ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions, consent decrees, or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we obtain FDA approval for RLYB212 or RLYB116, safety risks not identified in our prior clinical trials may first appear after we obtain approval and commercialize
these product candidates. Any new post-marketing adverse events may significantly impact our ability to market the drugs and may require that we recall and discontinue commercialization of the products. Furthermore, if any confirmatory
post-marketing trial fails to confirm the clinical profile or clinical benefits of RLYB212 or RLYB116, the FDA may withdraw its approval, which would materially harm our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either
in the United States or abroad. Further, the FDA&#146;s, EMA&#146;s and other comparable regulatory authorities&#146; policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval
of a product candidate or increase the costs and regulatory burden of commercialization. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain
regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition, and results of operations. Furthermore, <FONT
STYLE="white-space:nowrap">non-compliance</FONT> by us or any collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, may also result in significant financial penalties, which would adversely affect our business.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may seek Fast Track designation, Breakthrough Therapy designation, or PRIME designation for our product candidates, but we might not receive any such
designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a drug is
intended for the treatment of a serious or life-threatening condition, and <FONT STYLE="white-space:nowrap">non-clinical</FONT> or clinical data demonstrate the potential to address an unmet medical need for this condition, the product candidate may
qualify for FDA Fast Track designation, for which sponsors must apply. Sponsors of fast track products may have more frequent interactions with the FDA, and, in some circumstances, the FDA may initiate review of sections of a fast track
product&#146;s application before the application is complete. We may submit an application for Fast Track designation for RLYB212 and RLYB116. The FDA has broad discretion whether to grant this designation, and we may not receive it. Moreover, even
if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular time frame. We may not experience a faster development or regulatory review
or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development
program. Fast Track designation alone does not guarantee qualification for the FDA&#146;s priority review procedures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also may seek a Breakthrough Therapy
designation for RLYB212 or other product candidates if future results support such designation. A Breakthrough Therapy is defined as a drug (including biologic) that is intended, alone or in combination with one or more other drugs, to treat a
serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in
clinical development. Sponsors of products that have been designated as breakthrough therapies are eligible to receive more intensive FDA guidance on establishing an efficient drug development program, an organization commitment involving senior
managers, and may be eligible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">31 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
for rolling review. Drugs designated as breakthrough therapies by the FDA may also be eligible for other expedited review programs, including accelerated approval and priority review, if
supported by clinical data at the time the BLA or NDA is submitted to the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Designation as a Breakthrough Therapy is within the discretion of the FDA.
Accordingly, even if we believe that RLYB212 meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive Breakthrough Therapy designation, the receipt of
such designation may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if
RLYB212 qualifies as a Breakthrough Therapy, the FDA may later decide that RLYB212 no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the European Union, or EU, we may seek PRIME designation for some of our product candidates in the future. PRIME is a voluntary program aimed at enhancing the
EMA&#146;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The
program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the EU or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to
medicines under development and not authorized in the EU and the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility
criteria in respect of its major public health interest and therapeutic innovation based on information that can substantiate the claims. The benefits of a PRIME designation include the appointment of a CHMP rapporteur to provide continued support
and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an
opinion on approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME
designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase
the likelihood of EMA&#146;s grant of a marketing authorization. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be unsuccessful in obtaining or may be unable to maintain the benefits associated
with orphan drug designation, including the potential for market exclusivity. If our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as RLYB212 and RLYB116 or any of
our other product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory authorities in some jurisdictions, including the United States and the EU. may designate drugs for relatively small patient populations as orphan drugs.
Under the U.S. Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United
States, or a patient population of more than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA&#146;s Committee for Orphan
Medicinal Products evaluates, and the European Commission grants, an orphan drug designation principally to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically
debilitating condition affecting not more than five in 10,000 persons in the EU. In addition, the product under consideration is indicated for a condition where there exists no satisfactory method of diagnosis, prevention or treatment authorized in
the EU or, if such method exists, that the medicinal product will be of significant benefit to those affected by that condition. Each of the FDA and the European Commission has granted orphan drug designation for RLYB211 and RLYB212 for the
treatment of FNAIT. We may seek orphan drug designation in the United States and the EU for our other product candidates but may be unsuccessful in doing so. There can be no assurance that the FDA or the EMA&#146;s Committee for Orphan Medicinal
Products will consider orphan designation for any indication for which we apply or <FONT STYLE="white-space:nowrap">re-apply,</FONT> or that we will be able to maintain such designation. In the United States, orphan drug designation entitles a party
to financial incentives such as opportunities for grant funding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">32 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
towards clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. Orphan drug designation neither shortens the development time or regulatory review time
of a drug nor gives the drug any advantage in the regulatory review or approval process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product candidate with an orphan drug designation subsequently
receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same
drug or biologic for the same orphan designation for that time period, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient
product quantity. In the United States, the exclusivity period is seven years. The applicable exclusivity period is ten years in Europe, but such exclusivity period can be reduced to six years in Europe if a product no longer meets the criteria for
orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for
designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Similarly, in the EU, the market exclusivity can be broken if the
holder of the marketing authorization for the original orphan medicinal product is unable to supply sufficient quantities of the medicinal product. In addition, in both the United States and EU, if a different drug is subsequently approved for
marketing for the same or a similar indication as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity, which only protects against approval of
the &#147;same&#148; drug for the same indication. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may seek accelerated approval by the FDA for one or more of our product candidates. Accelerated
approval by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing
approval. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may in the future seek an accelerated approval for our one or more of our product candidates. Under the accelerated approval program, the FDA
may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a
surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. As a condition of approval, the FDA requires that a sponsor of a product receiving accelerated approval perform a post-marketing confirmatory
clinical trial or trials. In addition, the FDA currently requires as a condition for accelerated approval the <FONT STYLE="white-space:nowrap">pre-submission</FONT> of promotional materials to FDA for review. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and
receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval.
Furthermore, if we decide to submit an application for accelerated approval there can be no assurance that such submission or application will be accepted or that the FDA will determine that the product candidate is eligible for or grant accelerated
approval. A failure to obtain any planned accelerated approval for our product candidates would result in a longer time period to commercialization of our product candidates, if approved, could increase the cost of development of our product
candidates and could harm our competitive position in the marketplace. If we receive accelerated approval for any of our product candidates, the FDA may withdraw accelerated approval if, among other things, a confirmatory trial required to verify
the predicted clinical benefit of the product fails to verify such benefit or if such trial is not conducted with due diligence. Withdrawal of any accelerated approval could substantially harm our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Although RLYB211 and RLYB212 have received FDA designation as rare pediatric disease drug products, any marketing application we submit for these products may not
qualify for issuance of a rare pediatric disease priority review voucher. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, RLYB211 and RLYB212 have received designation from the FDA
as rare pediatric disease drug products. Receipt of rare pediatric disease designation is a prerequisite to qualifying for receipt of a rare pediatric disease priority review voucher upon approval of a marketing application for the rare pediatric
disease drug product. The priority review voucher may be used to obtain priority review of a future marketing application that would not otherwise qualify to receive priority review. Priority review shortens the FDA&#146;s goal for taking action on
a marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">33 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
application from ten months to six months for an original BLA or NDA from the date of filing. As an alternative to using the priority review voucher to obtain priority review of one of its own
marketing applications, the sponsor of a rare pediatric disease drug product receiving a priority review voucher may also sell or otherwise transfer the voucher to another company. The voucher may be further transferred any number of times before
the voucher is used, as long as the sponsor making the transfer has not yet submitted an application relying on the priority review voucher. The FDA may also revoke any rare pediatric disease priority review voucher if the rare pediatric disease
product for which the voucher was awarded is not marketed in the United States within one year following the date of approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is no guarantee that, if we
ever submit and obtain approval for RLYB211 or RLYB212 or any other product candidate for which we may obtain rare pediatric disease designation in the future, we will receive a rare pediatric disease priority review voucher. In addition to
receiving rare pediatric disease designation, in order to receive a rare pediatric disease priority review voucher, the NDA or BLA must be granted priority review, rely on clinical data derived from studies examining a pediatric population and
dosages of the drug intended for that population, not seek approval for a different adult indication in the original rare pediatric disease product application and be for a drug that does not include a previously approved active ingredient. Under
current statutory sunset provisions, even if a marketing application meets all of these requirements, FDA may only award a voucher prior to September&nbsp;30, 2026 and only if the approved product received rare pediatric disease drug product
designation prior to September&nbsp;30, 2024. We cannot be certain that we will receive approval for any of our rare pediatric disease designated products prior to the statutory sunset date, if ever. Moreover, even if we believe that our marketing
application meets the other requirements to be eligible to receive a priority review voucher upon approval, FDA may disagree. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The successful
commercialization of any product candidate we develop will depend in part on the extent to which regulatory authorities and private health insurers establish coverage and reimbursement. Failure to obtain or maintain coverage and reimbursement for
our product candidates, if approved, could limit our or our collaborators&#146; ability to market those products and decrease our or our collaborators&#146; ability to generate revenue. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to obtain coverage and reimbursement for any product candidates by governmental healthcare programs, such as Medicare and Medicaid, private health insurers,
and other third-party payors is essential for most patients to be able to afford prescription medications. Our ability to achieve acceptable levels of coverage and reimbursement for products or procedures using our products by regulatory
authorities, private health insurers and other third-party payors will therefore have an effect on our ability to successfully commercialize any product candidates we develop. We cannot be sure that coverage and reimbursement will be available for
our product candidates, if and when such candidates obtain marketing approval, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause third-party payors to limit both
coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for any product we commercialize. We expect to experience pricing pressures in connection with the sale of our
product candidates due to the trend toward managed health care and additional legislative, administrative, or regulatory changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical
procedures and other treatments, has become intense and new products face increasing challenges in entering the market successfully. Third-party payors are increasingly challenging the price and examining the cost-effectiveness of new products in
addition to their safety and efficacy. To obtain or maintain coverage and reimbursement for any current or future product, we may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our
product. These studies will be in addition to the studies required to obtain regulatory approvals. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No uniform policy for coverage and reimbursement for products
exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor, and one third-party payor&#146;s decision to cover a particular product does not ensure that other
payors will also provide similar coverage. Additionally, the process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the price of such product or establishing the
reimbursement rate that the payor will pay for the product once coverage is approved. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for
the use of our product candidates to each payor separately, with no assurance that coverage and reimbursement will be obtained or will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">34 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
consistent across payors. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations
are likely. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to obtain a satisfactory financial return on our product candidates.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We or our collaborators may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the
increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control
mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could
restrict the amount that we or our collaborators are able to charge for products we or our collaborators commercialize. Accordingly, in markets outside the United States, the reimbursement for products we or our collaborators commercialize may be
reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if a product candidate we
develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors and the medical community.
Commercial success also will depend, in large part, on the coverage and reimbursement of our product candidates and associated screening and/or diagnostic tests by third-party payors, including private insurance providers and government payors.
Various factors will influence whether our product candidates are accepted in the market if approved for commercial sale, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the efficacy, safety and tolerability of our products, and potential advantages compared to alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the clinical indications for which the product is approved, and product labeling or product insert requirements of the
FDA, EMA or other comparable foreign regulatory authorities, including any limitations or warnings contained in a product&#146;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of treatment in relation to alternative treatments, including any similar treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability and access to screening and/or diagnostic tests; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of third-party coverage and reimbursement for any of our products that are approved and any screening
and/or diagnostic testing, as appropriate; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any restrictions on the use of our product together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Market acceptance of our product candidates is heavily dependent on patients&#146; and physicians&#146; perceptions that our product candidates are safe and effective
treatments for their targeted indications and willingness to use screening and/or diagnostic tests to identify at-risk target populations for our therapeutics. The perceptions of any product are also influenced by perceptions of competitors&#146;
products that are in the same class or that have a similar mechanism of action. Because we expect sales of our product candidates, if approved, to generate substantially all our revenues in the foreseeable future, the failure of our product
candidates to find market acceptance would harm our business and could require us to seek additional financing. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If approved, our product candidates that are
regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Biologics Price Competition and
Innovation Act of 2009, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, or the ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway
establishes legal authority for the FDA to review and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">35 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
approve biosimilar biologics, including the possible designation of a biosimilar as &#147;interchangeable&#148; based on its similarity to an approved biologic. Under the BPCIA, reference
biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four
years after the date of first licensure of the reference product In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT
STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as their BLA does not rely on the reference product, sponsor&#146;s data or submit the
application as a biosimilar application. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty, and any new policies or processes
adopted by the FDA could have a material adverse effect on the future commercial prospects for our biological products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that any of the product
candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be
shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than
anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT>
products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. The approval of a biosimilar of our product candidates could have a material adverse impact on our business due to increased
competition and pricing pressure. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the FDA, EMA or other comparable foreign regulatory authorities approve generic versions of any of our small molecule
investigational products that receive marketing approval, or such authorities do not grant our products appropriate periods of exclusivity before approving generic versions of those products, the sales of our products, if approved, could be
adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once an NDA is approved, the product covered thereby becomes a &#147;reference listed drug&#148; in the FDA&#146;s publication,
&#147;Approved Drug Products with Therapeutic Equivalence Evaluations,&#148; commonly known as the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications, or
ANDAs, in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials to assess safety and efficacy. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form,
strength, route of administration and conditions of use or labelling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent.
Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a
significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may not approve an ANDA for a
generic product until any applicable period of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity for the reference listed drug has expired. The FDCA provides a period of five years of <FONT STYLE="white-space:nowrap">non-patent</FONT>
exclusivity for a new drug containing a new chemical entity. Specifically, in cases where such exclusivity has been granted, an ANDA may not be submitted to the FDA until the expiration of five years unless the submission is accompanied by a
Paragraph IV certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference
listed drug. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generic drug manufacturers may seek to launch generic products following the expiration of any applicable exclusivity period we obtain if our products
are approved, even if we still have patent protection for such products. Competition that our products could face from generic versions of our products could materially and adversely affect our future revenue, profitability, and cash flows and
substantially limit our ability to obtain a return on the investments we have made in those product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to establish sales,
marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing any product candidates we develop, if approved. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to market and successfully commercialize any product candidates we develop, if approved, we must build our sales and marketing capabilities or enter into
collaborations with third parties for these services. We currently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">36 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. If we commercialize any of our product candidates that may be approved ourselves,
we will need to develop an <FONT STYLE="white-space:nowrap">in-house</FONT> marketing organization and sales force across rare disease therapeutic areas, which will require significant expenditures, management resources, and time. There are
significant expenses and risks involved with establishing our own sales and marketing capabilities, including our ability to hire, train, retain, and appropriately incentivize a sufficient number of qualified individuals, generate sufficient sales
leads and provide our sales and marketing team with adequate access to physicians who may prescribe our products, effectively manage a geographically dispersed sales and marketing team, and other unforeseen costs and expenses. We will have to
compete with other pharmaceutical and biotechnology companies to recruit, hire, train, and retrain marketing and sales personnel. Any failure or delay in the development of a product candidate that affects the expected timing of commercialization of
the product candidate or results in the failure of the product candidate to be commercialized could result in us having prematurely or unnecessarily incurred costly commercialization expenses. Our investment would be lost if we are unable to retain
or reposition our sales and marketing personnel. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also enter into collaborations for the sales and marketing of our product candidates, if approved. To the
extent that we depend on collaborators for sales and marketing activities, any revenues we receive will depend upon the success of those collaborators&#146; sales and marketing teams and the collaborators&#146; prioritization of our products and
compliance with applicable regulatory requirements, and there can be no assurance that the collaborators&#146; efforts will be successful. If we are unable to build our own sales and marketing team or enter into a collaboration for the
commercialization of product candidates we develop, if approved, we may be forced to delay the commercialization of our product candidates or reduce the scope of our sales or marketing activities, which would have an adverse effect on our business,
operating results and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We intend to continue to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> rights to additional product candidates or collaborate with third parties
for the development and commercialization of our product candidates. We may not succeed in identifying and acquiring businesses or assets, <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property rights or establishing and
maintaining collaborations, which may significantly limit our ability to successfully develop and commercialize our other product candidates, if at all, and these transactions could disrupt our business, cause dilution to our stockholders or reduce
our financial resources. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We acquired all rights to RLYB211 and RLYB212 from Prophylix in 2019 and rights to RLYB116 and RLYB114 from Sobi in 2019. We also
have entered into joint ventures with Exscientia for the development of small molecule therapeutics for rare diseases. An important component of our approach to product development is to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT>
rights to product candidates, products or technologies, acquire other businesses or enter into collaborations with third parties. We may not be able to enter into such transactions on favorable terms, or at all. Any such acquisitions, <FONT
STYLE="white-space:nowrap">in-licenses</FONT> or collaborations may not strengthen our competitive position, and these transactions may be viewed negatively by analysts, investors, customers, or other third parties with whom we have relationships.
We may decide to incur debt in connection with an acquisition, or <FONT STYLE="white-space:nowrap">in-license</FONT> or issue our common stock or other equity securities as consideration for the acquisition, which would reduce the percentage
ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the sellers of the acquired business. In addition, we may
not be able to successfully integrate the acquired personnel, technologies, and operations into our existing business in an effective, timely, and <FONT STYLE="white-space:nowrap">non-disruptive</FONT> manner. Such transactions may also divert
management attention from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> responsibilities, increase our expenses, and reduce our cash available for operations and other uses. We cannot predict the number,
timing or size of future acquisitions or <FONT STYLE="white-space:nowrap">in-licenses</FONT> or the effect that any such transactions might have on our operating results. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not realize the anticipated benefits of any current or future collaboration, each of which involves or will involve numerous risks, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may shift its priorities and resources away from our product candidates due to a change in business
strategies, or a merger, acquisition, sale, or downsizing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may seek to renegotiate or terminate its relationships with us due to unsatisfactory clinical results,
manufacturing issues, a change in business strategy, a change of control or other reasons; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">37 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may cease development in therapeutic areas that are the subject of our collaboration;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may not devote sufficient capital or resources towards our product candidates, or may fail to comply with
applicable regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may change the success criteria for a product candidate, thereby delaying or ceasing development of such
candidate; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a significant delay in initiation of certain development activities by a collaborator will also delay payment of
milestones tied to such activities, thereby impacting our ability to fund our own activities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator could develop a product that competes, either directly or indirectly, with our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator with commercialization obligations may not commit sufficient financial resources or personnel to the
marketing, distribution, or sale of a product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator with manufacturing responsibilities may encounter regulatory, resource, or quality issues and be unable to
meet demand requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may terminate a strategic alliance; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a dispute may arise between us and a collaborator concerning the research, development, or commercialization of a product
candidate resulting in a delay in milestones or royalty payments or termination of the relationship and possibly resulting in costly litigation or arbitration, which may divert management&#146;s attention and resources; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may use our products or technology in such a way as to invite litigation from a third-party.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing, or
commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we
are unable to establish and maintain collaborations on acceptable terms or to successfully transition away from terminated collaborations, we may have to delay or discontinue further development of one or more of our product candidates, undertake
development and commercialization activities at our own expense, or find alternative sources of capital, which would have a material adverse impact on our clinical development plans and business. If we fail to establish and maintain collaborations
related to our product candidates, we could bear all of the risk and costs related to the development of any such product candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise for which we
have not budgeted. This could negatively affect the development and commercialization of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may face significant competition in identifying
and acquiring businesses or assets, <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property rights and seeking appropriate collaboration partners for our product candidates, and the negotiation process may be time-consuming and
complex. In order for us to successfully partner our product candidates, potential collaborators must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and
other products or product candidates available for licensing from or in connection with collaborations with other companies. Our success in acquiring business or assets or in partnering with collaborators may depend on our history or perceived
capability of successful product development. Even if we are successful in our efforts to acquire businesses or assets, <FONT STYLE="white-space:nowrap">in-license</FONT> intellectual property rights or establish collaborations, we may not be
successful in developing such products candidates or technologies or able to maintain such collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our reliance on a central team consisting of a limited number of employees and third parties who provide various administrative, research and development, and
other services across our organization presents operational challenges that may adversely affect our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;31, 2021, we had 22
full-time employees, upon whom we rely for various administrative, research and development, business development and other support services shared among our subsidiaries and the Exscientia joint venture. The size of our centralized team may limit
our ability to devote adequate personnel, time, and resources to support the operations of all of our subsidiaries and the Exscientia joint venture, including their research and development activities, the management of financial, accounting, and
reporting matters, and the oversight of our third-party vendors and partners. If our centralized team or our third party vendors and partners </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">38 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
performing such functions fail to provide adequate administrative, research and development, or other services across our entire organization, our business, financial condition, and results of
operations could be harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties
we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Misconduct by our employees and independent contractors, including principal investigators, CROs, consultants, vendors and any third parties we may engage
in connection with research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization, could include intentional, reckless or negligent conduct or unauthorized activities that violate:
(i)&nbsp;the laws and regulations of the FDA, and other similar regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii)&nbsp;manufacturing standards;
(iii)&nbsp;data privacy, security, fraud and abuse and other healthcare laws and regulations; or (iv)&nbsp;laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business
arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of
pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these or other laws could also involve the improper use or misrepresentation of information obtained
in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not
always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government agency could allege such fraud or other misconduct, even
if none occurred. If any such actions are instituted against us or them and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the
imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions,
individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We currently rely and will rely on third parties for the manufacture of drug substance for our preclinical studies and clinical trials and expect to continue to
do so for commercialization of any product candidates that we may develop that are approved for marketing. We also rely and will rely on third parties for the design and manufacture of companion diagnostics related to RLYB212 and any other product
candidates that may require a companion diagnostic. Our reliance on third parties may increase the risk that we will not have sufficient quantities of such drug substance, product candidates, or any products that we may develop and commercialize, or
that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing RLYB211, RLYB212 and RLYB116 or any other product candidate. Instead, we rely on and expect to continue to rely on contract manufacturers for the
supply of cGMP-drug substance and drug product of RLYB211, RLYB212 and RLYB116 and any other product candidates we develop and, in the future, for commercial supply. Reliance on third parties may expose us to more risk than if we were to manufacture
our product candidates ourselves. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may be unable to establish necessary supply agreements with third-party manufacturers or to do so on acceptable terms. Even if
we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible breach of the manufacturing agreement by the third-party; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible termination or nonrenewal of the agreement by the third-party at a time that is costly or inconvenient for
us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reliance on the third-party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related
reporting; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">39 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible inability of third-party suppliers to supply and/or transport materials, components and products to us in a
timely manner as a result of disruptions to the global supply chain, including in connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third-party manufacturers may fail to comply with cGMP regulations or similar regulatory requirements outside the United States. Any failure to follow cGMP or other
regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to
comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of our product
candidates for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Moreover, our failure, or the failure of our
third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of
product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations, and prospects.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While we provide oversight of manufacturing activities, we have limited ability to control the execution of manufacturing activities by, and are or will be
dependent on, our contract manufacturing organizations, or CMOs, for compliance with cGMP requirements for the manufacture of our product candidates by our CMOs. As a result, we are subject to the risk that our product candidates may have
manufacturing defects or fail to comply with regulatory requirements, which we have limited ability to prevent. CMOs may also have competing obligations that prevent them from manufacturing our product candidates in a timely manner. If a CMO cannot
successfully manufacture drug substance that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial
distribution of our product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance, and qualified personnel, and we were not involved in developing our
CMOs&#146; policies and procedures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The facilities and processes used to manufacture our product candidates are subject to inspection by the FDA, EMA and other
comparable foreign authorities. If the FDA, EMA or other comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds
deficiencies in the future, we may need to find alternative manufacturing facilities or conduct additional studies, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for, or
commercialize our product candidates, if approved. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or
otherwise inconvenient for us. Finding new CMOs or third-party suppliers involves additional cost and requires our management&#146;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Any significant
delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates. If we were unable to
find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We rely on and
will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates. We have limited ability to control the process or timing of the acquisition of these raw materials by our CMOs. The <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic may also have an impact on the ability of our CMOs to acquire raw materials. Moreover, we currently do not have any agreements for the production of these raw materials. Supplies of raw materials
could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable time frame, at an acceptable cost, or at all. In addition, a disruption in the supply of raw materials could delay the
commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also
impair our ability to cost effectively manufacture our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">40 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
candidates. There are a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative suppliers to prevent a
possible disruption of the manufacture of our product candidates. Moreover, our product candidates utilize drug substances that are produced on a small scale, which could limit our ability to reach agreements with alternative suppliers. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the intellectual property and
proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes, misappropriates or otherwise violates the intellectual property or the proprietary rights of others in the course of
providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for, or commercialize our
product candidates, if approved. Further, the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our ability to procure sufficient supplies for the development of our product candidates will depend on the severity
and duration of the spread of the virus, and the actions undertaken to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its effects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition,
given our limited experience in developing and commercializing companion diagnostics, we do not plan to develop companion diagnostics internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in
developing and obtaining approval for companion diagnostics if required. Reliance on these third-party collaborators exposes us to risks due to our limited control of their activities, including compliance by them with cGMP regulations or similar
foreign requirements and inspection of their manufacturing facilities by the FDA or comparable foreign regulatory authorities and their obtaining, maintaining and protecting their intellectual property rights necessary to develop and manufacture
companion diagnostics while not infringing on the intellectual property rights of others. We or our third-party collaborators also will need to source raw materials for any companion diagnostics, including obtaining amounts sufficient for widespread
adoption of testing and a potential commercial launch of RLYB212, if approved, and we may be dependent on our collaborators to identify and obtain reliable sources of raw materials. Our collaborators also may breach their agreements with us or
otherwise fail to perform to our satisfaction, which could impact the development timeline of our product candidates, and we may incur additional costs and delays if we need to transition to a new third-party companion diagnostic partner. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We rely, and will continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials. If we fail to effectively
oversee and manage these third parties, if they do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We rely, and will continue to rely, on CROs, <FONT STYLE="white-space:nowrap">CRO-contracted</FONT> vendors, and clinical trial sites to ensure the proper and timely
conduct of our clinical trials. Our reliance on CROs for clinical development activities limits our control over these activities, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol
and legal, regulatory, and scientific standards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and our CROs will be required to comply with the GLP requirements for our preclinical studies and GCP
requirements for our clinical trials. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators, and clinical trial sites. If we, or our CROs, fail to comply with GCP requirements, the
clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot
assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements and may require a large number of patients. Our failure or any failure by our
CROs, investigators, CMOs or other third parties to comply with regulatory requirements or to recruit enough patients may delay ongoing or planned clinical trials or require us to repeat clinical trials, which would delay the regulatory approval
process. Failure by us or by third parties we engage to comply with regulatory requirements can also result in fines, adverse publicity, and civil and criminal sanctions. Moreover, our business may be implicated if any of these third parties
violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our CROs, vendors and clinical trial
investigators are not our employees, and we do not control whether they devote sufficient time and resources to our clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom
they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">41 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
disclosure or misappropriation of our intellectual property by CROs and other third parties involved in our preclinical studies and clinical trials, which may reduce our trade secret protection
and allow our potential competitors to access and exploit our proprietary technology. If our CROs and other third parties involved in our trials do not successfully carry out their contractual duties or obligations, or fail to meet expected
deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or
terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidates that we develop. As a result, our financial results and the commercial prospects for any product candidates that we develop
would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our relationship with any CROs terminates, we may not be able
to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#146;s time and focus. In addition, there is a natural transition
period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no
assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Healthcare Laws and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if
approved, and may affect the prices we may set. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States and other jurisdictions, there have been, and we expect there will continue to be,
a number of legislative and regulatory changes, and additional proposed changes, to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S.
federal and state levels that seek to reduce healthcare costs and improve the quality of health care. For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private
insurers. The ACA expanded health care coverage through a Medicaid expansion and the implementation of the individual mandate for health insurance coverage. The ACA also imposed an annual fee payable on manufacturers of branded prescription drugs
and biologic agents (other than those designated as orphan drugs) and included changes to the coverage and reimbursement of drug products under government healthcare programs. Such changes included an expansion in the Medicaid drug rebate program
and an increase in the statutory minimum rebates a manufacturer must pay under the program as well as a new Medicare Part D coverage gap discount program requiring manufacturers to offer <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period in exchange for coverage of the drugs under Medicare Part D. Under the Trump
administration, there were ongoing efforts to modify or repeal all or certain provisions of the Healthcare Reform Act. For example, tax reform legislation was enacted at the end of 2017 that eliminated the tax penalty established under the ACA for
individuals who do not maintain the mandated health insurance coverage beginning in 2019. The ACA has also been subject to judicial challenge. The case Texas v. Azar, which challenges the constitutionality of the ACA, including provisions that are
unrelated to healthcare reform but were enacted as part of the ACA, was argued before the Supreme Court in November 2020. The Supreme Court is expected to issue a decision sometime in 2021. Pending resolution of the litigation, all of the provisions
in the ACA but the individual mandate to buy health insurance remain in effect. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beyond the ACA, there have been ongoing health care reform efforts, including
a number of recent actions. Some recent healthcare reform efforts have sought to address certain issues related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including an expansion of telehealth coverage under Medicare,
accelerated or advanced Medicare payments to healthcare providers and payments to providers for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">COVID-19-related</FONT></FONT> expenses and lost revenues. Other reform efforts affect
pricing or payment for drug products, which was a focus of the Trump Administration. For example, subsequent to the ACA, the Medicaid Drug Rebate Program was subject to statutory and regulatory changes and the discount that manufacturers of Medicare
Part D brand name drugs must provide to Medicare Part D beneficiaries during the coverage gap increased from 50% to 70%. Several regulations were issued in late 2020 and early 2021, some of which have been and may continue to be subject to scrutiny
and legal challenge. For example, courts temporarily enjoined a new &#147;most favored nation&#148; payment model for select drugs covered under Medicare Part B that was to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">42 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
take effect on January&nbsp;1, 2021 and would limit payment based on international drug price, and the Centers for Medicare &amp; Medicaid Services within the U.S. Department of Health and Human
Services, or CMS, subsequently indicated that the rule will not be implemented without further rulemaking. As another example, revisions to regulations under the federal anti-kickback statute would remove protection for traditional Medicare Part D
discounts offered by pharmaceutical manufacturers to PBMs and health plans. The revisions to the federal anti-kickback statute regulations referenced above were initially scheduled to take effect in 2022 but have now been delayed to 2023. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The nature and scope of health care reform in the wake of the transition from the Trump administration to the Biden administration remains uncertain but early actions
suggest additional changes as well as challenges to actions taken under the Trump administration. The Department of Justice under the Biden administration informed the Supreme Court in connection with case Texas v. Azar, that the government no
longer takes the position that the individual mandate is unconstitutional and cannot be severed from the rest of the ACA. President Biden temporarily halted implementation of new rules that were issued immediately prior to the transition from the
Trump administration to the Biden administration that had not yet taken effect (which include a number of health care reforms) to allow for review by the new administration. By Executive Order, President Biden directed federal agencies to reconsider
rules and other policies that limit Americans&#146; access to health care and consider actions that will protect and strengthen that access. President Biden supported reforms to lower prescription drug prices during his campaign for the presidency.
The American Rescue Plan Act of 2021, comprehensive <FONT STYLE="white-space:nowrap">COVID-19</FONT> relief legislation enacted early under the Biden administration, includes a number of healthcare-related provisions, such as support to rural health
care providers, increased tax subsidies for health insurance purchased through insurance exchange marketplaces, financial incentives to states to expand Medicaid programs and elimination of the Medicaid drug rebate cap effective in 2024. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General legislative cost control measures may also affect reimbursement for our product candidates. The Budget Control Act, as amended, resulted in the imposition of 2%
reductions in Medicare (but not Medicaid) payments to providers in 2013 and will remain in effect through 2030 (except May&nbsp;1, 2020 to December 31, 2021) unless additional Congressional action is taken. The Congressional Budget Office has
indicated that the American Rescue Plan Act of 2021 will likely trigger a statutory provision that requires that automatic payment cuts be put into place if a statutory action creates a net increase in the deficit and require reductions in Medicare
spending. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us could have an adverse impact on
our results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Adoption of new legislation at the federal or state level could affect demand for, or pricing of, any future products if approved for
sale. We cannot, however, predict the ultimate content, timing or effect of any changes to the ACA or other federal and state reform efforts. There is no assurance that federal or state health care reform will not adversely affect our future
business and financial results. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug
pricing practices. Specifically, there have been administration efforts, Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare,
review the relationship between pricing and manufacturer patient assistance programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and
regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be implemented in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which
could result in reduced demand for our product candidates or additional pricing pressures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Individual states in the United States have also become increasingly
aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could
harm our business, results of operations, financial condition, and prospects. Furthermore, there has been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">43 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These reforms could reduce the ultimate demand for
our product candidates or put pressure on our product pricing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In markets outside of the United States, reimbursement and healthcare payment systems vary
significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative
action in the United States or any other jurisdiction. If we, or any third parties we may engage, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not
able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business operations and current and future relationships with contractors, investigators, healthcare professionals, consultants, third-party payors, patient
organizations, customers, and others will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business operations
and current and future arrangements with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and
regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our product candidates, if approved. Such laws, some of
which may apply only after our products are approved for marketing, include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person
from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting,
receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and
Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to privacy
protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such
products prior to approval or for <FONT STYLE="white-space:nowrap">off-label</FONT> use and regulates the distribution of samples; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government
or provide certain discounts or rebates to regulatory authorities or private entities, often as a condition of reimbursement under government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal Open Payments (or federal &#147;sunshine&#148; law), which requires pharmaceutical and medical device
companies to monitor and report certain financial interactions with certain healthcare providers to the CMS for <FONT STYLE="white-space:nowrap">re-disclosure</FONT> to the public, as well as ownership and investment interests held by physicians and
their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities
that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring
pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health
care providers or marketing expenditures; and state laws governing privacy, security, and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing
interactions with and payments to healthcare providers and laws governing the privacy and security of personal information, such as, where applicable, the General Data Protection Regulation, or GDPR, which
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">44 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
imposes obligations and restrictions on the collection, use, and disclosure of personal data relating to individuals located in the EU and the European Economic Area, or EEA, (including health
data). See &#147;&#151;Our business operations may subject us to data protection laws, including the GDPR, the United Kingdom GDPR, the California Consumer Privacy Act and other similar laws&#148;; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">laws and regulations prohibiting bribery and corruption such as the FCPA, which, among other things, prohibits U.S.
companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international
organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare and other laws and regulations will involve substantial
costs. Given the breadth of the laws and regulations and narrowness of any exceptions, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, regulatory authorities may possibly
conclude that our business practices may not comply with healthcare laws and regulations, including our consulting agreements and other relationships with healthcare providers. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject
to actions including the imposition of civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, individual imprisonment,
contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements, or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Further, defending against
any such actions can be costly, time consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business operations may subject us to data protection laws, including the GDPR, the United Kingdom GDPR, the California Consumer Privacy Act and other similar
laws. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The GDPR applies to companies established in the EEA, as well as to companies that are not established in the EEA and which collect and use personal
data in relation to (i)&nbsp;offering goods or services to, or (ii)&nbsp;monitoring the behavior of, individuals located in the EEA. If we conduct clinical trial programs in the EEA (whether the trials are conducted directly by us or through a
clinical vendor or collaborator), or enter into research collaborations involving the monitoring of individuals in the EEA, or market our products to individuals in the EEA, we will be subject to the GDPR. The GDPR puts in place stringent
operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data (or reliance on another appropriate legal basis), the provision of
robust and detailed disclosures to individuals about how personal data is collected and processed (in a concise, intelligible and easily accessible form), an individual data rights regime (including access, erasure, objection, restriction,
rectification and portability), maintaining a record of data processing, data export restrictions governing transfers of data from the EEA, short timelines for data breach notifications to be given to data protection regulators or supervisory
authorities (and in certain cases, affected individuals) of significant data breaches, and limitations on retention of information. The GDPR also puts in place increased requirements pertaining to health data and other special categories of personal
data, as well as a definition of pseudonymized (i.e., <FONT STYLE="white-space:nowrap">key-coded)</FONT> data. Further, the GDPR provides that EEA member states may establish their own laws and regulations limiting the processing of genetic,
biometric, or health data, which could limit our ability to collect, use, and share such data and/or could cause our costs to increase. In addition, there are certain obligations if we contract third-party processors in connection with the
processing of personal data. If our or our collaborators&#146; or service providers&#146; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices
requiring us to change the way we use personal data, or fines of up to 20&nbsp;million Euros or up to 4% of our total worldwide annual revenue of the preceding financial year, whichever is higher, as well as compensation claims by affected
individuals, including class-action type litigation, negative publicity, reputational harm and a potential loss of business and goodwill. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">45 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, from January&nbsp;1, 2021, we may also have to comply with the UK GDPR, which, together with the amended UK Data
Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR with fines up to the greater of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million (&pound;17.5 million) or 4% of global
turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how
data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to <FONT STYLE="white-space:nowrap">six-month</FONT> grace period agreed in the EU and UK Trade and Cooperation Agreement, ending
June&nbsp;30, 2021 at the latest, whilst the parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United
Kingdom long term without additional measures. These changes could lead to additional costs and increase our overall risk exposure. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Recent legal developments in
Europe have created complexity and uncertainty regarding transfers of personal data from the EEA and the United Kingdom to the United States. Most recently, on July&nbsp;16, 2020, the Court of Justice of the European Union, or CJEU, invalidated the <FONT
STYLE="white-space:nowrap">EU-US</FONT> Privacy Shield Framework, or Privacy Shield, under which personal data could be transferred from the EEA to US entities who had self-certified under the Privacy Shield scheme. While the CJEU upheld the
adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them
alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis taking into account
the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional
measures is currently uncertain. The CJEU went on to state that if a competent supervisory authority believes that the standard contractual clauses cannot be complied with in the destination country and the required level of protection cannot be
secured by other means, such supervisory authority is under an obligation to suspend or prohibit that transfer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These recent developments may require us to review
and amend the legal mechanisms by which we make and/ or receive personal data transfers to/ in the United States. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard
contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among
countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated
pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and
technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled
in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. While we do not believe that we are directly subject to HIPAA as either a &#147;covered entity&#148; or
&#147;business associate,&#148; U.S. sites at which we conduct clinical trials are likely to be covered entities and thus must ensure that they obtain adequate patient authorization or establish another basis under HIPAA to disclose a clinical trial
subject&#146;s individually identifiable health information to us and other entities participating in our clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, The California
Consumer Privacy Act, or the CCPA, came into effect in January 2020 and, among other things, requires new disclosures to California individuals and affords such individuals new abilities to opt out of certain sales of personal information, and
increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach
litigation. Because we have not yet generated revenue and do not meet the CCPA&#146;s other jurisdictional tests, we do not yet meet the applicable threshold for CCPA to apply to our business. If our business becomes subject to CCPA in the future,
it could increase our compliance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">46 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
costs and potential liability. Further, the California Privacy Rights Act, or the CPRA, recently passed in California, which will impose additional data protection obligations on covered
businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency
authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January&nbsp;1, 2023, though the obligations for covered businesses will
apply to any personal information collected after January&nbsp;1, 2022. Similar laws have been proposed or passed at the U.S. federal and state level, including the Virginia Consumer Data Protection Act, which will take effect on January&nbsp;1,
2023. We will need to review periodically our operations in comparison to developments in such laws. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are subject to environmental, health and safety laws
and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release,
and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction,
laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including
liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future
environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to
obtain, maintain and enforce patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or
identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success
depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others, or may license from others, particularly patents, in the United States and other countries with respect to
any proprietary technology and product candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States and select other countries related to our technologies and product candidates that are
important to our business and by <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property related to such technologies and product candidates. If we are unable to obtain or maintain patent protection in jurisdictions important to
our business with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, defend or license all necessary or
desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. In some
circumstances involving technology that we license from third parties, we do not have the sole right to control the preparation, filing and prosecution of patent applications or to maintain, enforce and defend the
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents. Therefore, these <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner
consistent with the best interests of our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent rights of pharmaceutical and biotechnology companies generally are highly uncertain, involve complex
legal and factual questions and have been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged in the U.S. or in numerous foreign
jurisdictions. Various courts, including the United States Supreme Court, have rendered decisions that affect the scope of patent eligibility of certain inventions or discoveries relating to biotechnology. These
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">47 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
decisions conclude, among other things, that abstract ideas, natural phenomena and laws of nature are not themselves patent eligible subject matter. Precisely what constitutes a law of nature or
abstract idea is uncertain, and certain aspects of our technology could be considered ineligible for patenting under applicable law. In addition, the scope of patent protection outside the United States is uncertain, and laws of foreign countries
may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law precludes the patentability of methods of treatment of the human body. With respect to both owned and <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents that protect our technology and product candidates, in whole or in part,
in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Changes in either the patent laws or interpretation of the patent laws in the United States or other countries may
diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, affect the value or narrow the scope of our patent rights. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, third parties may have intellectual property rights relating to our product candidates of which we are unaware. Publications of discoveries in the scientific
literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases are not published at all. Therefore, neither we nor
our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or <FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future, or that
either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
rights are uncertain. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, or our licensors, may be subject to a third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the
United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of
others in the United States and/or foreign countries. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or
product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents
and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance.
Even if our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or
otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may be
challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which
could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such challenges also may result in
substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Furthermore, our competitors may be able to circumvent our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patents by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. For these reasons, our owned and <FONT STYLE="white-space:nowrap">in-</FONT> licensed patent portfolio may not
provide us with sufficient rights to exclude others from using or commercializing technology and products similar or identical to any of our technology and product candidates for any period of time. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent terms may not protect our competitive position for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its
earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are
obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">48 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are approved for use or commercialized. As a result, our owned
and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours during periods when commercial exclusivity would be valuable to us. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, which if granted
could extend the term of our marketing exclusivity for any product candidates we may develop, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States,
the term of a patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may be eligible for limited patent term extension, or PTE, which permits patent term restoration as compensation for the patent term lost during the FDA
regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a PTE of up to five years beyond the expiration date of the patent. The length of the PTE is related to the
length of time the drug is under regulatory review. A PTE cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. In addition, the patent term of only one patent applicable to an approved drug may
be extended, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other <FONT STYLE="white-space:nowrap">non-United</FONT>
States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for PTEs on patents covering those product candidates, there is no
guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted and, even if granted, the length of such extensions. We may not be granted PTE either in the United States or in any foreign
country, even where that patent is eligible for PTE, if, for example, we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant
patents or otherwise fail to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the regulatory authority could be less than we request. If we obtain such
an extension, it may be for a shorter period than we had sought. If we are unable to obtain any PTE or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our
patent rights, and our business, financial condition, results of operations and prospects could be materially harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, for any future licensed patents,
we may not have the right to control prosecution, including filing with the USPTO or any foreign agency, of a petition for PTE under the Hatch-Waxman Act or analogous foreign provisions. Thus, for example, if one of our licensed patent applications,
if granted, is eligible for PTE under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a PTE is filed, or obtained from the USPTO. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our
products. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Changes in either the patent laws or interpretation of patent laws in the United States or other jurisdictions, including patent reform
legislation such as the U.S. Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications and
the maintenance, enforcement or defense of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These changes include provisions that
switched the United States from a first- <FONT STYLE="white-space:nowrap">to-invent</FONT> system to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-inventor-to-file</FONT></FONT> system, affect the way patent applications
are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents and enable third-party submission of prior art to the USPTO during patent prosecution, and provide additional
procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, under the
Leahy-Smith Act and pursuant to foreign laws outside of the United States, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed
invention. Such laws could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are
particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">49 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has increased uncertainty with respect to the validity and enforceability of
patents once obtained. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or
changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and
unsuccessful. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competitors and other third parties may infringe, misappropriate or otherwise violate patents or other intellectual property that we or our
licensors may own, obtain or acquire. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property claims, which can be expensive and time-consuming. Any claims we assert against others could
provoke them to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The issuance of
a patent is not conclusive as to its inventorship, scope, validity or enforceability. In a patent infringement proceeding, the perceived infringers could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable.
In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are common. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of
novelty, obviousness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or
made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include
<FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, such as opposition proceedings in the European
Patent Office. The outcomes of allegations of invalidity or unenforceability are unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art of which the patent examiner and we or our licensing
partners were unaware during prosecution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An adverse result in any such proceeding could put one or more of our current or future owned or <FONT
STYLE="white-space:nowrap">in-</FONT> licensed patents at risk of being invalidated or interpreted narrowly and could put any of our owned or <FONT STYLE="white-space:nowrap">in-</FONT> licensed patent applications at risk of not yielding an issued
patent. A court may also refuse to stop the third-party from using the technology at issue in a proceeding, for example, on the basis that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents do not cover that technology.
Furthermore, if the breadth or strength of protection provided by our current or future patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or
commercialize current or future products, diagnostic tests, or services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interference or derivation proceedings provoked by third parties or brought by us or
declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it
from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license is offered and our
competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the
uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into
development partnerships that would help us bring our product candidates to market. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, because of the substantial amount of discovery required in
connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during litigation. Any of the foregoing could allow third parties to develop and
commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">50 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third parties may allege that we are infringing, misappropriating or otherwise violating their intellectual property
rights, the outcome of which would be uncertain and could have a material adverse effect on our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends upon our ability
and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of
third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries. We may become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual
property rights with respect to our technology and product candidates, including interference proceedings, post grant review, inter partes review and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions. Numerous
United States and foreign issued patents and pending patent applications, which are owned by third parties, including our competitors, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical
industries expand and more patents are issued, the risk increases that our technologies or product candidates may be subject to claims that they infringe the patent rights of third parties. Our competitors and others may have significantly larger
and more mature patent portfolios than we have. In addition, future litigation may be initiated by patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide
little or no deterrence or protection. Competitors may also assert that our product candidates infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated
and require significant resources and management attention to defend. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain greater visibility as a public
company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. Because patent applications can take many years to issue, pending patent applications may
result in issued patents that our product candidates infringe. For example, there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the discovery, use
or manufacture of our product candidates or technologies. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates, or we may incorrectly conclude that third-party intellectual
property is invalid or that our activities and product candidates do not infringe the intellectual property rights of third parties. Thus, we do not know with certainty that our technology and product candidates, or our development and
commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third-party&#146;s intellectual property rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A court could
hold that third-party patents are valid, enforceable and infringed. In order to successfully challenge the validity of any such United States patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one
that requires us to present clear and convincing evidence as to the invalidity of the claims of any such United States patent, there is no assurance that a court would invalidate the claims of any such United States patent. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Parties making claims against us may obtain injunctive or other equitable relief. For example, if any third-party patents were held to cover the manufacturing process
of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidates. In the event of a successful
claim of infringement against us, we may also have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, indemnify customers, collaborators or other third parties, seek new regulatory approvals, and
redesign our infringing products, which may not be possible or practical. If we are found to infringe, misappropriate or otherwise violate a third-party&#146;s intellectual property rights, we may be required to obtain a license from such
third-party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license,
it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. Claims
that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">51 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to
spend substantial resources and distract our personnel from their normal responsibilities. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if resolved in our favor, litigation or other legal
proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities, which would impair our ability to pursue our business. In
addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect
on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not
have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our adversaries may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater
financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other
proceedings could compromise our ability to compete in the marketplace. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining patent protection depends on compliance with various
procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the
USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications. The USPTO and various foreign governmental patent agencies
require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application and prosecution process. In certain circumstances, we may rely on our licensing partners to pay these fees to, or
comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on an annuity service, outside firms, and outside counsel to remind us of the due dates and to make payment after we instruct them
to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application
include failure to respond to office actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be
able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the current and future patents and patent applications covering our product candidates, our competitors might be able to enter the
market with similar or identical products or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to obtain licenses from third parties on commercially reasonable terms, our business could be harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to our existing licensing agreements, it may be necessary for us to use the patented or proprietary technology of third parties to commercialize our
products, if approved, in which case we would be required to obtain a license from these third parties. The <FONT STYLE="white-space:nowrap">in-licensing</FONT> and acquisition of third-party intellectual property rights is a competitive area, and a
number of more established companies are also pursuing strategies to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may
have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to
us. In addition, we expect that competition for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquisition of third-party intellectual property rights for product candidates that are attractive to us may increase in the future, which
may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, such as substantial licensing or royalty
payments, our business could be materially harmed. If we are unable to obtain a necessary license, the third parties owning such intellectual property rights could seek an injunction prohibiting our sales or we may be unable to otherwise develop or
commercialize the affected product candidates, which could materially harm our business. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same
technologies licensed to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">52 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing
intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may
not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations,
and prospects significantly. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with our obligations in our intellectual property licenses with third parties, or otherwise experience
disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are party
to license agreements that impose, and we may enter into additional licensing and funding arrangements with third parties that may impose, among other things, diligence, development, and commercialization timelines, milestone payment, royalty,
insurance and other obligations on us. Under our existing licensing agreements, including our license agreement with Affibody, we are obligated to pay milestones and royalties on net product sales of product candidates or related technologies to the
extent they are covered by the agreements. If we fail to comply with such obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to
develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements, or our counterparties may require us to grant them
certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or
restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us
to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects, or impede, delay
or prohibit the further development or commercialization of, one or more product candidates that rely on such agreements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Disputes may arise regarding intellectual
property that is or becomes subject to a licensing agreement, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of rights granted under the license agreement and other matters of contract interpretation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether and the extent to which our technology and processes infringe the intellectual property rights of the licensor
that are not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether our licensor or its licensor had the right to grant the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the
intellectual property rights without their authorization; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our involvement in the prosecution of licensed patents and our licensors&#146; overall patent enforcement strategy;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the amounts of royalties, milestones or other payments due under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the sublicensing of patent and other rights under collaborative development relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such
agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or
increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes
over intellectual property that we have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">53 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected
technology and product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite
our efforts, our licensors or future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates
and technology covered by these license agreements. If these <FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors could seek regulatory
approval for and market products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property and proprietary rights throughout the world. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third parties may attempt to develop and commercialize competitive products in foreign countries where we do not have any patent protection and/or where legal recourse
may be limited. This may have a significant commercial impact on our foreign business operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Filing, prosecuting, and defending patents on product candidates
in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where
such protection is nominally available, adequate judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries
outside the United States, or from selling our inventions in such countries or importing products made using our inventions into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not
obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products
may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of
patents, trade secrets and other intellectual property protection, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing
products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect, to the same extent as the United States or at all, inventions that constitute new methods of treatment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention
from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail
in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to
obtain a significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many countries, including India, China and certain countries
in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these
countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our
competitive position may be impaired and our business, financial condition, results of operations, and prospects may be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">54 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual
property. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property as an inventor, <FONT STYLE="white-space:nowrap">co-inventor,</FONT> owner or <FONT STYLE="white-space:nowrap">co-owner.</FONT> For example, we or
our licensors or collaborators may have inventorship or ownership disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against
these and other claims challenging inventorship or our or our licensors&#146; or collaborators&#146; ownership of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property. If we or our
licensors or collaborators fail in defending any such claims, we may be required to pay monetary damages and we may also lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is
important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse
effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims by third parties asserting that our employees,
consultants or contractors have wrongfully used or disclosed confidential information of such third parties, or that they have wrongfully used or disclosed alleged trade secrets of their current or former employers, or that we have misappropriated
their intellectual property, or that they own what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our employees, consultants and contractors were
previously employed at or engaged by universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Many of them executed proprietary rights,
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and/or <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment or engagement. Although we try to ensure that the individuals who work for
us do not use the intellectual property rights, proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, we may be subject to claims that we or they have, inadvertently or otherwise,
used, infringed, misappropriated or otherwise violated the intellectual property rights, or disclosed the alleged trade secrets or other proprietary information, of these former employers, competitors or other third parties. We may also be subject
to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. Any litigation or the threat of litigation may adversely affect our ability to hire employees or engage consultants
and contractors. A loss of key personnel or their work product could hamper or prevent us from developing and commercializing products and product candidates, which could harm our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute
agreements assigning such intellectual property to us, we may be unsuccessful in obtaining such an agreement from each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with
them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could
have a material adverse effect on our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail in prosecuting or defending any such claims,
we may be required to pay monetary damages, and we may also lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive position and prospects. Such intellectual property rights could be
awarded to a third-party, and we could be required to obtain a license from such third-party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be <FONT
STYLE="white-space:nowrap">non-exclusive.</FONT> Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented
<FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">55 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
manufacturers, consultants, advisors and other third parties. We also enter into confidentiality agreements with our employees and consultants. We cannot guarantee that we have entered into such
agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets,
and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and
time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently
developed by a competitor or other third-party, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, we expect that, over time, our trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary information may be disseminated within the
industry through independent development, the publication of journal articles and the movement of personnel to and from academic and industry scientific positions. Consequently, without costly efforts to protect our proprietary technology, we may be
unable to prevent others from exploiting that technology, which could affect our ability to expand in domestic and international markets. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other
third-party, our competitive position would be materially and adversely harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also seek to preserve the integrity and confidentiality of our data and trade
secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. These security measures may be breached, and we may not have adequate remedies for any breach. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be
adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest
and our business may be adversely affected. Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and
trade names or may be forced to stop using these trademarks or trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trademarks or trade names
similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark or trade name infringement claims brought by owners of other registered trademarks or
trade names that incorporate variations of our trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, we may not
be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks and trade names may be ineffective and could result in substantial costs and diversion of
resources and could adversely impact our financial condition or results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily address all potential
threats. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain a competitive advantage. For example: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we or our license partners or current or future collaborators might not have been the first to file patent applications
covering our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> pending patent applications or those
we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future will not lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by
our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our competitors or other third parties might conduct research and development activities in countries where we do not have
patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">56 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we cannot ensure that any of our pending patent applications, if issued, or those of our licensors, will include claims
having a scope sufficient to protect our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our
commercially viable product candidates or will provide us with any competitive advantages; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if
approved, before the relevant patents that we own or license expire; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may choose not to seek patent protection in order to maintain certain trade secrets or know- how, and a third-party may
subsequently file a patent covering such intellectual property. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Should any of these events occur, they could have a material adverse effect on
our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Employees, Managing Our Growth and Our Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are highly dependent on the expertise of the principal members of our management, scientific, and clinical teams. Our scientific and clinical development personnel
have extensive experience developing and implementing novel clinical trial designs and successfully conducting clinical trials in never-before treated patient populations. If we lose one or more of our executive officers or key employees, our
ability to execute our programs and implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited
number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given
the competition among numerous biotechnology and pharmaceutical companies for similar personnel. We may also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our employees were previously employed by Alexion, a potential competitor. To the extent we employ or engage personnel from competitors, we may be subject to
allegations that such individuals have been improperly solicited or have divulged proprietary or other confidential information, or that their former employers own their research output. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and
commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to
continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect to expand our development,
regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, regulatory
affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or lease or acquire new facilities, and continue to recruit
and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">57 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business and operations would suffer in the event of system failures. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite the implementation of security measures, our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from
computer viruses, unauthorized access, natural and manmade disasters (including hurricanes), terrorism, war, and telecommunication and electrical failures. While we do not believe that we have experienced any such system failure or accident to date,
if such an event were to occur and cause interruptions in our or their operations, it could result in delays and/or material disruptions of our research and development programs. For example, the loss of preclinical or clinical trial data from
completed, ongoing, or planned trials, or the loss of other proprietary data, could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we currently rely on third
parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption were to result
in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability, and the development of our product candidates could be delayed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our proprietary or confidential information may be lost, or we may suffer security breaches. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of
personally identifiable information and other data relating to individuals. In the ordinary course of our business, we and third parties with which we have relationships will continue to collect and store sensitive data, including clinical trial
data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in data centers and on networks. The secure processing, maintenance and transmission of this information is
critical to our operations. Despite our and our collaborators&#146; security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, breaches due to employee error, technical
vulnerabilities, malfeasance, or other disruptions. Several proposed and enacted federal, state and international laws and regulations obligate companies to notify individuals of security breaches involving personally identifiable information, which
could result from breaches experienced by us or by third parties, including collaborators, vendors, contractors, or other organizations with which we have formed strategic relationships. Although, to our knowledge, neither we nor any such third
parties have experienced any material security breach, and even though we may have contractual protections with such third parties, any such breach could compromise our or their networks and the information stored therein could be accessed, publicly
disclosed, lost or stolen. Any such access, disclosure, notifications, <FONT STYLE="white-space:nowrap">follow-up</FONT> actions related to such a security breach or other loss of information could result in legal claims or proceedings, liability
under laws that protect the privacy of personal information, and significant costs, including regulatory penalties, fines, and legal expenses, and such an event could disrupt our operations, cause us to incur remediation costs, damage our
reputation, and cause a loss of confidence in us and our or such third parties&#146; ability to conduct clinical trials, which could adversely affect our reputation and delay the clinical development of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to this Offering and Our Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We do not know
whether a market will develop for our common stock or what the market price of our common stock will be, and, as a result, it may be difficult for you to sell your shares of our common stock. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before this offering, there was no public trading market for our common stock. If a market for our common stock does not develop or is not sustained, it may be
difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations may be below the
expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The market price
of our common stock may be volatile, which could result in substantial losses for investors purchasing shares in this offering. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The initial public offering
price for our common stock was determined through negotiations with the underwriters. This initial public offering price may vary from the market price of our common stock after the offering. As a result, you may not be able to sell your common
stock at or above the initial public offering price. Some of the factors that may cause the market price of our common stock to fluctuate include: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">58 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success of existing or new competitive product candidates or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and results of preclinical studies for any product candidates that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure or discontinuation of any of our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success of the development of companion diagnostics, if required, for use with our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or
announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">commencement or termination of collaborations for our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments or disputes concerning patent applications, issued patents, or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the level of expenses related to any of our research programs or product candidates that we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the results of our efforts to develop additional product candidates or products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sales of our common stock by us, our insiders or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">effects of public health crises, pandemics and epidemics, such as <FONT STYLE="white-space:nowrap">COVID-19;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">variations in our financial results or those of companies that are perceived to be similar to us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">general economic, industry, and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the other factors described in this &#147;Risk Factors&#148; section and elsewhere in this prospectus.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced
extreme price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may
seriously affect the market price of our common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. The market price of our common
stock may decline below the initial public offering price, and you may lose some or all of your investment. Following periods of such volatility in the market price of a company&#146;s securities, securities class action litigation has often been
brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>You
will incur immediate and substantial dilution as a result of this offering. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase common stock in this offering, you will incur immediate and
substantial dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing the difference between the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, and our pro forma net tangible book value per share after
giving effect to this offering. To the extent that shares are issued upon the exercise of options or the underwriters exercise their option to purchase additional shares, you will incur further dilution. For a further description of the dilution you
will experience immediately after this offering, see &#147;Dilution.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If securities analysts do not publish research or reports about our business or if
they publish negative evaluations of our stock, the price of our stock could decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for our common stock will rely in part on the
research and reports that industry or financial analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading
price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts
cease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">59 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A significant portion of our total outstanding shares is restricted from immediate resale but may be sold into the market in the near future, which could cause
the market price of our common stock to decline significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of a substantial number of shares of our common
stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. After this
offering, we will have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding,
or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to purchase additional shares in full, in each case based on
the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding as of March&nbsp;31, 2021. Of these shares,
the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their
option to purchase additional shares in full) we are selling in this offering may be resold in the public market immediately, unless purchased by our affiliates. The
remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares are currently restricted under securities laws or as a result of <FONT STYLE="white-space:nowrap">lock-up</FONT> or other agreements, but
will be able to be sold after this offering as described in the &#147;Shares Eligible for Future Sale&#148; section of this prospectus. Moreover, after this offering, holders of an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will have rights, subject to conditions, to require us to file registration statements covering their shares or to include
their shares in registration statements that we may file for ourselves or other stockholders. We also plan to register all shares of common stock that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding
options. Once we register these shares, they can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described
in the &#147;Underwriting&#148; section of this prospectus. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Insiders will continue to have substantial influence over us after this offering, which could limit your ability to affect the outcome of key transactions,
including a change of control. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After this offering, our directors and executive officers and their affiliates will beneficially own shares representing
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and
affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. The interests of these holders may not always coincide with our corporate interests or the interests of
other stockholders, and they may act in a manner with which you may not agree or that may not be in the best interests of our other stockholders. This concentration of ownership may have the effect of delaying or preventing a change in control of
our company and might affect the market price of our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is
especially relevant for us because biotechnology and pharmaceutical companies have experienced significant share price volatility in recent years. Because of the potential volatility of our stock price, we may become the target of securities
litigation in the future. Securities litigation could result in substantial costs and divert management&#146;s attention and resources from our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of
gain. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the
development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, of our common stock will be your sole source of gain on an
investment in our common stock in the foreseeable future. See &#147;Dividend Policy&#148; for additional information. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an &#147;emerging growth
company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may remain an emerging growth company until December&nbsp;31, 2026. For so long as we remain an emerging growth
company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">60 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or SOX Section&nbsp;404, not being required to comply with any
requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements,
reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
As a result, the information we provide stockholders will be different than the information that is available with respect to other public companies. In this prospectus, we have not included all of the executive compensation related information that
would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there
may be a less active trading market for our common stock, and our stock price may be more volatile. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the JOBS Act provides that an emerging growth
company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise
apply to private companies. We have elected not to &#147;opt out&#148; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt
the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period, or (ii)&nbsp;no longer
qualify as an emerging growth company. Therefore, the reported results of operations contained in our financial statements may not be directly comparable to those of other public companies. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Provisions in our amended and restated certificate of incorporation, our amended and restated bylaws and Delaware law may have anti-takeover effects that could
discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective prior to the closing of this offering, and Delaware
law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you might otherwise receive a
premium for your shares. Our amended and restated certificate of incorporation and bylaws, which will become effective prior to the closing of this offering, include provisions that: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">authorize &#147;blank check&#148; preferred stock, which could be issued by our board of directors without stockholder
approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">create a classified board of directors whose members serve staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">specify that special meetings of our stockholders can be called only by our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">prohibit stockholder action by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our
stockholders, including proposed nominations of persons for election to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though
less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that our directors may be removed only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">specify that no stockholder is permitted to cumulate votes at any election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expressly authorize our board of directors to modify, alter or repeal our amended and restated bylaws; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated
certificate of incorporation and amended and restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These provisions, alone or together, could delay or prevent hostile takeovers and
changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">61 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section&nbsp;203
of the General Corporation Law of the State of Delaware, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction
in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any provision
of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their
shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our amended and restated certificate
of incorporation will designate the state or federal courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability
to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation,
which will become effective prior to the closing of this offering, will provide that, subject to limited exceptions, the state or federal courts (as appropriate) within the State of Delaware will be exclusive forums for (1)&nbsp;any derivative
action or proceeding brought on our behalf, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)&nbsp;any action asserting a claim against us
arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, (4)&nbsp;action against us or any of our directors or officers involving a claim or defense arising pursuant to
the Exchange Act or the Securities Act, or (5)&nbsp;any other action asserting a claim against us that is governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock
shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This exclusive forum provision will not apply to claims which are vested in the exclusive
jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions
arising under federal securities laws, including suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder. This choice of forum provision may limit a stockholder&#146;s ability to bring a
claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find
these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such
matters in other jurisdictions, which could adversely affect our business and financial condition. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the
Securities Act be brought in federal court are &#147;facially valid&#148; under Delaware law, there is uncertainty as to whether other courts will enforce our federal forum provision. If the federal forum provision is found to be unenforceable, we
may incur additional costs associated with resolving such matters. The federal forum provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot specify with certainty the particular uses of the net proceeds we will receive from this offering. Our management will have broad discretion in the
application of the net proceeds, including for any of the purposes described in &#147;Use of Proceeds.&#148; Accordingly, you will have to rely upon the judgment of our management with respect to the use of the proceeds, with only limited
information concerning management&#146;s specific intentions. Our management may spend a portion or all of the net proceeds from this offering in ways that our stockholders may not desire or that may not yield a favorable return. The failure by our
management to apply these funds effectively could harm our business, financial condition, results of operations and prospects. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that
loses value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">62 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General Risks </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A variety
of risks associated with operating internationally could materially adversely affect our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business strategy includes potentially expanding
internationally. Doing business internationally involves several risks, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">multiple, conflicting, and changing laws and regulations, such as privacy regulations, tax laws, export and import
restrictions, economic sanctions laws and regulations, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additional potentially relevant third-party patent rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">complexities and difficulties in obtaining protection and enforcing our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulties in staffing and managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient <FONT
STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limits in our ability to penetrate international markets; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and
regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of
disease, boycotts, curtailment of trade, and other business restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">certain expenses, including, among others, expenses for travel, translation, and insurance; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that
may fall within the purview of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, its books and records provisions, or its anti-bribery provisions, as well as other applicable laws and regulations prohibiting bribery and
corruption. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of
operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. federal income tax reform could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The rules dealing with U.S. federal, state, and local income taxation are constantly under review through the legislative process and by the Internal Revenue Service
and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to
occur in the future. For example, the Tax Cuts and Jobs Act, or the TCJA, was enacted in 2017 and significantly reformed the Code. The TCJA, among other things, contains significant changes to corporate and individual taxation, some of which could
adversely impact an investment in our common stock. Additionally, on March&nbsp;27, 2020, President Trump signed into law the CARES Act, which included certain changes in tax law intended to stimulate the U.S. economy in light of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including temporary beneficial changes to the treatment of NOLs, interest deductibility limitations and payroll tax matters. There also may be technical corrections legislation or other
legislative changes proposed with respect to the TCJA and CARES Act, the effects of which cannot be predicted and may be adverse to us or our stockholders. Future changes in tax laws could have a material adverse effect on our business, cash flows,
financial condition or results of operations. In particular, the recent presidential and congressional elections in the United States could result in significant changes in, and uncertainty with respect to, tax legislation, regulation and government
policy directly affecting our business or indirectly affecting us because of impacts on our customers and suppliers. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an
investment in our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential clinical trial or product liability lawsuits against us could cause us to incur substantial liabilities and limit
commercialization of any products that we may develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The use of any product candidates we may develop in clinical trials and the sale of any products for
which we obtain marketing approval exposes us to the risk of clinical trial and product liability claims. Clinical trial or product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others
selling or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">63 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot
successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, clinical trial or product liability claims may result in: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">impairment of our business reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">withdrawal of participants from our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">significant costs to defend the litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">distraction of management&#146;s attention from our primary business; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">substantial monetary awards to patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inability to commercialize a product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">decreased market demand for any product; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">loss of revenue. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The clinical trial and product liability insurance we currently carry, and any additional clinical trial and product liability insurance coverage we acquire in the
future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in
sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any product candidate, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain
product liability insurance on commercially reasonable terms or in adequate amounts. A successful clinical trial or product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our
insurance coverage, could adversely affect our results of operation and business, including preventing or limiting the commercialization of any product candidates we develop. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic
downturn, or additional global financial crises, could result in a variety of risks to our business, including weakened demand for our product candidates, if approved, or our ability to raise additional capital when needed on acceptable terms, if at
all. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. Similarly, the significant volatility associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has caused
significant instability and disruptions in the capital and credit markets. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate
all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will incur increased costs as a
result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a public company, and particularly after we are no longer an &#147;emerging growth company,&#148; we will incur significant legal, accounting, and other expenses
that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Market, and other applicable securities rules and regulations
impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance, and other
personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these
requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us as a public company may make
it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We are currently evaluating these rules and
regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">64 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing
bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or SOX Section&nbsp;404, we will be required to furnish a report by our management on our internal
control over financial reporting beginning with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC after we become a public company. However, while we remain an emerging growth company, we will
not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&nbsp;404 within the prescribed period, we will be
engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt
a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a
continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over
financial reporting is effective as required by SOX Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial
statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">65 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_3"></A>SPECIAL NOTE REGARDING <FONT STYLE="white-space:nowrap">FORWARD-LOOKING</FONT>
STATEMENTS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements that are based on management&#146;s beliefs and
assumptions and on information currently available to management. All statements other than statements of historical facts contained in this prospectus are <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements. In some cases, you can
identify <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148;
&#147;target,&#148; &#147;project,&#148; &#147;contemplate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions, although not
all <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements contain these words. <FONT STYLE="white-space:nowrap">Forward-looking</FONT> statements include, but are not limited to, statements concerning: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of our planned IND and CTA submissions for RLYB212 and RLYB116, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, timing, progress, results, and cost of our research and development programs, and our current and future
preclinical and clinical studies, including statements regarding the timing of initiation and completion of our clinical trials for RLYB211, RLYB212, and RLYB116, and the natural history study for our FNAIT prevention program, and related
preparatory work, and the period during which the results of the trials will become available; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success, cost and timing of our clinical development of our product candidates, including RLYB212, RLYB116 and
RLYB114; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of our planned nomination of a compound for our ENPP1 program under our joint venture with Exscientia;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to initiate, recruit and enroll patients in and conduct our clinical trials at the pace that we project;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions,
limitations or warnings in the label of any of our product candidates, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to compete with companies currently marketing or engaged in the development of treatments for diseases that
our product candidates are designed to target, including PNH and gMG; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our reliance on third parties to conduct our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our reliance on third parties to manufacture drug substance for use in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the size and growth potential of the markets for RLYB212, RLYB116, RLYB114 and any of our current product candidates or
other product candidates we may identify and pursue, and our ability to serve those markets; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to expand our pipeline through collaborations, partnerships and other transactions with third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to identify and advance through clinical development any additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the commercialization of our current product candidates and any other product candidates we may identify and pursue, if
approved, including our ability to successfully build commercial infrastructure or enter into collaborations with third parties to market our current product candidates and any other product candidates we may identify and pursue;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to retain and recruit key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain adequate intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations regarding government and third-party payor coverage and reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our estimates of our expenses, ongoing losses, capital requirements and our needs for or ability to obtain additional
financing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expected uses of the net proceeds to us from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or
arrangements, including potential business development opportunities and potential licensing partnerships, and our ability to attract collaborators with development, regulatory and commercialization expertise; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">66 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our financial performance; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments and projections relating to our competitors or our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">other risks and uncertainties, including those listed under the section titled &#147;Risk Factors.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements in this prospectus are only predictions and are based largely on our
current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements speak only
as of the date of this prospectus and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this prospectus entitled &#147;Risk Factors&#148; and &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this prospectus. Because <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements are inherently subject to risks and uncertainties, some of
which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements as guarantees of future events. The events and circumstances reflected
in our <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the <FONT
STYLE="white-space:nowrap">forward-looking</FONT> statements. Moreover, we operate in an evolving environment. New risks and uncertainties may emerge from time to time, and it is not possible for management to predict all risks and uncertainties.
Except as required by applicable law, we are not obligated to publicly update or revise any <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements contained herein, whether as a result of any new information, future events, changed
circumstances or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">67 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that the net proceeds to us from the sale of the shares of our common stock in this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters
exercise their option to purchase additional shares in full, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price
range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) the net proceeds to us from this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase
(decrease) the net proceeds to us from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public offering price per
share, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;31, 2021, we had
cash and cash equivalents of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. The principal purposes of this offering are to increase our financial flexibility, create a public market for our
common stock and to facilitate our access to the public equity markets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to use the net proceeds from this offering, together with our cash on hand, as
follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to
advance our FNAIT prevention program, including completion of our Phase 1/2 clinical trial for RLYB211 and completion of our Phase 1 and Phase&nbsp;1b clinical trials for RLYB212; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to
advance our complement program, including completion of our Phase&nbsp;1a clinical trial and initiation of our Phase 1b clinical trial for RLYB116 and initiation of our Phase 1 clinical trial for RLYB114; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to
advance our joint ventures with Exscientia, including the initiation of our Phase&nbsp;1 clinical trial for our ENPP1 inhibitor; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any remaining proceeds for business development activities and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also use a portion of the net proceeds from this offering to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or invest in products, technologies or
businesses. The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our preclinical development efforts, our operating costs and other factors described under &#147;Risk Factors&#148; in this
prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition. As of the
date of this prospectus, we cannot predict with complete certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the actual amounts that we will spend on the uses set forth above. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based upon our current operating plan, we believe that the anticipated net proceeds from this offering, together with our existing cash and cash equivalents, will be
sufficient to fund our operating expenses and capital expenditure requirements for more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; from the date of this prospectus. This estimate and our
expectation regarding the sufficiency of the net proceeds from this offering to advance the preclinical and clinical development of RLYB212, RLYB116 and any other product candidates are based on assumptions that may prove to be wrong, and we could
exhaust our available capital resources sooner than we expect. We do not anticipate that the expected net proceeds from this offering, together with our existing cash, will be sufficient for us to fund any of our product candidates through
regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates, if approved. We may satisfy our future cash needs through the sale of equity securities, debt
financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">68 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the
application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from this offering in <FONT STYLE="white-space:nowrap">short-term,</FONT> <FONT STYLE="white-space:nowrap">interest-bearing</FONT> obligations, <FONT
STYLE="white-space:nowrap">investment-grade</FONT> instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">69 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never made any cash distributions to our members. Subsequent to our Reorganization, we do not anticipate paying any dividends on our capital stock. We intend
to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the
discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors our board of directors deems relevant, and subject to the restrictions contained in any
future financing instruments. Our ability to pay cash dividends on our capital stock in the future may also be limited by the terms of any preferred securities we may issue or agreements governing any indebtedness we may incur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">70 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_6"></A>THE REORGANIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>LLC Entity (Rallybio Holdings, LLC) </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Currently, the capital structure of
Rallybio Holdings, LLC, or the LLC Entity, consists of four classes of membership units: common units; Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred units; Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred units; and Series
B preferred units. The LLC Entity is the direct parent company of five subsidiaries: Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC, IPC Research, LLC and Rallybio IPD, LLC. Except for Rallybio IPD, LLC, which will become the parent of the
other subsidiaries as a result of the Reorganization, the subsidiaries of the LLC Entity focus on developing, identifying, acquiring, and, if approved, commercializing our product candidates, as well as developing and holding intellectual property.
Rallybio IPB, LLC jointly owns the joint venture entities with Exscientia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Reorganization </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the completion of this offering, we intend to complete a series of transactions pursuant to which (i)&nbsp;Rallybio IPD, LLC will be converted from a Delaware
limited liability company to a Delaware corporation and change its name to Rallybio Corporation, or the Corporation, (ii)&nbsp;the Corporation will form four direct subsidiaries, each a Delaware limited liability company, or collectively the Merger
Subs, (iii)&nbsp;each of the Merger Subs will consummate a separate merger with one of the LLC Entity&#146;s direct subsidiaries, other than Rallybio IPD, LLC, or collectively the Asset Subsidiaries, with the Asset Subsidiaries surviving the mergers
and the LLC Entity receiving common stock of the Corporation in exchange for its interest in each Asset Subsidiary, which will result in the Asset Subsidiaries becoming subsidiaries of the Corporation and the Corporation becoming the only direct
subsidiary of the LLC Entity, and (iv)&nbsp;following this series of mergers, the LLC Entity will liquidate and distribute 100% of the capital stock of the Corporation, consisting solely of common stock, to the unitholders of the LLC Entity. As a
result of the Reorganization, the unitholders of the LLC Entity will become the holders of common stock of the Corporation, and the Corporation will become the registrant for purposes of this offering, and our consolidated financial statements will
be reported from the Corporation. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the Reorganization, the unitholders of the LLC Entity will receive 100% of the common stock of the
Corporation outstanding as of immediately prior to the completion of the offering. The common stock of the Corporation will be allocated to the holders of existing units in the LLC Entity as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred units and Series
<FONT STYLE="white-space:nowrap">A-2</FONT> preferred units of the LLC Entity will receive an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock of the Corporation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">holders of Series B preferred units of the LLC Entity will receive an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock of the Corporation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">holders of common units of the LLC Entity will receive an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock of the Corporation
(including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of restricted common stock, which will continue to be subject to vesting in accordance with the vesting schedule applicable to such
restricted common units); and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">holders of incentive units in the LLC Entity will receive a number of shares of common stock of the Corporation in respect
of each incentive unit based upon a conversion price to be determined by our board of directors immediately prior to the Reorganization. Shares of common stock issued in respect of unvested incentive units will be shares of restricted common stock
and will continue to be subject to vesting in accordance with the vesting schedule applicable to such incentive units. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of
common stock that holders of incentive units will receive in the Reorganization will be based on the fair value per common unit, as determined by our board of managers, immediately prior to the Reorganization. In this prospectus, we have assumed a
fair value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common unit, which is the midpoint of the price range per share set forth on the cover page of this prospectus. Based on an assumed fair value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common unit, the incentive units will convert into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
our common stock. At a fair value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common unit, which is the high end of the price range per share set forth on the cover page of this prospectus, the incentive units
would convert into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. At a fair value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common unit, which is the low end of the price range set forth on the cover page of this prospectus, the incentive units would convert into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">71 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the Reorganization, based on an assumed fair value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per common unit, which is the midpoint of the price range per share set forth on the cover page of this prospectus, the holders of existing units in the LLC Entity will
collectively own an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock of the Corporation as of immediately prior to the consummation of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Holding Company Structure </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the consummation of the
Reorganization, the Corporation will be a holding company and the direct parent of: Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC and IPC Research, LLC. Except as disclosed in this prospectus, the audited consolidated financial statements for
the years ended December&nbsp;31, 2020 and 2019 and the notes thereto, the unaudited condensed consolidated financial statements for the three months ended March 31, 2021 and 2020 and the notes thereto, and selected historical consolidated financial
data and other financial information included in this prospectus are those of the LLC Entity and do not give effect to the Reorganization. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On the effective
date of the Reorganization, the members of the board of managers of the LLC Entity will become the members of the Corporation&#146;s board of directors and the officers of the LLC Entity will become the officers of the Corporation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The purpose of the Reorganization is to reorganize our corporate structure so that the entity that is offering common stock to the public in this offering is a
corporation rather than a limited liability company, and so that our existing investors will own our common stock rather than units in a limited liability company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">72 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our cash and capitalization as of March&nbsp;31, 2021: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on a pro forma basis, to give effect to (i)&nbsp;the Reorganization, including the issuance by Rallybio Corporation of an
aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of its common stock and the subsequent distribution of those shares to members of Rallybio Holdings, LLC, prior to the completion of
this offering, as if the Reorganization had occurred as of March&nbsp;31, 2021, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range
set forth on the cover page of this prospectus and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation and amended and restated bylaws; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on a pro forma as adjusted basis, to give further effect to our issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and
estimated offering expenses. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pro forma as adjusted information below is illustrative only and our capitalization following the closing of
this offering will change based on the initial public offering price and other terms of this offering determined at pricing. You should read the information in this table together with the financial statements and related notes as appearing at the
end of this prospectus and the information set forth under the sections titled &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO<BR>FORMA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS<BR>ADJUSTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred units:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Members&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred units , no par value;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued or outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common units, no par value; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;units authorized, issued and
outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;units authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total members&#146; (deficit), actual; total unitholders&#146; equity, pro forma and pro forma as
adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is
the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) each of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; deficit and
total capitalization on a pro forma as adjusted basis by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this
prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of
this prospectus, would increase (decrease) each of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; deficit and total capitalization on a pro forma as adjusted basis by
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">73 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The outstanding share information in the table above as of March&nbsp;31, 2021 excludes: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">shares of our common stock reserved for issuance under the Rallybio Corporation 2021 Equity Incentive Plan, or the 2021
Plan, which will become effective in connection with this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">shares of common stock reserved for issuance under the Rallybio Corporation 2021 Employee Stock Purchase Plan, or the
ESPP, which will become effective in connection with this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">74 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_8"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the initial public
offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
historical net tangible book value (deficit) and historical net tangible book value (deficit) per share have not been presented as there were no common shares outstanding as of March&nbsp;31, 2021. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pro forma net tangible book value as of March&nbsp;31, 2021 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. Pro forma net tangible book value represents the amount of our total tangible assets less our liabilities, after giving effect to (i)&nbsp;the
Reorganization, including the issuance by Rallybio Corporation of an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of its common stock and the subsequent distribution of those
shares to members of Rallybio Holdings, LLC, prior to the completion of this offering, as if the Reorganization had occurred as of March&nbsp;31, 2021, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus and (ii)&nbsp;the filing and effectiveness of our amended and restated
certificate of incorporation and amended and restated bylaws . Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total number of shares outstanding as of March&nbsp;31, 2021 after giving effect
to the pro forma adjustments described above. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving further effect to our issuance and sale of shares of common stock in this offering at an assumed initial
public offering price $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of March&nbsp;31, 2021 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This represents an immediate increase in pro forma as adjusted net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to existing stockholders and an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in pro forma as adjusted net tangible
book value per share to new investors participating in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the assumed initial public
offering price per share paid by new investors. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net tangible book value per share of common stock as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in net tangible book value per share of common stock attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share of common stock after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution per share of common stock to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The dilution information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering
determined at pricing. A $1.00 increase (decrease) in the assumed initial price to the public of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page
of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and increase (decrease) the dilution per share to investors participating in this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. An increase of 1,000,000 in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase the pro forma as adjusted net tangible book
value by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and the dilution per share to new investors
participating in this offering would be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that the assumed initial price to the public remains the same, and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. A decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease the pro forma as adjusted
net tangible book value by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and the dilution per
share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">75 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
to investors participating in this offering would be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that the assumed initial price to
the public remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the
underwriters exercise in full their option to purchase additional shares of common stock from us in this offering, our pro forma as adjusted net tangible book value per share after the offering would be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, representing an immediate increase in pro forma as adjusted net tangible book value per share of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to new investors purchasing common stock in this offering, assuming an initial public offering price of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes, as of March&nbsp;31, 2021, on the pro forma as adjusted basis described above, the total
number of shares of common stock purchased from us, the total consideration and the average price per share (1)&nbsp;paid by existing stockholders and (2)&nbsp;to be paid by new investors participating in this offering at the assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. As the table shows, new investors purchasing common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;PURCHASED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL&nbsp;CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AVERAGE<BR>PRICE&nbsp;PER<BR>SHARE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this offering. If the underwriters&#146; option to purchase
additional shares is exercised in full, the number of shares of common stock held by existing stockholders would be reduced to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of common stock to be outstanding upon
completion of this offering, and the number of shares of common stock held by new investors participating in this offering will be increased to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock to be
outstanding upon completion of the offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new investors by
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. We may also increase or decrease
the number of shares we are offering. An increase (decrease) of 1,000,000 in the number of shares offered by us would increase (decrease) total consideration paid by new investors by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public offering price. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The share
information presented in the tables and discussions above as of March&nbsp;31, 2021 excludes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">shares of our common stock reserved for issuance under the 2021 Plan, which will become effective in connection with this
offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">shares of common stock reserved for issuance under the ESPP, which will become effective in connection with this offering.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">New investors will experience further dilution when any new options are issued and exercised under our equity incentive plans or we issue
additional shares of common stock, other equity securities or convertible debt securities for lower consideration per share than in this offering in the future. In addition, we may choose to raise additional
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">76 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
capital through the sale of equity or convertible debt securities due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future
operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">77 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_9"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should read the following selected financial data together with the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations&#148; of this prospectus and our financial statements and the related notes included elsewhere in this prospectus. The statements of operations and comprehensive loss data for the years ended December&nbsp;31, 2020 and 2019 and
the balance sheet data as of December&nbsp;31, 2020 and 2019 have been derived from our audited financial statements included elsewhere in this prospectus. The statements of operations and comprehensive loss data for the three months ended
March&nbsp;31, 2021 and 2020 and our balance sheet as of March&nbsp;31, 2021 have been derived from our unaudited financial statements included elsewhere in this prospectus. In the opinion of management, the unaudited financial data reflect all
adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of such financial information in those statements. Our historical results are not necessarily indicative of the results that may be expected in the future.
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED&nbsp;MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statement of Operations and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing right
obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common unit, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">
(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average common units outstanding&#151;basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,659,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,715,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,228,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,968,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted average common stock outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 11 to our audited consolidated financial statements and Note 8 to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for details on the calculation of basic and
diluted net loss per common unit attributable to common stockholders. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">78 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets, less current liabilities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">79 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the &#147;Selected
Financial Data&#148; section of this prospectus and our financial statements and related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus,
including information with respect to our plans and strategy for our business and related financing, includes <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements that involve risks and uncertainties. As a result of many factors,
including those factors set forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by the <FONT STYLE="white-space:nowrap">forward-looking</FONT>
statements contained in the following discussion and analysis. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering,
developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Our mission at Rallybio is aligned with our expertise, and we believe we have assembled the best people,
partners and science to forge new paths to life-changing therapies. Since our launch in January 2018, we have acquired a portfolio of promising product candidates that consists of five programs, and we are focused on further expanding our portfolio
with the goal of making a profound impact on the lives of even more patients. We are drawing on our decades of knowledge and experience with a determination to tackle the undone, the too difficult, the inaccessible &#150; and change the odds for
rare disease patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, or FNAIT, a potentially life-threatening
rare hematological disease that impacts fetuses and newborns. We are evaluating RLYB211, a polyclonal anti-HPA-1a antibody, in a Phase 1/2 clinical trial, which we believe has established proof of concept for RLYB211 and provides support for our
proposed mechanism of action. We plan to move this program forward with our lead product candidate, RLYB212, a monoclonal anti-HPA-1a antibody, and submit an Investigational New Drug application, or IND, for RLYB212
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We are also focused on developing therapies that address diseases of complement dysregulation, including paroxysmal nocturnal
hemoglobinuria, or PNH, generalized myasthenia gravis, or gMG, and ophthalmic disorders. RLYB116 is a novel, potentially long-acting, subcutaneously administered inhibitor of complement factor 5, or C5, in development for the treatment of patients
with PNH and gMG. We expect to submit a clinical trial application, or CTA, for RLYB116 in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. RLYB114 is a pegylated C5 inhibitor in preclinical
development for the treatment of complement-mediated ophthalmic diseases and we expect to submit a CTA for this product candidate in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Additionally, in
collaboration with Exscientia Limited, or Exscientia, we have two discovery-stage programs focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since inception, we have devoted substantially all of our resources to raising capital, organizing and staffing our company, business planning, conducting discovery and
research activities, acquiring or discovering product candidates, establishing and protecting our intellectual property portfolio, developing and progressing our product candidates, preparing for clinical trials and establishing arrangements with
third parties for the manufacture of our product candidates and component materials, including activities relating to our preclinical development and manufacturing activities for each of our five programs and our Phase 1/2 clinical trial for
RLYB211. We do not have any product candidates approved for sale and have not generated any revenue from product sales. Since our inception, we have funded our operations primarily through equity financings and have received proceeds of
approximately $182.0&nbsp;million, net of issuance costs of $0.5&nbsp;million, from the sale of our preferred units. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have devoted most of our financial
resources to research and development, including our preclinical development and manufacturing activities for each of our five programs and our Phase 1/2 clinical trial for RLYB211. We have not commercialized any products and have never generated
revenue from the commercialization of any product. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred significant operating losses since inception, including net losses of $26.4&nbsp;million
and $17.6&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively, and net losses of $13.3 million and $3.9 million for the three months ended March 31, 2021 and 2020, respectively. As of March&nbsp;31, 2021, we had
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">80 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
an accumulated deficit of $60.3&nbsp;million. These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs
associated with our operations. We expect to incur significant additional operating losses in the foreseeable future as we advance our programs through preclinical and clinical development, expand our research and development activities, acquire and
develop new product candidates, complete preclinical studies and clinical trials, finance our business development strategy, seek regulatory approval for the commercialization of our product candidates and commercialize our products, if approved.
Our expenses will increase substantially if and as we: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">file an IND and initiate a Phase 1 clinical trial for RLYB212, our lead product candidate for our FNAIT prevention
program; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">file an IND or a CTA and initiate our clinical trials for RLYB116 and other product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate a natural history alloimmunization study of FNAIT to support our development program and related regulatory
submissions for RLYB212; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue to develop and conduct clinical trials with respect to RLYB211; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seek regulatory approvals for RLYB212, RLYB116 and any other product candidates, as well as for any related companion
diagnostic, if required; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue and expand upon our discovery and development joint ventures with Exscientia; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue to discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">hire additional clinical, scientific, and commercial personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">add operational, financial, and management personnel, including personnel to support our product development and planned
future commercialization efforts and to support our transition to a public company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates or technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">secure a commercial manufacturing source and supply chain capacity sufficient to produce commercial quantities of any
product candidate for which we obtain regulatory approval; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish a sales, marketing and distribution infrastructure to commercialize our programs, if approved, and for any other
product candidates for which we may obtain marketing approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result, we will need substantial additional funding to support our continuing
operations and pursue our growth strategy. Our inability to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. There can be no assurances, however, that the current
operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;31, 2021, we had cash and
cash equivalents of $127.7&nbsp;million. We believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements for more
than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from the date of this prospectus. This estimate and our expectation regarding the sufficiency of the net proceeds from this offering to advance the
preclinical and clinical development of RLYB212, RLYB116, and any other product candidates are based on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#147;&#151;Liquidity and
Capital Resources.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has impacted and may continue to impact our preclinical studies and clinical trials, including at our
clinical sites and the startup activities for our clinical trials, as well as our manufacturing and supply chain, and the pandemic may affect our ability to timely complete our clinical trials and delay the initiation and/or enrollment of any future
clinical trials, disrupt regulatory activities or have other adverse effects on our business and operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are monitoring the potential impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business and financial statements. To date, we have not incurred impairment losses in the carrying values of our assets as a result of the COVID-19 pandemic and we are not aware of any
specific related event or circumstance that would require us to revise our estimates reflected in our financial statements. We plan to continue many of the protective measures we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">81 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
implemented in response to the pandemic and are assessing when and how to resume normal operations for office-based personnel. The effects of the public health directives and our work-from-home
policies may disrupt our business and delay clinical programs and timelines and future clinical trials, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct
business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, results of operations and financial condition, including our ability to obtain financing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be certain what the overall impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will be on our business and prospects. The extent to which
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will directly or indirectly impact our business, results of operations, financial condition and liquidity, including planned and future clinical trials and research and development costs,
will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the actions taken to contain or treat it, including the availability
and administration of vaccines, and the duration and intensity of the related effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses consist primarily of costs incurred in connection with our research and development activities, including our drug discovery efforts
and the development of our product candidates. We expense research and development costs as incurred, which include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">external research and development expenses incurred under agreements with third parties, such as contract research
organizations, or CROs, as well as investigative sites and consultants that conduct our clinical trials and other scientific development services; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs related to manufacturing material for our clinical trials, including fees paid to contract manufacturer
organizations, or CMOs; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> expenses and the cost of acquiring and manufacturing
clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">employee-related expenses, including salaries, bonuses, benefits, equity-based compensation and other related costs for
those employees involved in research and development efforts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs of outside consultants, including their fees, and related travel expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of acquiring and developing clinical trial materials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expenses to acquire technologies, such as intellectual property, to be used in research and development including <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development, or IPR&amp;D, that has no alternative future use at the time of asset acquisitions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs related to compliance with regulatory requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">facilities, depreciation and other indirect costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Costs for certain activities are recognized based on an evaluation of the progress to completion of each specific contract using information and data provided to us by
our vendors and analyzing the progress of our research studies or other services performed. Significant judgments and estimates are made in determining the expenses incurred balances at the end of any reporting period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our direct, external research and development expenses consist primarily of fees paid to outside consultants, CROs, CMOs and research laboratories in connection with
our process development, manufacturing and clinical development activities. Our direct external research and development expenses also include fees incurred under license and intellectual property purchase agreements. We track these external
research and development costs on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not allocate
employee costs, costs associated with our development efforts and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified.
We use internal resources and third-party consultants primarily to conduct our research and development activities as well as for managing our process development, manufacturing and clinical development activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">82 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The successful development of our product candidates is highly uncertain. We plan to substantially increase our research
and development expenses in the foreseeable future as we continue the development of our product candidates and manufacturing processes and conduct discovery and research activities for our clinical programs. We cannot determine with certainty the
timing of initiation, the duration or the completion costs of current or future clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical development timelines, the
probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing
basis in response to the results of ongoing and future clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#146;s commercial potential. We will need to raise substantial additional capital in the future.
Our clinical development costs are expected to increase significantly with our ongoing clinical trials. We anticipate that our expenses will increase substantially, particularly due to the numerous risks and uncertainties associated with developing
product candidates, including the uncertainty of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope, rate of progress and expenses of our ongoing research activities and clinical trials and other research and
development activities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successful enrollment in and completion of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether our product candidates show safety and efficacy in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continued acceptable safety profile of the products following any regulatory approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any changes in the outcome of any of these variables with respect to the development of our product candidates in clinical development could mean a significant change
in the costs and timing associated with the development of these product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to
discontinue, delay or modify clinical trials of some product candidates or focus on others. For example, if the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or EMA, or another regulatory authority were to delay our
planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to
expend significant additional financial resources and time on the completion of clinical development of that product candidate. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate that our research and
development expenses will continue to increase as we continue our current research programs, initiate new research programs, continue our preclinical development of product candidates and conduct future clinical trials for any of our product
candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and
administrative expenses consist primarily of salaries, benefits and equity-based compensation for our personnel in executive, legal, business development, finance and accounting, and other administrative functions. General and administrative
expenses also include legal fees relating to intellectual property and corporate matters, professional fees paid for accounting, auditing, tax and consulting services, insurance costs, travel expenses and direct and allocated facility costs not
otherwise included in research and development expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate that our general and administrative expenses will increase as we increase headcount that
provide administrative support to our research and development activities. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs, as well as investor
and public relations expenses associated with operating as a public company. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses
as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">83 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Total Other Income, Net </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total other income, net, includes interest income earned on cash and cash equivalents, interest expense and other income and expense items. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Loss on investment in joint venture </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognizes its <FONT
STYLE="white-space:nowrap">pro-rata</FONT> share of losses in the loss on investment in joint venture with Exscientia on its consolidated statements of operations and comprehensive loss, with a corresponding change to the investment in joint venture
on the consolidated balance sheets for equity method investments for which it does not have a controlling interest in. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the Three Months Ended March&nbsp;31, 2021 and 2020 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our results of operations: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our research and development costs for each of the periods presented: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Direct research and development by program</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB211</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB212</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB116</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other program candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Other unallocated research and development costs</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Personnel expenses (including equity-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">84 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses were $9.0&nbsp;million for the three months ended March&nbsp;31, 2021, compared to
$1.9&nbsp;million for the three months ended March&nbsp;31, 2020. The increase of $7.1&nbsp;million was primarily due to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $3.7&nbsp;million increase in costs related to the development of RLYB212 and a $2.4&nbsp;million increase in costs
related to the development of RLYB116 mainly attributable to increased external clinical manufacturing activities for both programs as compared to the same period in 2020; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $0.6&nbsp;million increase in personnel-related costs, including equity-based compensation expense, primarily due to an
increase in research and development related headcount as compared to the same period in 2020; </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $3.8&nbsp;million for the three months ended March&nbsp;31, 2021, compared to $1.9&nbsp;million for the three months ended
March&nbsp;31, 2020. The increase of $1.9&nbsp;million primarily related to an increase in payroll and personnel-related costs, including equity-based compensation, primarily due to an increase in general and administrative related headcount and
other professional fees associated with operating activities and the preparations for becoming a public company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Total Other Income, Net </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total other income, net, was $31,000 for the three months ended March&nbsp;31, 2021, compared to $95,000 for the three months ended March&nbsp;31, 2020. The decrease of
$64,000 is primarily attributable to a reduction in interest income as compared to the same period in 2020. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Loss on investment in joint venture </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the three months ended March&nbsp;31, 2021, the loss recognized was $0.5&nbsp;million as compared to $0.1&nbsp;million for the same period in 2020. The increase in
the loss recognized is due to increases in research cost recognized by the joint venture during 2021 as compared to 2020. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the Years Ended
December&nbsp;31, 2020 and 2019 </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our results of operations: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">85 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our
research and development costs for each of the periods presented: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Direct research and development by program</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB211</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB212</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB116</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other program candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Asset acquisitions IPR&amp;D expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Other unallocated research and development costs</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Personnel expenses (including equity-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses were $17.6&nbsp;million for the year ended December&nbsp;31, 2020, compared to $11.4&nbsp;million for the year ended December&nbsp;31,
2019. The increase of $6.3&nbsp;million was primarily due to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $3.5&nbsp;million increase in costs related to the development of RLYB212 and a $5.1&nbsp;million increase in costs
related to the development of RLYB116 mainly attributable to increased external manufacturing activities for both programs as compared to the same period in 2019 when the assets were acquired; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $2.8&nbsp;million increase in personnel-related costs, including equity-based compensation expense, primarily due to an
increase in research and development related headcount as compared to the same period in 2019; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $0.9&nbsp;million increase in RLYB211 related to an increase in clinical development costs as compared to the same
period in 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a decrease of $6.1&nbsp;million in asset acquisition related IPR&amp;D expenses related to the asset acquisitions made in
2019. No asset acquisitions were executed in 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $7.7&nbsp;million for the year ended December&nbsp;31, 2020, compared to $6.3&nbsp;million for the year ended December&nbsp;31,
2019. The increase of $1.4&nbsp;million primarily related to an increase in payroll and personnel-related costs, including equity-based compensation, primarily due to an increase in general and administrative related headcount and other professional
fees associated with operating activities and the preparations for becoming a public company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Total Other Income, Net </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total other income, net, was $0.4&nbsp;million for the year ended December&nbsp;31, 2020, compared to $0.2&nbsp;million for the year ended December&nbsp;31, 2019. The
increase of $0.2&nbsp;million is primarily attributable to the change in fair value of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing right obligation expense for the year ended 2019, no such charges for financing obligation rights
were taken for the same period in 2020. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Loss on investment in joint venture </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the year ended December&nbsp;31, 2020, the loss recognized was $1.5&nbsp;million as compared to $0.1&nbsp;million for the same period in 2019. The joint venture
with Exscientia was established in July 2019 and the increase in the loss recognized is due to increases in research and development cost recognized by the joint venture during 2020 as compared to 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">86 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sources of Liquidity </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, we have funded our
operations primarily through equity financings, and through March&nbsp;31, 2021, had received proceeds of approximately $182.0&nbsp;million, net of issuance costs of $0.5&nbsp;million, from the sale of our preferred units. As of March&nbsp;31, 2021,
we had $127.7&nbsp;million of cash and cash equivalents. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Uses of Liquidity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years,
other than our manufacturing, licensing and lease obligations described further below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital
expenditure requirements for more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from the date of this prospectus. We have based this estimate on assumptions that may prove to be wrong, and we
could expend our capital resources sooner than we expect. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to incur significant expenses and operating losses in the foreseeable future as we advance our
product candidates through clinical development, seek regulatory approval and pursue commercialization of any approved product candidates. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating
as a public company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of the numerous risks and uncertainties, length of time and scope of activities associated with research, development and
commercialization of pharmaceutical product candidates, we are unable to estimate the actual amount of funds we will require for development, approval and any approved marketing and commercialization activities. Our future capital requirements, both
near and long-term, will depend on many factors, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, progress, timing, costs and results of our clinical trials through all phases of development, including
our ongoing Phase 1/2 clinical trial for RLYB211, the planned clinical trials for RLYB212 and RLYB116 and the development of any other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the identification, assessment, acquisition and/or development of additional research programs and additional product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA and other comparable foreign
regulatory authorities, including any additional clinical trials required by the FDA, EMA or other comparable foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of the FDA, EMA and other comparable foreign regulatory authorities to accept our clinical trial designs,
as well as data from our completed and planned preclinical studies and clinical trials, as the basis for review and approval of RLYB212, RLYB116 and any other product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress, timing and costs of the development by us or third parties of companion diagnostics, if required, for
RLYB212 or any other product candidates, including design, manufacturing and regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of filing, prosecuting and enforcing our patent claims and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third
parties against us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with potential clinical trial liability or product liability claims, including the costs associated
with obtaining insurance against such claims and with defending against such claims; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to develop and commercialize products that are considered medically and/or financially differentiated to
competitive products by physicians, patients and payers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost and timing of completion of commercial-scale manufacturing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of making royalty, milestone or other payments under any future
<FONT STYLE="white-space:nowrap">in-license</FONT> agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">87 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to maintain our collaboration with Exscientia on favorable terms and establish new collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional product candidates or
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the severity, duration and impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which may adversely
impact our business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of establishing sales, marketing and distribution capabilities for our product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, progress and timing of our commercialization of RLYB212, RLYB116, if approved, or any other product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of third-party coverage and reimbursement for and pricing of any approved products; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A change in the outcome of any of these, or other variables with respect to the development of any of our product candidates, could significantly change the costs and
timing associated with the development of that product candidate. We will need to continue to rely on additional financing to achieve our business objectives. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
addition to the variables described above, if and when any of our product candidates successfully complete development, we will incur substantial additional costs associated with regulatory filings, marketing approval, post-marketing requirements,
maintaining our intellectual property rights and regulatory protection, in addition to other commercial costs. We cannot reasonably estimate these costs at this time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time, if ever, as we generate significant revenue from product sales, we expect to finance our operations through the sale of equity, debt financings,
marketing and distribution arrangements and collaborations, strategic alliances and licensing arrangements or other sources. We currently have no credit facility or committed sources of capital. If we raise additional funds through debt financing,
we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and we may need to dedicate a substantial additional portion of any
operating cash flows to the payment of principal and interest on such indebtedness. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required
to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be
required to delay, limit, reduce or terminate product candidate development or future commercialization efforts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Cash Flows </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our cash flows for each of the periods presented: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED&nbsp;MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,072</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Operating Activities </I></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities was $11.9
million for the three months ended March 31, 2021 as compared to $5.5 million for the three months ended March 31, 2020. The increase in cash used in operations was primarily due to the increase of $7.1 million in research and development for the
increased efforts advancing the development of RLYB211, RLYB212 and RLYB116 product candidates and $1.9 million in general and administrative expenses as compared to the same period the prior year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities was $22.0&nbsp;million for the year ended December&nbsp;31, 2020 as compared to $15.0&nbsp;million for the year ended December
31, 2019. The increase in cash used in operations was primarily due to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">88 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the increase of $6.3&nbsp;million in research and development for the increased efforts advancing the development of RLYB211, RLYB212 and RLYB116 product candidates and $1.4&nbsp;million in
general and administrative expenses as compared to the same period the prior year. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing Activities </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities was $0.6 million for the three months ended March 31, 2021 and 2020. Net cash used in investing activities was primarily related
to the investments in our joint venture during both periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities was $2.1&nbsp;million for the year ended December&nbsp;31, 2020
as compared to $0.2&nbsp;million for the year ended December 31, 2019. The increase in net cash used in investing activities was primarily related to the investments in our joint venture as compared to the same period the prior year. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Financing Activities </I></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There was no cash provided by financing activities
for the three months ended March 31, 2021 as compared to $85.1 million for the three months ended March 31, 2020. There were no financing events for the three months ended March 31, 2021 as compared to the same period in the prior year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities was $144.9&nbsp;million for the year ended December&nbsp;31, 2020 as compared to $31.6&nbsp;million for the year ended
December 31, 2019. The increase in financing activities was primarily attributable to the net proceeds from the issuance of Series B Preferred units of $144.9&nbsp;million as compared to the net proceeds from the issuance of Series A-2 Preferred
units of $31.6&nbsp;million from the prior year. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our contractual obligations as of December&nbsp;31, 2020: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAYMENTS DUE BY PERIOD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LESS&nbsp;THAN</B><br><B>1 YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;YEARS</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;YEARS</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MORE&nbsp;THAN</B><br><B>5 YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The contractual obligation amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms,
including fixed or minimum services to be used, fixed, minimum or variable price provisions and the approximate timing of the actions under the contracts. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Purchase and Other Obligations </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We enter contracts in the normal course of
business with CROs and other third-party vendors for clinical trials and testing and manufacturing services. Aside from those included in the table above, most contracts do not contain minimum purchase commitments and are cancellable by us upon
written notice. Payments that may be due upon cancellation consist of payments for services provided or expenses incurred. These payments are not included in the table above as the amount and timing of such payments are not known. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may incur contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable under agreements we have entered into with
various third-party entities pursuant to which we have acquired <FONT STYLE="white-space:nowrap">or&nbsp;in-licensed</FONT> intellectual property. Due to the uncertainty of the achievement and timing of the events that require payment under these
agreements, the amounts to be paid by us are not fixed or determinable at this time and have not been included in the table above. See &#147;Business&#151;License Agreement&#148; and &#147;Business&#151;Asset Purchase Agreements&#148; and Note 3
&#147;Asset Acquisitions&#148; to our audited consolidated financial statements included elsewhere in this prospectus for a description of these agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
consolidated financial statements are prepared in accordance with&nbsp;accounting principles generally accepted in the United States or U.S. GAAP. The preparation of our consolidated financial statements and related disclosures
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">89 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our
consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or
conditions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While our significant accounting policies are described in more detail in Note 2 &#147;Summary of Significant Accounting Policies and Basis of
Presentation and Principles of Consolidation&#148; to our audited consolidated financial statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used
in the preparation of our consolidated financial statements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of the process of preparing our consolidated financial statements, we are required to estimate our research and development expenses that are incurred as of
each reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and with vendors to identify services that have been performed on our behalf and estimating the level of service performed
and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones
are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if
necessary. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes
and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in
which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the
level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid balance accordingly.
<FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received
rather than when the payment is made. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we do not expect our estimates to be materially different from amounts incurred, if our estimates of the status and
timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Incentive Units </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, we have periodically
granted incentive units to employees&nbsp;which vest over a four-year period. These incentive units have been issued in the form of profits interests providing the employee with compensation equal to the increase in the value of the unit over a
participation threshold per unit, as determined at the time of grant. The holder, therefore, has the right to participate in distributions of profits only in excess of such participation threshold. The participation threshold is based on the
valuation of a single common unit on or around the grant date. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We measure equity-based compensation based on the grant date fair value of the unit-based
awards and recognize equity-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period of the respective award. Unit-based compensation expense is classified in our
consolidated statements of operations and comprehensive loss based on the function to which the related services are provided or in the same manner in which the grantee&#146;s payroll costs are classified. Forfeitures are accounted for as they
occur. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As there has been no public market for our common units, the estimated fair value of our common units has been determined by our board of managers after
considering valuation reports provided by an independent third-party valuation firm. In accordance with the guidance outlined in the American Institute of Certified Public Accountants&#146; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">90 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Accounting and Valuation Guide,&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation,&nbsp;a third-party valuation firm prepared valuations of our common units using
an option pricing method, or OPM, which uses market approaches, and a Black-Scholes option pricing model to estimate our enterprise value. The OPM treats common units and preferred units as call options on the total equity value of a company, with
exercise prices based on the value thresholds at which the allocation among the various holders of a company&#146;s securities changes to value the common units of the company. A discount for lack of marketability of the common units is then applied
to arrive at an indication of value for the common units as of the valuation date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are significant judgments related to volatility and time to liquidity as
well as estimates inherent in these valuations. These judgments and estimates include assumptions regarding our future operating performance, the stage of development of our product candidates, the timing of a potential IPO or other liquidity events
and the determination of the appropriate valuation methodology at each valuation date. The assumptions underlying these valuations represent management&#146;s best estimates, which involve inherent uncertainties and the application of management
judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our equity-based compensation expense could be materially different. Following the completion of this offering, the fair value
of our common stock will be determined based on the quoted market price of our common stock. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Reorganization, holders of common and
incentive units of Rallybio Holdings, LLC, or the LLC Entity, will receive shares of common stock and restricted stock of Rallybio Corporation, or the Corporation, based upon a conversion price to be determined by our board of directors immediately
prior to the Reorganization. Holders of incentive units of the LLC Entity that are vested as of the consummation of the Reorganization will, with respect to such units, receive shares of common stock of the Corporation. Holders of incentive units of
the LLC Entity that are unvested as of the consummation of the Reorganization will, with respect to such units, receive shares of restricted stock of the Corporation. The shares of restricted common stock will be subject to the same vesting
conditions as the incentive units for which such shares are exchanged. The following table summarizes by grant date the number of incentive units granted from January&nbsp;5, 2018 through March&nbsp;31, 2021, the participation threshold price per
incentive unit and the pro forma number of shares of common stock that will be issued in the Reorganization for each grant of incentive units: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>GRANT DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCENTIVE&nbsp;UNITS<BR>GRANTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OUTSTANDING&nbsp;INCENTIVE<BR>UNITS&nbsp;AS&nbsp;OF&nbsp;MARCH&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PARTICIPATION<BR>THRESHOLD&nbsp;PRICE<BR>PER UNIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA<BR>COMMON&nbsp;STOCK<BR>ISSUED&nbsp;IN&nbsp;RESPECT<BR>OF&nbsp;INCENTIVE&nbsp;UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">July 2018 &#150; January 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">July 2019 &#150; December 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">May 2020 &#150; December 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,232,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,232,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jan 2021 &#150; March 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,069,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,069,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company and Smaller Reporting Company </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an emerging growth
company, or EGC, under the Jumpstart Our Business Startups Act of 2012, or JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting
requirements under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, for EGCs include presentation of only two years of audited financial statements in a registration statement for an IPO, an exemption from the requirement to provide
an auditor&#146;s report on internal controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements. Additionally, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or
revised accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#147;opt out&#148; of such extended transition period,
which means that when a standard is issued or revised and it has different application dates for public or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">91 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i)&nbsp;irrevocably
elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer qualify as an EGC. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies.
Therefore, the reported results of operations contained in our consolidated financial statements may not be directly comparable to those of other public companies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may remain classified as an EGC until the end of the fiscal year in which the fifth anniversary of this offering occurs, although if the market value of our common
stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of any June&nbsp;30 before that time or if we have annual gross revenues of $1.07&nbsp;billion or more in any fiscal year, we will cease to
be an EGC as of December&nbsp;31 of the applicable year. We also will cease to be an EGC if we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to rely on&nbsp;certain of&nbsp;the other exemptions and reduced reporting requirements provided by the JOBS Act. As an EGC, we are not required to, among
other things, provide an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section&nbsp;404(b), and comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (auditor discussion and analysis). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also a &#147;smaller reporting company&#148; meaning that the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the
proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue was less than $100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller
reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue was less than $100.0&nbsp;million
during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a smaller reporting company at the time we cease to be an
EGC, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited
financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020 and March 31, 2021, we did not have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined in
Item&nbsp;303(a)(4)(ii) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recently Issued Accounting Pronouncements </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2
&#147;Summary of Significant Accounting Policies and Basis of Presentation and Principles of Consolidation&#148; to our audited consolidated financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">92 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company built around a team
of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Our mission
at Rallybio is aligned with our expertise, and we believe we have assembled the best people, partners and science to forge new paths to life-changing therapies. Since our launch in January 2018, we have acquired a portfolio of promising product
candidates that consists of five programs, and we are focused on further expanding our portfolio with the goal of making a profound impact on the lives of even more patients. We are drawing on our decades of knowledge and experience with a
determination to tackle the undone, the too difficult, the inaccessible &#150; and change the odds for rare disease patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced program is for the
prevention of fetal and neonatal alloimmune thrombocytopenia, or FNAIT, a potentially life-threatening rare hematological disease that impacts fetuses and newborns. We are evaluating RLYB211, a polyclonal anti-HPA-1a antibody, in a Phase 1/2
clinical trial, which we believe has established proof of concept for RLYB211 and provides support for our proposed mechanism of action. We plan to move this program forward with our lead product candidate, RLYB212, a monoclonal anti-HPA-1a,
antibody and submit an Investigational New Drug application, or IND, for RLYB212 in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We are also focused on developing therapies that address diseases of
complement dysregulation, including paroxysmal nocturnal hemoglobinuria, or PNH, generalized myasthenia gravis, or gMG, and ophthalmic disorders. RLYB116 is a novel, potentially long-acting, subcutaneously administered inhibitor of complement factor
5, or C5, in development for the treatment of patients with PNH and gMG. We expect to submit a clinical trial application, or CTA, for RLYB116 in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
RLYB114 is a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases and we expect to submit a CTA for this product candidate
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Additionally, in collaboration with Exscientia Limited, or Exscientia, we have two discovery-stage programs focused on the identification of small
molecule therapeutics for patients with rare metabolic diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Approach </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At Rallybio, we do not accept that millions of patients suffering from devastating rare diseases should have to live without transformative treatments. There are an
estimated 25 to 30&nbsp;million people affected by as many as 7,000 rare diseases in the United States alone, with a significantly greater number of affected people globally. We are building a diversified pipeline of product candidates that we
believe have the potential to transform the lives of patients in need. Our goal is to deliver therapeutics that provide meaningful clinical benefits to patients so they can become unbound and undefined by the diseases from which they suffer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe the success of our company is built on three key strengths: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Our extensive knowledge of rare diseases and our scientific expertise positions us to identify therapies with the
potential for transformative impact.</B> We seek to acquire and develop product candidates that possess a clear mechanism of action and that aim to address diseases with a well-understood pathophysiology for which there is a significant unmet
medical need. We believe that a product candidate&#146;s mechanism of action should target the causal biology of the disease to provide the highest probability of dramatically improving the lives of patients. We believe that our team&#146;s
extensive experience in rare diseases and our scientific expertise position us to identify opportunities where these links can be made, which may go unnoticed by others. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Our ability to source, to identify and to evaluate potential high-quality product candidates</B>. We apply decades of
experience across drug discovery, research, development, regulatory strategy and manufacturing to source, to identify and to evaluate therapeutic targets and product candidates that we believe have a high probability of success. Our ability to
source these product candidates is facilitated by our extensive network of relationships with leaders in industry and in academic clinical centers worldwide. We view ourselves as partners of choice given our team&#146;s track record of success in
developing and delivering new therapies to patients. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">93 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Our team&#146;s proven execution capability to drive product candidates through clinical development to regulatory
approvals. </B>We have assembled a team with a proven history of successfully advancing product candidates from discovery to clinical development and through regulatory approval. Members of our team have played critical roles in the approval of more
than 30 drugs, including seven approvals for rare disease therapeutics since 2013, and secured approvals from regulatory authorities in the Americas, Europe and Asia. In doing so, our employees previously developed and implemented novel clinical
trial designs and successfully conducted clinical trials in never-before treated patient populations. We believe this collective prior experience positions us to efficiently and expertly execute at each step in the research and development process
and enhances the value we can bring to product candidates and to patients. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our founders, Martin W. Mackay, Ph.D., Stephen Uden, M.D., and Jeffrey M. Fryer, CPA, were previously executives at Alexion Pharmaceuticals, Inc., or Alexion, and
worked together to successfully build, develop, and launch transformative therapies for patients with rare diseases. Several members of our team were integral in the successful development and/or approval of therapies such as Strensiq (asfotase
alfa) for patients with perinatal-, infantile-, and juvenile-onset hypophosphatasia, or HPP, Kanuma (sebelipase alfa) for patients with lysosomal acid lipase deficiency, or <FONT STYLE="white-space:nowrap">LAL-D,</FONT> Nulibry (fosdenopterin) for
patients with molybdenum cofactor deficiency, or MoCD Type A, Soliris (eculizumab) for patients with refractory gMG, Soliris for patients with relapsing neuromyelitis optica spectrum disorder, or NMOSD, Ultomiris
<FONT STYLE="white-space:nowrap">(ravulizumab-cwvz),</FONT> for patients with PNH and Ultomiris for patients with atypical hemolytic uremic syndrome, or aHUS. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
deep commitment to high ethical and professional standards is fundamental to our mission to bring new and transformative medicines to vulnerable patient populations suffering from rare diseases. We believe our team&#146;s prior contributions have
made a significant positive impact on the lives of thousands of patients around the world. As a strong and experienced team, we believe we can transform the lives of thousands more. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pipeline is illustrated in the chart below. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g09q91.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:8pt; font-family:ARIAL"><B>FNAIT: Fetal and neonatal alloimmune thrombocytopenia; <FONT STYLE="white-space:nowrap">HPA-1a:</FONT> Human
platelet antigen 1a; PNH: Paroxysmal nocturnal hemoglobinuria; gMG: Generalized myasthenia gravis; ABD: Albumin binding domain; HPP: Hypophosphatasia; ENPP1: Ectonucleotide pyrophosphatase/phosphodiesterase 1; PoC: Proof of concept; IND:
Investigational new drug; CTA: Clinical trial application; HV: Healthy volunteer </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Prevention of FNAIT </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced program is targeting the prevention of FNAIT, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and
newborns. FNAIT can arise during pregnancy due to an immune incompatibility between an expectant mother and her fetus in a specific platelet antigen called human platelet </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">94 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
antigen 1, or <FONT STYLE="white-space:nowrap">HPA-1.</FONT> This incompatibility can cause an expectant mother to develop antibodies that attack the platelets of her fetus. The destruction of
platelets in the fetus can result in severely low platelet counts, or thrombocytopenia, potentially leading to devastating consequences including miscarriage, stillbirth, death of the newborn, or severe lifelong neurological disability in those
babies who survive. There is currently no approved therapy for the prevention or treatment of FNAIT. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that there are over 22,000 pregnancies at high
risk of developing FNAIT each year in the United States, Canada, United Kingdom, other major European countries and Australia. Because there are no approved therapies to prevent FNAIT, expectant mothers are not currently screened for FNAIT risk. As
a result, the vast majority of pregnancies at risk for FNAIT go unidentified and untreated. In those pregnancies that are identified as <FONT STYLE="white-space:nowrap">at-risk,</FONT> typically due to the delivery of a prior FNAIT affected child,
expectant mothers may be treated with weekly intravenously-administered high doses of immunoglobulin G, or IVIG, along with the oral steroid immunosuppressant prednisone. However, IVIG administration does not prevent the immune response, called
alloimmunization, and is costly, time-intensive, difficult to tolerate and associated with significant treatment-related complications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The lead product candidate
in our FNAIT prevention program is RLYB212, a preclinical-stage monoclonal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody. We are evaluating RLYB211, a polyclonal
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody, in a Phase 1/2 clinical trial, which we believe has established proof of concept for RLYB211 and provides support for our proposed mechanism of
action. RLYB211 is derived from the plasma of women who have developed antibodies to <FONT STYLE="white-space:nowrap">HPA-1a</FONT> as a result of a prior HPA-1 incompatible pregnancy. Data generated from the first cohort of healthy participants in
our Phase 1/2 clinical trial for RLYB211 demonstrated the ability of an <FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT> antibody to rapidly eliminate transfused <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive platelets from the
circulation of healthy HPA-1a negative participants. Based on these results, we believe that targeting <FONT STYLE="white-space:nowrap">HPA-1a</FONT> with an anti-HPA-1a antibody has the potential to prevent maternal alloimmunization and therefore
the occurrence of FNAIT. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the common mechanism of action, we believe that both product candidates will drive rapid elimination of <FONT
STYLE="white-space:nowrap">HPA-1a</FONT> positive platelets in the circulation of expectant mothers and potentially prevent them from alloimmunizing. Consequently, we are prioritizing the development of RLYB212 based on its favorable attributes,
including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential for subcutaneous administration of RLYB212, which is the preferred route of administration based on primary
market research of OB/GYNs and maternal-fetal specialists in the United States and Europe, compared to RLYB211&#146;s intravenous injection administration; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a pharmacokinetic profile for RLYB212 that has the potential to maintain circulating concentrations of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody at levels that are very close to peak exposure levels through the entire treatment period, thus maximizing the capacity of RLYB212 to neutralize fetal
antigen relative to RLYB211; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability to produce RLYB212 using standard monoclonal antibody manufacturing methods compared to the long-term need to
source plasma for RLYB211 from women who had developed antibodies to HPA-1a as a result of a prior HPA-1 incompatible pregnancy. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to
submit an IND for RLYB212 in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and to initiate a Phase 1 clinical trial in healthy participants
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We anticipate reporting additional data from our Phase 1/2 clinical trial for RLYB211
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of Disorders Due to Complement Dysregulation
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our next two programs target diseases related to complement pathway dysregulation. The complement system plays a central role in innate immunity, as well
as, shaping adaptive immune response. Dysregulation of the complement pathway has been implicated in the pathogenesis of a growing number of diseases, making it an attractive target for therapeutic intervention. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Antibody inhibitors of C5 have been successfully developed to treat diseases caused by complement pathway dysregulation, including PNH, aHUS, refractory gMG and
relapsing NMOSD. Despite the approval of antibody-based C5 inhibitors for patients with these diseases, we believe there remains significant need in the market for safe, effective, patient-friendly and accessible therapies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team has a track record of success and significant expertise in designing, developing and securing approval for complement inhibitors, including Soliris and
Ultomiris, for patients with severe and rare complement-mediated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">95 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
diseases around the world. We believe this knowledge and expertise positions us to successfully advance our programs and deliver transformative benefits to patients in need. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced product candidate in this therapeutic area is RLYB116, an inhibitor of complement factor C5, which is a central component of the complement pathway.
RLYB116 is an Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> molecule attached to an albumin binding domain that has the potential to drive the rapid, complete and sustained inhibition of C5 with a subcutaneous injection.
We plan to pursue PNH and gMG as our lead indications for RLYB116, with additional complement-mediated indications to follow. We expect to submit a CTA for RLYB116
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and to initiate a Phase 1 clinical trial by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our second C5 inhibitor, RLYB114, is a pegylated <FONT STYLE="white-space:nowrap">C5-targeted</FONT>
Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> molecule with pharmacokinetic properties designed for the treatment of complement-mediated ophthalmic diseases. Preclinical data generated with RLYB114 demonstrate that it is
well-tolerated in animal models with no serious adverse effects. RLYB114 is in preclinical development, and we expect to submit a CTA for RLYB114 in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
</P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Artificial Intelligence Drug Discovery Collaboration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
have established a partnership with Exscientia, an Oxford, <FONT STYLE="white-space:nowrap">UK-based</FONT> artificial intelligence-driven pharmatech company that is a leader in the use of computational tools and machine learning capabilities to
rapidly and efficiently discover novel small molecule drug candidates. Our partnership consists of two joint ventures that each focus on the discovery and development of small molecule therapeutics for the treatment of patients with rare metabolic
diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The first of these programs is targeting Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1, or ENPP1, for the treatment of patients with HPP, a
potentially life-threatening disease due to defects of skeletal mineralization. Patients with HPP suffer from deficiencies in breaking down pyrophosphate due to loss of function mutations in the gene ALPL, which encodes Tissue <FONT
STYLE="white-space:nowrap">Non-specific</FONT> Alkaline Phosphatase, or TNSALP. ENPP1 is an enzyme involved in regulating extracellular levels of pyrophosphate, a natural inhibitor of calcium mineralization in bone formation. We believe that a small
molecule inhibitor of ENPP1 has the potential to bring meaningful benefit to HPP patients by reducing excess levels of pyrophosphate, thereby removing an inhibitor of calcium mineralization and bone formation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The incidence of HPP has been reported to be 1 in 100,000 to 1 in 300,000 (United States and Canada) for severe disease and 1 in 6,370 (EU) for less severe forms. In
functional in vitro assays, we have observed that our lead ENPP1 inhibitors can promote mineralization. We intend to nominate a compound for clinical development in this program
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we have a second joint venture with Exscientia,
which is currently in the discovery stage, to identify a small molecule modulator for patients with an undisclosed rare metabolic disorder.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our mission at Rallybio is aligned with our expertise: to identify and accelerate the development of life-transforming therapies for patients with severe and rare
disorders. To achieve this mission, our strategy includes the following key components: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Establish a leading rare disease company through a team that delivers transformative medicines to patients.</B> We
believe our team&#146;s expertise and knowledge are fundamental to our long-term success. Our research and development team is led by experienced drug development executives who were integral in the approvals of more than 30 drugs from leading
companies, including Alexion, Astellas Pharma Inc., Wyeth, LLC and Pfizer Inc. We plan to continue to leverage our team&#146;s expertise to enable focused clinical development of multiple product candidates in parallel, resulting in a diversified
portfolio that we believe will provide multiple opportunities to create value by significantly improving the lives of patients. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Advance RLYB212 into and through clinical development for the prevention of FNAIT. </B>Our polyclonal antibody,
RLYB211, is currently being evaluated in a Phase 1/2 clinical trial. We expect to release topline data from this trial in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which we believe establishes
proof of concept for RLYB211 and an </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">96 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
<FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT> antibody approach. We plan to submit an IND for RLYB212
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and to initiate a Phase 1 clinical trial by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. To further
support our clinical development, we plan to initiate a global natural history study of FNAIT in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Advance RLYB116 and RLYB114 into and through clinical development for the treatment of diseases of complement
dysregulation. </B>We intend to submit a CTA for RLYB116 for treatment of PNH and gMG in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with the goal of initiating a Phase 1 clinical trial
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We plan to pursue PNH and gMG as our lead indications for RLYB116. We also plan to evaluate the development of RLYB116 for the treatment of
additional rare complement-mediated diseases. In addition, we are proceeding with preclinical development of RLYB114 for complement-mediated ophthalmic indications. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Identify and advance pipeline product candidates for rare metabolic diseases through our joint ventures with
Exscientia.</B> We have entered into a partnership with Exscientia to identify and develop candidates that are aligned with our overall drug discovery and development strategy. We plan to identify a lead candidate for our ENPP1 program
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We also continue to execute on a second target with Exscientia with the goal of identifying a small molecule modulator for the treatment of an
undisclosed rare metabolic disorder and expect to pursue additional small molecule targets in collaboration with Exscientia in additional joint ventures. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Expand our pipeline through partnering, acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> additional
product candidates that target validated biology. </B>We&nbsp;are focused on developing drugs that directly impact known disease pathways which we believe will allow us to increase the probability of clinical, regulatory and commercial success. We
continue to accelerate our business development activities and actively pursue the acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of additional product candidates as well as partnerships and collaborations. Our team has strong
relationships with key academic and industry leaders in the rare disease field built from our past success in developing and commercializing therapies for rare diseases. We plan to continue to leverage these relationships to further our business
development opportunities and thereby expand our pipeline. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Maximize the value of pipeline product candidates through commercial independence in key markets and select
partnerships. </B>We plan to build a fully integrated and focused commercial organization to launch our rare therapeutics, if approved, in key markets. We believe our commercial organization can be efficiently targeted at groups of specialists who
typically treat patients with the diseases to be addressed by our product candidates. For certain other markets, we plan to explore strategic partnerships to efficiently deliver our therapeutics to patients, with the goal of transforming patient
care in our focus areas around the globe. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Company </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were founded in January 2018 by Drs. Mackay and Uden and Mr.&nbsp;Fryer to identify and accelerate the development of life-transforming therapies for patients with
severe and rare disorders. At Alexion, Dr.&nbsp;Mackay was Global Head of Research&nbsp;&amp; Development, Dr.&nbsp;Uden served as Head of Research, and Mr.&nbsp;Fryer was Chief Tax Officer. Many of our employees have worked together extensively
during their careers across different companies. During these years of collaboration, several members of our team were integral in the successful development and/or approval of transformative therapies for thousands of patients with rare diseases.
As a focused, cohesive and experienced Rallybio team, we hope to transform the lives of many thousands more. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have raised over $180&nbsp;million from
investors including 5AM Ventures, Canaan Partners, Connecticut Innovations, Fairview Capital, <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital, Mitsui&nbsp;&amp; Co. Global Investment, New Leaf Venture Partners, Pivotal bioVenture Partners,
Solasta Ventures, Tekla Capital Management, TPG, and Viking Global Investors. In addition, employees of Rallybio have invested over $2.3&nbsp;million to date in our Series A-1, Series A-2, and Series B financing transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Candidates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RLYB211 and RLYB212 for the prevention of FNAIT
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing two <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody product candidates, RLYB211 and
RLYB212, for the prevention of FNAIT, a maternal fetal blood disorder that can cause potentially devastating outcomes including miscarriage, neonatal death and severe life-long neurological disability. RLYB211 is a polyclonal <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody isolated from the plasma of women who developed HPA-1a antibodies due to a prior HPA-1 incompatible pregnancy, and we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">97 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
believe early data generated from the first cohort of our ongoing Phase 1/2 clinical trial for RLYB211 in healthy male participants supports the potential of our approach to prevent material
alloimmunization and therefore the occurrence of FNAIT. RLYB212 is a monoclonal antibody directed at the same <FONT STYLE="white-space:nowrap">HPA-1a</FONT> target and we intend to advance this product candidate into clinical trials
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Maternal fetal blood disorders </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FNAIT is one of several devastating disorders that is caused by an immune incompatibility of a mother and fetus during pregnancy. One of the best-characterized prenatal
immune incompatibility disorders is Rh disease. This condition arises when the mother is RhD negative and her fetus is RhD positive. RhD incompatibility may lead to destruction of red blood cells in the fetus and can result in severe outcomes
including miscarriage or loss of a newborn. RhD disease is treated by giving <FONT STYLE="white-space:nowrap">at-risk</FONT> expectant mothers low doses of antibodies to RhD. These antibodies remove fetal red blood cells that have crossed into the
mother&#146;s circulation, thereby preventing her from developing an immune response that could destroy the red blood cells in the fetus. Since the approval of the first Rho (D)&nbsp;Immune Globulin in 1968, known as RhoGAM, expectant mothers in
many countries, including North America and Europe, are routinely screened for their RhD status, and Rh disease is largely prevented in <FONT STYLE="white-space:nowrap">at-risk</FONT> expectant mothers. We are pursuing a similar approach to
preventing FNAIT with our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>FNAIT disease background </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Like Rh disease, FNAIT is a disorder that occurs during pregnancy when an expectant mother&#146;s immune system attacks a specific antigen on the platelets of her
fetus, leading to their destruction. This results in an increased risk of bleeding in the fetus and newborn. In the majority of cases, the effects of FNAIT are mild; however, up to 20% of FNAIT cases experience intracranial hemorrhage, or ICH, which
can lead to devastating outcomes such as miscarriage, stillbirth, loss of the newborn and severe lifelong neurological disabilities in those babies that survive. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FNAIT is caused by a mismatch in the type of human platelet antigen 1, or <FONT STYLE="white-space:nowrap">HPA-1,</FONT> that is expressed by the expectant mother and
the fetus. There are two predominant forms of <FONT STYLE="white-space:nowrap">HPA-1,</FONT> known as <FONT STYLE="white-space:nowrap">HPA-1a</FONT> and <FONT STYLE="white-space:nowrap">HPA-1b,</FONT> which are expressed on the surface of platelets.
These two alleles differ by a single amino acid. Individuals who are homozygous for <FONT STYLE="white-space:nowrap">HPA-1b,</FONT> meaning that they have two copies of the <FONT STYLE="white-space:nowrap">HPA-1b</FONT> allele and no copies of the <FONT
STYLE="white-space:nowrap">HPA-1a</FONT> allele, are also known as <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative. Upon exposure to <FONT STYLE="white-space:nowrap">HPA-1a,</FONT> these individuals can develop antibodies to that antigen in
a process known as alloimmunization. In expectant mothers, alloimmunization can occur upon mixing of fetal blood with maternal blood. When alloimmunization occurs in an expectant mother, the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibodies that develop in the mother can cross the placenta and destroy platelets in the fetus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Pathophysiology of FNAIT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g29j64.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">98 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are no approved therapies to treat or prevent FNAIT and, therefore, expectant mothers are not currently screened for
FNAIT risk. Today, expectant mothers at risk of FNAIT are typically only identified following the delivery of an FNAIT affected child. These mothers may be treated during subsequent pregnancies with weekly administration of IVIG, along with the oral
steroid immunosuppressant prednisone. While IVIG administration can potentially mitigate the detrimental effects of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibodies, it does not prevent
alloimmunization, and IVIG is costly, time-intensive, difficult to tolerate and associated with significant treatment-related complications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Babies with FNAIT are
typically diagnosed at the time of delivery by the presence of low platelet counts identified during routine analysis, the presence of petechiae on the skin or due to the manifestations of severe complications such as ICH or gastrointestinal
bleeding. Upon diagnosis, babies with FNAIT may receive platelet transfusions and may be admitted to the neonatal intensive care unit. In severe cases, babies may suffer life-long neurological disability or may not survive. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We project that there may be over 22,000 pregnancies annually that are at high risk of FNAIT in the United States, Canada, United Kingdom, other major European
countries and Australia. These pregnancies represent expectant mothers who are <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative, who are at high risk of alloimmunization and who are carrying an <FONT STYLE="white-space:nowrap">HPA-1a</FONT>
positive fetus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While the frequency of <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative status in <FONT STYLE="white-space:nowrap">non-Caucasian</FONT>
populations is not established, studies show that approximately 2% of the Caucasian population is <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative. Based on this frequency and live birth rates of Caucasian women from 2018, we estimate that
there are approximately 110,000 <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative expectant mothers in the aforementioned countries each year. From this population of expectant mothers, a subset is at higher risk of FNAIT due to the presence
of a specific HLA allele, known as DRB3*01:01. Genetic studies have found that expectant mothers who have this specific HLA allele are approximately 25 times more likely to develop antibodies to <FONT STYLE="white-space:nowrap">HPA-1a</FONT> than
those without this allele. This higher-risk group represents approximately 27% of <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative expectant mothers, or approximately 30,000 individuals. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From this population, an estimated 89% of women would not already have antibodies to <FONT STYLE="white-space:nowrap">HPA-1a</FONT> and, of these, an estimated 86%
would be expected to be carrying an <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive fetus. As illustrated below, based on these estimates, we project there may be over 22,000 pregnancies annually that are at high risk of FNAIT. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FNAIT Pregnancies At Risk </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g31l69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given the well-established prevalence of <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negativity in the Caucasian population, our
current estimates of the FNAIT <FONT STYLE="white-space:nowrap">at-risk</FONT> population are derived from the estimated proportion of Caucasian births from approximately eight million live births per year in the above-mentioned countries. However,
we are committed to ensuring that all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">99 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
expectant mothers of any race or ethnicity who are at high risk of FNAIT are identified and eligible for treatment. We intend to initiate a natural history study of FNAIT
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, in part to obtain better prevalence estimates of the FNAIT <FONT STYLE="white-space:nowrap">at-risk</FONT> population in racial and ethnic groups
that may have been underrepresented in previously published studies. We believe that data from this study will better inform the size of the total FNAIT <FONT STYLE="white-space:nowrap">at-risk</FONT> population. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that screening for FNAIT risk can be performed routinely and cost effectively as part of standard prenatal testing provided to expectant mothers during
pregnancy. Testing for maternal <FONT STYLE="white-space:nowrap">HPA-1</FONT> type and presence of the <FONT STYLE="white-space:nowrap">HLA-DRB3*01:01</FONT> allele could occur during the first trimester, at the same time as other routine blood work
and risk screening, and we don&#146;t expect that an additional blood draw would be required. Importantly, U.S. and EU physicians have advised that our approach and timing for FNAIT screening would fit well within the established first trimester
prenatal testing paradigm and could slot in at the same time as routine blood typing and Rh testing. Based on our global market research with maternal-fetal medicine specialists, obstetricians and payers, we believe there is not only high awareness
of the catastrophic impact of FNAIT, but also a strong desire to both screen and provide preventive therapy to <FONT STYLE="white-space:nowrap">at-risk</FONT> expectant mothers, if there were an approved product to prevent FNAIT and affordable
screening tests. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe screening and preventive treatment can have a significant impact on this potentially devastating disease. For example, screening
and treatment in Rh disease have been highly effective in reducing the number of affected births. In developed countries with access to prenatal testing and treatment, the prevalence of Rh disease is 2.5 per 100,000 compared to 276 per 100,000
worldwide. We believe that applying a similar approach to the prevention of FNAIT could lead to a significant reduction in the number of babies at risk for FNAIT. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are working in partnership with Grifols Laboratory Solutions to include screen tests for maternal <FONT STYLE="white-space:nowrap">HPA-1</FONT> type, maternal <FONT
STYLE="white-space:nowrap">HLA-DRB3*D1:01</FONT> status, maternal <FONT STYLE="white-space:nowrap">HPA-1a</FONT> antibodies and fetal <FONT STYLE="white-space:nowrap">HPA-1</FONT> genotype in our clinical development program. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to initiate a natural history trial of FNAIT in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which is
described below, in which we plan to implement this screening paradigm in a broad population of expectant mothers of different racial and ethnic characteristics to identify those at risk of developing FNAIT. We also plan to use this trial to
operationalize the FNAIT-risk laboratory test paradigm prior to implementing the laboratory tests in a future registration trial. We anticipate that data from this natural history trial, combined with data available from other literature-reported
FNAIT screening studies, may be sufficient to serve as a basis for future regulatory discussions regarding the use of historical control data to support a future single arm Phase 2/3 registrational trial. We also believe that the experience in
recruiting expectant mothers into this trial will accelerate recruitment into future FNAIT trials. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our solution: RLYB211 and RLYB212 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing RLYB211, a polyclonal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody isolated from the plasma of
women who developed <FONT STYLE="white-space:nowrap">HPA-1a</FONT> antibodies due to a prior <FONT STYLE="white-space:nowrap">HPA-1</FONT> incompatible pregnancy, and RLYB212, a monoclonal <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody developed from transformed memory <FONT STYLE="white-space:nowrap">B-cells</FONT> isolated from a mother with severe FNAIT affected pregnancies. Our dual approach is rooted in our goal to
provide a preventive therapy for FNAIT to mothers at risk as soon as practicable. We believe the early data generated from our ongoing RLYB211 Phase 1/2 clinical trial support the mechanism of action of RLYB211, and by extension that of RLYB212, to
remove fetal <FONT STYLE="white-space:nowrap">HPA-1a</FONT> platelets from HPA-1a negative expectant mothers and potentially prevent maternal alloimmunization, thereby eliminating the risk of FNAIT. We acquired all rights to both product candidates
from Prophylix AS, or Prophylix, in 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2020, we announced that we dosed the first participant in our Phase 1/2 trial of RLYB211. We anticipate
submitting an IND for RLYB212 in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and initiating a Phase 1 trial
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We anticipate reporting additional data from our Phase 1/2 clinical trial for RLYB211 in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are prioritizing the development of RLYB212 based on the
following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Dose administration.</B> RLYB212 is dosed subcutaneously while RLYB211 is administered via intravenous bolus injection.
Subcutaneous administration simplifies the treatment regimen for <FONT STYLE="white-space:nowrap">at-risk</FONT> expectant mothers and is highly preferred by physicians in both the United States and EU, based on primary market research.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">100 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Pharmacokinetic profile.</B> Our pharmacokinetic modeling suggests that weekly subcutaneous administration of RLYB212
could maximize the capacity of RLYB212 to neutralize fetal antigen over the course of treatment compared to RLYB211, by maintaining higher trough levels and limiting fluctuations from peak to trough. </P></TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Standard manufacturing and stable supply</B>. Commercial quantities of RLYB212 are expected to be produced by standard
monoclonal antibody production methods. RLYB211, however, is purified from plasma collected from women who developed <FONT STYLE="white-space:nowrap">HPA-1a</FONT> antibodies due to a prior HPA-1 incompatible pregnancy. If RLYB211 is clinically
successful in preventing FNAIT, the number of women with <FONT STYLE="white-space:nowrap">HPA-1a</FONT> antibodies would decrease significantly, negatively impacting our ability to source a long-term supply of commercial product.
</P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical development of RLYB211: providing support for the RLYB212 approach </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are conducting a Phase 1/2 single-blind, placebo-controlled, dose escalation proof of concept trial designed to establish the dose of RLYB211 needed to rapidly clear
<FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive platelets transfused to <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative healthy male participants. In this trial, the elimination of transfused platelets is intended to serve as a
surrogate for assessing the ability of RLYB211 to drive rapid elimination of <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive fetal platelets from an expectant mother&#146;s circulation, thereby potentially preventing <FONT
STYLE="white-space:nowrap">HPA-1a</FONT> maternal alloimmunization and the occurrence of FNAIT in fetuses and newborns. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trial is designed to enroll a total of
24 participants across three cohorts, each investigating a different dose of RLYB211. In cohorts 1 and 2, platelet transfusion precedes single dose administration of either placebo or RLYB211 at 1,000 IU in cohort 1 and 4,000 IU in cohort 2. Data
from cohorts 1 and 2 will be used to evaluate the trial&#146;s primary endpoint of time to platelet clearance. Data from cohort 3, investigating a 10,000 IU dose, will be used to establish the RLYB211 pharmacokinetic profile. Safety will be assessed
across all cohorts. The trial is being conducted at the Clinical Research department of Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine and Pharmacology (TMP) in Frankfurt/Main, Germany in
collaboration with the German Red Cross (Deutsches Rotes Kreuz) Blood Service <FONT STYLE="white-space:nowrap">Baden-W&uuml;rttemberg-Hessen</FONT> in Frankfurt/Main, Germany. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the first cohort of this trial, a dose of 10x10<SUP STYLE="font-size:85%; vertical-align:top">9</SUP> <FONT STYLE="white-space:nowrap">HPA-1ab</FONT> platelets was
transfused into healthy participants to simulate a fetal bleed into the maternal circulation one hour before a 1,000&nbsp;IU dose of RLYB211. As illustrated below, administration of RLYB211 markedly accelerated the clearance of the transfused <FONT
STYLE="white-space:nowrap">HPA-1a</FONT> positive platelets compared with placebo, resulting in a half-life of mismatched platelets of 0.32 hours as compared to 65.29 hours with placebo (p value &lt;0.001). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">101 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RLYB211 Led to Rapid Clearance of Transfused <FONT STYLE="white-space:nowrap">HPA-1a</FONT> Platelets
from Healthy Participants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g35h67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Data from the first cohort provides proof of concept of the ability of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibodies to rapidly clear <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive transfused platelets in <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative individuals. These data support
the potential for the administration of an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody to drive the rapid elimination of HPA-1a positive fetal platelets from an expectant mother&#146;s
circulation, thereby preventing HPA-1a maternal alloimmunization and the occurrence of FNAIT in fetuses and newborns. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given these positive results, we are now
seeking a protocol amendment in which four healthy <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative male participants will receive RLYB211 seven days prior to an <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive platelet challenge. We
believe this amendment will allow the trial to more closely mimic the situation in expectant mothers who would be eligible to receive an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody as a
preventive treatment in anticipation of potential exposure to <FONT STYLE="white-space:nowrap">HPA-1a</FONT> platelets from their fetuses. Data from this cohort are expected
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>RLYB212 preclinical data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A mouse model of FNAIT has been created in which the amino acids comprising the <FONT STYLE="white-space:nowrap">HPA-1a</FONT> antigen are reconstituted in the mouse
gene. These transgenic mice (referred to as APLDQ mice based on the amino acid changes) recapitulate multiple aspects of FNAIT. Administration of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibodies
to APLDQ mice leads to destruction of APLDQ platelets and severe thrombocytopenia. Injection of platelets from APLDQ mice into wild-type mice can induce an <FONT STYLE="white-space:nowrap">HPA-1a</FONT> specific immune response. Finally, wild-type
female mice <FONT STYLE="white-space:nowrap">pre-immunized</FONT> with APLDQ platelets, when bred with APLDQ male mice, give birth to severely thrombocytopenic pups, many of which exhibit an accompanying bleeding phenotype. Treatment of these
pregnant female mice with IVIG resulted in lowering the level of anti-APLDQ antibodies in the fetus and a reduction in thrombocytopenia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">102 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In a prophylactic treatment model, a single large bolus intravenous injection of 1 x 10<SUP
STYLE="font-size:85%; vertical-align:top">8</SUP> APLDQ platelets (equivalent to about <FONT STYLE="white-space:nowrap">one-sixth</FONT> of the total blood volume in the host) was administered to wild-type mice. At a dose of 0.4 &micro;g (yielding a
peak concentration of approximately 0.2 &micro;g/ml), RLYB212 was able to drive rapid and complete elimination of APLDQ platelets, as shown in the first graph below, and prevent a host antibody response, as shown in the second graph below. As shown
in third graph below, this dose correlates to a concentration of RLYB212 projected to bind approximately 10% of the <FONT STYLE="white-space:nowrap">HPA-1a</FONT> antigen present on the transfused APLDQ platelets. Thus, the approximately 10%
receptor binding is sufficient to clear platelets and prevent alloimmunization. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RLYB212 Induced Rapid Elimination of APLDQ Platelets </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g89t00.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RLYB212 Prevented the Development of
Antibodies to APLDQ Platelets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g15s86.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">103 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Ten Percent of APLDQ Platelets Bound by 0.4 &micro;g Dose of RLYB212 at C<SUB
STYLE="font-size:85%; vertical-align:bottom">max</SUB> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g16s84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical development of RLYB212 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate initiating a Phase 1 single and multiple dose trial for RLYB212 in <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative healthy participants
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The trial will evaluate the safety, tolerability and pharmacokinetics of RLYB212 following subcutaneous single dose administration and subcutaneous
weekly doses for an estimated period of up to 12 weeks. The general design of the planned trial is illustrated below. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Design of the Initial Phase
1 Trial of RLYB212 in <FONT STYLE="white-space:nowrap">HPA-1a</FONT> Negative Healthy Participants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g78e05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A subsequent Phase 1b proof of concept trial will assess the ability of RLYB212 to rapidly eliminate transfused <FONT
STYLE="white-space:nowrap">HPA-1a</FONT> positive platelets from the circulation of <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative healthy male participants in a design similar to that of the RLYB211 Phase 1/2 trial. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Design of the Phase 1b Trial of RLYB212 in Healthy Male Participants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g87q67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to successful completion of our planned Phase 1/1b trial and discussions with regulatory authorities, which have not yet
occurred, we plan to conduct a registrational enabling Phase 2/3 trial of RLYB212 in expectant mothers at higher FNAIT risk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">104 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Prospective FNAIT Natural History Alloimmunization Study </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to initiate a prospective, non-interventional, multinational natural history study in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The primary objective of
the study will be to determine the frequency of women who are HPA-1a antibody negative and have the HLA allele DRB3*01:01, and are therefore at higher FNAIT risk among pregnant women of different racial and ethnic characteristics who present for
prenatal care at gestation weeks 10 to 14. A secondary objective will be to identify the frequency of HPA-1a alloimmunization and pregnancy outcomes among women identified to be at higher FNAIT risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RLYB116 for the treatment of disorders due to complement dysregulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB116 is an inhibitor of complement factor C5, a central component of the complement pathway, which plays a central role in innate immunity as well as shaping
adaptive immune response. Dysregulation of the complement pathway has been implicated in the pathogenesis of a growing number of diseases, making it an attractive target for therapeutic intervention. Antibody inhibitors of C5 have been successfully
developed to treat diseases caused by immune dysfunction, including PNH, aHUS, refractory gMG and relapsing NMOSD. Despite approved products for these indications, we believe there remains an unmet need in patients with these diseases for therapies
that are more patient-friendly and accessible. RLYB116 is an Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> molecule, which is an antibody mimetic protein that has a much smaller molecular weight than a traditional
antibody and may also be easier and less costly to produce. In contrast to <FONT STYLE="white-space:nowrap">C5-targeted</FONT> antibody therapeutics that are administered intravenously, RLYB116 has the potential to be administered as a small volume
subcutaneous injection. Additionally, RLYB116 includes an albumin binding domain, which may extend the half-life of the Affibody&reg; domain. In addition, amino acid changes have been made to RLYB116 that are intended to enhance stability. We view
RLYB116 as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pipeline-in-a-product.</FONT></FONT></FONT> Our lead indications for RLYB116 are PNH and acetylcholine receptor, or AChR,
antibody positive gMG. However, we plan to evaluate the development of RLYB116 for the treatment of additional rare complement-mediated diseases. We believe RLYB116 could potentially enable more patients suffering from PNH and gMG to be treated
globally and could also provide a meaningful therapeutic impact for patients suffering from a broad number of other diseases of complement dysregulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on
our team&#146;s experience studying and developing therapies targeting the complement system, we believe there are four important attributes that could support clinical and commercial success in the treatment of patients suffering from
complement-mediated diseases. These include a mechanism of action targeting terminal complement, the ability to produce rapid, complete and sustained inhibition of C5, a safety profile consistent with C5 antibodies currently approved for therapeutic
use and pricing flexibility to treat a broad range of complement-mediated diseases. We believe RLYB116 has the potential to demonstrate these attributes, and if so, could have a life-transforming impact for patients. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The complement system </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The complement system includes over 30
proteins in plasma and on cell surfaces that support the body&#146;s adaptive or antibody-based immune system in the destruction of pathogenic bacteria. Complement proteins circulate in the blood in an inactive form prior to activation in response
to infection. Activation occurs through a pathway of proteolytic cleavage events initiated by pathogen recognition and resulting in pathogen destruction. Three complement pathways are known and are referred to as the classical, lectin and
alternative pathways. In the classical pathway, antibodies bind to antigens, which in turn trigger a protease cascade that activates complement protein C3 and then complement protein C5. Activation of C5 convertase generates C5b which can initiate
formation of membranes pores and subsequent lysis of cells. The binding of C5b to host cells is normally prevented by the presence of specific glycoproteins on the cell surface. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>PNH disease background </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">PNH is a rare, potentially life-threatening
hematologic disease characterized by complement-mediated destruction of red blood cells, or hemolysis. Early signs of PNH include hemoglobinuria, or dark colored urine, resulting from excretion of hemoglobin from lysed red blood cells, which is more
prominent in the morning and decreases during the day. More serious symptoms of PNH include anemia, excessive weakness, fatigue, severe abdominal pain, severe headaches and recurrent infections. PNH leads to over a
<FONT STYLE="white-space:nowrap">60-fold</FONT> increase in the risk of venous thromboembolism compared to the general population and these thrombotic events lead to between 40% and 67% of deaths in PNH patients. Approximately two thirds of patients
with PNH develop chronic kidney disease, or CKD, and kidney failure is the cause of death in 8% to 18% of PNH patients. In the absence of disease-modifying treatment, PNH results in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">105 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the death of approximately 35% of affected individuals within five years of diagnosis. An analysis conducted in 2006 estimated that there were approximately 4,700 patients living with PNH in the
United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In patients with PNH, blood precursor cells acquire a mutation in a gene encoding a protein that anchors a specific set of proteins on the cell
surface. When these proteins, known as glycoproteins, are in place on the blood precursor cells, then the cells are protected from immune attack. However, in patients with PNH, these mutations cause the absence of these glycoproteins and renders red
blood cells susceptible to destruction by the complement pathway. Once the cells are destroyed, by a mechanism known as lysis, the hemoglobin from these cells is then removed from circulation by the kidneys and excreted in the urine. Excess
hemoglobin and additional proteins from lysed red blood cells causes the kidney damage seen in most PNH patients. The observed increase in the rate of thrombosis in PNH patients is believed to be related to altered platelet function as well as to
other activities associated with the C5a protein, such as vasoconstriction and increases in inflammation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Current treatments for PNH and their limitations
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The only curative treatment currently available for PNH is a stem cell transplant from a related donor. However, this procedure is associated with
significant risk and is typically used only in those patients with severe disease, such as life-threatening thrombosis or dangerously low blood counts. Various supportive therapies include anticoagulants, red blood cell transfusions and supplements
of iron and folate. These therapies provide some relief from symptoms but do not address the underlying cause of the disease. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are two approved
disease-modifying drugs for PNH: eculizumab, marketed by Alexion as Soliris; and ravulizumab, marketed by Alexion as Ultomiris. Both of these products are antibodies that bind to complement C5 and prevent its cleavage by C5 convertase to C5a and
C5b, thus blocking a central step in the complement pathway. Both products are roughly equivalent in their ability to block C5 cleavage, prevent hemolysis, minimize the need for transfusions and to stabilize hemoglobin. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Eculizumab and ravulizumab are each administered intravenously by healthcare professionals: eculizumab at biweekly intervals and ravulizumab at eight-week intervals.
Despite the requirement for intravenous administration and limitations on access, wide adoption of these drugs has led to worldwide sales of eculizumab and ravulizumab which in 2020 exceeded $5&nbsp;billion. We believe that a product that works
through a similar mechanism but with a more convenient route of administration and improved patient access has the opportunity to further transform PNH therapy for patients. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential benefits of our approach </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are pursuing PNH as part of
our initial development strategy for three reasons. First, PNH has a well-understood disease pathophysiology driven by complement, providing a sound biological rationale for a <FONT STYLE="white-space:nowrap">C5-targeted</FONT> intervention. Second,
PNH offers the opportunity for early clinical validation using objective endpoints, including impact on lactate dehydrogenase, a component of red blood cells that is increased in circulation as a result of hemolysis. And third &#150; and most
importantly &#150; we believe that with a patient-friendly and accessible therapy, RLYB116 could potentially provide transformative therapeutic impact for unserved and underserved patients with PNH globally. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Generalized myasthenia gravis disease background </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generalized
myasthenia gravis is a potentially life-threatening, rare autoimmune neuromuscular disorder. Patients with gMG develop antibodies that attack critical signaling proteins at the junction between nerve and muscle cells, thereby inhibiting the ability
of nerves to communicate properly with muscles. This inhibition leads to muscle weakness, which can occur in ocular muscles leading to droopy eyelids as well as blurred or double vision due to partial paralysis of eye movements and in the muscles in
the face, neck, throat and jaw, causing problems in chewing and swallowing. gMG can also cause respiratory problems, speech difficulties and weakness in skeletal muscles leading to problems in limb function. The symptoms of the disease can be
transient and can remit spontaneously in the early stages of the disease. However, as the disease progresses, symptom-free periods become less frequent and disease exacerbations can last for months. Up to 20% of gMG patients experience respiratory
crisis at least once in their lives. During crisis, a decline in respiratory function can become life-threatening and often requires intubation and mechanical ventilation, and hospital stays for patients in crisis last a median of seventeen days.
According to a comprehensive epidemiological study of gMG in western Denmark form 1975-89, From the time of diagnosis, the overall survival rates at 3, 5, 10 and 20 years are estimated to be 85%, 81%, 69% and 63%, respectively. In addition, patients
with gMG suffer from poor quality of life due to the impact of their disease on physical function as well as the burden of treatment-related adverse events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">106 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The most common proteins that have been targeted by these autoimmune antibodies are AchR, which are within the
neuromuscular junction and bind to the acetylcholine neurotransmitter released by the nerve; and muscle-specific kinase, or MuSK, a tyrosine kinase involved in propagating neuronal signals. The presence of these autoimmune antibodies blocks the
signaling from neurons to muscles which results in outward signs of muscle weakness. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pathology in gMG arises not only from interrupting signal transduction,
but from physical destruction of the post-synaptic membrane through activation of the complement pathway. Over 80% of patients with gMG have antibodies to AchR and these antibodies can lead to complement-driven lysis of the post-synaptic membrane.
Eculizumab is approved for the treatment of AchR antibody-positive gMG based on its ability to lead to significant improvements in the Myasthenia Gravis-Specific Activities of Daily Living scale and the Quantitative Myasthenia Gravis score which
measures muscle weakness. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the prevalence of gMG is estimated to be 14 to 20 per 100,000, with as many as 60,000 patients estimated to be
living with the disease. As with many autoimmune diseases, there are no known genetic alterations that specifically cause gMG. In most patients, the disorder arises spontaneously. Approximately 3% of patients have a primary relative with gMG,
suggesting that there are genetic factors that may predispose development of the disease, but these genes have yet to be identified. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Current treatments
for gMG and their limitations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the first-line setting, patients presenting with symptomatic gMG are commonly treated with acetylcholinesterase inhibitors
such as pyridostigmine in order to improve neuromuscular transmission. As the disease progresses, patients may receive immunosuppressive therapies such as azathioprine, glucocorticoids, mycophenolate and cyclosporine. These therapies are used
off-label for patients with gMG and unfortunately, each of these can be associated with substantive treatment burden and in some cases, can lead to disease worsening. Soliris (eculizumab) has been approved in the United States, EU, Japan and other
markets for the treatment of patients with refractory gMG who are anti-AChR positive. Substantive symptom improvements have been noted with eculizimab treatment at the first assessment at one week after first dose administration. Rituximab may also
be used off-label and is believed to have more benefit in patients with gMG with anti-MuSK antibodies compared to those with anti-AChR antibodies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For patients
with severe myasthenia or recurrent exacerbation and crisis, there are a number of methods utilized to reduce circulating IgG antibodies, as published studies have shown that decreases in circulating IgG antibody levels are correlated with increased
relief of symptoms and decreases in the length of hospital stays. These procedures include: plasma exchange, a process whereby blood is taken from a patient and IgG antibodies are physically removed from the plasma before it is returned to the
patient; and administration of IVIG, which provides therapeutic benefit through multiple hypothesized mechanisms, including the saturation of the FcRn receptor, which may lead to increased degradation of the endogenous autoimmune antibodies. Both
procedures are burdensome for patients and repeat administration is usually required to obtain significant reduction in symptoms. In addition, the large volumes of intravenous fluid associated with the administration of IVIG can lead to pulmonary
edema and kidney complications in elderly patients. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential benefits of our approach </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are pursuing AChR antibody positive gMG as part of our initial development strategy for two reasons. First, complement overactivity is known to contribute to the
disease pathophysiology of gMG, again providing a sound biological rationale for a <FONT STYLE="white-space:nowrap">C5-targeted</FONT> intervention. Second &#150; and most importantly &#150; we believe there is significant unmet need that we can
address. We believe the convenience of subcutaneous self-administration may enable treatment of a broad population of gMG patients at both earlier and late stages of disease. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our solution: RLYB116 </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB116 is an engineered protein that
includes an Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> molecule and an albumin binding domain. We acquired rights to RLYB116 from Swedish Orphan Biovitrum AB, or Sobi. RLYB116 has been designed to be optimized for C5
binding, stability, and long half-life in serum. Potential benefits of RLYB116 include: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Subcutaneous administration</B>. The low molecular weight allows for a higher concentration of active molecules than
antibodies in an equivalent volume. This increases the probability of being able to deliver RLYB116 in a volume suitable for subcutaneous administration. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">107 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Efficiency of manufacturing</B>. RLYB116 is expressed in <I>E coli</I>, providing for a more streamlined manufacturing
process compared to antibodies or other biologics expressed in mammalian cell culture, which typically require larger scale and longer manufacturing times. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Less frequent dosing</B>. Linkage of the Affibody<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> domain to
an albumin binding domain may lengthen the dosing interval of RLYB116 by extending the biological half-life. </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Broader indication opportunity</B>. Linkage to an albumin binding domain also may improve distribution to tissues
throughout the body creating the potential for additional tissue targets and indications. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Potentially lower risk of treatment conversion</B>. Due to 1:1 binding to C5, there is potentially lower risk of immune
complex formation when switching from treatment with an antibody. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Favorable stability.</B> The Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> platform
provides the possibility of delivering highly stable and soluble therapeutic agents that allow for high-concentration <FONT STYLE="white-space:nowrap">low-volume</FONT> products. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Affibody Scaffold and RLYB116 Structure </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g10h99.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pharmacodynamic properties of RLYB116 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An ex vivo hemolytic inhibition assay suggests that RLYB116 may inhibit C5-mediated red blood cell destruction at a dose that could be clinically useful. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical development plans for RLYB116 </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to submit a CTA for
RLYB116 in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with the goal of initiating a Phase&nbsp;1 clinical trial of RLYB116 in healthy adult participants
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. This trial will evaluate the safety, tolerability and pharmacokinetics of RLYB116 following subcutaneous administration of a single dose and multiple
doses. We also plan to incorporate a measure of pharmacodynamic activity into the single and multiple ascending dose segments of the trial. The trial is planned to enroll up to 48 participants in the single ascending dose segment and evaluate up to
6 dose levels. The multiple ascending dose segment of the trial is planned to enroll up to 84 participants and up to 7 dosing strategies. A Phase&nbsp;1b trial is planned in patients with PNH to assess the effect of RLYB116 on measures of
pharmacodynamic activity as well as safety and pharmacokinetics. We anticipate conducting subsequent trials in patients with PNH and AChR antibody positive gMG, which are both indications in which C5 inhibition has been clinically validated. Beyond
these initial indications, we plan to evaluate the development of RLYB116 for the treatment of additional rare complement-mediated diseases, given the growing numbers of diseases understood to be mediated by complement dysregulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RLYB114 for the treatment of ophthalmic disorders </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB114 is comprised of a
<FONT STYLE="white-space:nowrap">C5-targeted</FONT> Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> molecule conjugated to polyethylene glycol, or PEG. The addition of PEG to protein therapeutics is a well-established
method of extending the half-life and reducing the immunogenicity of these molecules in the body. Given the role of the complement system in retinal and ocular pathology, we are exploring a range of ophthalmic diseases, including inflammatory and
degenerative disorders, for the development of RLYB114. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">108 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential role of complement in ocular diseases </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Photoreceptors and the retina encounter a number of innate immune activators. Dysregulation of the complement system may drive ocular inflammation and contribute to
vision loss in multiple diseases such as <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or AMD. A number of genetic studies have shown links between alterations in genes encoding various complement factors and the risk of
development of AMD. Several clinical trials of inhibitors of the complement pathway including C5 inhibitors have been conducted, with reports of modest efficacy. Reasons for this limited efficacy are unknown but could include the disease stage
treated, level of intervention in the complement pathway, drug delivery mechanism and ability of the therapeutic to cross Bruch&#146;s membrane to the retinal pigment epithelium. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical studies </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on an animal intravitreal
pharmacokinetic study, RLYB114 may have a half-life comparable to Lucentis and Eylea. RLYB114 was also well tolerated in this study with no major signs of ocular toxicities. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our solution: RLYB114 </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB114 is in preclinical development. We
plan to test multiple PEG moieties for C5 affinity and hemolysis inhibition in vitro, and characterize the pharmacokinetic and safety profile after intravitreal administration in a rabbit model. Based on this series of nonclinical experiments, we
expect to select a lead candidate for GLP toxicology studies and GMP manufacturing to support a regulatory submission in advance of the conduct of a first-in-human study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Artificial Intelligence drug discovery collaboration with Exscientia </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
have established a partnership with Exscientia, an artificial intelligence, or AI, and machine learning drug discovery company. Exscientia has built dedicated AI systems that learn from a wide range of data and apply enhanced knowledge through
iterations of design. Our partnership currently consists of two joint ventures that each focus on the discovery and development of small molecules for the treatment of patients with rare metabolic diseases. The first of these joint ventures is
targeting ENPP1, an enzyme involved in regulating extracellular levels of pyrophosphate, a natural inhibitor of calcium mineralization in bone formation, for the treatment of patients with HPP. Our second joint venture with Exscientia is focused on
identifying a small molecule modulator for the treatment of patients with an undisclosed rare metabolic disorder.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Exscientia is a leader in the application of
artificial intelligence to drug discovery. Their proprietary platform is built upon validated artificial intelligence technology that has delivered multiple candidates to the clinic, including the first ever
<FONT STYLE="white-space:nowrap">AI-designed</FONT> therapeutic candidate. Their approach is designed to streamline the drug discovery process by significantly reducing the number of compounds synthesized, thereby reducing the time and cost of drug
discovery. For Rallybio, this creates an attractive opportunity to continue building an early pipeline through a multi-target, shared-risk, joint venture with Exscientia, combining their rapid and streamlined target execution process with our rare
disease development expertise and track record of delivering therapies to patients. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>RE Ventures I: ENPP1 inhibitor program for the treatment of patients with
hypophosphatasia </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing an ENPP1 inhibitor for the treatment of patients with HPP, a rare, potentially life-threatening genetic disease
characterized by mutations in the ALPL gene. These mutations lead to diminished activity of the TNSALP enzyme and the accumulation of inorganic pyrophosphate, or PPi, which inhibits bone mineralization causing multiple skeletal pathologies. ENPP1 is
a Type&nbsp;II transmembrane glycoprotein that cleaves ATP, producing PPi, and is a major source of PPi production in cells. We believe that controlling inhibition of ENPP1 may reduce PPi levels and restore balance within the bone mineralization
process. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>HPP disease overview </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">HPP is an inherited disorder that
affects the development of bones and teeth. More than 300 mutations in the ALPL gene associated with HPP have been identified. These mutations are associated with a wide range of disease severity. The most severe forms of the disorder tend to occur
before birth and in early infancy. These infants have short limbs, an abnormally shaped chest, soft skull bones, poor feeding, failure to gain weight, respiratory complications and high levels of calcium in the blood, or hypercalcemia, which can
lead to life-threatening complications. In other cases, the disease is not recognized until later in childhood where it manifests as rickets, pain, decreased mobility, deficits of growth and fractures. Children with less severe HPP can experience
early loss of primary teeth and may have short stature with bowed legs or knock knees, enlarged wrist and ankle joints and an abnormal skull shape. Findings in adults include a softening of the bones, known as osteomalacia, and recurrent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">109 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
fractures in the foot and thigh bones that can lead to chronic pain. The incidence of HPP has been reported to be 1 in 100,000 (United States and Canada) to 1 in 300,000 (EU) for severe disease
and 1 in 6,370 (EU) for less severe forms. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The various manifestations of HPP are caused by the combination of a lack of phosphate and an excess of PPi due to a
deficiency of TNSALP, the enzyme that converts PPi to phosphate. This deficiency negatively impacts bone formation by reducing the hydrolysis of PPi to phosphate required for normal bone formation, resulting in a
<FONT STYLE="white-space:nowrap">build-up</FONT> of PPi, a potent inhibitor of mineralization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Strensiq, an enzyme replacement therapy marketed by Alexion, is the
only approved therapy to treat patients with perinatal-, infantile- and juvenile-onset HPP. The therapy has been shown to lead to significant improvements in morbidity and mortality in patients with perinatal- and infantile-onset HPP, and
improvements in morbidity for patients with juvenile-onset HPP. However, Strensiq has limitations, including its dosing regimen and patient access. Strensiq is administered by subcutaneous injection either three or six times per week using a
weight-based dosing scale, which can be both onerous and painful for patients. Furthermore, a population of adult patients may have difficulty accessing the therapy given reimbursement dynamics in countries around the world as a result of
weight-based dosing that drives high costs for heavier patients. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our solution: an ENPP1 small molecule inhibitor </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing an orally available, small molecule ENPP1 inhibitor designed to reduce PPi levels through the controlled inhibition of ENPP1, which we hypothesize may
restore the balance of PPi and phosphate needed to promote bone mineralization. This program is in its early stages and preclinical and clinical development is required. If an ENPP1 inhibitor is successfully advanced through clinical development and
obtains marketing approval, we believe that an oral small molecule ENPP1 inhibitor, administered as a stand-alone therapy or in combination with Strensiq, could have significant benefit in managing HPP and improving the lives of patients. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Lead molecules demonstrated encouraging activity in functional assays. We are currently optimizing these lead molecules and anticipate selecting a development candidate
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. There are many public and private
biopharmaceutical companies, universities, government agencies and other research organizations actively engaged in the research and development of products that may be like our product candidates or address similar markets. In addition, the number
of companies seeking to develop and commercialize products and therapies competing with our product candidates is likely to increase. However, we seek to build our portfolio with key differentiating attributes to provide a competitive advantage in
the markets we target. The success of our product candidates, if approved, is likely to be a result of their efficacy, safety, convenience, price, the level of biosimilar or generic competition and/or the availability of reimbursement from
government and other third-party payors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>FNAIT</I></B>. There are currently no approved therapies for the prevention or treatment of FNAIT. In one frequently
used approach to manage pregnancies where the mother is known to have a history of FNAIT, physicians administer high levels of IVIG. Companies that currently market IVIG include ADMA Biologics, Bio Products Laboratory, CSL Behring, Grifols, Kedrion
Biopharma, Leadiant Biosciences, Octapharma and Takeda Pharmaceutical Company Limited. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>PNH</I></B>. The only curative treatment currently available for PNH
is a stem cell transplant from a related donor. However, this procedure is associated with significant risk and is used only in those patients with severe disease, such as life-threatening thrombosis or dangerously low blood counts. Various
supportive therapies include anticoagulants, red blood cell transfusions and iron and folate supplements. These therapies provide some relief from symptoms but do not address the underlying cause of the disease. There are two approved
disease-modifying drugs for PNH: eculizumab, marketed by Alexion as Soliris; and ravulizumab, marketed by Alexion as Ultomiris. Both of these products are antibodies that bind complement C5. There are several companies in <FONT
STYLE="white-space:nowrap">mid-</FONT> to late-stage clinical trials developing treatments for PNH. These include Akari Therapeutics, Alnylam Pharmaceuticals, Apellis Pharmaceuticals, Novartis, Regeneron Pharmaceuticals and Roche. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">110 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>MG</I></B>. Very early-stage MG is symptomatically treated by the use of acetylcholinesterase inhibitors such as
pyridostigmine bromide, marketed as Mestinon by Bausch Health. Eculizumab is also approved for the treatment of generalized MG in patients who are positive for anti-AChR antibodies. There are several other companies developing assets in <FONT
STYLE="white-space:nowrap">mid-</FONT> to late-stage clinical development for the treatment of MG using a variety of approaches and modalities. These companies include Argenx SE, Catalyst Pharmaceuticals, CureVac, Horizon Therapeutics, Immunovant,
Inc. and UCB Biopharma. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>HPP</I></B>. There is one approved treatment for HPP, asfotase alfa, marketed by Alexion as Strensiq, is an alkaline phosphotase
enzyme replacement therapy, and the only approved therapy for the treatment of perinatal-, infantile- and juvenile-onset HPP. Alexion is developing a second generation enzyme replacement therapy, which is currently in preclinical development, and AM
Pharma has an active discovery program. There are several companies pursuing ENPP1 small molecule inhibitors for the treatment of cancer, including AbbVie, Inc., Angarus Therapeutics, Avammune Therapeutics, and Stingray Therapeutics. We are not
aware of other small molecule inhibitors in development for the treatment of patients with HPP. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our competitors may have significantly greater name
recognition and financial, manufacturing, marketing, product development, technical, commercial infrastructure, and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in
even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies
complementary to, or necessary for, our programs. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success depends, in part, on our ability to
obtain, maintain, defend, and enforce patent rights and other intellectual property rights that protect our business, preserve the confidentiality of our trade secrets, and operate without infringing the valid and enforceable intellectual property
rights of others. In addition to our efforts to protect our product candidates and methods of using them, we also seek to secure or acquire patent rights regarding other products and methods that are important to the general development of
commercial products. We utilize a multi-layered approach that includes acquiring intellectual property rights through purchase or exclusive license, filing and prosecuting U.S. and foreign patent applications directed to our own innovations, and
developing and protecting proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> to maintain our competitive position. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ongoing efforts to secure patent
rights that protect our business constitute a key component of our business strategy. We also strive to protect as trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how,</FONT> certain aspects of our programs and technological
innovations that are commercially valuable but are not amenable to or appropriate for patent protection. We achieve this, in part, through the use of confidentiality agreements with our employees, consultants, scientific advisors, collaborators,
licensors, and contractors, and by striving to maintain physical security of our premises and digital security of our electronic information and technology systems. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding our commitment to protecting our intellectual property rights, we, like other pharmaceutical and biopharmaceutical companies, are subject to several
sources of uncertainty that can affect those rights. For example, we cannot be certain that any patents that we currently own or <FONT STYLE="white-space:nowrap">in-license,</FONT> or that we may own or
<FONT STYLE="white-space:nowrap">in-license</FONT> in the future, will not be challenged, held to be invalid and/or unenforceable, have the scope of their claims narrowed, or be circumvented by others. Nor can we be certain that such patents will
successfully protect our products or our business from competition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly, with respect to patent applications that are currently pending, or that may be
pending in the future, we cannot be certain that such patent applications will result in the issuance of granted patents, or of patent claims with the desired claim scope. In order to secure an issued patent, an invention claimed in a patent
application must meet certain legal requirements for patentability, which differ between countries based on each country&#146;s particular patent laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
addition, because of the significant amount of time required for clinical development and regulatory review of products candidates, we cannot be certain that any of our product candidates will be commercialized while there is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">111 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
significant patent term remaining on patents relating to those products. The term of a patent depends upon the legal requirements for determination of patent term in the country in which that
patent is granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United States, a
patent&#146;s term may, in certain cases, be lengthened by patent term adjustment, or PTA, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in examining and granting the patent. Likewise, a patent&#146;s
term may be shortened if it is terminally disclaimed over an earlier-expiring patent with a common owner or inventor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The term of a U.S. patent relating to an
approved drug product may also be extended to compensate the patentee for delays due to the regulatory approval process. Such a patent term extension, or PTE, cannot exceed five years, and cannot extend the remaining term of a patent beyond a total
of 14 years from the date of product approval. Furthermore, the term can be extended for only one patent applicable to each regulatory review period and only those claims covering the approved product, or a method for using it or manufacturing it,
may be extended. In the future, if any of our product candidates receive approval by the U.S. Food and Drug Administration, or the FDA, we expect to apply for PTE on any issued patents covering those products, depending upon the length of the
clinical studies for each product and other factors. There can be no assurance that we will benefit from any PTE or favorable adjustments to the terms of any patents we currently own or <FONT STYLE="white-space:nowrap">in-license</FONT> or that we
may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to and separate from patent exclusivity, the FDA may also grant marketing
exclusivity of varying lengths in connection with the approval of a New Chemical Entity (5 years), Biologic (12 years), or Orphan Drug indication (7 years). Marketing exclusivity may also be granted for new clinical studies (3 years) and pediatric
studies (6 months) on approved drugs. Depending on the length of the regulatory approval process and the ability to make use of the procedures for obtaining PTE, any FDA exclusivity period may in part or in whole overlap with any patent exclusivity
to which we are entitled. We intend to pursue relevant marketing exclusivities in the US and in foreign countries in which any candidate product is approved. However, we cannot be certain that any such exclusivities will be granted or, if granted,
will insulate our commercial product(s) from competition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to trade secrets, while we have confidence in the protective measures that we employ, such
measures can be breached, and we may not have adequate remedies for any such breach. We also cannot be certain that any of our activities will not be subject to the intellectual property rights of others. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March 31, 2021, we owned two patent families that were acquired from Prophylix and relate to the current product candidates in our FNAIT prevention program,
RLYB211 and RLYB212. The patent family covering RLYB212 and its use in treating and preventing FNAIT includes patents issued in Australia, Europe, Mexico, Russia and the United States. Patent applications in this family are pending in Brazil,
Canada, Israel and the United States. The granted patents in this family will expire in 2035, excluding any PTA or PTE that may be awarded. The patent family covering administration of RLYB211 for the prophylactic treatment of FNAIT includes patents
issued in the United States, Europe and Canada. The foreign patents and one of the U.S. patents will expire at the end of 2026, while the other U.S. patent expires in November 2030 due to a PTA granted by the U.S. Patent and Trademark Office. In
addition, we exclusively <FONT STYLE="white-space:nowrap">in-license</FONT> certain rights to technology from Versiti Blood Research Institute Foundation, Inc. pertaining to a mouse model of FNAIT. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March 31, 2021, we owned two patent families relating to the current product candidates in our complement program, RLYB114 and RLYB116, and certain aspects of
their use. These two patent families, which were acquired from Sobi, currently include three granted U.S. patents and one pending U.S. patent application, with granted patents and/or pending patent applications in more than 25 additional countries
worldwide, including granted patents in Australia, Canada, Europe (all European Patent Convention contracting states) and Japan. In the U.S., Australia and the European Patent Convention contracting states, both patent families have been granted and
are scheduled to expire between 2033 and 2034, excluding any PTA or PTE. In Canada and Japan, currently one patent family has been granted and is scheduled to expire in 2033. The second family patents are pending in Canada and Japan. We have also <FONT
STYLE="white-space:nowrap">in-licensed</FONT> certain patent rights relating to our current product candidates from Affibody, including patent rights relating to the Affibody<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> molecule
technology and Albumod albumin binding molecule technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">112 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreement </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Product License Agreement with Affibody AB </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2019, our
subsidiary IPC Research, LLC, or IPC Research, and Sobi entered into a Contract Assignment Agreement pursuant to which Sobi assigned to, and IPC Research assumed, all obligations in a certain Product License Agreement, referred to herein as amended
as the PLA, between Sobi and Affibody AB, or Affibody, dated March&nbsp;9, 2012, as amended on January&nbsp;1, 2018 and December&nbsp;22, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the
PLA, we obtained a license to the Affibody<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform technology and a particular albumin binding domain, or ABD, in order to further develop and commercialize certain Affibody ligands, which
we are now developing as RLYB116 and RLYB114. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the PLA, Affibody grants us (a)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right under
certain patents to use the Affibody ligands alone or as a fusion protein and (b)&nbsp;an exclusive right to use the Affibody ligands alone or as a fusion protein, in each case, for human therapeutic use. Affibody also grants us (a)&nbsp;a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> right under certain patents to use the ABD in combination with the Affibody ligands as a fusion protein and (b)&nbsp;an exclusive right to use the ABD solely in combination with the Affibody ligands as
a fusion protein, in each case, for human therapeutic use. Affibody grants us a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under applicable <FONT STYLE="white-space:nowrap">know-how</FONT> needed to practice the rights and
licenses granted under the PLA. All licenses to us are sublicensable, provided that each sublicense is consistent with the terms and conditions of the PLA. Under the PLA, Affibody has an exclusive right under any product patents, which are a
category of certain patents that we own, to use the specific Affibody ligands outside of human therapeutics and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right under <FONT STYLE="white-space:nowrap">know-how</FONT> needed to practice
the Affibody ligands outside of human therapeutics. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the PLA, Affibody is the exclusive owner of, and controls prosecution, maintenance, and defense of
intellectual property covering, platform technology. We are the exclusive owner of, and control prosecution, maintenance, and defense of intellectual property covering, product technology. Affibody agrees to disclose to us any improvement to the
Affibody technology that it deems commercially reasonable for us to practice and grants us an option to license any such improvement. We have the first right to enforce product patents against a third-party infringer and Affibody retains the first
right to enforce any other licensed patent. We agree to not provide or make available any Affibody Ligand to a third-party on a standalone basis except for research purposes or to commercialize a licensed product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We agree to use commercially reasonable efforts to develop and commercialize a licensed product. We also will pay Affibody certain regulatory milestones up to an
aggregate amount of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>7.5&nbsp;million and (a) a <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> royalty on annual net sales of products if such products are covered by a valid claim of a
product patent or a platform patent or <FONT STYLE="white-space:nowrap">(b)&nbsp;low-single-digit</FONT> royalties on annual net sales of products that are not covered by any such valid claim. Our obligation to pay royalties expires on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis on the later of (a)&nbsp;the expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of a patent covering a licensed product or (b)&nbsp;the 10th anniversary following first commercial sale of such product in such country. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The PLA will terminate when we are no longer obligated to pay royalties to Affibody. Either party may terminate the PLA upon material breach of the PLA by the other,
subject to a cure period, or immediately in the case of the other party&#146;s insolvency, bankruptcy or a similar event. Affibody may terminate the PLA immediately if we or any of our affiliates or third party transferees commences any proceeding
challenging the validity of the licensed patents or any of Affibody&#146;s other patents or challenging the confidentiality or substance of the licensed know-how or licensed technology. We may terminate the PLA for convenience upon 90 days prior
written notice and upon payment of any amounts due to Affibody through the effective date of such termination. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Affibody terminates the PLA or if we terminate
the PLA for convenience, (a) all rights and licenses granted under the PLA will terminate, (b) at Affibody&#146;s request, we must transfer all rights to the product technology free of charge to Affibody and (c) we must return or destroy all of
Affibody&#146;s confidential information. Furthermore, if we terminate for convenience, we must grant Affibody an exclusive, royalty free perpetual right to use all regulatory filings, approvals and data provided to regulatory authorities in support
of such filings or approvals that relate to the licensed product. However, if we terminate the PLA as a result of Affibody&#146;s material breach of the PLA or its insolvency or bankruptcy, we will retain our license and rights under the PLA,
provided that we will remain bound by certain obligations under the PLA with respect milestone payments, royalties (subject to a reduction in rate, in the case of material breach), audits and indemnity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">113 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Asset Purchase Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Asset Transfer Agreement with Swedish Orphan Biovitrum AB </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March
2019, through IPC Research, we entered into an agreement with Sobi, pursuant to which we acquired the right, title and interest in assets related to certain C5 inhibitor compounds. We are currently developing the assets acquired from Sobi as RLYB116
and RLYB114. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We paid Sobi an upfront purchase price of $5.0&nbsp;million and we are obligated to pay Sobi an aggregate amount of up to $51.0&nbsp;million upon
achievement of certain development milestones and an aggregate amount of up to $65.0&nbsp;million upon achievement of certain sales milestones. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also will pay
Sobi tiered, low single-digit royalties on annual net sales to third parties for products containing any compound transferred under the agreement as an active ingredient. Our obligation to pay royalties expires, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and product-by-product basis, on the later of (a)&nbsp;the 10th anniversary following first commercial sale of such product in such country and
(b)&nbsp;the expiration date in such country of the last to expire of any issued patent included in the patent rights acquired from Sobi that includes at least one valid claim covering the sale of such product in such country. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are obligated to use commercially reasonable efforts to research, develop and exploit at least one product that contains a compound transferred under the agreement
as an active ingredient in each of the United States, EU and Japan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If, prior to the commercial launch in the United States of the first product containing the
compounds, we decide to divest our rights in the assets acquired from Sobi or to terminate all research, development and commercialization activities in respect of the acquired compounds, we must notify Sobi and negotiate in good faith with Sobi a
possible business transaction relating to the assets. This right of negotiation will not apply to a transaction to sell all or substantially all of the assets of IPC Research or an affiliate of IPC Research, a pledge of the assets as collateral or a
sale or transfer of the assets to an affiliate of IPC Research that agrees to be bound by the right of negotiation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Asset Purchase Agreement with Prophylix
AS </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2019, though our subsidiary Rallybio IPA, LLC, or Rallybio IPA, we entered into an agreement with Prophylix to acquire all of Prophylix&#146;s
rights, title and interest in, to and under all assets, properties and rights related to Prophylix&#146;s plasma-derived <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> immunoglobulin, which we are
developing as RLYB211, and Prophylix&#146;s monoclonal antibody, which we are developing as RLYB212. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We paid Prophylix an upfront purchase price of approximately
$1.2&nbsp;million and reimbursed Prophylix approximately $1.8&nbsp;million for certain manufacturing costs incurred by Prophylix. We are obligated to pay Prophylix an aggregate of up to $19.0&nbsp;million upon achievement of certain development
milestones and an aggregate of up to $20.0&nbsp;million upon achievement of certain sales milestones. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also will pay Prophylix tiered, <FONT
STYLE="white-space:nowrap">mid-single-digit</FONT> royalties on annual net sales of products containing the monoclonal antibody and tiered <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-to-high-single</FONT></FONT> and <FONT
STYLE="white-space:nowrap">low-double-digit</FONT> royalties on annual net sales of products containing plasma-derived <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> immunoglobulin, subject to certain
offsets for royalties payable under certain third-party licenses. Furthermore, the then-applicable royalty rate will be reduced by a <FONT STYLE="white-space:nowrap">mid-double</FONT> digit percentage for the remaining royalty term on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis if it becomes reasonably likely that the Prophylix patents may no longer be enforceable in such country due to a challenge of the enforceability of
the patents or the enforceability of the royalty payments following the expiration of all valid claims of the patents in such country. Our obligation to pay royalties terminates on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis on the later of (a)&nbsp;the expiration
of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of a Prophylix patent covering a product, (b)&nbsp;expiration of regulatory exclusivity for the product in such country or (c) the 10<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> year anniversary following first commercial sale of such product in such country. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event the FDA grants a
priority review voucher for one of our product candidates developed using the technology acquired from Prophylix, we will pay Prophylix either: (a)&nbsp;if we sell such priority review voucher to a <FONT STYLE="white-space:nowrap">third-party</FONT>
within 12 months of its receipt, a <FONT STYLE="white-space:nowrap">mid-double</FONT> digit percentage of the proceeds we receive from the sale, net of taxes, or (b)&nbsp;if we do not sell the priority review voucher to a third-party within 12
months of receipt, a <FONT STYLE="white-space:nowrap">mid-double</FONT> digit percentage of the fair market value of the priority review voucher as determined in accordance with the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">114 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are obligated to use commercially reasonable efforts to develop and commercialize products containing plasma-derived <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> immunoglobulin in the United States and in at least one major European market. The agreement provides that if we provide notice to Prophylix that we determined
that commercialization of products containing plasma-derived <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> immunoglobulin is not feasible due to an insufficient plasma supply following our continued and
diligent efforts to obtain a sufficient plasma supply, then our obligation to develop products containing plasma-derived <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> immunoglobulin will cease, and we
will be obligated to use commercially reasonable efforts to develop and commercialize products containing the monoclonal antibody in the United States and in at least one major European market. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If, after using commercially reasonable efforts to develop and commercialize products containing plasma-derived <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> immunoglobulin and the monoclonal antibody in the United States and in at least one major European market, we decide not to pursue any further development or commercialization activities for such
products, then Prophylix will have the right to repurchase the remaining assets acquired under the agreement for approximately $1.2&nbsp;million. Prophylix also will have the right to repurchase the remaining assets acquired under the agreement for
approximately $1.2&nbsp;million if we elect to transfer all or substantially all of the assets acquired under the agreement to a third-party who does not agree to assume our obligations to develop and commercialize the products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Joint Venture Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2019, we entered into a partnership with
Exscientia and created RE Ventures I, LLC, or RE Ventures, which is jointly owned by Exscientia and one of our wholly-owned subsidiaries. The joint venture was formed to initiate early-stage drug discovery of available small molecules targeting
ENPP1 for the treatment of HPP, and thereafter for the future research, development, manufacture, sale and exploitation of any company-owned technology and compounds, including any resulting compound identified by the steering committee of the joint
venture. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the RE Ventures operating agreement, we received a 50% interest in the joint venture in exchange for an initial contribution of &pound;0.5 million
($0.6 million, based on the exchange rate at the time).&nbsp;RE Ventures used this initial capital to fund stage 1 of the ENPP1 program, and we committed to fund additional amounts if costs of stage 1 exceeded the initial funding. In June 2020, RE
Ventures determined that the stage 1 objective of discovering compounds for ENPP1 with a certain potency had been achieved. In 2020, we contributed &pound;1.1&nbsp;million ($1.3 million, based on the exchange rate at the time) in support of ongoing
Stage 2 development of the ENPP1 program. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that either Member does not fund a portion of committed additional amounts, the other Member may contribute
the unfunded amount and the respective membership interests in RE Ventures will be adjusted accordingly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A steering committee is responsible for oversight of RE
Ventures&#146; research and deployment plans as well as intellectual property and regulatory matters. A <FONT STYLE="white-space:nowrap">two-person</FONT> board of managers manages the business and affairs of RE Ventures and is responsible for all
management and other responsibilities not specifically reserved to the steering committee or to the Members. Each Member designates one member to the board. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each
Member is subject to customary restrictions on its transfer of interests in RE Ventures, including a right of first refusal, <FONT STYLE="white-space:nowrap">co-sale</FONT> right and drag-along provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing and Supply </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not own or operate, and currently have no
plans to establish, any internal manufacturing facilities. We currently rely and expect to continue to rely on third-party contract manufacturer organizations, or CMOs, for the manufacture of our product candidates for preclinical and clinical
testing, as well as for commercial production of any product candidates that are approved. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently rely on multiple CMOs for all of our preclinical and
clinical supply requirements, including drug substances and drug products, and label and packaging for our preclinical research and clinical trials. We believe that we will be able to contract with other CMOs to manufacture drug substances if our
existing sources of drug substances were no longer available to us or with sufficient capacity, but there is no assurance that the drug substance capacity would be available from other CMOs on acceptable terms, on the timeframe that our business
would require, or at all. We do not currently have supply commitments or other arrangements in place with our existing CMOs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">115 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have any current contractual relationships for the manufacture of commercial supplies of any of our product
candidates if they are approved by the regulatory authorities, and we intend to enter into agreements with a CMO and one or more <FONT STYLE="white-space:nowrap">back-up</FONT> manufacturers for the commercial production of our product candidates as
they near phase 3 clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any products to be used in clinical trials and any approved product that we may commercialize will need to be manufactured in
facilities, and by processes, that comply with the FDA&#146;s current Good Manufacturing Practice, or cGMP, requirements and comparable requirements of the regulatory agencies of other jurisdictions in which we are seeking approval. We currently
employ internal resources to manage our CMOs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that RLYB212, RLYB116 and RLYB114 can be manufactured in reliable and reproducible biologic and chemical
processes from readily available starting materials. We also believe that, despite being derived from human plasma, RLYB211 can also be manufactured in a reliable process, although our ability to source a sustained, dependable long-term supply will
be challenging, including due to the scarcity of potential donors who maintain an adequate level of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibodies and because supply of plasma will decrease if
RLYB211 becomes clinically successful in preventing FNAIT. We believe that our manufacturing processes are amenable to <FONT STYLE="white-space:nowrap">scale-up</FONT> and will not require unusual or expensive equipment. We expect to continue to
develop, on our own or with our collaborators, product candidates that can be produced cost-effectively at contract manufacturing facilities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to rely on
third parties for the manufacture of any in vitro diagnostic device, companion diagnostics or companion drug delivery systems we develop. For example, we have engaged a third-party to assist in developing laboratory screening tests and in our
evaluation of potential companion diagnostics in conjunction with our development of RLYB212. Depending on the regulatory pathway and technology solutions we choose, we may engage third parties to continue the development and manufacturing of any
device developed to support our therapeutic products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The research, development, testing, manufacture, quality control, packaging, labeling, storage, record-keeping, distribution, import, export, promotion, advertising,
marketing, sale, pricing and reimbursement of drug and biologic products are extensively regulated by governmental authorities in the United States and other countries. The processes for obtaining regulatory approvals in the United States and in
foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory requirements, both <FONT STYLE="white-space:nowrap">pre-approval</FONT> and post-approval, require the expenditure of
substantial time and financial resources. The regulatory requirements applicable to drug and biological product development, approval and marketing are subject to change, and regulations and administrative guidance often are revised or reinterpreted
by the agencies in ways that may have a significant impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>U.S. Government Regulation of Drug and Biological Products </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the FDA regulates human drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and in the case of biologics, also under the Public
Health Service Act, or the PHSA, and their implementing regulations. Failure to comply with the applicable U.S. requirements may result in FDA refusal to approve pending NDAs or BLAs or delays in development and may subject an applicant to
administrative or judicial sanctions, such as issuance of warning letters, or the imposition of fines, civil penalties, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or civil or
criminal prosecution brought by the FDA and the U.S. Department of Justice or other governmental entities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA must approve our product candidates for
therapeutic indications before they may be marketed in the United States. For drug products, the FDA must approve a NDA, and for biologic products, the FDA must approve a BLA. An applicant seeking approval to market and distribute a new drug or
biologic in the United States generally must satisfactorily complete each of the following steps: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">completion of preclinical laboratory tests and animal studies according to good laboratory practices, or GLP, regulations
or other applicable regulations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">116 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manufacture and testing of the therapeutic or biologic moiety and its respective product formulation according to good
manufacturing practices, or cGMP, regulations or other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin and must be updated
annually and amended when certain changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approval by an independent institutional review board, or IRB, or ethics committee representing each clinical trial site
before each clinical trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good
clinical practices, or GCPs, and other clinical-trial related regulations to evaluate the safety and efficacy of the investigational product for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparation and submission to the FDA of an NDA or BLA requesting marketing approval for one or more proposed indications,
including payment of application user fees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">review of the NDA or BLA by an FDA advisory committee, where applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug or
biologic and its respective finished product is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity, strength, quality and purity;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of any FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the
clinical data submitted in support of the NDA or BLA; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDA review and approval of the NDA or BLA, which may be subject to additional post- approval requirements, including the
potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS and any other potential post- approval studies required by the FDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preclinical Studies and IND </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before testing any drug or biological product
candidate in humans, the product candidate must undergo rigorous preclinical testing. The preclinical developmental stage generally involves laboratory evaluations of drug chemistry/biology, formulation, and stability, as well as in vitro and animal
studies to assess safety and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety and toxicology studies. The sponsor
must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin.
An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case,
the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Imposition of a clinical hold could cause significant delays or difficulties in initiating and/or completing planned clinical trials in a timely
manner. Certain long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may initiate or continue after an IND for an investigational product candidate is submitted to the FDA and human clinical trials
have been initiated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Human Clinical Trials in Support of an NDA or BLA </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials involve the administration of an investigational product candidate to healthy volunteers or patients with the disease to be treated under the
supervision of qualified investigators. Clinical trials are conducted under protocols detailing the objectives of the study, inclusion and exclusion criteria, dosing procedures and the parameters to be used in monitoring the safety and effectiveness
criteria to be evaluated. Each protocol, as well as any subsequent amendments, must be submitted to the FDA as part of the IND. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An IRB representing each
institution that is participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must thereafter conduct a continuing review of the trial. The IRB will consider,
among other things, clinical trial design, patient informed consent, ethical factors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">117 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and the safety of human subjects. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to clinical trial subjects or their legal
representatives and must operate in compliance with FDA regulations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials must also comply with extensive GCP standards intended to ensure protection of
human subjects and the quality and integrity of the study data, including requirements for obtaining subjects&#146; informed consent. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the
clinical trial sponsor, known as a data safety monitoring board or committee. This group may recommend continuation of the trial as planned, changes in trial conduct or cessation of the trial at designated checkpoints based on access to certain data
from the study. The FDA may at any time while clinical trials are ongoing impose a partial or complete clinical hold based on concerns for patient safety and/or noncompliance with regulatory requirements. This order issued by the FDA would cause
suspension of an ongoing trial until all outstanding concerns have been adequately addressed, and the FDA has notified the company that investigations may proceed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Human clinical trials to evaluate therapeutic indications to support NDAs and BLAs for marketing approval are typically conducted in three sequential phases that may
overlap or be combined: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 1: The product candidate is initially introduced into human subjects and tested for safety, dosage tolerance,
absorption, metabolism, distribution, and excretion, and if possible, to gain early evidence for effectiveness. Phase 1 trials may be conducted in healthy volunteers or, in the case of some products for severe or life-threatening diseases, including
many rare diseases, the initial human testing is often conducted in patients with the target disease or condition. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 2: Clinical trials are conducted in a limited patient population with a specified disease or condition to identify
possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted to obtain
information prior to beginning larger and more expensive Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 3: Clinical trials are undertaken with an expanded patient population to further evaluate dosage, and to provide
substantial evidence of clinical efficacy and safety in an expanded patient population, often at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product candidate and
provide, if appropriate, an adequate basis for product labeling. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used
to gain additional experience from the treatment of patients in the intended therapeutic indication, to document a clinical benefit in the case of drugs or biologics approved under FDA&#146;s accelerated approval regulations and to generate
additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA. Failure to exhibit due diligence with regard
to conducting Phase 4 clinical trials could result in withdrawal of approval for the product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA or the sponsor may suspend or terminate a clinical trial at
any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical
trial is not being conducted in accordance with the clinical protocol, GCP or other IRB requirements or if the drug has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Information about certain clinical trials, including details of the protocol and eventually study results, also must be submitted within specific time frames to the
National Institutes of Health for public dissemination on the ClinicalTrials.gov data registry. Similar requirements for posting clinical trial information in clinical trial registries exist in the EU and in other countries outside the United
States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the development of a new drug or biological product, sponsors have the opportunity to meet with the FDA at certain points, including prior to
submission of an IND, at the end of phase 2 and before submission of an NDA or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">118 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
BLA. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of development. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional nonclinical studies and must also develop additional information about the physical
characteristics of the drug or biological product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches
of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, potency and purity of the final drug or biological product. For biological products in particular, the PHSA
emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined in order to help ensure safety, purity and potency. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo
unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Marketing Application Submission and FDA Review </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the
product&#146;s chemistry, manufacturing, controls (CMC) and proposed labeling, are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. Data may come from company-sponsored clinical
trials intended to test the safety and efficacy of a product&#146;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality to
establish the safety and efficacy of the investigational product to the satisfaction of the FDA. The fee required for the submission of an NDA or BLA under the Prescription Drug User Fee Act, or PDUFA, is substantial (for example, for FY2021 this
application fee is approximately $2.9 million), and the sponsor of an approved NDA or BLA is also subject to an annual program fee, currently more than $300,000 per program. These fees are typically adjusted annually, but exemptions and waivers may
be available under certain circumstances. No user fee is required for orphan drug product applications, except when an application also includes an indication for a <FONT STYLE="white-space:nowrap">non-rare</FONT> disease or condition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA conducts a preliminary review of all NDAs and BLAs within 60 days of receipt and informs the sponsor by the 74th day after the FDA&#146;s receipt of the
submission whether an application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the application must be resubmitted with the additional
information. The resubmitted application is also subject to review before the FDA accepts it for filing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the submission is accepted for filing, the FDA
begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from the filing date in which to complete its initial review of a
standard application and respond to the applicant and six months from the filing date for an application with &#147;priority review.&#148; The review process may be extended by the FDA for three additional months to consider new information or in
the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. Despite these review goals, it is not uncommon for FDA review of an NDA or BLA to extend beyond the
PDUFA goal date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before approving a NDA or BLA, the FDA will typically conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the
manufacturing facilities for the therapeutic/biologic to determine whether the manufacturing processes and facilities comply with GMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities comply
with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with GCP requirements and the
integrity of the clinical data submitted to the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the FDA may refer any NDA or BLA, including applications for novel product candidates which
present difficult questions of safety or efficacy, to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. Typically, an advisory committee is a panel of
independent experts, including clinicians and other scientific experts. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">119 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
approval. The FDA also may require submission of a REMS, if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the
drug or biological product. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS and the FDA will not approve the NDA or BLA without a REMS. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Pediatric Research Equity Act of 2003, or PREA, an NDA or BLA or certain supplements thereto must contain data that are adequate to assess the safety and
effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless this requirement is
waived, deferred or inapplicable. Sponsors must submit a pediatric study plan to FDA outlining the proposed pediatric study or studies they plan to conduct, including study objectives and design, any deferral or waiver requests and other information
required by regulation. The FDA must then review the information submitted, consult with the sponsor and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. In general, PREA requirements do not apply
to drugs or biologics for indications granted orphan drug designation by the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA reviews an NDA or BLA to determine, among other things, whether a product
is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#146;s identity, strength, quality and purity. The approval process is lengthy and often difficult, and the FDA may refuse
to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. After evaluating the application and all related information, including the advisory committee
recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA may issue either an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the
product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL generally outlines the deficiencies in
the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other
significant and time- consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the applicant may either resubmit the NDA or BLA addressing all of the deficiencies identified in the letter or
withdraw the application. If and when those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the NDA or BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in response
to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria
for approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product receives regulatory approval from the FDA, the approval is limited to the conditions of use (e.g., patient population, indication)
described in the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling,
require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#146;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other
conditions, including distribution and use restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product
based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further
testing requirements and FDA review and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Regulation of Combination Products </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain products may be comprised of components, such as drug or biologic components and device components that would normally be regulated under different types of
regulations, and frequently by different centers at the FDA. These products are known as combination products. We expect to rely on a delivery system, such as <FONT STYLE="white-space:nowrap">pre-filled</FONT> syringes, <FONT
STYLE="white-space:nowrap">pen-injectors</FONT> and/or autoinjectors to deliver certain of our product candidates. Although we have not yet selected the delivery system to use for administration of such product candidates, including RLYB212 and
RLYB116, we expect that, if approved, any such product candidate would be regulated as a combination product, because it is composed of both a drug or biological product and a delivery system &#147;device.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">120 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the FDCA and its implementing regulations, the FDA is charged with assigning a center with primary jurisdiction, or
a lead center, for review of a combination product. The designation of a lead center generally eliminates the need to receive approvals from more than one FDA center for combination products, although the lead center may consult with other centers
within the FDA. The determination of which center will be the lead center is based on the &#147;primary mode of action&#148; of the combination product. Thus, if the primary mode of action of a drug-device combination product is attributable to the
drug product, the FDA center responsible for review of the drug product would have primary jurisdiction for the combination product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A combination product
involving a novel drug or biological product and delivery system generally would have a drug or biologic primary mode of action. A combination product with a drug or biologic primary mode of action would be reviewed and approved pursuant to the drug
or biologic approval processes. In reviewing the NDA or BLA for such a product, however, the FDA review division reviewing the application could consult with their counterparts in the device center to ensure that the device component of the
combination product met applicable requirements regarding safety, effectiveness, durability and performance. Approval may require the performance of certain clinical studies, such as clinical usability or human factors studies to demonstrate the
safety and/or effectiveness of the device component of the combination product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similar considerations apply to regulation of drugs combined with delivery systems
outside the United States, including in the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Expedited Programs for Serious Conditions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a
serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation, priority review designation and accelerated approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or
life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors.
Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The FDA also may review sections of the NDA or BLA for a fast track product on a rolling basis
before the complete application is submitted if the sponsor and the FDA agree on a schedule for the submission of the application sections and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA. Fast track
designation may be rescinded by the FDA if the designation is no longer supported by data emerging from the clinical trial process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, a new drug or
biological product may be eligible for Breakthrough Therapy designation if it is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical
evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough
Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient development program beginning as early as Phase 1 and FDA organizational commitment to expedited development, including
involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate. Breakthrough designation may be rescinded by the FDA if the designation is no longer supported. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may designate a product for priority review if it is a drug or biologic that treats a serious condition and, if approved, would provide a significant
improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case- <FONT STYLE="white-space:nowrap">by-case</FONT> basis, whether the proposed drug or biologic qualifies for priority
review. Significant improvement over available therapies may be illustrated, for example, by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented
enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation
of such applications and to shorten the FDA&#146;s goal for taking action on a marketing application from ten months to six months for an original BLA or NDA from the date of filing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">121 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval and
may not ultimately expedite the development or approval process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Finally, the FDA may grant accelerated approval to a product for a serious or life-threatening
condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also
grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict
an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. For drugs granted accelerated approval, FDA generally requires sponsors to
conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. Failure to conduct required post-approval studies with due diligence, failure to confirm a clinical benefit
during the post-approval studies, or dissemination of false or misleading promotional materials would allow the FDA to withdraw the product approval on an expedited basis. All promotional materials for product candidates approved under accelerated
approval are subject to prior review by the FDA unless FDA informs the applicant otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Post-approval Requirements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, governing, among other
things, monitoring and recordkeeping activities, reporting of adverse experiences with the product and product problems to the FDA, product sampling and distribution, manufacturing and promotion and advertising. Although physicians may prescribe
legally available products for unapproved uses or patient populations (i.e., <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> uses&#148;), manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws
and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant
liability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be
required to submit and obtain FDA approval of a new NDA/BLA or an NDA/BLA supplement, which may require the applicant to develop additional data or conduct additional preclinical studies and clinical trials. The FDA may also place other conditions
on approvals including the requirement for a REMS to assure the safe use of the product, which may require substantial commitment of resources post-approval to ensure compliance. A REMS could include medication guides, physician communication plans
or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or
dispensing of products. Product approvals may be withdrawn for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards or if problems occur following initial marketing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FDA regulations require that drug and biological products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include
requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution,
laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and satisfy the FDA or comparable foreign regulatory authorities&#146; satisfaction
before any product is approved and our commercial products can be manufactured. In addition, for any of our product candidates that include a device delivery system, the device component will be subject to aspects of the Quality System Regulations,
or QSRs, applicable to medical devices. Manufacturers of drug-device combination products may either opt to comply with all quality regulations governing each component of the product separately, or may take a &#147;streamlined approach&#148; to
cGMP that allows the manufacturer to demonstrate compliance with the drug cGMPs along with compliance with several specific provisions from the device QSR&#151;namely, management responsibility, design controls, purchasing controls, corrective and
preventive action, installation, and servicing, as applicable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We rely, and expect to continue to rely, on third parties for the production of clinical and
commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">122 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
including requirements for quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP.
Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by
the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Future inspections by
the FDA and other regulatory agencies may identify compliance issues at the facilities of our CMOs that may disrupt production or distribution or require substantial resources to correct. In addition, the discovery of conditions that violate these
rules, including failure to conform to cGMPs, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA or BLA, including
voluntary recall and regulatory sanctions as described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once an approval of a drug/biologic product is granted, the FDA may withdraw the approval if
compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or
frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information, imposition of post-market clinical trials requirement to assess
new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other
safety information about a product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">mandated modification of promotional materials and labeling and issuance of corrective information; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, warning letters, untitled letters or other enforcement-related letters or clinical holds on post-approval clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal of the FDA to approve pending NDAs/BLAs or supplements to approved NDAs/BLAs, or suspension or revocation of
product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions or the imposition of civil or criminal penalties; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated
modification of promotional materials and labeling and the issuance of corrective information. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the distribution of prescription
pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors
by the states. Additionally, the Drug Supply Chain Security Act, or DSCSA, imposes requirements related to identifying and tracing certain prescription drugs distributed in the United States, including most biological products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>United States Patent Term Restoration and Hatch-Waxman Marketing Exclusivity </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depending upon the timing, duration and specifics of FDA approval for our product candidates, some of our United States patents may be eligible for limited patent term
extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch Waxman Amendments permit restoration of the patent term up to five years as compensation for patent
term lost during the FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date, and only those claims covering such approved drug
product, a method for using it or a method for manufacturing it may be extended. The patent-term restoration period is generally <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the submission date
of an NDA or BLA plus the time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension, and the application for the extension must be submitted prior to the expiration
of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">123 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications.
The FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if
the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA, or a
505(b)(2) NDA submitted by another company for another version of such drug. However, an application may be submitted after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT>
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDCA also provides three years of exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than
bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity covers only the conditions of use associated with the new clinical
investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent for other conditions of use. Three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant
submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, both drugs and biologics can obtain pediatric exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity
periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance
with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Biosimilars and Reference Product Exclusivity for
Biological Products </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2010, the Patient Protection and Affordable Care Act was enacted in the United States and included the Biologics Price Competition
and Innovation Act of 2009, or the BPCIA. The BPCIA amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference
biological product. To date, the FDA has approved a number of biosimilars. No interchangeable biosimilars, however, have been approved. The FDA has also issued several guidance documents outlining its approach to reviewing and approving biosimilars
and interchangeable biosimilars. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the BPCIA, a manufacturer may submit an application that is &#147;biosimilar to&#148; or &#147;interchangeable with&#148; a
previously approved biological product or &#147;reference product.&#148; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar
product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the
reference product and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to
exclusive use of the reference biologic. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product, although to
date no such products have been approved for marketing in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biosimilar applicant must demonstrate that the product is biosimilar based on data
from analytical studies showing that the biosimilar product is highly similar to the reference product, data from animal studies (including toxicity) and data from one or more clinical studies to demonstrate safety, purity and potency in one or more
appropriate conditions of use for which the reference product is approved. In addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of
administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity, and potency. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A reference biological
product is granted 12 years of data exclusivity from the time of first licensure of the product, and the first approved interchangeable biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed.
The FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">124 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The BPCIA is complex and only beginning to be interpreted and implemented by the FDA. In addition, recent government
proposals have sought to reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent
litigation. As a result, the ultimate impact, implementation and meaning of the BPCIA is subject to significant uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Orphan Drug Designation and
Exclusivity </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for the treatment of rare diseases or
conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which
there is no reasonable expectation that the cost of developing and making the product available for the disease or condition will be recovered from sales of the product in the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan drug designation qualifies a company for certain tax credits. In addition, if a product candidate that has orphan drug designation subsequently receives the
first FDA approval for that drug for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication
for seven years following product approval unless the subsequent product candidate is demonstrated to be clinically superior. Absent a showing of clinical superiority, the FDA cannot approve the same product made by another manufacturer for the same
indication during the market exclusivity period unless it has the consent of the sponsor or the sponsor is unable to provide sufficient quantities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A sponsor may
request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but
each sponsor seeking orphan drug designation must file a complete orphan disease designation application. To qualify for orphan exclusivity, however, the drug must be clinically superior to the previously approved product that is the same drug for
the same condition. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB211 and RLYB212 have each been granted orphan drug designation by the FDA for the prevention of FNAIT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rare Pediatric Disease Designation and Priority Review Vouchers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2012,
Congress enacted the Food and Drug Administration Safety and Innovation Act requiring the FDA to award priority review vouchers to sponsors of certain&nbsp;rare pediatric disease&nbsp;product applications. This program is designed to encourage
development of new drug and biological products for prevention and treatment of &#147;rare pediatric diseases&#148; by, upon initial approval of an application meeting certain specified criteria, providing companies with a voucher that can be
redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a&nbsp;rare pediatric disease&nbsp;drug product receiving a priority review voucher may sell or otherwise transfer the voucher to
another company. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted an application relying on the priority review voucher. The FDA may also revoke
any rare pediatric disease priority review voucher if the&nbsp;rare pediatric disease&nbsp;product for which the voucher was awarded is not marketed in the United States within one year following the date of approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to receive a rare pediatric disease priority review voucher upon BLA or NDA approval, the product must receive designation from the FDA as a drug for a rare
pediatric disease prior to submission of the marketing application. A &#147;rare pediatric disease&#148; is a disease that is serious or life-threatening, in which the serious or life-threatening manifestations primarily affect individuals aged from
birth to 18 years and affects fewer than 200,000 people in the United States, or affects more than 200,000 people in the United States but there is no reasonable expectation that the cost of developing and making available in the United States a
drug for such disease or condition will be recovered from sales in the United States of such drug.&nbsp;In addition to receiving rare pediatric disease designation, in order to receive a rare pediatric disease priority review voucher, the NDA or BLA
must be given priority review, rely on clinical data derived from studies examining a pediatric population and dosages of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">125 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
drug intended for that population, not seek approval for a different adult indication in the original rare pediatric disease product application and be for a drug that does not include a
previously approved active ingredient. In addition, under current statutory sunset provisions, even if a marketing application meets all of these requirements, FDA may only award a voucher prior to September&nbsp;30, 2026 and only if the approved
product received rare pediatric disease drug product designation prior to September&nbsp;30, 2024. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB211 and RLYB212 have each been granted rare pediatric
disease designation by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>FDA Approval or Clearance of Companion Diagnostics </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the FDCA, <I>in vitro </I>diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its<I>
</I>implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and<I> </I>development, preclinical and clinical testing, premarket clearance or approval, registration and listing,
manufacturing, labeling, storage, advertising<I> </I>and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require<I> marketing clearance via 510(k) notification or
approval via Premarket Approval (&#147;PMA&#148;) application from the FDA prior to commercial distribution. </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2014, the FDA issued final guidance
clarifying the requirements that will apply to approval of therapeutic products and <I>in vitro </I>companion diagnostics. According to the guidance, for novel drugs and biologics, a companion diagnostic device and its corresponding<I>
</I>therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#146;s labeling. Approval or<I> </I>clearance of the companion diagnostic device will ensure that the device has been
adequately evaluated and has adequate performance<I> </I>characteristics in the intended population. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the therapeutic products<I> </I>and <I>in vitro </I>companion
diagnostic devices on issues related to <FONT STYLE="white-space:nowrap">co-development</FONT> of the products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA previously has required <I>in vitro
</I>companion diagnostics intended to select the patients who will respond to a product candidate to obtain <FONT STYLE="white-space:nowrap">pre-market</FONT> approval, or PMA, simultaneously with approval of the therapeutic product candidate. The
PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA
with reasonable assurance of the device&#146;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. PMA applications are subject to an application
fee, which for fiscal year 2021 is $365,657. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A clinical trial is typically required for a PMA application and, in some cases, the FDA may require a clinical study
in support of a 510(k) submission. A manufacturer that wishes to conduct a clinical study involving the device is subject to the FDA&#146;s investigational device exemption, or IDE, regulation. The IDE regulations distinguish between significant and
<FONT STYLE="white-space:nowrap">non-significant</FONT> risk device studies and the procedures for obtaining approval to begin the study differ accordingly. Also, some types of studies are exempt from the IDE regulations. A significant risk device
presents a potential for serious risk to the health, safety, or welfare of a subject. Significant risk devices are devices that are substantially important in diagnosing, curing, mitigating, or treating disease or in preventing impairment to human
health. Studies of devices that pose a significant risk require both FDA and an IRB approval prior to initiation of a clinical study. Many companion diagnostics are considered significant risk devices due to their role in diagnosing a disease or
condition. <FONT STYLE="white-space:nowrap">Non-significant</FONT> risk devices are devices that do not pose a significant risk to the human subjects. A <FONT STYLE="white-space:nowrap">non-significant</FONT> risk device study requires only IRB
approval prior to initiation of a clinical study. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical
devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. In the United States, device manufacturers are also subject to
FDA&#146;s medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it
markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, and FDA&#146;s correction and removal reporting regulations, which require that manufacturers report to the FDA corrections or removals if
undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health. A medical device manufacturer&#146;s manufacturing processes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">126 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and those of its suppliers are required to comply with the applicable portions of the Quality System Regulation, which covers the methods and documentation of the design, testing, production,
processes, controls, quality assurance, labeling, packaging, and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign
facilities that export products to the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Regulation Outside of the United States </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution
of our products outside of the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the <FONT
STYLE="white-space:nowrap">27-member</FONT> EU, before we may commence clinical trials or market products in those countries or areas. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The United Kingdom&#146;s,
or the U.K., withdrawal from the EU took place on January&nbsp;31, 2020. The EU and the U.K. reached an agreement on their new partnership in the Trade and Cooperation Agreement, or the Agreement, to be applied from January 1, 2021. The Agreement
focuses primarily on free trade by ensuring no tariffs or quotas on trade in goods, including healthcare products such as medicinal products. Thereafter, the EU and the U.K. will form two separate markets governed by two distinct regulatory and
legal regimes. As such, the Agreement seeks to minimize barriers to trade in goods while accepting that border checks will become inevitable as a consequence that the U.K. is no longer part of the single market. As of January&nbsp;1, 2021, the
Medicines and Healthcare products Regulatory Agency, or the MHRA, becomes responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law whereas Northern Ireland will continue to
be subject to EU rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law the
body of EU law instruments governing medicinal products that <FONT STYLE="white-space:nowrap">pre-existed</FONT> prior to the U.K.&#146;s withdrawal from the EU. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With the exception of the EU/EEA applying the harmonized regulatory rules for medicinal products, the approval process and requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approval in other countries
and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval
in one country or jurisdiction may negatively impact the regulatory process in others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Union Drug Development, Review and Approval </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, our product candidates also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a
marketing authorization from the competent regulatory agencies has been obtained. Similar to the United States, the various phases of preclinical and clinical research in the EU are subject to significant regulatory controls. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual EU Member States govern the
system for the approval of clinical trials in the EU. Under this system, an applicant must obtain prior approval from the competent national authority of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant
may only start a clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an IMPD (investigational medicinal product
dossier principally based on the Common Technical Document developed by the International Council for Harmonization) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, and where relevant the implementing national
provisions of the individual EU Member States and further detailed in applicable guidance documents issued by the European Commission and European Medicines Agency. All suspected unexpected serious adverse reactions to the investigated drug that
occur during the clinical trial have to be reported to the competent national authority and the Ethics Committee of the Member State where the clinical trial takes place. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">127 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014, or the Clinical Trials Regulation, was adopted and it
is anticipated to come into application in late 2021 but could be delayed, subject to the full functionality of the Clinical Trials Information System (CTIS) through an independent audit. The Clinical Trials Regulation will come into application in
all the EU Member States, repealing the current Clinical Trials Directive 2001/20/EC. Conduct of all clinical trials performed in the EU will continue to be bound by currently applicable provisions until the new Clinical Trials Regulation becomes
applicable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation will
come into application and on the duration of the individual clinical trial. According to the transitional provisions, if a clinical trial continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable the
Clinical Trials Regulation will at that time begin to apply to the clinical trial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Clinical Trials Regulation aims to simplify and streamline the approval of
clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the &#147;EU portal&#148;; a single set of documents to be prepared and submitted for the application as
well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member
States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical
trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials
Regulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For any of our product candidates that incorporate a medical device to administer the medicinal product and are intended to be commercialized as a
single integral product intended exclusively for use in the given combination and not usable separately, then the combination product is regulated by Directive 2001/83/EC or Regulation (EC) 726/2004 as a medicinal product. However, the medical
device used for administration must satisfy the requirements for its general safety and performance under EU law governing general medical devices. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EU
regulatory regime currently provided under Directive 93/42/EEC, or the Medical Devices Directive, will be replaced by Regulation (EU) 2017/745 on medical devices, or the Medical Devices Regulation. The Medical Devices Regulation will come into
application on May&nbsp;26, 2021, subject to the transitional provisions for certain medical devices to remain on the EU market if they were certified under the Medical Devices Directive for a limited period. There are significant changes to the EU
regulatory system governing medical devices under the Medical Devices Regulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Medical Devices Regulation, data relating to the general safety and
performance of the medical device must be contained in an application for marketing authorization for the combination product. Such information must be provided by the manufacturer of the medical device in its EU declaration of conformity or the
relevant certificate issued by a notified body allowing the medical device manufacturer to affix a European Conformity (&#147;CE&#148;) mark to the medical device. If the dossier submitted to support the marketing authorization does not include the
results of the conformity assessment and where for the conformity assessment of the device, if used separately, the involvement of a notified body is required in accordance with the Medical Devices Regulation, the medicinal products authority such
as the EMA can require the applicant for a marketing authorization to provide an opinion on the conformity of the device part with the relevant general safety and performance requirements issued by a designated notified body. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Marketing authorization applications, or MAA, can be filed either under the <FONT STYLE="white-space:nowrap">so-called</FONT> centralized or national authorization
procedures, albeit through the Mutual Recognition or Decentralized procedure for a product to be authorized in more than one EU member state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Centralized
Procedure </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The centralized procedure provides for the grant of a single marketing authorization following a favorable opinion by the European Medicines Agency,
or EMA, that is valid in all EU Member States, as well as Iceland, Liechtenstein </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">128 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and Norway, which are part of the EEA. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products,
advanced-therapy medicines (such as gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of specified diseases, such as HIV/ AIDS, cancer, diabetes, neurodegenerative
disorders or autoimmune diseases and other immune dysfunctions and viral diseases. The centralized procedure is optional for products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in
the interest of public health. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in
response to questions asked by the Committee for Medicinal Products for Human Use, or the CHMP. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest,
particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is of 150 days, excluding stop-clocks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>National Authorization Procedures </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are also two other possible routes
to authorize medicinal products in several EU countries, which are available for medicinal products that fall outside the scope of the centralized procedure: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Decentralized procedure</I></B>. Using the decentralized procedure, an applicant may apply for simultaneous
authorization in more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure. The applicant may choose a member state as the
reference member State to lead the scientific evaluation of the application. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Mutual recognition procedure</I></B>. In the mutual recognition procedure, a medicine is first authorized in one EU
Member State (which acts as the reference member state), in accordance with the national procedures of that country. Following this, further marketing authorizations can be progressively sought from other EU countries in a procedure whereby the
countries concerned agree to recognize the validity of the original, national marketing authorization produced by the reference member state. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the above-described procedures, before granting the marketing authorization, the EMA or the competent authorities of the Member States of the EEA assess the
risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conditional Marketing Authorization
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In specific circumstances, E.U. legislation (Article 14&#150;a Regulation (EC) No 726/2004 (as amended by Regulation (EU) 2019/5 and Regulation (EC) No
507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full
marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1)&nbsp;the product candidate is intended for the treatment, prevention or medical diagnosis
of seriously debilitating or life-threatening diseases; (2)&nbsp;the drug candidate is intended to meet unmet medical needs of patients; (3)&nbsp;a marketing authorization may be granted prior to submission of comprehensive clinical data provided
that the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required; (4)&nbsp;the risk-benefit balance of the product candidate is positive,
and (5)&nbsp;it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization
holder, including obligations with respect to the completion of ongoing or new studies and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the
risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP
of applications for a conditional marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Pediatric Studies </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to obtaining a marketing authorization in the EU, applicants have to demonstrate compliance with all measures included in an
<FONT STYLE="white-space:nowrap">EMA-approved</FONT> Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">129 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
unless the EMA has granted a product-specific waiver, a class waiver or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization
procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form, or route of administration for a medicine
that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness
and safety in adults. The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate because (a)&nbsp;the product is likely to be ineffective or unsafe in part or all of the pediatric population;
(b)&nbsp;the disease or condition occurs only in adult population; or (c)&nbsp;the product does not represent a significant therapeutic benefit over existing treatments for pediatric population. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP. This compliance check requirement applies to
(a)&nbsp;a marketing authorization application based on a full stand-alone dossier provided under Article 8(3) of Directive 2001/83/EC and (b)&nbsp;an application for variation or line-extension for a new pharmaceutical form or a new indication
where the product is protected by a subsisting supplementary protection certificate (a form of patent extension under EU law) or a patent that qualifies for grant of a supplementary protection certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Union Regulatory Data Exclusivity </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, new products
authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants
from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference
product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference
product in the EU. The <FONT STYLE="white-space:nowrap">ten-year</FONT> market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an
authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Union Orphan Designation and Exclusivity </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The criteria for
designating an orphan medicinal product in the EU are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1)&nbsp;it is intended for the diagnosis,
prevention or treatment of a life- threatening or chronically debilitating condition, (2)&nbsp;either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b)&nbsp;the product, without the
benefits derived from orphan status, would not generate sufficient return in the EU to justify investment and (3)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or
if such a method exists, the product will be of significant benefit to those affected by the condition. The term &#145;significant benefit&#146; is defined in Regulation (EC) 847/2000 to mean a clinically relevant advantage or a major contribution
to patient care. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing
authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. During this ten year market exclusivity period, the EMA or the competent authorities of the Member States of the EEA, cannot accept an application
for a marketing authorization for a similar medicinal product for the same indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal
product, and which is intended for the same therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the marketing
authorization application if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of,
the regulatory review and approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">130 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">ten-year</FONT> market exclusivity in the EU may be reduced to six years if, at the
end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing
authorization may be granted to a similar product for the same indication at any time if: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically
superior; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the applicant consents to a second orphan medicinal product application; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the applicant cannot supply enough orphan medicinal product. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB211 and RLYB212 have each been granted orphan drug designation by the EMA for the prevention of FNAIT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRIME Designation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EMA grants access to the Priority Medicines, or
PRIME, program to investigational medicines for which it determines there to be preliminary data available showing the potential to address an unmet medical need and bring a major therapeutic advantage to patients. As part of the program, EMA
provides early and enhanced dialogue and support to optimize the development of eligible medicines and speed up their evaluation, aiming to bring promising treatments to patients sooner. Rallybio anticipates that it will request PRIME designation
for certain of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Periods of Authorization and Renewals </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a <FONT
STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority
with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid. Once
renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any
authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the <FONT
STYLE="white-space:nowrap">so-called</FONT> sunset clause). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rest of the World Regulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For other countries outside of the EU and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance with cGCP requirements and the applicable regulatory requirements and the ethical
principles that have their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among
other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Coverage, Pricing and Reimbursement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of any biopharmaceutical
products, if and when approved by the FDA or analogous authorities outside the United States, will depend in significant part on the availability of third-party coverage and reimbursement for the products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, third-party payors include government healthcare programs such as Medicare and Medicaid, private health insurers, managed care plans and other
organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services, including biopharmaceutical products. Significant uncertainty exists regarding coverage and
reimbursement for newly approved </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">131 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
healthcare products. Coverage does not ensure reimbursement. It is time consuming and expensive to seek coverage and reimbursement from third-party payors. We may need to conduct expensive
pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA regulatory approvals. Third-party payors may take into account clinical practice guidelines in
determining coverage and there may be significant delays before our products are addressed by such guidelines and we cannot predict what position such guidelines would take with respect to our products if and when addressed. Third-party payors may
limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication, or utilize other mechanisms to manage utilization (such as requiring prior authorization for
coverage for a product for use in a particular patient). Limits on coverage may impact demand for our products. Even if coverage is obtained, third-party reimbursement may not be adequate to allow us to sell our products on a competitive and
profitable basis. As result, we may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing
vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of
our product candidate to currently available therapies (so called health technology assessment, or HTA) in order to obtain reimbursement or pricing approval. For example, subject to the requirements set out in Directive 89/105/EEC relating to the
transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems, EU Member States have the legal competence to set national measures of an economic nature on
the marketing of medicinal products in order to control public health expenditure on such products. Accordingly, EU Member States can restrict the range of medicinal products for which their national health insurance systems provide reimbursement
and to control the prices of medicinal products for human use. An EU Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the
medicinal product on the market. Other EU Member States allow companies to fix their own prices for drug products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. There can be no assurance that
any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price
structures of the United States and generally tend to be significantly lower. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The downward pressure on health care costs in general, particularly prescription
drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as
part of cost containment measures. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member
States and parallel import or distribution (arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states) can further reduce prices. Any country that has price controls or reimbursement limitations for drug
products may not allow favorable reimbursement and pricing arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other U.S. Health Care Laws and Regulations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, biopharmaceutical manufacturers and their products are subject to extensive regulation at the federal and state level, such as laws intended to
prevent fraud and abuse in the healthcare industry. These laws, some of which will apply only if and when we have an approved product, include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from
knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting,
receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and
Medicaid; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">132 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to privacy
protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products
prior to approval or for <FONT STYLE="white-space:nowrap">off-label</FONT> use and regulates the distribution of samples; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or
provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal Open Payments (or federal &#147;sunshine&#148; law), which requires pharmaceutical and medical device companies to
monitor and report certain financial interactions with certain healthcare providers to the Center for Medicare&nbsp;&amp; Medicaid Services within the U.S. Department of Health and Human Services for
<FONT STYLE="white-space:nowrap">re-disclosure</FONT> to the public, as well as ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">analogous state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring
pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health
care providers or marketing expenditures; and state laws governing privacy, security and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">laws and regulations prohibiting bribery and corruption, such as the FCPA, which, among other things, prohibits U.S.
companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international
organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, exclusion from participation in federal and state health care
programs, such as Medicare and Medicaid. Ensuring compliance is time consuming and costly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similar healthcare laws and regulations exist in the EU and other
jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of personal information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Health Care Reform in the United States and Potential Changes to Health Care Laws </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Health care reform has been a significant trend in the U.S. health care industry and elsewhere. In particular, government authorities and other third-party payors have
attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services. Under the Trump administration, there were efforts to repeal or modify prior health care reform legislation and regulation
and to implement new health care reform measures, including measures related to payment for drugs under government health care programs. The nature and scope of health care reform in the wake of the transition from the Trump administration to the
Biden administration remains uncertain but early actions include additional health care reform as well as challenges to actions taken under the Trump administration. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There has been heightened governmental scrutiny in recent years over the manner in which manufacturers set prices for their marketed products, which has resulted in
proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing and reform government program reimbursement methodologies for pharmaceutical and biologic products. At the state level,
individual states are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">133 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. These measures could reduce the ultimate
demand for our products, once approved, or put pressure on our product pricing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot predict the likelihood, nature or extent of government regulation that
may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional federal and state health care reform measures will be adopted in the future, any of which could limit the
amounts that federal and state governments will pay for health care products and services. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For a more detailed discussion of health care reform in the U.S.,
see &#147;Risk Factors&#151;Risks Related to Healthcare Laws and Other Legal Compliance Matters.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Data Privacy Regulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>U.S. Privacy Law </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are numerous U.S. federal and state laws and
regulations related to the privacy and security of personal information, including laws requiring the safeguarding of personal information and laws requiring notification to governmental authorities and data subjects as well as remediation in the
event of a data breach. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been several developments in recent years with respect to U.S. state data privacy laws. In 2018, California passed into law the
CCPA, which took effect on January&nbsp;1,&nbsp;2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#146;s requirements are similar to those found in the GDPR, including
requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain
cases, request the erasure of such personal information. The CCPA also affords California residents the right to <FONT STYLE="white-space:nowrap">opt-out</FONT> of &#147;sales&#148; of their personal information. The CCPA contains significant
penalties for companies that violate its requirements. It also provides California residents a private right of action, including the ability to seek statutory damages, in the event of a breach involving their personal information. Compliance with
the CCPA is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. On November&nbsp;3, 2020, California voters passed a ballot initiative
for the CPRA, which will significantly expand the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention and sharing of personal information of California residents be reasonably necessary and proportionate
to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA will also expand personal
information rights of California residents, including creating a right to opt out of sharing of personal information with third parties for advertising, expanding the lookback period for the right to know about personal information held by
businesses, and expanding the right to erasure for information held by third parties. Most CPRA provisions will take effect on January&nbsp;1, 2023, though the obligations will apply to any personal information collected after January&nbsp;1, 2022.
Similar laws have been proposed or passed at the U.S. federal and state level, including the Virginia Consumer Data Protection Act, which will take effect on January&nbsp;1, 2023. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General data protection regulation (GDPR) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many countries outside of the
United States maintain rigorous laws governing the privacy and security of personal information. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located
in the EEA, and the processing of personal data that takes place in the EEA, is subject to the GDPR, which became effective on May&nbsp;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal
data, and it imposes heightened requirements on companies that process health and other sensitive data, such as requiring in many situations that a company obtain the consent of the individuals to whom the sensitive personal data relate before
processing such data. Examples of obligations imposed by the GDPR on companies processing personal data that fall within the scope of the GDPR include providing information to individuals regarding data processing activities, implementing safeguards
to protect the security and confidentiality of personal data, appointing a data protection officer, providing notification of data breaches and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the
transfer of personal data to countries outside the EEA, including the United States, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">134 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to
<FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million, or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with
supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase the cost of doing business or require
companies to change their business practices to ensure full compliance. In July 2020, the Court of Justice of the European Union, or the CJEU, invalidated the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield framework, one of the
mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for
transfers of personal data from the EEA to the United States. Following the withdrawal of the U.K. from the EU, the U.K. Data Protection Act 2018 applies to the processing of personal data that takes place in the U.K. and includes parallel
obligations to those set forth by GDPR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our employees are driven by our mission to identify and accelerate the development of transformative therapies for patients with rare disorders. We believe that our
deep commitment to high ethical and professional standards is fundamental to our mission, and we are determined to build a culture that values diversity, inclusiveness and equity, and empowers a skilled and experienced workforce to perform at the
highest levels. We commit our resources and make investments, including through recruiting, training and collaboration, to promote the culture that we desire, and we expect our employees to embrace the company&#146;s values and culture in all that
we do. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;31, 2021, we employed 22 full-time employees. Of our full-time employees, 13 employees are engaged in new product sourcing through business
development, research, manufacturing, product development and clinical development, and 9 are engaged in finance, human resources, legal and other administrative functions. None of our employees are represented by a labor union or covered by a
collective bargaining agreement. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our human capital resources objectives include, as applicable,
identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the
granting of stock-based and cash-based incentive awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We offer a benefits
program that provides resources to help employees manage their health, finances and life outside of work. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our corporate headquarters is located at 234 Church Street, Suite 1020, New Haven, CT 06510, where we lease and occupy 4,500 square feet of office space. The current
term of our New Haven lease expires May&nbsp;31, 2025. We also lease 117 square feet of office space at 400 Farmington Avenue, Suite R2846, Farmington, CT 06032. The current term of our Farmington lease expires January&nbsp;31, 2022. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe our existing facilities are sufficient for our current needs. To meet the future needs of our business, we expect to lease additional or alternate office
space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the
opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and
settlement costs, diversion of management resources, negative publicity and reputational harm and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">135 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our executive officers and directors,
their ages as of March&nbsp;31, 2021, and their positions, are as set forth below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>POSITION(S)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">64</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Chairman</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Operating Officer and Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey M. Fryer, CPA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer and Treasurer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">70</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Management</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rob Hopfner, R.Ph., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">48</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ronald M. Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">38</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kush M. Parmar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Timothy M. Shannon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">62</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Martin W. Mackay, Ph.D., </I></B>is a <FONT
STYLE="white-space:nowrap">co-founder</FONT> of, and has been Chief Executive Officer and Chairman of the board of directors of, Rallybio since January 2018. From March 2013 to December 2017, Dr.&nbsp;Mackay served as the Executive Vice President
and Global Head of Research&nbsp;&amp; Development at Alexion Pharmaceuticals, Inc., or Alexion, and, from July 2010 to January 2013, Dr.&nbsp;Mackay served as the President of Research&nbsp;&amp; Development at AstraZeneca PLC. Prior to
AstraZeneca, Dr.&nbsp;Mackay worked at Pfizer, Inc., or Pfizer, for 15 years where he held positions of increasing responsibility, including president, head of pharmatherapeutics research and development. Dr.&nbsp;Mackay currently serves on the
board of directors of 5:01 Acquisition Corp, Charles River Laboratories International, Inc., and Novo Nordisk A/S. Dr.&nbsp;Mackay earned a BSc First Class&nbsp;in microbiology from Heriot-Watt University and a Ph.D. in molecular genetics from the
University of Edinburgh. Dr.&nbsp;Mackay&#146;s extensive experience serving on other boards and leading research and development organizations at both global pharmaceutical and biotechnology companies provides our board of directors with a unique
combination of expertise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stephen Uden, M.D.,</I></B><B> </B>is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of, and has been President, Chief
Operating Officer and Chief Scientific Officer of Rallybio since January 2018. Previously, Dr.&nbsp;Uden served as Senior Vice President, Research at Alexion from June 2014 to October 2017. Prior to Alexion, Dr.&nbsp;Uden served in various
leadership roles in the research organizations of Novartis (Japan), Wyeth (Japan), Neurogen and Pfizer. Dr.&nbsp;Uden earned a BSc in biochemistry and an M.B., B.S. in medicine from the University of London. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Jeffrey M. Fryer</I></B><B>, CPA, </B>is<B> </B>a <FONT STYLE="white-space:nowrap">co-founder</FONT> of, and has been Chief Financial Officer and Treasurer of
Rallybio since January 2018. Previously, Mr.&nbsp;Fryer served as Vice-President and Chief Tax Officer of Alexion from April 2008 to April 2017. Prior to Alexion, Mr.&nbsp;Fryer lead the corporate tax functions at Chemtura Corporation and Lydall,
Inc., and served for over ten years with PwC as a senior tax manager. He earned an M.S. in taxation from the University of Hartford and a B.S. in business administration with a concentration in accounting from Bryant University. Mr.&nbsp;Fryer is a
member of the Dean&#146;s Advisory Council for the Bryant University School of Business. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Steven Ryder, M.D., </I></B>has been Chief Medical Officer of
Rallybio since January 2019. Previously, Dr. Ryder served as Chief Development Officer at Alexion from July 2013 to December 2018. From April 2008 to April 2013, Dr. Ryder served as President of Astellas Pharma Global Development at Astellas Inc, or
Astellas. Prior to joining Astellas, Dr. Ryder worked at Pfizer for 21 years where he held positions of increasing responsibility, including head of worldwide clinical development. Dr.&nbsp;Ryder earned an M.D. from the Icahn School of Medicine at
Mount Sinai. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">136 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Helen M. Boudreau </I></B>has served as a member of our board of directors since September 2020. From June 2018 to June 2019, Ms.&nbsp;Boudreau served as Chief
Operating Officer of the Bill&nbsp;&amp; Melinda Gates Medical Research Institute, a <FONT STYLE="white-space:nowrap">non-profit</FONT> biotech. Previously, she served as Chief Financial Officer from July 2017 to June 2018 and as a board member from
February 2016 to July 2017 of Proteostasis Therapeutics, Inc. From October 2014 to June 2017, Ms.&nbsp;Boudreau served as Chief Financial Officer of FORMA Therapeutics, Inc., and from September 2008 to September 2014, Ms.&nbsp;Boudreau served in
senior finance roles at Novartis AG, including Chief Financial Officer Novartis Corporation US and Chief Financial Officer Global Oncology. Prior to Novartis, Ms.&nbsp;Boudreau served in roles of increasing responsibility in strategy and finance at
Pfizer Inc. from April 1999 to September 2008, including Vice President Finance Customer Business Unit and Commercial Operations and Vice President Finance, Pfizer Global Research and Development. Ms.&nbsp;Boudreau worked earlier in her career at
PepsiCo Inc. and YUM! Brands, Inc., McKinsey&nbsp;&amp; Company and Bank of America Corporation. Ms.&nbsp;Boudreau currently serves as a board member of Evaxion Biotech A/S, Field Trip Health Ltd., Premier, Inc. and Shattuck Labs Inc.
Ms.&nbsp;Boudreau previously served on the board of directors of Proteostasis Therapeutics, Inc. Ms.&nbsp;Boudreau earned a B.A. in Economics from the University of Maryland, where she graduated <I>summa cum laude</I>, and an M.B.A. from the Darden
Graduate School of Business at the University of Virginia. We believe Ms.&nbsp;Boudreau is qualified to serve on our board of directors because of her financial expertise and extensive experience as an executive and director with biotechnology
companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rob Hopfner, R.Ph., Ph.D, </I></B>has served as a member of our board of directors since March 2020. Since October 2017, Dr.&nbsp;Hopfner has
served as a Managing Partner at Pivotal bioVenture Partners LLC, a venture capital firm. Prior to Pivotal, Dr.&nbsp;Hopfner served as a Principal at Bay City Capital LLC, a venture capital firm, from June 2007 to October 2009 and as a Managing
Director and Partner from October 2009 to September 2017. Dr.&nbsp;Hopfner currently serves as a board member of Vaxcyte, Inc. and Inozyme Pharma, Inc., and on the boards of a number of private life sciences companies. Dr.&nbsp;Hopfner earned a
B.Sc. in Pharmacy and a Ph.D. in Pharmacology from the University of Saskatchewan and an M.B.A. from the University of Chicago. We believe Dr.&nbsp;Hopfner is qualified to serve on our board of directors because of his experience in advising public
and private life sciences companies, as well as his research in the pharmaceutical field. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Ronald M. Hunt </I></B>has served as a member of our board of
directors since March 2019. Since 2005, Mr.&nbsp;Hunt has served as a Managing Director and Member of New Leaf Venture Partners, L.L.C., a venture capital firm. Previously, Mr.&nbsp;Hunt served at the Sprout Group, a venture capital firm and was a
consultant with consulting firms Coopers&nbsp;&amp; Lybrand Consulting and The Health Care Group, Inc. Mr.&nbsp;Hunt worked earlier in his career in various sales and marketing positions at Johnson&nbsp;&amp; Johnson and SmithKline Beecham
Pharmaceuticals PLC. Mr.&nbsp;Hunt currently serves as a board member of Harpoon Therapeutics, Inc. and Iterum Therapeutics, Ltd., a clinical-stage therapeutics company, and on the boards of a number of private pharmaceutical and healthcare
companies. Mr.&nbsp;Hunt previously served on the board of directors of Neuronetics, Inc. Mr.&nbsp;Hunt earned a B.S. from Cornell University and an M.B.A. from the Wharton School of the University of Pennsylvania. We believe Mr.&nbsp;Hunt is
qualified to serve on our board of directors because of his investment experience, his experience in the pharmaceutical industry and service on the boards of other public and private biopharmaceutical and biotechnology companies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Lucian Iancovici, M.D., </I></B>has served as a member of our board of directors since May 2020. Dr. Iancovici is currently a Managing Director of TPG Growth,
where he has worked since January 2018. From September 2012 to October 2017, Dr. Iancovici served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies. From January 2015 to October 2017, Dr.
Iancovici was a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. From 2011 to 2012, Dr. Iancovici was an associate at McKinsey &amp; Company. Lucian is a board certified internal medicine doctor,
who trained at Columbia University Medical Center in New York prior to joining McKinsey and Company. Dr. Iancovici earned his bachelor&#146;s degree in economics and an M.D., both from Tufts University. We believe that Dr. Iancovici is qualified to
serve on our board of directors because of his extensive experience in the venture capital industry, and his medical and scientific background and training. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Kush M. Parmar, M.D., Ph.D., </I></B>has served as a member of our board of directors since April 2018. Dr.&nbsp;Parmar is currently a Member of 5AM Venture
Management, LLC, where he has worked since 2010. Dr.&nbsp;Parmar also serves as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">137 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and as member of the board of directors of 5:01 Acquisition Corp, positions he has held since its inception in September 2020.
Dr.&nbsp;Parmar currently serves as a board member of Akouos, Inc., Entrada Therapeutics, Inc., Ensoma Inc., Homology Medicines, Inc. and Vor Biopharma Inc., and previously served on the board of directors of Arvinas, Inc., Audentes Therapeutics,
Inc. and scPharmaceuticals, Inc. Dr.&nbsp;Parmar earned a B.A. in molecular biology and medieval studies from Princeton University, a Ph.D. in experimental pathology from Harvard University and an M.D. from Harvard Medical School. We believe that
Dr.&nbsp;Parmar is qualified to serve on our board of directors because of his extensive experience in the venture capital industry, medical and scientific background and training, and service on the boards of other public and private
biopharmaceutical and biotechnology companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Timothy M. Shannon, M.D., </I></B>has served as a member of our board of directors since April 2018.
Dr.&nbsp;Shannon has been both a <FONT STYLE="white-space:nowrap">Non-Managing</FONT> Member of Canaan Partners IX LLC, a Managing Member of Canaan Partners X LLC, a Managing Member of Canaan Partners XI LLC, and a Managing Member of Canaan Partners
XII LLC, all entities affiliated with Canaan Partners, a venture capital firm, since November 2009. While at Canaan, Dr.&nbsp;Shannon served in a number of executive roles at biotechnology companies, including as President and Chief Executive
Officer of Aldea Pharmaceuticals, Inc. and of Arvinas, Inc. Prior to Canaan, Dr . Shannon served as Executive Vice President of R&amp;D and Chief Medical Officer of Curagen Corporation and Senior Vice President of Global Medical Development, Bayer
Healthcare LLC. Dr.&nbsp;Shannon currently serves as chairman of the board of directors of Arvinas, Inc. and of Ideaya Biosciences, Inc., as well as several privately held companies. Dr.&nbsp;Shannon previously served as a board member of NextCure
Inc., and CytomX Therapeutics, Inc. Dr.&nbsp;Shannon earned a B.A. in chemistry from Amherst College and an M.D. from the University of Connecticut. We believe Dr.&nbsp;Shannon is qualified to serve on our board of directors because of his extensive
experience in the venture capital industry, his executive leadership experience, his medical background and training, and his service on the boards of other public and private biopharmaceutical companies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Paula Soteropoulos </I></B>has served as a member of our board of directors since October 2020. Ms.&nbsp;Soteropoulos currently serves as the Executive Chairman
of Ensoma, a private venture-backed company. She previously served as Chief Executive Officer and President of Akcea Therapeutics, Inc. from January 2015 to September 2019, where she was also a member of the board of directors. Prior to Akcea,
Ms.&nbsp;Soteropoulos served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc., and prior to Moderna, she served in various roles of increasing responsibility at Genzyme
Corporation, including as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms.&nbsp;Soteropoulos currently serves on the board of directors of uniQure N.V. Ms.&nbsp;Soteropoulos also serves as a Strategic Advisor to 5AM Venture
Management, LLC. Ms.&nbsp;Soteropoulos earned both a B.S. in chemical and biochemical engineering and an M.S. in chemical and biochemical engineering from Tufts University, and holds an executive management certificate from the Darden Graduate
School of Business at the University of Virginia. Ms.&nbsp;Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University. We believe Ms.&nbsp;Soteropoulos is qualified to serve on our board of
directors because of her extensive experience in the biotechnology industry, her executive leadership experience and her service on the boards of other public and private biopharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition and Election of Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of managers currently
consists of eight members, all of whom were elected as managers pursuant to our Operating Agreement. The Operating Agreement will terminate prior to the consummation of this offering and there will be no further contractual obligations regarding the
election of our directors. Following the Reorganization, the board of directors of Rallybio Corporation, or the Corporation, will consist of the same eight members who will be duly elected in accordance with the bylaws of the Corporation. Our
directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are no family
relationships among any of our directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Classified Board of Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with our amended and restated certificate of incorporation, which will be in effect prior to the consummation of this offering, our board of directors
will be divided into three classes of directors. At each annual meeting of stockholders, a class of directors will be elected for a <FONT STYLE="white-space:nowrap">three-year</FONT> term to succeed the class whose terms
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">138 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
are then expiring, to serve from the time of election and qualification until the third annual meeting following their election or until their earlier death, resignation or removal. Upon the
closing of this offering, our directors will be divided among the three classes as follows: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Class&nbsp;I directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our 2022 annual meeting of stockholders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Class&nbsp;II directors will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our
2023 annual meeting of stockholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Class&nbsp;III directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our 2024 annual meeting of stockholders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation for the Corporation will provide that the authorized number of directors may be changed only by resolution of our
board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of
<FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered <FONT STYLE="white-space:nowrap">three-year</FONT> terms may delay or prevent a change of our management or
a change in control. See the section of this prospectus captioned &#147;Description of Capital <FONT STYLE="white-space:nowrap">Stock&#151;Anti-takeover</FONT> Effects of Our Amended and Restated Certificate of Incorporation and Bylaws&#148; for a
discussion of these and other <FONT STYLE="white-space:nowrap">anti-takeover</FONT> provisions found in our amended and restated certificate of incorporation and amended and restated bylaws, which will be in effect prior to the consummation of this
offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director Independence </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the rules of the Nasdaq
Stock Market, independent directors must comprise a majority of a listed company&#146;s board of directors within one year of the completion of its initial public offering. In addition, the rules of the Nasdaq Stock Market require that, subject to
specified exceptions, each member of a listed company&#146;s audit and compensation committees be independent and that director nominees be selected or recommended for the board&#146;s selection by independent directors constituting a majority of
the independent directors or by a nominating and corporate governance committee comprised solely of independent directors. Under the rules of the Nasdaq Stock Market, a director will only qualify as &#147;independent&#148; if, in the opinion of that
company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that such person is &#147;independent&#148; as defined
under the rules of the Nasdaq Stock Market and the rules under the Securities Exchange Act of 1934, as amended, or the Exchange Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Audit committee members must
also satisfy the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the Exchange Act. In order to be considered independent for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3,</FONT> a
member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory or
other compensatory fee from the listed company or any of its subsidiaries or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our
board of directors has determined that each of our directors, with the exception of Dr.&nbsp;Martin&nbsp;W. Mackay , is an &#147;independent director&#148; as defined under applicable rules of the Nasdaq Stock Market, including, in the case of all
the members of our audit committee, the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the Exchange Act, and in the case of all the members of our compensation committee, the independence criteria
set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1</FONT> under the Exchange Act and are <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; as defined in <FONT STYLE="white-space:nowrap">Section&nbsp;16b-3</FONT>
of the Exchange Act. In making such determination, our board of directors considered the relationships that each such <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our Company and all other facts and circumstances that our
board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. Dr.&nbsp;Martin&nbsp;W. Mackay is not an
independent director under these rules because he is our Chief Executive Officer. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Board Committees </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which will operate
pursuant to a charter adopted by our board of directors that will become effective prior to the consummation of this offering. Our board of directors may also establish other committees from time to time to assist us and the board of directors in
their duties. Upon the effectiveness of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">139 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
registration statement of which this prospectus forms&nbsp;a part, the composition and functioning of all of our committees will comply with all applicable requirements of the <FONT
STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act, the Nasdaq Stock Market and the Exchange Act. Upon our listing on the Nasdaq Global Market, each committee&#146;s charter will be available on the corporate governance section of our website at
www.rallybio.com. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase shares of
our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The audit committee&#146;s
responsibilities upon completion of this offering will include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appointing, approving the compensation of, and evaluating the qualifications, performance and independence of, our
independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the work of our independent registered public accounting firm, including through the receipt and consideration
of reports from such firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit and permitted
<FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures, including earnings releases; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing with management and our independent registered public accounting firm any material issues
regarding accounting principles and financial statement presentations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing disclosures about any significant deficiencies or material weaknesses in our internal controls, including
disclosures in our annual and quarterly reports; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">coordinating our board of directors&#146; oversight of our internal control over financial reporting, disclosure controls
and procedures, code of business conduct and ethics, procedures for complaints and legal and regulatory matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">discussing our risk management policies with management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing practices and guidance regarding hiring employees from our independent registered public accounting firm and
procedures for the receipt and retention of accounting related complaints and concerns; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">meeting independently with our independent registered public accounting firm and management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving any related person transactions in accordance with Company policy; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing our guidelines and policies governing risk assessment and risk management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing the audit committee report required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing, at least annually, the adequacy of the audit committee&#146;s charter; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing, at least annually, an evaluation of the performance of the audit committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All audit services and all <FONT STYLE="white-space:nowrap">non-audit</FONT> services, other than de minimis <FONT STYLE="white-space:nowrap">non-audit</FONT> services,
to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The members of our audit committee
are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;chairs the audit committee. Our board of directors
has determined that each member of our audit committee has sufficient knowledge in financial and auditing matters to serve on the audit committee. Our board of directors has also determined
that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is an &#147;audit committee financial expert,&#148; as defined under Item&nbsp;407 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT>
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to satisfy the member independence requirements for the audit committee prior to the end of the transition period provided under the rules of the Nasdaq
Stock Market and SEC rules and regulations for companies completing their initial public offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation committee&#146;s responsibilities upon completion of this offering will include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing our overall management compensation strategy, including base salary, incentive compensation and <FONT
STYLE="white-space:nowrap">equity-based</FONT> grants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">140 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving corporate goals and objectives relevant to compensation of our chief executive officer and other
executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to our board of directors the compensation of our chief executive officer and other executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations to the board of directors with respect to
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing and administering our cash and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing, considering and selecting, to the extent determined to be advisable, a peer group of appropriate companies for
purposing of benchmarking and analysis of compensation for our executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to our board of directors any stock ownership guidelines for our executive officers and <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">retaining, appointing or obtaining advice of a compensation consultant, legal counsel or other advisor and determining the
compensation and independence of such consultant or advisor; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing, if required, the compensation committee report on executive compensation for inclusion in our annual report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our annual proxy statement in accordance with SEC proxy and disclosure rules; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">monitoring our compliance with the requirements of <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> relating to
loans to directors and officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving all employment contract and other compensation, severance and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">change-in-control</FONT></FONT> arrangements for our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing and periodically reviewing policies and procedures with respect to perquisites as they relate to our
executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing the risks associated with our compensation policies and practices; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing and presenting to our board of directors management&#146;s plans for succession to senior management positions
based on guidelines developed and recommended by the compensation committee to the full board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and overseeing the Company&#146;s strategies, initiatives and programs with respect to the Company&#146;s
management of human capital resources, including talent management, employee engagement and diversity and inclusion; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing, at least annually, the adequacy of the compensation committee&#146;s charter; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing, on an annual basis, an evaluation of the performance of the compensation committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The members of our compensation committee
are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;chairs the compensation committee. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our nominating and
corporate governance committee&#146;s responsibilities upon completion of this offering will include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">identifying individuals qualified to become members of our board of directors consistent with criteria approved by the
board and receiving nominations for such qualified individuals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to our board of directors the persons to be nominated for election as directors and to each committee of the
board; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing a policy under which our stockholders may recommend a candidate to the nominating and corporate governance
committee for consideration for nomination as a director; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and recommending committee slates on an annual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to our board of directors qualified candidates to fill vacancies on our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developing and recommending to our board of directors a set of corporate governance principles applicable to us and
reviewing the principles on at least an annual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations to our board with respect to our board leadership structure and board committee
structure; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">141 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing, in concert with our board of directors, our policies and program with respect to significant issues of
corporate public responsibility; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">making recommendations to our board of directors processes for annual evaluations of the performance of our board of
directors and committees of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the process for annual evaluations of our board of directors and committees of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">considering and reporting to our board of directors any questions of possible conflicts of interest of members of our
board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing with management the company&#146;s social corporate responsibility activities, policies, and program;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">providing new director orientation and continuing education for existing directors on a periodic basis;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing plans for director succession; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the integrity of our information technology systems, process and data; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing, at least annually, the adequacy of the nominating and corporate governance committee&#146;s
charter; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and overseeing the Company&#146;s initiatives regarding environmental, social and governance matters, including
related risks and opportunities, and the Company&#146;s public disclosure with respect to such matters; and </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing, on an annual basis, an evaluation of the performance of the nominating and corporate governance committee.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The members of our nominating and corporate governance committee
are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;chairs the nominating and corporate governance
committee. Our board of directors has determined that each member of the nominating and corporate governance committee satisfies the independence standards of the applicable rules of the Nasdaq Stock Market. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors may establish other committees from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Role
of the Board in Risk Oversight </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has, and, upon the completion of this offering, its committees will also have, an active role in
overseeing the management of our risks. Our board of directors is responsible for general oversight of risks and regular review of information regarding our risks, including credit risks, liquidity risks and operational risks. The compensation
committee will be responsible for overseeing the management of risks relating to our executive compensation plans and arrangements. The audit committee will be responsible for overseeing the management of risks relating to accounting matters and
financial reporting. The nominating and governance committee will be responsible for overseeing the management of risks associated with the independence of our board of directors and potential conflicts of interest. Although each committee will be
responsible for evaluating certain risks and overseeing the management of such risks, the entire board of directors will be regularly informed through discussions from committee members about such risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the closing of this offering,
we will adopt a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons
performing similar functions, which will become effective upon the effectiveness of the registration statement of which this prospectus forms&nbsp;a part. Following this offering, a current copy of the code will be posted on the investor section of
our website. In addition, we intend to post on our website all disclosures that are required by law or Nasdaq Stock Market rules concerning any amendments to, or waivers from, any provision of the code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">142 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_13"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following discussion and analysis of compensation arrangements should be read with the compensation tables and related disclosures set forth below. This
discussion contains forward looking statements that are based on our current plans and expectations regarding future compensation programs. The compensation programs that we adopt in the future may differ materially from the programs summarized in
this discussion. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Introduction </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This section provides an overview of
the compensation awarded to, earned by, or paid to our principal executive officer and our next two most highly compensated executive officers listed below in respect of their service to us for the fiscal year ended December&nbsp;31, 2020. We refer
to these individuals as our named executive officers. Our named executive officers are: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Martin W. Mackay, Ph.D., Chief Executive Officer and Chairman; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Stephen Uden, M.D., President, Chief Operating Officer and Chief Scientific Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Jeffrey M. Fryer, Chief Financial Officer and Treasurer. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, the board of managers of Rallybio Holdings, LLC, or the LLC Entity (referred to as our board of managers for purposes of this executive and
director compensation discussion), was responsible for determining the compensation of our executive officers, based on recommendations from the compensation committee of our board of managers. Following this offering, the compensation committee of
the board of directors of Rallybio Corporation, or the Corporation, will be responsible for making such determinations. Drs. Mackay and Uden, and Mr.&nbsp;Fryer are our founders and, since our inception, have received identical compensation.
Following this offering, the compensation committee may make similar recommendations regarding the compensation payable to our founders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary
compensation table </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the compensation awarded to, earned by, or paid to our named executive officers in respect of their service
to us for the fiscal year ended December&nbsp;31, 2020: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME AND PRINCIPAL POSITION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SALARY</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK<BR>AWARDS</B><br><B>($) <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NONEQUITY<BR>INCENTIVE&nbsp;PLAN<BR>COMPENSATION<BR>($) <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL OTHER<BR>COMPENSATION</B><br><B>($) <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; font-size:9.5pt; font-family:ARIAL"><I>Chief Executive Officer and Chairman</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; font-size:9.5pt; font-family:ARIAL"><I>President, Chief Operating Officer and Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey M. Fryer, CPA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; font-size:9.5pt; font-family:ARIAL"><I>Chief Financial Officer and Treasurer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown in this column represent the grant date fair value of incentive units granted to Drs. Mackay and Uden and Mr.&nbsp;Fryer in fiscal year 2020 computed in accordance with FASB ASC Topic 718, excluding
the effect of estimated forfeitures. The assumptions used to value the incentive units for this purpose are set forth in Note 7 to our audited consolidated financial statements included elsewhere in this prospectus. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown in this column represent annual bonuses earned with respect to fiscal year 2020 that were paid in February 2021 under our annual bonus program as described below under &#147;Annual Bonuses.&#148;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown in the &#147;All Other Compensation&#148; column reflect SIMPLE IRA matching contributions made by the LLC Entity, described below under &#147;Employee and Retirement Benefits.&#148; </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">143 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Narrative disclosure to summary compensation table </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Agreements with our named executive officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Drs. Mackay and Uden
and Mr.&nbsp;Fryer are each party to an employment agreement with our operating company subsidiary, Rallybio, LLC, which sets forth the terms and conditions of the executive officer&#146;s employment with us. The material terms of the agreements are
described below. The terms &#147;cause&#148; and &#147;good reason&#148; referred to below are defined in the respective named executive officer&#146;s agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each employment agreement provides for an initial annual base salary, subject to review for increase by our board of managers or a committee of our board of managers,
which base salary has since been increased by our board of managers. Each employment agreement also provides for a target annual bonus equal to 40% of annual base salary, with the actual amount of the bonus payable based upon the achievement of
performance goals as determined by our board of managers or a committee of our board of managers. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Annual base salary </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The employment agreement with each named executive officer establishes an annual base salary for the executive officer, which was determined at the time that the named
executive officer commenced employment with us and is subject to periodic review. Effective January&nbsp;1, 2020, the annual base salaries of Drs. Mackay and Uden and Mr.&nbsp;Fryer were increased from $370,000 to $379,500. Effective January&nbsp;1,
2021, the annual base salaries of our named executive officers were increased to $420,000. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Annual bonuses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to fiscal year 2020, each of Drs. Mackay and Uden and Mr.&nbsp;Fryer was eligible to receive an annual bonus, with the target amount of such bonus for each
named executive officer set forth in his employment agreement with us. For fiscal year 2020, the target bonus amount, expressed as a percentage of annual base salary, for each of Drs. Mackay and Uden and Mr.&nbsp;Fryer was 40%. Annual bonuses for
fiscal year 2020 for our named executive officers were based on the attainment of <FONT STYLE="white-space:nowrap">pre-established</FONT> corporate objectives as determined by our board of managers, including those related to building a world-class
team, business development, expanding the LLC Entity&#146;s pipeline, financing, and developmental and clinical goals. Following the end of fiscal year 2020, our board of managers determined that the performance goals were met at target and each of
Drs. Mackay and Uden and Mr.&nbsp;Fryer earned a bonus of $151,800. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Severance upon termination of employment; change of control; restrictive covenants.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Employment Agreements</I>. Each of Drs. Mackay and Uden and Mr.&nbsp;Fryer is entitled to severance payments and benefits in connection with certain
qualifying terminations of employment under his respective employment agreement. If the executive officer&#146;s employment is terminated by us without cause, as a result of our <FONT STYLE="white-space:nowrap">non-extension</FONT> of the employment
term or by him for good reason, he will be entitled to receive (i)&nbsp;any earned and payable, but unpaid, prior year annual bonus (or current year bonus if the termination is on the last day of the calendar year) and (ii) continued payment of his
annual base salary for a period of six months following termination (or payment of a lump sum amount equal to six months&#146; annual base salary, if the termination of employment is in connection with a sale of the company). If the executive
officer&#146;s employment is terminated by reason of his death or disability, he will be entitled to receive (i)&nbsp;any earned and payable, but unpaid, annual bonus and (ii)&nbsp;continued payment of his annual base salary for a period of six
months following termination. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Severance Subject to Release of Claims</I>. Our obligation to provide a named executive officer with severance payments and other
benefits under his respective employment agreement is conditioned on the executive officer signing a release of claims in favor of us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restrictive
Covenants</I>. Under their respective employment agreements, each of Drs. Mackay and Uden and Mr.&nbsp;Fryer has agreed not to compete with us during his employment and for one year following his termination of employment or solicit our customers,
employees, representatives, agents, vendors, joint venturers or licensors during his employment and for one year following his termination of employment. In addition, each named executive officer has agreed to a perpetual <FONT
STYLE="white-space:nowrap">non-disparagement</FONT> covenant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Equity</I>. Upon a change of control (as defined in each named executive officer&#146;s award
agreement or the Rallybio Holdings, LLC 2018 Share Plan, or the 2018 Plan), each named executive officer&#146;s restricted common units granted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">144 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
to him on April&nbsp;19, 2018 that have not vested will vest, and the proceeds to be received in connection with such change of control in respect of such accelerated units will be held in escrow
to be released on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the change of control, subject to forfeiture if the named executive officer&#146;s employment is terminated by us with cause or by him for good reason prior to
such date. The escrow funds will be released immediately if the named executive officer&#146;s employment is terminated by us without cause or by him for good reason during such <FONT STYLE="white-space:nowrap">one-year</FONT> period. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Equity compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Drs. Mackay and Uden and Mr.&nbsp;Fryer received
incentive equity grants in fiscal year 2020 under the 2018 Plan. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;31, 2020, each of Drs. Mackay and Uden and Mr.&nbsp;Fryer was granted an award
of 665,000 incentive units, which vested as to 25% of the underlying units on April&nbsp;1, 2021 and vest in 36 equal monthly installments thereafter, generally subject to the executive officer&#146;s continued employment with us through the
applicable vesting date. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2021, each of our named executive officers received an award of 2,255,000 incentive units under the 2018 Plan, which vest
as to 25% of the underlying units on January&nbsp;1, 2022 and in 36 equal monthly installments thereafter, generally subject to the executive officer&#146;s continued employment with us through the applicable vesting date. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Employee and retirement benefits </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently provide broad-based
health and welfare benefits that are available to all of our employees, including our named executive officers, including health, life and AD&amp;D, disability, vision, and dental insurance. In addition, we maintain a SIMPLE IRA retirement plan for
our full-time employees. The SIMPLE IRA plan provides that we will make matching employer contributions to the SIMPLE IRA plan equal to up to 3% of eligible compensation contributed to the plan by an eligible employee for the applicable year
(subject to tax code limits). Other than the SIMPLE IRA plan, we do not provide any qualified or <FONT STYLE="white-space:nowrap">non-qualified</FONT> retirement or deferred compensation benefits to our employees, including our named executive
officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding awards at fiscal <FONT STYLE="white-space:nowrap">year-end</FONT> 2020 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information concerning outstanding equity awards held by each of our named executive officers as of December&nbsp;31, 2020: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK AWARDS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>UNITS&nbsp;THAT&nbsp;HAVE<BR>NOT VESTED</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARKET&nbsp;VALUE<BR>OF UNITS THAT<BR>HAVE NOT<BR>VESTED</B><br><B>($)&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Steve Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey M. Fryer, CPA<SUP STYLE="font-size:85%; vertical-align:top"> (5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Because the LLC Entity was not publicly traded during fiscal year 2020, there is no ascertainable public market value for these units. The market value reported in this table is based upon our board of manager&#146;s
determination of the fair market value of the LLC Entity&#146;s equity, $0.47 per common unit, which was determined taking into account an independent valuation as of January 1, 2021, the closest valuation date to fiscal <FONT
STYLE="white-space:nowrap">year-end.</FONT> Where applicable, the fair market value of an incentive unit included in this table reflects the value of a common unit less any unsatisfied distribution threshold. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an award of 1,499,999 restricted common units of the LLC Entity issued on April&nbsp;19, 2018 pursuant to a contribution and restricted share agreement with each named executive officer, which vested as to
25% of the common units on the date of grant and as to the remaining common units in four equal installments on each of April&nbsp;20, 2019, April&nbsp;20, 2020, April&nbsp;20, 2021 and April&nbsp;20, 2022, generally subject to the executive
officer&#146;s continued employment with us through the applicable vesting date. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">145 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an award of 400,000 restricted common units of the LLC Entity granted on April&nbsp;19, 2018 under the 2018 Plan, which became eligible to vest upon the initiation of a clinical program through one of our
affiliates, on September&nbsp;12, 2019. Twenty-five percent of the underlying common units vested on September&nbsp;12, 2020, and the remaining common units vest in 36 equal monthly installments thereafter, generally subject to the executive
officer&#146;s continued employment with us through the applicable vesting date. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an award of 665,000 incentive units of the LLC Entity granted on July&nbsp;31, 2020 under the 2018 Plan, which vest as to 25% of the underlying units on April&nbsp;1, 2021 and vests in 36 equal monthly
installments thereafter, generally subject to the executive officer&#146;s continued employment with us through the applicable vesting date. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Fryer&#146;s grants are held by a revocable trust. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director compensation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the compensation awarded to, earned by or paid to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during the fiscal
year ended December&nbsp;31, 2020. Dr.&nbsp;Mackay does not receive compensation for his service as a director. His compensation for 2020 is included with that of our other named executive officers above. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FEES&nbsp;EARNED&nbsp;OR<BR>PAID IN CASH</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK<BR>AWARDS</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rob Hopfner, R.Ph., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ronald Hunt<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kush M. Parmar, M.D., Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ketan Patel, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(3)(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Timothy M. Shannon, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent cash fees earned in fiscal year 2020. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the grant date fair value of incentive units granted to Mses. Boudreau and Soteropoulos computed in accordance with FASB ASC Topic 718, excluding the effect of estimated
forfeitures. The assumptions used to value the incentive units for this purpose are set forth in Note 7 to our audited consolidated financial statements included elsewhere in this prospectus. As of December&nbsp;31, 2020, Ms.&nbsp;Boudreau and
Ms.&nbsp;Soteropoulos held 12,115 and 8,077 vested incentive units of the LLC Entity, respectively. </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Directors who are affiliated with our investors do not receive compensation in respect of their service as members of our board of managers. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Patel resigned from our board of managers effective January&nbsp;30, 2021. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director compensation
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the time each of Ms.&nbsp;Boudreau and Ms.&nbsp;Soterpoulos was appointed to our board of managers, we agreed to pay each of them a cash retainer of
$35,000 for board service and Ms.&nbsp;Boudreau a cash retainer of $5,000 for service as chair of the audit committee, and to provide each of them a grant of incentive units, as reported in the table above. The incentive units vest in 48 equal
monthly installments, generally subject to the director&#146;s continued service through the applicable vesting date. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director compensation policy
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, we expect to adopt a formal <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy for members
of our board of directors, the terms of which will be described in a subsequent filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity and cash plans </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2018 Share Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2018, our board of managers approved the 2018
Plan. The 2018 Plan has been amended from time to time to increase the aggregate number of common units of the LLC Entity reserved for issuance under the 2018 Plan, and was most recently amended on January&nbsp;20, 2021. The 2018 Plan permits the
grant of options to purchase common units, restricted common units and other awards that are convertible into or otherwise based on common units. Subject to adjustment, the maximum number of common units that may be granted under the 2018 Plan is
22,972,360. As of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;incentive units
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;restricted common units were outstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">146 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
under the 2018 Plan and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common units remained available for future issuance. It is anticipated that
no further awards will be made under the 2018 Plan following the completion of this offering. In connection with this offering, we intend to adopt a new omnibus equity plan under which we will grant equity-based awards in connection with or
following this offering. This summary is not a complete description of all provisions of the 2018 Plan and is qualified in its entirety by reference to the 2018 Plan, which is filed as an exhibit to the registration statement of which this
prospectus is part. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Plan administration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of managers
administers the 2018 Plan. Our board of managers has the discretionary authority to grant awards, to construe award agreements and the 2018 Plan, to prescribe, amend and rescind rules and regulations relating to the 2018 Plan, to determine the terms
and provisions of the award agreements and to make all other determinations in the judgment of our board of managers necessary or desirable for the administration of the 2018 Plan. Our board of managers may delegate any or all of its powers to a
committee. As used in this summary, the term &#147;Administrator&#148; refers to our board of managers and its authorized delegates, as applicable. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Eligibility </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our and our affiliates&#146; employees, officers,
managers, directors, advisors and consultants are eligible to participate in the 2018 Plan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Vesting; terms of awards </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator determines the terms and conditions of all awards granted under the 2018 Plan, including the time or times an award vests or becomes exercisable, the
terms on which an award remains exercisable. The Administrator may at any time accelerate the vesting or exercisability of an award. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Transferability of
awards </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as the Administrator may otherwise determine, options may not be transferred other than by will or by the laws of descent and distribution or
pursuant to a qualified domestic relations order. Common units may not be transferred unless the transfer complies with all provision of the 2018 Plan and the operating agreement of the LLC Entity. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Effect of certain transactions </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of change of control, as
defined in the 2018 Plan, the Administrator may, with respect to outstanding awards, provide for the acceleration of exercisability or issuance of common units in respect of any award, in full or in part or the
<FONT STYLE="white-space:nowrap">cash-out</FONT> of awards. If not accelerated or cashed out, the awards will be assumed or substituted by the successor company, and to the extent not assumed or substituted, any outstanding option will terminate and
awards of common units will be repurchased. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Adjustment provisions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If, through or as a result of any recapitalization, reclassification, distribution, common unit split, reverse common unit split, liquidation, exchange of common units,
<FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, consolidation or other similar transaction, (i)&nbsp;the outstanding common units are increased, decreased or exchanged for a different number or kind of common units or other securities
or (ii)&nbsp;additional common units or new or different common units or other <FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such common units or other securities, an appropriate and proportionate adjustment
will be made to (x)&nbsp;the maximum number and kind of common units reserved for issuance under the 2018 Plan, (y)&nbsp;the number and kind of securities underlying awards then outstanding and (z)&nbsp;the exercise price for each option, without
changing the aggregate purchase price as to which such options remain exercisable. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amendments and termination </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator may at any time amend the 2018 Plan and may at any time terminate the 2018 Plan as to future grants. However, except as expressly provided in the 2018
Plan, the Administrator may not alter the terms of the plan so as to adversely affect a participant&#146;s rights under an award without the participant&#146;s consent. Any amendments to the 2018 Plan will be conditioned on member approval to the
extent required. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Compensation plans </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Equity
Incentive Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, our board of directors intends to adopt the Rallybio Corporation 2021 Equity Incentive Plan, or the 2021
Plan, and, in connection with and following this offering, all equity-based awards will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">147 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
granted under the 2021 Plan. The following summary describes what we expect to be the material terms of the 2021 Plan. This summary is not a complete description of all provisions of the 2021
Plan and is qualified in its entirety by reference to the 2021 Plan, which will be filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Administration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2021 Plan will be administered by our
compensation committee, which will have the discretionary authority to interpret the 2021 Plan and any awards granted under it, determine eligibility for and grant awards, determine the exercise price, base value from which appreciation is measured
or purchase price, if any, applicable to any award, determine, modify, accelerate and waive the terms and conditions of any award, determine the form of settlement of awards, prescribe forms, rules and procedures relating to the 2021 Plan and awards
and otherwise do all things necessary or desirable to carry out the purposes of the 2021 Plan or any award. Our board of directors may at any time act in the capacity of the administrator of the 2021 Plan (including with respect to such matters that
are not delegated to our compensation committee). Our compensation committee (or our board of directors) may delegate such of its duties, powers and responsibilities as it may determine to one or more of its members (or one or more other members of
our board of directors), may delegate the power to grant awards to our officers, to the extent permitted by law, and may delegate to employees and other persons such ministerial tasks as it deems appropriate. As used in this summary, the term
&#147;Administrator&#148; refers to our compensation committee, our board of directors or any authorized delegates, as applicable. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Eligibility </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our employees, directors and consultants are eligible to participate in the 2021 Plan. Eligibility for stock options intended to be incentive stock options, or ISOs, is
limited to our employees or employees of certain affiliates. Eligibility for stock options, other than ISOs, and stock appreciation rights, or SARs, is limited to individuals who are providing direct services to us or certain affiliates on the date
of grant of the award. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Authorized Shares </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to adjustment
as described below, the number of shares of our common stock that may be delivered in satisfaction of awards under the 2021 Plan is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. The share
pool will automatically increase on January 1st of each year from 2022 to 2031 by the lesser of (i)&nbsp;four percent of the number of shares of our common stock outstanding as of such date and (ii)&nbsp;the number of shares of our common stock
determined by our board of directors on or prior to such date. Up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares may be delivered in satisfaction of ISOs. The number of shares of our common
stock delivered in satisfaction of awards under the 2021 Plan will not be reduced by (i)&nbsp;any shares withheld by us in payment of the exercise price or purchase price of an award or in satisfaction of tax withholding requirements or
(ii)&nbsp;any shares underlying any portion of an award that is settled in cash or that expires, becomes unexercisable, terminates or is forfeited to or repurchased by us without the delivery (or retention, in the case of restricted or unrestricted
stock) of shares of our common stock. The number of shares available for delivery under the 2021 Plan will not be increased by any shares that have been delivered under the 2021 Plan and are subsequently repurchased using proceeds directly
attributable to stock option exercises. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares that may be delivered under the 2021 Plan may be authorized but unissued shares, treasury shares or previously
issued shares acquired by us. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director Limits </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2021 Plan
provides that the aggregate value of all compensation granted or paid to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any calendar year for his or her services as a director during such calendar year may not
exceed $750,000 ($1,000,000 for the director&#146;s first year of service on our board of directors) in the aggregate. This limitation does not apply to any compensation granted or paid for services other than as a director, including as a
consultant or advisor to us or one of our subsidiaries. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Types of Awards </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2021 Plan provides for the grant of stock options, SARs, restricted and unrestricted stock and stock units, performance awards and other awards that are convertible
into or otherwise based on our common stock. Dividend equivalents may also be provided in connection with awards under the 2021 Plan. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Stock options and SARs.</I> The Administrator may grant stock options, including ISOs, and SARs. A stock option is a
right entitling the holder to acquire shares of our common stock upon payment of the applicable </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">148 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
exercise price. A SAR is a right entitling the holder upon exercise to receive an amount (payable in cash or shares of equivalent value) equal to the excess of the fair market value of the shares
subject to the right over the base value from which appreciation is measured. The exercise price per share of each stock option, and the base value of each SAR, granted under the 2021 Plan will be no less than 100% of the closing price of a share on
the date of grant (or, if no closing price is reported for that date, the closing price on the immediately preceding day on which a closing price is reported) (110% in the case of certain ISOs). Other than in connection with certain corporate
transactions or changes to our capital structure, stock options and SARs granted under the 2021 Plan may not be repriced, amended or substituted for with new stock options or SARs having a lower exercise price or base value, nor may any
consideration be paid upon the cancellation of any stock options or SARs that have a per share exercise or base price greater than the closing price of a share on the date of such cancellation, in each case, without shareholder approval. Each stock
option and SAR will have a maximum term of not more than ten years from the date of grant (or five years, in the case of certain ISOs). </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Restricted and unrestricted stock and stock units.</I> The Administrator may grant awards of stock, stock units,
restricted stock and restricted stock units. A stock unit is an unfunded and unsecured promise, denominated in shares, to deliver shares or cash measured by the value of shares in the future, and a restricted stock unit is a stock unit that is
subject to the satisfaction of specified performance or other vesting conditions. Restricted stock are shares subject to restrictions requiring that they be forfeited, redelivered or offered for sale to us if specified performance or other vesting
conditions are not satisfied.&nbsp;&nbsp;&nbsp;&nbsp; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Performance awards.</I> The Administrator may grant performance awards, which are awards subject to performance vesting
conditions. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Other share-based awards.</I> The Administrator may grant other awards that are convertible into or otherwise based on
shares of our common stock, subject to such terms and conditions as it determines. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Substitute awards.</I> The Administrator may grant substitute awards in connection with certain corporate transactions,
which may have terms and conditions that are inconsistent with the terms and conditions of the 2021 Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Vesting; Terms of Awards
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator determines the terms and conditions of all awards granted under the 2021 Plan, including the time or times an award vests or becomes
exercisable, the terms and conditions on which an award remains exercisable and the effect of termination of a participant&#146;s employment or service on an award. The Administrator may at any time accelerate the vesting or exercisability of an
award. No term of an award will provide for automatic &#147;reload&#148; grants of additional awards upon the exercise of a stock option or SAR. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Transferability of Awards </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as the Administrator may otherwise
determine, awards may not be transferred other than by will or by the laws of descent and distribution. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Effect of Certain Transactions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of certain covered transactions (including a consolidation, merger or similar transaction, a sale of all or substantially all of our assets or shares of
our common stock, our dissolution or liquidation or such other corporate transaction as is determined by the Administrator), the Administrator may, with respect to outstanding awards, provide for (in each case, on such terms and subject to such
conditions as it deems appropriate): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The assumption, substitution or continuation of some or all awards (or any portion thereof) by the acquiror or surviving
entity; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The acceleration of exercisability or delivery of shares in respect of any award, in full or in part; and/or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A cash payment in respect of some or all awards (or any portion thereof) equal to the difference between the fair market
value of the shares subject to the award and its exercise or base price, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as the Administrator may otherwise determine, each award
will automatically terminate or be forfeited immediately upon the consummation of the covered transaction, other than awards that are substituted for, assumed or that continue following the covered transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">149 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Adjustment Provisions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of certain corporate transactions, including a stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or
other change in our capital structure, the Administrator will make appropriate adjustments to the maximum number of shares that may be delivered under the 2021 Plan and the number and kind of securities subject to, and, if applicable, the exercise
or purchase prices (or base values) of, outstanding awards and any other provisions affected by such event. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clawback </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator may provide that any outstanding award, the proceeds of any award or shares acquired under any award and any other amounts received in respect of any
award or shares acquired under any award will be subject to forfeiture and disgorgement to us, with interest and other related earnings, if the participant to whom the award was granted is not in compliance with any provision of the 2021 Plan or any
award or any <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">no-hire,</FONT> <FONT STYLE="white-space:nowrap">non-disparagement,</FONT>
confidentiality, invention assignment or other restrictive covenant, or any company policy that relates to shares of our common stock or that provides for clawback, or as otherwise required by law or applicable stock exchange listing standards. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amendments and Termination </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator may at any time amend
the 2021 Plan or any outstanding award and may at any time terminate the 2021 Plan as to future grants. However, except as expressly provided in the 2021 Plan or the applicable award, the Administrator may not alter the terms of an award so as to
materially and adversely affect a participant&#146;s rights without the participant&#146;s consent (unless the Administrator expressly reserved the right to do so in the 2021 Plan or at the time the award was granted). Any amendments to the 2021
Plan will be conditioned on shareholder approval to the extent required by applicable law or stock exchange requirements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Employee Stock Purchase Plan
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, our board of directors intends to adopt the Rallybio Corporation 2021 Employee Stock Purchase Plan, or the ESPP. The ESPP
is intended to qualify as an &#147;employee stock purchase plan&#148; under Section&nbsp;423 of the Code. The following summary describes what we expect to be the material terms of the ESPP. This summary is not a complete description of all
provisions of the ESPP and is qualified in its entirety by reference to the ESPP, which will be filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Administration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ESPP will be administered by our compensation
committee, which will have the discretionary authority to interpret the ESPP, determine eligibility under the ESPP, prescribe forms, rules and procedures relating to the ESPP and otherwise do all things necessary or desirable to carry out the
purposes of the ESPP. Our board of directors may at any time act in the capacity of the administrator of the ESPP (including with respect to such matters that are not delegated to our compensation committee). Our compensation committee (or our board
of directors) may delegate to one or more of its members (or one or more members of our board of directors) such of its duties, powers, and responsibilities as it may determine and to employees or other persons as it determines such ministerial
tasks as it deems appropriate. As used in this summary, the term &#147;Administrator&#148; refers to our compensation committee, our board of directors or any authorized delegates, as applicable. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Shares Subject to the ESPP </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to adjustment as described below,
the number of shares of our common stock available for purchase pursuant to the exercise of options under the ESPP is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. The share pool will
automatically increase on January 1st of each year from 2022 to 2031 by the least of (i)&nbsp;one percent of the number of shares of our common stock outstanding as of such date, (ii)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock and (iii)&nbsp;the number of shares of our common stock determined by our board of directors on or prior to such date (up to
a maximum of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares in the aggregate). Shares will not be treated as delivered, and will not reduce the number of shares in the aggregate unless and
until, and to the extent, they are actually delivered to a participant. If any option granted under the ESPP expires or terminates for any reason without having been exercised in full or ceases for any reason to be exercisable in whole or in part,
the unpurchased shares subject to such option will remain available for purchase under the ESPP. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Eligibility </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Participation in the ESPP will generally be limited to our employees and employees of our subsidiaries (i)&nbsp;who have
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">150 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
been continuously employed by us or one of our subsidiaries, as applicable, for a period of at least
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;calendar days as of the first day of an applicable offering period, (ii)&nbsp;whose customary employment with us or one of our subsidiaries, as
applicable, is for more than five months per calendar year, (iii)&nbsp;who customarily work 20 hours or more per week and (iv)&nbsp;who satisfy the requirements set forth in the ESPP. The Administrator may establish additional or other eligibility
requirements, or change the requirements described in this paragraph, to the extent consistent with Section&nbsp;423 of the Code. Any employee who owns (or is deemed under statutory attribution rules to own) shares possessing five percent or more of
the total combined voting power or value of all classes of shares of us or our parent or subsidiaries, if any, will not be eligible to participate in the ESPP. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General Terms of Participation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ESPP allows eligible employees to
purchase shares of our common stock during specified offering periods. Unless otherwise determined by the Administrator, offering periods under the ESPP will be six months in duration and commence on the first business day of January and July of
each year. During each offering period, eligible employees will be granted an option to purchase shares of our common stock on the last business day of the offering period. A participant may purchase a maximum
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares with respect to any offering period (or such other number as the Administrator may prescribe). No participant will be granted an option under
the ESPP that permits the participant&#146;s right to purchase shares of our common stock under the ESPP and under all other employee stock purchase plans of us or our parent or subsidiaries, if any, to accrue at a rate that exceeds $25,000 in fair
market value (or such other maximum as may be prescribed by the Code) for each calendar year during which any option granted to the participant is outstanding at any time, determined in accordance with Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The purchase price of each share issued pursuant to the exercise of an option under the ESPP on an exercise date will be 85% (or such other percentage as specified by
the Administrator) of the lesser of: (a)&nbsp;the closing price of a share of our common stock on the date the option is granted (or, if no closing price is reported for that date, the closing price on the immediately preceding day on which a
closing price is reported), which will be the first day of the offering period, and (b)&nbsp;the closing price of a share of our common stock on the exercise date (or, if no closing price is reported for that date, the closing price on the
immediately preceding day on which a closing price is reported), which will be the last business day of the offering period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator may change the
commencement and exercise dates of offering periods, the purchase price, the maximum number of shares that may be purchased with respect to any offering period, the duration of any offering periods and other terms of the ESPP, in each case, without
shareholder approval, except as required by law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Participants in the ESPP will pay for shares purchased under the ESPP through payroll deductions. Participants may
elect to authorize payroll deductions between 1% and 15% of the participant&#146;s eligible compensation each payroll period. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Transfer Restrictions
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For participants who have purchased shares under the ESPP, the Administrator may impose restrictions prohibiting the transfer, sale, pledge or alienation
of such shares, other than by will or by the laws of descent and distribution, for such period as may be determined by the Administrator. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Adjustments
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of a stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or other change in our capital
structure that constitutes an equity restructuring, the Administrator will make appropriate adjustments to the aggregate number and type of shares available for purchase under the ESPP, the number and type of shares granted under any outstanding
options, the maximum number and type of shares purchasable under any outstanding option and/or the purchase price per share under any outstanding option. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Corporate Transactions </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of certain covered transactions
(including a consolidation, merger or similar transaction, a sale of all or substantially all of our assets or shares of our common stock, our dissolution or liquidation or such other corporate transaction as is determined by the Administrator), the
Administrator may provide that each outstanding option will be assumed, exchanged for a substitute option or cancelled with the balances of participants&#146; accounts returned, or that the option period will end before the date of the proposed
covered transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">151 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amendments and Termination </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator has discretion to amend the ESPP to any extent and in any manner it may deem advisable, provided that any amendment that would be treated as the
adoption of a new plan for purposes of Section&nbsp;423 of the Code will require shareholder approval. The Administrator may suspend or terminate the ESPP at any time. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Cash Incentive Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, our board
of directors intends to adopt the Rallybio Corporation 2021 Cash Incentive Plan, or the Cash Incentive Plan. Following its adoption, the Cash Incentive Plan will provide for the grant of cash-based incentive awards to our executive officers and key
employees. The following summary describes what we expect to be the material terms of the Cash Incentive Plan. This summary is not a complete description of all provisions of the Cash Incentive Plan and is qualified in its entirety by reference to
the Cash Incentive Plan, which will be filed as an exhibit to the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Administration </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Cash Incentive Plan will be administered by our compensation committee and its delegates, except that our board of directors may at any time administer the Cash
Incentive Plan. As used in this summary, the term &#147;Administrator&#148; refers to our compensation committee, our board of directors or any authorized delegates, as applicable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator will have the discretionary authority to interpret the Cash Incentive Plan and any awards, determine eligibility for and grant awards, adjust the
performance criterion or criteria applicable to awards, determine, modify or waive the terms and conditions of any award, prescribe forms, rules and procedures relating to the Cash Incentive Plan and awards and otherwise do all things necessary or
desirable to carry out the purposes of the Cash Incentive Plan or any award. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Eligibility and Participation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Executive officers and key employees of us and our subsidiaries will be eligible to participate in the Cash Incentive Plan and will be selected from time to time by the
Administrator to participate in the Cash Incentive Plan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Awards; Performance Criteria </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Awards under the Cash Incentive Plan will be made based on, and subject to achieving, specified criteria established by the Administrator. For each award granted under
the Cash Incentive Plan, the Administrator will establish the performance criteria applicable to the award, the amount or amounts payable if the performance criteria are achieved and such other terms and conditions as the Administrator deems
appropriate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Payments Under an Award </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A participant will be
entitled to payment under an award only if all conditions to payment have been satisfied in accordance with the Cash Incentive Plan and the terms of the award, except as otherwise determined by the Administrator in accordance with the Cash Incentive
Plan. Following the end of a performance period, the Administrator will determine whether and to what extent the applicable performance criteria have been satisfied and will determine the amount payable under each award. The Administrator has the
discretionary authority to increase or decrease the amount actually paid under any award. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recovery of Compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Payments in respect of an award will be subject to forfeiture and disgorgement to us if the participant violates a
<FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality or other restrictive covenant or to the extent provided in any applicable company policy that provides for forfeiture
or disgorgement, or as otherwise required by law or applicable stock exchange listing standards. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amendment and Termination </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator may amend the Cash Incentive Plan or any outstanding award for any purpose, and may at any time terminate the Cash Incentive Plan as to any future
grant of awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">152 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of transactions since January&nbsp;5, 2018, the date on which Rallybio, LLC was incorporated, to which we have been a party in which the
amount involved exceeded the lesser of (i) $120,000 or (ii)&nbsp;one percent of the average of our total assets at year end for the last two completed fiscal years, and in which any of our executive officers, directors, promoters or beneficial
holders of more than 5% of our capital stock had or will have a direct or indirect material interest, other than compensation arrangements which are described under the section of this prospectus captioned &#147;Executive and Director
Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2018 Reorganization </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2018, Drs. Mackay
and Uden and Mr.&nbsp;Fryer, collectively the Founders, formed Rallybio, LLC. Each Founder made an initial capital contribution of $300 and each received 3,000,000 common units of Rallybio, LLC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2018, the Founders formed Rallybio Holdings, LLC, or the LLC Entity, each contributing $1 in exchange for 1 common unit in the LLC Entity. Subsequently, as
part of a reorganization in April 2018, the Founders contributed all of their common units in Rallybio, LLC to the LLC Entity in exchange for common units of the LLC Entity. As a result of their contribution, the Founders were each issued 1,899,999
common units in the LLC Entity, of which 374,999 common units were vested immediately, 1,125,000 common units vest in four equal yearly installments on the anniversary date of the reorganization, and 400,000 common units would begin vesting upon
achieving a clinical development milestone. In September 2019, this clinical development milestone was achieved and 25% of these common units vested on the one year anniversary of the date such milestone was achieved, and the remaining 75% vests in
equal monthly increments over the next <FONT STYLE="white-space:nowrap">thirty-36</FONT> months until fully vested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Private Placements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> Preferred Units </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, we entered into a Series A Preferred Share Purchase Agreement to sell up to 5,999,999 units of Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Redeemable Convertible Preferred Units, or Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units, to investors at a purchase price of $1.00 per unit, and up to 26,956,516 units of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable
Convertible Preferred Units, or Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units, upon the Company&#146;s achievement of certain milestone events, to investors at a purchase price of $1.15 per unit. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, we completed the sale of 5,549,999 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units to investors at a purchase price of $1.00 per
unit for an aggregate purchase price of $5,549,999. In addition, we issued an aggregate of 450,000 Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units to the Founders in exchange for their capital contributions of convertible debt totaling
$450,000 owed to the Founders by Rallybio, LLC. The following table summarizes purchases of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units by our directors, executive officers and holders of more than 5% of our equity and their
respective affiliates. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME OF UNITHOLDER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACQUISITION<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SERIES <FONT STYLE="white-space:nowrap">A-1</FONT><BR>CONVERTIBLE<BR>PREFERRED&nbsp;UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>PURCHASE&nbsp;PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">5AM Ventures V, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;20,&nbsp;2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,795,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,795,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canaan XI L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;20, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,795,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,795,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;20, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,795,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,795,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey M. Fryer Revocable Trust dated April&nbsp;18, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;20, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;20, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;20, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Parmar, a member of our board of directors, is a managing member of 5AM Partners V, LLC, the general partner of 5AM Ventures V, L.P. and, as a result, may be deemed to share voting and investment power with
respect to the shares held by 5AM Ventures V, L.P. 5AM Ventures V, L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Shannon, a member of our board of directors, is a manager of Canaan Partners XI LLC, the general partner of Canaan XI L.P. and, as a result, may be deemed to share voting and investment power with respect to
the shares held by Canaan XI L.P. Canaan XI L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">153 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hunt, a member of our board of directors, is a managing director at New Leaf Venture Partners, L.L.C., an entity affiliated with New Leaf Ventures III, L.P. and, as a result, may be deemed to share voting and
investment power with respect to the shares held by New Leaf Ventures III, L.P. New Leaf Ventures III, L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Preferred Units </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2019, we completed the sale of 7,826,083 shares of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units to investors and 521,740 Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Units to the Founders and employees at a purchase price of $1.15 per unit for an aggregate purchase price of $9,599,996. In July 2019, we completed the sale of 8,695,652 shares of our Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Units to investors at a purchase price of $1.15 per unit for an aggregate purchase price of $10,000,000. In October 2019, we completed the sale of 10,434,781 shares of our Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Units to investors at a purchase price of $1.15 per unit for an aggregate purchase price of $11,999,998. The following table summarizes purchases of our Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Units by our directors, executive officers and holders of more than 5% of our equity and their respective affiliates. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME OF UNITHOLDER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACQUISITION<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SERIES <FONT STYLE="white-space:nowrap">A-2</FONT><BR>CONVERTIBLE<BR>PREFERRED<BR>UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>PURCHASE&nbsp;PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">5AM Ventures V, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,538,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,918,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canaan XI L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,538,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,918,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,538,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,918,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mainstar Trst, Cust. FBO Jeffrey M. Fryer R2180643</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">5AM Ventures V, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;23,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,820,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,243,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canaan XI L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;23, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,820,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,243,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;23, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,820,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,243,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">5AM Ventures V, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;8,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,384,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,891,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canaan XI L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;8, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,384,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,891,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;8, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,384,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,891,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Parmar, a member of our board of directors, is a managing member of 5AM Partners V, LLC, the general partner of 5AM Ventures V, L.P. and, as a result, may be deemed to share voting and investment power with
respect to the shares held by 5AM Ventures V, L.P. 5AM Ventures V, L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Shannon, a member of our board of directors, is a manager of Canaan Partners XI, LLC, the general partner of Canaan XI L.P. and, as a result, may be deemed to share voting and investment power with respect to
the shares held by Canaan XI L.P. Canaan XI L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hunt, a member of our board of directors, is a managing director at New Leaf Venture Partners, L.L.C., an entity affiliated with New Leaf Ventures III, L.P. and, as a result, may be deemed to share voting and
investment power with respect to the shares held by New Leaf Ventures III, L.P. New Leaf Ventures III, L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series&nbsp;B Preferred Units </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, or the Initial Closing,
we entered into a Series B Preferred Share Purchase Agreement, or the Series B Agreement, to initially sell up to 92,269,898 Series B Preferred Units, or the Series B Units, at a purchase price of $1.4824 per unit. At the Initial Closing, we
completed the sale of 61,457,763 shares of Series B Units to investors at a purchase price of $1.4824 per unit for an aggregate purchase price of $91,104,988. In addition, the Series B Agreement gave us an option to sell up to an additional
27,606,455 Series B Units within 60 days of the Initial Closing. In April 2020, or the Second Closing, we completed the sale of 1,416,621 shares of Series B Units to investors at a purchase price of $1.4824 per unit for an aggregate purchase price
of $2,099,999. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2020, or the Final Closing, we completed the sale of 37,402,537 shares of Series B Units to investors at a purchase price of $1.3903 per
unit, or the Updated Purchase Price, for an aggregate purchase price of $51,999,999. To ensure the investors who participated in the Initial Closing and the Second Closing, or the Initial Purchasers, received the benefit of the Updated Purchase
Price, the LLC Entity issued additional Series B Units, for no additional consideration, to the Initial Purchasers such that the number of Series B Units that each Initial Purchaser held as of the Final Closing was increased to the number of Series
B Units that each Initial Purchaser </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">154 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
would have received with the Updated Purchase Price in respect of the aggregate purchase price paid by each investor. The LLC Entity issued an aggregate of 4,072,180 additional Series B Units to
the investors who participated in the Initial Closing, and an aggregate of 93,864 additional Series B Units to the investors who participated in the Second Closing. The following table summarizes purchases of units of our Series B Units by our
directors, executive officers and holders of more than 5% of our equity and their respective affiliates. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME OF UNITHOLDER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACQUISITION<BR>DATE(S)<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SERIES B<BR>CONVERTIBLE<BR>PREFERRED<BR>UNITS<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>PURCHASE<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Viking Global Opportunities Illiquid Investments
<FONT STYLE="white-space:nowrap">Sub-Master&nbsp;LP</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;14,&nbsp;2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,578,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">The Rise Fund Rascal L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;14, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,385,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with 5AM Ventures<SUP STYLE="font-size:85%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27,&nbsp;2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,227,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pivotal bioVenture Partners Fund I L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,789,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Life Sciences Fund VI LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,789,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Tekla Capital Management LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,789,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canaan XI L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,315,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,157,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mainstar Trst, Cust. FBO Jeffrey M. Fryer R2180643</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents the date in which the unitholder first acquired Series B Units. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reflects aggregate ownership of Series B Units, including all Series B Units acquired at the Final Closing, if applicable. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Iancovici, a member of our board of directors, is a Managing Director of TPG Growth, an affiliated entity of The Rise Fund Rascal L.P. Dr. Iancovici has no voting or investment power with respect to the shares
held by The Rise Fund Rascal L.P. The Rise Fund Rascal L.P. holds more than 5% of our voting stock prior to this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Parmar, a member of our board of directors, is a managing member of 5AM Partners V, LLC, the general partner of 5AM Ventures V, L.P. and, as a result, may be deemed to share voting and investment power with
respect to the shares held by 5AM Ventures V, L.P. Dr.&nbsp;Parmar is also a managing partner of 5AM Opportunities I (GP), LLC, the general partner of 5AM Opportunities I, L.P. Entities affiliated with 5AM Ventures, including 5AM Ventures V, L.P.
and 5AM Opportunities I, L.P., collectively hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Hopfner, a member of our board of directors, is a managing partner at Pivotal bioVenture Partners, an affiliated entity of Pivotal bioVenture Partners Fund I L.P. and, as a result, may be deemed to share voting
and investment power with respect to the shares held by Pivotal bioVenture Partners I L.P. Pivotal bioVenture Partners I L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Shannon, a member of our board of directors, is a manager of Canaan Partners XI LLC, the general partner of Canaan XI L.P. and, as a result, may be deemed to share voting and investment power with respect to
the shares held by Canaan XI L.P. Canaan XI L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hunt, a member of our board of directors, is a managing director at New Leaf Venture Partners, L.L.C., an entity affiliated with New Leaf Ventures III, L.P. and, as a result, may be deemed to share voting and
investment power with respect to the shares held by New Leaf Ventures III, L.P. New Leaf Ventures III, L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Affiliations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some of our directors are affiliated with and, prior
to the closing of this offering have served on our board of directors as representatives of entities which beneficially own or owned 5% or more of our voting securities, as indicated in the table below: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>DIRECTOR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AFFILIATED EQUITYHOLDER</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kush Parmar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5AM Ventures V, L.P. and 5AM Opportunities I, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Timothy M. Shannon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Canaan XI L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Rise Fund Rascal L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ronald Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">New Leaf Ventures III, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rob Hopfner, R.Ph., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Pivotal bioVenture Partners Fund I L.P.</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">155 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Operating Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant
to the terms of our Operating Agreement, we have granted certain unitholders certain information rights and the right to participate in future stock issuances, which rights terminate prior to the consummation of this offering, as well as certain
registration rights. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information regarding these registration rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant
to the terms of our Operating Agreement, the following directors were elected to serve as members on our board of directors and, as of the date of this prospectus, who continue to so serve: Mses. Helen M. Boudreau and Paula Soteropoulos, Drs. Rob
Hopfner, Lucian Iancovici, Martin W. Mackay, Kush Parmar, Timothy M. Shannon, and Mr.&nbsp;Ronald Hunt. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Operating Agreement will terminate prior to the
consummation of this offering, and members previously elected to our board of managers pursuant to such agreement will serve as directors of the Corporation until they resign, are removed or their successors are duly elected by the holders of our
common stock. The composition of our board of directors after this offering is described in more detail under &#147;Management&#151;Composition of the Board of Directors.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director and Officer Indemnification and Insurance </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have agreed to
indemnify each of our directors and executive officers against certain liabilities, costs and expenses, and have purchased directors&#146; and officers&#146; liability insurance. We also maintain a general liability insurance policy which covers
certain liabilities of directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Related Person
Transaction Policy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors intends to adopt a written related person transaction policy, to be effective upon the effectiveness of the
registration statement of which this prospectus forms&nbsp;a part, setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in
Item&nbsp;404 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> under the Securities Act of 1933, as amended, or the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or
relationships, in which we were or are to be a participant, where the amount involved exceeds the lesser of (i) $120,000 or (ii)&nbsp;one percent of the average of our total assets at year end for the last two completed fiscal years, in any fiscal
year and a related person had, has or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest,
indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked with considering all relevant facts and circumstances, including, but not limited to,
whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the transactions described in this section occurred
prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">156 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth certain information with respect to the beneficial ownership of our common stock
at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, as adjusted to reflect the sale of common stock offered by us in this offering, for: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each person who we know beneficially owns more than 5% of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">all of our directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, a person is deemed to be a
&#147;beneficial&#148; owner of a security if that person has or shares voting power or investment power, which includes the power to dispose of or to direct the disposition of such security. Except as indicated in the footnotes below, we believe,
based on the information furnished to us, that the individuals and entities named in the table below have sole voting and investment power with respect to all shares of common stock beneficially owned by them, subject to any applicable community
property laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Percentage ownership of our common stock before this offering is based
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021,
after giving effect to the Reorganization, including the issuance by the Corporation of an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of its common stock and the subsequent
distribution of those shares to members of the LLC Entity in the Liquidation, prior to the completion of this offering, as if such distribution had occurred as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus. Percentage ownership of our common stock after this
offering is based on shares of our common stock outstanding as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, after giving effect to the transactions as described above and our issuance of
shares of our common stock in this offering. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options or other rights held by such person
that are currently exercisable or that will become exercisable within 60&nbsp;days of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 are considered outstanding, although these shares are not
considered outstanding for purposes of computing the percentage ownership of any other person. Unless noted otherwise, the address of all listed stockholders is 234 Church Street, Suite 1020, New Haven CT, 06510. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">157 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE OF<BR>SHARES BENEFICIALLY<BR>OWNED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME OF BENEFICIAL OWNER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SHARES<BR>BENEFICIALLY<BR>OWNED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>BEFORE<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AFTER<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>5% or greater stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with 5AM Ventures<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Viking Global Opportunities Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP<SUP
STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canaan XI L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">The Rise Fund Rascal, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Life Sciences Fund VI LP<SUP
STYLE="font-size:85%; vertical-align:top"> (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pivotal bioVenture Partners Fund I L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tekla Capital Management LLC<SUP STYLE="font-size:85%; vertical-align:top"> (8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rob Hopfner, R.Ph., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ronald M. Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kush M. Parmar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Timothy M. Shannon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey M. Fryer, CPA<SUP STYLE="font-size:85%; vertical-align:top"> (9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All executive officers and directors as a group (11&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Less than 1% </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in respect of shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> preferred units held by 5AM Ventures V, L.P.; (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in
respect of shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred units held by 5AM Ventures V, L.P.; (iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be
received in the Reorganization in respect of shares of Series B preferred units held by 5AM Ventures V, L.P and (iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received
in the Reorganization in respect of shares of Series B preferred units held by 5AM Opportunities I, L.P. 5AM Partners V, LLC is the general partner of 5AM Ventures V, L.P. and may be deemed to have sole investment and voting power over the shares
held by 5AM Ventures V, L.P. Dr.&nbsp;Kush Parmar is a managing member of 5AM Partners V, LLC, and may be deemed to share voting and dispositive power over the shares held by 5AM Ventures V, L.P. 5AM Opportunities I (GP), LLC is the general partner
of 5AM Opportunities I, L.P. and may be deemed to have sole investment and voting power over the shares held by 5AM Opportunities I, L.P. Dr.&nbsp;Parmar is a managing member of 5AM Opportunities I (GP), LLC, and may be deemed to share voting and
dispositive power over the shares held by 5AM Opportunities I, L.P. Dr.&nbsp;Parmar is also a member of our board of directors. The address of the above persons and entities is 501 2nd Street, Suite 350, San Francisco, California 94107.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in respect of shares of Series B preferred units
held by Viking Global Opportunities Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP, or the Opportunities Fund. The Opportunities Fund has the authority to dispose of and vote the shares directly owned by it, which power
may be exercised by its general partner, Viking Global Opportunities Portfolio GP LLC, or the Opportunities GP, and by Viking Global Investors LP, which provides managerial services to the Opportunities Fund. O. Andreas Halvorsen, David C. Ott and
Rose Shabet, as Executive Committee members of Viking Global Partners LLC (the general partner of VGI) and Viking Global Opportunities GP LLC, the sole member of Opportunities GP, have shared authority to direct the voting and disposition of
investments beneficially owned by VGI and Opportunities GP. The address of the above entities is c/o Viking Global Opportunities Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP, 280 Park Avenue, New York, New York 10017.
</TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Consists of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
common stock to be received in the Reorganization in respect of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred units held by Canaan XI L.P.;
(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in respect of shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred
units held by Canaan XI L.P.; and (iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in respect of shares of Series B preferred units held
by Canaan XI L.P. Canaan Partners XI LLC is the general partner of Canaan XI, L.P. and may be deemed to have sole investment and voting power over the shares held by Canaan XI, L.P. Investment, voting and dispositive decisions with respect to the
shares held by Canaan XI L.P. are made by the managers of Canaan XI LLC, collectively. Dr.&nbsp;Shannon, a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">158 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
member of our board of directors, is a manager of Canaan Partners XI LLC. The address of the above person and entity is 2765 Sand Hill Road, Menlo Park, California 94025. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in respect of shares of Series B preferred units
held by The Rise Fund Rascal, L.P., a Delaware limited partnership. The general partner of The Rise Fund Rascal, L.P. is The Rise Fund SPV GP, LLC, a Delaware limited liability company, whose managing member is The Rise Fund GenPar, L.P., a Delaware
limited partnership, whose general partner is The Rise Fund GenPar Advisors, LLC, a Delaware limited liability company, whose sole member is TPG Holdings&nbsp;I, L.P., a Delaware limited partnership, whose general partner is TPG Holdings&nbsp;IA,
LLC, a Delaware limited liability company, whose sole member is TPG Group Holdings (SBS), L.P., a Delaware limited partnership, whose general partner is TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability company, whose sole member
is TPG Group Holdings (SBS) Advisors, Inc., a Delaware corporation. David Bonderman and James&nbsp;G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. and may therefore be deemed to beneficially own the securities held by
The Rise Fund Rascal, L.P. Messrs.&nbsp;Bonderman and Coulter disclaim beneficial ownership of the securities held by The Rise Fund Rascal, L.P. except to the extent of their pecuniary interest therein. Dr.&nbsp;Lucian Iancovici, a member of our
board of directors, is a Managing Director of TPG Growth, an affiliated entity of The Rise Fund Rascal, L.P. Dr.&nbsp;Iancovici has no voting or dispositive power over the shares held by The Rise Fund Rascal, L.P. The address of each of The Rise
Fund Rascal, L.P., Messrs.&nbsp;Bonderman and Coulter and Dr. Iancovici is 301&nbsp;Commerce Street, Suite 3300, Fort Worth, Texas 76102. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in respect of shares of <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> preferred units held by New Leaf Ventures III, L.P.; (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the
Reorganization in respect of shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> preferred units held by New Leaf Associates III, L.P.; and
(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in respect of shares of Series&nbsp;B preferred units held by New Leaf
Ventures&nbsp;III, L.P. New Leaf Venture Management&nbsp;III, L.L.C. is the general partner of New Leaf Associates&nbsp;III, L.P., which in turn is the General Partner of New Leaf Ventures&nbsp;III, L.P., and may be deemed to have sole investment
and voting power over the shares held by New Leaf Ventures&nbsp;III, L.P. Ronald Hunt is a managing director at New Leaf Venture Partners, L.L.C. and may be deemed to share voting and dispositive power over the shares held by New Leaf Ventures III,
L.P. Mr.&nbsp;Hunt is also a member of our board of directors. The address of the above person and entity is 420&nbsp;Lexington Avenue, Suite 408, New York, New York 10170. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in respect of shares of Series&nbsp;B preferred
units held by <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Life Sciences Fund&nbsp;VI LP. <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Life Sciences Advisors Fund&nbsp;VI LP, or
<FONT STYLE="white-space:nowrap">F-Prime</FONT> Advisors, is the general partner of <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Life Sciences Fund&nbsp;VI LP. <FONT STYLE="white-space:nowrap">F-Prime</FONT> Advisors is solely
managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC. Each of the entities listed above
expressly disclaims beneficial ownership of the securities listed above except of any pecuniary interest therein, if any. The address of the above entities is 245&nbsp;Summer Street, Boston, Massachusetts 02210. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in respect of shares of Series B preferred units
held by Pivotal bioVenture Partners Fund I, L.P. Pivotal bioVenture Partners Fund I G.P., L.P. is the general partner of Pivotal bioVenture Partners Fund I, L.P. and may be deemed to have sole investment and voting power over the shares held by
Pivotal bioVenture Partners Fund I, L.P. Dr.&nbsp;Rob Hopfner is a managing partner at Pivotal bioVenture Partners and may be deemed to share voting and dispositive power over the shares held by Pivotal bioVenture Partners Fund I, L.P.
Dr.&nbsp;Hopfner is also a member of our board of directors. The principal business address of Pivotal bioVenture Partners Fund I, L.P. is 501 Second Street, Suite 200, San Francisco, CA 94107. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in respect of shares of Series B preferred units
held by Tekla Healthcare Investors, (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in respect of shares of Series B preferred units held
by Tekla Healthcare Opportunities Fund and (iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be received in the Reorganization in respect of shares of Series B preferred
units held by Tekla Life Sciences Investors. Tekla Capital Management LLC, or TCM, is an investment adviser to Tekla Healthcare Investors (NYSE: HQH), Tekla Healthcare Opportunities Fund (NYSE: THQ) and Tekla Life Sciences Investors (NYSE: HQL),
collectively referred to as the Tekla Funds. Daniel R. Omstead, Ph.D., serves as President and Chief Executive Officer of the Tekla Funds. Each of TCM and Daniel R. Omstead, through his control of TCM, has sole power to dispose of the shares
beneficially owned by the Tekla Funds. Neither TCM nor Daniel R. Omstead has the sole power to vote or direct the vote of the shares beneficially owned by the Tekla Funds, which power resides in the Board of Trustees for each Tekla Fund. TCM carries
the voting of shares under written guidelines established by the Board of Trustees. The address for the Tekla Funds is 100 Federal Street, 19th Floor, Boston, Massachusetts 02110. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All shares owned by Jeffrey M. Fryer are held in two accounts, one trust and one Roth IRA. Mr. Fryer shares voting and dispositive power over the shares held in these two accounts. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">159 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws as they will
be in effect prior to the consummation of this offering are summaries and are qualified in their entirety by reference to our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect prior to the
consummation of this offering. Copies of these documents are filed as exhibits to the registration statement of which this prospectus is a part. The description of our common stock reflects the completion of the Reorganization, which will occur
immediately prior to the completion of this offering. See &#147;The Reorganization&#148; for more information concerning the Reorganization. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the closing of this offering, our authorized capital stock will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, with a par value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock, with a par value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, all of which
preferred stock will be undesignated. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;31, 2021, assuming the Reorganization and the closing of this offering, there
were&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding, held
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stockholders of record, and no shares of preferred stock outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of our common stock are entitled to one vote for each
share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the
election. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the
future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive an amount of our net assets available for distribution
to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding
shares of common stock are, and the shares offered by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be
adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of our amended and restated certificate of incorporation that will be in effect prior to the consummation of this offering, our board of
directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting
rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The purpose of authorizing our
board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with
possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a <FONT STYLE="white-space:nowrap">third-party</FONT> to acquire, or could discourage a
<FONT STYLE="white-space:nowrap">third-party</FONT> from seeking to acquire, a majority of our outstanding voting stock. Upon the closing of this offering, there will be no shares of preferred stock outstanding, and we have no present plans to issue
any shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investor Rights Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The LLC
Entity is party to an Amended and Restated Investor Rights Agreement with the investors party to our Operating Agreement, or the Investor Rights Agreement. Pursuant to the terms of this agreement, we granted these stockholders certain information
rights and the right to participate in future stock issuances, which rights terminate prior to the consummation of this offering, as well as certain registration rights. Following the Reorganization, we will enter into a registration rights
agreement, described below, with the shareholders of Rallybio Corporation, or the Corporation, immediately prior to the completion of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">160 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following
the Reorganization and prior to the completion of this offering, we will enter into a Registration Rights Agreement with the shareholders of the Corporation, or the Registration Rights Agreement. The Registration Rights Agreement will grant the
parties thereto certain registration rights in respect of the &#147;registrable securities&#148; held by them, which securities include (i)&nbsp;the shares of our common stock held by our shareholders following the Reorganization and prior to the
consummation of this offering and (ii)&nbsp;any common stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or
in replacement of, the shares referenced in clause (i)&nbsp;above. The registration of shares of our common stock pursuant to the exercise of these registration rights would enable the holders thereof to sell such shares without restriction under
the Securities Act when the applicable registration statement is declared effective. Under the Registration Rights Agreement, we will pay all expenses relating to such registrations, including the fees of one counsel for the participating holders,
and the holders will pay all underwriting discounts and commissions relating to the sale of their shares. The Registration Rights Agreement will also include customary indemnification and procedural terms. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock (after giving effect to the
Reorganization, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and the
subsequent conversion of preferred stock into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock) will be entitled to such registration rights pursuant to the Registration Rights
Agreement. These registration rights will expire on the earlier of (i)&nbsp;such time after this offering as Rule&nbsp;144 or another similar exemption under the Securities Act is available for the sale of all of such holder&#146;s shares without
limitation during a <FONT STYLE="white-space:nowrap">three-month</FONT> period without registration and (ii)&nbsp;the third anniversary of the consummation of this offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At any time beginning 180&nbsp;days after
the effectiveness of the registration statement of which this prospectus forms&nbsp;a part, the holders of at least 30% of the registrable securities then outstanding may request that we file&nbsp;a registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> with respect to at least 20% of the registrable securities then outstanding, if the aggregate offering price of the registrable securities requested to be registered would exceed $20&nbsp;million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once we are eligible to use a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> the holders of not less than 25% of the registrable
shares then outstanding may request that we file&nbsp;a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> with respect to such holders&#146; registrable securities then outstanding, if the aggregate offering price of
the registrable securities requested to be registered would exceed $3&nbsp;million. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that we propose to register any of our securities under the Securities Act, either for our own account or for the account of other security holders, the
stockholders party to the Investor Rights Agreement will be entitled to certain &#147;piggyback&#148; registration rights allowing them to include their registrable securities in such registration, subject to certain marketing and other limitations.
As a result, whenever we propose to file&nbsp;a registration statement under the Securities Act other than with respect to a demand registration or a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> or <FONT
STYLE="white-space:nowrap">S-8,</FONT> these holders will be entitled to notice of the registration and will have the right to include their registrable securities in the registration subject to certain limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Anti-takeover</FONT> Effects of Our Amended and Restated Certificate of Incorporation and Our Bylaws </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws, which will be in effect prior to the consummation of this offering, will contain
certain provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors, but which may have the effect of delaying, deferring or preventing a future takeover or change in control of us
unless such takeover or change in control is approved by our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These provisions include: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Classified board.</I> Our amended and restated certificate of incorporation will provide that our board of directors will be divided into three classes of directors,
with the classes as nearly equal in number as possible. As a result, approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of our board of directors will be elected each year. The classification of directors will have
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">161 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the effect of making it more difficult for stockholders to change the composition of our board of directors. Our amended and restated certificate of incorporation will also provide that, subject
to any rights of holders of preferred stock to elect additional directors under specified circumstances, the number of directors will be fixed exclusively pursuant to a resolution adopted by our board of directors. Upon completion of this offering,
we expect that our board of directors will have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;members. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Action
by written consent; special meetings of stockholders.</I> Our amended and restated certificate of incorporation will provide that stockholder action can be taken only at an annual or special meeting of stockholders and cannot be taken by written
consent in lieu of a meeting. Our amended and restated certificate of incorporation and the bylaws will also provide that, except as otherwise required by law, special meetings of the stockholders can only be called pursuant to a resolution adopted
by a majority of our board of directors. Except as described above, stockholders will not be permitted to call a special meeting or to require our board of directors to call a special meeting. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Removal of directors.</I> Our amended and restated certificate of incorporation will provide that our directors may be removed only for cause by the affirmative vote
of at least 75% of the voting power of our outstanding shares of capital stock, voting together as a single class. This requirement of a supermajority vote to remove directors could enable a minority of our stockholders to prevent a change in the
composition of our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Advance notice procedures.</I> Our bylaws will establish an advance notice procedure for stockholder proposals to be
brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice
of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary
timely written notice, in proper form, of the stockholder&#146;s intention to bring that business before the meeting. Although the bylaws will not give our board of directors the power to approve or disapprove stockholder nominations of candidates
or proposals regarding other business to be conducted at a special or annual meeting, the bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a
potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Supermajority
approval requirements. </I>The DGCL generally provides that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#146;s certificate of incorporation or bylaws, unless either a
corporation&#146;s certificate of incorporation or bylaws requires a greater percentage. Our amended and restated certificate of incorporation and bylaws will provide that the affirmative vote of holders of at least 75% of the total votes eligible
to be cast in the election of directors will be required to amend, alter, change or repeal specified provisions. This requirement of a supermajority vote to approve amendments to our amended and restated certificate of incorporation and bylaws could
enable a minority of our stockholders to exercise veto power over any such amendments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized but unissued shares.</I> Our authorized but unissued shares of
common stock and preferred stock will be available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital,
corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means
of a proxy contest, tender offer, merger or otherwise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Exclusive forum. </I>Our amended and restated certificate of incorporation will provide that, subject to
limited exceptions, the state or federal courts within the State of Delaware will be exclusive forums for (1)&nbsp;any derivative action or proceeding brought on our behalf, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by
any of our directors, officers or other employees to us or our stockholders, (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and
restated bylaws, (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws or (5)&nbsp;any other action asserting a claim against us that is
governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or to any claim for which the federal courts have
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">162 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
exclusive jurisdiction. Our amended and restated certificate of incorporation will also provide that, unless we consent in writing to the selection of an alternative forum, the U.S. federal
district courts shall be the exclusive forum for the resolution of any claims arising under the Securities Act. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware and certain federal
securities law, these provisions may have the effect of discouraging lawsuits against our directors and officers. See &#147;Risk Factors&#151;Risks Related to This Offering and Our Common Stock&#151;Our amended and restated certificate of
incorporation will designate the state or federal courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability to
obtain a favorable judicial forum for disputes with us or our directors, officers or employees.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Section&nbsp;203 of the DGCL </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the DGCL. In general, Section&nbsp;203 prohibits a publicly held Delaware
corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a <FONT STYLE="white-space:nowrap">three-year</FONT> period following the time that this stockholder becomes an interested stockholder,
unless the business combination is approved in a prescribed manner. A &#147;business combination&#148; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder.
An &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#146;s voting stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:
before the stockholder became interested, the corporation&#146;s board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of the
transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of
determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by
the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by
the interested stockholder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its original certificate of
incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a
result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The transfer agent and registrar for our common stock is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to apply to have our common stock approved for listing on
the Nasdaq Global Market under the symbol &#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">163 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately prior to this offering, there was no public market for our common stock, and no predictions can be made about the effect, if any, that market sales of our
common stock or the availability of such shares for sale will have on the market price prevailing from time to time. Nevertheless, future sales of our common stock in the public market, or the perception that such sales may occur, could adversely
affect the market price of our common stock and could impair our ability to raise capital through future sales of our securities. See &#147;Risk Factors&#151;Risks Related to This Offering and Our Common Stock&#151;A significant portion of our total
outstanding shares is restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well.&#148; Furthermore,
although we intend to apply to have our common stock approved for listing on the Nasdaq Global Market, we cannot assure you that there will be an active public trading market for our common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, based on the number of shares of our common stock outstanding as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, and after giving effect to the Reorganization, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and the subsequent conversion of preferred stock
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, we will have an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock if the underwriters exercise in full their option to purchase additional shares). Of these shares of our common stock, all of the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares sold
in this offering (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise in full their option to purchase additional shares) will be freely tradable without restriction
or further registration under the Securities Act, except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act, whose sales would be subject to the Rule&nbsp;144 resale restrictions
described below, other than the holding period requirement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All remaining shares of common stock held by existing stockholders immediately prior to the completion
of this offering will be &#147;restricted securities&#148; as such term is defined in Rule&nbsp;144. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption
from registration under Rules&nbsp;144 or 701 under the Securities Act, which are summarized below. We expect that substantially all of these shares will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT
STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, we estimate that
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be available for sale in the public market, subject in some cases to applicable volume limitations under
Rule&nbsp;144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and each of our directors and executive officers and holders of substantially all of our outstanding capital stock, who will collectively
own&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock upon the closing of this offering (based on our shares outstanding as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, and after giving effect to the Reorganization, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and the subsequent conversion of preferred stock into shares of our common
stock, have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180&nbsp;days after the date of this prospectus without first obtaining the written
consent of Jefferies LLC and Cowen and Company, LLC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the
shares subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. For a further description of these <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements, please see &#147;Underwriting.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the date of the initial public filing of the prospectus, certain of our employees, including our executive
officers, and/or directors may enter into written trading plans that are intended to comply with <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> under the Securities Exchange Act. Sales under these trading plans would not be permitted until
the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements relating to the offering described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;144 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Affiliate Resales of Restricted Securities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, beginning
90&nbsp;days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90&nbsp;days before a sale, who has
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">164 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
beneficially owned shares of our common stock for at least six months would be entitled to sell (subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to above, if
applicable) in &#147;broker&#146;s transactions&#148; or certain &#147;riskless principal transactions&#148; or to market makers, a number of shares within any <FONT STYLE="white-space:nowrap">three-month</FONT> period that does not exceed the
greater of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1% of the total number of shares then outstanding of our common stock, which will equal
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters
exercise their option to purchase additional shares in full) of our common stock immediately after this offering; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the average weekly trading volume in shares of our common stock on
the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;during the four calendar weeks preceding the filing of a notice on Form&nbsp;144 with respect to such sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Affiliate resales under Rule&nbsp;144 are also subject to the availability of current public information about us. In addition, if the number of shares being sold under
Rule&nbsp;144 by an affiliate during any <FONT STYLE="white-space:nowrap">three-month</FONT> period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file&nbsp;a notice on Form&nbsp;144 with the SEC
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;concurrently with either the placing of a sale order with the broker or the execution directly with a market maker. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-affiliate</FONT> Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, beginning 90&nbsp;days after the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate of ours
at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell such shares subject
only to the availability of current public information about us (as well as the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to above, if applicable). If such person has held our shares for at least one year, such person can
resell under Rule&nbsp;144(b)(1) without regard to any Rule&nbsp;144 restrictions, including the <FONT STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public information requirement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule&nbsp;144.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;701 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, under Rule&nbsp;701, any of an issuer&#146;s
employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration statement under the Securities
Act is entitled to sell such shares 90&nbsp;days after such effective date in reliance on Rule&nbsp;144. An affiliate of the issuer can resell shares in reliance on Rule&nbsp;144 without having to comply with the holding period requirement, and <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule&nbsp;144 without having to comply with the current public information and holding period requirements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The SEC has indicated that Rule&nbsp;701 will apply to typical options granted by an issuer before it becomes subject to the reporting requirements of the Exchange Act,
along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Plans </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to file one or more registration statements on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register all shares of our common stock subject to outstanding options and shares of our common stock issued or issuable under our incentive plans. We expect to file the
registration statement covering shares offered pursuant to our incentive plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without
restriction under the Securities Act and the sale by affiliates in the public market, subject to compliance with the resale provisions of Rule&nbsp;144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, the holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock or their transferees (after giving effect to the Reorganization, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and the subsequent conversion of preferred stock
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock) will be entitled to various rights with respect to the registration of these
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">165 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act
immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. Shares covered by a registration statement will be
eligible for sale in the public market upon the expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">166 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO
<FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF OUR COMMON STOCK </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion is a summary of the material U.S. federal income tax
consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all
potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the U.S.
Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case, in effect
as of the date hereof. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied
retroactively in a manner that could adversely affect a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no
assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of
Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances,
including the impact of the alternative minimum tax or the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special
rules, including, without limitation: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. expatriates and former citizens or <FONT STYLE="white-space:nowrap">long-term</FONT> residents of the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion
transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">banks, insurance companies and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">partnerships or other entities or arrangements treated as partnerships or other pass-through entities for U.S. federal
income tax purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who hold common stock that constitutes &#147;qualified small business stock&#148; under Section&nbsp;1202 of the
Code, or &#147;Section&nbsp;1244 stock&#148; under Section&nbsp;1244 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who acquired our common stock in a transaction subject to the gain rollover provisions of the Code (including
Section&nbsp;1045 of the Code); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons that acquired our common stock pursuant to the exercise of warrants or conversion rights under convertible
instruments; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who have elected to mark securities to market; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to our common stock
being taken into account in an applicable financial statement. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion does not address the tax treatment of entities or arrangements
treated as partnerships or other <FONT STYLE="white-space:nowrap">pass-through</FONT> entities or arrangements, or persons who hold our common stock through partnerships or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">167 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">pass-through</FONT> entities or arrangements, for U.S. federal income tax purposes. If an entity or arrangement treated as a partnership or other pass-through
entity for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner, member, or other beneficial owner of such partnership or other pass-through entity will depend on the status of such partner, member, or other
beneficial owner, the activities of the partnership or other pass-through entity, and certain determinations made at the level of the partner, member, or other beneficial owner, as applicable. Accordingly, partnerships or other pass-through entities
holding our common stock and the partners, members and other beneficial owners thereof should consult their tax advisors regarding the U.S. federal income tax consequences of the purchase, ownership and disposition of our common stock to them. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S.
FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS, AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Definition of a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148;
is any beneficial owner of our common stock that is neither a &#147;U.S. person&#148; nor an entity or arrangement treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes,
is or is treated as any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a corporation or any other entity taxable as a corporation for U.S. federal income tax purposes created or organized in or
under the laws of the United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and all substantial decisions of which are
subject to the control of one or more &#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code) or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax
purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described in the section
entitled &#147;Dividend Policy,&#148; we do not anticipate declaring or paying any distributions to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such
distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S.
federal income tax purposes will constitute a return of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any remaining excess
will be treated as capital gain and will be treated as described below under &#147;&#151;Sale or Other Taxable Disposition.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion below
on effectively connected income, FATCA, and backup withholding, dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will be subject to U.S. federal tax withholding at a rate of 30% of the gross amount of
the dividends or such lower rate specified by an applicable income tax treaty, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable documentation) certifying qualification for the lower treaty rate. This certification must be provided to us or the applicable withholding agent
before the payment of dividends and must be updated periodically. If the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds our common stock through a financial institution or other agent acting on the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be required to provide appropriate documentation to the agent, which then will be required to provide
certification to us or the applicable withholding agent, either directly or through other intermediaries. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a
reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their
entitlement to benefits under any applicable income tax treaty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">168 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent
establishment of fixed base in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI,</FONT> certifying that the dividends are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any such effectively connected dividends will be
subject to U.S. federal income tax on a net income basis at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may
be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on its effectively connected earnings and profits attributable to such dividends, as adjusted for certain items. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sale or Other Taxable Disposition </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion below on backup
withholding and FATCA, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a
trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment or fixed base in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the United States
for 183&nbsp;days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real property
holding corporation, or USRPHC, for U.S. federal income tax purposes, at any time during the five-year period preceding such disposition (or the Non-U.S. Holder&#146;s holding period, if shorter). </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the same U.S. federal income tax rates
applicable to United States persons (as defined in the Code). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable
income tax treaty) on its effectively connected earnings and profits attributable to such gain, as adjusted for certain items. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon
the sale or other taxable disposition of our common stock, which may be offset by certain <FONT STYLE="white-space:nowrap">U.S.-source</FONT> capital losses (even though the individual is not considered a resident of the United States), provided
that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to the
third bullet point above, we believe we currently are not, and we do not anticipate becoming, a USRPHC. Generally, a corporation is a USRPHC if the fair market value of its USRPIs equals or exceeds 50% of the sum of the fair market value of its
worldwide real property interests plus its other assets used or held for use in a trade or business. Because the determination of whether we are a USRPHC depends on the fair market value of our USRPIs relative to the fair market value of our <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there can be no assurance we are not currently a USRPHC or will not become a USRPHC in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our
common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded&#148; (as defined by applicable Treasury Regulations) on an established securities market, and such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the <FONT STYLE="white-space:nowrap">five-year</FONT> period ending on the date of the sale or other
taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rule
described above. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable income tax treaties that may
provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">169 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason
to know the holder is a United States person and the Non U.S. Holder either certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status by furnishing a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN,</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI</FONT> or otherwise establishes an exemption. We must report annually to the IRS and to each Non-U.S. Holder the gross
amount of the distributions on our common stock paid to such holder and the tax withheld, if any, with respect to such distributions, regardless of whether any distributions constitute dividends or whether any tax was actually withheld. In addition,
proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain <FONT STYLE="white-space:nowrap">U.S.-related</FONT> brokers generally will not be subject to backup withholding or
information reporting if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the Non U.S. Holder otherwise establishes an
exemption. Proceeds of a disposition of our common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker that does not have certain enumerated relationships
with the United States generally will not be subject to backup withholding or information reporting. Non-U.S. Holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of
the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Backup withholding is not an additional tax. Any
amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely
furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Withholding taxes may be imposed under Sections&nbsp;1471 to 1474 of the Code (such Sections together with any related Treasury Regulations, other Treasury Department
and IRS guidance issued thereunder, and intergovernmental agreements, legislation, rules and other official guidance adopted pursuant to such intergovernmental agreements, commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) on
certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends on
our common stock paid to a &#147;foreign financial institution&#148; or a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless such institution furnishes proper documentation
(typically on IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E)</FONT></FONT> indicating that (1)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (2)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (3)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. Foreign financial institutions located in jurisdictions that have an
intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the applicable Treasury Regulations and administrative
guidance, withholding under FATCA generally applies to payments of dividends on our common stock. While withholding under FATCA would have also applied to payments of gross proceeds from the sale or other disposition of our common stock on or after
January&nbsp;1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers and withholding agents generally may rely on these proposed Treasury Regulations until final Treasury Regulations are
issued. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If withholding under FATCA is required on any payment related to our common stock, investors not otherwise subject to withholding (or that otherwise would
be entitled to a reduced rate of withholding) on such payment may be entitled to seek a refund or credit from the IRS. Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their
investment in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">170 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions set forth in the underwriting agreement,
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021, among us and Jefferies LLC, Cowen&nbsp;&amp; Company, LLC and Evercore Group L.L.C., as the representatives of the
underwriters named below and the joint book-running managers of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number of shares of
common stock shown opposite its name below:<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>UNDERWRITER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cowen&nbsp;&amp; Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters
of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are purchased. If an
underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of
their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common stock as permitted by applicable
laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as to the
liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters
reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise
discretionary authority. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commission and Expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have
advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a
concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. After the offering, the initial public offering price and concession to dealers may be reduced by the representatives. No
such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">171 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the
underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have also agreed to pay the filing fees incident to, and the fees and disbursements of counsel for the underwriters in connection with, the clearance of this offering by
the Financial Industry Regulatory Authority, Inc. in an amount up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Determination of
Offering Price </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there has not been a public market for our common stock. Consequently, the initial public offering price for our common
stock will be determined by negotiations between us and the representatives. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and
the underwriters believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
offer no assurances that the initial public offering price will correspond to the price at which the common stock will trade in the public market subsequent to the offering or that an active trading market for the common stock will develop and
continue after the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to apply for listing of
our common stock on the Nasdaq Global Market under the symbol &#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stamp Taxes
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase shares of common stock offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the
country of purchase, in addition to the offering price listed on the cover page of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an
aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If
the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter&#146;s initial purchase commitment as indicated in the table
above. This option may be exercised only if the underwriters sell more shares than the total number set forth on the cover page of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>No Sales of
Similar Securities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our officers, directors and holders of all, or substantially all, our outstanding capital stock, have agreed, subject to specified
exceptions, not to directly or indirectly: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open
&#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-l(h)</FONT> under the Exchange Act, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">172 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities
exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this prospectus
without the prior written consent of Jefferies LLC and Cowen &amp; Company, LLC. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This restriction terminates after the close of trading of the
common stock on and including the 180th day after the date of this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies LLC and Cowen&nbsp;&amp; Company, LLC may, in their sole discretion and at
any time or from time to time before the termination of the 180-day period release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements between the underwriters
and any of our stockholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing consent to the sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, pursuant to Regulation
M under the Exchange Act, as amended, certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering.
These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#147;covered&#148;
short sales or &#147;naked&#148; short sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to
purchase additional shares of our common stock in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock
in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they
may purchase shares through the option to purchase additional shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Naked&#148; short sales are sales in excess of the option to purchase additional shares
of our common stock. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the
price of the shares of our common stock in the open market after pricing that could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A stabilizing bid is
a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on
behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of
raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open
market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased
in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor any of the underwriters make any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of
the activities may be discontinued at any time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also engage in passive market making transactions in our common stock on the Nasdaq Global
Market in accordance with Rule&nbsp;103 of Regulation&nbsp;M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must
display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are
exceeded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">173 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
prospectus in electronic format may be made available by <FONT STYLE="white-space:nowrap">e-mail,</FONT> or on the web sites or through online services, maintained by one or more of the underwriters or their affiliates. In those cases, prospective
investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for
online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any other web site
maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Activities and Relationships </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters and certain of their
affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging,
financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our
affiliates, for which they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and
certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of
their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge
their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps
or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock offered
hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or
instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling
Restrictions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in EEA </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
relation to each member state of the European Economic Area which has implemented the Prospectus Regulation, or each, a Relevant Member State, no offer of shares of our common stock which are the subject of the offering contemplated by this
prospectus has been or will be made to the public in that Relevant Member State, except that with effect from and including the Relevant Implementation Date, an offer of such shares of our common stock may be made to the public in that Relevant
Member State: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to any legal entity which is a &#147;qualified investor&#148; as defined in the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), as
permitted under the Prospectus Regulation, subject to obtaining the prior consent of the representatives of the underwriters; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">in any other circumstances falling within Article 3(2) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of shares of our common stock shall require us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 16 of the Prospectus Regulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to the
public&#148; in relation to any shares of our common stock in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares of our common stock to be offered so as
to enable an investor to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">174 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
decide to purchase or subscribe the shares of our common stock, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Regulation in that Relevant
Member State, and the expression &#147;Prospectus Regulation&#148; means Prospectus Regulation (EU) 2017/1129 (and amendments thereto, to the extent implemented in the Relevant Member States) and includes any relevant implementing measure in the
Relevant Member State. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in United Kingdom </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to our
shares of common stock which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">in any other circumstances falling within Section&nbsp;86 of the FSMA, provided that no such offer of the shares shall
require the Company or the underwriters to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an
&#147;offer to the public&#148; in relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to
decide to purchase or subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Bermuda </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities may be offered
or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including
companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Australia </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus is not
a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to the categories of
exempt persons set out below. Accordingly, if you receive this prospectus in Australia, you confirm and warrant that you are either: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have
provided an accountant&#146;s certificate to us which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a person associated with us under Section&nbsp;708(12) of the Corporations Act; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor
under the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You warrant and agree that you will not offer any of
the shares of our common stock issued to you pursuant to this prospectus for resale in Australia within 12 months of those shares of our common stock being issued unless any such resale offer is exempt from the requirement to issue a disclosure
document under section 708 of the Corporations Act. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Hong Kong </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No shares of our common stock have been offered or sold, and no shares of our common stock may be offered or sold, in Hong Kong, by means of any document, other than to
persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in the Securities and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">175 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the
Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32) or the Securities and Futures Ordinance (Cap. 571) of Hong Kong. No document, invitation or
advertisement relating to the shares of our common stock has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of
which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to shares of our common stock which are or are intended to be disposed of only to persons
outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong
Kong, and the shares of our common stock may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the shares of our common stock will be required, and is deemed by the acquisition of the shares of our common
stock, to confirm that he is aware of the restriction on offers of the shares of our common stock described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been offered any shares of our common stock
in circumstances that contravene any such restrictions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Israel </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel
Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares of our common stock is directed only at, (i)&nbsp;a limited number of persons in accordance with the Israeli
Securities Law and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment
advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to
time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are
required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to
Prospective Investors in Japan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law
No.&nbsp;25 of 1948 of Japan, as amended), or FIEL, and the underwriters will not offer or sell any shares of our common stock, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means,
unless otherwise provided herein, any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in
Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from <FONT STYLE="white-space:nowrap">S-30</FONT> the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws,
regulations and ministerial guidelines of Japan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Singapore </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in
connection with the offer or sale, or the invitation for subscription or purchase, of the shares of our common stock may not be issued, circulated or distributed, nor may the shares of our common stock be offered or sold, or be made the subject of
an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA,
(ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to,
and in accordance with the conditions of, any other applicable provision of the SFA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">176 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the shares of our common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person
which is: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which
is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the
beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares of our common stock pursuant to an offer made under Section&nbsp;275
of the SFA except: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising
from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations
2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Switzerland </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares of our common stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or the SIX, or on any other stock exchange
or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for
listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus, nor any other offering or marketing material, relating to the
shares of our common stock, or the offering, may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither this prospectus, nor any
other offering or marketing material relating to the offering, us or the shares of our common stock, have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with and the offer of
shares of our common stock will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of shares of our common stock has not been and will not be authorized under the Swiss Federal Act on Collective Investment
Schemes, or the CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares of our common stock. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Canada </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(A) Resale Restrictions
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of shares of our common stock in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private
placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these shares of our common stock are made. Any resale of the shares of our common stock in
Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable
Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the shares of our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(B) Representations
of Canadian Purchasers </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By purchasing shares of our common stock in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us
and the dealer from whom the purchase confirmation is received that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is entitled under applicable provincial securities laws to purchase the shares of our common stock without
the benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as defined under National Instrument <FONT STYLE="white-space:nowrap">45-106&#151;Prospectus</FONT> Exemptions, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">177 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is a &#147;permitted client&#148; as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103&#151;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where required by law, the purchaser is purchasing as principal and not as agent, and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser has reviewed the text above under Resale Restrictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(C) Conflicts of Interest </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers are hereby notified that each
of the underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument <FONT STYLE="white-space:nowrap">33-105&#151;Underwriting</FONT> Conflicts from having to provide certain conflict of interest
disclosure in this document. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(D) Statutory Rights of Action </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any amendment thereto) such as this document contains a misrepresentation, provided that the
remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any
applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(E) Enforcement of Legal Rights </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our directors and officers as well,
as the experts named herein, may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the
assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of
Canada. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(F) Taxation and Eligibility for Investment </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian
purchasers of shares of our common stock should consult their own legal and tax advisors with respect to the tax consequences of an investment in the shares of our common stock in their particular circumstances and about the eligibility of the
shares of our common stock for investment by the purchaser under relevant Canadian legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">178 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Ropes&nbsp;&amp; Gray,&nbsp;LLP, Boston, Massachusetts. Certain
legal matters will be passed upon for the underwriters by Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">179 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial statements as of December 31, 2020 and 2019 and each of the two years then ended included in this prospectus have been audited by Deloitte &amp; Touche
LLP, an independent registered public accounting firm, as stated in their report appearing herein. Such financial statements are so included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">180 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_22"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> under the Securities Act with respect to the shares of
common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further
information about us and the shares of common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not
necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. The SEC also maintains an Internet website that contains
reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that site is www.sec.gov. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon
the effectiveness of the registration statement, we will be subject to the informational requirements of the Exchange Act and, in accordance with the Exchange Act, will file reports, proxy and information statements and other information with the
SEC. Such annual, quarterly and special reports, proxy and information statements and other information can be accessed at the SEC&#146;s website referenced above. We also intend to make this information available on the investor relations section
of our website, which is located at www.rallybio.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">181 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_23"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Audited financial statements for the years ended December 31, 2020 and 2019:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_1">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_4">Consolidated Statements of Changes in Redeemable Convertible Preferred Units and Members&#146;
 Deficit </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unaudited financial statements for the three months ended March 31, 2020 and 2019:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_7">Unaudited Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_8">Unaudited Condensed Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_9">Unaudited Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred
 Units and Members&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_10">Unaudited Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_11">Notes to Unaudited Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the members and the Board of Managers of Rallybio Holdings, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on
the Financial Statements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the accompanying consolidated balance sheets of Rallybio Holdings, LLC and subsidiaries (the &#147;Company&#148;) as
of December&nbsp;31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, changes in redeemable convertible preferred units and members&#146; deficit, and cash flows, for each of the years then ended and the
related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2020 and 2019, and the
results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These financial statements are the responsibility of the
Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our
audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">/s/ Deloitte &amp; Touche LLP </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Hartford, Connecticut </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">April&nbsp;27, 2021 </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have served as the Company&#146;s auditor since 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_2"></A>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Balance Sheets </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities and members&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Commitments and contingencies (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred units:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A preferred units, no par value, 33,478,255 units authorized, issued and outstanding as of
December&nbsp;31, 2020 and 2019; liquidation preference of $37,600 as of December 31, 2020 and 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B preferred units, no par value, 104,442,965 units authorized, issued and outstanding as of
December&nbsp;31, 2020; liquidation preference of $145,204 as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Members&#146; deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common units, no par value, 5,700,000 authorized, issued and outstanding as of December&nbsp;31, 2020 and
2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive units, 17,772,360 and 6,033,957 authorized, 6,865,704 and 1,633,000 issued and outstanding as of
December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred units, and members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_3"></A>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expenses):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income and expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing right
obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common unit, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average common units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,659,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,715,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_4"></A>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_4"></A>Consolidated Statements of Changes in Redeemable Convertible Preferred Units and Members&#146; Deficit </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES A REDEEMABLE<BR>CONVERTIBLE&nbsp;PREFERRED<BR>UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B REDEEMABLE<BR>CONVERTIBLE PREFERRED<BR>UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCENTIVE UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>MEMBERS&#146;<BR>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Units, net
of issuance costs of $33</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,478,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,423,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Series B Redeemable Convertible Preferred Units, net of issuance costs of $319</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,442,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,232,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,442,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,865,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_5"></A>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows from Operating Activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Equity based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing right
obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows used in Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,935</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,072</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Series A preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Series B preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preferred unit issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents&#151;beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents&#151;end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Supplemental Schedule of Noncash Investing and Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">(Decrease) in Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing right obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unfunded investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses for purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_6"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. BUSINESS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio Holdings, LLC holds 100% of the outstanding membership
units in five wholly-owned subsidiaries&#151;Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC, Rallybio, IPD, LLC, and IPC Research, LLC (collectively, the &#147;Company&#148;). Rallybio Holdings, LLC was incorporated in Delaware on
March&nbsp;22, 2018. The Company is a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing, and delivering therapies to
meaningfully improve the lives of patients suffering from severe and rare diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has raised $37.6&nbsp;million in
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> financing and $145.2&nbsp;million in Series&nbsp;B financing. Refer to Note 6 &#147;Redeemable Convertible Preferred Units&#148;. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is seeking to complete an initial public offering (&#147;IPO&#148;). Prior to the completion of the IPO, the Company intends to complete a series of
transactions pursuant to which (i)&nbsp;Rallybio IPD, LLC, will be converted from a Delaware limited liability company to a Delaware corporation (the &#147;Corporation&#148;), (ii)&nbsp;the Corporation will form four direct subsidiaries
(collectively the &#147;Merger Subs&#148;), (iii)&nbsp;each of Rallybio Holdings, LLC&#146;s other four direct subsidiaries (collectively the &#147;Asset Subsidiaries&#148;) will consummate a separate merger each with one of the Merger Subs, with
the Asset Subsidiaries surviving the mergers and Rallybio Holdings, LLC receiving common stock of the Corporation in exchange for its interest in each Asset Subsidiary, which will result in the Asset Subsidiaries becoming subsidiaries of the
Corporation and the Corporation becoming the only direct subsidiary of Rallybio Holdings, LLC, and (iv)&nbsp;following this series of mergers, Rallybio Holdings, LLC will liquidate and distribute 100% of the stock of the Corporation to the common
and preferred unitholders of Rallybio Holdings, LLC. These transactions are collectively referred to as the &#147;Reorganization.&#148; As a result of the Reorganization, the unitholders of Rallybio Holdings, LLC will become the stockholders of the
Corporation, and the Corporation will become successor to Rallybio Holdings, LLC and the issuer of common stock in the IPO, and the Company&#146;s consolidated financial statements will be reported from the Corporation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, the World Health Organization characterized the novel coronavirus as a global pandemic. Although there is significant uncertainty as to the likely
effects this disease may have in the future, to date there has not yet been a significant impact to the Company&#146;s operations or financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Basis of Presentation&#151;</B>The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted
(&#147;GAAP&#148;) in the United States. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards Updates (&#147;ASU&#148;) promulgated
by the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Principles of Consolidation&#151;</B>The consolidated financial statements include the accounts
of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Use of
Estimates</B>&#151;The preparation of the Company&#146;s consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated
financial statements. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements are appropriate, actual results could differ from those estimates. The most significant estimates are
those used in the determination of the fair value of its common units and incentive units awarded to employees, for purposes of recording equity-based incentive compensation, as well as contracted research and development accruals. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Liquidity and Ability to Continue as a Going Concern</B>&#151;The accompanying consolidated financial statements have been prepared assuming that the Company will
continue as a going concern. Management has evaluated whether there are conditions and events that raise substantial doubt about the Company&#146;s ability to continue as a going </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
concern within one year after the date the financial statements are issued. Since its inception, the Company has incurred net losses and negative cash flows from operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the years ended December&nbsp;31, 2020 and December&nbsp;31, 2019, the Company incurred a net loss of $26.4&nbsp;million and $17.6&nbsp;million, respectively,
and used $22.0&nbsp;million and $15.0&nbsp;million in cash for operations, respectively. In addition, as of December&nbsp;31, 2020, the Company had an accumulated deficit of $47.0&nbsp;million. The Company expects to continue to generate operating
losses and negative cash flows in the foreseeable future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company currently expects that the cash and cash equivalents on hand of $140.2 million as of
December&nbsp;31, 2020, will be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date the consolidated financial statements are issued. Additional funding will be needed to finance future clinical, <FONT
STYLE="white-space:nowrap">pre-clinical,</FONT> manufacturing, and commercial activities. To date, the Company has principally financed its operations through private placements of redeemable convertible preferred units. In the event the Company
does not complete an IPO, the Company will seek additional funding through private equity and debt financings and other arrangements. There is no assurance the Company will be successful in obtaining such additional financing on terms acceptable to
it, if at all, and it may not be able to enter into other arrangements. If the Company is unable to obtain funding, it could be forced to delay, reduce or eliminate our research and development programs, portfolio expansion or commercialization
efforts, which could adversely affect its business prospects and ability to continue operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is subject to risks common to companies in the
biopharmaceutical industry. There can be no assurance that the Company&#146;s research and development will be successfully completed, that adequate protection for its intellectual property will be maintained, that any products developed will obtain
required regulatory approval, or that any approved products will be commercially viable. Even if the development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales and ultimately net income.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Variable Interest Entity</B>&#151;The Company evaluates its ownership, contractual, and other interests in entities to determine if it has any variable interest
in a variable interest entity (&#147;VIE&#148;). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available historical information, among other factors. If the Company determines that an entity in
which it holds a contractual, or ownership, interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets
both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could
potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company&#146;s involvement with a VIE will cause the consolidation conclusion to change. Changes in
consolidation status are applied prospectively. The Company evaluated its investment in REV-I (defined in Note 9) and concluded that it represented a VIE and was not deemed the primary beneficiary. If the Company is not deemed to be the primary
beneficiary in a VIE, the Company accounts for the investment or other variable interests in a VIE in accordance with the applicable GAAP (See Note 9). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Equity
Method Investments</B>&#151;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, <I>Investments &#150; Equity Method and Joint Ventures</I>. The Company recognizes its <FONT
STYLE="white-space:nowrap">pro-rata</FONT> share of income and losses in &#147;loss on investment in joint venture&#148; on the consolidated statements of operations and comprehensive loss, with a corresponding change to the investment in joint
venture on the consolidated balance sheets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Financial Instruments</B>&#151;The Company&#146;s principal financial instruments are comprised of cash and cash
equivalents, accounts payable, and accrued liabilities. The carrying value of all financial instruments approximates fair value. During 2019, the Company also recorded, at fair value, a free-standing financial instrument related to the obligation to
issue future Series <FONT STYLE="white-space:nowrap">A-2</FONT> units at <FONT STYLE="white-space:nowrap">pre-determined</FONT> prices upon the achievement of specific milestone events. As of December&nbsp;31, 2019, all Series <FONT
STYLE="white-space:nowrap">A-2</FONT> units were sold and therefore there is no longer a financing obligation outstanding. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Concentrations of credit
risk&#151;</B>Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. Periodically, the Company may maintain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#146;s deposits are held
at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Cash and
Cash Equivalents&#151;</B>The Company classifies amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market funds, with original maturities of three months or less at time of purchase as cash and cash
equivalents. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Property and Equipment</B>&#151;Property and equipment are recorded at cost and consists of computer and other equipment, furniture and
fixtures, leasehold improvements, and capitalized software. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three to six years. Maintenance and repairs which do not extend the
lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation are removed from the related accounts, and any resulting gain or loss is recognized as a component of income or
loss in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Impairment of Long-Lived Assets</B>&#151;When indications of potential impairments are
present, the Company evaluates the carrying value of long-lived assets. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than carrying value. No such impairments were
recorded during the years ended December&nbsp;31, 2020 or 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Income Taxes</B>&#151;Rallybio Holdings, LLC is taxed under the provisions of <I>Subchapter
K&#151; Partners and Partnerships </I>of the Internal Revenue Code. Under those provisions, Rallybio Holdings, LLC does not pay federal or state corporate income taxes on its taxable income. Instead, the members include net income or loss for
Rallybio Holdings, LLC on their individual tax returns. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC, IPC Research, LLC, and Rallybio IPD, LLC have elected,
for United States federal and state income tax purposes, to be each treated as and taxed as corporations. These entities are not eligible to file a consolidated federal income tax return and will file separately as stand-alone taxpayers.
Accordingly, each entity, on a standalone basis, uses the asset and liability method of accounting for income taxes, as set forth in Accounting Standards Codification (ASC) 740, <I>Accounting for Income Taxes</I>. Under this method, deferred tax
assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently
enacted tax rates. The Company evaluates whether deferred tax assets are more likely than not of being realized in determining whether a valuation allowance is necessary. As of December 31, 2020 and 2019, the Company determined that it is not more
likely than not that deferred taxes will be realized and as a result recorded a valuation allowance against its deferred tax assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Research and Development
Expenses</B>&#151;Research and development expenses are comprised of costs incurred in performing research and development activities including personnel salaries, benefits, and equity-based compensation; external research and development expenses
incurred under arrangements with third parties, such as contract research organization agreements, investigational sites, and consultants; the cost of developing and manufacturing clinical study materials, program regulatory costs, expenses
associated with obligations under asset acquisitions, license agreements and other direct and indirect costs. Costs incurred in connection with research and development activities are expensed as incurred. Costs are considered incurred based on an
evaluation of the progress to completion of each contract using information and data provided by the respective vendors, including the Company&#146;s clinical sites. Depending upon the timing of invoicing by the service providers, the Company
recognizes prepaid expenses or accrued expenses related to these costs. These prepaid expenses or accrued expenses are based on management&#146;s estimates of the work performed under service agreements, milestones achieved, and experience with
similar contracts. The Company monitors each of these factors and adjusts estimates accordingly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Preferred Units</B>&#151;The Company records all preferred
units at their respective fair values less issuance costs on the dates of issuance. The preferred units are recorded outside of members&#146; deficit because, in the event of certain deemed liquidation events, which are events that are not
considered solely within the Company&#146;s control, such as a merger, acquisition or sale of all or substantially all of the Company&#146;s assets, the preferred units will become </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
redeemable. The preferred units could also become redeemable due to certain change of control clauses that are outside of the Company&#146;s control. In the event of a change of control of the
Company, proceeds received from the event will be distributed to the preferred units in accordance with the liquidation preferences set forth in the Company&#146;s Operating Agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Deferred Offering Costs</B>&#151;The Company capitalizes certain legal, professional accounting and other third-party fees that are specific incremental costs
directly attributable to an <FONT STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred offering costs until such equity financings are consummated. After consummation of an equity financing, these costs are recorded as a
reduction of the common or preferred units generated as a result of the offering. Should the <FONT STYLE="white-space:nowrap">in-process</FONT> equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to
operating expenses in the consolidated statements of operations and comprehensive loss. Preferred unit issuance costs are presented as a direct reduction of the carrying amount of the Series B preferred units and totaled $319,265 for the year ended
December&nbsp;31, 2020. Preferred unit issuance costs are presented as a direct reduction of the carrying amount Series A preferred units and totaled $33,443 for the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Equity-Based Compensation&#151;</B>The Company accounts for equity-based compensation in accordance with ASC 718, Compensation&#151;Stock Compensation (&#147;ASC
718&#148;). Generally, equity-based compensation is measured at the grant date for all equity-based awards made to employees based on the fair value of the awards and is recognized over the requisite service period, which is generally the vesting
period. Equity-based compensation for awards with performance conditions are recognized over the service period when achievement of the performance condition is probable. The Company has elected to recognize the actual forfeitures by reducing the
equity-based compensation in the same period as the forfeitures occur.&nbsp;The Company classifies equity-based compensation in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipients&#146;
payroll costs are classified. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has issued incentive units and restricted common units to employees. Incentive units granted to employees generally vest
over a four-year period. The incentive units are common units issued in the form of profits interests, providing the employee with compensation equal to the increase in the value of the unit over a participation threshold of the unit, as determined
at the time of grant. The incentive units have defined rights within the Company&#146;s Operating Agreement. The holder, therefore, has the right to participate in distributions of profits only in excess of such participation threshold. The
participation threshold is based on the valuation of a single common unit on or around the grant date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of the Company&#146;s restricted common units
and incentive units is determined using an option pricing method (&#147;OPM&#148;) which uses market approaches and a Black-Scholes option pricing model to estimate its enterprise value. An OPM is then used which treats common units and preferred
units as call options on the total equity value of the Company, with exercise prices based on the value thresholds at which the allocation among the various holders of the Company&#146;s securities changes to value the common units of the Company. A
discount for lack of marketability of the common units is then applied to arrive at an indication of value for the common units as of the valuation date. Volatility is determined by comparing companies operating in the Company&#146;s comparable
industry as well as the Company&#146;s capital structure and risk profile relative to its peer group. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Fair Value Measurements</B>&#151;ASC Topic 820,&nbsp;Fair
Value Measurement&nbsp;(&#147;ASC 820&#148;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#146;s own assumptions
(unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the
Company&#146;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would
be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a
three-tiered value hierarchy that distinguishes between the following: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level&nbsp;1&#151;Quoted market prices in active markets for identical
assets or liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level&nbsp;2&#151;Inputs other than Level&nbsp;1 inputs that are either directly or indirectly observable,
such as quoted market prices, interest rates and yield curves. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level&nbsp;3&#151;Unobservable inputs for the asset or liability (i.e. supported by
little or no market activity). Level&nbsp;3 inputs include management&#146;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values
requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level&nbsp;3. A financial instrument&#146;s level within the fair value hierarchy is based on
the lowest level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In determining fair value, the Company utilizes valuation techniques that maximize
the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of the Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing obligation was measured on a recurring basis and is considered a Level&nbsp;3
instrument in the fair value hierarchy. See Note 6 &#147;Redeemable Convertible Preferred Units&#148; for more information on the Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing obligation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the Company&#146;s Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing right obligation for the year ended December 31, 2019:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding&#151;December 31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Milestones achieved</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding&#151;December 31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Segment information</B>&#151;Operating segments are defined as components of an enterprise for which discrete financial information is regularly reviewed by the
chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating
decisions. All tangible assets of the Company are held in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Basic and Diluted Net Loss Per Unit</B>&#151;The Company calculates basic net loss
per unit by dividing the net loss by the weighted average number of common units outstanding during the period, without consideration of potential dilutive securities. Unvested restricted common units as of December&nbsp;31, 2020 and 2019 are not
considered participating securities and as such are excluded from the weighted average number of shares used for calculating basic and diluted net loss per share. Diluted net loss per unit is computed by dividing the net loss by the sum of the
weighted average number of common units outstanding during the period plus the dilutive effects of potentially dilutive securities outstanding during the period. Potentially dilutive securities include restricted common units, incentive units, and
redeemable convertible preferred units. The dilutive effect of redeemable convertible preferred units is calculated using the <FONT STYLE="white-space:nowrap">if-converted</FONT> method. The Company has generated a net loss for all periods
presented, therefore diluted net loss per unit is the same as basic net loss per unit since the inclusion of potentially dilutive securities would be anti-dilutive. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Recent Accounting Pronouncements</B>&#151;In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases</I>. This guidance
requires an entity to recognize lease liabilities and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for all leases on the balance sheet and to disclose key information about the entity&#146;s
leasing arrangements. ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December&nbsp;15, 2022, with earlier adoption
permitted. ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> must be adopted using a modified retrospective approach for all leases existing at, or entered into after the date of initial adoption, with an option to elect to use certain transition
relief. The Company is currently evaluating the impact of adopting ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> on its consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company to take advantage of an extended
transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an emerging growth company, the Company has elected to take advantage of this
extended transition period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. ASSET ACQUISITIONS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2019, the
Company, through one of its wholly-owned subsidiaries, entered into an asset purchase agreement and acquired intellectual property from Swedish Orphan Biovitrum AB. The purchase price includes an upfront payment of $3.0&nbsp;million with additional
payments of $1.0&nbsp;million due in September 2020 and March 2021. The assets were expensed upon purchase given the uncertainty of probable future revenue streams and are included in research and development expense on the consolidated statements
of operations and comprehensive loss. Discounted obligations in the amount of $1.0&nbsp;million and $1.9&nbsp;million which includes accretion of interest, are included in accrued expenses and accrued expenses long-term on the consolidated balance
sheets as of December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively. Interest expense related to the discounted obligation was $49,422 and $39,281 for the years ended December 31, 2020 and 2019, respectively. In the event that the Company
achieves certain milestones, milestone payments will become due, as well as royalties due on future sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2019, the Company, through one of its wholly
owned subsidiaries, entered into an asset purchase agreement and acquired intellectual property from Prophylix AS for $1.2&nbsp;million. Pursuant to the agreement, the Company assumed liabilities for a sign on licensing fee in the amount of
$0.1&nbsp;million, reimbursements for a manufacturing fee in the amount of $0.5&nbsp;million and manufacturing liabilities in the form of future commitments of approximately $1.2&nbsp;million. The assets purchased and liabilities assumed, with the
exception of the manufacturing commitment, were expensed upon purchase given the uncertainty of probable future revenue streams and are included in research and development expense on the consolidated statements of operations and comprehensive loss.
Costs associated with the manufacturing commitment are expensed to research and development within the consolidated statements of operations and comprehensive loss, as the manufacturer fulfills its obligations. In the event that the Company achieves
certain development and commercial milestones, milestone payments will become due, as well as royalties on future sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. PROPERTY AND EQUIPMENT, NET </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment consisted of the following as of December&nbsp;31, 2020 and 2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computer and other equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Capitalized software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment&#151;net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depreciation expense totaled $62,030 and $26,344 for the years ended December&nbsp;31, 2020 and 2019, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. ACCRUED EXPENSES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued
expenses consisted of the following at December&nbsp;31, 2020 and 2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Asset purchase obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unfunded obligation in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">$4,264</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">$2,949</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. REDEEMABLE CONVERTIBLE PREFERRED UNITS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Preferred Units</B>&#151;In
April 2018, Rallybio Holdings, LLC entered into a Series A Preferred Stock Purchase Agreement (the &#147;Series A Agreement&#148;) with a total potential aggregate purchase price $37.0&nbsp;million. Under the terms of the Series A Agreement,
Rallybio Holdings, LLC agreed to sell 5,999,999 units of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redeemable Convertible Preferred Units (&#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units&#148;) to investors at a price of
$1.00 per share and up to 26,956,516 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Units (&#147;Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units&#148;), upon the Company&#146;s achievement of
certain milestone events, to investors at a price of $1.15 per share (the &#147;Series A Financing Right Obligation&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, Rallybio Holdings, LLC
sold 5,549,999 Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units to investors in exchange for $5.5&nbsp;million. Additionally, the Company issued 450,000 Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units to the Company&#146;s founders
in exchange for a capital contribution of convertible debt totaling $0.5&nbsp;million owed to the founders by Rallybio, LLC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series A
Agreement, the Company entered into a Connecticut Presence Agreement (the &#147;CPA&#148;) with Connecticut Innovation, Incorporated (&#147;CII&#148;) relating to Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Units that would be issued to CII. The CPA provides that the proceeds from CII&#146;s investment in the Company&#146;s preferred units be paid back to CII at a specified price. The CPA is only exercisable upon
the Company&#146;s breach of the covenant which requires it to maintain a Connecticut presence, as defined within the CPA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series A
Agreement, the Company granted investors the right to purchase Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units at future milestone dates and at a predetermined price. Since the investors held rights that imposed an obligation on the Company
to issue Preferred Units that were potentially redeemable, the future tranche rights were considered a freestanding instrument and were recorded at the fair value of the tranche right and classified as a liability. Changes in the fair value of this
liability are recorded in prior period earnings. The milestones were met during 2019, and preferred units were redeemed by the investor and the liability attributable to the tranche rights was reclassified to Series A Preferred Units, as such, the
freestanding instrument and the fair value of the tranche right a liability was $0.0 as of December&nbsp;31, 2019. Refer to Note 2 fair value measurements. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
2019, upon achievement of certain milestones, the Company sold 27,478,256 Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units to investors, founders and employees in exchange for $31.6&nbsp;million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, with subsequent offerings through May 2020, the Company entered into a Series B Preferred Stock Purchase Agreement (the &#147;Series B Agreement&#148;)
with a total aggregate purchase price $145.2 million. Under the terms of the Series B Agreement, the Company agreed to sell 104,442,965 units of Series B Redeemable Convertible Preferred Units (&#147;Series B Units&#148;) to investors at a price of
$1.39028 per share. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Series A and B Preferred Units, (&#147;preferred units&#148;) have the following rights, preferences, and privileges: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voting Rights</I></B>&#151;The holders of the preferred units are entitled to vote together as a single class and on an as converted to common units basis in
accordance with each such holder&#146;s percentage interests. In addition, the preferred units holders shall have the right to vote separately as a series on any matter which would adversely alter or change the rights, powers or preferences of one
series without a similar effect on the other series. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conversion Rights&#151;</I></B>Each preferred unit is convertible, at the option of the holder thereof, at any time
and from time to time, and without the payment of additional consideration, into fully paid and nonassessable common units. The number of common units into which each preferred unit may be converted shall be determined by dividing the number of
preferred units by their applicable original issue price, potentially subject to adjustment for anti-dilution provisions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each preferred unit is automatically
converted into fully paid and nonassessable common units upon either the closing of the sale of common units to the public at a price of at least $2.08542 per unit in a firm commitment underwritten public offering pursuant to an effective
registration statement under the Securities Act of 1933, as amended, resulting in at least $50.0&nbsp;million of gross proceeds to the Company, or at the occurrence of an event, specified in writing by the preferred units holders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dividends</I></B>&#151;The holders of preferred units may receive distributions declared and paid on the preferred units when determined by the Company&#146;s
Board of Managers. The Company may not declare, pay or set aside any distributions on any common units unless the preferred units holders first receive, or simultaneously receive, a distribution on each outstanding preferred unit in an amount at
least equal to the greater of 8% of the applicable original issue price of the preferred units, per year, from and after the date of the issuance on a <FONT STYLE="white-space:nowrap">non-cumulative</FONT> basis of any preferred units or the <FONT
STYLE="white-space:nowrap">pro-rata</FONT> distribution that the preferred units holder would receive had they converted their preferred units into common units. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No dividends were declared or paid during the years ended December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Redemption Rights</I></B>&#151;The preferred units are only redeemable pursuant to a deemed liquidation event. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-Dilution Provisions</I></B>&#151;If the Company makes adjustments to any class of units for dividends, splits, combinations or other similar events, or
issues additional securities at a purchase price less than current conversion price for issued and outstanding preferred units, the preferred units conversion price shall be adjusted in accordance with a formula, as defined in the Company&#146;s
Operating Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation</I></B>&#151;The preferred units have preferential rights with respect to any dissolution or liquidation of the Company and
with respect to a sale of the Company. In the event of a dissolution, liquidation, or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, the holders of the preferred units are entitled to receive, in preference to the holders of the
common units and the incentive units, an amount equal to their original issue price. After payment of this preferential amount, remaining proceeds are distributed in accordance with a formula as defined in the Operating Agreement for the Company.
This formula provides additional preferences to the preferred unit holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. MEMBERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Common Units</B>&#151;In 2018, the Company issued 4,500,000 common units to its founders, including 3,375,000 restricted common units that vest over a four year
period. In 2018, the Company also issued 1,200,000 restricted common units to the founders, pursuant to restricted share purchase agreements, which begin vesting upon achievement of certain performance conditions. These restricted common units vest
into common units and therefore have been presented as common units within the consolidated statement of changes in redeemable convertible preferred units and members&#146; deficit. Restricted common units issued to the founders vest 25% upon the <FONT
STYLE="white-space:nowrap">1-year</FONT> anniversary of the Company initiating a clinical program through one of its controlled subsidiaries, monthly thereafter over the next 36 months. In 2019, it was determined that the performance condition of
these restricted common units became probable, vesting started, and the units began being expensed over the vesting period. No other restricted common units were granted in 2020 or 2019. Each common unit entitles the holder to one vote on all
matters submitted to a vote of the Company&#146;s members. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At December&nbsp;31, 2020 and 2019, of the 4,500,000 common units issued to the founders, 2,812,500 and
1,968,750 of these restricted common units were fully vested, respectively, and the remaining 1,687,500 and 2,531,250 units vest over the remaining weighted average period of 1.30 and 2.33 years, respectively. During the years ended
December&nbsp;31, 2020 and 2019, the Company recognized $0.1&nbsp;million of equity-based compensation expense relating to the issuance of these restricted common units for both years. As of December&nbsp;31, 2020 and 2019, there was
$0.2&nbsp;million and $0.3&nbsp;million of compensation expense relating to these restricted common units that remains to be amortized over the weighted average period of 1.30 and 2.33 years, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At December&nbsp;31, 2020 and 2019, of the 1,200,000 restricted common units issued to the founders that were issued
subject to performance-based vesting conditions, 375,000 and 0 of these restricted common units were fully vested, respectively, and the remaining 825,000 and 1,200,000 units are expected to vest over the remaining weighted average period of 2.70
and 3.71 years, respectively.&nbsp;During the years ended December&nbsp;31, 2020 and 2019, the Company recognized equity-based compensation expense of $95,584 and $13,125, respectively, on these restricted common units. At December&nbsp;31, 2020 and
2019, there was $0.1&nbsp;million and $0.2&nbsp;million of compensation expense that remained to be amortized over a weighted average period of 2.70 and 3.71 years, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Incentive Units</B>&#151;At December&nbsp;31, 2020 and 2019, the Company has reserved 18,972,360 and 7,233,957 common units, respectively, for issuance to officers
and other employees of the Company pursuant to the Rallybio Holdings, LLC 2018 Share Plan (&#147;2018 Share Plan&#148;). The reserve includes 1,200,000 restricted common units that were issued to the founders in 2018, discussed further below. At
December&nbsp;31, 2020 and 2019, 10,906,656 and 4,400,957 incentive units, respectively, remained available for future grants. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the years ended 2020 and
2019, 5,232,704 and 1,423,000 incentive units were issued to employees of the Company, respectively. During the years ended December&nbsp;31, 2020 and 2019, the Company recognized equity-based compensation expense of $0.5&nbsp;million and
$0.1&nbsp;million, respectively, relating to the issuance of incentive units. At December&nbsp;31, 2020 and 2019, there was $2.2&nbsp;million and $0.5&nbsp;million of equity-based compensation expense that remains to be amortized over a weighted
average period of 3.22 and 3.36 years, respectively. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The assumptions that went into the option pricing models for determining the fair value of our incentive
units granted in 2020 and 2019 are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected time to liquidity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table provides a summary of the activity under the 2018 Share Plan for incentive
units granted to employees. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCENTIVE&nbsp;UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,423,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,232,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,865,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At December&nbsp;31, 2020 and 2019, 6,865,704 and 1,633,000 incentive units granted under the 2018 Share Plan are outstanding and expected to vest, respectively. At
December&nbsp;31, 2020 and 2019, 495,182 and 112,292 incentive units are fully vested, respectively, and the remaining 6,370,522 and 1,520,708 units are expected to vest over a weighted average period of 3.12 and 3.49 years, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Equity-based compensation, including common and incentive units are classified in the consolidated statements of
operations and comprehensive loss for years ended December&nbsp;31, 2020 and 2019 as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and Administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. INCOME TAXES </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The combined provision for income taxes of tax paying
subsidiaries of the Company is comprised of the following for the years ended December&nbsp;31, 2020 and 2019: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s effective income tax rates are different from the federal statutory tax rates in
2020 and 2019 predominantly due to the valuation allowance, tax credits, state taxes, and the federal net operating loss carryback tax benefit described below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">U.S. federal statutory tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State income taxes, net of federal income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Effective Tax Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#147;CARES Act&#148;) was enacted in response to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The CARES Act, among other things, allows net operating losses incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of
previously paid income taxes. The CARES Act also eliminates the 80% of taxable income limitation allowing corporate entities to fully utilize net operating loss carryforwards to offset taxable income in 2018, 2019 and 2020. During 2019, two of the
Company&#146;s wholly owned, subsidiaries generated federal net operating losses in 2019, and in December 2020, each subsidiary filed Forms 1139 to carryback these losses and offset all remaining taxable income in the 2018 tax year. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">GAAP requires balance sheet presentation to reflect when the assets are expected to be monetized. Forms 1139 were filed in December 2020, and a refund is expected
within the next twelve months. The Company has reclassed the amount of <FONT STYLE="white-space:nowrap">tax-effected</FONT> net operating losses, which have been utilized on the Form 1139 carryback claims, from a deferred tax asset to a current
income tax receivable. Since the Company has provided a valuation allowance against the Company&#146;s deferred tax assets, this reclass has an impact on total income tax expense/(benefit). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December&nbsp;27, 2020 the Consolidated Appropriations Act, 2021 (&#147;CAA&#148;) was signed into law. The CAA includes the COVID-related Tax Relief Act of 2020
(&#147;COVID TRA&#148;). The Company is continuing to assess the effect of the CAA and does not believe it will result in a material impact to the Company&#146;s income tax provision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and
tax reporting purposes. The combined temporary differences and carryforwards of each tax paying component of the Company that give rise to a significant portion of the deferred income tax benefits and liabilities are as follows at December&nbsp;31,
2020 and 2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B><U>DEFERRED INCOME TAX ASSETS:</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>(in
thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At December&nbsp;31, 2020, the Company has approximately $38.7&nbsp;million of federal net operating loss carryforwards, which do not expire, and approximately
$38.8&nbsp;million of state net operating loss carryforwards, which begin expiring in 2038. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has provided a valuation allowance against the
Company&#146;s deferred tax assets, since, in the opinion of management, based upon the history of losses by the Company; it is not more likely than not that the benefits will be realized. All or a portion of the remaining valuation allowance may be
reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ASC 740 addresses the determination of whether
tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax
position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has no material uncertain tax positions that qualify for either recognition or disclosure in consolidated financial
statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It is the Company&#146;s policy to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&nbsp;31,
2020 and 2019, the Company has accrued no interest and penalties related to uncertain tax positions. The Company does not have any outstanding U.S. federal income tax or material state and local tax matters for periods through December&nbsp;31,
2020. There are no federal or state and local income tax returns currently under examination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. INVESTMENT IN JOINT VENTURE </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2019, the Company through one its wholly-owned subsidiaries, entered into an agreement to establish a joint venture with Exscientia Limited
(&#147;Exscientia&#148;) to initiate early stage drug discovery on available small molecules and thereafter the future research, development, manufacture, sale and exploitation of any company-owned technology and compounds, including candidate
compounds that result therefrom. In July 2019, the Company and Exscientia completed the formation of the joint venture entity, RE Ventures I, LLC, a limited liability corporation <FONT STYLE="white-space:nowrap">(&#147;REV-I&#148;).</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each member received a 50% interest when the joint venture was created. Pursuant to the operating agreement, at inception of the joint venture the Company was obligated
to initially contribute &pound;0.5&nbsp;million, or $0.6&nbsp;million, to fund stage I development. The Company&#146;s initial investment in REV-I in the amount of $0.6&nbsp;million at December 31, 2019 was unfunded and included in accrued expenses
on the consolidated balance sheets. The unfunded obligation was subsequently funded in January 2020. In 2020, REV-I determined that the stage 1 development objective had been achieved. During 2020, the Company funded an additional $1.3 million
associated with stage 2 development costs. The Company did not provide any additional financial support outside of capital contributions to REV-I during the years ended December 31, 2020 and 2019. The Company held a 50% interest in the joint venture
as of December 31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on management&#146;s analysis, the Company is not the primary beneficiary of
<FONT STYLE="white-space:nowrap">REV-I</FONT> since it does not have both (1)&nbsp;the power to direct the activities that most significantly impact the entity&#146;s economic performance which consists primarily of research and development
activities and (2)&nbsp;the obligation to absorb the losses of the VIE or the right to receive the benefits from the VIE, which could be significant to the VIE. The research and development activities of REV-I are controlled by a management board
under the joint control of the Company and Exscientia. All decisions are made by consensus with each member having one vote. Accordingly, the VIE is not consolidated in the Company&#146;s financial statements as of December&nbsp;31, 2020. The
Company accounts for its 50% interest under the equity method of accounting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December&nbsp;31, 2020 and 2019, the Company recorded its
allocable share of <FONT STYLE="white-space:nowrap">REV-I&#146;s</FONT> losses, which totaled $1.5&nbsp;million and $0.1&nbsp;million, respectively, as a loss on investment in joint venture within the consolidated statements of operations and
comprehensive loss. After recognition of its share of losses for the year, the carrying value and maximum exposure to risk of the <FONT STYLE="white-space:nowrap">REV-I</FONT> investment as of December&nbsp;31, 2020 and 2019, was $0.3&nbsp;million
and $0.5&nbsp;million, respectively, which was recorded in investment in joint venture in the accompanying consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. COMMITMENTS AND
CONTINGENCIES </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Purchase Commitments&#151;</B>We enter contracts in the normal course of business with contract research organizations and other
third-party vendors for clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments that may be due upon cancellation consist
of payments for services provided or expenses incurred. As of December&nbsp;31, 2020, and 2019 there were no amounts accrued related to termination charges. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Lease Commitments</B>&#151; In June 2019, the Company entered into a <FONT STYLE="white-space:nowrap">six-year</FONT> lease to occupy office space located in New
Haven, Connecticut, with the option to extend the initial term of the lease for one additional five year term. Pursuant to the lease the Company was obligated to pay for its share of costs related to the
<FONT STYLE="white-space:nowrap">build-out</FONT> of new space. All costs associated with the <FONT STYLE="white-space:nowrap">build-out</FONT> of the new space have been capitalized as leasehold improvements and are being amortized over the life of
the lease. In October 2020, the Company modified the existing New Haven lease agreement and leased additional space that coincides with the original lease term expiration date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rent expense was $87,833 and $42,429 for the years ended December&nbsp;31, 2020 and 2019, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Future minimum annual lease payments are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B><U>YEAR ENDING DECEMBER&nbsp;31</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>(in
thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">$507</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. NET LOSS PER COMMON UNIT </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic and diluted loss per common unit were calculated as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B><U>NET LOSS PER COMMON UNIT</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>(in thousands except
share and per share amounts)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common units-basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of common units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,659,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,715,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common unit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following common stock equivalents have been excluded from the calculations of diluted loss per common unit because their inclusion would have been antidilutive:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B><U>ANTIDILUTIVE UNITS</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unvested restricted common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,512,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,731,250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,865,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A Preferred Units, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Preferred Units, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,442,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,299,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,842,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. SUBSEQUENT EVENTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company evaluated all material subsequent events
through April&nbsp;27, 2021, the date the consolidated financial statements were available to be issued. The following events occurred subsequent to December&nbsp;31, 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2021, the Board of Managers of the Company approved an increase in the employee stock plan incentive pool shares available by an additional 4,000,000 common
units, for issuance to officers, managers, employees and consultants of the Company pursuant to the 2018 Share Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_7"></A>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities and members&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred units:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A preferred units, no par value, 33,478,255 units authorized,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">issued and outstanding as of March&nbsp;31, 2021 and December&nbsp;31,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2020; liquidation preference of $37,600 as of March&nbsp;31, 2021 and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B preferred units, no par value, 104,442,965 units authorized,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">issued and outstanding as of March&nbsp;31, 2021 and December&nbsp;31,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2020; liquidation preference of $145,204 as of March&nbsp;31, 2021 and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Members&#146; deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common units, no par value, 5,700,000 issued and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">outstanding as of March&nbsp;31, 2021 and December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive units, 19,934,704 and 6,865,704 issued and outstanding as of March&nbsp;31, 2021 and
December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred units, and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the condensed consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_8"></A>Condensed Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expenses):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common unit, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average common units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,228,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,968,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the condensed consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_9"></A>Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Units and Members&#146; Deficit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES A REDEEMABLE</B><br><B>CONVERTIBLE&nbsp;PREFERRED<BR>UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B REDEEMABLE</B><br><B>CONVERTIBLE&nbsp;PREFERRED<BR>UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCENTIVE UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share<BR>amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>MEMBERS&#146;<BR>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Series B Redeemable Convertible Preferred Units, net of issuance costs of $248</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,457,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance, March&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,457,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,442,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,865,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,069,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance, March&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,442,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,934,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the condensed consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_10"></A>Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows from Operating Activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Equity based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(630</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows used in Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Series B preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents&#151;beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents&#151;end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Supplemental disclosures of noncash activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B preferred unit issuance costs in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B preferred unit receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the condensed consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_11"></A>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. BUSINESS AND LIQUIDITY </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio Holdings, LLC holds 100% of the
outstanding membership units in five wholly-owned subsidiaries&#151;Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC, Rallybio, IPD, LLC, and IPC Research, LLC (collectively, the &#147;Company&#148;). Rallybio Holdings, LLC was incorporated in
Delaware on March&nbsp;22, 2018. The Company is a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing, and delivering
therapies to meaningfully improve the lives of patients suffering from severe and rare diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has raised $37.6&nbsp;million in <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> financing and $145.2&nbsp;million in Series&nbsp;B financing. Refer to Note 4 &#147;Redeemable Convertible Preferred Units&#148;. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is seeking to complete an initial public offering (&#147;IPO&#148;). Prior to the completion of the IPO, the Company intends to complete a series of
transactions pursuant to which (i)&nbsp;Rallybio IPD, LLC, will be converted from a Delaware limited liability company to a Delaware corporation (the &#147;Corporation&#148;), (ii)&nbsp;the Corporation will form four direct subsidiaries
(collectively the &#147;Merger Subs&#148;), (iii)&nbsp;each of Rallybio Holdings, LLC&#146;s other four direct subsidiaries (collectively the &#147;Asset Subsidiaries&#148;) will consummate a separate merger each with one of the Merger Subs, with
the Asset Subsidiaries surviving the mergers and Rallybio Holdings, LLC receiving common stock of the Corporation in exchange for its interest in each Asset Subsidiary, which will result in the Asset Subsidiaries becoming subsidiaries of the
Corporation and the Corporation becoming the only direct subsidiary of Rallybio Holdings, LLC, and (iv)&nbsp;following this series of mergers, Rallybio Holdings, LLC will liquidate and distribute 100% of the stock of the Corporation to the common
and preferred unitholders of Rallybio Holdings, LLC. These transactions are collectively referred to as the &#147;Reorganization.&#148; As a result of the Reorganization, the unitholders of Rallybio Holdings, LLC will become the stockholders of the
Corporation, and the Corporation will become successor to Rallybio Holdings, LLC and the issuer of common stock in the IPO, and the Company&#146;s condensed consolidated financial statements will be reported from the Corporation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, the World Health Organization characterized the novel coronavirus as a global pandemic. Although there is significant uncertainty as to the likely
effects this disease may have in the future, to date there has not yet been a significant impact to the Company&#146;s operations or financial statements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Liquidity and Ability to Continue as a Going Concern</B>&#151;The accompanying consolidated financial statements have been prepared assuming that the Company will
continue as a going concern. Management has evaluated whether there are conditions and events that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date the financial statements are
issued. Since its inception, the Company has incurred net losses and negative cash flows from operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the three months ended March&nbsp;31 2021 and
2020, the Company incurred a net loss of $13.3&nbsp;million and $3.9&nbsp;million, respectively, and used $11.9&nbsp;million and $5.5&nbsp;million in cash for operations, respectively. In addition, as of March&nbsp;31, 2021, the Company had an
accumulated deficit of $60.3&nbsp;million. The Company expects to continue to generate operating losses and negative cash flows in the foreseeable future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company currently expects that the cash and cash equivalents on hand of $127.7&nbsp;million as of March&nbsp;31, 2021, will be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date the consolidated
financial statements are issued. Additional funding will be needed to finance future clinical, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> manufacturing, and commercial activities. To date, the Company has principally financed its
operations through private placements of redeemable convertible preferred units. In the event the Company does not complete an IPO, the Company will seek additional funding through private equity and debt financings and other arrangements. There is
no assurance the Company will be successful in obtaining such additional financing on terms acceptable to it, if at all, and it may not be able to enter into other arrangements. If the Company is unable to obtain funding, it could be forced to
delay, reduce or eliminate our research and development programs, portfolio expansion or commercialization efforts, which could adversely affect its business prospects and ability to continue operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that
the Company&#146;s research and development will be successfully completed, that adequate protection for its intellectual property will be maintained, that any products developed will obtain required regulatory approval, or that any approved
products will be commercially viable. Even if the development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales and ultimately net income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Unaudited Financial Information</B>&#151;Our condensed consolidated financial statements included herein have been prepared in conformity with accounting principles
generally accepted in the United States of America, or GAAP, and pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In our opinion, the information furnished reflects all adjustments, all of which are of a
normal and recurring nature, necessary for a fair presentation of the financial position and results of operations for the reported interim periods. We consider events or transactions that occur after the balance sheet date but before the financial
statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for
the full year or any other interim period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&nbsp;reviews&nbsp;new accounting standards as issued. As of March&nbsp;31, 2021 the Company has not
identified any new standards that it believes will have a significant impact on the Company&#146;s financial statements. However, the Company is still evaluating the impact of adopting ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT>
<I>Leases</I> on its condensed consolidated financial statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There were no changes to the Company&#146;s significant accounting policies during the three
months ended March&nbsp;31, 2021 other than noted below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Deferred Offering Costs</B>&#151;The Company capitalizes incremental legal, professional accounting and
other third-party fees that are directly associated with the IPO as other current assets until the IPO is consummated. After consummation of the IPO, these costs will be recorded in members&#146; deficit as a reduction of additional <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT> generated as a result of the offering. As of March&nbsp;31, 2021, there were deferred offering costs of approximately $0.3&nbsp;million included in prepaid
expenses and other assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. ACCRUED EXPENSES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued expenses
consisted of the following as of March&nbsp;31, 2021and December&nbsp;31, 2020: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Asset purchase obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. REDEEMABLE CONVERTIBLE PREFERRED UNITS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Preferred Units</B>&#151;In April 2018, Rallybio Holdings, LLC entered into a Series A Preferred Stock Purchase Agreement (the &#147;Series A Agreement&#148;) with a
total potential aggregate purchase price $37.0&nbsp;million. Under the terms of the Series A Agreement, Rallybio Holdings, LLC agreed to sell 5,999,999 units of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redeemable Convertible Preferred
Units (&#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units&#148;) to investors at a price of $1.00 per share and up to 26,956,516 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Units
(&#147;Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units&#148;), upon the Company&#146;s achievement of certain milestone events, to investors at a price of $1.15 per share (the &#147;Series A Financing Right Obligation&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, Rallybio Holdings, LLC sold 5,549,999 Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units to
investors in exchange for $5.5&nbsp;million. Additionally, the Company issued 450,000 Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units to the Company&#146;s founders in exchange for a capital contribution of convertible debt totaling
$0.5&nbsp;million owed to the founders by Rallybio, LLC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series A Agreement, the Company entered into a Connecticut Presence Agreement (the
&#147;CPA&#148;) with Connecticut Innovation, Incorporated (&#147;CII&#148;) relating to Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units that would be issued to CII. The CPA provides
that the proceeds from CII&#146;s investment in the Company&#146;s preferred units be paid back to CII at a specified price. The CPA is only exercisable upon the Company&#146;s breach of the covenant which requires it to maintain a Connecticut
presence, as defined within the CPA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series A Agreement, the Company granted investors the right to purchase Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Units at future milestone dates and at a predetermined price. Since the investors held rights that imposed an obligation on the Company to issue Preferred Units that were potentially redeemable, the future
tranche rights were considered a freestanding instrument and were recorded at the fair value of the tranche right and classified as a liability. Changes in the fair value of this liability are recorded in prior period earnings. The milestones were
met during 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2019, upon the achievement of the certain milestones, the Company sold 27,478,256 Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units to
investors, founders and employees in exchange for $31.6&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020 the Company entered into a Series B Preferred Stock Purchase Agreement (the
&#147;Series B Agreement&#148;) with a total aggregate purchase price of $91.1&nbsp;million. Under the terms of the Series B Agreement, the Company agreed to sell 61,457,763 units of Series B Redeemable Convertible Preferred Units (&#147;Series B
Units&#148;) to investors at a price of $1.48 per share. The Company received proceeds of $85.1&nbsp;million as of March&nbsp;31, 2020. The remaining $6.0&nbsp;million was received on April&nbsp;1, 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April and May 2020, the Company entered into subsequent offerings of the Series B Agreement increasing the total aggregate purchase price $145.2&nbsp;million. Under
the terms of the updated Series B Agreement, the Company agreed to sell 104,442,965 total Series B Units to investors at a price of $1.39028 per share. An additional 4.2&nbsp;million units were granted to investors in May 2020 who participated in
prior offerings. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Series A and B Preferred Units, (&#147;preferred units&#148;) have the following rights, preferences, and privileges: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voting Rights</I></B>&#151;The holders of the preferred units are entitled to vote together as a single class and on an as converted to common units basis in
accordance with each such holder&#146;s percentage interests. In addition, the preferred units holders shall have the right to vote separately as a series on any matter which would adversely alter or change the rights, powers or preferences of one
series without a similar effect on the other series. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conversion Rights&#151;</I></B>Each preferred unit is convertible, at the option of the holder thereof,
at any time and from time to time, and without the payment of additional consideration, into fully paid and nonassessable common units. The number of common units into which each preferred unit may be converted shall be determined by dividing the
number of preferred units by their applicable original issue price, potentially subject to adjustment for anti-dilution provisions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each preferred unit is
automatically converted into fully paid and nonassessable common units upon either the closing of the sale of common units to the public at a price of at least $2.08542 per unit in a firm commitment underwritten public offering pursuant to an
effective registration statement under the Securities Act of 1933, as amended, resulting in at least $50.0&nbsp;million of gross proceeds to the Company, or at the occurrence of an event, specified in writing by the preferred units holders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dividends</I></B>&#151;The holders of preferred units may receive distributions declared and paid on the preferred units when determined by the Company&#146;s
Board of Managers. The Company may not declare, pay or set aside any distributions on any common units unless the preferred units holders first receive, or simultaneously receive, a distribution on each outstanding preferred unit in an amount at
least equal to the greater of 8% of the applicable original issue price of the preferred units, per year, from and after the date of the issuance on a <FONT STYLE="white-space:nowrap">non-cumulative</FONT> basis of any preferred units or the <FONT
STYLE="white-space:nowrap">pro-rata</FONT> distribution that the preferred units holder would receive had they converted their preferred units into common units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No dividends were declared or paid during the three months ended March&nbsp;31, 2021 and 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Redemption Rights</I></B>&#151;The preferred units are only redeemable pursuant to a deemed liquidation event. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-Dilution Provisions</I></B>&#151;If the Company makes adjustments to any class of units for dividends, splits, combinations or other similar events, or
issues additional securities at a purchase price less than current conversion price for issued and outstanding preferred units, the preferred units conversion price shall be adjusted in accordance with a formula, as defined in the Company&#146;s
Operating Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation</I></B>&#151;The preferred units have preferential rights with respect to any dissolution or liquidation of the Company and
with respect to a sale of the Company. In the event of a dissolution, liquidation, or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, the holders of the preferred units are entitled to receive, in preference to the holders of the
common units and the incentive units, an amount equal to their original issue price. After payment of this preferential amount, remaining proceeds are distributed in accordance with a formula as defined in the Operating Agreement for the Company.
This formula provides additional preferences to the preferred unit holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. MEMBERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Common Units</B>&#151;As of March&nbsp;31, 2021 and December&nbsp;31, 2020, the Company has authorized 165,393,580 and 161,393,580 common units, respectively,
pursuant to the terms of the Company&#146;s Operating Agreement, which includes 137,921,220 common units reserved for issuance upon conversion of preferred units. Additionally, of the total common units authorized, 22,972,360 and 18,972,360 common
units are reserved for issuance to officers and employees of the Company pursuant to the Rallybio Holdings, LLC 2018 Share Plan (&#147;2018 Share Plan&#148;) at March&nbsp;31, 2021 and December&nbsp;31, 2020, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2018, the Company issued 4,500,000 common units to its founders, including 3,375,000 common units that vest over a four year period. In 2018, the Company also issued
1,200,000 restricted common units to the founders, pursuant to restricted share purchase agreements, which begin vesting upon achievement of certain performance conditions. These restricted common units vest into common units and therefore have been
presented as common units within the condensed consolidated statement of changes in redeemable convertible preferred units and members&#146; deficit. Restricted common units issued to the founders vest 25% upon the
<FONT STYLE="white-space:nowrap">1-year</FONT> anniversary of the Company initiating a clinical program through one of its controlled subsidiaries, and monthly thereafter over the next 36 months. In 2019, it was determined that the performance
condition of these restricted common units became probable, vesting started, and the units started expensing over the vesting period. No other common or restricted common units were granted or forfeited in the three months ended March&nbsp;31, 2021.
Each common unit entitles the holder to one vote on all matters submitted to a vote of the Company&#146;s members. The weighted average fair value of both the 4,500,000 common units and 1,200,000 restricted common units granted during 2018 was
$0.15. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of both March&nbsp;31, 2021 and December&nbsp;31, 2020, of the 4,500,000 common units issued to the founders, 2,812,500 of these restricted common units
were fully vested, and 1,687,500 units remain unvested. For each of the three months ended March&nbsp;31, 2021 and 2020, the Company recognized $31,641, of equity-based compensation expense relating to the issuance of these restricted common units.
As of&nbsp;March&nbsp;31, 2021 there was $0.1&nbsp;million of compensation expense relating to these restricted common units that remains to be amortized over the weighted average period of 1.1 years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At March&nbsp;31, 2021 and December&nbsp;31, 2020, of the 1,200,000 restricted common units issued to the founders that were issued subject to performance-based vesting
conditions, 450,000 and 375,000 of these restricted common units were fully vested, respectively, and 750,000 and 825,000 units remain unvested, respectively.&nbsp;During the three months ended March&nbsp;31, 2021 and 2020, the Company recognized
equity-based compensation expense of $10,461 and $38,501, respectively, on these restricted common units. At March&nbsp;31, 2021 there was $0.1&nbsp;million of compensation expense that remained to be amortized over a weighted average period of 1.3
years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Incentive Units</B>&#151;As of March&nbsp;31, 2021 and December&nbsp;31, 2020, the Company is authorized to issue up to an aggregate of 22,972,360 and
18,972,360 incentive units, respectively pursuant to the Plan. The reserve includes 1,200,000 restricted common units that were issued to founders in 2018. Incentive units are granted to employees and generally vest over a four year period. As of
March&nbsp;31, 2021, 1,837,656 incentive units, remained available for future grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the three months ended March&nbsp;31, 2021, the Company granted 13,069,000 incentive units to employees under
the Plan. The weighted average fair value of incentive units granted to employees in the three months ended March&nbsp;31, 2021 was $0.33 per unit. The Company did not grant any incentive units for the three months ended March&nbsp;31, 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the three months ended March&nbsp;31, 2021 and 2020, the Company recognized equity-based compensation expense of $479,791 and $34,588, respectively, relating to
the issuance of incentive units. At&nbsp;March&nbsp;31, 2021, there was $6.1&nbsp;million of equity-based compensation expense remaining that is expected to be amortized over a weighted average period of 3.5 years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The assumptions that went into the option pricing models for determining the fair value of our incentive units granted for the three months ended March&nbsp;31, 2021
are as follows: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31, 2021</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">77.3%&nbsp;-&nbsp;99.5%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.58&nbsp;-&nbsp;1.00</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">.09%&nbsp;-&nbsp;0.1%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of underlying common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$0.47</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table provides a summary of the activity for the three months ended March&nbsp;31, 2021 under the 2018 Share Plan for incentive units granted to
employees: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCENTIVE<BR>UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED<BR>AVERAGE<BR>GRANT&nbsp;DATE<BR>FAIR&nbsp;VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,865,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,069,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,934,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At March&nbsp;31, 2021 and December&nbsp;31, 2020, the Company had 19,934,704 and 6,865,704 incentive units granted under the 2018 Share Plan that are outstanding and
expected to vest, respectively. At March&nbsp;31, 2021 and December&nbsp;31, 2020, 715,913 and 495,182 incentive units are fully vested, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Equity-based
compensation, including common and incentive units are classified in the condensed consolidated statements of operations and comprehensive loss for the three months ended March&nbsp;31, 2021 and 2020 as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and Administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. INVESTMENT IN JOINT VENTURE </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has a 50% interest of the joint
venture entity, RE Ventures I, LLC, a limited liability corporation <FONT STYLE="white-space:nowrap">(&#147;REV-I&#148;).</FONT> For the three months ended March&nbsp;31, 2021, the Company funded an additional $0.5&nbsp;million associated
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
with stage 2 development costs. For the three months ended March&nbsp;31, 2020 the Company funded the initial investment in <FONT STYLE="white-space:nowrap">REV-I</FONT> of $0.6&nbsp;million that
was included in accrued expenses on the consolidated balance sheets as of December&nbsp;31, 2019. The Company did not provide any additional financial support outside of capital contributions to <FONT STYLE="white-space:nowrap">REV-I</FONT> during
the three months ended March&nbsp;31, 2021 and 2020. The Company held a 50% interest in the joint venture as of March&nbsp;31, 2021. As of March&nbsp;31, 2021, based on management&#146;s analysis, the company is not the primary beneficiary of <FONT
STYLE="white-space:nowrap">REV-1</FONT> and accordingly, the entity is not consolidated in the Company&#146;s financial statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the three months ended
March&nbsp;31, 2021 and 2020, the Company recorded its allocable share of <FONT STYLE="white-space:nowrap">REV-I&#146;s</FONT> losses, which totaled $0.5&nbsp;million and $0.1&nbsp;million, respectively, as a loss on investment in joint venture
within the condensed consolidated statements of operations and comprehensive loss. After recognition of its share of losses for the period, the carrying value and maximum exposure to risk of the <FONT STYLE="white-space:nowrap">REV-I</FONT>
investment as of March&nbsp;31, 2021 and December&nbsp;31, 2020, was $0.3&nbsp;million and $0.3&nbsp;million, respectively, which was recorded in investment in joint venture in the accompanying condensed consolidated balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. COMMITMENTS AND CONTINGENCIES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Purchase Commitments</B>&#151;We enter
contracts in the normal course of business with contract research organizations and other third-party vendors for clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are
cancellable by us upon written notice. Payments that may be due upon cancellation consisting of payments for services provided or expenses incurred. As of March&nbsp;31, 2021, and December&nbsp;31, 2020 there were no amounts accrued related to
termination charges. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Lease Commitments</B>&#151; In June 2019, the Company entered into a <FONT STYLE="white-space:nowrap">six-year</FONT> lease to occupy
office space located in New Haven, Connecticut, with the option to extend the initial term of the lease for one additional five year term. Pursuant to the lease the Company was obligated to pay for its share of costs related to the <FONT
STYLE="white-space:nowrap">build-out</FONT> of new space. All costs associated with the <FONT STYLE="white-space:nowrap">build-out</FONT> of the new space have been capitalized as leasehold improvements and are being amortized over the life of the
lease. In October 2020, the Company modified the existing New Haven lease agreement and leased additional space that coincides with the original lease term expiration date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rent expense was $26,495 and $20,367 for the three months ended March&nbsp;31, 2021 and 2020, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been no significant changes to the disclosure of payments we have committed to make under our contractual obligations as summarized in our Audited Financial
Statements for the year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. NET LOSS PER COMMON UNIT </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic and diluted loss per common unit were calculated as follows: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>NET LOSS PER COMMON UNIT</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>(in thousands except share and
per share amounts)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common units-basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of common units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,228,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,968,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common unit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following common stock equivalents have been excluded from the calculations of diluted loss per common unit
because their inclusion would have been antidilutive: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>ANTIDILUTIVE UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unvested restricted common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,437,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,731,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,934,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A Preferred Units, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Preferred Units, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,442,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,457,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,293,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,300,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. SUBSEQUENT EVENTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company evaluated all material subsequent events
through June&nbsp;7, 2021, the date the condensed consolidated financial statements were available to be issued. The Company noted the following material events occurred subsequent to March&nbsp;31, 2021. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2021, the Company contributed an additional $1.5&nbsp;million to <FONT STYLE="white-space:nowrap">REV-I</FONT> associated with stage 2 development costs. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g01k65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PRELIMINARY PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART&nbsp;II </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Not Required in Prospectus </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13. Other Expenses of
Issuance and Distribution. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by the
registrant in connection with the sale of common stock being registered. All amounts are estimates except for the SEC registration fee, the FINRA filing fee and the Nasdaq Global Market listing fee: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>ITEM</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT<BR>TO&nbsp;BE&nbsp;PAID</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Transfer agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be completed by amendment </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As permitted by Section&nbsp;102(b)(7) of the DGCL, we plan to include in our amended and restated certificate of incorporation a provision to eliminate the personal
liability of our directors for monetary damages for breach of their fiduciary duties as directors, subject to certain exceptions. In addition, our amended and restated certificate of incorporation and bylaws will provide that we are required to
indemnify our officers and directors under certain circumstances, including those circumstances in which indemnification would otherwise be discretionary, and we are required to advance expenses to our officers and directors as incurred in
connection with proceedings against them for which they may be indemnified, in each case except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;145(a) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director,
officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses
(including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably
believed to be in or not opposed to the best interest of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by
judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not
opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was unlawful. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;145(b) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was
serving at the request of the corporation as a director, officer, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#146; fees) actually and reasonably incurred by him in
connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification
shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought
shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other
court shall deem proper. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into indemnification agreements with our directors and, prior to the completion of this offering, intend to enter into
indemnification agreements with certain of our officers. These indemnification agreements will provide broader indemnity rights than those provided under the DGCL and our amended and restated certificate of incorporation. These indemnification
agreements are not intended to deny or otherwise limit <FONT STYLE="white-space:nowrap">third-party</FONT> or derivative suits against us or our directors or officers, but to the extent a director or officer were entitled to indemnity or
contribution under the indemnification agreement, the financial burden of a <FONT STYLE="white-space:nowrap">third-party</FONT> suit would be borne by us, and we would not benefit from derivative recoveries against the director or officer. Such
recoveries would accrue to our benefit but would be offset by our obligations to the director or officer under the indemnification agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting
agreement will provide that the underwriters are obligated, under certain circumstances, to indemnify our directors, officers and controlling persons against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain directors&#146; and officers&#146; liability insurance for the benefit of our directors and officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following list
sets forth information regarding all unregistered securities sold by us since January&nbsp;1, 2018. No underwriters were involved in the sales and the certificates representing the securities sold and issued contain legends restricting transfer of
the securities without registration under the Securities Act or an applicable exemption from registration. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(a) &nbsp;&nbsp;&nbsp;&nbsp;Issuances of units
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, certain investors purchased an aggregate of 5,549,999 of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred units for an
aggregate of $5,549,999 at a price of $1.00 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, we issued an aggregate of 450,000 Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred
units to the Founders in exchange for their capital contributions of convertible debt for an aggregate of $450,000. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2019, certain investors purchased an
aggregate of 7,826,083 of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred units and our Founders and certain employees purchased an aggregate of 521,740 of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred units for
an aggregate of $9,599,996 at a price of $1.15 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2019, certain investors purchased an aggregate of 8,695,652 of our Series <FONT
STYLE="white-space:nowrap">A-2</FONT> preferred units for $10,000,000 at a price of $1.15 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2019, certain investors purchased an aggregate of
10,434,781 of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred units for $11,999,998 at a price of $1.15 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, certain investors
purchased an aggregate of 61,457,763 of our Series B preferred units for approximately $91,104,988 at a price of $1.4824 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2020, certain investors
purchased an aggregate of 1,416,621 of our Series B preferred units for approximately $2,099,999 at a price of $1.4824 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2020, certain investors
purchased an aggregate of 37,402,537 of our Series B preferred units for approximately $51,999,999 at a price of $1.3903 per unit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also in May 2020, investors who purchased Series B preferred units in March 2020 and April 2020 received an aggregate of
4,166,044 additional Series B preferred units, for no additional consideration, to provide such investors with the benefit of the lower purchase price paid by investors at the May 2020 closing in accordance with the terms of the Series B Purchase
Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through March&nbsp;31, 2021, we have issued an aggregate of 4,500,000 common units, for a purchase price of $0.79 per unit, which was paid through the
contribution of the holders&#146; equity interests in a subsidiary of the LLC Entity.</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(b) &nbsp;&nbsp;&nbsp;&nbsp;Grants </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through March&nbsp;31, 2021, we have granted an aggregate of 19,934,704 incentive units, with a grant date fair value range of $0.10&#150;$0.43&nbsp;per unit, to
employees, directors and consultants pursuant to the 2018 Share Plan. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through March&nbsp;31, 2021, we have granted the Founders an aggregate of 1,200,000
restricted shares (common), under the 2018 Plan, with a grant date fair value of $0.15 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The issuances of the above securities were exempt either pursuant
to Rule&nbsp;701, as transactions pursuant to a compensatory benefit plan, or pursuant to Section&nbsp;4(a)(2), as transactions by an issuer not involving a public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(a)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See the Exhibit Index attached to this
Registration Statement, which is incorporated by reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;Financial Statement Schedules </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes
thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17. Undertakings. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as indemnification for
liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or
paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">1.&nbsp;&nbsp;&nbsp;&nbsp;For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed
as part of this Registration Statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the Registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this
Registration Statement as of the time it was declared effective. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">2.&nbsp;&nbsp;&nbsp;&nbsp;For the purpose of determining any liability under the
Securities Act, each <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>EXHIBIT<BR>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>DESCRIPTION OF DOCUMENT</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">1.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">2.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Merger Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">3.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation of the Registrant (to be effective prior to the consummation of this offering).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">3.2*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws of the Registrant (to be effective prior to the consummation of this offering).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">4.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Specimen stock certificate evidencing shares of common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">4.2*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Registration Rights Agreement, among the Registrant and certain of its stockholders, to be in effect immediately prior to completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">5.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Ropes&nbsp;&amp; Gray&nbsp;LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.1+**</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Asset Purchase Agreement, by and between Rallybio IPA, LLC and Prophylix AS, dated June&nbsp;28, 2019.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.2+**</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Asset Transfer Agreement, by and between Swedish Orphan Biovitrum AB (PUBL) and IPC Research, LLC, dated March&nbsp;15, 2019.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.3+**</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Product License Agreement, by and between Affibody AB and Swedish Orphan Biovitrum AB (PUBL), dated March 9, 2012, and assigned to IPC Research, LLC on March 15, 2019.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.4+**</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment No. 1 to Product License Agreement, by and between Affibody AB and Swedish Orphan Biovitrum AB (PUBL), dated January 1, 2018, and assigned to IPC Research, LLC on March 15, 2019.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.5+**</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment No. 2 to Product License Agreement, by and between Affibody AB and IPC Research, LLC, dated December 22, 2020.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.6+</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Operating Agreement of RE Ventures I, LLC, by and between Rallybio IPB, LLC and Exscientia Limited, dated July 19, 2019.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.7#*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement, between the Registrant and each of its directors and executive officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.8#**</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Rallybio Holdings, LLC 2018 Share Plan, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.9#*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2021 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.10#*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2021 Cash Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.11#*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2021 Employee Stock Purchase Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">21*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">List of Subsidiaries of the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Deloitte&nbsp;&amp; Touche&nbsp;LLP independent registered public accounting firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.2*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Ropes&nbsp;&amp; Gray&nbsp;LLP (included in Exhibit&nbsp;5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">24.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page).</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">**</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">#</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">+</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) have been redacted because they are both not material and the registrant customarily and actually treats such information as private or confidential. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of New Haven, Connecticut, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>RALLYBIO HOLDINGS, LLC</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Martin W. Mackay, Ph.D. <BR><I>Chief Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Martin W. Mackay and
Jeffrey M. Fryer, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> filed herewith, and any and all <FONT STYLE="white-space:nowrap">pre-effective</FONT> and <FONT STYLE="white-space:nowrap">post-effective</FONT> amendments to said registration statement, and any
registration statement filed pursuant to Rule&nbsp;462(b) under the Securities Act of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of the Company, and to file or cause to be
filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and
thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or
substitutes, shall do or cause to be done by virtue of this Power of Attorney. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, this
registration statement has been signed by the following persons in the capacities and on the dates indicated: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Chief Executive Officer and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Jeffrey M. Fryer, CPA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Chief Financial Officer and Treasurer (Principal Accounting and Financial Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Rob Hopfner, R.Ph., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Ronald M. Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Kush M. Parmar, MD, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Timothy M. Shannon, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Execution Copy </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:2%; margin-right:2%; font-size:10pt; font-family:Times New Roman"><B>Portions of this Exhibit have been redacted because they are both (i) not material and (ii) the registrant
customarily and actually treats such information as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#147;[***]&#148;.</B> </P></div>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPERATING AGREEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RE VENTURES I, LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS OPERATING AGREEMENT (the &#147;<U>Agreement</U>&#148;) is made and entered into as of July&nbsp;19, 2019 (the &#147;<U>Effective
Date</U>&#148;) by the parties listed on <B><U>Schedule A</U> </B>(each a &#147;<U>Member</U>&#148; and, together with any Member subsequently admitted to the Company, collectively the &#147;<U>Members</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITNESSETH </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
parties hereto have formed and become members of a limited liability company named RE VENTURES I, LLC (the &#147;<U>Company</U>&#148;) under and pursuant to the Act for the purpose of engaging in such business activities authorized under the Act and
as may be approved from time to time by the Members, subject to the limitations contained in this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Members have
formed the Company to initiate early stage drug discovery on available small molecules targeting Ectonucleotide pyrophosphatase phosphodiesterase 1 (&#147;<U>ENPP1</U>&#148;) for the treatment of Hypophosphatasia and the further research,
development, manufacture, sale and exploitation of Company-owned technology; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties hereto agree that their respective
rights, powers, duties and obligations as members shall be governed by this Agreement as of the date of their admittance, and the management, operations and activities of the Company shall be governed by this Agreement on and after the date first
above written; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the terms, covenants and conditions contained herein, the parties hereto hereby
agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes
of this Agreement, unless the context otherwise requires: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Act</U>&#148; means the Delaware Limited Liability Company Act, 6 Del.
C. &#167;&#167; <FONT STYLE="white-space:nowrap">18-101,</FONT> <I>et. seq.</I>, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Additional
Capital Contribution</U>&#148; has the meaning set forth in Section&nbsp;3.4(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Adjusted Capital Account</U>&#148; means the
balance, if any, in a Member&#146;s Capital Account as of the end of the relevant year, increased by the amount of the minimum gain that such Member is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treated as being obligated to restore pursuant to the next to last sentence of Regulation Sections <FONT STYLE="white-space:nowrap">1.704-2(g)(1)</FONT> and (i)(5). The foregoing definition of
Adjusted Capital Account is intended to comply with the provisions of Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-l(b)(2)(ii)(d)</FONT> and shall be interpreted consistently therewith. The Capital Accounts of the Members may be
adjusted, at the discretion of the Tax Matters Representative, to reflect the fair market value of the assets of the Company, as determined by the Tax Matters Representative, upon an event described in Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.704-l(b)(2)(iv)(f)(5).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means, with respect to any
specified Person, (a)&nbsp;any Person that directly or indirectly controls, is controlled by or is under common control with such specified Person; (b)&nbsp;any Person that directly or indirectly controls 50% or more of the outstanding equity
securities of the specified Person or of which the specified Person is directly or indirectly the owner of 50% or more of any class of equity securities; or (c)&nbsp;any Person that is an officer of, manager of, director of, partner in or trustee
of, or serves in a similar capacity with respect to, the specified Person or of which the specified Person is an officer, director, manager, partner or trustee, or with respect to which the specified Person serves in a similar capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agreement</U>&#148; means this Operating Agreement of the Company, as amended, modified or supplemented from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Arbitration Rules</U>&#148; has the meaning set forth in Section&nbsp;5.13. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Board</U>&#148; means the Board of Managers described in Article V of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Candidate Compounds</U>&#148; means a candidate quality compound as agreed from time to time by the SC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Capital Account</U>&#148; means the Capital Account maintained for each Member pursuant to Section&nbsp;3.1 and adjusted in
accordance with the Regulations under Section&nbsp;704 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Capital Call Notice</U>&#148; means a written notice form
the Company requiring Capital Contributions pursuant to Section&nbsp;3.4. A &#147;Capital Call Notice&#148; shall set forth (i)&nbsp;the aggregate amount to contributed by the Members, (ii)&nbsp;the amount contributed by each of the Members,
(iii)&nbsp;the number of Shares, if any, each Member will receive upon making its required Capital Contribution, and (iv)&nbsp;the date on which the contribution is due from each such Member, which date shall not be less than [***] days from the
date that the Capital Call is delivered to the Member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Capital Contribution(s)</U>&#148; means the total amount of cash and the
aggregate fair market value of all property, including intangible property (net of liabilities) (as determined in good faith by the Board on the date of contribution of such property or, in the absence of a Board, as determined in good faith by a
Majority in Interest) contributed by a Member to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Certificate</U>&#148; means the Certificate of Formation of the
Company, as filed with the Office of the Secretary of State, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the United
States Internal Revenue Code of 1986, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Shares</U>&#148; has the meaning set forth in Section&nbsp;4.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148; means RE VENTURES I, LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Offer</U>&#148; has the meaning set forth in Section&nbsp;7.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Offer Notice</U>&#148; has the meaning set forth in Section&nbsp;7.2(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Distribution Threshold</U>&#148; means with respect to each Incentive Share, an amount equal to the amount of distributions that
would be made to all outstanding Shares if, immediately prior to the issuance of an Incentive Share, all the assets of the Company were sold for their respective fair market values, the liabilities of the Company were paid in full, and the remaining
proceeds were distributed in accordance with Article VIII. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Effective Date</U>&#148; has the meaning set forth in the initial
paragraph of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>ENPP1</U>&#148; has the meaning set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>ENPP1 Program</U>&#148; has the meaning set forth in Section&nbsp;2.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Event of Dissociation</U>&#148; means the bankruptcy or dissolution of a Member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Excluded Opportunity</U>&#148; has the meaning set forth in Section&nbsp;5.12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exscientia</U>&#148; means Exscientia Limited, a company limited by shares incorporated in Scotland </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exscientia Service Agreement</U>&#148; means a research services agreement as between the Company and Exscientia dated on or about
the date hereof that sets forth the services to be provided by Exscientia to the Company during Stage 1 and Stage 2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fiscal
Year</U>&#148; means the fiscal year ending December 31 or such other fiscal year required by the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Gross Income</U>&#148;
means all items of income and gain that are included in the definition of Income or Loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Incentive Shares</U>&#148; has the
meaning set forth in Section&nbsp;4.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Income and Loss(es)</U>&#148; means taxable income or loss plus income exempt from
federal income tax and reduced by any expenditures of the Company described in Section&nbsp;705(a)(2)(B) of the Code or treated as Section&nbsp;705(a)(2)(B) of the Code expenditures pursuant to Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.704-l(b)(2)(iv)(i)</FONT> as determined in accordance with the accounting methods followed by the Company for federal income tax purposes, adjusted to reflect
<FONT STYLE="white-space:nowrap">book-tax</FONT> disparities as required by Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-1(b)(2)(iv)(g).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Interest</U>&#148; means the entire ownership interest of a Member in the Company at any particular time, including, without
limitation, the right of such Member to participate in the Company&#146;s Income or Losses, distributions and any and all benefits to which a Member may be entitled as provided in this Agreement and the Act, together with the obligations of such
Member to comply with all the terms and conditions of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Legal Representative</U>&#148; means, with respect to any individual, a duly
appointed executor, administrator, guardian, conservator, personal representative or other legal representative appointed as a result of the death or incompetence of such individual. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Majority in Interest</U>&#148; means, unless the context otherwise requires, the holders of more than 50% of the Percentage Interest
of Members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Manager</U>&#148; shall refer to any Person named as a Manager in this Agreement and any Person who becomes a
Manager as permitted by this Agreement, in each such Person&#146;s capacity as (and during the period during which such Person serves as) a member of the Board. &#147;Managers&#148; shall refer collectively to all such Persons in such capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Member</U>&#148; has the meaning set forth in the initial paragraph of this Agreement and shall include any Person who becomes an
additional, substitute or replacement Member as permitted by this Agreement, in such Person&#146;s capacity as a Member of the Company. &#147;Members&#148; shall refer collectively to all such Persons in such capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Member Representative</U>&#148; has the meaning set forth in Section&nbsp;7.7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-Contributing</FONT> Member</U>&#148; has the meaning set forth in Section&nbsp;3.4(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Offeror</U>&#148; has the meaning set forth in Section&nbsp;7.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Participating Member</U>&#148; has the meaning set forth in Section&nbsp;3.4(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Percentage Interest</U>&#148; means, with respect to any Member at any time of determination, the fraction, expressed as a
percentage, that the Shares held by such Member bears to the total issued and outstanding Shares at such time. The Share Ledger shall set forth, among other things, the Percentage Interests of the Members as modified from time to time pursuant to
this Agreement. The sum of the Percentage Interests of the Members shall equal 100%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means any natural person,
partnership, joint venture, association, corporation, limited liability company, trust, estate or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Phase II
Clinical Study</U>&#148; means a clinical study that would satisfy the requirements of 21 C.F.R. &#167; 312.21(b) or equivalent regulation in countries other than the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Proposed Sale</U>&#148; has the meaning set forth in Section&nbsp;7.7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Proposed Shares</U>&#148; has the meaning set forth in Section&nbsp;7.3(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchase Right</U>&#148; has the meaning set forth in Section&nbsp;3.4(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchaser</U>&#148; has the meaning set forth in Section&nbsp;7.3(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Qualified Financing</U>&#148; means the issuance and sale by the Company to one or more venture capital, institutional or other
investors (including natural persons, corporations, partnerships, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trusts, limited liability companies, associations or other entities) of equity securities of the Company that are senior or pari passu in rights and preferences to the Shares, where the aggregate
gross proceeds received by the Company equals or exceeds [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>R&amp;D Plan</U>&#148; has the meaning set forth in
Section&nbsp;5.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>R&amp;D Program</U>&#148; means the research and development program contemplated by the R&amp;D Plan and any
future research and development plans initiated by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rallybio</U>&#148; means Rallybio IPB, LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulations</U>&#148; means the regulations (including any temporary regulations) issued under the Code by the Department of the
Treasury, as they may be amended from time to time, or any applicable successor regulations. Reference herein to any particular section of the Regulations shall be deemed to refer to the corresponding provision of any applicable successor
regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Requisite Interest</U>&#148; means unless the context otherwise requires, the holders of greater than [***] of the
Percentage Interest of Members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Right of First Refusal Shares</U>&#148; has the meaning set forth in Section&nbsp;7.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sale of the Company</U>&#148; means (a)&nbsp;a consolidation, merger or capital reorganization of the Company (except (i)&nbsp;into
or with a wholly-owned subsidiary of the Company with requisite Member approval or (ii)&nbsp;a merger in which the beneficial owners of the Company immediately prior to such transaction hold more than fifty percent (50%) of the voting power in the
resulting entity), (b) a sale of all or substantially all of the assets of the Company or (c)&nbsp;a Share Sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SC</U>&#148;
has the meaning set forth in Section&nbsp;5.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SC Members</U>&#148; has the meaning set forth in Section&nbsp;5.3(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Secretary of State</U>&#148; means the Secretary of the State of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Senior Executives</U>&#148; means the Chief Executive Officer of Rallybio and the Chief Executive Officer of Exscientia holding such
office at such time, or their respective designees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Share Ledger</U>&#148; has the meaning set forth in Section&nbsp;9.1(b).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Share Offer Notice</U>&#148; has the meaning set forth in Section&nbsp;7.2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Share Sale</U>&#148; means a transaction or series of related transactions in which a Person, or a group of related Persons, acquires
Shares representing more than 50% of the outstanding voting power of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shares</U>&#148; has the meaning set forth in
Section&nbsp;4.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stage 1</U>&#148; has the meaning set forth in Section&nbsp;3.4(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stage 1 Completion</U>&#148; has the meaning set forth in Section&nbsp;3.4(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stage 1 Contribution</U>&#148; has the meaning set forth in Section&nbsp;3.4(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stage 1 Objective</U>&#148; means the discovery of [***] potency compounds for ENPP1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stage 2</U>&#148; has the meaning set forth in Section&nbsp;3.4(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stage 2 Contribution</U>&#148; has the meaning set forth in Section&nbsp;3.4(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stage 2 Objective</U>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Target Balance</U>&#148; means, with respect to any Member as of the close of any period for which allocations are made under Article
VI, the amount such Member would receive (or be required to contribute) in a hypothetical liquidation of the Company as of the close of such period, assuming for purposes of any hypothetical liquidation (i)&nbsp;a sale of all of the assets of the
Company at prices equal to the gross fair market value of such assets <FONT STYLE="white-space:nowrap">re-determined</FONT> as of the end of the applicable Fiscal Year, and (ii)&nbsp;the distribution of the net proceeds from such sale to the Members
pursuant to Section&nbsp;8.4 (for this purpose, treating all outstanding Shares as fully vested), after the payment of all actual Company indebtedness and any other liabilities related to the Company&#146;s assets (limited, in the case of
nonrecourse liabilities, to the collateral securing or otherwise available to satisfy such liabilities). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax
Distribution</U>&#148; has the meaning set forth in Section&nbsp;6.6(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Matters Representative</U>&#148; has the meaning
set forth in Section&nbsp;9.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Terminated Manager</U>&#148; has the meaning set forth in Section&nbsp;5.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer</U>&#148; means the sale, assignment, transfer, pledge, hypothecation, mortgage or disposition, by gift or otherwise, of
Shares. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORGANIZATION OF THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Formation and Name of Company</U>. The Members have caused the Certificate to be filed with the Office of the
Secretary of State on July 18, 2019. The Members shall further execute, and shall cause the filing or recording with the proper offices of, any other certificates or instruments required by any limited liability company act, fictitious name act or
similar statute in effect from time to time. The Board shall cause the Company to be qualified as a foreign limited liability company in those jurisdictions where qualification is deemed by them to be necessary or appropriate. The name of the
Company is RE VENTURES I, LLC. The Board may change the name of the Company at any time and from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Purpose</U>. The purpose of the Company is to engage in any lawful act or activity for which limited liability
companies may be organized under the laws of the State of Delaware and, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to activities conducted in other jurisdictions, under the laws of such other jurisdictions, including to initiate early stage drug discovery on available small molecules targeting
ENPP1 and thereafter the further research, development, manufacture, sale and exploitation of any Company-owned technology and compounds, including Candidate Compounds that result therefrom (the &#147;<U>ENPP1 Program</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Registered Office; Registered Agent</U>. The Company&#146;s registered office initially shall be located at 251
Little Falls Drive, Wilmington, Delaware 19808. The Board may establish places of business of the Company within and without the State of Delaware, as and when required by its business and in furtherance of its purposes, and may appoint agents for
service of process in all jurisdictions in which the Company shall conduct business. The Board may cause the Company to change from time to time its resident agent for service of process, or the location of its principal office. The registered agent
for service of process for the Company in the State of Delaware shall initially be Corporation Service Company located at the registered office described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Principal Place of Business</U>. The principal place of business of the Company will initially be 400 Farmington
Avenue, Suite R2818, Farmington, CT 06032 or such other place within or without the State of Delaware as the Board from time to time shall designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>. The term of the Company commenced upon the filing of the Certificate with the Secretary of State and
shall continue in perpetuity, unless the Company is earlier dissolved in accordance with either the provisions of this Agreement or the Act. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAPITAL
CONTRIBUTIONS AND LIABILITY OF MEMBERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Capital Accounts</U>. For each Member (and each permitted
assignee), the Company shall establish and maintain a separate Capital Account which shall generally be credited with the amount of Capital Contributions contributed by any Member plus the Member&#146;s distributive share of Company Income and
decreased by the amount of cash plus the fair market value of any property (net of liabilities) distributed to a Member plus the Member&#146;s distributive share of Company Losses. The Capital Accounts shall be maintained in compliance with
Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-1(b).</FONT> If, as a result of an exercise of a noncompensatory option to acquire an interest in the Company, a Capital Account reallocation is required under Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.704-1(b)(2)(iv)(s)(3),</FONT> the Company shall make corrective allocations pursuant to Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-1(b)(4)(x).</FONT> The provisions of this
Agreement shall be interpreted and applied in a manner consistent with such section of the Regulations. Upon the admission of additional Members, the Company shall adjust Capital Accounts as provided in Section&nbsp;3.8(b). This Agreement shall
apply to the Capital Account of each Member as of the date admitted as set forth on <B><U>Schedule A</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Capital Contributions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall record each Member&#146;s contribution to the capital of the Company in the Share Ledger.
The value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> capital contribution to the Company shall be as stipulated in the Share Ledger. For avoidance of doubt, the parties acknowledge and agree that certain Members may enter into Services
Agreements and unless otherwise agreed to by the Members, the services provided thereunder shall not be considered <FONT STYLE="white-space:nowrap">non-cash</FONT> capital contributions to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Each of Rallybio and Exscientia has made on or prior to the
date of this Agreement the initial capital contribution set forth opposite such Member&#146;s name under the heading &#147;Initial Capital Contribution&#148; on <B><U>Schedule A</U> </B>attached hereto (each, an &#147;<U>Initial Capital
Contribution</U>&#148;). Each Member&#146;s initial Shares as of the date of this Agreement are reflected opposite such Member&#146;s name on <B><U>Schedule A</U> </B>hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<U>No Withdrawal of or Interest on Capital</U>. No interest shall accrue on any contributions to the capital of the
Company, and no Member shall have the right to withdraw or to be repaid any capital contributed by him, her or it or to receive any other payment in respect of his, her or its interest in the Company, including without limitation as a result of the
withdrawal or resignation of such Member from the Company, except as specifically provided in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Mandatory Capital Contributions; Additional Capital Contributions</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Upon receipt of a Capital Call Notice from the Company, [***] shall contribute Four Hundred Fifty Thousand
Pounds Sterling (&pound;450,000) to the Company (the &#147;<U>Stage 1 Contribution</U>&#148;) to fund the outsourced costs associated with Stage 1 of the ENPP1 Program as further described in the R&amp;D Plan (&#147;<U>Stage 1</U>&#148;). For
avoidance of doubt, no additional Shares will be issued to Exscientia and Rallybio in connection with the capital contribution made in accordance with this Section&nbsp;3.4(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that the aggregate outsourced costs associated with Stage 1, including the first payment payable
under the Exscientia Service Agreement, exceed [***] and the Board determines that additional funds are needed to achieve the Stage 1 Objective, upon receipt of a Capital Call Notice from the Company, Rallybio and Exscientia shall make equal capital
contributions to the Company in accordance with this Section&nbsp;3.4(b) and the terms set forth in the applicable Capital Call Notice. For purposes of calculating the number of additional Common Shares issued pursuant to a Capital Call Notice to
both Members as contemplated by this Section&nbsp;3.4(b), the Members agree that the <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation prior to completion of the Stage 1 Objective will be [***] Pounds Sterling (&pound;[***]). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;If the SC determines that the Stage 1 Objective has been achieved (the &#147;<U>Stage 1
Completion</U>&#148;), it shall deliver written confirmation of such to the Board. Upon the Board&#146;s confirmation of the Stage 1 Completion, the Company shall deliver to Exscientia and Rallybio a Capital Call Notice. Upon receipt of such Capital
Call Notice, [***] shall contribute an amount equal to Eight Hundred Thousand Pounds Sterling (&pound;800,000) minus the amount of cash remaining in the Company&#146;s bank account on the day immediately prior to sending Exscientia and Rallybio such
Capital Call Notice, to the Company (the &#147;<U>Stage 2 Contribution</U>&#148;) to fund the outsourced costs associated with Stage 2 of the ENPP1 Program as further described in the R&amp;D Plan (&#147;<U>Stage 2</U>&#148;). For avoidance of
doubt, no additional Shares will be issued to Exscientia and Rallybio in connection with the capital contribution made in accordance with this Section&nbsp;3.4(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;In the event that the aggregate outsourced costs associated with Stage 2, including the second payment
payable under the Exscientia Service Agreement, exceed [***] and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Board determines that additional funds are needed to achieve the Stage 2 Objective, upon receipt of a Capital Call Notice from the Company, Rallybio and Exscientia shall make equal capital
contributions to the Company in accordance with this Section&nbsp;3.4(d) and the terms set forth in the applicable Capital Call Notice. For purposes of calculating the number of additional Common Shares issued pursuant to a Capital Call Notice to
both Members as contemplated by this Section&nbsp;3.4(d), the Members agree that the <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation following the Stage 1 Objective but prior to completion of the Stage 2 Objective will be [***] Pounds
Sterling (&pound;[***]). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;In the Event that a Member does not make any portion of such additional Capital
Contributions pursuant to a Capital Call Notice delivered in accordance with Section&nbsp;3.4(b) or Section&nbsp;3.4(d) (a &#147;<U><FONT STYLE="white-space:nowrap">Non-Contributing</FONT> Member</U>&#148;), then the other Member (the
&#147;<U>Participating Member</U>&#148;) may contribute directly to the Company up to the entire amount of the unfunded portion of such additional Capital Contribution and if such contributions are made by the Participating Member, the <FONT
STYLE="white-space:nowrap">Non-Contributing</FONT> Member&#146;s portion of the capital call (to the extent contributed by the Participating Member) shall be deemed an &#147;<U>Additional Capital Contribution</U>&#148; by the Participating Member
and recorded as a Capital Contribution for such Participating Member in its Capital Account, and both the <FONT STYLE="white-space:nowrap">Non-Contributing</FONT> Member&#146;s and the Participating Member&#146;s Percentage Interests will be
adjusted to reflect such Additional Capital Contribution. If a Participating Member makes an Additional Capital Contribution, then the <FONT STYLE="white-space:nowrap">Non-Contributing</FONT> Member shall have the right to purchase (the
&#147;<U>Purchase Right</U>&#148;) all or a portion of the Common Shares transferred to the Participating Member on account of the Additional Capital Contribution if such <FONT STYLE="white-space:nowrap">Non-Contributing</FONT> Member pays to the
Participating Member all or any portion of such Additional Capital Contribution plus interest calculated at the rate of [***]% per annum measured from the date the Participating Member made the Additional Capital Contribution; provided, that such
Purchase Right shall expire upon the earlier of (i)&nbsp;a Qualified Financing, and (ii) [***] after the Participating Member made the applicable Additional Capital Contribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in this Article III or required by law, no Member shall be obligated to
contribute any additional capital to the Company. The Board may determine from time to time after achievement of the Stage 2 Objective that additional capital is necessary or appropriate to enable the Company to conduct its activities, including
further research and development with respect to [***] and may seek (but not require) additional capital contributions from Members and others, on such terms as the Board may propose by written notice in its sole discretion, subject to the
provisions of this Agreement. Any Member that makes an additional Capital Contribution (above those mandatory contributions contemplated by this Article III) shall receive additional Common Shares as set forth in the notice and his Percentage
Interest shall be adjusted accordingly; <U>provided</U> each Member shall have the option to contribute [***] of any additional capital requested by the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to this Section&nbsp;3.4(f). For purposes of calculating the number of additional Shares issued to the Members pursuant to this Section&nbsp;3.4(f), the Members agree that the <FONT
STYLE="white-space:nowrap">pre-money</FONT> valuation of the Company upon achievement of the Stage 2 Objective will be [***] Pounds Sterling (&pound;[***]) until the earlier of (i)&nbsp;a Qualified Financing, and (ii)&nbsp;a Member&#146;s Percentage
Interest reaching one of the thresholds set forth in Section&nbsp;3.4(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;In the event that a Member
fails to make a capital contribution pursuant to a Capital Call Notice delivered in accordance with Section&nbsp;3.4(a), Section&nbsp;3.4(b), Section&nbsp;3.4(c) or Section&nbsp;3.4(d), the <FONT STYLE="white-space:nowrap">non-breaching</FONT>
Member may make an Additional Capital Contribution in accordance with Section&nbsp;3.4(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;Each
Member&#146;s Percentage Interest shall be 50% from the Effective Date through the achievement of the Stage 2 Objective provided each Member satisfies its obligations set forth in in this Section&nbsp;3.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary herein, neither Member&#146;s Percentage Interest shall decrease
below (i) [***] on a fully diluted basis prior to [***]; or (ii) [***] on a fully diluted basis at any time after [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Managers as Members</U>. Any Manager may hold an interest in the Company as a Member, and such Person&#146;s
rights and interest as a Manager shall be distinct and separate from such Person&#146;s rights and interest as a Member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Liability of Members</U>. Except to the extent required under the Act or as described in Section&nbsp;6.8, the
liability of the Members for the losses, debts and obligations of the Company shall be limited to their Capital Contributions. Without limiting the foregoing, (a)&nbsp;no Member, in his, her or its capacity as a Member (or, if applicable, as a
Manager), shall have any liability to restore any negative balance in his, her or its Capital Account, and (b)&nbsp;the failure of the Company to observe any formalities or requirements relating to the exercise of its powers or management of its
business or affairs under this Agreement or the Act shall not be grounds for imposing personal liability on the Members or Managers for liabilities of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Member Securities Representations</U>. Each Member, by execution of this Agreement or an amendment hereto
reflecting such Member&#146;s admission to the Company, hereby represents and warrants to the Company (unless the Company agrees in writing with such Member that any such representation or warranty need not be made) that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;He, she or it is acquiring the Shares for his, her or its own account for investment only, and not with a
view to, or for sale in connection with, any distribution thereof in violation of the Securities Act, or any rule or regulation thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;He, she or it understands (i)&nbsp;that the Shares he, she or it is acquiring has not been registered under
the Securities Act or applicable state securities laws and cannot be resold unless subsequently registered under the Securities Act and such laws or unless an exemption from such registration is available, (ii)&nbsp;that such registration under the
Securities Act and such laws is unlikely at any time in the future and that neither the Company nor the Members nor the Managers are obligated to file a registration statement under the Securities Act or such laws and (iii)&nbsp;that the Transfer of
the Shares are restricted in accordance with the terms of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;He, she or it has had such opportunity as he, she or it has
deemed adequate to ask questions of and receive answers from the Managers concerning the terms and conditions of this Agreement and the Shares, and to obtain from representatives of the Company such information that the Company possesses or can
acquire without unreasonable effort or expense, as is necessary to evaluate the merits and risks of an investment in the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;He, she or it has, either alone or with his, her or its professional advisers, sufficient experience in
business, financial and investment matters to be able to evaluate the merits and risks involved in investing in the Company and to make an informed investment decision with respect to such investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;He, she or it can afford a complete loss of the value of his, her or its investment in the Company and is
able to bear the economic risk of holding such investment for an indefinite period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;If it is an entity,
it is duly organized, validly existing and in good standing under the laws of its state of organization and that it has full organizational power to execute and deliver this Agreement and to perform its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;He, she or it is an &#147;accredited investor&#148; as defined in Rule 501(a) of Regulation D promulgated
under the Securities Act; provided, however, that such representation need not be made in connection with the issuance of Incentive Shares to him, her or it pursuant to Rule 701 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;If he or she is an individual, then he or she resides in the state, province or other jurisdiction identified
in his or her address set forth on <B><U>Schedule A</U></B>; if it is a partnership, corporation, limited liability company or other entity, then the office in which its principal place of business is located is identified in its address set forth
on <B><U>Schedule A</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;If he, she or it is not a United States person (as defined by
Section&nbsp;7701(a)(30) of the Code), he, she or it has satisfied himself, herself or itself as to the full observance of the laws of his, her or its jurisdiction in connection with any invitation to subscribe for the Shares or any use of this
Agreement, including (i)&nbsp;the legal requirements within his, her or its jurisdiction for the purchase of the Shares, (ii)&nbsp;any foreign exchange restrictions applicable to such purchase, (iii)&nbsp;any governmental or other consents that may
need to be obtained and (iv)&nbsp;the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or Transfer of the Shares. His, her or its subscription and payment for and continued beneficial
ownership of the Shares will not violate any applicable securities or other laws of his, her or its jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Admission of New Members</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Board Approval</U>. Subject to Section&nbsp;3.8(b) below, additional Persons,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including those awarded Incentive Shares pursuant to Section&nbsp;4.3, may be admitted to the Company as Members from time to time by the Board at a price per Share or for other consideration
(including past or future service) to be determined by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution of this Agreement;
Initial Capital Contributions</U>. As a condition to becoming a Member of the Company, all additional Members shall execute and deliver to the Company a joinder agreement or such number of counterpart signature pages to this Agreement as the Board
may require, evidencing such Member&#146;s intent to be bound by all of the terms and conditions of this Agreement. The initial Capital Contribution, if any, of any additional Member shall be paid in cash or cash equivalent at the time of such
Member&#146;s admission into the Company, or in consideration otherwise acceptable to the Board in its sole discretion. <B><U>Schedule A</U> </B>and the Share Ledger shall be amended to reflect each additional Member admitted to the Company. Upon
the admission of additional Members and the contribution of their initial Capital Contribution, if any, the Company shall adjust Capital Accounts in accordance with Regulations Sections <FONT STYLE="white-space:nowrap">1.704-</FONT> 1(b)(2)(iv)(f)
and (g). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIMITED LIABILITY COMPANY INTERESTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Limited Liability Company Interests to Be Evidenced by Shares</U>. All Interests in the Company shall be
denominated in units referred to as &#147;<U>Shares</U>.&#148; Initially, the total number of Shares of all classes that the Company shall have authority to issue shall be 10,000,000 Shares. The Shares shall initially consist of Common Shares and
Incentive Shares (collectively, the &#147;<U>Common Shares</U>&#148;). The Common Shares and any other class of Shares issued hereunder shall hereinafter collectively be referred to as the &#147;<U>Shares</U>.&#148; The Board may, in its discretion,
increase the number of authorized Shares from time to time. Shares shall be issuable from time to time in one or more classes or series, with such designations, preferences and rights as shall be fixed by the Board in the exercise of its sole
discretion, subject to the Act and obtaining any consent required under this Agreement. The Board is hereby authorized to take all actions that it deems necessary or appropriate in connection with the issuance of Shares and the fixing of the
designations, preferences and rights including amending this Agreement in any manner that is deemed necessary or appropriate to provide for each such issuance, and to admit additional Members in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Common Shares</U>. Each &#147;<U>Common Share</U>&#148; will represent an Interest in the Company, will be
designated as a Common Share of the Company and will be entitled to the distributions provided for such Shares in Section&nbsp;6.6 and Article VIII. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Shares</U>. Each &#147;<U>Incentive Share</U>&#148; will represent an Interest in the Company, will be
designated as an Incentive Share of the Company and will be entitled to the distributions provided for such Shares in Section&nbsp;6.6 and Article VIII. Shares may be reserved for issuance pursuant to a Company equity incentive plan for managers,
officers or employees of, consultants to or other Persons that provide services to the Company and/or any of its Affiliates pursuant to agreements with such individuals, which shall be in a form and substance satisfactory
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the Board and such Persons shall become Members in accordance with Section&nbsp;3.8. Grants of Incentive Shares pursuant to this Section&nbsp;4.3 shall be determined from time to time by the
Board. In the event that any of such Incentive Shares are redeemed or otherwise repurchased by the Company, the number of such Incentive Shares shall again be available for grant by the Board in accordance with this Section&nbsp;4.3 and shall be
added to the number of available Incentive Shares. The Incentive Shares are intended to be &#147;profits interests&#148; for U.S. federal income tax purposes as that term is defined in Revenue Procedure <FONT STYLE="white-space:nowrap">93-27,</FONT>
<FONT STYLE="white-space:nowrap">1993-2</FONT> C.B. 343, as clarified by Revenue Procedure <FONT STYLE="white-space:nowrap">2001-43,</FONT> <FONT STYLE="white-space:nowrap">2001-2</FONT> C.B. 191. The provisions of this Agreement will be interpreted
in accordance with such intent. The Incentive Shares shall have Capital Accounts associated therewith on the date of issuance of zero dollars and shall not at any time receive any distribution that would cause the Capital Account associated
therewith to have a negative value. In accordance with the foregoing, it is intended that at the time of issuance of any Incentive Shares that there shall be no liquidation value attributable thereto. Notwithstanding anything to the contrary in this
Agreement, the Board may defer any distribution that would otherwise be made in respect of any Incentive Shares pursuant to this Agreement, to the extent the Board determines such reduction is necessary or appropriate to procure that such Incentive
Shares will be treated as a &#147;profits interest&#148; as that term is defined in Revenue Procedure <FONT STYLE="white-space:nowrap">93-27,</FONT> <FONT STYLE="white-space:nowrap">1993-2</FONT> C.B. 343, as clarified by Revenue Procedure <FONT
STYLE="white-space:nowrap">2001-43,</FONT> <FONT STYLE="white-space:nowrap">2001-2</FONT> C.B. 191. The Company and the Members holding Incentive Shares shall file all tax returns consistent with such characterization. Upon issuance of any Incentive
Shares, the Board shall specify the Distribution Threshold in respect of such Incentive Shares (&#147;<U>Incentive Share Distribution Threshold</U>&#148;). The Incentive Share Distribution Threshold shall be adjusted by the Board from time to time
to take into account any Capital Contributions, including any Capital Contributions of Members holding Incentive Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting</U>. At all meetings of Members (and in actions in lieu of meetings), the holders of the Common Shares
shall be entitled to vote in accordance with each such holder&#146;s Percentage Interest. There shall be no cumulative voting with respect to any Shares. The number of authorized Shares may be increased or decreased (but not below the number of
shares thereof then outstanding) by the affirmative vote of a Majority in Interest and without a separate class vote of Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Issuances</U>. Shares shall be issued at the direction of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Shares Fully Paid and Nonassessable</U>. Upon issuance of the Shares as provided in this Agreement, the Shares
so issued shall be deemed to be validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificates</U>. The Company
may, but shall not be required to, issue to Members a certificate or certificates signed by a Manager specifying the series or class of Shares held by such Member which signature may be a facsimile or other electronic signature. If a certificate for
Shares is worn out or lost it may be renewed on production of the worn out certificate or on satisfactory proof of its loss together with such indemnity as may be required by the Board. Upon the issuance of any substitute share certificate
evidencing such Shares, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto. Each certificate shall bear legends on the reverse side thereof substantially in
the following form: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE &#147;<U>SECURITIES ACT</U>&#148;), AND HAVE BEEN ISSUED IN RELIANCE ON AN EXEMPTION FROM REGISTRATION PROVIDED FROM REGULATIONS UNDER
THE SECURITIES ACT. THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, EXCEPT (A)&nbsp;PURSUANT TO AND IN CONFORMITY WITH (I)&nbsp;AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
(II)&nbsp;ANY THEN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES ACT AND (B)&nbsp;PURSUANT TO AND IN CONFORMITY WITH ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. OTHER THAN PURSUANT TO AND IN CONFORMITY WITH AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, NO SUCH OFFER OR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY BE MADE UNLESS, IF REQUESTED BY IT, RE VENTURES I, LLC (THE &#147;<U>COMPANY</U>&#148;) HAS RECEIVED A WRITTEN
LEGAL OPINION OF COUNSEL (SUCH COUNSEL AND OPINION REASONABLY ACCEPTABLE TO IT) TO THE EFFECT THAT SUCH OFFER OR SALE DOES NOT VIOLATE THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THIS SECURITY IS SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND OTHER TERMS AND CONDITIONS SET FORTH IN THE OPERATING AGREEMENT OF THE
COMPANY, DATED AS OF JULY 19 2019, AS SUCH AGREEMENT MAY BE AMENDED FROM TIME TO TIME, COPIES OF WHICH MAY BE OBTAINED FROM THE COMPANY AT ITS PRINCIPAL EXECUTIVE OFFICES.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Management of the Company</U>. The business and affairs of the Company shall be managed by or under the
direction of a Board of Managers, who may exercise all of the powers of the Company except as otherwise provided by law or this Agreement (including, without limitation, Section&nbsp;5.5 below). In the event of a vacancy in the Board, the remaining
Managers, except as otherwise provided by law, may exercise the powers of the full Board until the vacancy is filled. All management and other responsibilities not specifically reserved to (i)&nbsp;the SC in this Agreement, or (ii)&nbsp;the Members
in the Act or in this Agreement shall be vested in the Board, and the Members shall have no voting rights except as specifically provided in this Agreement. Each Manager shall devote such time to the affairs of the Company as may be reasonably
necessary for performance by the Manager of his, her or its duties hereunder, provided such Person shall not be required to devote full time to such affairs. Each Manager shall, in the performance of his, her or its duties as such, owe to the
Members fiduciary duties, including duties of loyalty and care, of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
type owed by the directors of a corporation to the stockholders of such corporation under the laws of the State of Delaware. Specifically, but not by way of limitation, but subject to the
provisions of Section&nbsp;5.5, the Board shall be authorized in the name and on behalf of the Company to cause the Company to do all things necessary or appropriate to carry on the business and purposes of the Company, including without limitation
the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;to issue the Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;to conduct the business of the Company in any state, territory or possession of the United States or in any
foreign jurisdiction; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;to acquire by purchase, lease, exchange or otherwise, and to sell, finance,
refinance, encumber and otherwise deal with, any real, personal or intellectual property, including, without limitation, subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;to borrow money and issue evidences of indebtedness or to guarantee loans and to secure the same by mortgage,
deed of trust, pledge or other lien on any assets or property of the Company and to pay, prepay, extend, amend or otherwise modify the terms of any such borrowings and to raise additional capital; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;to employ executive, administrative and support personnel in connection with the business of the Company, to
pay salaries, expense reimbursement, employee benefits, fringe benefits, bonuses and any other form of compensation or employee benefit to such Persons, at such times and in such amounts as may be determined by the Board in its sole discretion, in
order to provide executive, administrative and support services in connection with the business of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;to hire or employ such agents, employees, managers, accountants, attorneys, consultants and other Persons
necessary or appropriate to carry out the business and operations of the Company, and to pay fees, expenses, salaries, wages and other compensation to such Persons as may be determined by the Board in its sole discretion; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;to pay, extend, renew, modify, adjust, submit to arbitration, prosecute, defend or compromise, upon such
terms as it may determine and upon such evidence as it may deem sufficient, any obligation, suit, liability, cause of action or claim, including taxes, either in favor of or against the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;to determine the appropriate accounting method or methods to be used by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;to cause the Company to make or revoke any of the elections referred to in Sections 108, 704, 709, 754 or
1017 of the Code or any similar provisions enacted in lieu thereof, or in any other Section of the Code; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;to establish and maintain reserves for such purposes and in such amounts as it deems appropriate from time to
time; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;to pay all organizational expenses and general and administrative expense of the Company from
Company funds; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp;to open accounts and deposit, maintain and withdraw funds
in the name of the Company in banks, savings and loan associations, brokerage firms or other financial institutions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(m)&nbsp;&nbsp;&nbsp;&nbsp;to deal with, or otherwise engage in business with, or provide services to and receive compensation therefor
from, any Person who has provided or may in the future provide any services to, lend money to, sell property to or purchase property from the Company, including without limitation, any Member or Manager; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(n)&nbsp;&nbsp;&nbsp;&nbsp;to pay any and all fees and to make any and all expenditures that it, in its sole discretion, deems necessary
or appropriate in connection with the organization of the Company, the management of the affairs of the Company and the carrying out of its obligations and responsibilities under this Agreement, including, without limitation, fees, reimbursements
and expenditures payable to a Member or Manager; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(o)&nbsp;&nbsp;&nbsp;&nbsp;to cause the Company and its properties and assets to
be maintained and operated in such manner as the Board may determine, subject, however, to obligations imposed by applicable laws or by any mortgage or security interest encumbering the Company and such properties and assets from time to time, and
by any lease, rental agreement or other agreement pertaining thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(p)&nbsp;&nbsp;&nbsp;&nbsp;to cause to be obtained and
continued in force all policies of insurance required by any mortgage, lease or other agreement relating to the Company&#146;s business or any part thereof, or determined by the Board to be in the best interests of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(q)&nbsp;&nbsp;&nbsp;&nbsp;to cause to be paid any and all taxes, charges and assessments that may be levied, assessed or imposed upon
any of the assets of the Company, unless the same are contested by the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(r)&nbsp;&nbsp;&nbsp;&nbsp;to define and institute
all Company policies; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(s)&nbsp;&nbsp;&nbsp;&nbsp;to exercise all powers and authority granted by the Act to Managers, except as
otherwise provided in this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(t)&nbsp;&nbsp;&nbsp;&nbsp;to approve the R&amp;D Plan and any modifications thereto, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(u)&nbsp;&nbsp;&nbsp;&nbsp;to approve any subsequent research and development plans proposed by the SC or a Member; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(v)&nbsp;&nbsp;&nbsp;&nbsp;to determine the patent strategy for all Company-owned technology; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(w)&nbsp;&nbsp;&nbsp;&nbsp;to approve the ENPP1 Program budget on an annual basis; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(x)&nbsp;&nbsp;&nbsp;&nbsp;to perform any other act that the Board may deem necessary, convenient or desirable for the Company or its
business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Managers</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Number and Designation</U>. Except as contemplated by Section&nbsp;5.2(c), each Member agrees to vote, or
cause to be voted, all Shares owned by such Member, or over which such Member has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that the size of the Board shall be set and remain at two
(2)&nbsp;Managers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Board Composition</U>. Each Member Agrees to vote, or cause to be voted, all
Shares owned by such Member has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that at each annual or special meeting of Members at which an election of Managers is held or pursuant to any
written consent of the Members, the following persons shall be elected to the Board: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;one (1)&nbsp;individual
which shall be designated by Exscientia, which individual shall initially be [***]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;one
(1)&nbsp;individual which shall be designated by Rallybio, which individual shall initially be [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Manager</U>. Notwithstanding anything to the contrary in this Article V, in the event one
Member&#146;s Percentage Interest is greater than [***], then the Members shall vote to increase the number of authorized Managers to three (3)&nbsp;and such Member with a Percentage Interest greater than [***] shall have the right to designate two
(2)&nbsp;of the three (3)&nbsp;Managers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. Upon the death, resignation or removal of
any Manager (a &#147;<U>Terminated Manager</U>&#148;): (i) such Terminated Manager shall have no further authority under this Agreement as a Manager; (ii)&nbsp;such Terminated Manager shall have no further obligations or rights under this Agreement
(except for liabilities and rights accruing prior to the date of death, resignation or removal, including rights to indemnification under Section&nbsp;5.10 that related to actions or omissions occurring during such Person&#146;s service as a
Manager); and (iii)&nbsp;no writing or instrument shall be required to be executed by the Company or the Terminated Manager to reflect such cessation of service, except that the Terminated Manager (or his, her or its Legal Representative or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> as provided in the following paragraph) shall execute and deliver any agreement, instrument, certificate or document, including an amendment to the
Certificate, which may be reasonably required to reflect that the Terminated Manager is no longer a Manager of the Company. Each Person now or hereafter serving as a Manager of the Company, by execution of this Agreement, an amendment hereto or an
instrument acknowledging that it is bound hereby, hereby constitutes and appoints each other Person who may from time to time be serving as a Manager, and each of them acting singly, such Manager&#146;s agent and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for the purpose of executing and delivering any and all agreements, instruments and other documents (including, without limitation, an amendment to the Certificate) as are necessary or
appropriate to reflect that he, she or it is no longer a Manager of the Company following the death, resignation or removal, which power of attorney is hereby agreed and acknowledged to be coupled with an interest and irrevocable, and shall survive
the death, dissolution, bankruptcy or incapacity of any Manager until such time as the withdrawal of such Manager from the Company has been reflected by all necessary or appropriate agreements, instruments and other documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation</U>. Any Manager may resign by delivering
his, her or its written resignation to the Company at its principal office or to the Company&#146;s Chief Executive Officer or Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or
upon the happening of some other event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal and Appointment of Successor; Vacancies</U>. Any
Manager may be replaced or removed with or without cause by a Majority in Interest; provided that any Manager elected Pursuant to Section&nbsp;5.2(b) or Section&nbsp;5.2(c) may not be removed without cause unless such removal is directed or approved
by the affirmative vote of the Member entitled to designated that Manager. Any vacancies created by the resignation, removal or death of a Manager shall be filled pursuant to the provisions of Section&nbsp;5.2(b) or Section&nbsp;5.2(c) or by any
remaining Manager elected by the same Member entitled under Section&nbsp;5.2(b) or 5.2(c) to fill such vacancy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Regular Meetings</U>. Regular meetings of the Board may be held at such time and place, either within or
without the State of Delaware, as shall be determined from time to time by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Special
Meetings</U>. Special meetings of the Board may be held at any time and place, within or without the State of Delaware, designated by the Company&#146;s Chief Executive Officer or by a majority in number of the Managers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Meetings</U>. Notice of any meeting of the Board shall be given to each Manager by the
Company&#146;s Chief Executive Officer or Secretary or by one of the Managers calling the meeting. Notice shall be duly given to each Manager (i)&nbsp;in person, by telephone or by facsimile at least 72 hours in advance of the meeting, (ii)&nbsp;by
messenger, to the Manager&#146;s last known business or home address at least 72 hours in advance of the meeting, (iii)&nbsp;by electronic mail at least 72 hours in advance of the meeting, provided that such Manager has provided the Company with an
electronic mail address, or (iv)&nbsp;by mailing written notice to the Manager&#146;s last known business or home address at least 7 days in advance of the meeting. A notice or waiver of notice of a meeting of the Board need not specify the purposes
of the meeting. Any Manager attending such a meeting shall be deemed to have waived notice of such meeting, except where a Manager attends such meeting for the express purpose of objecting to the transaction of any business because the meeting was
not properly called. Unless otherwise indicated in the notice of any such meeting, any and all business may be transacted at such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Meetings by Telephone Conference Calls</U>. Managers or any members of any committee designated by the
Managers may participate in a meeting of the Board or such committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation by such means
shall constitute presence in person at such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Quorum</U>. A majority of the total number of
the members of the Board shall constitute a quorum at all meetings of the Board. In the absence of a quorum at any such meeting, a majority of the Managers present may adjourn the meeting from time to time without further notice other than
announcement at the meeting, until a quorum shall be present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Action at Meeting</U>. At any meeting
of the Board at which a quorum is present, the vote of a majority of those present shall be sufficient to take any action, unless a different vote is required by law, the Certificate or this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Action by Consent</U>. Any action required or permitted
to be taken at any meeting of the Board or of any committee of the Board may be taken without a meeting, if all members of the Board or committee, as the case may be, consent to the action in writing or by electronic transmission, and such consents
are filed with the minutes of proceedings of the Board or committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Committees</U>. The Board may,
by resolution passed by a majority of the whole Board, designate one or more committees, each committee (other than the SC) to consist of one or more of the Managers. The Board may designate one or more Managers as alternate members of any
committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members of the committee present at any meeting and not disqualified from
voting, whether or not he, she or they constitute a quorum, may unanimously appoint one of such alternate members of the Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided
in the resolution of the Board and subject to the provisions of the Act, the Certificate and this Agreement, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Company. Each
such committee shall keep minutes and make such reports as the Board may from time to time request. Except as the Board may otherwise determine, any committee may make rules for the conduct of its business but, unless otherwise provided by the
Managers or in such rules, its business shall be conducted as nearly as possible in the same manner as is provided in this Agreement for the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation of Managers</U>. The Company shall reimburse the <FONT STYLE="white-space:nowrap">non-</FONT>
employee Managers for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel expenses incurred in connection with attending meetings of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>. The Company shall cause Directors&nbsp;&amp; Officers liability insurance to be maintained
until such time as the Board determines that such insurance should be discontinued, in an amount and on terms and conditions satisfactory to the Board, but, in any event, no less than $2,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Liability for Election of Recommended Managers</U>. No Member, nor any Affiliate of any such Member,
shall have any liability solely as a result of designating an individual for election as a Manager in accordance with the provisions of this Agreement, for any act or omission by such designated individual in his or her capacity as a Manager, nor
shall any Member or any Affiliate of such Member have any liability solely as a result of voting for any such designee in accordance with the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Steering Committee</U>. For so long as each of Exscientia and Rallybio each have a Percentage Interest equal to
or greater than [***], the Members will form a steering committee (the &#147;<U>SC</U>&#148;), which will be comprised of an equal number of representatives from each Member, as provided further below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Responsibilities</U>. The SC shall be responsible for overall oversight of the initial R&amp;D Plan and
any subsequent research and development plans and certain intellectual property matters and regulatory matters, in each case, as set forth in this Agreement. The SC shall have the following responsibilities: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;to engage in any kind of activity and to perform and carry out
contracts of any kind necessary to, or in connection with, or incidental to the accomplishment of, the purposes of the Company as set forth in the R&amp;D Plan and any subsequent research and development plans; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;to designate criteria for the Stage 1 candidates and Candidate Compound nominations; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;to oversee completion of the Stage 2 Objective; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;to manage the operational aspects of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;to execute on the patent strategy for all Company-owned technology, as determined by the Board, including
prosecution, enforcement and defense of Company intellectual property rights; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;to monitor progress of
activities under the initial R&amp;D Plan and any subsequent research and development plans; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;to recommend
modifications to the initial R&amp;D Plan and any subsequent research and development plans, as applicable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;to propose additional or new research and development plans; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;to recommend new programs for the Members to consider; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;to perform such other functions as the Board may delegate to the SC or the Members may otherwise agree in
writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Membership; Chair</U>. The SC shall be comprised of four (4)&nbsp;members (the &#147;<U>SC
Members</U>&#148;), with two (2)&nbsp;members appointed by Exscientia and two (2)&nbsp;members appointed by Rallybio. The SC shall be chaired by a representative of Rallybio and either Member may appoint substitute or replacement members of the SC
to serve as their representatives upon notice to the other Member; provided that the Members shall use reasonable efforts to maintain continuity in representation on the SC. The initial SC Members shall be appointed by the Members within thirty
(30)&nbsp;days following the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Decision Making</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Decisions by Consensus</U>. Decisions within the scope of the SC&#146;s authority shall be made by consensus
with each SC Member having one (1)&nbsp;vote. A quorum comprised of three (3)&nbsp;members of the SC must be present in order for the SC to vote on any and all decisions within the scope of the SC&#146;s authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Escalation to Senior Executives</U>. In the event that the
SC does not reach a consensus agreement with respect to any material decision within five (5)&nbsp;business days following a vote on such decision, the matter may, at the request of either Member, be referred to the Senior Executives for resolution.
If the Senior Executives do not reach agreement on such matter within ten (10)&nbsp;business days after the date on which the matter is referred to them, then the Members shall submit such matter to arbitration pursuant to Section&nbsp;5.13. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>SC Meetings</U>. The SC shall meet <FONT STYLE="white-space:nowrap">in-person</FONT> or via teleconference
on a quarterly basis or more frequently as necessary to make decisions or confirmations required herein or as may be otherwise agreed upon. The Company shall reimburse the <FONT STYLE="white-space:nowrap">non-employee</FONT> SC Members for all
reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel expenses incurred in connection with attending meetings of the SC. Written notice of each meeting of the SC shall be given to each SC
Member (i) in person, by telephone or by facsimile at least 72 hours in advance of the meeting, (ii)&nbsp;by messenger, to the SC Member&#146;s last known business or home address at least 72 hours in advance of the meeting, (iii)&nbsp;by electronic
mail at least 72 hours in advance of the meeting, provided that such SC Member has provided the Company with an electronic mail address, or (iv)&nbsp;by mailing written notice to the SC Member&#146;s last known business or home address at least 7
days in advance of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Member Control</U>. Notwithstanding anything to the contrary in this
Section&nbsp;5.3, in the event one Member&#146;s Percentage Interest is greater than [***], then the SC shall be disbanded and such Member shall assume all decision making authority for matters that are delegated to the SC by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4&nbsp;&nbsp;&nbsp;&nbsp;<U>R&amp;D Plan</U>. Within thirty (30)&nbsp;calendar days following the Effective Date, the Members shall prepare
a research and development plan mutually agreeable to the Members based on the initial draft outline attached as <B><U>Exhibit 1</U> </B>(the &#147;<U>R&amp;D Plan</U>&#148;), which shall be presented to the Board for approval. The R&amp;D Plan
shall describe the stages of, and each Members&#146; responsibilities related to the ENPP1 Program. The Members intend for the R&amp;D Plan to be reviewed or modified, as applicable, as least annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Members</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Place of Meetings</U>. All meetings of Members shall be held at such place within or without the State of
Delaware as may be designated from time to time by the Board or the Company&#146;s Chief Executive Officer or, if not so designated, at the principal place of business of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Meetings</U>. No meeting of Members is required to be held. If so determined by the Board, there may be
held an annual meeting of Members for the transaction of such business as may properly be brought before the meeting. Such annual meeting, if held, shall be held on a date to be fixed by the Board or the Company&#146;s Chief Executive Officer at the
time and place to be fixed by the Board or the Company&#146;s Chief Executive Officer and stated in the notice of the meeting. If no annual meeting is held in accordance with the foregoing provisions, a special
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting may be held in lieu of the annual meeting, and any action taken at that special meeting shall have the same effect as if it had been taken at the annual meeting, and in such case all
references in this Agreement to the annual meeting of the Members shall be deemed to refer to such special meeting. Special meetings of Members may be called at any time by the Board or the Company&#146;s Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Meetings</U>. Except as otherwise provided by law, written notice of each meeting of Members,
whether annual or special, shall be given no less than ten nor more than sixty (60)&nbsp;days before the date of the meeting to each Member entitled to vote at such meeting. The notices of all meetings shall state the place, date and hour of the
meeting. The notice of a special meeting shall state, in addition, the purpose or purposes for which the meeting is called. If mailed, notice is given when deposited in the United States mail, postage prepaid, directed to the Member at his, her or
its address as it appears on the records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Quorum</U>. Except as otherwise provided by
law or this Agreement, a Majority in Interest, present in person or represented by proxy, shall constitute a quorum at all meetings of the Members for the transaction of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjournments</U>. Any meeting of Members may be adjourned to any other time and to any other place at
which a meeting of Members may be held under this Agreement by the Members present or represented at the meeting, although less than a quorum, or, if no Member is present, by any officer entitled to preside at or to act as Secretary of such meeting.
It shall not be necessary to notify any Member of any adjournment of less than 30 days if the time and place of the adjourned meeting are announced at the meeting at which adjournment is taken, unless after the adjournment a new record date is fixed
for the adjourned meeting. At the adjourned meeting, the Company may transact any business that might have been transacted at the original meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting and Proxies</U>. Except as otherwise provided by this Agreement, each Member of record shall be
entitled to vote at a meeting of Members, or to express consent or dissent to Company action in writing without a meeting. A Member may vote or express such consent or dissent in person or may authorize another Person or Persons to vote or act for
him, her or it by written proxy executed by the Member or his, her or its authorized agent and delivered to any officer of the Company. No such proxy shall be voted or acted upon after three years from the date of its execution, unless the proxy
expressly provides for a longer period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Action at Meeting</U>. When a quorum is present at any
meeting, the Members representing a Majority in Interest shall decide any matter to be voted upon by the Members at such meeting, except when a different vote is required by express provision of law, the Certificate or this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Action without Meeting</U>. Any action required or permitted to be taken at any annual or special meeting
of Members may be taken without a meeting, without prior notice and without a vote, if a consent in writing or by electronic transmission, setting forth the action so taken, is signed by the Members having not less than the minimum aggregate
Percentage Interests that would be necessary to authorize or take such action at a meeting at which all Members to vote on such action were present and voted. Prompt notice of the taking of an action without a meeting by less than unanimous written
consent shall be given to those Members who have not consented in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Member Approval Requirements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the provisions of Section&nbsp;5.1 and 5.7 or any other provisions of this Agreement to the
contrary, without the prior written approval by a Majority in Interest of the Members entitled to vote, the Managers shall not cause the Company to (and the Company shall not): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;liquidate, terminate or dissolve the Company; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;consummate a Sale of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Enumeration</U>. The officers of the Company may, but are not required to, consist of a President and
Chief Executive Officer, a Treasurer, a Secretary and such other officers with such other titles as the Board shall determine, including one or more Vice Presidents, Assistant Treasurers and Assistant Secretaries. Each officer shall devote such time
to the affairs of the Company as may be reasonably necessary for performance by the officer of his or her duties hereunder, provided such officers shall not be required to devote full time to such affairs, unless otherwise determined by the Board.
Each officer of the Company shall, in the performance of his or her duties as such, owe to the Members fiduciary duties, including duties of loyalty and care, of the type owed by officers of a corporation to the stockholders of such corporation
under the laws of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Election</U>. Officers may be appointed by the Board by
written consent or at any of its meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Qualification</U>. No officer need be a Member or a
Manager. Any two or more offices may be held by the same person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenure</U>. Except as otherwise
provided by law, by the Certificate or by this Agreement, each officer shall hold office until his or her successor is elected and qualified, unless a different term is specified in the vote choosing or appointing such officer, or until such
officer&#146;s earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation and Removal</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Any officer may resign by delivering his or her written resignation to the Company at its principal office or to
the Company&#146;s Chief Executive Officer, President or Secretary or any Manager. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Any officer may be removed at any time, with or without cause, by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Except as the Board may otherwise determine, no officer who
resigns or is removed shall have any right to any compensation as an officer for any period following such resignation or removal, or any right to damages on account of such removal, whether such officer&#146;s compensation be by the month or by the
year or otherwise, unless such compensation is expressly provided in a duly authorized written agreement with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Vacancies</U>. The Board may fill any vacancy occurring in any office for any reason and may, in its
discretion, leave unfilled for such period as it may determine any office. Each such successor shall hold office for the unexpired term of such officer&#146;s predecessor and until such officer&#146;s successor is elected and qualified, or until
such officer&#146;s earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>President and Chief Executive Officer</U>.
The President and Chief Executive Officer shall, subject to the direction of the Board, have general charge and supervision of the business of the Company, and shall perform such other duties and shall have such other powers as the Board may from
time to time prescribe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Treasurer</U>. The Treasurer shall perform such duties and shall have such
powers as the Chief Executive Officer may from time to time prescribe. In addition, the Treasurer shall perform such duties and have such powers as are incident to the office of treasurer, including without limitation the duty and power to keep and
be responsible for all funds and securities of the Company, to deposit funds of the Company in depositories selected in accordance with this Agreement, to disburse such funds as ordered by the Board, to make proper accounts of such funds and to
render as required by the Board statements of all such transactions and of the financial condition of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Secretary</U>. The Secretary shall perform such duties and shall have such powers as the Chief Executive
Officer may from time to time prescribe. In addition, the Secretary shall perform such duties and have such powers as are incident to the office of the secretary, including without limitation the duty and power to give notices of all meetings of
Members and special meetings of the Board, to attend all meetings of Members and the Board and keep a record of the proceedings, to maintain the Share Ledger and prepare lists of Members and their addresses as required and to be custodian of the
Company records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Salaries</U>. Each officer of the Company shall be entitled to such salary,
compensation or reimbursement as shall be fixed or allowed from time to time by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Interpretation
of Rights and Duties of Managers and Members</U>. To the fullest extent permitted by the Act and other applicable law, and to the extent not inconsistent with the specific provisions of this Agreement or the Certificate, it is the intention of the
parties that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;the Board shall have the power to do any and all acts, statutory and otherwise, with
respect to the Company that the board of directors of a Delaware corporation would have with respect to such Delaware corporation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;no Member, in his, her or its capacity as a Member, shall have any power or authority whatsoever with respect
to the management of the business and affairs of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Binding the Company</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as the Board may generally or in any particular case or cases otherwise authorize, and subject to the other provisions of this
Agreement and the Certificate, the Chair of the Board, if any, the President, the Treasurer and the Secretary, each SC Member, or any of them acting singly, may execute all deeds, leases, contracts, bonds, notes, checks, drafts or other obligations
to be made, accepted or endorsed by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Contracts with Members</U>. With the approval of the
Board in each case, the Company may engage in business with, or enter into one or more agreements, leases, contracts or other arrangements for the furnishing to or by the Company of goods, services or space with any Member or Affiliate of a Member,
and may pay compensation in connection with such business, goods, services or space, provided in each case the amounts payable thereunder are reasonably comparable to those that would be payable to unaffiliated Persons under similar agreements, and
if the determination of such amounts is made in good faith it shall be conclusive absent manifest error. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification and Exculpation</U>. No Manager, or his, her or its Affiliates, or any officer of the Company,
or any SC Member, or the Tax Matters Representative shall have any liability to the Company or to any Member for any loss suffered by the Company that arises out of any action or inaction of any Manager or his, her or its Affiliates or officer or SC
Member or the Tax Matters Representative, if such Manager or his, her or its Affiliates or officer or SC Member or the Tax Matters Representative, as the case may be, in good faith, determined that such course of conduct was in the best interests of
the Company and if such course of conduct did not constitute gross negligence or willful misconduct of such Manager or his, her or its Affiliates or officer or SC Member or the Tax Matters Representative. Each Manager and his, her or its Affiliates,
each officer, each SC Member and the Tax Matters Representative shall be indemnified by the Company against any losses, judgments, liabilities, expenses and amounts paid in settlement of any claims sustained by it with respect to actions taken by
such Manager or his, her or its Affiliates or officer or SC Member or the Tax Matters Representative on behalf of the Company, provided that the Company shall not indemnify any Person with respect to any matter as to which such Person shall have
been adjudicated in any proceeding to have acted with gross negligence or willful misconduct. Without limiting the foregoing, such indemnification may include payment by the Company of expenses incurred in defending a civil or criminal action or
proceeding in advance of the final disposition of such action or proceeding, upon receipt of an undertaking by the Person indemnified to repay such payment if such Person shall be adjudicated not to be entitled to indemnification under this
Section&nbsp;5.11, which undertaking may be accepted without reference to the financial ability of such Person to make repayment. Any indemnification to be provided hereunder may be provided although the Person to be indemnified is no longer a
Manager or an Affiliate of a Manager or an officer or a SC Member or the Tax Matters Representative. Any indemnity under this Section&nbsp;5.11 shall be paid from, and only to the extent of, Company assets, and no Member shall have any personal
liability on account thereof. The indemnification provided for herein shall not be deemed exclusive of any other rights to which those indemnified may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitled under any agreement, vote of Members or disinterested Managers or otherwise, both as to action in their official capacity and as to action in another capacity while holding such office,
and shall continue as to a Person who has ceased to be a Manager (or an Affiliate of a Person who has ceased to be a Manager) or officer or SC Member or the Tax Matters Representative and shall inure to the benefit of the heirs, executors and
administrators of such a Person. Any repeal or modification of the foregoing provisions of this Section&nbsp;5.11 by the Members shall not adversely affect any right or protection of a Manager or officer or SC Member or the Tax Matters
Representative existing at the time of, or increase the liability of any Manager or officer or SC Member or the Tax Matters Representative with respect to any acts or omissions of such Manager or officer or SC Member or Tax Matters Representative
occurring prior to, such repeal or modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Excluded Opportunity</U>. The Members expressly
acknowledge and agree that each other Member may engage independently or with others, for its own account and for the accounts of others, in other business ventures and investment activities of every nature and description whether such ventures are
competitive with the Company&#146;s business or otherwise. Without limiting the foregoing, in the event that a Manager acquires knowledge of an Excluded Opportunity that may be an opportunity for both the Company and the Manager or Member, the
Members expressly renounce any interest or expectancy that such Manager or Member offer an opportunity to participation, or be informed about such Excluded Opportunity. An &#147;<U>Excluded Opportunity</U>&#148; is any matter, transaction or
interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of a Manager, so long as such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes
into the possession of, such Manager&#146;s capacity as a partner, member, director, shareholder, employee agent or other related Person of a Member or otherwise in a manner unrelated to the Manager&#146;s service to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration</U>. Any material decision on which (a)&nbsp;the Managers cannot reach agreement or (b)&nbsp;the
Senior Executives cannot reach agreement pursuant to Section&nbsp;5.3(c)(ii), shall be resolved by binding arbitration pursuant to the Rules of Arbitration of the International Chamber of Commerce in force at the time of the commencement of the
arbitration (the &#147;<U>Arbitration Rules</U>&#148;). There shall be three (3)&nbsp;arbitrators. Each Member shall nominate one arbitrator. The president of the arbitral tribunal shall be nominated by the
<FONT STYLE="white-space:nowrap">co-arbitrators</FONT> within 30 days from the confirmation of the two <FONT STYLE="white-space:nowrap">co-arbitrators.</FONT> If a Member fails to appoint an arbitrator or the Member-nominated arbitrators fail to
nominate the president, such arbitrators shall be appointed in accordance with the Arbitration Rules. The decision of the arbitral tribunal shall be binding upon the Members. The place of the arbitration shall be New York, New York. The language of
the arbitration shall be English. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALLOCATION OF INCOME AND LOSS; DISTRIBUTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Allocation of Income and Loss</U>. After giving effect to the special allocations set forth in Section&nbsp;6.2,
Income and Loss for any year or portion thereof shall be allocated among the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Members in such ratio or ratios as may be required to cause Capital Account balances of the Members (determined after crediting to each Member&#146;s Capital Account any amount that the Member is
deemed obligated to restore under Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-2)</FONT> to equal, as nearly as possible, their Target Balances. The contribution agreements and other agreements between the Company and the Members,
together with this Agreement, constitute the &#147;partnership agreement&#148; of the Company for purposes of Section&nbsp;704 of the Code and the Regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Allocations</U>. Notwithstanding any other provision of this Article VI, the following special
allocations shall be made in the following order: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Minimum Gain Chargeback</U>. If there is a net
decrease in Company Minimum Gain (as such term is defined by Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-2(d)</FONT> but substituting the term &#147;Company&#148; for the term &#147;partnership&#148; as the context requires)
during any Fiscal Year, the Members shall be specially allocated Gross Income for such Fiscal Year (and, if necessary, subsequent Fiscal Years) in an amount equal to the portion of such Member&#146;s share of the net decrease in Company Minimum
Gain, determined in accordance with Regulation Section <FONT STYLE="white-space:nowrap">l.704-</FONT> 2(g)(2). Allocations pursuant to the previous sentence shall be made in proportion to the respective amounts required to be allocated to the
Members pursuant thereto. The items to be so allocated shall be determined in accordance with Regulation Section <FONT STYLE="white-space:nowrap">l.704-2(f)(6).</FONT> This Section&nbsp;6.2(a) is intended to comply with the minimum gain chargeback
requirement in such section of the Regulations and shall be interpreted consistently therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Member Minimum Gain Chargeback</U>. If during any Fiscal Year there is a net decrease in Member
Nonrecourse Debt Minimum Gain (as such term is defined by Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-2(i)(3)</FONT> but substituting the term &#147;Member&#148; for the term &#147;partner&#148; as the context requires), then each
Member shall be specially allocated Gross Income for such Fiscal Year (and, if necessary, for subsequent Fiscal Years) in the manner provided in Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-</FONT> 2(i)(4). This Section&nbsp;6.2(b)
is intended to comply with the partner nonrecourse debt chargeback provisions of Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-2(i).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Qualified Income Offset</U>. If any Member unexpectedly receives an adjustment, allocation or distribution
of the type contemplated by Regulations Section&nbsp;1.704 1(b)(2)(ii)(d)(4), (5) or (6), items of Company income and gain shall be specially allocated to such Member in an amount and manner sufficient to eliminate, to the extent required by the
Regulations, the deficit balance in the Adjusted Capital Account of such Member as quickly as possible. It is intended that this Section&nbsp;6.2(c) qualify as a &#147;qualified income offset&#148; within the meaning of Regulations
Section&nbsp;1.704 1(b)(2)(ii)(d) and shall be interpreted consistently therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation on
Allocation of Net Loss</U>. If the allocation of Losses (or items of loss or deduction) to a Member as provided in Section&nbsp;6.1 hereof would create or increase an Adjusted Capital Account deficit, there shall be allocated to such Member only
that amount of Losses (or items of loss or deduction) as will not create or increase an Adjusted Capital Account deficit. The Losses (or items of loss or deduction) that would, absent the application of the preceding sentence, otherwise be allocated
to such Member shall be allocated to the other Members in accordance with their relative Interests, subject to the limitations of this Section&nbsp;6.2(d). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Additional Adjustments</U>. To the extent that
an adjustment to the adjusted tax basis of any Company asset pursuant to Code Section&nbsp;734(b) or Code Section&nbsp;743(b) is required, pursuant to Regulations Section&nbsp;1.704 1(b)(2)(iv)(m)(2) or Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.704-</FONT> 1(b)(2)(iv)(m)(4), to be taken into account in determining Capital Accounts as the result of a distribution to a Member in complete liquidation of its Interest, the amount of such
adjustment to the Capital Accounts shall be treated as an item of gain (if the adjustment increases the basis of the asset) or loss (if the adjustment decreases such basis), and such gain or loss shall be specially allocated to the Members in
accordance with their Interests in the Company in the event that Regulations Section&nbsp;1.704 1(b)(2)(iv)(m)(2) applies, or to the Members to whom such distribution was made in the event that Regulations Section&nbsp;1.704 1(b)(2)(iv)(m)(4)
applies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Member Nonrecourse Deductions</U>. Member Nonrecourse Deductions (as defined in Regulation
Section <FONT STYLE="white-space:nowrap">l.704-2(i)(2)</FONT> but substituting the term &#147;Member&#148; for the term &#147;partner&#148; as the context requires) shall be allocated as prescribed in Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.704-</FONT> 2(i)(1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Noncompensatory Options</U>. If,
as a result of an exercise of a noncompensatory warrant or option to acquire an Interest, a Capital Account reallocation is required under Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-1(b)(2)(iv)(s)(3),</FONT> the Company shall
make corrective allocations pursuant to Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-1(b)(4)(x).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Curative Allocations</U>. The allocations set forth in Sections 6.2(a) through 6.2(g) hereof (the
&#147;Regulatory Allocations&#148;) are intended to comply with certain requirements of Regulations Sections 1.704 1(b) and 1.704 2(i). Notwithstanding the provisions of Section&nbsp;6.1, the Regulatory Allocations shall be taken into account in
allocating other items of income, gain, loss and deduction among the Members so that, to the extent possible, the net amount of such allocations of other items and the Regulatory Allocations to each Member shall be equal to the net amount that would
have been allocated to each such Member if the Regulatory Allocations had not occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Allocations for Tax
Purposes</U>. In accordance with Section&nbsp;704(c) of the Code and the Regulations thereunder, taxable income, gain, loss or deduction with respect to any property contributed to the Company shall, solely for tax purposes, be allocated among the
Members so as to take account of any variations between the adjusted basis of such property to the Company for federal income tax purposes and its initial &#147;book value&#148; as such term is defined in
<FONT STYLE="white-space:nowrap">Section&nbsp;1.704-</FONT> 3(a)(3). Taxable income, gain, loss or deduction attributable to contributed property shall be allocated among the Members as required by Section&nbsp;704(c) of the Code for tax purposes,
but shall not affect the Capital Accounts, except as required by Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-l(b)(2)(iv).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Determination by the Board of Certain Matters</U>. Liabilities shall be determined in accordance with generally
accepted accounting principles, applied on a consistent basis; and, consistent therewith, the Board may create reserves for estimated accrued expenses, liabilities or contingencies. All matters not expressly provided for by the terms of this
Agreement concerning the valuation of assets of the Company, and the allocation of Income, Loss, items of income, deduction, gain, loss, credit and other matters, among the Members, including taxes thereon, and accounting procedures shall be
determined by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Transfer</U>. If any Interest in the Company is
Transferred, the proportionate Capital Account and Percentage Interest attributable to such Interest in the Company shall continue to be attributable to such Interest in the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Distributions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Distributions Upon a Sale or Liquidation</U>. In the event of a Sale of the Company, a liquidation, dissolution
or winding up under Article VIII, a recapitalization, or other similar <FONT STYLE="white-space:nowrap">non-</FONT> ordinary course distribution of capital in which the proceeds from such transaction are received by the Company, such proceeds shall
be distributed to the Members in proportion to their Percentage Interests in exchange for the Shares held by such Members. Each Member shall take all necessary or desirable actions in connection with the distribution of the aggregate consideration
from any such transaction as reasonably requested by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in this Section&nbsp;6.6(a) to the contrary, for
each Member holding Incentive Shares, any distributions made pursuant to this Section&nbsp;6.6(a) with respect to such Incentive Shares, as applicable, shall be made only after the aggregate distributions made pursuant to this Section&nbsp;6.6(a) to
other Members equal to such Member&#146;s Incentive Share Distribution Threshold, if any, for each such respective Member&#146;s Incentive Shares. The amount of any distributions not made to such Member by reason of the previous sentence shall
instead be distributed to the other Members (including any Member holding Incentive Shares whose Distribution Threshold has been met) in accordance with this Section&nbsp;6.6(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Distributions of Available Cash</U>. Except upon dissolution of the Company pursuant to Article VIII, and
subject to the reasonably anticipated business needs and opportunities of the Company and the requirements of any lender, including the establishment of reasonable reserves, any cash available for distribution by the Company from the operations of
the Company in the ordinary course of its business shall be distributed, at the sole discretion of the Board, after payment of expenses, to the Members in proportion to their Percentage Interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Distributions</U>. Notwithstanding the foregoing, if the Company has Income for federal income tax
purposes for any calendar year, then the Board shall cause the Company to distribute at least enough cash (a &#147;<U>Tax Distribution</U>&#148;) to each Member so that each Member receives sufficient cash, when combined with all other distributions
pursuant to this Section&nbsp;6.6 and Section&nbsp;8.4 to such Member in the current calendar year, to pay his, her or its income tax liability with respect to such Member&#146;s share of the Income of the Company for such year to the extent such
Income for the current year exceeds the amount of unused Losses allocated to such Member in prior years, if any, assuming that each Member is subject to the maximum corporate federal, state and local income tax rates for a resident of New York, New
York with respect to his, her or its share of such Income. Notwithstanding the foregoing, any Tax Distribution may be reduced or not made with respect to any calendar year to the extent that the Board reasonably determines that there is not adequate
cash available to pay current operating expenses and to pay or establish reasonable reserves for future expenses, debt payments, capital improvements and replacements. Tax Distributions shall be advanced against and shall reduce the amount of future
distributions to each Member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Distribution of Assets in Kind</U>. No Member shall have the right to require
any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution of any assets of the Company in kind. If any assets of the Company are distributed in kind, such assets shall be distributed on the basis of their fair market value as determined in
good faith by the Board. Any Member entitled to any interest in such assets shall, unless otherwise determined by the Board, receive separate assets of the Company and not an interest as a tenant- <FONT STYLE="white-space:nowrap">in-common</FONT>
with other Members so entitled in any asset being distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding</U>. The Company is authorized
to withhold from distributions, or with respect to allocations to the Members, and to pay over to any federal, state, local or foreign government, any amounts required to be so withheld and/or paid pursuant to the Code or any provisions of any other
federal, state or local law or any foreign law. All amounts withheld and/or paid pursuant to the Code or any provision of any federal, state, local or foreign tax law with respect to any distribution or allocation to the Members, which amounts were
withheld as a result of a Member&#146;s status or other specific characteristics, shall be treated as amounts distributed to the Member with respect to which such amount was withheld and/or pursuant to this Section&nbsp;6.8 for all purposes under
this Agreement. To the extent that the aggregate of such payments allocable to a Member for any period exceeds the cash distributions to which such Member is entitled for such period, the Board shall notify such Member as to the amount of such
excess and such Member shall make a prompt payment to the Company of such amount by wire transfer, which payment shall not constitute a Capital Contribution and, consequently, shall not affect the Capital Account of such Member. For the avoidance of
doubt, amounts described in this Section&nbsp;6.8 include amounts paid by the Company pursuant to an audit of the Company subject to the Bipartisan Budget Act of 2015. The Company will cooperate with any reasonable request from any Member to obtain
reduction of or relief from any withholding, including without limitation, any withholding imposed pursuant to Section&nbsp;1446 of the Code. The provisions of this Section&nbsp;6.8 shall survive indefinitely and shall not terminate, without regard
to any transfer of a Member&#146;s Shares, withdrawal as a Member, or liquidation, dissolution or termination of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Tax Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;For any Fiscal Year or other period during which any part of an Interest in the Company is transferred between the
Members or to another person, the portion of the Income and Losses and other items of income, gain, loss, deduction and credit that are allocable with respect to such part of an Interest shall be apportioned between the transferor and the transferee
by taking into account their varying Interests during such Fiscal Year pursuant to Code Section&nbsp;706 and Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.706-4,</FONT> using any method or convention permitted by law and chosen by the
Board. For purposes of making such allocations, the Board is hereby authorized to select any method, convention or extraordinary item permitted under Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.706-4</FONT> as the Board determines
necessary or appropriate, which selection shall be set forth in a dated, written statement maintained with the Company&#146;s books and records. The Members hereby agree that any such selection by the Board is made by &#147;agreement of the
partners&#148; within the meaning of Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.706-4(f).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that the Code or any Regulations require allocations of items of income, gain, loss, deduction or
credit different from those set forth in this Article VI, the Board is hereby authorized to make new allocations in reliance on the Code and such Regulations, and no such new allocation shall give rise to any claim or cause of action by any Member.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Members acknowledge and are aware of the income tax
consequences of the allocations made by this Article VI and hereby agree to be bound by the provisions of this Article VI in reporting their shares of Income and Losses and other items of income, gain, loss, deduction and credit for United States
federal, state and local income tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;All matters concerning the allocations and other determinations
provided for in this Article VI and any accounting procedures not expressly provided for in this Agreement shall be determined by the Board in its good faith discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;No Member shall file a notice of inconsistent treatment under Section&nbsp;6222(b) of the Code or otherwise take
any position for tax purposes that is inconsistent with the position taken by the Company without first providing the Company with reasonable advance written notice under the circumstances (which in no event shall be less than thirty (30)&nbsp;days
prior to the date on which such inconsistent position may be taken) of such Member&#146;s intent and the manner in which the Member&#146;s intended treatment of an item is (or may be) inconsistent with the treatment of that item by the Company
and/or the other Members. After giving such notice, the Member proposing to take such inconsistent position shall work with the Company in good faith in an effort to resolve such inconsistent treatment. Any Member who fails to comply with the
requirements of this Section&nbsp;6.9(e) shall indemnify and hold harmless the Company and the other Members for any and all costs incurred by them (including reasonable attorney and/or other professional fees) that arise in connection with any
inconsistent tax position taken by such Member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Each Member acknowledges and agrees that it has not received
and is not relying upon tax advice from any other party hereto, and that it has and will continue to consult its own tax advisors. Each Member agrees to retain records and information relating to the filing of any tax returns or any audit,
litigation or other proceeding related to taxes associated with the matters described herein to the extent required by applicable law, and to cooperate to the extent reasonably requested by any other party in connection therewith, including, upon
request, providing records and information that are relevant to such matters and making employees available on a mutually convenient basis to provide such additional information as may reasonably be requested by such other party. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSFERS
OF INTERESTS; DISSOCIATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions</U>. No Member may Transfer all or any portion of his, her or
its Interest without the prior written consent of a Requisite Interest, unless such Transfer is to (i)&nbsp;an Affiliate of such Member, or (iii)&nbsp;another Member of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Right of First Refusal</U>. If any Member proposes to Transfer any Shares to a third party (the
&#147;<U>Offeror</U>&#148;) who is not an Affiliate of such Member and such Member has obtained the prior written consent of a Requisite Interest to such Transfer, such Member shall first make an offering of such Shares (the &#147;<U>Right of First
Refusal Shares</U>&#148;) to the Company and then to the holders of Shares in accordance with the following provisions: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The Offeror shall communicate to the Company in writing
(i)&nbsp;his, her or its bona fide intention to offer such Shares, (ii)&nbsp;the number of Shares to be offered and (iii)&nbsp;the terms and conditions of such offer (&#147;<U>Company Offer Notice</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Within [***] calendar days after receipt of the Company Offer Notice, the Company may communicate in writing
its desire to purchase all of the Right of First Refusal Shares at the price and terms upon which the Offeror proposes to Transfer all of the Right of First Refusal Shares (the &#147;<U>Company Offer</U>&#148;). The Company Offer shall close no more
than [***] days after the expiration of the [***]-day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;If the Company does not deliver a timely
Company Offer, the Offeror shall communicate to each holder of Shares in writing (i)&nbsp;his, her or its bona fide intention to offer such Shares, (ii)&nbsp;the number of Shares to be offered and (iii)&nbsp;the terms and conditions of such offer
(the &#147;<U>Share Offer Notice</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Within [***] calendar days after receipt of the Share Offer
Notice, each holder of Shares shall have the right and option, by written notification to the Offeror, to purchase (i)&nbsp;all of the Right of First Refusal Shares, if it is the only other holder of Shares, or (ii), if there are more than one other
holder of Shares, his, her or its proportionate percentage of the Right of First Refusal Shares (based upon the ratio of the number of Shares then owned by such holder to the aggregate number of Shares then owned by all eligible holders other than
the Offeror) at the price and terms upon which the Offeror proposes to Transfer the applicable Right of First Refusal Shares. Each participating holder shall have a right of oversubscription (based upon the ratio of the number of Shares then owned
by such participating holder to the aggregate number of Shares then owned by all such participating holders) such that if any holder fails to exercise his, her or its right and option under this paragraph, those participating holders shall, among
them, have the right to purchase up to the balance of the remaining Right of First Refusal Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;The
Offeror may, during the [***] calendar day period following the expiration of the period provided in Section&nbsp;7.2(d), offer the Right of First Refusal Shares to any Person or Persons at a price equal or greater than, and upon terms and
conditions equivalent or more favorable to the Offeror than those specified in the Company Offer Notice and Share Offer Notice. If the Offeror does not consummate the sale of the Right of First Refusal Shares within such period, the right provided
hereunder shall be deemed to be expired and such Right of First Refusal Shares shall not be offered unless first reoffered to the Company and holders of Shares in accordance herewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Co-Sale</FONT> Right</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. If at any time a Member desires to Transfer in connection with a Sale of the Company all or
any part of the Shares then owned by him, her or it (the &#147;<U>Proposed Shares</U>&#148;) to any party (the &#147;<U>Purchaser</U>&#148;) who is not an Affiliate of such Member, other than sales to be made pursuant to Section&nbsp;7.2, each
Member shall have the right to sell to the Purchaser, as a condition to such sale by the selling Member, at the same price per share and on the same terms </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and conditions as involved in such sale by the selling Member, such Member&#146;s pro rata portion of the number of Shares equal to the aggregate number of Proposed Shares (after the exercise of
any right of first refusal under Section&nbsp;7.2) multiplied by a fraction, the numerator of which is the number of Shares owned by such Member (on a fully diluted basis) in the aggregate and the denominator of which is the sum of all Shares owned,
in the aggregate, by all Members (other than the selling Member) immediately prior to the consummation of the proposed sale (including any Shares that all Members have collectively agreed to purchase pursuant to Section&nbsp;7.2), plus the number of
Shares held by the selling Member (on a fully diluted basis). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Intent to Participate</U>. If
a Member wishes to participate in any sale under this Section&nbsp;7.3, it shall notify the selling Member in writing of such intention as soon as practicable after such Member&#146;s receipt of the Share Offer Notice made pursuant to
Section&nbsp;7.2, and in any event within the time period specified in Section&nbsp;7.2. If any Member fails to notify the selling Member that it wishes to sell such Member&#146;s full proportionate share, the Shares not so sold may be sold by the
other Members proportionately in accordance with their then respective interests in the Shares of the Company (on a fully diluted basis), and the selling Member shall promptly notify each such other Member of such option. The procedure of <FONT
STYLE="white-space:nowrap">pro-ration</FONT> set forth herein shall continue in ten day intervals until either all of the Members have given notice of their intent to sell or all such Members have declined to sell or failed to provide notice of
their intent to sell. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Sale to Transferee</U>. The selling Member and the Members, if participating,
shall sell to the Purchaser all, or at the option of the Purchaser, any part of the Shares proposed to be sold by them on the terms and conditions set forth in the Share Offer Notice; provided, however, that any purchase of less than all of such
Shares by the Purchaser shall be made from the selling Member and the Members pro rata based upon the relative amount of the Shares that the selling Member and the Members are otherwise entitled to sell pursuant to Section&nbsp;7.3(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Member&#146;s Agreement</U>. Each Member hereby severally agrees that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;it shall not Transfer all or any part of his, her or its Interest in the Company except as permitted by this
Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;in no event shall all or any part of an Interest be Transferred to a minor or an
incompetent except in trust or pursuant to the Uniform Gifts to Minors Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Prohibited
Transfers</U>. Any Transfer in contravention of any of the provisions of this Agreement shall be void and of no effect, and shall neither bind nor be recognized by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignees</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Status of Assignees</U>. An assignee of the Interest of a Member, or any portion thereof, shall become a
substituted Member entitled to all the rights of a Member if, and only if, the assignee executes and delivers a joinder agreement so specifying or an additional signature page to this Agreement (and to the Certificate, if required), which agreement
or signature page shall be executed by the Company&#146;s Chief Executive Officer or other Person authorized by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Board and by such assignee, and such other instruments, in form and substance satisfactory to the Board (acting exclusive of any Manager who is, or is affiliated with, the assigning Member), as
may be necessary, appropriate or desirable to effect such substitution and to confirm the agreement of the assignee to be bound by the terms and provisions of this Agreement. Any such assignee shall confirm in such joinder agreement or signature
page that the representations and warranties contained in Section&nbsp;3.7 are true and correct as to such assignee as of the date of such assignment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignees Subject to This Agreement</U>. Any Person who acquires in any manner whatsoever an Interest or
any part thereof in the Company, whether or not such Person has accepted and assumed in writing the terms and provisions of this Agreement or been admitted into the Company as a Member as provided in Section&nbsp;3.8, shall be deemed, by acceptance
of the acquisition thereof, to have agreed to be subject to and bound by all of the obligations of this Agreement with respect to such Interest and shall be subject to the provisions of this Agreement with respect to any subsequent Transfer of such
Interest </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Drag Along</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Actions to be Taken</U>. In the event that (x)&nbsp;the Board and (y)&nbsp;a Majority in Interest (the
&#147;<U>Electing Members</U>&#148;) approve a Sale of the Company in writing, then each Member hereby agrees: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;if such transaction requires Member approval, with respect to all Shares that such Member owns or over which such
Member otherwise exercises voting power, to vote (in person, by proxy or by action by written consent, as applicable) all Shares in favor of, and adopt, such Sale of the Company (together with any related amendment to the Certificate or this
Agreement required in order to implement such Sale of the Company) and to vote in opposition to any and all other proposals that could delay or impair the ability of the Company to consummate such Sale of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;if such transaction is a Share Sale, to sell the same proportion of Shares beneficially held by such Member as is
being sold by the Electing Members to the Person to whom the Electing Members propose to sell their Shares and, except as permitted in Section&nbsp;7.7(b), on the same terms and conditions as the Electing Members; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;to execute and deliver all related documentation and take such other action in support of such Sale of the
Company as shall reasonably be requested by the Company or the Electing Members in order to carry out the terms and provision of this Section&nbsp;7.7, including without limitation executing and delivering instruments of conveyance and transfer, and
any purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens, claims and encumbrances), <FONT
STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, and any similar or related documents; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;not to deposit, and to cause their Affiliates not to deposit, except as provided in this Agreement, any Shares
owned by such party or Affiliate in a voting trust or subject any Shares to any arrangement or agreement with respect to the voting of such Shares, unless specifically requested to do so by the acquiror in connection with such Sale of the Company;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;to refrain from exercising any dissenters&#146; rights or rights
of appraisal under applicable law at any time with respect to such Sale of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;if the consideration
to be paid in exchange for the Shares pursuant to this Section&nbsp;7.7 includes any securities and due receipt thereof by any Member would require under applicable law (A)&nbsp;the registration or qualification of such securities or of any Person
as a broker or dealer or agent with respect to such securities or (B)&nbsp;the provision to any Member of any information other than such information as a prudent issuer would generally furnish in an offering made solely to &#147;accredited
investors&#148; as defined in Regulation D promulgated under the Securities Act, the Company may cause to be paid to any such Member in lieu thereof, against surrender of the Shares which would have otherwise been sold by such Member, an amount in
cash equal to the fair value (as determined in good faith by the Board) of the securities which such Member would otherwise receive as of the date of the issuance of such securities in exchange for the Shares; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;in the event that the Electing Members, in connection with such Sale of the Company, appoint a Member
representative (the &#147;<U>Member Representative</U>&#148;) with respect to matters affecting the Members under the applicable definitive transaction agreements following consummation of such Sale of the Company, (A)&nbsp;to consent to
(x)&nbsp;the appointment of such Member Representative, (y)&nbsp;the establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations and (z)&nbsp;the payment of such Member&#146;s pro
rata portion (from the applicable escrow or expense fund or otherwise) of any and all reasonable fees and expenses to such Member Representative in connection with such Member Representative&#146;s services and duties in connection with such Sale of
the Company and its related service as the representative of the Members, and (B)&nbsp;not to assert any claim or commence any suit against the Member Representative or any other Member with respect to any action or inaction taken or failed to be
taken by the Member Representative in connection with its service as the Member Representative, absent fraud or willful misconduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Exceptions</U>. Notwithstanding the foregoing, a Member shall not be required to comply with this
Section&nbsp;7.7 in connection with any proposed Sale of the Company (the &#147;<U>Proposed Sale</U>&#148;) unless: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the liability for indemnification, if any, of such Member in the Proposed Sale and for the inaccuracy of any
representations and warranties made by the Company or its Members in connection with such Proposed Sale is several and not joint with any other Person (except to the extent that funds may be paid out of an escrow established to cover breach of
representations, warranties and covenants of the Company as well as breach by any Member of any of identical representations, warranties and covenants provided by all Members), and is pro rata in proportion to, and does not exceed, the amount of
consideration paid to such Member in connection with such Proposed Sale; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;upon the consummation of the
Proposed Sale, each holder of Shares will receive the same amount of consideration per Share as is received by other holders of Shares in respect of their Shares; provided, however, that, notwithstanding the foregoing, if the consideration to be
paid in exchange for the Shares pursuant to this Section&nbsp;7.7(b)(ii) includes any securities and due receipt thereof by any Member would require under applicable law (x)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration or qualification of such securities or of any Person as a broker or dealer or agent with respect to such securities or (y)&nbsp;the provision to any Member of any information other
than such information as a prudent issuer would generally furnish in an offering made solely to &#147;accredited investors&#148; as defined in Regulation D promulgated under the Securities Act, the Company may cause to be paid to any such Member in
lieu thereof, against surrender of the Shares which would have otherwise been sold by such Member, an amount in cash equal to the fair value (as determined in good faith by the Board) of the securities which such Member would otherwise receive as of
the date of the issuance of such securities in exchange for the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Record Ownership</U>. The Company,
the Board and the officers of the Company shall be entitled to treat the record owner of any Interest as reflected on the Share Ledger as the absolute owner thereof in all respects, and shall incur no liability for distributions of cash or other
property made in good faith to such owner until such time as a written assignment of such Interest has been received and accepted by the Company and recorded on the Share Ledger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Dissociation</U>. Upon an Event of Dissociation with respect to a Member, the Company shall have the option (to
be exercised in the sole discretion of the Board within 90 days of the occurrence of such event) to purchase any Shares held by such Member at a price equal to the fair market value (as determined in good faith by the Board, excluding any Manager
that is subject to such Event of Dissociation) of such Shares, paid, as determined by the Board, excluding any Manager that is subject to such Event of Dissociation, in either one lump sum or in installments over a period not to extend beyond the
third anniversary of such event. The holder of any Shares with respect to which the Company has exercised its right of repurchase in accordance with this Section&nbsp;7.9 shall cease to have any rights with respect to such Shares immediately upon
such exercise by the Company. The Company&#146;s rights under this Section&nbsp;7.9 shall be in addition to, and not exclusive of, any other rights the Company may have at law, in equity or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Performance</U>. Each party acknowledges and agrees that each party hereto will be irreparably damaged
in the event any of the provisions of this Article VII are not performed by the parties in accordance with their specific terms or are otherwise breached. Accordingly, the parties agree that the Company and each of the Members shall be entitled to
an injunction to prevent breaches of this Article VII, and to specific enforcement of this Article VII and its terms and provisions (including, without limitation, specific performance or the rescission of purchases, sales and other transfers of
Shares not made in strict compliance with this Agreement) in any action instituted in any court of the United States or any state having subject matter jurisdiction. Further, each party waives any claim or defense that there is an adequate remedy at
law for such breach or threatened breach. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISSOLUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Events Causing Dissolution</U>. The Company shall be dissolved and its affairs wound up upon: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The approval of the Board and the affirmative vote or written consent of a Majority in Interest; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;The entry of a decree of judicial dissolution under <FONT
STYLE="white-space:nowrap">Section&nbsp;18-802</FONT> of the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of Membership</U>. No Member
shall resign or withdraw from the Company except that, subject to the restrictions set forth in Article VII and any legend on any relevant Share certificate, any Member may Transfer his, her or its Interest in the Company to an assignee and an
assignee may become a Member in place of the Member which assigned his, her or its Interest with respect to the Interest Transferred. The death, retirement, resignation, expulsion, bankruptcy or dissolution of any Member or the occurrence of any
other event that terminates the continued membership of any Member shall not in and of itself cause the Company to be dissolved or its affairs to be wound up and, upon the occurrence of any such event, the Company shall be continued without
dissolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedures On Dissolution</U>. Dissolution of the Company shall be effective on the day on
which occurs the event giving rise to the dissolution, but the Company shall not terminate until the Certificate shall have been canceled and the assets of the Company shall have been distributed as provided herein. Notwithstanding the dissolution
of the Company, prior to the termination of the Company, as aforesaid, the business of the Company and the affairs of the Members, as such, shall continue to be governed by this Agreement. The Board or, if there be no Board, a liquidator appointed
with the consent of the Members, shall liquidate the assets of the Company, apply and distribute the proceeds thereof as contemplated by this Agreement and cause the cancellation of the Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Distributions Upon Liquidation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;In connection with any dissolution or liquidation of the Company, after payment of liabilities owing to
creditors, the Board or liquidator shall set up such reserves as it deems reasonably necessary for any contingent or unforeseen liabilities or obligations of the Company. Such reserves may be paid over by the Board or such liquidator to a bank, to
be held in escrow for the purpose of paying any such contingent or unforeseen liabilities or obligations and, at the expiration of such period as the Board or liquidator may deem advisable, such reserves shall be distributed to the Members or their
assigns in the manner set forth in paragraph (b)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;After paying such liabilities and providing
for such reserves, and subject to Section&nbsp;8.4(c) below, the Board or liquidator shall cause the remaining net assets of the Company to be distributed to and among the Members, after adjustment for all Income and Losses incurred in connection
with the dissolution of the Company and liquidation of its assets as set forth in Section&nbsp;6.6(a), </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;In the event that any part of such net assets consists of notes or accounts receivable or other <FONT
STYLE="white-space:nowrap">non-cash</FONT> assets, the Board or liquidator may take whatever steps it deems appropriate to convert such assets into cash or into any other form that would facilitate the distribution thereof. If any assets of the
Company are to be distributed in kind, such assets shall be distributed on the basis of their fair market value, as determined by the Board or liquidator, net of any liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FISCAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Books and Records; Share Ledger</U>. The Board shall keep, or cause the Company&#146;s Secretary, if any, or
another designated Person to keep: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;(i) complete and accurate books and records of the Company on the
accrual basis method of reporting in accordance with generally accepted accounting principles in the United States, which shall be maintained and be available, in addition to any documents and information required to be furnished to the Members
under the Act, at the office of the Company for examination and copying by any Member or Manager, or his, her or its duly authorized representatives, at the Member&#146;s or Manager&#146;s reasonable request and at the Member&#146;s or
Manager&#146;s expense during ordinary business hours and (ii)&nbsp;a current list of the full name and last known address of each Member and Manager, a copy of this Agreement, any amendments thereto, the Certificate, including all certificates of
amendment thereto, executed copies of all powers of attorney, if any, pursuant to which this Agreement, any amendment, the Certificate or any certificate of amendment has been executed, copies of the Company&#146;s financial statements and federal,
state and local income tax returns and reports, if any, for the three most recent Fiscal Years; provided, however, that the Company shall have no obligation to deliver or mail a copy of the Certificate or any amendment thereto to the Members; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;a share ledger which shall set forth the Capital Contribution and Percentage Interest of each Member, as
modified from time to time pursuant to this Agreement (the &#147;<U>Share Ledger</U>&#148;). The Share Ledger is confidential and shall not be available to inspection by any Member or any other party, except as permitted by the Board in its sole
discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Reports</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall prepare and deliver to each Member regular financial and operational reports regarding the
business and operations of the Company. Such reports shall include, without limitation, (i)&nbsp;quarterly management reports, consisting of a balance sheet, a statement of profits and losses and a state of cash flows as of the end of each such
calendar quarter, and (ii)&nbsp;regularly updated budgets and forecasts for the business and operations of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Within ninety (90)&nbsp;days after the end of each Fiscal Year, the Board shall cause to be prepared and made
available to all Members a financial report of the Company for such Fiscal Year, including a balance sheet and a profit and loss statement, and, if such profit and loss statement is not prepared on a cash basis, a statement of changes in financial
position. Within ninety (90)&nbsp;days after the end of each Fiscal Year, the Board shall furnish (or cause to be furnished) to all Members such information as may be needed to enable the Members to file their federal income tax returns and any
required state income tax return. The cost of all such reporting shall be paid by the Company as a Company expense. Any Member may, at any time, at his, her or its own expense, cause an audit of the Company books to be made by a certified public
accountant of his, her or its own selection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Fiscal Year</U>. The fiscal year of the Company shall end on
December 31 of each year or such other date as required by the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Matters Representative</U>. The
Board shall designate an individual to serve as the &#147;partnership representative&#148; within the meaning of Section&nbsp;6223(a) of the Code (the &#147;<U>Tax Matters Representative</U>&#148;) of the Company. If at any time such Person is not
eligible under the Code to serve, is removed by the Board, or refuses or is unable to serve, as the Tax Matters Representative, another Tax Matters Representative shall be designated by the Board. The Tax Matters Representative is hereby authorized
to and shall perform all duties of a Tax Matters Representative under the Code and shall serve as Tax Matters Representative until his, her or its resignation or until the designation of his, her or its successor, whichever occurs sooner. The Tax
Matters Representative (a)&nbsp;shall consult with the Board regarding any notice of proposed partnership adjustment received by the Tax Matters Representative and (b)&nbsp;shall not take any binding action with respect to such notice without the
consent of the Board. The initial Tax Matters Representative shall be Jeffrey M. Fryer. Each Member shall furnish the Company on a timely basis with such information and forms as the Company may require and are necessary to prepare and file the
Company&#146;s income tax returns, to comply with any laws or rules governing the obligations of withholding tax, to allow the Company or the Members to be subject to a reduced rate of tax, and to allow the Company to provide information pursuant to
Chapter 63 of the Code (including to make any election or computation under the Partnership Tax Audit Rules), including information about the direct or indirect owners of a Member, to the extent the Member is reasonably able to obtain such
information. This obligation to provide information shall continue even if the Member is no longer a Member of the Company. Within seventy five (75)&nbsp;days after the end of each fiscal year on a draft basis and no later than September 1st of the
following fiscal year on a final basis, the Company shall deliver to each Member such Member&#146;s Schedule <FONT STYLE="white-space:nowrap">K-1</FONT> and similar state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> forms and such
other information, if any, with respect to the Company as may be necessary for the preparation of such Member&#146;s federal, state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax returns, including a statement showing such Member&#146;s
share of the Company&#146;s income, gain or loss, expense and credit for such fiscal year for federal, state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income tax purposes. From time to time, as reasonably requested, the Company shall
deliver to each Member such information as is reasonably necessary for such Member to determine the taxable income of the Company allocable to such Member for purposes of making estimated quarterly tax payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Treatment as a Partnership</U>. The Members agree that the Company will be treated as a partnership for federal
income tax purposes. The Board and the Tax Matters Representative shall not cause the Company to file, and the Company shall not file, a federal tax election under <FONT STYLE="white-space:nowrap">Section&nbsp;301.7701-3</FONT> of the Treasury
Regulations to treat the Company as an association taxable as a corporation for federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Management Agreement</U>. The Company may engage Rallybio to perform some or all of the functions described in
this Article IX. In the event the Company engages Rallybio to perform such functions, Rallybio will be reimbursed for its reasonable and documented costs and expenses in accordance with the terms of the management services agreement as between the
Company and Rallybio which is being entered into on or about the date hereof; provided that the payment of any fees and expenses under such agreement (exclusive of payments to third parties providing services on behalf of, or for the benefit of, the
Company) which exceed $40,000 per month shall be approved by the holders of a Requisite Interest. To the extent Exscientia performs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services for the Company beyond the scope of what is contemplated under this Agreement, Exscientia and the Company shall use commercially reasonable efforts to enter into a similar services
agreement with Exscientia. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Except for notices of meetings of Managers and Members, notice of which shall be given in the
manner provided in Sections 5.2(g) and 5.5(c), respectively, any and all notices under this Agreement shall be effective (a)&nbsp;on the fourth business day after being sent by registered or certified mail, return receipt requested, postage prepaid,
(b)&nbsp;on the first business day after being sent by express mail, receipt confirmed telecopy, or commercial overnight delivery service providing a receipt for delivery, (c)&nbsp;on the date of hand delivery or (d)&nbsp;on the date actually
received, if sent by any other method. In order to be effective, all such notices shall be addressed, if to the Company, at its principal business address identified in Section&nbsp;2.4 of this Agreement, or, if to a Member, at the last address of
record on the Company&#146;s books. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Word Meanings</U>. The words such as &#147;herein,&#148;
&#147;hereinafter,&#148; &#147;hereof&#148; and &#147;hereunder&#148; refer to this Agreement as a whole and not merely to a subdivision in which such words appear unless the context otherwise requires. The singular shall include the plural and the
masculine gender shall include the feminine and neuter, and vice versa, unless the context otherwise requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Binding Provisions</U>. Subject to the restrictions on Transfers set forth herein, the covenants and agreements
contained herein shall be binding upon, and inure to the benefit of, the parties hereto, their heirs, Legal Representatives, successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Applicable Law</U>. This Agreement shall be construed and enforced in accordance with the laws of the State of
Delaware, including the Act, as interpreted by the courts of the State of Delaware, notwithstanding any rules regarding choice of law to the contrary (provided that, as set forth in Section&nbsp;5.8, to the extent not inconsistent with the specific
provisions of this Agreement, the Act or the Certificate, the authority of the Board shall be determined by reference to the Delaware General Corporation Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts; Electronic Signature</U>. This Agreement may be executed in several counterparts and as so
executed shall constitute one agreement binding on all parties hereto, notwithstanding that all of the parties have not signed the original or the same counterpart. A facsimile or other electronic signature of this Agreement shall be treated as an
original signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability of Provisions</U>. Each provision of this Agreement shall be considered
separable. To the extent that any provision of this Agreement is prohibited or ineffective under the Act, this Agreement shall be considered amended to the smallest degree possible in order to make the Agreement effective under the Act (and, if the
Act is subsequently amended or interpreted in such manner as to make effective any provision of this Agreement that was formerly rendered invalid, such provision shall automatically be considered to be valid from the effective date of such amendment
or interpretation) and considering the intent of the parties hereto and the bargained for consideration or benefits to be received by each party hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Section Titles</U>. Section titles are for descriptive
purposes only and shall not control or alter the meaning of this Agreement as set forth in the text. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments and Waivers</U>. Except as otherwise specifically provided in this Agreement, including, without
limitation, Sections 3.8(b), 4.1, 5.6 and 5.11 of this Agreement, this Agreement or the Certificate may be amended and the observance of any term of this Agreement or the Certificate may be waived (either generally or in a particular instance, and
either retroactively or prospectively) only by written approval of a Majority in Interest; provided, the sections of this Agreement that require the approval of a Requisite Interest, including, without limitation, Section&nbsp;5.6 may be amended and
the observance of any term of this Agreement in said sections may be waived (either generally or in a particular instance, and either retroactively and prospectively) only by written approval of the holders of a Requisite Interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Reorganization into Corporate Form</U>. Subject to Section&nbsp;5.6, a Majority in Interest may effect a
reorganization of the Company into a corporation (a &#147;<U>Successor Corporation</U>&#148;) by whatever means such holders deem desirable, including by causing the Members to exchange their shares for capital stock in a newly formed corporation;
provided, however, that it shall be a condition precedent to such reorganization that in connection with such reorganization (a)&nbsp;that each Member&#146;s relative percentage ownership interest of the outstanding common stock and preferred stock,
if any, of the Successor Corporation immediately after such reorganization is such Member&#146;s relative percentage ownership interest in the Company immediately prior to such reorganization (giving effect to all preferred returns contemplated
herein) and (b)&nbsp;the relative preferences, powers, rights, qualifications, limitations and restrictions in respect of the outstanding common stock and preferred stock, if any, of the Successor Corporation immediately after such reorganization is
the same as the relative preferences, powers, rights, qualifications, limitations and restrictions in respect of the Common Shares immediately prior to such reorganization, including with respect to liquidation preferences and any accruing
distributions. In such case, all Members shall provide all necessary cooperation, including, without limitation, the execution of any documents (including any voting agreement) or filings that may be required. All Members will work together in good
faith to accomplish the reorganization in the most <FONT STYLE="white-space:nowrap">tax-advantageous</FONT> manner reasonably available. The Company and the Members shall use commercially reasonable efforts to cause the conversion to be structured
on a <FONT STYLE="white-space:nowrap">tax-free</FONT> basis, and to the extent requested by any Member classified as a corporation for U.S. federal income tax purposes, to cause the converted corporation to combine any such requesting Member with
the converted corporation on a <FONT STYLE="white-space:nowrap">tax-free</FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Third Party
Beneficiaries</U>. The provisions of this Agreement are not intended to be for the benefit of any creditor (other than a Member who is a creditor) or other Person (other than a Member or Manager in his, her or its capacity as such) to whom any
debts, liabilities or obligations are owed by (or who otherwise have any claim against) the Company or any of the Members or Managers. Moreover, notwithstanding anything contained in this Agreement, no such creditor or other Person shall obtain any
rights under this Agreement or shall, by reason of this Agreement, make any claim in respect of any debt, liability or obligation (or otherwise) against the Company or any Member or Manager. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Irrevocable Proxy and Power of Attorney</U>. Each party to
this Agreement hereby constitutes and appoints as the proxies of the party and hereby grants a power of attorney to the President and Chief Executive Officer of the Company, and a designee of the Electing Members, and each of them, with full power
of substitution, solely with respect to the election of persons as members of the Board in accordance with Section&nbsp;5.2 and votes regarding any Sale of the Company pursuant to Section&nbsp;7.7 (excluding the initial vote by the Members described
in the first sentence of Section&nbsp;7.7(a)), and hereby authorizes each of them to represent and to vote, if and only if the party (a)&nbsp;fails to vote or (b)&nbsp;attempts to vote (whether by proxy, in person or by written consent), in a manner
which is inconsistent with the terms of this Agreement, all of such party&#146;s Shares in favor of the election of persons as members of the Board or approval of any Sale of the Company pursuant to and in accordance with the terms and provisions of
this Agreement or to take any action necessary to effect such terms and provisions. Each of the proxy and power of attorney granted pursuant to the immediately preceding sentence is given in consideration of the agreements and covenants of the
Company and the parties in connection with the transactions contemplated by this Agreement and, as such, each is coupled with an interest and shall be irrevocable unless this Section&nbsp;10.11 expires. Each party hereto hereby revokes any and all
previous proxies or powers of attorney with respect to the Shares and shall not hereafter, unless and until this Section&nbsp;10.11 terminates, purport to grant any other proxy or power of attorney with respect to any of the Shares, deposit any of
the Shares into a voting trust or enter into any agreement (other than this Agreement), arrangement or understanding with any Person, directly or indirectly, to vote, grant any proxy or give instructions with respect to the voting of any of the
Shares, in each case, with respect to any of the matters set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement</U>. This
Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior written or oral agreements and understandings relating to such subject matter. The Members and
Managers hereby agree that each Member and each Manager shall be entitled to rely on the provisions of this Agreement, and no Member or Manager shall be liable to the Company or any other Member or Manager for any action or refusal to act taken in
good faith reliance on the terms of this Agreement. The Members and the Managers hereby agree that the duties and obligations imposed on the Members and Managers as such shall be those set forth in this Agreement, which is intended to govern the
relationship among the Company, the Members and the Managers, notwithstanding any provision of the Act or common law to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.13&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver of Partition</U>. Each Member agrees that irreparable damage would be done to the Company if any Member
brought an action in court to dissolve the Company. Accordingly, unless otherwise expressly authorized in this Agreement, each Member agrees that he, she or it shall not, either directly or indirectly, take any action to require partition or
appraisal of the Company or of any of the assets or properties of the Company, and notwithstanding any provisions of this Agreement to the contrary, each Member (and his, her or its successors and assigns) accepts the provisions of the Agreement as
his, her or its sole entitlement on termination, dissolution and/or liquidation of the Company and hereby irrevocably waives any and all right to maintain any action for partition or to compel any sale or other liquidation with respect to his, her
or its interest in, or with respect to, any assets or properties of the Company; and each Member agrees that he, she or it shall not petition a court for the dissolution, termination or liquidation of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.14&nbsp;&nbsp;&nbsp;&nbsp;<U>Judicial Venue</U>. Except as specifically set forth in
Section&nbsp;5.13, any legal action or proceeding with respect to this Agreement shall be brought only in the courts of the State of New York located in New York, New York or of the United States of America for the Southern District of New York, and
by execution and delivery of this Agreement, each Member hereby accepts the jurisdiction of the aforesaid courts with respect to any such action or proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.15&nbsp;&nbsp;&nbsp;&nbsp;<U>Jury Trial Waiver</U>. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION
BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE SHARES OR THE SUBJECT MATTER HEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE <FONT STYLE="white-space:nowrap">ALL-ENCOMPASSING</FONT> OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT
RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH
OF THE PARTIES HERETO AND THESE PROVISIONS SHALL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND
VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.16&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>.
Each Member agrees that such Member shall keep confidential and shall not disclose, divulge or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of
this Agreement, unless such confidential information (a)&nbsp;is known or becomes known to the public in general (other than as a result of a breach of this Section&nbsp;10.16 by such Member), (b) is or has been independently developed or conceived
by the Member without use of the Company&#146;s confidential information or (c)&nbsp;is or has been made known or disclosed to the Member by a third party without a breach of any obligation of confidentiality such third party may have to the Company
of which the Member is aware; provided, however, that a Member may disclose confidential information (i)&nbsp;to its attorneys, accountants, consultants and other professionals to the extent necessary to obtain their services in connection with
monitoring its investment in the Company; (ii)&nbsp;to any prospective purchaser of any Shares from such Member, if such prospective purchaser agrees in writing to be bound by the provisions of this Section&nbsp;10.16; (iii) to any existing or
prospective Affiliate, partner, member, stockholder or wholly owned subsidiary of such Member in the ordinary course of business, if such Person agrees in writing to be bound by the provisions of this Section&nbsp;10.16; or (iv) as may otherwise be
required by law, provided that the Member promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.17&nbsp;&nbsp;&nbsp;&nbsp;<U>Publicity</U>. The Members agree that either Member may issue, itself or jointly with the other Member, a
press release promptly following the Effective Date in a form agreed upon by the Members, a draft of which is attached hereto as <U>Schedule B</U>. Neither Member shall use the name, insignia, symbol, trademark, trade name or logotype of the other
Member or its Affiliates in any publication, press release, promotional material or other form of publicity without the prior written consent of the other Member, except for those disclosures made pursuant to this Section 10.17. Rallybio or
Exscientia may publicly disclose any information previously contained in any press release or announcement approved by the other Member in accordance with this Section 10.17 without a requirement of
<FONT STYLE="white-space:nowrap">re-approval.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.18&nbsp;&nbsp;&nbsp;&nbsp;<U>Aggregation of Shares</U>. All Shares held or acquired by
Affiliated Persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and the exercise of any such rights may be allocated among such Affiliated Persons in such manner as such Affiliated
Persons may determine in their discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.19&nbsp;&nbsp;&nbsp;&nbsp;<U>Further Assurances</U>. At any time or from time to time after
the date hereof, the parties agree to cooperate with each other, and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further action as the other party may reasonably request in
order to evidence or effectuate the consummation of the transactions contemplated hereby and to otherwise carry out the intent of the parties hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.20&nbsp;&nbsp;&nbsp;&nbsp;<U>Delays or Omissions</U>. No delay or omission to exercise any right, power or remedy accruing to any party
under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such <FONT STYLE="white-space:nowrap">non-breaching</FONT> or <FONT STYLE="white-space:nowrap">non-</FONT>
defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a
waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any
party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.21&nbsp;&nbsp;&nbsp;&nbsp;<U>Rules of Usage</U>. In this Agreement, unless a clear intention appears otherwise: (a) the singular number
includes the plural number and vice versa; (b)&nbsp;reference to any Person includes such Person&#146;s successors and assigns but, if applicable, only if such successors and assigns are not prohibited by this Agreement, and reference to a Person in
a particular capacity excludes such Person in any other capacity or individually; (c)&nbsp;reference to any gender includes each other gender; (d)&nbsp;reference to any agreement, document or instrument means such agreement, document or instrument
as amended or modified and in effect from time to time in accordance with the terms thereof; (e)&nbsp;reference to any law means such law as amended, modified, codified, replaced or reenacted, in whole or in part, and in effect from time to time,
including rules and regulations promulgated thereunder; (f) &#148;hereunder,&#148; &#147;hereof,&#148; &#147;hereto,&#148; and words of similar import shall be deemed references to this Agreement as a whole and not to any particular section or other
provision hereof; (g) &#148;including&#148; (and with correlative meaning &#147;include&#148;) means including without limiting the generality of any description preceding such term; (h) &#148;or&#148; is used in the inclusive sense of
&#147;and/or&#148;; (i) with respect to the determination of any period of time, &#147;from&#148; means &#147;from and including&#148; and &#147;to&#148; means &#147;to but excluding&#148;; (j) references to documents, instruments or agreements
shall be deemed to refer as well to all addenda, schedules or amendments thereto; and (k)&nbsp;section references shall be deemed to refer to all subsections thereof, unless otherwise expressly indicated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page(s) Follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties hereto have executed this Agreement as of the day and year first above written.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP><B>RE VENTURES I, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey Fryer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>By: Jeffrey Fryer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>Title: Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP><B>MEMBERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP><B>RALLYBIO IPB, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey Fryer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>By: Jeffrey Fryer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>Title: Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP><B>EXSCIENTIA LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Georgy Egorov</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>By: Georgy Egorov</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>Title: Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to RE VENTURES I, LLC Operating Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RE VENTURES I, LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Common</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Initial&nbsp;Capital&nbsp;Contribution</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value of</B><br><B>Initial&nbsp;Capital<BR>Contribution</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B><br><B>Interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Admitted</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rallybio IPB, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1,250,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The cash consideration set forth in Section&nbsp;3.4(a) and Section 3.4(c).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&pound;1,250,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">50%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;19,&nbsp;2019</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exscientia Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1,250,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The cash consideration set forth in Section&nbsp;3.4(a) and Section 3.4(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&pound;1,250,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">50%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;19,&nbsp;2019</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g99471g01k65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g01k65.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1= 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %R2^620X0DE-! 0      !D< 5H  QLE1QP"   ".HT< @4 !5!R:6YT
M #A"24T$)0      $&WL@;C9!'*,$ AL'"C%O<DX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <@            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ " [_^-0 "  (X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              ".   !Y0
M   !                          $              >4   ".
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   ".     %)G
M:'1L;VYG   !Y0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    C@    !29VAT;&]N9P   >4    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M8GZ#&?X2QW\VQ"<0>$Q'S=%.PDO*C]=_KGU&]YP"6AO-&)C^L&C_ (1]
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%S)"(U)Q@1@9&BABD:$D)2<I-T-4L7?1X?_$ !P!  $% 0$!
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MV+6)FH@XR"DTPHN(.$H(*9LQR@EH4022T_/XJ^%:YFIY"2S*H]YD9FNMV1M
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M5L??JIOO^^;;<.>^W=_*(>0[<^H>L7"<38^W53IO^<V^W/<!';?O#U >@<P
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MP\4@HLHY=,(V29)-G,[@.(*6 <]35./=C74\JW(!D(!.I"JH+L;  \CC+D]
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M1Z?_ +]^W.#/U#7_ ,14_P#;18Y3_!_J-]KVL+]!?0=SU'6V'9!Y@(#L(#N
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MAKR^( =00'92 %C&O+O]WK>]_L[8^1T.CMQ\>)0&X\\:H!ON CR?X7VYB/\
M]CY<^SN;?L?D7^>?Y51_'G;'7_0Q^HZ_XOE^#CYC65/37#'XL=4UZ2L'+2&F
M+514&6+,T3,0R6>_*5@:L(6+=+*HM_%'WQ!.H5.[1Z!P*YGFC2WQD60[IL82
MN98BY]PY)E"N@K\NE:II$8@&5"7:PO;3Z62(D7"DQLVAUZEI(BG[RW(^K6^W
M;3RUOO?#$..\RXFRU36&0\:9(IMXI,FS3?-;+7;%%R46#<Z7BF!TN@Z'W!PW
M)]+QF^(V>L5BJ(O$$5DU$RXJ>EJ::5H:B"6&538QR(RM?;0$:@]"+@[@D8CE
M6!L00?3?T[_5A=;B\:JXO6[8L:<+_1S-Q^5[UDS(T!(9DM=2=)S=/IL#6'99
M!**?3L<=>,=IP[TA;=<7C1THV@6M;;1JJJDI(KL6>VX;R]LJCGX@S-33PP0.
MM+'*.66620<O,J'WAS"\<8(NY<L!RK<OQ+R7D;0 :7W]=>^P'6Y'479&QC1(
MG%N-L>XR@3*G@L=4>IT2%,OMXQHFHP,?7XXRNPB'BBSCT14V$0[XCL(]L//,
MU1/-.]N>>629[;<TCEVMY78X8)N23U)/SP&O'?#7TCX\XF<UJ>C=0UT>:A7F
M1\E94<8=E%ZNWA2R>5(.PNI)BU(2OMY9RQCXVXNI&.21E5GAF[=%1RHL5!SO
M=S\62SY8,A,5,JI!3P<P,OC%8/#=3J_(6944L -BQ  VIO[69 V<-PS^=:(9
MXD:L<L:4I5E? 2H!1&Y1(3 PFY4+'DYFMRH]C@&#Z0'?<0[O3[B'GW>6_,1-
MRW';;8-^V?Q<8%=Q2-#.G/632<7O]1F6[#AN&Q38;":"L=?6@$COW5X:13=]
M#."SL/*BMXORVQ>HIL4B*@5HNLMWD4Q.E<93Q#+P\:B6-('6I$:.)^>P,9<I
MR^&RDFS-<:Z:],5^:9_E/#E&U?G5?2Y=1F2.$5%5*(D,S\Q2--"7=E5VY%5C
MRJ[V"JQ%Q,"X?QU3M,.+,'1<C^*F*X'$E;H$;(7)BPDT[O1VT A%,33D<=@W
MC'K25A@237;&8)LUFJ@)"EW!$#0)ZYZNKES!"(I*B9JE3"64([MX@,9)YUL3
M<&]^M\2J6MI\PIZ>OHY5FI:R&.IIIX[\DL$R"2*5"0IY71E9387!!M8X$1F3
MV<S0YDFUO[12+#EO"J4F[4=N:G2YJ"EJBU.L(JJDAF-KKTQ*Q2)CF/X;4DTN
MQ;$$J3)FW03(D&II>-\WIXQ',E-5\HL))D=9#VYFB=%;U*@GJ2=<31.X%B ;
M"VUC]?3[-.F-R8RX$N@_&F)LBXQ2A+S:);*$"A7+%E6RS\6ZR-%Q"$M&39F5
M,=MZ\A7:FF[>1;=-^M'UX\@_8&682+YRU4\,L6HXNSBHJ8*@O%&M._B)31HP
M@9N4K>4%R\A 8VYGY5/O*H..&9R0=!;H!8'UL;GYCON!BY^B;0IA/030[;CO
M!SBYNH.YV\;I,K7B=:SLB$M\&C(0J+1=C$PB"#%-E%H&*B9LJL9=1<YW)R"D
MFG5YKF]7G$T<]6(@\47A+X2%%Y>=GN068EKL;FX%@+ 80[ER"0!;L+?><:Z:
M<+O2JRUA&UQH1EW+G,]J>7(RXW!T:J?''];7J[E<*\+78$3Q[A54&_OGAD>&
M!4H>$ ( \<_S$Y9^:2\7L?AB*WA#Q.02"0#Q+WOS#>VVF.^(W+R6%K6VUM\_
MMM]^,M4?"\TK:PLRU#.V9HN[O+Y28.OUR&4KMQ=040>+K%BE;1')O8Y)LN"Z
MOQ&9? NL5=(RS<Z:0"F*95 ,OS_,<LI9:2E:)89F=W#Q*[<TB*C68FX]U18=
M#?N<"R,@(%K;Z]/37%Y;U?Z/B^K2EWR1<*O0J;"D;'F+5<)N/KM>C".W*#%G
M[]+RSQHP:F=/7+=HV*LN0R[I=%ND"BJI"&JH89JB188(I)I7ORQQ(SNU@2;*
MH)-@"38: $X0 2; 7)Z#"-G&VU58ZU_:M<+XPTMIER@%%BSXVB[976BRJ>0K
MW>[&R$L)5U%"$6E8.)708LV$F!2,WDE(2Z[$RL<5!\Z]9X4R^?)LMJZG,/[O
MXQ$[1N=8888V]^0:\KM<DK\0"J#J2!+B0HI+6%S?IH -;GU]0!<]\.2:,=/,
M?I3TMX4P"P]U47QY1XV/L#QH7NH2EOD!/,W.63$!*)TY*TR,N[0$_P!?NZJ)
M!-] %#S#-*ULQS"JK&N/'E9D!_=C%EB7_3&JCU&(KMS,6[G3TZ>F+/E$=^?=
MZ!Y"([[[EZG\@W$>@\M]AZ]H&$X&)K.X1FCO6Y.C>K_6IRA93.1%-UD_%<@P
MK=EFB()%2;_,[9]'2\#8E&Z:::*,C(1)YE-LDFT2E$FR::9+[*^),SRI/"AD
M6:G%[4]0#)&I)N2A!5TN=2JL%N2>6Y)PXLK*+;CL>GIBJF&_9X]$>-[C'7*_
M3V7,^*Q"Z;EC6<EV"&)3U%6Y@40"6BJU"0[Z813.!1-'O9<T4Z(!DGC!R@<Y
M!L:KC3-9XFBA2FH@XLST\;>)8BQY6D9PI_\ D%YAT(PMIV.P O>YZF_V;Z[=
MNV#K145&047'PD)',(B&B&36-BHJ+9H,(V-CF**;9FR8,FOA-FC-JW330;-T
M$TT6Z1"IID(0@ &29F=F=V+,Q+,S$EF8FY))U))U).I.&-]\5>QYHMP;B_4]
MEW5S48N?:YAS;!M:]>G3J?=/*^NQ;'@#B>-@U0!./=.CUF)4<*D7.0PI*>"D
MB"ZA33YLTJYZ"FRV1D-+2N7A 0!P3SZ,^Y YVL+#?6]L++L5"FUEV[]?ZG&\
M\G8MQYFFC3V-,K4Z OE$M#,6,Y6;''IOXU\EW_$24\-0W?;/&:I$W#%\T.B^
MCW2:3MDX;N4DU"1(*B>EE2>GE>&:,W22-BK*=CJ.A&A!N"+@@C"02IN#8X!)
M;O9N-&,S87LG4<GZA,=U^0<F77IT+:*O*Q+9(YA/[G'/I^JR$P1J0/H2&5?S
M#@H; =PH(;AK8^.,T5 LL%%.Z@ 2O$ZOIU(20+?O95%];#J]X[=0">IUUP3_
M $<</?2_H6@7T9@FBBUL,TW*VLN1;0Y)8,A61!,2J$9R$^=)L1G&%5(1<(2#
M91,,9<I7)V!G("OVH<SSK,,W<-6371#>.&,<D,9.A*H";L1NS%FZ7MIAMY&?
M<Z=!TWOB\A>@?P#_ -=JK",4JU3Z1FN=W$1>Z9.GQ_F:H>">L7%L=9!%Z1FL
M+EE'S*K$??T :.C&6CI=F55Y&F57(+9Z@<K<L*KI!/:2-N29?A:Y -M1S$7(
M(.S $C8@Z6\L_*)^36'C%J3.,KK6R3BO*@K9=FL1=!((F,D4%4T-IE$<A+05
M,7-+3EG^CF0^&-!1]ZXG--9_+\IB'&60%V1?=VMM=3]69KR0)[%([71;7^M$
M6[X% 0%6#BUS 8PJI@H8P]F%?,D'*T<;6!L[%23;K[LJ]-=5![B^,9!G/_$#
MED1HI^%^'L[>$>&F9O79?"]1:P65T3.LO#<WG1TSG4LH)OCS5[2CJ%U&W.$O
M6LF>CX^J5MU[W"8AK#MBHS5.)RG51>*PSMY&,6+KN)D>.R2TY/R#4#L3/HU,
MJ*H"TM142*]6UE4Z1 KKKJ/<]U5.Q/,SD:7!%PW1?DZXVXZS6DS?\J=;!!EM
M!+XM'POELL1A9K@E9VII)J>.%^51)(*FKK9HRT/C4ZA3@I+=BFS;H-&C9%LV
M:H(MFS=N5-%!N@B0$DD44DRD(FDBD4I$TR 4I$RE(3NE#N=K0  6 L!H -@.
MV/HA$2-$CC14CC541$4*B(H"JBJ  JJH 50    !;'<"*GF0.H?J+^[MZ=.F
MX?YE,'+L85CCP5/W Z&_44>NP[<P'GOTZA]PY=C!C($E.8=T0]-CA]O00Z^>
M_/EU'GN8,9>$I]_+]?KU\_(>G7TV$!'L8,0$U/\ %Y_JY\N8?J]>O/[=.Q@Q
M4;71I1+K5TQY#TX+W=7'*=\5JJPV]*OIVL\6-9ML): *$$I.5XKP'GP<66_Q
M=H+?WGWG]OX7@*V649B<JKX:X1"<PB0>$9#&&\2-X_C"O:W->W*;VMI>X6C<
MC<UK^5[8IKH%X+6FG0M9D,GHR,]F?-+1NLVBL@75E&QT=4B.DCMWB](J+ [I
MO"2#QLH=JO+R,I/2Z;8ZS:.?1[=T]1=6><<4YAF\9IR$I:4D%H82Q,EB"!-(
MUBX4@$*%1;ZE20+*>5G!%@H/0?ROV_'7!@Q34_Q"(\Q^H.N_+]7GYA_J/,.V
M:PUC(J9_,3!R /S<N8[FWV-T]/\ T/7L8,<]PW+KU 1YCY!L&WU^7\=A]-^8
M&#$[AOOT'GWAZB'7\_\ +IN'4!$.Q@Q!(;[] V^H>@;<OSA_+R]0[&#$[AON
M/U"/4?,>0_G\@ZAN'3EMT[&#$!,WW#EW>H^NX\^\/(>OKZ[^1@Q.X;<.H<RC
MU$>@;?O]0'GZ?8!Y@8,02&^^_P!7/<>I@#G^<!^P^?H/GV,&.\.@>7+IZ=C!
#C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g99471g09q91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g09q91.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &.:^8W0X0DE-! 0      !@< 5H  QLE1QP"   "'C@< E  !$=E;F$X
M0DE-!"4      !#<!!K(X,(#P[5'R-$D7+3M.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             "[P  !V0
M 0                         !              =D   "[P
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "[P    !29VAT
M;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M^9-7O9O\P?\ '@]4V[$>PV,<QS&D%S@. 9CLI568]T^B6V1SM$_P_E+D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJREEZTY@""19@R[1LZY2.4$5-8'.8PW#CFP9K"<KM7W61,K1=>3NC=+4V9B
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M@QDZARY<@;,E'KUBX7DQ%D1=B05&G@ 0JJEU=[WP\(5E8R7S @AF%X\E@BJ
M0$!4,\V^3G//Z':3RUZ;L<9C<$"%&LP?QYQ0\^)6RFL\DTF:&6B,R;G8FTI
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MC?-J>N)P_P"SCA?WR:9\]IV=<V]^#)_CY*?2FG2CP4[&.#W<71OFU/7$X?\
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M$)CZ_*749C(9!%88+&WPV?+"[Y_-&0T@!QTYF+*+.X0UR!<S+L796&JR2DA
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MI2FE*Y$[W_[0#3\SL&^>N5M?0Z,_F9^$S?NL/4<9YAXVK?O%!46"$9E-&R3
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M;[^5>QK=QJ7TN4K3CY-M;ZVV4I92VE%*LO,DB[LW_@8#YAI2G,DB[LW_ (&
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M>9)%W9O_  ,!\PUCU:G,DB[LW_@8#YAI2G,DB[LW_@8#YAI2G,DB[LW_ (&
M^8:4IS)(N[-_X& ^8:4IS)(N[-_X& ^8:4JKPD.?OB4>O3E[Y%.X6UK8E:)!
MWVIVUL]RREZC*Z^ZE*>YQW75K7\-=*5:.9)%W9O_  ,!\PTI3F21=V;_ ,#
M?,-*4YDD7=F_\# ?,-*4YDD7=F_\# ?,-*4YDD7=F_\  P'S#2E.9)%W9O\
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MPFP8$SD_+LXU+658HJ0NDSJ$P^4*%(QTNL;\9J1!UF;00D,<M32OD]15*/\
M\?")EP4FD5P^KE+/A%0R1'6!=6)98\LFJOUB,"6+!D$&.W](7REK6-\N\;;6
M)(L>T#?EK5;9-PB\^7A(*3;GS;^3QB6NL'1M?)5@R+@@V.I%,-IHC,BZ\D9
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MB1 F'C6-W#2/# 2\SLXU2/)*%+)K;2"0B)(E2\9=UR 38 =NPWF^P7X]NWB
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M.!1:W&@N1/VZE%4Z&G:ZUB5:(-ZVV]59S)([ -K$F3*SN50S32REUV[&76E
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MN%92C95#JPS N7M[NUN]/CJGW[43 T8Y'P?+"T!N:7'BL+OC\&$V(0.4SF\
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MWGVU[)5A3#4Z;U:3?$F,IDTK(5Y;5K*H%%9"WK*W3%(6YDU42XIXG60N!J"
MY<UR><E6**311S<W3L3MB/$XB(WBQ$T9R:N\<LB'("6"75@<@8DY=UR3:]+
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M=*4TI32E-*5593_2C7^*A?[)YI2K5I2FE*:4II2FE*Y9[3_?+^%?_P"78W_
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MZ4J;TI32E-*4TI4&;^Z&_+C'_L<:4J<TI32E-*4TI32E<R=K7OC?"F?]$O\
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M^ZPWU>)-N)WFPYR:F*#\V?8M<RS^(#H!)\1,8Y'Q\</;'8OFZ%E)L2!QPG.
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MP*[!LDA9;9IY0QOE4AT)011HH:+-E!C"A18LV8%>N).:Y)I4"GA'#;J*R2,
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M^^ZY8Y*PXXM8XOK<X%7M^M0RHYBJLV4HT\KA@S AC"6&5;'H>,Q1;@-BH2I
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MFE*:4II2N8>[+_?Q7\T<"^>65]?0Z,_F9^$S?NL/4<9YAXVK;5:Z7VPW<C=
M:.:S2F0LJ5C-&- ]Q+G>B#7K3FBV1\<<N,\O[S6R*E8_<4ZTH<I475WK*_-Z
M_"ZZVJU<&>^;+EXPV3K\O_=DZ_+?+UUJFL:7R^31*EZ^*Q^;UHB];**%266L
M<YKRR]:RMFU4>#@46B$ID$:S"W2DR*ZJ4CE),I?B:/K!X\,CJ0X@>DY@?WU<
M<G\X;#:P&RKAYL-AP8R;%Y)$1X#DM=(U77N&=G-E16CFOQ[3<[CSWYJ@<CY;
MW9P:$SF?TA<"O1B4-:RGHC6&2DBO8[KD(S&CPV^9-LCL6)%E$X0P;9!>$T(T
MPH487W*6)BF*]EZ%X</HZ66*'6S?G'*:W6(!;4HZMJS"2#)*QA"ESE(VEB-L
M7(N=EAQ=J_+MXMN[M6K[Y'D_<[:A0W#(@Q/MF3=0<L3D>,,M8_9,KRY&%7EG
M+O%Z#R=3^5NHI91TW"E8Y8LU)MRT@5&MB[2*D'D@)!@+99'9"2&RI/AYF.59
M<H6<B**,2;"ROM5E0,5,@RKML//Q;MUM@))._=\=J^T;DC>&Y EY"^A,"17%
M-2;UE%F..LAWO).D+QM Y4Q1&E3<Y!$@SJ4RT[*(NBU*PUP\CJP:X4Z:E20Y
MV]>5,.CLZH));,5!D::*T>::6,DJL3*XCC1'-I5#ALP*JP GKMN[FY=@X[\M
MQN[=>.'Y-WG22]PU.03&D.=6\M1QR8+EL_8 ?MXO.R+F-N5S9+'@666VR -#
MQ+>90@^;C1*TL]ZQ5K4F,5%3+#HV.Q22>4<7YW#IG!>(*XR+,T?6-(QBE17!
M47W'- S=KM[#LWWX]O%M%;+8>,3TR!.+Y&MHW.IRX_1H-MB):,4#Q]VXM)1T
M1U\1>O6<PO8!WS1NO*0E&;%9Q8L)>L6QX28LUX\2L*NFHVH8H\S:Q7S2!;2-
ME"@QW<'K&N?Z0)1EJ1?CWW].?G^NM;9=2M>$OP#2E..M=D>Z[BI3W:_[\=GW
MX->N/VFQG]I:/_AM(T.\<_U&M[N1?^+=^C7Z-9=33D7_ (MWZ-?HTI3D7_BW
M?HU^C2E.1?\ BW?HU^C2E.1?^+=^C7Z-*4Y%_P"+=^C7Z-*4Y%_XMWZ-?HTI
M7-3"5MWMIF_BG)KQTVY[&N.G%7CIQNMQ_%QT_P".MG$^T>B_AND_\.!JH]DW
MQ>*NE?(O_%N_1K]&L:K4Y%_XMWZ-?HTI3D7_ (MWZ-?HTI3D7_BW?HU^C2E.
M1?\ BW?HU^C2E:-Y,MN]L/VB4Y->.NV#>U6E.*O'6E)YLQXZ\6M2#VGTA\.T
M9^ZTC5?Z7[/UUME(L=0N6@W$:DD5$F 3HFJ97&.V=MS>\JX=KOG)"E+>1?8Z
M=N'3NKQ5.^VYVB\>MG/56SQRBKX$FE1PZ2,KA0H8';E   Y@ +7W6!&T"UK#
MDJG6;>,)V*O5K<60_JC\:B'6K<%0OM3%H,Z,4F+).^VY,:A:A;9?=:.M:UO=
MV6$%*W/[+'-O3HS%6 U\M@<PZX[[WN>4\6V_6];['946')VO3Y:M +%T!C+5
MJS!0\.-09NF;]#J#*ERW.+!T4?-B2[E7JCET2M?G#+]0BZ56>N'Q4@\<KJN7
M:ZM_-YY9"2\C,2"#<\1"BUAL LB@ ; %    I8<@J]\B_P#%N_1K]&N533D7
M_BW?HU^C2E.1?^+=^C7Z-*4Y%_XMWZ-?HTI7*79Y#8Q*]UW"JTD0(<9JSW;8
MRHA1^UL<50ZIM'P)6_D4OMK6RMW)MX_N<=*:VM)#_@-!'_\ PSC_ /[\5_K4
M<9VVV#DY6Y0:Z(]AO&7<''O!B/\ DUBTL>4^#[*=AO&7<''O!B/^32ECRGP?
M93L-XR[@X]X,1_R:4L>4^#[*=AO&7<''O!B/^32ECRGP?941(,.XSM!&;J06
M/VUH,?5I=08CQTK1LI7C]VS2ENV3SV^RI?L-XR[@X]X,1_R:4L>4^#[*=AO&
M7<''O!B/^32ECRGP?93L-XR[@X]X,1_R:4L>4^#[*=AO&7<''O!B/^32ECRG
MP?94D*QG!0;Q-^)B(4>\2X^IN6P])-:SC]RO)OI9QTTI;MD_)]0%3*UEW2<9
M_-N^\)S_ .FO;"._\-*FI[D7_BW?HU^C2E.1?^+=^C7Z-*4Y%_XMWZ-?HTI3
MD7_BW?HU^C2E.1?^+=^C7Z-*5"1ZV[F]7^;=]]Y#^"OX) 3I7\'X*Z4J;Y%_
MXMWZ-?HTI3D7_BW?HU^C2E.1?^+=^C7Z-*4Y%_XMWZ-?HTI4&;MNXPW\V[[^
M,?P5_$<?\-*5.<B_\6[]&OT:4IR+_P 6[]&OT:4IR+_Q;OT:_1I2G(O_ !;O
MT:_1I2G(O_%N_1K]&E*YD;6;;O;'.%,IR:\=/82\=.*O'3CPA).+CI^#C_!K
M<Q_M-H+^\_XB*JCV3?L^*NF_(O\ Q;OT:_1K#JU.1?\ BW?HU^C2E.1?^+=^
MC7Z-*4Y%_P"+=^C7Z-*4Y%_XMWZ-?HTI3D7_ (MWZ-?HTI4!%;;NC87^;=][
MFWX*_P#\=/\ AI2I_D7_ (MWZ-?HTI3D7_BW?HU^C2E.1?\ BW?HU^C2E.1?
M^+=^C7Z-*4Y%_P"+=^C7Z-*4Y%_XMWZ-?HTI3D7_ (MWZ-?HTI3D7_BW?HU^
MC2E.1?\ BW?HU^C2E.1?^+=^C7Z-*5S"W94K3/%>.E:?_I' _NTK3_\ >65_
M[]?0Z,_F9^$S?NL/4<9YAXS6QL\E9>"X<W=S0"8MCQJ*R'-A\6?O1&.; ;T4
M(M>-S%R!IJ^#*VC%$:/:V%F3P9=1#B?M7#7JJ5^=%&LN+P,3KG208962[#,"
M0"MU(89ALZTAMNP@[:'8#S&J<,W"DHP;NC@F1W[@XI)"L6AV-,KVN8DFD9RY
M*7#J]?&ILKC*,#(@]'1N-L'LZ,R^.Q=JC'HZV>!BK0I(F=M[WHV##KG9.A)$
M626;#D2=9AXP+3*)W,@+N5B2-W)=R&!"DV@'?;;V]F_MGX^(;!LVG95-;[U)
M63C<T,-L710JC#F4>;R!$-D2PRP'EIE.1,18M'1U:.#862 QT,55DTSD0Z5+
M"Q[5K04ZO'%ND;*)7]38Q)&FOD4R9F0M%E++'$TCD*':179EU<2,F9B<PNN0
MR,V_9NW[1;BV7-A?M<PWFP^QYO<D306 )*XUBS9\7$U72ABN3$R,SD*M<;R3
M(+>68^9QN,G1<NQ:07 )Q89+[28]=R:<$&KD6P)"FXDR&C$)8:YR%:VM$-HD
M&N2$I,9'1HYU#ZQH\K )E(8ABR,W:Y>/M$W'*.WX*G"V[-U;/999&7V/B$ :
M)QP."E<FFK<'C:K]%3*3XT84G0:-R-6]](+(L+C0<52CH9:_:*KMG-2%]!9B
M%T<-3'G$RS'6,T:1%Y[?F BZIG2P3.9&;V65MQ49E7Y+'8.UOOS\GQ;=YV55
MXKN^R*4)$'$CB\( ,'[8"1CB+J4OA@:)1V6P?;))&<@RV3(1=8DP9LC.7Y2%
M#G ]HT02(AW0 F-2O;J2@'>31T*JH225V&82616>1XY<:A3#JLEB2N'C9D>[
M ,'5K'5LS;MVVW'NW;_E//66\8[D);/90,9/(1%FT0)Y3?X>926.S(K(*E3@
M_!KC-MLU"4<P\*/(XX-#QKX7&S%CZQZ71? S-&B"#M5JEYY\''"C6ED,BP#$
M%'C5<J'%##:M[2,RSJ6!=+64JZYC8$S?;NX[> GT^/DJHSFO7_",X'!/O]L"
M.-F>Z(LX#._]H%+E!V:=IK0>26'K<MHJ_8M"I-LS>7HW.&S<B^114L3=KVJ3
M&JG1&*<JI==(X%5:PS!6P^/+*#O 8JI(&PE1?<*'B[9^HUN9T3BO<S'_  ,.
M\VUFU-.B<5[F8_X&'>;:4IT3BO<S'_ P[S;2E.B<5[F8_P"!AWFVE*=$XKW,
MQ_P,.\VTI3HG%>YF/^!AWFVE*=$XKW,Q_P ##O-M*5SLPTR9O.$QWRQMVT;.
MH\$V_;+7X8"X;I+!A+\RYW"4+O1@M2RYBP=E:#V%"+EJ@DL]HR:4<WJ];I<C
M7Q"(-#:-D"*';&:25G"@.RJN#*AF N0I9LH)-KFV^JCV3?%XJZ)]$XKW,Q_P
M,.\VUD5:G1.*]S,?\##O-M*4Z)Q7N9C_ (&'>;:4IT3BO<S'_ P[S;2E.B<5
M[F8_X&'>;:4K2[(PL8WW\[4P3<<P0!E-MF\DB3#(LVZ0HB0#S?:"B)?/A]B=
MK1V\%HEBJ0YRX1469)DG]C:].UXXHII0HIT3CW*J77&Z.56(&95:+2!8 [P&
M*J2 ;'*+[A5?Z7[/UUMTLRQNW(*"'#2$(%46%Y588L@!2()"TJUM4)*,K[+7
M-C!.MMU+WER5&]E;:TN4I6E=9X1RH8(Q4G*&"G*6.Y0;6N>3?5J^Q@-QX5;-
M7HMA#"3-\LJW9.V#4&\;/'"%BZBZ#5=NFHDX613:N;U4DK[[T[&R]U]M+45*
MVBK*2&5E(%R""" ;6)!%P#<;^4<M*]BD<AB/5^J@8PEUJA1TYZH+%6=;M;NK
M<ERORD*=10KULXXEE.2G7J"W%=_JK^3%CLV':;#MGD';VCY:4I'(96U.Z@*,
M5M66N;I74%BJVJN+;E++D$ZT0XKUK;DE;;DK:UOI<FI2MM*V74HL=NP[!<[-
MPY3VMHI7W]$XKW,Q_P ##O-M12G1.*]S,?\  P[S;2E.B<5[F8_X&'>;:4KG
M'LO9M#&Z#A01I=JW*CHUNHQL+C@\B@D^91\8XVJX/*.!P1HYM50%,5R;UX16
M:,4T$%7SMR[O3N7754NV-(HBX'0C*BJTF"G9V50"[#'8A0SD %B% 4$W(  W
M 5'&>8>,UT<Z)Q7N9C_@8=YMK'J:=$XKW,Q_P,.\VTI3HG%>YF/^!AWFVE*=
M$XKW,Q_P,.\VTI42>BL83"%[[(X!LOL&O;K+[ X^VZVZULI6VZVZC>E;;J5I
M2M*TK2M*TXZ5TI4MT3BO<S'_  ,.\VTI3HG%>YF/^!AWFVE*=$XKW,Q_P,.\
MVTI3HG%>YF/^!AWFVE*=$XKW,Q_P,.\VTI4(M%HQ22#DJ1P#1.X&:4N3H('\
MBZ^Q^ MLONLZWY-;[+5%+;;JTX[:7WTI6E+KN-2IOHG%>YF/^!AWFVE*=$XK
MW,Q_P,.\VTI3HG%>YF/^!AWFVE*=$XKW,Q_P,.\VTI3HG%>YF/\ @8=YMI2H
M8#%8Q>P4NOC@&^ZA4_92Z\0/NK2U,Z2LLMX[F]:\FRRVVRRW[EMEMMMM*6TI
M2BE3/1.*]S,?\##O-M*4Z)Q7N9C_ (&'>;:4IT3BO<S'_ P[S;2E.B<5[F8_
MX&'>;:4J%,Q6,65$<B. ;>6:967<D./MY5EUJ_'9=Q-Z<JVO%3CMKQTKQ4XZ
M:4J:Z)Q7N9C_ (&'>;:4IT3BO<S'_ P[S;2E.B<5[F8_X&'>;:4IT3BO<S'_
M  ,.\VTI3HG%>YF/^!AWFVE*YQ;9VK4EP@O"8@"+5L_!1OV&W1T*\02="0//
M&&9"\+<S#EK+V@OG1VFFZ(]9(H=>N4[%W/55;;;J;..C1=$:$=457D]4<[A0
M&?+B(PN=@+ME!(6Y-@;"PJH]DWQ>*NCO1.*]S,?\##O-M8U6IT3BO<S'_ P[
MS;2E.B<5[F8_X&'>;:4IT3BO<S'_  ,.\VTI3HG%>YF/^!AWFVE*=$XKW,Q_
MP,-\VTI4%&8M&%(\'44C@%12\>VNOOO$#[[[KJV4K6ZZZYO6ZZM:_=K6M:UT
MI4[T3BO<S'_ P[S;2E.B<5[F8_X&'>;:4IT3BO<S'_ P[S;2E.B<5[F8_P"!
MAWFVE*=$XKW,Q_P,.\VTI3HG%>YF/^!AWFVE*=$XKW,Q_P ##O-M*4Z)Q7N9
MC_@8=YMI2G1.*]S,?\##O-M*4Z)Q7N9C_@8=YMI2N:NZ06,&9V5L&CF(ZQ7$
ML!N5L8M&[2U2ZV8Y8I;<I:W33I?=;2M:4K=2M:4K6E*\6OH=&?S,_"9OW6'J
M.,\P\9K?S''WQRY^>B>?MF&L6??%_P""+Q&IJ^.PPA^^$DWPQ@\(@E':P1ZZ
M:(+NA"[]K<Q>KC5E;+KV3ATR459++MZIJJ-%W#:Z^J#A9._D'9590Q"O8. ;
M!@IS 'E -B >, [P*?54C6E*TK2M*5I7CXZ5I3BKRN.MW'3[E>56M:UX_N\=
M>/[NJTJM.H9$GLE83)Y' SJ5"FUS,9(' ]LL58-[['*=;&CM1.Y5O=U%Z]0M
M52NM5L;O7K>R^U%VX35Z"614:,.PC8W9 2%:Q!VC<=H!YP#O LJR\FVE*6TM
MI2E.+BIQ4XJ<5>.G%3[E.*M*5I_=7W=<Z4K2E:5I6E*TK3BK2M*5I6GN^Y7C
M^[3W:^Y7W/=KI2O]TI6B<O\ ?+L _$CW7?QQV?:U(_:;&?VEH_\ AM(U!WKS
M_4:S;*,_"X4@7E4IC)03B4%('T6+Y1O(A7(\64&DEH^\?OXXU>JR)..)RUNI
M#:$&[1T6Y_K8NK'T8Q=626^>/"-+ECC=6Q#H)%@RL"RL,X <V3/JSK<I(7)L
MSF3K*7MZ>&I1UN QLQ)-A[UW(V'5$'R[]<G!IP+J L:/(TS2<R9F1CC4A'0S
MZZ4,56LG--&,9N10>WJ%[.M5N148.<J6 C.T !98FSW#FR%7*NPR$&-29+D=
M;M%+CQ[]FX@?756C^Z[$IVYRLNO*XV*;BFQ:AN50B6 Q5B:YO( &K8D\<A^M
MH^\O>XY-<VM9 L,7.T<BT0B;]V^1;77? 8A+ !'8MERQR1LQ.2)QE :[C+,F
M8H"$VEK 7I<<W/LWW''S5/+;C<7H%6 F]](K7CTB< W#5()/D9,WDP0!'9==
M'U(6M%[)=<]=P^0I2ENI8&JUYD:JO*K5342K6HP4Y1GLEE"-?719"CM)&'$N
M?5Y1)&8SU]\Y  WTN+VX_P#;[?BXZ^D=N8P\8=-FXF3K%+WJ;>U@R'QV6/)(
M1>O S*4LF0R&MP"DJ)W/8:0:35HLP$N$7$05I)TKKP5MY&P<#B5!+1A0-K,S
MQB-5S&,EI2XC6TH,1#,")!JR,^REP>/T]-W*-HV5GE)2U5--6SE<A6RQ2SEV
M7I7\F^VEUO+25ML43NXJTY5BEEM]E>.V^VVZE:4\A%B1R;*FOGI2N:N$O?2]
M_'Q<]C7[UN/ULXGVCT7\-TG_ (,#51[)OV?%72K6-5J:4II2FE*:4K1S)GOA
M^T7XL&]KY^;,=:D'M/I#X=HS]UI&J_T_V?KJ_2?$<F.VSF,N\>X:D<:EKR</
MKI:8.R4+-W+>81\T/N%.4@T-<OA1-%,M=#49H'G-'XR&TL78!;G+9,,KR3$H
MIBD$V)C>-85U:HC1 Q,AS#-* RDKK3$T65I20S6):IV\@Y>3;\AXME_!5)E6
MW[+4HQG%XPVE0>,2&,SK*<D KL)5(UW<2!S# ^9L61@<,R .C4>DIDZ&DN1Q
ML@ODS@.',L!ECI!(@8+AF9,YTCQ>'CGD<HSH\4",#&@$C1XO#8ART+2.BHR0
ME,@9E+6.558JBQMV^+M;+;]_QU]$^VOS@NWR@^A$W= 9.=A</AF.BCR?Y%JD
M"'"\GYAD\D;2%.U=^F50>PO)_1\2L0;'W(]PA<@SN&-A09Y8CQT0:$21!D61
MWF410@L3!AXU*6 RD2P!V *!AON684()O8VO;;S$_;R_)4=[&;)C\7(XTY/#
MX\(-R',+U^0%91R8<OD0O(THFAB-K71M^*$,(01AHR1HL:-(N67:OU73RU-Z
MT;B175K=&PKJW"L[HN' #00IJS"D:N ZLQE65D)NZ@@ 7!+-46/-MOL)V[^+
MBVF]@?CJ11P#F)=4$RK)4XR.:EHXO(R(C-N7C;X]#!](^F\QJW$/Q(IB$;,K
M6CU9I.0Y!E(S"HU&Q\T8=.IFLE'1>&&<Y,Y*N$5L+AU"2'/:8L&8L6S"\+ H
MF8V)U45UCS;03M\&X6'CX]YK<"*IN4P;:CP2[!N%')1>\6^-JR%VVM<EGSA*
MY<HLX=5OO<I*V.J,TG*S45:O:)9J7-&2%=9TELYLP8 *,P0(#90#91R$6OO:
MV8[2:M5BU2E?E_-\+QM?X.'?%PCT"SU'\PF361MQN/Y<"5QI%HQ(&" L=M=P
M0&73)K'IO%5F[RYW96Y))!NZ2N1_GW+67?S-?;)P?QVF-%Z'EPKX=5APDT;Z
M^21"6;&XIAE"127%AM)(VU0L%.V^T#QFKS_*D^#F[A=U?DVQU]L.N721I?W;
M ?/3^;4SCD/@^VG\J3X.;N%W5^3;'7VPZ=)&E_=L!\]/YM3..0^#[:?RI/@Y
MNX7=7Y-L=?;#ITD:7]VP'ST_FU,XY#X/MI_*D^#F[A=U?DVQU]L.G21I?W;
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MQR,R*+"P4#BJP]..LQ:\]*T<R9[X?M%^+!O:^?FS'6I![3Z0^':,_=:1JO\
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M T?>+RL0:#<4PD#B$K N*1QAUQD\DTP; 0]"X4ZU0DZB)0'D=9,0LT(*+ B
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M-).U).RWCXK4[+:6VV4]WCXJ6TI3W?P?=U-:RJJ*J* %50J@;@JBP [0 M5
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M]2ZK9%\^:"2CEHU44M6<(#WBJ5EUC96ZW2C91HC%(6&=M(X%@MQF*KAM(!F
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M\O2'&"]'+U>55LBBM>:V*KFZ57B>NRRZ@,8V4/NA0%Y1L#89A*@588)I2ZR
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MMM)I:V[T[9[=8%%;/HJMS\W-R<.7JY0'B7(:/PB/QJ,,+F\JQY/'A1>'M'9
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M,81^91AA)A$M/O9(U1EY!:&E"S^PF<OB#D:'701./K&C/JS](]>?HG;U.ZU
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M14I7B$*CMD@;BX='VDC %1%!MC*3E&KLT6&E9J15M%&"$J<R("#,#^JZ2Q*
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MU[%3&039+,2PVMM!78+ACLWC:3:.7!="X]9<.>BY6PYP+QF3588+*S8E3FQ
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5C@4$F,L!<JUKVO8VJ.,\P^O[:__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g99471g10h99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g10h99.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1N"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &V:^<!0X0DE-! 0      !@< 5H  QLE1QP"   "'C@< E  !$=E;F$X
M0DE-!"4      !#<!!K(X,(#P[5'R-$D7+3M.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             "MP  !F<
M 0                         !              9G   "MP
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "MP    !29VAT
M;&]N9P  !F<    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M06T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@ W@(- P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
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MC(XV-1&L8UK41$1.8%9F9F9B69B69B>26)Y))_))/).MHU554*H"JH 50
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MS/4UDT4JQ^P95XDWMC<]@LI0S"1X^Q(I6FL$<TT;,JK)"Y8*W1EG7AO@=2.
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MO5]!G86OSJGRW3%6X!)'1\M<UK?8DRN2)S7K/Y\_CFV-5PT<[C(Q3!WB$<@
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M**U;;XIR#JQXMWV=A]H[>LOF<QDZ2W(79*=*299'JLI/:P]= \HF8@K"&7[
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M><@AC6-1]IS.9J82JMFRLTK33)5J5:T9FM7+<H8Q5Z\0([2.%9B694559F8
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M;R3ZVM&CJ8SK[3 6BP1V$!Q403(91A8I&L$>C9%BCQQZD>F\N7RJ93%'$XV
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M-:GRECLZVTZ@N-.U&Q1=:!:RQAN+ 5KI7-G9HCJ8',PG#JGM:#*;\!$9*O\
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M-&>&1U8$'R""/'W*P*L.0P()&J#*SQUL;>GD("15IG)/'R$/7CG_ !%B O\
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MW+<GD\_2OT,@RE?TFV/%F!,MM<.K(DX(E2A)8GDQ:,&^Y53&M56-6X*1A$X
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M5D57-19"GMC1&M8Q&,:Q*;TF]7\YLNMGL<+$,]/&W!+7QDE2JE>.&5(W$2-
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M+&R26)'[-[=MT5ML?*&L@\9-W3XG-=I.<S>=6;"HIL_GAM'8#4194N:USLI
MVK*@OL[).327P\+)!"Q!XS(RH2_DCO3X;;_IE/-OO;<=H[>D Q>Y,6IFD:M"
MUM(4R%$6RM@24;@$=FI([K)%+(\;1&(!HTNY=W^MU:MZ8;QGIG=<7;.;-SCB
MO"MR=:$EB;$Y-J7-1H,ECC[U+(1(KQV*\$<XG2P7AJ.?\8/,8LYV GZ)K!P)
M:B;/27FBFK6U%<XK*5N,GT": 6V<TGX*^NA+'A@@L)(7N)8&.OW$K'^]W?\
MZ:10KETW9*\J6$MK5IB<V;'3(3Y-:1IO7!3O-.T3LYA#+[?N2#HK+1XSTE]:
M);4FWY-APQPRUGQ[7\B:HI5!+BJN&?()D$ME9&BKUDGB$?U)CD,I@KLTCHTZ
M_C9TT'T%U%C>KQ3FVD]"*1/;VK(EACLKRT+EL;8N&%RJ^(92B'PB1O5TC1(8
M$D<LGN5=2=[;GEWAN;)9YXC72W(B5JY8,T%2"-8:\;,. S]$#R$?:9'?J O
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MCJO(9*XBD1K,*RCN@=PJ,>QC<L \8#G@'02H "[QJ2S@<."#U<KX)ZDD> P
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M_'GD _D\_&\O7F[K0LH@-B8E>15M?&2TSU'? B.>]&3,F1KX9&^JHZ.5J/\
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MC5;1^DC=;(81TGA)9V3KR_?W' ZZ[EHPP^HE>-/9B]GK(\:GE3W/*$$RA@.
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MG5_26KK]1MNXQJ]HD6JOJ![I*;KK%W4$,<]N-#8Q#&:2<8I]<&&(H1'J1.+
MNP7!JUWC+$22_P ,P@G^$@XY+@_:&YX'')*\$,.3XL?\[<?"H0>?CEASX_M_
M7]?S^=2)^J^OK_;_ +U_Z_[N46O37SC34;_EG]/>A\@-9_G,Q6F%PV_(C#CO
M665:MGF]*X"-L(AQD$+FDAVC!XX!9R&,-%,&&@9,$DJ23R9P].O6:WL['?N+
M*T),MAT:1JA@G$-VD)F[R11F3F.6N79Y$0M$\;R.5E9>L:ZP^L'[-]#U$S!W
M3@<I#@-PS+$N06S7>?'9)ZZ".&S((OXU:V(UCBDE5)XY8XX^84D#2O1O&3Z=
M0?4G84/;G:>UA[$W%<;/9T8M>%.+25]P2DGOO#9CU4RUL872OD ;\ (P1'H3
M\9$L<#H:K?GK9+N/"OMS;^+?"XN>)8+<L\J/;FK(1UJ0I#_"KPL%"S'O*\J'
MH#&"_:A]*_V:(=G;CBWANW.1[BSE2=[6/@JPR1T(+C]O^G3RV>)K=B,L9*Z^
MU!'!-Q+_ !&5"DG/,"ZVLUS0?[5O_7\N--5+C35K+_79O]UI/\6CXTU=/&FG
M&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG
M&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG
M&FG&FJ)9"Q'#FA3*Y(3!B1)58OM>D1,<D,BL=_8Y&/56K_8OHO.\4C0RQRIQ
MWBD21>PY'9&##D?IR/.O*>%;$$U=^0D\4D+E3PP65&1NI_!X8\'\'SKRW[3J
MW3>*V@T64VU?JHB)-#4&YJ_ R(1]'8-SVB@L:#5U%]/:Q#V43*YIBV&,L@VP
M3V;QF'?#((,<'O\ 8C<./]0*5+(XF>@\:T[$-^E-D9HKD!N4I(;>/LU8ZY>!
MO?,0BR4,O=(1(T!99'BD^3.XMH9?THR>2Q&>JY..5LE4GQ63BQ->?'V1C\A%
M:HY:E>EM*EI?IA,T^'FA]E[!A2V$E@22#=[Z>?0U\?W"WOR3-V>6Q='C"Z6J
M,L:5,PFVU=Q"X$ZVJ,Y]T:E=1#5,SVR.BG<&38MC($2+Y2 @\4>M.\*<.VVV
M>MVO?RES)1V;44%DW?W5CZLBS15[-WVXO=MO91"JNBRI!V27MU267/?[-OIY
MD;.\XO423&6\5A,=AYZM*>S57&_OO*WH'J36:>.$LXBH)3FE:1XY6KR6?;>
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MY"S.DG)@KX%C(C>Q[&;6IR;=M;@RUJQ5B0N*D4(C[6"OV*#[B,099S[:< <
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M.--.--.--.--4R;_ &CO]Z_^I>--<7&FG&FG&FG&FG&FG&FG&FG&FL>[_M7
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MF8CL6\<< 8V\X_I.^/7G#JZ[LK1V^OZS[5KJP:H?N<%+5LFNP $D2LBT=99
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C::<::<::<::<::<::<::<::<::<::<::<::<::<::<::_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g99471g15s86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g15s86.jpg
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M45)R,S0V87%S=I*QLK7!T15T@8*1LQ8DMC5#8J&TP@EC\/$8)2935G6#_]H
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MNB[L 68<\%^V/*2&R2K$,I!!4J"&!!P0:TI4'=F)RJGH%;UX 1?K\':=/8[
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M4:H1\I'A7W[Y6_'KWK6V6BL9U][;3#IRUREA/>6"0MK(N5LSR%N*:BDSVY^
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MZ15UCOT['&M15/[X)'$2"\8%8A<;NAC._ORC6F26/H :J[$P5CGC(QGZ/?\
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M[22(M!$Z^9XT#:E>1::#PM!J3D,D^E,QDAW,"Q(U"@57E+X2RC2W[:?#RJ3
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MGVMVT)#R$$(K$&L>XN[6U"FYN(8 YPG=D2/<??M#$$XR,XX'OQ6VVUR;GEN
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MM-AB#D\D/T#;4*G9JMQ9YNR31T9L_I1AZS$Q\*$ 64A%$5;#V ^^#.J9;/\
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M6@SE"HR_2\&*N;)D]!YA)PS&&>JS.1[V47)P$R4$$7K1_5^C5C"F]T1!^QO
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M5?#YLS6JZFV@G( *@F5LFR%WJ5>L V(6$ :P-_C;DXA6JXNX2BC0^+,V SU
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M/ (TQ(#UPVZFXD!3R>HVCLR@1UUH$1YM\C=N)U3<J LS.&*@*7 'E5B<M\W
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MB=M_90@#!BI0QDEHP2RB((RY*CU&S.:QY(I7A$*0R]V(WS2DQLJ2K*)AA)&
MCD-P71P%9B,?&;&&*E[L)V_G5K7_ '9T0C57U.%-F+JO M->\%']@($QR7:K
M6;L,98[U'ZR;2:GLP!X&'L2C86V2E\ TC+FVP:1M37JYH-32>/B386**,LK.
MKS,Q1U<!7[85=R%E/*.V 21NY]17I6N'N+B;MRI$\5M&H>-H6+Q=XNVR15;
M62-,E0"4P"0M8_X2-)\G3W=9.UB(@7:&GE"[PZ6.57H;TWP(F=ZV VXEJ\)
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M9%4@E9(<=!/=9===31)%%%/7.ZBJJJF==$TT],9WWWWVUUTUQG;;.,8SG@D
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M+@Q$EZ;PWE%H8!369W^_!\"9SPBG(58V,MHA12;9EXW-0<$P>W=%>".K]8:
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M.@/'*UZ6Z8@T'5M'N[Z73%F33KBRE@1)X9)7FC@O!,5,)A>1HUGA6?=%VP8
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M4XI3BE.*4XI3BE.*4XI3BE:)[0_FWWQ^J.P?W7<^8]W]ZW'YF3]PUJ/7_P"
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M\/W'KXK^$7^"&C_I);_PO5:G/UX_P HW]3U9_N4R<S[7[VM_S$/^VM=9Z)_
MSI']&- _A5I6X>7ZV>G%*<4IQ2G%*<4IQ2M,/G7>DY-8[9;<AKF//=@LY[4[
MMC\YI$FZ"/K"-@-ADFC.N3NP[2AB$U3&99.HU[O[2BB@FWN(VHZ.$[@ED"E
MQ"D$$#C@^HSZ[3[US@^\59,$+2"5HU,@((8Y."HPK8SMW*/1L9'&#P*X9LZJ
M=<&=ZGD@ I>O]'.S6F9,,YV(CXAX+^Q6,?AVL9E6:#]26@-IL1WQJ\3]N;00
MPYL\:)NLG1=7!-,G49I2%!D;R%2O)X*#"'/J2@X4G.T<+@506MNI=A#&#('5
M_*"&60YD&#P!(>9   YY;)K,:LI>K:29W)BJR%,\-;GISU>7KZ.U)7.>W5-N
M!9QSWIW<2#'9W)#9FML96]1Q.)RW,S8W- /R[<"*,C1W>0@NQ8@8&?<,D\ <
M#)))QZDDGDU.*&.$%8D" G)QG+' 4$DY)(4!1DG   X %5O^(K\F_(9^UO\
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MKT68TFPLM&NM)6"8W2ZM:Z<NW3+.,1B.=9T@9[696%NMN0UQ) 4F2._%M$W
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M;F$Y^=)"T,CR-)JFOZ-:7QM;ER\<YFM;9WC(\\4UT(CN5@1O0.2C#&/1@R@
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M=S[O?[A[JOP\ZODRNSIS_192/79V"AL\LJ/NTVE-AJMC8]/,>BH;K]!L[7&
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MT9#&^5N)S6Y NSJ[ 1$Y:, K.;@9J&PZ!M0R:03> B-)Y'D(+L6(&!GW#).
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C3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g99471g16s84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g16s84.jpg
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M 0$! 0$! 0$! ?_  !$( -P!,P,!$0 "$0$#$0'_Q  ?  $  @(" P$!
M        !P@&"0(* P0% 0O_Q  ]$  !! ,!  $"! 0$! 0%!0 % P0&!P !
M @@)$1(3%!4A%B(X=PH7([@8)#$U,E.3TR5169?8)R@S04+_Q  = 0$  @,!
M 0$!             P0! @4&!P@)_\0 1!$  @(" 0," P0'!@,'! ,  0(
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M8A;!9QD^XC($ $(E(^Y),P0C\YVP0KW*H-;(.(LK5^.R0IVRD DEM$J2-DD
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M_BA/_JG^2/\ [-07_P##W,2;E5_X9_\ 4?\ K'_"'_BA/_JG^2/_ +-07_\
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M(8!UV/*L R,I#HX#(RL 9P_47ISHOJOI.5T/K_3\?J?3,U.%^+DUK8C:8,K
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M#[>Y_D//F52\Z_X>3PM*O(WCD1Z"J@VUN>"TU%5;1+PV6FX4]ELKE:KJP9<
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MA<16&K%#,R ($"'D7?N$J2X;7PZ75G*-I892,9D E&2R";R6;SF36984[E/
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M0?;]TNFT*UO9L!UL# <5/SIG97G#T#;OGF-^4XO5,]C=K4[W\BQ.36)(!/\
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M2B,,CD2[0EHN2$84@R>'&CR1/B/#,?(MZ*$TC%ZNX*FY #3DE>8X[)1F9O!
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MS=!N@EQVHLLJIRFEQQUWWUSSSO>L@$D  DDZ 'DDGV 'S)F"0H+,0% )))
M &R23X  \DGP!*T%/?OA0&'82 [[/\I@PI4>T+#21KT)4PAL^'/F_#IF[:]D
M9:VVLDY;JIJH[XUO:G/?/VZWO>M9EE9&*NI5E.F5@001\B#Y!A&6U5>LBQ'
M*LAY*P/L01L'?\)6*;_-_P#$[7W*W1[W-2K_ $A]WWZA#Z069UU]NM[W^#Q7
M &5]./K]/Y?R^E/OW]-<_7>]9K).VY_NG_37_P#<H[9/^*5^*^&:73A)J^;P
M=\Z[TU;UM39(3R[4UK?V?3NVBU9*I([W]-J*=M]JII_7KENIWK2?6R([L%16
M=C[*BEF/\@ 29K8!2ALNLKIK'N]MBH@W[;8G7GV'G9,A<!\\/R >LA2;[X]?
MA[N&>1LLN[:QZX;EDSL%6[UTT<JL7"/3AL"BL)<J,7B7:)+AK='/3)9)5LY_
M![YVIR960E75E8>ZL"I'\P0")E.U8@=;ZW1O(:IA8K#>O#*2#_,;^?TF VU\
M;_SN_)W$"0;W5Z7\Y^:*LZY[D0'S;5\:_BL>YF8QNY<1U"8DHZL_<\"4"2C7
MG11>W[+Z$_8J1919T\13T\L8>1]UO2[CR #!E]B58$'1/L1X(^NM?.4^I8E>
M;B6XRLRNQ1DL;R Z-L @>2I&P?F-[&]:,J?#-\#]M^#/0QCTMZ0L6LI')PD3
MD,.K6(54\DAX<BM)]MV9>72$]*(O$%FZR05!Z,$@QXEY^-P:5(/BC)9CP.<W
M^H=3KRJA34CA2P9VLX@_#O2J%9A[G9)/RT!\YQND]&NPKVR+[*RP1D1*BS#X
MM;9F94^0T% /OLD:U.T1G&GHXQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$@&<>9:ELB<C9].&LZD3X4:BLD;Q-[;]N:J9:209\R
M*0^0$:50G"-1E"\>+C1IH>\(PITIR=%B3RWXQD0+?LY5N=%XJ57PPY!$YZ;8
M8=SCS ()! 8>"1['4@?'JL<.X=B"K!#;;VN2$,C&D/VB58!@2A^(!O< C%6?
MBKS6SE4FEO=?.2BTKW9RC^+R&;6!):S'.[JY?<6^2BM3'Y22K.%EK,Y*F>9J
M5B43"D#NC\ET\<]ZD\B_5,F^T@#EK7 ;"J&(K_ &<#DP30XAB0-#0\":C$QP
MS-V]\S82K.[5@W;[I6IF-:FS9YE5!;DV_P 3;^4/\*>:1T3D,0U$YD2;R1>N
MG#F32&Y[ID]EB.J?).#%3)0^V)%8).S(,UK4J](DH6SATK!M03\N=>M$>7<@
M.+$<G(M+*VU''GI5KK5#W!I^2*H1N8 #<@=@ >P&L#"QPK+Q<\NWMVNN:P=H
MDU<;6L-B"LDE C  EC[LQ,[U94\$IB)\0NO1+L8&V7.2%^N6/R&72,_)),3<
MF9%)93,)>5.RR5R,V4=KNR1V1FB91SUTFEVZ_+H-TDHW=K&Y,03H : 4  :
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MBZ09,&+1OQM1=T\>.>TF[9L@GSTHLNLIPDGQSOOOKGG6]YD DZ ))]@/)/\
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M!;.VS$@A0.1T 2./@0>-0B'H S#!O JF9CZIM>6T2V9#% L?<5X3&PYN8.1
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M\TKR*+F9:KJ[&0;8(ZL0"2 ?!/C8(W[;&MS.V]BPUW8Q:IFIG3BP ,, V";
M(L":GZ3$92:D4>C14B4X9;#-.CQ>)2AJ)'+D>"K[B/F'3=BHS8.'">O%@H<C
MX2Q4'QY90"P ]SH,NSK0V/.S-Q8AL-0.[%1;&&CX1F95)/L.11M#>SQ) T)F
MV:S>?$DTD!PZ.2"72<DV#1N*A"LDD)AYWM-F*!@V#@F6).N]:WOALQ8-7#I?
MO6M[Y22[W]-_3Z9D L0H&RQ  ^I)T!_F9JS*BL[$!54LQ/L%4;)/\ !N>E!Y
M<+L"%1"> TB: 2;1<!+@Z!H<Y#F$14D$M#(](L(>\\/!9)-H]1X?#G?'#EBZ
MTJV7XY52[YT92K,IUM25.CL;!T='YC^,(P=$==Z=58;&CI@"-CY'1\CY&<Y+
M,HG#> :DLD8:.<2:2AX;'NC)!L/Y-RR0K=-@4<&;<J)Z>F2Z_':(\>A][ETI
MQURBGWOG?T!6;?$$\06.AO2CW)_@/F89U3CR8+R8(NSKDS?A4?4GY"?.YL:&
M]6.M4GZSKBP482UL;4?68$T-NH:Y/.XSLR.)K,TPY33 VTY9&6 X@Z)@MD0+
M@RS8-9&!7(YXMPYZ^'D5WX_$ #HCW&P=C8 .CK?$ZQW$[G:W^LX"SCH_@+%=
M@ZT=,-$ DC8V &&\VS6;QB(Q$X\\<<?=]G'/'W===]?;SKG[N^O_ !=]?36O
MKUU__KK?UWO_ /O>(G+$1B(Q$8B,1&(GC_!2_#Z2_"3_  N_O^]/[.?P^_Q-
M]=*?=Q]/MZ_$ZZZWW]=;^_?76^OKO>\1.>M:UK6M:UK6M:UK6M?36M:_;6M:
MU^VM:U_TUB)^XB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1*"?)N'D9_Q_)1,1[51
MDKNZ?(6P[M(*O(M#7C?V#0[KDPX!MG#-4HR#<(=E2#/3UEPJQ9N-*O6:7WN4
MK.(0+P6]NW?OSK?ZBT:V=Z)]AX/D^QE#J2LV(P4$MWL36@6UK+H.]#1( &SY
M'@'R/>:VK &R2KO^(!S>KYZ?MJ._)I\=]RVI:@.&O(Y7LMHEI-J;:US/HI#1
M*!=2,#(9%H)*X;8#1V=F9G4M@Y^0O9,L$-1T4(LJ0_:%?A#BY*(A;;+9Q<NI
M8D;Y,P9=!1I@-;!W1<-7W^]MKEZC@6VVJG%'I%E7;=47D5"(C)9LL>:,Q;B5
M5;)^TXA"/4ZOE6S*9FQ5Q&KIM53QY=<@AHPE^'/_ "[8/)>:6G 37:Z(]Z*1
M6/5./CPZ4+H]=QD=,IJ@+YY5DZJVXZ&:GO(ZC:)WZP2/AN4<4;Y@^')*_P![
MBN_:6,Q$R3C65.2MMGW6XH#\>.^WL1O;6FJ #$'B'<#\4IW[:;FF%Q_(1!H]
M-^ ?4CB/DPW7_FQG24@F[SU"3K&(<G M40\[$^FYR(-9&=!C( [.Q5'IQ#]%
M^3W3A@D(4[XFQR.&,Q7>FN#6]P+V0[:+L#L-H$L ?Q>1H^-5,SD+<Y%?CM,4
MI0*6<Y!J7D*E*Z*!B A9?*!N7CC+KW-?%4W5ZOJ3SK)20^KQ%"W'5MS6$\.B
MB*1RQ+_0%)N:JJ6MW+83TU)C@!8Z%/V?9?:R8EQR/!UM'5RRA>;NH9!76Z4O
M:!S-B/6H!&EK/AW?SL$Z(1-;\ESK2\KEUU=V350Q%:T6UVN6!W9>!NNJOX=$
M*6#66;T="M=[?A]&%S^AHY\J$]#0]U$X^N>\R-XJ<1C\>[#M#=V)7K8TSG;$
MH[8"6S$G.5QRW\0'WCI=<B_Y5Y=N7+A53G?6&6PXBDACJTL-G9%?;4*1L[X^
M-#7@39+*%ZBX0JI-'%N*D V]YW<$@:+Z\GR3./DZ[ZB]3^M#%\1\X.C'\(4Y
M*J"H"IU@A0'."%8*3J+RFP[4G0QV*9(QIK*3L'@[.LX"NIR7B\,#N3T@1'G9
MV^BD275O33VR-\K%LM?8*\PK*B*03OB&?F_LS$ ;"AFUQK:\G*-X(7A4U%%7
M%E<UEU:RRP: 4.4K%=9\JJ\FTSE5B'T=84CJW?R]ST=(Y#$IE%#?B\I'9!&W
M)-K)!U4J0:M6K3H,H'^I?MFZF2EW,N&P_E3MZZ7-LT4EE5UTNY*D#_<E*J58
M7@@ZT7#-[[\>%[?O\@-^-2.^QJ_^*6 LK(<0JREN7;X5ZUKSY?O#0]]D:^L?
M^C/:STN>];*599]F$(H6>?'>WJUC'E;4AR<RA,AOYU!O0_-(R(/'7<J9\RI@
M895W(;$I6/RB4AY&\9:#H[/!DW8K>K'T*0Z("!E<R>!XLM?.KN;(4Z_$J6,%
M*@[^$^8\C++'*[5EA4G![846KS1K^&1V6"EAR#"MK*59E8CQL;'UH&0ZM"A6
MOE]*RY;.))ZZ]?R:%S^$S.V+KM>9T1YEC0L9;5G55+RM\I#9X*6?40*#U^[_
M #T?%-E"U]Q9VBK+M.TY8>U8%+>]P"BB@,K*B(MEI)K1U%?PD=W;>"3JMA\.
MM+E";:/NPL9VR<MDL1[;KGHQU"VV5N;]/YI 3RH&[UV6_&V0^E ]UD9C[AGL
M6N;TO#"]3^G/$4+HP- 9_*!,&C42L>/>5 =N+"ZZX0=P6=,C+*;3!0DTG,?F
M<9C!AL[D( 0 D*TC)E<4FO6.K)4195D-8652Q*&XIMC\2Z*KHJ5+#PQ(T!G(
M%Q?-=;<A#3D8:T*CL$"V+C"W5?E+ 0[[#JZJ=L K;)QRW7!NI#DVBDIE=K2*
MF*#^3SQ3*XK([2DUA6R;B4"/5#6\UGG?4[ESJ3S,S$!,V*R DG^I%BR$;<E7
MH9BJR&-V(QGLG%U5@$%EN)D*50*@9A8RI\*Z 8J / &PNSYV2MY5,Z,UK54]
M0Q'5K6>TJC5(]GQMR8H').B2%)*C0THNF>L>(6O[5\(3FHS[>3B#=->V]DS8
MQ)V@F[K@85\_!S.G:3QNU><,D;68P-JC^;033[(-M]-OO^G7>ZX5DQ\A7!&K
M,?Q]'(L(]CK? M[?(RTUJ6YF$U3!@:LS9&_V:FA6]]'7=X#V]QXFR+*LZ$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1(.L7S=2]KO9>1G<+X,/Y]#HA )B[;G9*$5D,1@,Q(3^&""/Z$9&<*
MZC4M+F"HE]KCDDTT9,L$WFAA8@S<R+;8@4*V@K,RC0.F9>+$;!]P #\CH'W
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C&]#9.R0 3H;)"KK-,UF\8B,1&(C$1B(Q$8B,1&(C$1B)_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g99471g29j64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g29j64.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X7C1:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@
M4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z
M0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO
M>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R
M,2TP-"TR,E0Q-CHS-#HR."LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @
M(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,#0M,C)4,38Z,S0Z,CDK,#4Z
M,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T
M93XR,#(Q+3 T+3(R5#$V.C,T.C(Y*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*
M(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO
M>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I
M9VAT/C$R.#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX
M;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @
M(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%3
M04))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"
M04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=404%!
M04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O
M2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X
M9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF+SA!04519T%G045!07=%4B8C>$$[04%)4D%135)!9B]%
M06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!
M9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!
M44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP
M1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY5
M46YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0
M128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E
M6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N
M2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$
M8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#
M1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*
M:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P
M8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(
M:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ
M<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T98;G9M6'DS*V%L>#5P
M;28C>$$[=G1#,74S='1(6F]:66)+9'!+0C1)=VY&9W%(.3-)>G-Z9TAF:4U+
M;T)F3#,U-69P94\K+U1L:U5%16=.<S=(,%!5:SE-24=I4T)E4B8C>$$[45)K
M;"M856YI04-2:7%-=71/+TY'6'DV.79E83%A>&$O=T-S:W-2=&QC2TQ68E52
M>69"16=L6FIC>6(P*T5556EN5$-):W-424)2,"8C>$$[1'EP*V)L:'$X1C%D
M*UE)3'4P0G543F)44$Y);%IM;$5F=S!5=#9A<D-2.%-J9&A3;S5-1U-B8419
M9FU88BM:0V11=6):+TQH;'5N828C>$$[37ET3F-&6D=*9T-L;VLT:$YH5&PT
M*S)+<S%W2R].>%9Z3T%C8VPV<'%3:3(P3%-B5F5K9&I!9G!K5#%'+W=#1UDU
M=3A!<D5(4GI.-28C>$$[6DAZ675$4G-O=F1Z-C):5'%E<'1**U8P=&UN,G9R
M,$MY538K;5$W+T%013!81'%D-&=U3G!O9UI4-VU*955T46)39DUM;39G=7=G
M;B8C>$$[47EE.&)(:DE0<%)J;4=.;E!Y4C1O:V0W37908UEJ,64X:DA22FY8
M-VUZ87I.=T1P.5!Z66M%3$Y1539%-VM$;TLY.'A3-TE,85ER828C>$$[-$%Q
M9#EJ:$-#<GA3=GE!545S96='*U=#9$Y2>%=N3FY"<4I517%&0C=-9"]W=R]M
M444O:TIL3C=393ET5T1,4G991W57>'IX:S0R8B8C>$$[451G3SE-=DU':%=(
M;F)2851",3%Y>&AL+U)Z>&M$,4AO5U='4E<R25IT<3=%9FAM2G$Y340V9W@P
M;7!/3UA#9G!*94534G9'-TDV;"8C>$$[6%%L5U5I:$)'>$)'86MH,S1+>DMY
M1U%,-F,O-7<V+S0U,VUJ+VI.868X4FQY;5%::#9(<3)Q9FY,85@Q-TAP,FQW
M,W1N4$YD;3!U2"8C>$$[94=S14U7.75"141%5TUU-"M*>B]!3$AU17$X4&U0
M.$%.5V%Z,5 V,35E:# K5DQ/-T]N5&5T0WA.-&M31S)$07ES=D=35FU8-D)V
M5"8C>$$[06%305-L13)O9FXP2F)P;W)3,$I%:G)"84)R8VMX<E!+-G5T4W!#
M=$9#<V9*>E=R9SA.:5$R155A=%!.5C$W.'HW8E=W=&AO074W1R8C>$$[8C9M
M<%%Y=RMN1'EK;$8P=VPU>'5X0V5K4E9.:EAQ0E5L5V591F1I<G-69&ER<U9D
M:7)(.5<X;U%A:&581C4V+V]8331#<D]I9G9%5"8C>$$[,%I)5U98<C,Y5&PY
M1UI74%9'24%Q>"LR,T=Y85E32E!)+W-P:C,K07)M>G8W1T]#,&=U<F5%3'AU
M0VHK;D4W4"LX8WAY,U1(:T9O=R8C>$$[2$8Q2C)O=35Z2R]/:5546DE0-"]O
M+W$K3&EF:WI'55%!0T(Y;GIL*W8T23(R+TQI3TY633%Z8GIY:FY76#9N1VY(
M:WE/=G!+:FA9*R8C>$$[3$EE9R]A4%1+-6$K*U%)+WIV=C<R,D=H035K2"].
M*S=U6#-(-611>D=!=F5E<CE7:TII4U9*3T%I0W%S368W<5=&<7A"4&AB;#-/
M,B8C>$$[0T]U279B;BM$>D(U<&QO9V$S-69G8VE/5$UC=TA/9&ER.#0P5$YM
M031J,%HW<&12,$Q4-VQ/<V1U;'9+3S1E065M9G9!1&94;3)W1R8C>$$[.&9U
M9%)L:G<U0T\O9&IS9V\R63AN3VAU13,P861:3$\Y<U=5=4QQ0C!20C-K0352
M9CAL1EA,9G%G430P>'<U069.:FEW:VM!0W!0428C>$$[6FE5-3EV8E8O2W97
M9%AJ<SE3,5-A3WET<FU+2V5E1G52=69I4E=)2U5506MM:'$Q4C1:8DQ6>#1E
M16)L>'-E:TEK4V56<2MU>&9L:"8C>$$[-4I25&-79C%I861I.79A=5!R57)"
M5"MY:C!J05=T3U15<C1N36)I:V5B;3A)0U$S;C4P>7=P-F5G84Y&8GAJ-T5L
M>5%U,V=965)4+R8C>$$[04EF2F5%4WA/54),;2]/8GI03S%.43!R4G(R3VQ/
M13ER2DHY2'AY;D%C2&UK6E%I9%(Q4'EC,7!Z5%$U9$<Q4U1:6# U:F1W>4XQ
M;R8C>$$[64IJ15DO.$%9<V9K8V]-<&1466,S2&HT9'=!>'96:'%&:F)P9E17
M.&LY:SE!8FU-5E9'4#=%9TY':F(R64-V86]Y4$4U27I$;%-Z5"8C>$$[3F1T
M-7!Z1D9Z:F-#=D=10VA09TM%-%).;#9:93EL1VLV9U!64FAS-DU+2"M5,7%.
M+T1.:&AZ-V)U:S%U9S1I835P3BMC3V=R97=W*R8C>$$[6C=31VMQ.&)F5TMF
M>D=G:&QO4#5G0W)(+U8X8V\Q5TMJ>$1K6$4P3U4W=VQZ1'EG:DU):#)93#9B
M+S5W-B\T-3-M:B]!27I79B]%6B8C>$$[8W@X9V))=F-P3%!62G!P,FEL84IE
M5$)E56MG-4-Q:T%,4VE#9U!X3'9V;4M9>4YU94UM3TE&:2]G4'=F8S-(<"MQ
M:&=7;C(O-'I3="8C>$$[465P>4%!249F:#(U2')I25,W,$A.:C=V<TAC,4AP
M5V]X2GAH;CE/9S1G1U=2>'570F%J1%DP645E-'A'3U$U1DIZ=THS2#)$>5)/
M;28C>$$[,F0U8GE41S1M85E/9FA,4T9X4W!P4E-O-#=F-5)Y54EK8S)R3FMJ
M24-H6'<O86HX<V-D,DMU>%8R2W5X5C)+=DYM6G52,U!83T)*3B8C>$$[=E=!
M2T8Q97<R:T181GI-25E%<'IK8S!55DE!<69M8VQ#37!M;S=L16E!3$M7,F9N
M3'DQ94%M,3%31U=J2D=12#,U4WEE:V=O9"]I9B8C>$$[8DUN2F].4D0V;WE(
M4#="6BMX<FIM>&YK474O>&(U9#5Q9S%3,TIC5E9H2W!59W%'<GE"-# T:V(Q
M-VIX1T0X;&YQ*T=39D=H,VA48B8C>$$[>G0U5E9E4C%M,7!X9'=05U=P5TTX
M5TMI=%1U3G%D93%C:T]Z.50O36PP-F0O=T-0:#%2-"M0=D,W+T=8;&II1T=R
M,G)+6%=-37-Y<R8C>$$[3U1G<W130U%!47 S-EE0>4=O+VU3-5AY6'AS9F5&
M87AV.4$Q075,0S1T8G-X9T=145!(2GA$9EI*-$4P<C)Y<DQI>EDO<D5O*RMW
M>28C>$$[:DM%=59&9'%7:398<59Q8E,W=#!K:$HU8V9S:TAX0E=H1UI86C)S
M>31C;D9#4D)C9E=A9DAK:%5H665"96-V2BMP95AR>&QL57DR5"8C>$$[=%-#
M-U5(:6$Q259V-5=O3VUE;'=Z0UEV<3AA8U)G839*8C5F5RMB5DQC,E55:S X
M8G$T4TI3-V)-3C9!2$QS8V=$=3 U-&-55%0V128C>$$[+TQ,.' Y1S!A96)8
M3#8R13$X>FUA>%=517!B25-E25%%,%IH+TUE;$YV138W5EI.*T5/6'!R27,X
M,' O3FHX>$QM>6AF5'1&;#58."8C>$$[:FHQ8G!&4U))4%1A:D$X9WEL>G5V
M2'0S-UI:<#A":WAZ86E-9'5R=W4V37,Y>DQD,U5R,T8S3655<SAJ1FU9+TTO
M<7I/1TE28U1X:B8C>$$[27%$2&)!5UE85VE#4S=H:F)D5V119FM4;&-J<S,T
M>&-G1UAX>GA*<4)H;75&=%5L='!&:FYA;$9K2EAI86YW1F,Q<RM4=F$S561!
M,"8C>$$[;6)4<G-4,V5V,C=75G='5U=!3C9N<G$Y449):TA%,5!Z>6=Z-VU8
M:%AZ6%@K:#98;W5L5#(X1G!09%A5:V=M-'5R2G=+:EEG,7)W528C>$$[.4]V
M6&5U35IK<C180TXY,$)O9#=*3D)&335(<4U3:V=(66AQ8B]R>DUX>DQ83T%-
M8DQ/=$=U3&4V9VMS<CE"4%DS2RMH9'A.='E2=B8C>$$[8V)I;EEJ975B3TE%
M-&M&-5A7>$]/66Q&-%@U:#!S85AR;6]A8W!,2F%817--8G-+1FM2>49B+UI,
M435Q<'AO,#=02%!I05!E*VE0*R8C>$$[8T\O*T]D-6\O=T--,6XO>$=835A-
M-45/5#9+>6QM-T9867$W1EA9<3=&6%EQ-T9867$W1EAL1W1*6G9P.7EL-FMS
M;&]W<$Y(07-Z4R8C>$$[37!044Q"5U9Q.7=V8G)T;D195$E:05DQ>&1,<78Y
M;',Y5$]U2&9L.&8P35HX<S(Q-4HK6$9J6D-!43-S145536M';W=V16]K4FQ*
M5B8C>$$[:VQ55B]W06LP<%A.;'$U>$=S;$LW:5-48U1F,T].<'=F04%R975O
M4TPY065:2DQ9=&$R;FQS>3(X:V%25%)X-T]#>7%#>$9E3$-2828C>$$[<7%K
M0V]P=C!/9CA!;7-);#9P6CDW-3E0=T=R=W Q<TE)=69Y,W$U43)55VUA2$=8
M9%DO4354:6M::6M6-DEJ2E%L56I)03=$>%5%528C>$$[>#%M4#9J4$YY-3=D
M-#AV32]G;&UC575642LS.&1Y1E!K-UAP8E=1>F%:-6-I:S122EDS2W=S>&1Y
M4G53,W<P*TIU4'<W-6(O04-H:28C>$$[171P-7IZ-&AB2'=*16-O95-,=&9,
M5W9,0B]O,FHK6%0V8VHP0WAY3W!61D)T>4XO:$Y78FQL33E::78Q5'HX=3AF
M-7I)65I6=$=(-"8C>$$[-4MU:F%"-3<P,F)H8C(K:5=K5G=3='AC5SA-9VQJ
M44)1=D1C0CDK4DA/=G98<&MD4G%T3&M&:S5:16-G4TM0-G9G;DAI>7A/=VE'
M6B8C>$$[5U5L.'1L879Q0WAR93A&*W1,0U-9>$E6*U!H>3,T,396>E<T>$AX
M5'=8=S-T9D]M*V0X1R].2R]/2#9(:#!Y-4]S.%!Q0D9*1F9U928C>$$[=UAV
M>3A+8C4V1FE";U4X<$EJ93)*+VQ8;VUI>CA.9# Y<FDQ93)A-',S4794,6MD
M9S9.2G@T9VM2=GA+.41194=:8W9.=UIY<FQY6B8C>$$[=C4T.#@V:C59.'-P
M0G!.:$QE-G9Q4$]+,C1)>G!!<V$Q96%4:7)6-&PQ;W!P6#9->'!W-'!T,D$Q
M1C56-6EU8E$K6$Y(9S1L-R\V<R8C>$$[<RMO6&IS4S@P,#1%<D9G96A$369N
M;3,P*TEW:60K8G%-=5%4;GDU5W=7-$ER:DUT*TE)6FIL0F-M2S8R:SE/-6EK
M-TDV;C=J:TIC;28C>$$[,TAS45=75$QA1S=75S5H*W-*0D9Z5T=T03<X=4MQ
M9F)F3F)0:S<P8S):,FQP65=C:'4U,%=F549(.39".6AE>7AG,31G1&%O-C5J
M128C>$$[3CAD,$(U8G1H<2MS86IR9'<O<5%C5%I246YD44MQ-S K6$5F9FIY
M53@W64TY<BMH4$U&-W!C-5HT,C5344U+03AQ06HV4&E">DMG5"8C>$$[=%1J
M.&E9.3=,=$5L-5-5+S,T05(X*V]Z831*=6@Q*TMW>&(X-71%14=Q,D=S4FHY
M,W%L=6]K,C945S9Q:F9E=D4U:F%I1E-,5&]C;"8C>$$[=W)U97!F.$%/2'=P
M<"]M:B]J3F%F.%)L>E<U*UED;FHU4&]J2T=X,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W9.,FAL-4@T1S8K0GIG:B8C>$$[0U8X;G%X260V1W8Y2VDQ0S!K=$QU
M0G!,95=N<4HX47)X25EB:6@V:DQ-57-M3U%L2%EH175'46]P1&)F;&XU6'1'
M5G)7>&QG9%=J8B8C>$$[:VMS=W%9<$9L4V],54Y'5W4T>D]N,G!Q<&958C4O
M=VIQ2S=M9V%F14]8,W58.'1T05<Q5WI%3G@Y5%)U4S(O<4]60CE$-G8Q4'AF
M628C>$$[<#,W9D]P+VQ456-81G1X9"]$-3A8,W(K6'@Q6%0S*U9+3"]L4C51
M9&5","M52E)G5D5S=W%857%35'EQ9&U0,S5)9'-A<V1F.6E0,28C>$$[351P
M8U@T2TLP+SA!3')Y-7 Y>D9C,C%I-GI1;%=I679)94Q)>DU$,2]W07,Q>79,
M,FQQ8VM41U(R4&MZ:F=X>$YH3B\P:G O+TQ61"8C>$$[+W=!:D8O<FU"-$=4
M*V%F:S-C8V4Y039V-6@P4WAT5%!C,W-3<4LX5D1Q>G-2*WEI9S%9*W=Z3C!7
M:WEZ;E%I9FPY-U)N>E%!,TQZ-R8C>$$[.'AR;E1.93%(5%9H,7AJ<'-S8TQ8
M46%+4VM%:$9(4'!#:&1L1%909G1N8FIT5$1I:'<Q>%,X=3<S+W%D4&HY;G14
M;6M:2#!2<FQ,628C>$$[,S-C4% T;6QV-5<V:'!M9V%N<4U5="]'.6\X2FPU
M>DM&:7)%4T]61T]X-$Y82W-086=Y>4EK3T5E.7,W4C="3T1(1U5#6GEU:4](
M=B8C>$$[*TID<C-M=2LX,#-I,D9V8U172&QT0W!F:3AK4G5L6FAZ.592='<T
M<65#=#AZ-U=9*S X0FY5='4T=$TO6C-74GAC94UC4C9J<CEV3B8C>$$[:"]M
M4SAA4RMM0R]$2'E0<&].9T9R.$E!.$M:,%%Y4FQ%1TI":C502R]L-30U8T]1
M1TTK;TEO<V9D-C5427540TMK5&Q:8F='=EE:128C>$$[<WAV<WEB54QU,6=-
M571Z>49V34=G95)E<59O>71T-$9C,3AX<S=O4S57:55U<G%A<7!R=&Q-<DQU
M9E59>D912T1L1W91*T\K6350:R8C>$$[-45F26AR4U!-1C-P1G)*<#0U<6YQ
M;5I:94Q564U!1T)O3W9W9VI"5$MQ4U!5=%5T.5HX-4I*3$DQ=GI(1S-Q0E(U
M0W%O;V1I4G=6:28C>$$[3W8S,#9I9D59:7=,8UA)9E='6&%8>6AN9U9I3U$T
M9VM%169E2V<U<SA%=34Q*W)J63-2,S5O5V$S;C5C>%A)6&LY:&-X3TAP57%K
M:28C>$$[;4YH.&EX6$QD54A2-D-65$E:4"]!331G:6UN*UHO.$%J3F%F.%)L
M>E5A:FU(95EU5#9'>D=B6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[<3=&
M6%EQ-T9867$W1EA9<2M!-#!*24$S2C9$3BM(035P.5EO=6YZ>&@T:$Y.<SAG
M,S)(*RMX5'5F2$]7-U$Q>'I(:&EF,UDK,WHY,R8C>$$[:SDY,E0R5TY)3TM9
M=DU29"]W07IY2&XS;C1*+W%&=G)-9'4R;EAL:75N;UIX2R]*85-,24DV0F5*
M231G<652,C,K:DY54E)S,UED="8C>$$[:GAJ2DU4:61P0VM&65=7;71*2VPQ
M2DMZ:5!N6G=X46E4,5IQ,$-/96%&4C=G2#5:24=W>7E!>$EQ:4]T-V9R4E5L
M,V)45VQV8U132B8C>$$[6GAT2SET-E5,,6U!:5971%!'9'=P.5-G874U0CA-
M2&@W5WE'<#E80G503E)N9S K-31X*W Y655R5W)B3W X2VI,.4IR36U!,E!P
M-B8C>$$[:'$Q+UIU2%=2-%HQ>$1L3'%0,DID8V57-%-A>%-S;FE'2$PO04IP
M>G!9.6]%>#1Q=#1F2C)+27I-8DU34&HK<$PU.4)U57(V8DQ*5"8C>$$[=#EK
M+VIT*T]#2&%C0V%K0T4U4%HO2T)C0TIF669X.%5&3$),8DU"2VQ(66-L0G P
M<E-U,WEZ3&AK:FQ(<$]Z<G-M0V5N245X56E,2"8C>$$[>G$O<U!C;FPK64)9
M47102#9S87ER5D0S*T9S;WE/6FHU8F\V1'EF6EA54S8Q;V(O04%U1D5T<%0W
M3E!T8V4O:'1435%Y8W%%0F1P,R8C>$$[8S9613EU6F)L,6=3;C)J=69U<4UH
M8F5W3%<Y17-X3VPU85-U-35Q16,P-'-A.6=09DUJ2'IC3%!!8S)9,G@T5'%F
M,EEH52]*4FUY=R8C>$$[>'0Q97)N5S9E96%*4%4O2U16<3EA5W8O049%>%ID
M<6<V3%)N.39M4"]/3&UR-F1O,VPO>EAQ1V]Z96A:>%0R2W9*>%IZ>6M-:V%!
M2R8C>$$[9UII5V1W04%-,"MO:5-103E":3508WHU-SAL:7=&*V1B<VAA;$)*
M>DUY06A754U+<%AM1%)H=%-U62]H>75Q8F)203@R*U9413!W,28C>$$[;7A-
M4T-R4T,U:#1G5D,Q2C55*S!W2#!J0G=3-VQ1=6XK9G9*5B]A1S=T=&)S>F)I
M<$QY4W)&<W!#;'%31D1X-4U"6'!80V-C:#!7,"8C>$$[5'%0;7IY,W Q>&(R
M=#-Q14M85C%,1$)"8DLS<5-T2F-':U$Y3D]4,&(K86Q/.6-!9U0P5S!(82]M
M3C5&=556-'1C=$],>E!B<5AK128C>$$[9%AJ1$9V=#AF:'!',4@K>6%B2$I(
M1DQU4F%O,VYZ>6-U;GHV:3)R5S1S-V1P,655=#EO,G%H-7932#)P94MK2#DR
M1W(R=V5(2S9P3B8C>$$[<C$X.&54;75V<7$V,5IM-31H+U)%>6,V1G5&2U9R
M>35#;DAR6'1J-&-U-6)75S-N,WE88VDQ35=T,F8K;7A#83)6<&M2;5%H1T96
M8R8C>$$[<59A:WEF0S%',S99;DA,=5)A12]X;$XO>7ER+T%-168V6GI0.'53
M+VUJ-74U+VMS9GIN9C1Y;2\U6E8O-$DO,'@O;'E8.#!F3F8U3"8C>$$[2#@U
M,RM-<'8K5U9F*T-0.4UF-6-L+TY(>E@K4W@O3V0O:DMB+VQL6"]G:B]!17@O
M;'E8.#!F3F8U3$@X-3,K37!V.$%L;%@O04E)+R8C>$$[,'@O;'E8.#!F3F8U
M3$@X-3,K37!V*U=69BM#4#E-9C5C;"].2'I8*U-X+T]D+VI+8B]L;%@O9VHO
M5$@K6$IF>E(X,2]K<V9Z:U19928C>$$[83!N;D5D>$0V4TAO-FMT42LT<&U2
M<'4R0D]64T9"<7ID;D=)=4IT.&(V3F(P=35426A$=TEX0W-.=S1.0E5(=WIP
M93)-<&IH;T@V:B8C>$$[6'=2-TTV94TY4U1)6'=236@W.6=0=G10<D\V4WIU
M;W!I;U=D5T5K5GA1.'=Y:TU'56IF635Y=2]2-S)19V)%:&1O:E5D93%R6&(Y
M<B8C>$$[+UAP5$Y*2D961U5Q;U5R4E)X04EP<S-4*S-,2GDT:F96>&1.:$=+
M26E"568P;W929$]N;C!7-W5B5TTR=#EP5&97;C%P6G!!,T-I<28C>$$[<TU9
M6#1E9&%K1W1C>#AU<&I#55DO=T%5:3$U5#9X1U)S4S(T9C!S5W1.33%05614
M:'-,44=3-G9:1FII:DQ5.5-6:GA64U-A5DI0528C>$$[-UIL>#-96E1W06LX
M:'5M3V]E6'1C.'8V;&,V6')6:SAD-4AB;'91:F183EI!0D<S3TEY2T%$.%A8
M96Q/*T=C0TYJ<U=N2'%$;&E$:B8C>$$[3S%T84Y.8U-79D-E<&MI67%74%5J
M<4LU;6%+5S5(5#A7,&1O9VU-6D@V='=4.'$O4S-Q9'ET<F)T26%C:G-G.%1M
M6DA3*TI/=6IH4R8C>$$[-U$X2$=4,39E.6IC464V=5%$.%I*<3=(<E%:=5EX
M14DW8E!+-4IN2E!F8VYQ5UA7;FQY-#%D66\R<D):,35M8S!Q,4YQ2T-E.65V
M5"8C>$$[35!*2C)507E/>#AM,F5N>%-,6EAD>D,W.4I3-$E$1'55055-4&YM
M35I/4D5*4D]M;U!#,&5R=$<P=S(T;6I!8F12,7=H<S5*5'!D<B8C>$$[2'%V
M;4-W,%8W:#1R0TIW=TM#<4Q+4E-+<2M$4V-A,#=:3$I,=V]3>59::5!S1&<U
M<DI!2&5Y2'I.66%F<&QX1EE78WI46$A!0SAK628C>$$[8U(V;C=3<EAT;5HR
M4G%:-6]E2D]01'5A,W8P.4-E-'5P,7-A3E=.,69Z0T=(-5<V=79G3&%O+S9/
M27,R1W!)249/<#!O27DP558O>B8C>$$[:C-(-65F>60U=&HX=U-T1'!J6%=M
M.&YJ85):4%975FUG.5 P<7EC=E=684)C,4]A*TE6>F0W:C5-,7,O3"\X07IJ
M;F185C,Y5&M8,28C>$$[-$QE965C<$YE<5DT64EM4U9U4D\O1E9:='E39G1B
M-45Y>6AN45AM,"]W0V-D-#<Q6E!R87A8549,9FHV.39R2UDS:7%#0V%G:VQ%
M8B8C>$$[-E(Q0F\S;'!D:W1G<W8X06Y(>#='-G5J6C-A,E9L.5AJ;'5*2'4O
M5#E-6&HR<TUQ=#9H2$500WA(-UA#=3%A9U-V2VI::S P;C5(5R8C>$$[;6]7
M6&U7839I:'520D1C,E9W.&PP0C9D<S8R84UQ13=K3D=I34-+;FA5:EEN2W8S
M:$9-=&ML9E,O=T1N2$MA-VY33S9#,U8R=S5*1B8C>$$[3F4K;WI32UE1<6=6
M2DQ#-30X9C9.:RM,2VEG;G5K+VQL*U4O;6919$Y/:W,Q-35F<W9R8U5C354X
M=D(U6GI#<VI337A%;UI$8DM61B8C>$$[44\Y1'1K1&UN16TK83!#:G@K4E@U
M84-54V9O,E%K5"]!1FUH=6)G9WE60D9A=G93;$(X>F<O350W,311-DPX:79Y
M>6EJ16-E;'5Q028C>$$[:6]&>F-!:T1G94I):W)4;$5R9E!P:BM9;C-R=VA+
M=%%M=DEB4U-3>71X9#-1;TEO1VM%4W-3=TAX3U$S14%'<#)*.$%4;FYM2TU4
M228C>$$[0U(T63DY6#EJ,7-Y44YH6E-A1%AR<E5V2VPQ<4M.1G!.,4@Y66I7
M85=26'0Q94-2;W<O<7-Q:&]M2V9A-&IB33)7;&IJ,4%G8GE2,B8C>$$[,D$S
M,T8Q6&8U5S!X>6U737DK:S<K-V(Y1$A94$]N;4%&-U8Y6#AV4UA-46E);&%A
M4E5:44<Y8FMW64M(<G<T,"]W07)B86<R375Z<R8C>$$[4#%#1V)H3CE".%!/
M=68R9D=G86EF2S17;WAE8W9.,&XQ<5=,5F9,<VAJ64PY6&%744)"1W1:5U=J
M0C)&2VYV,#(V8GIL,F1P>%%-328C>$$[,W9O9&58:U!S66I56DXY-$EQ8GI8
M-6MH=3=M1U!6=$%K:$IK:W1:6G!(04599'1N6D=#1&EK8E8S<E5(8S562%$T
M1$5%=WI!-T$P3R8C>$$[=&5E+TUS>FYM0V0T2C5P+VY84E)A=75P-G)92F91
M1V(Q-#1:2TM&:FQ+<596:5=*2SAE;&%T5VQC=V-V6G58:2]D=VYW;7%S9#0O
M2"8C>$$[=S5T,&121W954F%,:C@T*U8U3#0R2V%N06)T5S1'3&Y4-&E33TY4
M=%AB<&Q2-T]Z:5!%64AH6D100S9S5WE#>2]V;"ME55E0<5I:928C>$$[5$)D
M6CAJ,G5Q3F-8,6MQ=S9O44LQ,E-50W5Z+T%/5B]L9F9N861O9WEX>$AC-%!9
M;7!J:'EY2D<P=&EH9%%S9DMX<V)85SEF<THT2B8C>$$[-UI"85(R151!2DI.
M1TA*6F=256(O=T-65' Q>FQS=70Q3712=S-'5F0T;T%B5D=H,"LS>F1N:3!C
M<UE/2$),859Y-'(Y5SEB,S-S528C>$$[=5!-=6A82&LO5#E$9S!/3TA63&55
M=F,V<4-P959A34MC<6,Y>7EM:$Y0:"LW8E-K3T=Q,S<S65ED4&MJ;DUZ2S1K
M8D1U-4QD3#AX828C>$$[<G!U;5A/:3A9-61/=D%22D9)2VA89FE0541,=E5"
M8W=S=4=%-5)K96-E5&M4,%54:T=4;$EF;V-M:E=993!U:W9K=#4P26M::$HV
M8R8C>$$[:V)#:%9K2$5S4T]T5GDR36E(27EX17)"2#=5-#%B4B].541J5DAU
M<&19=&150WDS3C1&36I$:'-%;$1H9T-M,4%D=D1)9FU"3U)'.28C>$$[*V8T
M,V-,4C5-8U-C9$-":6%R.4DY-E,V:DQZ9'!7059M,VMA:7)59T)A:TQ19$)M
M=S=02D]4-&9Q6'1E15DT4#@T9F-71&%N97E8;"8C>$$[>7I6<D5H26E!-E5R
M,2MN3W-X-'A#4&TK9%HX<'EZ.&AY4C-L<3!7-'5K:6(T95I02F@Q0W%+-UDU
M1'-J0TME;U)-:4M",$$R07I8>28C>$$[9&QJ1' W,UEI=E1V:TMB-UE8<F-F
M;5!6.61I,#=18E4S3C$V87EZ=6%E;6DQ;T]416A2.4]863AD=4QQ=%-)0FLR
M<V572G9,5VE*<B8C>$$[.3E-<#%S>C(O3F)65E-"5U5"5C1Q4G9254A39W(R
M>39/;6IW94=D=V1T+TXQ9S%T:VM$;'5X9$QY-S%/+V$X=6IZ;FQ)<6%F=T=B
M:B8C>$$[5&%A3TM(0DAA2612<7142UHT:GHO2#-*>BM95C!,1'E"1%IJ*S@Q
M2V1&3F8Y.7=J,4<O-&9H;5!Q871D1%IK4U1S15@K4G5Q-E)P6"8C>$$[:UAZ
M9F9A=G!W,5A4:W5T3E,T=$-)>5 S:W)2<34Y56AF9V1G9C9D4G)C<U-:04$Q
M>F0Q:C5--#!0.'=F>6%';E(S8656,7-N=DE9-R8C>$$[93E72S!G6EDO<G%Z
M5F=,9W%85FMI;"MY=38W57%E3U%L:GE8>F)!46]39FU:*U-L-V9W8R]+.&)W
M,VI'4S=U6G)304]J5$964U)9,28C>$$[.5%Y1U)K*TQI95%P5V@S>#A,24)Z
M5W=I,R]-1#AL6'-J1D8U8CEA2S1146DS5WIG;S=#9#5&:4Y(-F5Q1V9K4&<W
M.'-(:#5,-7)S="8C>$$[8CAZ4'E5=C1B4S-V+TPV,$5A26MB5V1V26M+,T5G
M:TM,=UEM;G%M=$9&9C)Q54YC9D-Y1&M6<TM1+TYF.&Q$8U<Y-T0U9D%L:FQA
M428C>$$[,T0R8TUB;S16<C!S:$)*850Q:U=M-$97<4=P:#A(2C-O-&=Y5V(X
M>69*+VQV4W1":CAU869B;E0Y95=383%72U-','0T2D]50EIB;"8C>$$[<4US
M4G!D1&PT14%D.7$O0VQ);7IY5%E4>GE&*UED=C5V:S%&26)*-U0Y2$=.5TUJ
M8W5::V569'9H6%EE:C$Y+V))6DU81%-15UA:528C>$$[;#50<2MM:E4Y3FYS
M5&-Z,F=N059R:3):56Q55D)01FU6=T]11D1T,'IH9%!M.$]9;E%L6%$X;G%S
M:T]+2D9K935!6&5L=%HK5G)M=R8C>$$[5TDV>45H6EEB4S130E));T9&:311
M>'=X.%)48C1C>4UE9FIZ:5I0:#<X>&9Z,TI,5UEC3TUJ-G9L*VEM35AM;GI5
M3%$K44Q:,T-U028C>$$[>GDR-'!X9&]L04-Q5'9':79T*W-#=7IX-5(Q,4UV
M;$QU=C<W1&IY:C-9>#EI>GDY8F983E%(<BM124Q"5EEX6$8T-6I8<7I2=7EX
M="8C>$$[1W!D86)J8VII9&IT:W164&=H='%43'5'+W9'.3=F<E)I1FYF2%1-
M1#55.'1'1C14<&1S635!>75V<$QU1TI*2%0O2T]A9CA!4#4W=B8C>$$[:FPX
M,TPX1TAC1DXO2G9L3U-6<%@P:3!A4G%C;4U+1W1'-41T+TYV:V@R:G%!2S0U
M9DY(-69(+TY#<3-L8GDP,&I3='!6;S!J34A:>B8C>$$[0D=36$)Q1S-(55I!
M83=05F-C=FU5*T1$=4-E5U@Y.'9Z>79".5-C=DHU8G(O=T-9='-S<RML-DY-
M>'5Z5DAU,7!W04<W3$<Q83AV928C>$$[;GEZ=2LP345X9T5U-G(Y>G%U=S59
M<#9R9VPQ0G)U2C4Q.')34U!73'DK,&$R=&)K;SEP87E/<TY#0DEP:RM*=59E
M=%0S4#,U>7=W4B8C>$$[:D]5:'IL5B]"-S-":6E*4VM/8W8P25I.2'5B<31G
M:6A:4TI7;W!*24%*-C<Y<WE-341/46E/6E)Q.#!C3T]74U@P=T9N.6I,.50X
M<B8C>$$[95E9+TQ.<6PR;')&8F%*>E--<4=%,&]U2#E5:W-24G0S0W%.<6(U
M4DQ667IK.$QI2$9'*U8W-SDO=T-U=&Y685!T1$9,2T1!5$IZ528C>$$[9#8Y
M3D1Q3"MF3FIK1G-Q=%9Q<%0Y:7!R.7=Y=T(S>#AK>FLQ;39E,$9H2&-M3S)H
M+VY9,%AL445E,WEW0TU14U%.>30S-65!;'AK5R8C>$$[4W=N>E1C4CAX8D=1
M.%@S<6YG4',Q0G Q>F]U=TU)2FQ-*U%(-F8P4$HK,D]Q35DT.%DV,E-0;%@V
M5T].6E,X4%5J26M58FM+9FE(>B8C>$$[0C,K-T]K;$$P.%!$34QP1C9,<6-D
M:'%&=$Q+85)(;$A),VAY-D@U03!Z2'EX='DX5U)M3GIR:6]+16Y-231Y-TM/
M555U,'DW:S%'-R8C>$$[:G196%9:2E1X57E-15=T3VA9;6=Y3U-O4DUJ>4%4
M-'(R2%$Y1#AY-E9P;G V,W%)=E$W3#E5:%5L>$5G53$K3FQ6.2\U96=P9S!'
M;R8C>$$[:FUG2GA"06M/=C=,9%9R-G1H=C5Y<T0U9'-9:#%F54E14C=#3U$U
M<V]#-4)W;T=G5#5-4CAV5T1Y>D%!8C=!6G,Y9TA86EIK;F1J6"8C>$$[-6YA
M>4PO6%):>#%%3VQ*.51!3S%:55DK<3,O0C=F25IR8VAS:W5Z,&U0:&=04&0V
M0B]Z:CEE-CE:95,O3TYX;T=N2G%U<DQ,6D,R<R8C>$$[6DMC2'%81&-Q=$AS
M<5906$U$3T%:0WI19&AJ-5!43&96=GIG=4Y5,#8Q;3AT,C%L6G!F;C8U8WA.
M0WET85)+<DET1VMK2V9%-R]%;R8C>$$[2B]L<'97:WAX,&0R,V1,8EAZ1BME
M5G9&9'9.-5%T<FU49UIB1W)12C94*V]I*VEO:FPK2D56;DE*4$DY83ES:UDT
M+S5Y3$QT3F(X-28C>$$[<G50551R1VA7,W)7,&9R-D9)171!64QM,VM32E9J
M+V530VAH;FU+<R]H=#$S5#19-4@S<4Q69%9M+T]'-C!J4V(V>CAU5U9L<C!D
M>B8C>$$[2DA)<4IB>6U'0C1O4W)O.'-P161E3%)V43$K16)$8D5E2%I&-TQU
M<EA/<"]N2&5E6#=V-G8U871D3C%'0U=Z3G)#:E%397)#.$Q'-R8C>$$[5#DV
M-TET1T-P5VXR5TDW5G=!67=E83=O4S,Q>C@V8F0U65(U37-48E12;31I:5%2
M3$A'-S(T;&M7<7HQ671D0W)!<E=V-U(W17AX+R8C>$$[>FQS=E9D2FYU<FEW
M:&YV3%)R1S=D9CA!4TQ::6I&6$))3D=J6C%+:R]%<'(P3SE$=&U.3&UY4F5"
M56@O=V199C<K;"\T6"MM85@K4B8C>$$[368X04]L.6IS=C54;C-",RM$<D0O
M9C!V+T,O,'@O:U1(+T]L.6DO>6Y0=41V.$A72"LO<&8K1B]P:B]);5 X06Y3
M*WAF-51N,T(S*R8C>$$[1')$+T%(.4PO=T%,+U1(*U)-9C@V6#),+TMC*S1/
M+W=D668W*VPO-%@K;5 X:5DO-3!V<U@K534Y=V0O9S9W+S,Y3"]!34PO045X
M+R8C>$$[:U1(+T%$<&99=CA!2V,K-$\O=V199C<K;"\T6"MM4#AI62\U,'9S
M6"M5-3EW5G)4>79P.79-<W9*-4]/-%9I3U P,$=7-&5Y355*6"8C>$$[6DQ8
M:S=1;DE6<TAX3$$W239U<&]Y;6]0=4TW8W=%9U%E4F5F:&ML:FM*4DY3:6)$
M3#E!5G178TMK,$YQ,%5B;5)8,D1K5F)X2%=U,B8C>$$[+W="*V-D<BMZ-#1*
M,%152W-%+S=N8G$K:39$=#)79D0T:UEC5U%3<552,'8K4&,O5#@Y,C=854IK
M64UR1&E$53DK;F8R*V5A<VEN<"8C>$$[8D5U8C!+1'I8839J-4Y6=%-U575,
M-GAU568V<DDS2#9Z1VI"=41Q3GE/2DER-V5/86%';D](5D%X:C9#4&PK4#!U
M:R]*;DAQ9C-9<28C>$$[331N8V9W*UE94&0V<$=:-5I%6#!59&EW:%0W2V=M
M;U562DY",G%4;34S3'4T,4555&1*6&1A:#9C3#-"0D-+9&A7:%EN64%::V%8
M4R8C>$$[;DQK14(O6317=C$X9%!H3U=826-H,VYU+U@U35EU8G%7-6YA5U-N
M2G5W-D%$<TTW8E0T23190T5E469+.61R2C9N2V-K+W%0>3EW5R8C>$$[>'E3
M;W=E36M-=E%J36=%:FLT0D%/>%983G)D3B]P04U-:"]B469#5#1L9D4K>'=%
M07!I5$AL=6U59'9,*S=H=5A:,6(K-VM"1&-V:R8C>$$[=S8O<GE09U<S4C%1
M1#)N.'-F>7,P.'1A86AQ>4\P<DXV:T9M-$A':3E$2T-.+T=M,W983EAM,650
M:FQJ:5)X>#4O6BMT>EE32FE$5B8C>$$[5WDW.'=V371N;U9M<VML2U-3<D1B
M:&<S17EU1TMH;E982W)135-A9$(S>4]H,#A-34)#2&Y1=C4O931U95A(3&9L
M,W9N*U<T,5!7.28C>$$[46QV=%%A:SDU3$A.3$)(55)+.%-E;DAX56QV<W!T
M,7IO34]N161Z>F16<4Y49G!(2FMC*W R+VQ84FIQ16E"-RM5.$Y09V5V1FY(
M,B8C>$$[;F%L4&A1158K:D)N>61!,6%F1#1K="M195)8,7A.8S-%,7I/-65E
M6C)K;&,Y5UIJ5FEF;51M05AD05!O3"]N178O941Z3"]X;71F*R8C>$$[27DU
M9V%R;4A*>&-N=BM9:F$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6'=61V,V3TQQ-4)%4G5Y:TUP2W-/:"8C>$$[1WAY,'A%:%(S1%-*
M>6I)4VEA25I(<%!053=7-45L16$S0W9Y54-R5G%0;WIN=%0W4&=M.%)R>6QY
M*V9.-B]3*S)N0T%.5$1I+W!1;R8C>$$[2#1G-V9C:$QI-V=H8FDU8S X1D(O
M5S)96CEN.#0V=RM:+S1L,F<Y<V1(3'!L+S!S9BM,43!M<W=+4#-%5$TY3W-L
M04(O<U9/*U=93R8C>$$[=UI8*SAL="]2+U=7:E9E,3A!4#-%1&9F4#E14#95
M>C!N>DAO17E!-GAA2D)Q:TM#3S Q4DE24$%254-L,V$Q06-"86IM=%0S2W14
M3B8C>$$[;&LP:&I%46=E1T$U,7-F9V9F.$%.-6%E<FQM>4=E43A5:C,O04DU
M95A21D@X<'9-;#=:<G%/:5AE;F$O8GE%=$ED3G5"5T]U-$5I5"8C>$$[3$%Y
M12]W071+-61,5G=I0UIE:T1V869!4%1D3W9.;FM3855U='1P.3@R=$QB,FM!
M145C83)(3TM+3DI4-G)S<G0Y:R]S:F9.8C)6<28C>$$[9%)-8U5Q.$M815%3
M5'@P6D5X,G%Q-&90=5HV:D)!8VAV.6YM;&UM+VQ(-7EN4E1/3&%%1G%',VUD
M;F5N:5!35G=0.$%G:&TQ>39U1R8C>$$[3TIL23%%9"]*;SA#+V8U4%-03$AK
M,WET-4]35S9U3'!)2D%O13DY97E,14%R8FA6-6-505!(-3518S1M4%-B1C%T
M,SEZ9$=!0G)Q:28C>$$[<%!Z-3AS5WEY,DAL*S-L,4<W0D-*975"1EIM;S-:
M5THY5G5*,BMW2SEJ,WE'3%%Y;5-2=&90-VM:.59(1T=.3'!0;7$K95I,*U-+
M."8C>$$[.6136F)L:'=%:$EB9S5A34EZ8T]F=VAT:#!P=&UX:'!S55I$2B]'
M3G9D+V(X,U0U3EI+431F-%5K=3EB.',K5W!(9UIJ<4=P44)Q4B8C>$$[=V=.
M17-O*WES:FMR,RLQ>')4-35F4$U4>5E9=$Q+5D4W0C5Z<G5T-FAR1C@Y-V9Y
M*W!-*WEG8DMI:F]I3#)56FI&,C!)0TEO2DY+928C>$$[=59&<T0V2"]!3V-3
M:B]O2&U8+VI.868X4FQZ03%834]2:350;T1-4G1D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5B8C>$$[9&ER-$AJ3V1$175T:T51:#)Y*TIA
M2D)L6&M/3G!R=2]H07%V,5%Y164V>4E0*TYS<T(S8TQ58W9I;'5T,GA385%5
M-DA*5$,T5'-K8B8C>$$[0VI::6QZ06)$3'9Y=W-D079T9F$S,61K:E%24$Q%
M.&]$4C%I2$YW=UE&0BLW1$YY9C11061Q,'!O*S-E,$UU:G=(3&IX*TQ+=TMV
M;"8C>$$[>&)!,7IL-G%(0TM/-VPT9% T>#1E3&<W*S@K5CE'5GAF:SEQ;6MV
M<D]Q46%N2G P9&]*2# R5T=9>'E34G%V35!.26YP.$%I-TXX3R8C>$$[-41D
M<49U9#=0.7--3W!Y66-5;RMR24MK96M:.&=!4%546BM54T-4>G)/,4=K;FEH
M2U5D-C9E6%AU,W(W56\P1%=F>G Q:C!)3DQN=28C>$$[<&)E4W%X,VLQ=D-9
M84M+:W1C4WA%9F4Q5#@X-T%X>%%&8D-U;C=(145P>5!*1F%T<5@U>6%"<4-$
M5UIR<#E.:61(=7)Q>G1O2&I-4"8C>$$[2VIC6F\T;#1K9TA:;54U5FUH:GDT
M-5)&16M(62]P.&U136]Y,T1!4$TK=3,O;4A62DPS54HU3&A1-R]6;S5'2E=+
M3FU,2W%R,$9+-28C>$$[3%$V1$9P.%EJ04%D+VUE.6IL>E-M8E5,2V-W<T]*
M<%1.<&EL5'(X,$QE<656.5%/=%(R.7).2U!6=$A%<TE*<'E&44=8=SDO;SDX
M=28C>$$[;E$S1')I0TYN;&5Q>BMV<4XQ3E@K.6UK9B]G;4IZ14QU;VA,<$=Y
M<W1G46-R9&-Q3$E0;W(O;D5C,7-033,O1V$P+S1J3&U"<7598R8C>$$[:D9Y
M9E%/67)A-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EAW
M1VI:=G=86&Q84G-T:5=U45I&-4TQ6DY.,2LS;"8C>$$[;#)T-38R.7=A,&]K
M=3-,+T%'2F\S,%I95',T=5A(64E49GIB<'I7.2]01V5X+VAM44XT=41I;#!9
M6$]H5G-X<&@R1TUS<3AH951T6B8C>$$[,4178D,K97=,851(8WA.3DQ/=C=Q
M4TU307-O1&9B0D=X;T-02$]F-V0Q<V-7;'DX378S9VA+<35G.$ID;F]T4$M5
M9U-04SES;#AQ-B8C>$$[3'%&*S%Z9'!02F%&1B\S1WI024E':TUS;'=:2DEI
M,WAN;$XY;'1L-D%:>"]S+T]72$(V:D=5=4EG4T@X,DEJ:C).9C=8,#4W13=U
M-"8C>$$[>31233,K3R\Y3$DT<$DT;S!I:5%2>'AQ1E-.4E)654-G04$V041.
M=V13:G=6,S%N-VIJ*UE8=UAN;FUR.&YF3$]S3C8K;D@Y1#-2828C>$$[<VI1
M<'IH66(Q+V,X:T-N+T%&4U!L;6)H-U=L2#9V54A(>6%'3757>GEV>E(K5R]M
M5'DW3$DW471E86-U-C,P2S%7;FDV9VQK*VYB,R8C>$$[>F,V6'1$2&PV,4QU
M9&1Q3DA/2&U&1'EX<7HR9#9K:6YP-RLK8FE"=EHP;65#;C4Y<T)"<D@Q*TM-
M2F%A;78Q:45,,$0O6FQ(+T)G;28C>$$[;F=2;4AK1D=N3S!S*TM(;4=*4W1L
M4DQL0D-43G-C<4Q)4&]V+VY%43$P+WI0+WAM=% X06E-=5E7<#5H=GAC;C!*
M;4LR=7A6,DMU>"8C>$$[5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5BMF<V(U=D%80E)#4&QG3$5H5U(X=$5M<558<69L,U1M.#-A2F)L6G<Q-V)J
M,"8C>$$[8BM744=Q,$I%8F8U6DU92# Y8W=T8C)X:3!C9EAD;FM/+SA!57<P
M,UI/6%5:4%)1:C%09#A'6F%**UAF;&9455EZ5WEA:$\Y3V-T,"8C>$$[:5-!
M52]K46=H9C$K*V-4<F9A3%!M3W@T23DP9C!L-C-49&HT<U$U8U(X,E1O63!J
M5TY&0WAO07%O0E%!1%E!05IQ:G$U2&4S665!1B8C>$$[=VM!-F)9+VUJ,W(T
M260V<#AC2#5O.38K0TAE<69(2#@P93EF0D1V5E!J:BMA4&5V9V@S<6Y(.#!E
M.69"1$=.8B],+WEX<6-)161R2"8C>$$[<#EW<'%L>&%):U)R+VQ+;T%99E!F
M,WIA85 R9WHT6EAF1T\V5&<V;G-N1FQ&5G=N=D1%=DTO:WDW:3AP,W1L9&Q:
M>%I+,7AP,31+5B8C>$$[-7%#-TE&<5=(3E%25'!7;61H<$\R8T]S1E(R>59:
M:BLS:SAV;C=->3939&YF1U16*R]Y94AY4&U34S))3U8K=5%*6E!P1"]N144Q
M,"8C>$$[+W=!>B]W1$=A,"\T:DQM1G%/66)S6$HY1%IJ3G)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69FYT2$IM-4)C2B8C>$$[14I*
M;&=+1EI8>5E,16@W1"M2<E9S9%8O-'EX9CA28D]-.7%Z-G-F=5 V2&]/=W@V
M6F4X37=S+TY$5"MA6CE"359U+W!24$U:-V$U.28C>$$[6C0K1'%O4S1I36%E
M:WIC-F=C;39:;V-M:31C07DR9'E"4FI6+W="53)B2'=$=%DU-WE'1S-W4#,Y
M>D9F3E=U6$YT-6MV8E-,>F-D328C>$$[-7%1;&XY4V%9470V34UJ:C%.-FQO
M,$QP46)C;3<P1V)8439A37--6DA$>"MF1E8W>39E+UDK-$].;7E%5$DT-BM(
M=5,Y4$YD-6-2+R8C>$$[5FPX.4(U6FU-4$Y.34M,>41R1U96=4M%3WAC54YA
M1&8R3UI",$U9;2]W079S3B\W>C0Y-3)994U4=#1N*WA66E!.13)O,TUA,C-N
M2B8C>$$[,4XQ4$MT=F)*66U0,'%P-C!33S-%5C1!<4-35%@U8W-J2%)$1T1X
M65!P07,X9#,P3F4O.&1%*TYX2&%F4'EA;#@P6#$P>G9A96-#;"8C>$$[>6]"
M4TTV95%05&%7<"M&;#16-$]G<69$8G53639'161P64YV-B]L."MD+VI:5&U*
M-50K>'$V."M-2C)N5'IC>3)W4#=Y1#E':7-20R8C>$$[<CA$,55T>5HU1D9!
M5#AX9V@R5TMO-$XK+W=!5&XU+TEF<U=7<#-V:C(O<6]O95EB:4M56#,K3795
M:D0R56,Y=4Q);%AB:5$V2GE7:28C>$$[3D]96F5L2V0K9W!8*U5I4G=E0E(Y
M5DAJ*R]V16)I>3A5:F9J-W5N-#4W<V]S4'I&.&XS.3-&6C(Q.%=U<'!"06M*
M:&Y5*W%63&-#5R8C>$$[44%'9U!5-7$X=EI/;WAX37!2.4E&.'AY*V)K>#%7
M3U)O2&8T<3-N2S@K<6%B8GHP<49U;W%G.4-..7,R9G-O3#%:2#E#6#9(52LP
M428C>$$[+W=!1B]W0310;F9Z.6]+-DIR:GAW8C).,'8Q;7E0:$<U4'=F-T)G
M5B](3S!Y4C145'HR;GDX8TQ9<$DR56MT-S95+S5W*TYD4#@P9B8C>$$[.%IR
M5"]I3759969M1R](>6921U5.:G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9F;FQ(8C-N*RM*4#A!9T<O<"8C>$$[;3)%;D5P17!B,V8K
M*UI0*T)B*VU316MC2E8P=#=V.$$S>DHO=TQF,'E9:T5C2F5X9FM61$],3%9G
M,&)Q9E5H-G%2*WDK8V@W54,U628C>$$[-C=J*V@S,UDR,%I8,VAN86574#EZ
M8V5R,TXQ9%A5.$-Y<&%24VE&6316;4DU0F93:6ID=&QO3V).;6=/<&PT4GAX
M:4EG,68Q5V$Y-28C>$$[4#)5-U59>'@X4DXO3%I+9%AS9E X5V\S.7AP5G)P
M='A:>DY%65EB:4YX37=#2W-H6FQ+9W0Q035(;T(P-S5E;D]M34EJ26-G:TPU
M8R8C>$$[=64S-$184'A!4UDX3DMC;'(K6GDS-6%#,3!N-F]$1T55<DU$=59A
M5GE2=418;%0V4'!M4'E::'5C=D8X4&=%135B,C1+57A99FUK:28C>$$[,CAI
M4C96-F=,:5I/16=!47-75&E12S%!5E4V+V5F:7E6-DTR1#1V-"]"4#1P2#<S
M8C97,G1F>E(O8SA,8E,O5453;60R5U1G5V-U2"8C>$$[:%=G-6-%05)H=#E*
M,T=!1%(W,S1T6'0Y;2]V3R]W0V],95@K:7!,6B]M>GIK3#)U:G-H0DE8:DPX
M5$E"-F9,+T%&:G4S:%1A;F5:+R8C>$$[2F1$;"](4#AE84QZ9C!'87!A55AE
M14%N9&=Q-U8V*TAI8S!H-'9.>DQ$:%IQ1S5#04)U6$]V2&9L4VY,<#%P,W@Y
M9FUT:&EV-6Y2>B8C>$$[:GDR<%9'2BMS>&1!9CAR3VDY;%%2<3=0.# O;V1.
M,CDV=$U13SA02V9096QA;'%F;%<R=C!I:V,V5$E6;%AI82ML8U5(3#5+-DM0
M.28C>$$[;&YE83!$66@T+U%81U)I97)Z1G)3."\S>$HO=T1F,'I71U1T:$8Y
M2V8X-&=1>E(V9C5N.5)'4W,Q<%1K0TLO1$PT-6I::3-11#9(>28C>$$[;&LW
M1EA9<3=&6%EQ-T9867$W1E@O.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @
M(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q
M+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R
M:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @
M(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<]
M(G@M9&5F875L="(^9S(Y:C8T/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F1E<V-R
M:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @
M/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@3F%M93H@(" @(" @
M(" @(" @("!G,CEJ-C0N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @
M<G(R,#8P,S0F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(R+4%P<BTR
M,#(Q(#$S.C0Y.C(R)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#(R+4%P
M<BTR,#(Q(# T.C$Y.C(R)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R
M+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A
M<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.^* HB Q(')A
M<W1E<B!I;6%G97,@:&%V92!A(')E<V]L=71I;VX@8F5L;W<@,C8U+B8C>$$[
M)B-X03OB@*(@,C4@8FQA8VL@=&5X="!C:&%R86-T97)S(&-H86YG960@=&\@
M;W9E<G!R:6YT+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P
M<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!#86QI8G)I
M)B-X03L@(" @(" @(" @0V%L:6)R:2U";VQD)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!
M.R @(" @(" @("!#35E+)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @
M(" @("!'<F%D:65N="8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&ET96US(&AA
M=F4@8F5E;B!F;&%G9V5D(&9O<B!#4SHF(WA!.R8C>$$[16UB961D960@:6UA
M9V4@:7,@;&]W(')E<R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @
M(" @(" @9S(Y:C8T+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R
M,C V,#,T)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" R,BU!<'(M,C R
M,2 Q-3HQ.#HS-B8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" R,BU!<'(M
M,C R,2 P-3HT.#HS-B8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV
M)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H
M:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03OB@*(@,2!R87-T
M97(@:6UA9V5S(&AA=F4@82!R97-O;'5T:6]N(&)E;&]W(#(V-2XF(WA!.R8C
M>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03L@(" @(" @(" @0V%L:6)R:28C>$$[(" @(" @(" @($-A
M;&EB<FDM0F]L9"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@
M<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0TU92R8C
M>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @1W)A9&EE;G0F(WA!
M.R8C>$$[5&AE(&9O;&QO=VEN9R!I=&5M<R!H879E(&)E96X@9FQA9V=E9"!F
M;W(@0U,Z)B-X03LF(WA!.T5M8F5D9&5D(&EM86=E(&ES(&QO=R!R97,F(WA!
M.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<R.6HV-"YA:28C
M>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C(P-C S-"8C>$$[3&]C86P@
M5&EM93H@(" @(" @(" @(" @,C(M07!R+3(P,C$@,34Z,C0Z,SDF(WA!.T53
M5"!4:6UE.B @(" @(" @(" @(" @,C(M07!R+3(P,C$@,#4Z-30Z,SDF(WA!
M.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@
M5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @
M($%R='=O<FLF(WA!.R8C>$$[XH"B(#$@<F%S=&5R(&EM86=E<R!H879E(&$@
M<F5S;VQU=&EO;B!B96QO=R R-C4N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @($-A;&EB<FDF(WA!.R @(" @(" @("!#86QI8G)I+4)O;&0F(WA!.R8C
M>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[(" @(" @(" @($--64LF(WA!.R @(" @(" @("!";&%C
M:R8C>$$[(" @(" @(" @($=R861I96YT)B-X03LF(WA!.U1H92!F;VQL;W=I
M;F<@:71E;7,@:&%V92!B965N(&9L86=G960@9F]R($-3.B8C>$$[)B-X03M%
M;6)E9&1E9"!I;6%G92!I<R!L;W<@<F5S)B-X03LM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M
M93H@(" @(" @(" @(" @("!G,CEJ-C0N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(Q-3$Q.#$F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(#(R+4%P<BTR,#(Q(#$V.C,T.C(R)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(#(R+4%P<BTR,#(Q(# W.C T.C(R)B-X03M38W)I<'0@5F5R<VEO;CH@
M(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N
M,R8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!
M.^* HB Q(')A<W1E<B!I;6%G97,@:&%V92!A(')E<V]L=71I;VX@8F5L;W<@
M,C8U+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!#86QI8G)I)B-X03L@
M(" @(" @(" @0V%L:6)R:2U";VQD)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @
M(" @("!#35E+)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!I=&5M<R!H879E(&)E96X@9FQA9V=E9"!F;W(@0U,Z)B-X03LF
M(WA!.T5M8F5D9&5D(&EM86=E(&ES(&QO=R!R97,F(WA!.RTM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID
M97-C<FEP=&EO;CX*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/G!H86YL;VX\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R
M96%T;W(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C0V,35&
M1D(Y-3E!,T5",3%!031$1C0X-D)"144S-3=#/"]X;7!-33I$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C0V,35&1D(Y
M-3E!,T5",3%!031$1C0X-D)"144S-3=#/"]X;7!-33I);G-T86YC94E$/@H@
M(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z9&%C-61E
M-C<M8C(P9BTT.6(R+6$X9#0M8C4V9C<W.3<T8S0Y/"]X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD
M969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HT-3$U1D9".34Y03-%
M0C$Q04$T1$8T.#9"0D5%,S4W0SPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HT-3$U1D9".34Y03-%
M0C$Q04$T1$8T.#9"0D5%,S4W0SPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.F1A8S5D938W
M+6(R,&8M-#EB,BUA.&0T+6(U-F8W-SDW-&,T.3PO<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^
M9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP
M34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW,4-$,3@P-C-%03-%0C$Q
M0C,Y-#A!-3)%14(Q,D0T.#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-"TR,E0Q,SHT-SHU-2LP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z-#8Q-49&0CDU.4$S14(Q,4%!-$1&-#@V0D)%13,U
M-T,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,#0M,C)4,38Z,S0Z,CDK,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9G@](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&1F>"\Q+C,O(CX*(" @(" @(" @/'!D9G@Z05!42U9%4CXU
M+C4N,"XQ-3 R."!0<F\@4')O9'5C=&EO;BTS,CPO<&1F>#I!4%1+5D52/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM
M;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @
M('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^
M"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @
M(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y4<G5E/"]X
M;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%10
M9SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE
M3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-C$R
M+C P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^-SDR+C P
M,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S
M/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*
M(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^0V%L:6)R
M:2U";VQD/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&86UI;'D^0V%L:6)R:3PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O
M;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E
M;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B V+C(S/"]S=$9N=#IV97)S:6]N
M4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A
M;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1FEL94YA;64^8V%L:6)R:6(N='1F/"]S=$9N=#IF;VYT1FEL94YA
M;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1.86UE/D-A;&EB<FD\+W-T1FYT.F9O;G1.86UE
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y#86QI8G)I
M/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14
M>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY6
M97)S:6]N(#8N,C,\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YC86QI
M8G)I+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM
M<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*
M(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE
M/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E
M/@H@(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TR.2!9
M/3<P($L]," Q/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C(X+C4Q-38P,CPO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-S N,S$R-3 P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3(W($T],C @63TQ
M-2!+/3 @,3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,C8N
M-C8V-S P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,3DN.3DY.3DX/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ-"XY,#(P,#$\
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!
M+P)= P$1  (1 0,1 ?_$ !\  0 !! (# 0             (!08'"00* @,+
M ?_$ &X0   & 0($ P0$!@H+!P\)"0$" P0%!@< $0@2(3$305$)%&%Q%2*!
MD188,J&Q\ H7(U:5P='4U>$D,T)359.EM;?D\3=26&)T=W@9)B<H-#@Y0U=H
M=867I[(E*39&1W*&PM8U5&1E9F=S=L;_Q  > 0$  04! 0$!
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M\_75TAJQMS9\-]_;U\S[SMMX:L$]&VY QG)/3E(VR?LV/PU<[&;,F(#SB(_
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MKBO+4Y%LFKI+?'5=Y$0U;%$M3)!W0D,X*Q.K\[1",@\H<L"!#6[V]KK+9%J
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M@>W<X)WU*OVPUF-=\7\$THDH*S5I7,HQRY@'<@/$7-',F4VW0#>['   1VY
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MJLL07F*@[9CFF8'.P_)D$X"YVS46\19(\P"#8'0%'H9FKXQ]P'N"(@5=0?\
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MML><7/#C<)!$KF-B,OTD)5H98R!'43(3;:+E&RJZ>ZB2:S%ZNF<Y0$P%,(@
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M.$(<_#4#@\T"NA!#*K,C9&6RA4C)8X&"Z #<^1DQWI0 #*5)(P64,HZ9SL<
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M02$%T$R)[N!Y=UE5 %14XB<YC"(#J]V^"+N4>)^\CD!D5RQ<,');*L21R;X
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MYA;,)%=BN\)'2!T0*/AK"@L=P55,K,HIE(KXE=X>4EDDCD!,%1&>>&8 =5R
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M;11A$M(HB:!BAS'(HFT*L85/K <XE#ZH .HL%*L$]7.KLQJY(Y&4@80QQ+$
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M;KI:R6;O4:-.Z,I9U;9'4B-P,#F#-RE /GG &L_QLB8#-GK=0Q4U 2<(F !
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M =]4-28TQC/O/O\ #Q]GU>W7"6,(; 'R^_?T\]4W.X'T_?SU7U?F)2E-D6K
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MF5,Y 9L<H/09!;.#G,%(9..)+.$O#V!8[C%N)PCI"S,#%Y&]GLC[G7@ZXY3
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MKZ>>1)0^'WQ[\_''EG7T-/V)H&WL]<LA_P"=-<=__9SC#6N^)1BNC'E3*/\
M[DNLJM/]JG_*O]BZ[1>L=U<]------------------------------------
M---------------------------------1\XHO\ <8LO_*X'_/3'6E/PA/\
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MG[2O2#:@*STPSQDK"+TO*36XPDRMD:X9#JSQ.OR#BJ5YQ.K4EI1F\W.HMHP
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ME, ]0$ $0ZB("._ZB._V!MK-K/4E##2S((Y0A9&#*R2",@-RL,,67G!*M&N
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MH:.I4@AA+3QL",8/EX(9&@=XU9J:4SP'<&*5H9J<NN"-S#/-&<Y!61AC?1E
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M[8 'AKV"R9BH586C452)KHD5%ND*A$G)P4<I%/R<Q4W"A2G7( @54X 90#&
M!U\[^<*4$TH1F1V3O'Y6>(<L;%<X+1J2J,1E <*0-?>1,\W*N0& /*,@,<L,
MXSACNP\3N=>XB::?-X:9"<X@8_(4I>8Q2$2*8W* <PE3333 1W$"$(0/JE*
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MQPU4UM/;J2[<244MGBJZRJAJ*BGAI*>L5*ZI,D%)4S<\-))&J0R,SC&K8NG
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M/)R\YUF_L@2C)_37#/E!)$ --U.U4N07  V.>#?QTW'D$2AOS%+.ON7F$1,
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MRXRSSN(XHQ/;U+N>B@O6*H)]K :\2=IO D2/+)Q)1JB*6=N[JSRJ!DD@4Q.
M-S@:U\![2'@C-VX@*N/_ *IMW_Z=UD7]3!V\=/Q=77(\/3;-G_M/5O\ QQ=F
M><?NMH,_Y&O_ &37M#VC?!0;;;/M9'?M_P#)-N__ $]K[_4O=O7_ /KFZ?\
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MD5T3I- $S2.3;-RF!2R]H/:%6\0R//4R"&FBRM';T),=.C$KS'&\L[+DR3$
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MKOU]^Q^/AT]F-7GN"!DX )Z$[_0"<'J?S>FVQWQO8*BV\!4W@)A]4W4"]P]
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MV,V=H@9%T@H1P@ *M'2([@ J(*@"K9P0B@$.!3IAS;#CTX>,Y&0<_0/#'O\
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M(YQ3 R3Q)+//B-GCIX&82S&))4DD**0B$MD\K8&=!,*?UC(4[PX5BJKE@"[
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MZ2;))H((MVHIHB551/QANMXNSWZYBYSP0P.E/'2".(DKRI)(ZL[MAF8M(VY
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M*7MFX#XBX(J^[;B&S1&Z<.53D&1JBG#")0Q.P+,:*<9(%/5(Q!:/(RMR& 1
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MJ".YB!1I"[?FK(71<?.91R@X8C=%NH;A04%)05$DE.E)20B>GDD89JJD]]'
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M?4+&\57K=9)TZ0*./>E&R2JNZJA$6@BF4O.<3'W,L"IMQ'<>;KOUU=HV+*B
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M-O+;6S;Q:>YC@D$[2&IA6-6"JC1F4X*A0<%0%<(P)++R\Z\V3J,+Z(=&F!,
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M3.J=+:79]<;=31UU-/-!3U,LJ21O*Z1"6%4QW:,Q YHY"[,F0Q#@@'!QP_\
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MW"EK+IP]6F:&1Q06@W29451Z9%/)Z29PJ*ID6(1]X0IRH \,"=!%)'!61<K
M=[4"!22?R;(O($R2>4L6Q[<ZUAY&]GQFFE8#]GG!LL3Y:GL?2>"[-9.,BFLJ
MS9^(^Z1W&%?\1XB@D<C7+&,QGK&$G*RD$E7+)5*A-P=G?PV())B5Q&UZ/^D6
M\B7):>_4<UPO\AJJ2.H2NCCM$S2Q6Z%K1!55;^CPU*T-2JJYDCEE1X@]6K8:
M1N4J8+TDJQ48[MRO=,U0@5IB*ADC =H^^3)4*54AB(R-ER<ZSU!<,O$54.+#
M@\L\-1,^9YET<)X'Q1E*\<4-!A8QCB6J5S%-G)-Y:Q]F&FYTL2=$RNVEIAO7
M<PX?E(:_I9+M0/I%M8IEH2,L2T%[E;Y;5=XGGH:%/3:ZJI8+94.YJII*J+NZ
M6>DFH8^_I2J&2CJT>G]&BY08T.8Q66&59Z9@DLI$422-.B_DP$.9$D61N1\[
M21X?G;HQ4!M1CJ6!..*YX"H>'K%PM<053E\(^RA]H3PLVB3N#JJN8/).=KQ
M5YC1XRE_0]UG'UA86!)BT+6+3,L8MC-N7KUG#+.20LBX)<I:^R0UT]7'<Z"5
M*WBBP7.)8EE$E/0PR.TS3<\""-H\GO8D9F0 %P.=0:*15311QM!*IBH*N!BQ
M4AY7"A0N')8-CU6( .=NAU//@NX2)7!_M"_VS+IPU7QL?('!-PMQ=7S+'@F]
MI="RA0\=6FIYOKEZ<&MJ2D-8YQ *I#14<G7IA!T9N#EB$<C[X^-8KQ=5K;!Z
M-%<H#Z/>;FTE&V5FGIIZB*6BD@_(D/'&>^=F[Q" <-S$!1)IH#%6<[0N ]-
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MVB2MUE9S'<D>.=-'<N43M6YW#9 B!#MF\^]3D)<4G92 F,B18Z*2GC[:!O\
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M2%D,05B2\?-&0S68AP_6B<B7\]3'#.VMH1G[P[:1I'B,RV; *BB@@R=M&QY
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MW7 %G;BT9"E6Q1VV1:MV=>A5#E#;8ISKS0%$WU3B0PEZICMHN\2=]=)]LB%
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MH/K_ "VQ@,D8V'G[O;K*Z4;+[1M\!O\ 7@_0/#7%4G2DWW5 !V#?<P!O\0*
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MWB?@.XP8_!G$S&VO'O$-&<4,MP;<5&-,DK,L?T2-H/$EDV\S#=Y5IF>SHGQ
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M5;YN&WM4-Q%;4U-'9DHJ:21FDBKQ64RU44%&E#$E*8D9X^]-3--6)SN6DRQ
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MFV(.&W]N<8SXXSY;8'78:SZCF4S1-MRB-$.3^:NX)^O<^'CJ="=A*@0-U $
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MRMEW+<KQH944'14'"Z)5TS@FLH38X[$MC<U,OLP/#R!\.N,ZY4O2".M=0P8
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M'#GSZ[]_X]^GV:BN.OL'VD@['V#RV\?#55>C>[V^1^&N_/\ L6/_ +P?*O\
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ML>8JBH6<R+;H:H1%BN-5Q_!R$PY\!M)W2[S;>N5.N-3E*ISR<[..V\:Q1$
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M>60RQF45+]PO>2&1TYPRR-)-,QMLL'([,8YN[20('#99HE 5W50IY>0<Y(
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MQI^_M?\ S#_SM/Q2L1_WFQ_PU_JFG]37V:?WN^_RM_Z;3\<_&G[^U_\ ,/\
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M1304\DKNJ)$):IY6$2E<9=F.O"6L+&0=&5-)." H<5#"Y,<B7)N(@1)!-0H
M3?<  @% /+;RP^4R3N6Q*0#N27*^>.53L/(#'ETZ]"(]-$H2)E15P,<N 0 .
MF0"Q)SOZQWS[12'5LC6(' 'C4$P+S<A6HB3J'03%,J8RAAV#;Q14+OON7SU]
M6&=L"./8G;U.49VP3EB3GKN"/'&O,M?2Q*>>7 QN2,' SC&3G.V//8>W6/I*
M[MY!8_A ^E5Q$2HM4DR-F1! 0'8Y4@3*4@;;CU*7H([]=3DHJC ,S11C&2Q/
M,_4]!LHWZ #QZ>6.R7JG<M'3+-5R9(6*)2J ^MCG9BJ@9ZDM])V/#D+!^#$2
MK;[FHDR;M""6'A&W(51PY,4?#*5(-@.X.&P%V$P)DYUUA*   7_A/@^[<?7^
MFX7X9A>:69E:XW*4,::WTBL!)/-(!A(T&P'SY9"L489F)UC?'W:1P_V-<&UW
M:+VAU,=)3TB-'8K! \9N%WN+JQIJ*EA<CO*B9\$G^QTL(>IG95CQJ!EPM<E<
MYY].RB@BLZ4$$4 ,(I,VA!$&S1$.@ 1 @\O-L J&$RAMS',.OU.X'X-M/ ?#
M=NX;L\86GHH1WTY4"6MK) #55LY WEJ)!S;DA$"1KA4 U_/9VN=J7$?;%QY?
M>.N)YF:LNM011T:NS4UHM<3$4%JHU..6GHX.5,X#32]Y42#O)G.K;(<2]OS?
MHV\]^FLNUK1AS@YZ@?3@]?9CQ\_#&N64=P 0\]]_AOU_7M]G;7T#)QYZCD$'
M!ZCX_';P\=>!TN<1$-]_S=OM_B[#\-?>1O+ZQKVDO)ML03[C\//V9UZRG5;F
M 0'ION'H.WZ!U]5GC.02#Y[[X]NVJI2*=3D;]"?'W^T=/JSY:R74\FS5=*9%
M%<%6+@#(NF#HI7#-TW-L"B+AJN4[=PD<.ADE4Q*._75UANO,G=3A94.Q1QD$
M#W^(\#C8].FL=JK,JN7ARCH X9,J03OS!E]93MYCRZ=:XYJ^/,B+'<PCY"C3
M2I@YF+T%7%7<J@  84%$BK/X<#FW^J";YH B!"$:I%'EI2VVFJLR44H5B<&&
M0DCR_)R'.,$[*^?/F& -2::[UMN @K834(,8E0!9E#9.74X5]CN1R-T.')SJ
MVI/%<O3UVPV*.52:NQ$6,FV61=P\B0H_6,QE&8.&;@0+L*B1%P<)<P NDD8=
M@@-0,C=W(A1SU5UP2/-<[,I/1E)&?'PU>J6\PS?E(F#@?."Y#I['1@KKY@.H
MS@$9U?\ 5VT>W.0C8@$YMNA3+FW[=1#Q@3-MUZF1, ?>.J#6Q,DJ"#C!/38;
M^.1\!D9W&_7(8+\/54X(Z8(SUWQU.,' .?+P&^I"5JOQ;HQ55D$"'$0V.Y,B
MB B/;E)L0#&'8! "D,(CZZJPV*><XBIY9>IV5F 'F6/J@>&2=M2)N+;?01]Y
M4U5+2A<9YF17/L"*2[$8V"J2?#PUN)X(/9^)9-EH[(.6"I)TF-7;N(^E$%1)
M_850Y56YYM(037CX4Y>54K8X).I(FP<B;4P'4PGBBM^2>:AA"BH=#S2*0R1J
M20>1QE';.061BJG(R2-KW9KY#>%>6EG,@A8+(A8+)$S ,AEAYN\A+*>95F5'
M9?6"XP3VL<1UYI%,F;=DT;LF$>T1;M&C5(B"#5LV3*FB@@BF4J:**29"IIID
M*4A"@     :T9=YBY8$\S,QR>I)/F2?'/7QVW.^LD@&/6/COO[\^S/3WG(U:
MV8)@I0<_7V I3[=0Z=!_CV\MO/U#5]X=IL]WMY?S@YQGP^YUAW$=3A9-R-FW
M^D?7D^\C<9WUK'RUE"K8P@92Y6QVN1J#UO'147'-5I.P6>P2CDC"!JM5A&@*
M/Y^S6&25;QD)#1Z2SQ^^<)(I$^L8Q=I%TI:5I9/F01-(Y! PJ*78Y.%& "22
M0!N2<9.M3P4D]TN*4M. 9:B98U+DA$YV"\TC $A%)R6P3CH"<#74$XULG9ZX
MHN).=1S-3K5BR+QI).8"J8:M;![$2U);'\%<[JQ13M-,YK/.-3M7SQV9,R1F
MBK1)@=2/(@HMDW"5J>]Q4UP?D,$R"1>Z<2( 6/J!U'*S(1R2,,>NK* "#B^7
MVIHN%4J;91R]_4JQ2HJF4QM*R@>NJMZT<+$\T*DY*,K'+-KTUJGMFC9LD*).
M9))-/F @ (@GT+S#L'U@#;J/< #?OOK<UKLU+00F"GBY4:62<JQ)59)F[R7E
MSGE4R,6Y5PH). ,XUI^_\35=RE66IF$DL5-!1K(H56>*FC$4(=A_9)%C54,C
M>L51>8G .I"4RNBJHER)?N8; 0  -AWZ;@&WV /SZ@/>^GEA3E7 /Z?YNN<C
M&!MOK7]3*9I",G&<L<^ .<>PYS@?]$[C4[,18Z=3#YD@DW,?G.0!Z"(".X!U
M';H >O7MW#5BN%8L$;,S ,02-P,#S(R/U;_1 E82,57(1, X_..,8 QD]<
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M=>@=-M4#1R D/R21Y]O,.ISE0,X]WN/35U2\4\P'=]]&Y P&0*2W@I#'&WB
MV>GGJO,GD@DDF\%5L58#\Z7[L1LY$P;"42D 2@<>@#L&^_0.^HLL4+EHN63D
M888<K/'@G!R=\>()VZ=<=+DK2/#B7D)<$8#!6((Z8R06(\CCW:D!<N,S.=NK
M[6H66U/W-=9L$(\(=J1&,;N4&R""!0?^Z$2/(B8&Z1SB],N514H*" " ;8)8
MNR3@FQ7">[VNT4T-QGK*FO-9(#431U%829VIWF+M3JX."D!CC VY=SK75DX
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M9H@<:-<MS#1G@A24DK-(D%?]K!P==S)I"7<S@T%+%*#=U'(% 3\DP=FX;(E
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M2#M2MG#,5!P)8^&K9 IM5%4R4-JI8)EG)@,]15+3]P;O%35-1-<H*F@AR#M
MX9X?X'LE9=;%<[79Z^EH+942V6JNKS7JNK9Y@M1+3FLK)I@T<:RO#!#SK(:5
MNZ5(765M7TZ\MU\MDY?<AV.6NEZM#PK^Q6F?=*R$O+/"-T6B2KIRKN<P(M6S
M=HU1*!$6K1N@U;IIMT4TR?JU9[%1V>D@HZ&GCIJ:%.6.*)0J("2QP!XLS%F8
MY+,2S$DDZY-N_$=7=*B6JJII)I926>21CEL* &9MAA5 55 (5=@!MJ]Z]4'3
MLZ7[B8"F, \O*.XAN'?;R^8AT#;8 'I>2Z1#P.QZ8Z^X$8&?IVZG6*2U#RMG
M).-BQ&% _P 7??PSC?IG;?4RL5XCD)1RV219J'$PD#HF;IOTZ#\O/;[PV'5G
MK:Y(5+,PV!P/#/M'V#!^K B.^<I&VWY[L?+R/NSOD #S&YS/Q*\1U'X%<;>"
MS-%SV>+1&'+3*D8Z2PP:2Q#)%MMD;E,*C>+9GW/'M5@34F7J8(I![LD[53U9
M>KO)<96I:9R(P2*B=22%!QF)".LAS@G.$7)WQAM@\$<'2W:>.OKXWBMD+AHT
M8$-5R+T^< >[!&6ZX'CS$8ZLUQM5@N]DG+;:Y5Y.62Q2+R8FY=^L9=Y(2#Y4
MRSAPLJ<1$3&.8>4H !$R<J:903(4H6=55%55 55  '0 #[]223U.NAHD2-.1
M%5$1.154 !5 P%4 8  &/HU8;D=]NF_41#RZ]OL[^O34:0C'3Q_7Y  ?? U6
MCZ8Z9.^1[B-M_9_1JWW8]!\MS 'IOMTVW\^VX^7W:@L=R??\/+P]PZ9]FI?@
M?>,_7CV?I^G>WG0]!^W\XB'S_-\]M1'Z>SX^?T'W==LZ]+LK'SV^_P!.N_/^
MQ8AWX!LJ".W_ 'SMN[?\WN,]:?X[_NO#_F4?_6S:S2Q?V@/\J_V)KLQ:PK5Y
MTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
MTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTUKL]K6.WL
MV^,+_F>E@^^0C _CUDO!YQQ/93_\]']C??'CTU;[M_<RN_S6;_8.OFI-3;AM
MT[?:/<!'8-_7[>@>NNJ4.0?#?.WM\_=X'X:TY,, ^P@X'3KG?ICW^'MU541V
M$ ';KMUZ==P_4>GEOZZN,)&3[C[<GX>&![<GITU%?P/LZ8W_ %_#?'QWK2!N
MW38?OZB.X"'^SSU<83C /3./'V>W8GIGP&K?*O,& Z]#[<;GV#P\?Y^:3N/I
MOL'IYCOM]FK@IQ@XQ[C^G?.VK8ZG!ZC'K=<G; ZCP^PC/7.;JK5KGJLZ]YA9
M!5J G*==L(BHS=<H&* .6IA\)7ZIC% XE!4@#NDHF8 ,&(\;=G?!_:+;/DSB
MVS4UTA0/Z+4L.ZKZ%Y% ,M#71<L],^0I94<PRE5$\<JY76QNR_MF[2>Q:_)Q
M%V<\3UUBJI>[%=1!A4V>[0Q,"*:[6JH[RDK8CNJO)&*B ,S4TT$AY]2^PUEM
M];;K68!A&&9763D$(Z!4:J%,P>/W!A*DW.9PHF9F0^X]5U%4 ZB=8@=^$NT'
M\#CB.P>D7;L[O4=\HH"9A9[LT5#=HE&?4@K,1VZM(PJAI!;V;]Z<9/ZN=F'^
MZ;=GG$E!\D]N_"TW"=3Z.T=;Q-P[#47CAV9.4=Y+4VK$UZMR%2S]W +TFQ/.
MI(75V9.Q58/PHF91U&HUQY(/E%W$45H=&)3>F*47(L%D3NDBE<+ HX%-(5$B
M'5.5$")%*F3FB]V3C'A*00\6\(WRRDDJDU5;ZF"GF*YRU//(AIJA#RL0\%1(
MA )5B!KLO@/BCLB[3J"*J[*.UGA/BZ!8TD]#IKU15-QI(7),,590AUN=$\8:
M.+NZV@BF0!1(.8Y:P JDXB0"*M@>\H&Y>1R@<H#L  )/%,@<H@ !R[<HAMY;
M:QL7.B8Y$ABSC8QOGVD\JNOO\-;1'#5XB4)) *L '!6IA9=L#*]XT3C'0$8/
M@=]M4\:Q83#RD8+"41$>551J(%'RV.9<=MAWV'J'GN.^^JWRC0 9,RC;JJR[
M^)) 0?4/LU";AV^,<)22LOE))3^K[ [3GK@=3GQ.JBTJMD4Y =DCF#<@;&$3
M$.L =QYA2%4@#W[CWZ;]=46N5$3RP^D3R$^JJ(3DGR#!6.^.@SC/7IJ7#PY?
M2!Z9\G4-.H]9WD4N!X9,?/&I \>8;^W<4V6<X[KIA+8K2BJN4P%&,9NCKK\^
MP#R':LA6<!S#L',<$2@(["8.HZSOACLX[3N,FB'#W"->M--CEN=PA^3Z'D;
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M<+W>+I+W]SJKM635U562=><SU+NY( "K'S!8E 6((H UMS=\)N8^#SABKR_
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MGC1,]>4#F)\2[=3CPSL!MC &IV5"MF$Z9A(/,(AMN7MU^7;X;?;K&ZVJZ@'
MQX>'EO[<;] -72GAQN=]\D^9\<>SW>\]!J8>/JJ@V#WUP1)NBD3QEUU (D0A
M$2"8RBRAN4H%3(!A,<X\H  ]0#< US4TUMHJFNJJ&WT%)67.1)+A4TE'3P5%
MPEC!6)ZN:&-):F2,,RQM,TCH&8*0"<WI&FD6-99)'2$$1(TCNL2D@D(A)" X
M!(4#)QG.-:P.-3VN>**.>Q8FX8EX?/&:H]H\9II0STSK'E<E$"&3!&9LC!04
M9J014 2_0L"NJ/CE]V?R4<?<!RJP<,5K]W65M/)!3NZL[,I$O=L=W"$950"2
M2WYN64'KK!.).*Z"E=Z.&=))P&0<K?DDDP2JO(-N9B ,+D@]2-=?>D<<O&BY
MKV0H6]S50M"^0LA0V0)23M-'8O;'5Y"!&+295^FOA50"K5UNG"MD6[%FU%_#
MN'$I)P<C$S4O)R+K<=S[$>%^/+/4V?B..N>UW&URVRHIZ2K[B.6FG)<2.I25
M)F5RLACF22DJ0BP5U-5TI>!]0MVK7?AV9C;?0VGCJXZI6J*?O&1XPJF-6#JR
MHRKR$J5GCYFD@EBE;O!5,:WC'CNRY;N?$GC&7SO;<A5F0;UN4_"^3JZM7MRY
M3$9S(IQHD(X:-4O=V[-N)%&T6W9D;MHYPDN8$=AV7LYI.!.%>$>#.S":@X)X
M<X6:GIUMT%!#5QU%MB(:6$O-S2-4U$IEJ*JID<SUM3/)//4=Z2SZ]?C*&]76
M^WCC2W5?$=?=::7T63TR6C6CK6R(I46/E3N8DY(X8P"E/'&$2)@3BQJ1AJ6E
MUTE09+'*82B F3-VW[!N ]1Z#ZAT^W9-3711*?651C&QW.WAG?IG[-M8 TA.
MS$,?[VO3;]\PV!WZ>[!/03CQGPVO7:S8%&@@ B3FW(/* ;@([[^6V_EYZQFO
MOD,,;-S !0268@$>?L!.W7)UX_*2L$]9F; 6&+<D[[>KG(SL/F@9QUZ63Q/\
M;^(>#^'D*)C$8?(N=3-U&ID6RB3VK4)R)13]YLSMN<4WLJU-N=&MM%15*H4/
MI99D3E27U]67.KNKD1,T-(20TY!5Y1L6$(_>L-N\W&#ZO,=AM#A7@"6I:*NO
M2F*G!5XJ/!$DF,,K2'&RY/K,PW"@(O5AUI\A7ZW9/MT[>KW//[+:[&^5?RTQ
M)+&6<.%U#="$#8$V[9N3E0:-&Y$FK1LFFW;))HID($01QPJ$C4*B#8#<D]22
M3N6))R2<D]=;QABCB1(XD2..)0B(B\H4*H 4 ; #/EG;QSK'3DP!S[]>G+Y]
M_3I^HAW[ZH,=B?OD^W4H?-/M./+Z_9UWVU07([B >@!Y>8CZ^73MV\^^HDAQ
MC/@,]-\=>OM^G5:($8'L\?#.3C&1G?KU^&K?=F[>O4VWQV\P^T/T>6H+' )^
MX)VV^G5?P^/W^^-6^Y'J/7IL'Z_KZ"/SC/T^/G[/O]SKW^9X;GZ=_;MX?5GS
M&N_3^Q8! > ?*P!N(!Q/6[J/<=\>XTUI_CO^Z\/^91_];-K-;'_:1_RTG^RG
MW^O79DUA6KQIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
MIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
MIIK75[6T=O9M<88A_P"1^5[_ /I&+_4/CK(^$/\ A-9?\]C^QM6^[?W,KO93
M2G;V*?N?9KYIK8P[AMOU^S;?L/WC]_RUU3&1D>1&Y]O7/P'A].=:AE4'(WP1
MX_5]6,^&JPF;8P#Z[#UW^SSZ]OEV^>ID+8/7QZ'X8]^^WNST&H.,H0<$KG]9
M^K.WL\]59N;??KWVV^?7I^GSVU<T.^-M]_B-]C]_/WQ)0=O,YZ8S[1X$[8Z=
M<=-5(H[@40ZCTWZ=.^P!O]G]?35QB)*CH-L>.=MB?CG<]/9OG5J=<,<[#./,
MD$;G'3QW^S7)(/4/0=PW_7X[:E(<CKD_#;V'W_7J%(NQ&X(.<'KC)&?=C/WS
MJ0_"FH5+B0PJ8X@!39"KR?EW6>%1*'7I]8R@!]H:C7+^YU4P.,0DMO\ O<';
MQ'3W;^6K-=1FW7%=SWE#5+C'B8'4?3]_,;4>)F..D]EA(!DSD66,4Q1$# 8I
MS"&P@8# /0>PA\^^K];XX:BA2*>*.:)X@CQRHLD;H5 971@592#@A@01U!Z:
MTQ:JJ>DJ%J*6>:FJ(3%+%/!(\,L3H05>.6,JZ,#@JR$$;%=:OK7,6".6.+.8
MD6X 4Q0(1VMX8 8=QY2"<4RCN'<  =PZ#UUAMZ[+^SJZ\YN/ G"56Y8\TLO#
M]K[YCDX!G6E6; \/RF/,';737#';UVT\/P0+8NUKM'ML2)RI!3\9\0+2J"!C
M%*U>U-D8(!$7N.#K#LA>KJB<W)9YDH!VV>K;;;?$>O4-O7].L%G[%>R>$B2/
ML]X45P3G_>BE(SUZ%2.N-@-;-IOPJ?PCJA&@F[:NT5T. 1^Z:X*2,C YDE5P
M!UV8';?.L?REAL$ASA(3DN]*.X"1U(O%TQW =]B*K&( #OML!0#8=MMAU<:/
MA#A6SE3:.&;!;&3!5Z"T6^D<$'YW/!3QMS#'SBQ.W75CN_:3VB\4*R\1\><9
MWZ.08>*[\37JXQ%3\X=U65LT83?'*%" ;8P !;.X[[[COOOOY[ZNAP#L",-S
M$G'0'P\QY:Q1AS AM^8$'.^01@]?9KS<[=1 -M^OV"("'Z=>ZGQ.>N_U']7P
MSC5*C)Y$!ZJ,'_C $-O[Q_1JEKM4W)1(<H& P"&P@&W4/ET]?GZ:MS(KC##[
M_?;5SBD>-@4.#]_?]\ZF5PA>T&XMN!681=84O!I6B>]>\RV);RFYL&/9,#&W
M7%FP]Z;R%:>*B/.:0K$A$KJJ 07OOB0"B?$KWPY07)&$J<LA! DB(5QM[B&W
M\&!Z;%?#)Z"Z21%2PR<[G!R<;]1O]]PV-=C^A>U7]E'[2&M,J1QY89HF',JG
M13CDY/)#('L&N)"D("E8SE#1D)-UA%501\)G+/X(Y Y4@</.4%3:PFX?XDX=
MG::U5%1-2DEBL#$,-]R]*24<8V+*K$^0Z:S**NMUQB$=0L0?! $P!&,?FR$#
M'@ /4.V<>.J;DKV"?!7DZ-7MO#EF"[52,E"E=0KJNVJOY9H)$50 Y!:D>;3C
MI Y# ).>Z',41 ><Q  FKU;^-KK%RQU:1R,NSB2-H)>NXVPH(\<QYV\-0:CA
M^@?)C$D>22.[<.GAC9PYQC.P=2!D#QU<G"#[,:'X0F]S1+?POUHN\BA"S]M"
MOGK+QICQBB+QW4X-@$G-*-EIJ2*D6PS))1%4S B"<:FW=MTUC?D]^%9VU<4=
MN/:]:^RWA"R35"<%W];/P1:*B)GI.(NTR5(8J_C&\154<,8X<[/:"HEEHQ4P
MU%OJ[C,L]0)Z.1D3;W!/#%#PM9JFZU<X$EPIQ-7U /*]+:5):&B@*%_ZXN$@
M <KRNJ JH5U!."LDX7]JO,W/**]#S;B_'5%O4DT^A*XPDY1<E+KD.V/$PL#6
M7"](>*0RI8KPS3,C$-8I63E!5D" W4\$$>U^#/P//P>+1P_P!1\5<%P\9\0\
M%TE1-67^ZSU:/Q+Q%=:J.YWB^7^EAK5BO$TMS5I*&*ZM7I04G)11%H1(), N
MG&'%L]5='H+H+=2U[JL4$4*,:.DA0PPP4TKPL81W7]F:+NS(Y,@Y3R\L,/\
MJ,N<KG(J2N4L_P!1/*NG KO99BPM=QDW/B#NKXKF=_!U0Y@,&Y .<2EZE*!2
MCT[-EXEB,,44=-(.Y41QEG7"Q*.54(]9CR@#&6!&YR2<ZUC1<,)2S2/'/$D,
MHR\$, C02<Q)D15Y$&<D$<F#MT(U)O&_L7^'6LJ(.L@VV^Y-=I&*8[,7+2GP
M*XEZB55C#D=3')N'0I+"3IOS"8!  M<M\JW'J!(@<8(4L=MNK-@_$>S&KW':
MJ5""W-(>F&;"GSV4*<[;C)'LVUL9QQPZX\Q&T;0N#,54BEB<O(^GF\4W%XW:
M)J-P,>5DU5#62:,X3,J1,JLDX.18"F4#E.(ZU-VK]L?!G8[PG4<9]H%7=)J,
M5"6VT6BUT\M1<+]>ZFEJZBBM5).T9H+?)4-2LJU-SFI:/F*1F?O6C1Y(M'$M
MVJ:6T\(4- :NI9FJ;C<)%2W6BDBD@$M3501RPU=8SI(R0P4A>;G7G8",.PD0
MY@7K,KTQ4#R!V:"JR2+<H$4?J$2,JB@V!8Q0!=R8 233.<.50W*<P%*8X:OM
MWX578U/V<<"]IE[XII.&+)QY6T-IM]+<6:HN-%=IZQ:"X45724<<DY2QU/>F
MZUJ0BE@IXO2BW)-"),GJ^%N(8:FYT-);I+G5VJEFJG2EY(UJA%"TL2P23R+$
MCU>%2!7E#<[<I;*L1Z:I?\>,J0OD"\62N8[AHE9RSLCFYS\5!LJY),1*#UA(
MR4DY:,T5D-R'Y3J$4V4*4Z9%N=)/H2]1M13I%!/'7TM53P5MOKJ0B2GKZ&JC
M66FJZ9XRRO%-&P975G4CUD=T*LV&<(WNFXEM2W&."6BFCGGI+A05.14T%=2N
M8ZBEF4JI'(PRI948J5+HK$J->O$/[?G@AP"D^@L.JR_%%D1L!T&S#'Q1C<?-
MGI-RD^E<B2C86+AH!P'F4JT?9.8 Y1,F @<;/%9KA7G?%-$W5G',V#^]C&-S
MX<Q7&^?'&3M4P0@DD$C.%4^.QR3G'UDC'3KC0=Q(>U;XZ..!1Q7[?> Q%B%Z
MH9-/$F)E7]=A7;(XB!6]LG2N1L5N,*0@5RC)/DX=<P>(G"M]]@V!POP)1I/'
M*T!FF!#&>H =E(/YBD<D>2.H',,_.WP<'XFXL,%/)%&_=E@5"QMC.<C<]6/7
M(V!]IZ9%X26\'2)*.7$B(N$U$C@<P%$3;&#<-Q#?\KN'F ]QUN^/ABD]&'J*
M3RX/,H/K8&#CICP)P<' /3?F/B"[U4DTB\S8+%E*L1SC)R!T)(V(R?/KUUMJ
MN.!X;)HL,C4-NW2++E13MD2W(0/=)4"E($LW2)L'N[_E_LPH%W3>\RP[@[$"
M0Z"XFSLULJP1&O,U#+G Y-RU,Q_?)\Z/?UHR4']CR<;EFEJX>_##OHE45',<
M\R''=U  \_F3#P8!NCDZOFF<*$)&$)(3B(*"F!3F%?PT&R>P;CSJJB4@   (
MB(CL !OOKY6<3*#R)*D9.0 &YY"?8BY.=P  /$Y'AJ$D594;0P3S#IS!#%&/
M#YQZ@#&=R,8W\=<+.6>.'+A&C(8]Z=N7TM.L7#^MU>FQI9F3F6S186ZJX2)C
MMX)BW*Y_<3JOI)%01#=)%;EVUC\MTJZMWC@AF=U YWJ>:"- V2"0P$K;#(Y5
M8'Q&^LFLG!]SO0:0U--3TL;]W(T<BR.'P&*80LW,!C.XP2-QX:6^([VH>9LM
MLW]1QDV+A7'[HJS9PC7WJB]VFV1P$ADI>U$3;*,45B"'BLH)"/#E,=!=Z]1$
M=X#TC2N)*R;TALY$>.6G0XP<1D^L0>ADVWR%7KK;MDX2M-D57CB](JCC-34
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M8J%#$@:G=2O;1^T5Q(X/$W5UCK, QYSL709+I+B.LJ)FZ@IN&B\E49&K*D<
MJ4Q%_?F#AP14G*;;D,0<%?LHX/GXICXU7A^@BXOI;?4V>.]^C(+G3T%1*CU-
M(99%9U#R0J)"<3<H:(L$9D-^3B:H]"6E%49;=.8ZI%1^>GFR@,4R-&S(Z%&#
M(5RC\P8>#:DS$?LAZU 1(E]X/XU=4J8%<NJ?E)TW(JL&P&518S5.<"@0?[E!
M20<F#M[P.VXY%\A54.ZRL0-_638;XWPV^P\NO7(U'%QI9>F![F!'0^!Y2/K.
MWO.KZ:_L@W#JYD@D^&#+K/<3>-[A8Z=(<G01)X7O*\=X@".W-S CR@(B &$
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M"RB""(2%1K8X^> ZPYNXEL96'&(PL8]RW$237(KJ46(W9P#O'Z<6T=7-TV3
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M!!!!'4$'!'D1KT%W*/*/K]4?U[?+UUZ&O388<P\O6'WZ^_RU4FZG8!^S??N
M_9^;X!Y:K1.5.!TZ_']&_C\<>&K?.AP1Y^63[AOD#Z?'H<9-RL'(AR"(]0$
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M9&^?;LV/K&GB#YAN/F._?]?GI\IMC&6^G^;(^G3T9<[9QX;-GI^OZM?HJF$
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MR /M_-J.[9./ ?;XG]'L^G551] Z_;OX^'M/VZMYPKL [;")N@#\.FX^GPW
M WW\^FJ+MC(QU]OA]\CX>1U]9LD]"/9GZLYQY9'7VZHZY]NGD'?]?G^?4*1\
M9\E^LX.>GLW\O9D:^H-L_1T_I\]?0D_8G@B/L^<M;_\ "EN'^CG&'Z_#6KN+
M#FY1G_Y6/'N[R7676;^U&/G,_P#LI_1]'EKM"ZQC5VTTTTTTTTTTTTTTTTTT
MTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
MTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTUK6]L0.WLQ>- ?3#,M_G.*U?.&O
M[O6O_.D^QM0KC_:%7_D)/]DZ^7NW7$NQ1ZA\1 ! ?7?T_7;70*MG;Q^W[_3[
M3OK7N=L'X'R\\[;_ */#5:06V'<-M_@.X?;VZ=?Y=2HW]NX^L9'CX?;G5-U)
M^'A^K5807 =AWW#L(;@(A\N_3<.G;M\]3%;;(SCQ&? ^('38^_KX==1RI0YW
MQXCW_JR/;OX:JB*P !0$=P\A_J'R_1TZ>M4'Q!^_W^CWZ\,H.Z[C?/L_2.OP
M]VN>FIL(!^?X>6X?'M_7JNK>1P=_;T]N,'PU19>I!^'QS_/[]<]%80$.H]!#
MIOT]/N'S]/SZD(_CXCJ/,??'QZ^VBZ==MQU'7/T>?Q\CX:J2:P&Y0'OZ]>@"
M !T$!^(>OV>4E7\B01OC8>[8?7OY C;&H3QD$E,Y/4;?9]\>/CKF$4$O4#=
MVZ]OO].O\6I,<Q&V<=-OJVW^@'5(@-L1AL=-L']?V_1KNS\,Q@'ASP,(B ".
M'<;#MOZT^''UU_/-VQG/:WVG'SX^XN/TWZOU^L' 8QP/P</+A>PCZ+72C6;]
MP]0^\-:WUEFFX>H?>&FFFX>H?>&FFHZWGB.K>/,FS6/K)"R2+&'Q(3)Y;2W7
M07;24BLZO(M,?Q\7RE=N;5*0F.K7.PZ*2JA9%O#OVI$TW"*0.-B6/LZN/$/#
M5%?[;6TSSUG%IX8-KD1TDIJ=8K&);_4563%':Z6MXAM5#6.R T[UD$K,T;MW
M>/5O$5-;[G-;ZF&14AM(N?I2LI621GKN2@CCV9JJ6&W5<\(!(D6%U # <UI'
MXPZ#%4.%M-HA+)%6:7Q@YR86AQC):P2)VT;'JR,O#1<L@W:1LJZCD&[Q0[XO
MNL<=!FZ4%=-5NNW3NR]C]_JK[6VRV5MNJK92<3Q<,F_54Z6^F$M54+3T=94T
MLDDU32Q5#R0J(/RM0LDT2A'21)&B'BZ@AH(:JJ@J8JF6V/<O0(D-1)RQ1F2:
M&*4*D<K1*KEI!RQ\J.2P*E1<[KBQPHTE9Z!&?EG4_7%HQF_@(VKV"4FSR<G;
MJA0@B&D7'Q[EXYDF%SOE3KDFW*D ,I*443.H*<5,JQULC[*>-9*6@K_0*2*@
MN*5,U/7U-TM]+1"EIK1=[\:R6JJ*B.&.FGLUANUQII"Y,U-2JRKS5=$M3*;B
MJRK+/!W\K3T[1))!'2U$LQEEJZ.A[E(HXV=I8ZROI*:5<#DEE()Q%.8^>?B;
MQ2FA;'*CNS(I4Q262ECNJ;9F"3@:_<92@6!2(=2$:U9RS>#ML.]AI-VS<*-6
M[CW7]V.5ZT,M'7LSXJ>2TQ+#;7:\K2-2"*\6R=H_E"STU_MZU<5/4RS4DM=:
M:N&LI89HUFDC[WU%,,H2H>)+6%JV+U %&91+S4E2@8P5DM!4&%I(U258*N%X
M)71BBOR^L0Z$\R%S[4Y2KW^\JD6)3J9882+8S$>1U('GXBPT7']UBIX&1V3-
M:+17)?6[,Z+PPI-46?OSUVV*LJ@THUO 5VI;I8+&I0WF\V^MJIZ.<Q4XH*NW
MWR_V:JH#,L\R53QFPR2AX1S2O-W$$,I1'E]0WZDEI:^N(84='401)-&&D-1%
M4T-OK8IPG(AB5A7JA#G"A.\=U#%5M*;XO\/1L!,V",5MMG:1591LS8T)2[*+
M6;1=4&MY19Q41*OXUE%+S;B@VN(LYXM1XDZ91AW2C]-JHS<)$NU%V1<7U-?1
MV^I2TVR6JN;VR05MZMHEHFBO]QX8FJZNEIZF>K2BCOUJK+8M2L+QSU0B2G:5
M9HV,2;BVT1P35$1JZI(J852F"BJN2=6H*>YI%#+)$D33M054548BX9(N<R!6
M1E'KB^*JJN;BE6I6!GX>.=.?HQ*:-"6Q?Z+F5\AM\;QL;;62]48!5COYZ0BD
M <O':S BDAXB+QU%L9*69^ZKLLNL5F:YTM?05=1'&:EJ(5MI3TJCCX=?B2IJ
MK3/'=:@W18*""KD,4$*3LM/AXHJF>FI9D?%%*U6*>6"HAC=N[$Q@JV[J8W!;
M=''5QM2IZ*9)Y(EYW<Q@R9#M$DDJ>5AXNL51=3E[##_A/8)!O5QM]>KS:G6]
M*0M5==UFUVJ!M,80D Z<?@7-QM+L2B%H!HLT3-'G;>"I).8Z/??+?V2<4U5V
MI+=6?)EOIY+I\D7"X2WBT/3VJXPW.U6JOM=4QKXH_EFBJ;U;EDMAF25A4+)S
MK3Q5-1 J.++7%2RU$/I51(M-Z73TZT=6)*JG>FJJJ"JB @9O0IXJ*H*U7(4!
MC*\IE:.-^<TXJ\4(2\16K)/,X6RSDZ2"CXAH6:E3$7=S32M1 /U3P4<+=Q+V
M-V6%9HM4G[95VFNJB_78M7KMK0E[*^*WHZNYVZ@FK;;0T!KJBKE-%2!DAHI;
ME5FG05]3WD=);H6K96E>GE6(HCP)/+!#+[3BFU":*FJ)TAJ9YQ!'"@FEPSSI
M30]XQ@BY6FJ'$*!1(I?)5V17=+T9YWQ[(T:GY!C',Y*060'X1E+;Q=:FY.=L
MCL8Z8FA)%P3%DXDU@) U^;G%A,@06\;&/#+E2<HF;!99N!>(*:^7CA^ICH:6
MNX?I_2;U)57*AIJ&VQ>D4='S55=//'3)S5]PHJ%,2$25-5"(R\3K*9J7R@DH
M:2X1-/+!7R=W1K%33R3U+]W--B*!$:1L04\T[>KE8HG+ ,I75"<<36*6IW@+
MNK4FA'2UXBY!\:BVXL>Q;XULS6F7RPNGAH<$4JK6+2\0AI*PB;Z.!8'CINLO
M'QDJ\93H^S3BJ58>2*U-)4TECJJ> 7VSFHGDXEMDMYL-OCA%87:ZW2UP25E-
M;@/2>0PQ2)'455+#-0?B2U)S\SU06.6MBD?T&L[N-;;4K1UU0[]SRBEI:IUA
MEJ,]WS<[*6CBE=*K <0.,K-*UB%AI21=/[A+72'KZ9H230(]7Q\M%MK4N)UV
MZ8((1CN:CFJI%_#>E6.\%1HFE$3*D?%K^ .)K92W.LK*6GB@L])9:RX,*ZED
M,$?$"54EJ3ECE8R/4Q451(C1\T)580LS/5T2U%6"_P!MJ9::&&61Y*R:MAIQ
MW$JAVH#$M4Q+*.58FFC4\V'!+Y0"&8QV!8>+"GUFP2<=,5FYLH*N6'(=?M%C
M4K<X[1C4\=UV'L\M8F;.(C)-5_6$XJ37<NY<ZK--HBS3\--VYDHYJXO]O[*+
MO<[?35%'<[-/77&W</7"UVY;C0Q/4MQ%<:RUTEOFFJZJE6GN9JJ5(HJ14G::
M29@6BCIJF6.WU'%5)35$D<U-6)!3U%P@JJDT\[B(6ZGAJ9:A$BBE,E,(I2[R
MED"*@(#M+&K91I&<,9Y$MMOI%1L:4K8Z.ZD&D^S*V=(E16B)Z2JTN#===)-)
MR$78XB1AWH$-S$702<)E5CWT>\=XO>^".)>';3:+W=[<U);KW%3RT$QEB<NE
M704UTH^\1'9XO2K;5T]9#S##1NT;%:B"HABNE%>K;<*NKHJ2H$M11-(LZ<KJ
M 8IY*6;E+ !A%4PR0OCHRAAF-XW?+&X>H?>&L4U==-P]0^\----P]0^\---8
M6XBG_P!&X4R$^ P%%M"IJ ("'3:09!_'KHC\$Q>;\(SLG7SXE/\ V;7YUI3\
M(T ]A_:2#T/#LN<^7I--OT/3J/;K5YQ,XS2XL>"ZUU^.1*]R!C! V1:/REYG
M2ZT*T5-.PZ&P"<0EX,792(E']U>-F/U1Y0V_=;C2V&)A61J/R9//@=8V^=GK
MGE.&QT&#OOO^.79Q>S:+^M),_+37("EER0%$^08'/,=B3A"?$;=-]=3MRH8H
MF(/,4Q1$I@$! 0.&X"40'J E$.H#ML(;:U\S;>\;'S^_](QUZ< P,D')Z>?W
M\_9MYC5$=+; ( .X]=Q[?#?H.WW[=_AJ@[$>\^)W^_UZ]J#\6QG[^SS]^K><
M*AL(B.P!W$.^_4?+\X?8'7O1)QOJJ0%7&_OSU._ZA_2-4197?<PCU_N0$?U[
M[??J+(VWM)Q\/'X#[/=KP 6/O\?=]_LU2%E-M]Q#IZ]=Q_-MZ?R]-6^63J =
MOZ=L>9SMT.,>>I 78 #[^7COY[^_H3KZ%W[$W'F]GOEH=]]^*>X_Z.<8:UKQ
M0W-<(S_\L@'A_P"\EZ_9K*[0,4A_RKY]_*@V]FVNT3K&]733333333333333
M333333333333333333333333333333333333333333333333333333333333
M333333333333333333333333333333333333336M+VQH[>S!XTQ'RPO+#]TG
M$[?GU>^&_P"[ML_SE?\ 9;4.X'%%5'K^0D_V3KY<Z"N^P=-P#OZA_$/KK?JL
M>H/O]_N\>NM?,/SAT/7[_?'V5ANX#8 $1Z?DCWV]0'T^._0=5E;/COU_H^_O
MWUYZX&-]]_/QQ[_+Z-5A!40$-AV^&_0>W3Y#U^T?74I'^K<CZOOY?;2=>IQ[
M]O#?/Z,_?%616#8! =P'J)?,/U]?N\]2E?.XQC.Z^7NW\=]NGTC5 J5.0#U.
M1X;=1]^GAU&JDDMT#8=R_9N'SW\@] Z]]NNJRMT(\/#R/C\?ON->"N<\O7)R
M.F-S\/+;W^6N>FIZ#T[;A]_VAZZK*_MP??\ I^_AOKP1G/MZGQQ]_AYC7,35
M$//H/F'3?X=NGS^'75=9#XDCPS[/+[X&J+)GKC/@>@R?#;R.>NWN\>>DY'<.
MWEMO^?KVVV'[ #H&I"OD;^_/OQU/W U%DBR#GQ\?'V?HZY&N[CPQ#OPX8#'U
MPWC4?OIT/K^?#MA.>UCM,/GQ[Q;_ -NUVOU8X&&."N$!Y<,6$?1:J4:N#,C/
M,$C092.P7,TJN9%?NHII'6._1\E,0%?C%Y%L2?F"0T8*:LQ,L887BL#&NEVT
M8ZEP:%DURL07*>P\&S<(4U_I:CCJCO5QX=@BJIJBW6"HIJ.X7"I2FE-!1FMJ
M@R4='/6=RM?4Q1RU,=)WQI4,YC9;E?([W+;9HN'IZ"ENDCPI%57**6>FIHFE
M45$X@APT\\<'.:>)V2)YN03.(^8'6E;;]QA\(W$/PMUS)?$;%<3>..)'(Q<6
MS5?D\0TK&=CJ$P]/&H(V>LK4L3K/(B/4E$7<BE*+NF[)BT49JI*N9-"48]*V
MFP]C_:WV>]J-RX;[.JKLRXC[..'3Q30W"EXNO7$MMN]'"*AWMES2] )%65"T
MKPTS4J123SS+,C)'2R4L^J*VY<<<%<3\'TEVXIAXMM7%5T^1YZ::R6^T55%/
M(8E6KI&M^6>&(RJ\JS-(L<:,C O*LT>W_7(6MW:QA<<68PLLG^&=SK<?(R,.
MO2)X)9\YD"A'N,4R=IL=-D4TD7:;= ]>?W"U.1.FB'T@WEW;&6!^P!%JED]F
MXIXGMM-\C66Y5%/3UB7N@-)!%3DU$?%5-:[=>:=F>%I'%P@L]JC"LY]'DI(I
MZ3N*@O*ULK+7;*F7TRLIHY)(6HI^^=I!W;6J6JJ*.0 .%4T\E95-D#\HLSI+
MWD>%%DL^'7 LY')24?6%'4//U4T8C[G;[NC%/X";J#BI@\18H6-)D63<T^24
MBF]C3;$L*#$Z MY-%5LU41OD_:+Q[0U#4U1=%BK+?=!4OWUGL;U=/7T-W2[=
MR\[VUIS317BF6KDMS2-;WG5^\IG2217AIP]8IXQ+'3%X:BE,0Y*NM$,E//2-
M2<XC%0(^]:CE,2U/**A4*\LH*(5O-KAC'K0SOPHV;4;OIV M#F.>7:\2$.:R
MUFQPENBK"G"/[&YB&\V-GK\9/2LJW9)/K#)E?N[ O)JS$P+ZRR\9\0S"+GJ:
M%9(*&OMD=1#9+'3U@MMRMM;9ZJWM6P6V.K>A%KN%304E)).T%OIC!%;XZ5:.
MC[B8MGMZ<^(YRKSP5+1O6UTD/I--4PUD50(9*AH5G-5!'42RJ@DJ)>\>H:4S
M3=Y1Y+!V'9]R9HY@@&2BY&7L &BK9:(B:BI&XW"8OLI))/(2?8RL::;M4E-R
M13I+H)'1</HMJ!(@#L"S*7CGC&WQ=[%7D4U53TEO(JK3:ZNBJZ>S6>CL-+3/
M#6T$]+4BBM5-0TQ5TD97C@JI2:LK.:,MDL\[<K0?E8I):C,57513Q25E9-7R
MR!X9TEC[ZJDFD!#*,,\28AS&/ N)L--V'[53:*"/264K=Z1A(RRVJ+F4%:*R
MJM3KM@83,=--IV/-#LZQ6(DJK&4;>\ S#WPKE1Z_4=>CQ9QG)4?NKDJ_2&1;
ME8GKJFVVJJHY%OLUUNUQM]115%%+0U K)KI=*LK/2R=WWWY$QK!3K%\%JLZQ
M_):Q=V&--6K!%4U44RFA2EI*>HCFCF6>/N4I:6(,DB\W)Z_,7D+>9>'?#A*X
M>I$IJ:< HT,R%BG.65,Y6YL816&0!)\29+((JDQM"15;2<HNB.4?<TY=%8D\
M924/X_&)QB;B+L;RS5XE$W?M0VU@9!Q/5<9>M U&:=T/$E;57)XWB:-^^:C=
M&H M*OT</V@4QI!1@4Y0IR">I!"FV16; D[[O%/R;#%3!E<,.03 BHS*:$VQ
M/@.6;5;)+=!1W'O7-9L$%8#7J[C%V)S,V>%L]4?3#=:R PMAGUN&"F8HEE:R
MH&FA9N4DP<B41N$O%G'U++=.&Y)!%401W.@KK>+%9/2K='16NMMEU@HW2VF>
MTB"T>G4=4ULEI2M$)HF;N@1J@EJL4JTMQ52\;M35$%1Z=6]U4-/4P5-*\JFI
M[NJ,E7W$T0J5E_+<C <QUXO.&? I(YI7W==>M6SXJ,#$I_MB9 8R814?6[1&
M-:- 2:5N0F6=+85>;MJ;;'<.\0J#..=RSI& 2*FJLFA[2^/3437"&XPRR0%Z
M^K;]SO#\]-Z547*UU,M\KZ9K0]'->9[I16AI.(JR%[O+4PTD3W!BR(WQ^&[$
M(DIWIW5'Y8(1\HW!).ZCIJJ-*&"05:S)1QTLU6%MT+K2)&\S"G #,+M)B'%]
M=D@M+5D^K#Y-907<G%W>X5I"0-(2!5TVT\2.L;!C/-2R;E0\5'SB3]I'NI%^
M6*;ME)5\#JTGB_BBXTWR7+-!=(#&HAIJJQV>Y24XIZ<HTM :BVU$]!*::-15
M5-"T$U1%30&JDD6D@,4L6BV02^E)&]-)S$O+%6U=,)#))S!9Q%41I.@D8F*.
M<2)&TDG=*IE?FIT1BK$,]4DH6#1DW4+#WVU3J,S&7N]H6EED-C)V*K7"2+?6
M]D1NY)LKQQ9ZU,K?A (N&#B2A%Q5BEU&IY%9Q5Q?079ZVN>FBK:RP6JA>CJ;
M%8I+7-P]/36ZZV>F-ADMKV0T)ACMERHT^3P(YXZ:M0)5(LHIPVNTSTBPP"5H
M8:ZKG6:.NKUJDN"2U-)62"O6I6N[X.U533-Z1ZR-)"<Q$J>#:,78/3>5"%L,
M4JB\E9V\%KT6TG[H@>?>7NQCD?($?.-(:6(6PU:;L34DY/P]L(_IR:H-62[-
M!LNU9J5[7Q1QPT-XK;=5(\-+0V-KC52T%E<4$-BMW[G.'ZBAFK:1C;KI0VZ5
MJ&@K+2T%X93+-',\B2S+XJK990])#41$/+/7>CQ+/6 SO75!N-PCG2&4"HI9
MJA1/40U0DHP>1&14*(:LSPMBEO.^\),I-U.L[4UR:[;O\@7F75<VA9E&P41:
M)Z+D[2\1F#LF=/8Q]9/.-'K*&&&7) ),E2O1/%FXUXLDH>[>>FBH9K5+PS%+
M3\/V.C2.UI-45U9:Z"JIK7"]&)YKO/47-:&6&>M],C:X-.IAQ52RVI9^8)*\
M\=6MR99+A73%JIHXX(:F>.6J=9BD=&D=-WZND(A84X0]YGFRV#\83CFUNI:N
M+/CW9O9&MC16L-G]Q=H7"LL:?:"M(XDR6/AC3E>C&3*04A&T<JLLA])"<)11
M5ZI0I...**&*U0TER2!;+);9;<Z6^V=_$]GN<]XM9FJ31&HK10W&IGGIUK9:
MA420TP7T4+"ON6R6R=JIY:=G-:M2E0#45/(ZU=,E)4\D8F$<)GIXT21H%C9B
MO>9[TES5&-=HN+B3U@07>P$?/SHO91-]9K,^KJ4];K*HLLO%5^2EGT#7W5AM
M5@5</?H",C"R,I)'</ 544$X19[C?>*#06^2.&X5%!0B&E:"UVR"XO06FVJB
M)5W"FI(*^XQ6^U6]8X?3ZFJ-/2TPCAY57EU52GH;8*BH5G@CJ)^\E$E34R4X
MJ*NI+,T5/)*\%.U155!:3T>.(22REGR3G61-8[JX:::::::CWQ7#MPZ9</S"
M7PJFX6 0';JBZ:JE#?R 3$ !'OL([==M="_@H2F'\(OLD< '/%4,9!SC$U'6
M1$[;Y <D>T#.VM/?A PBH[%^T>(DC/#56VP!WC>*0#!\R@'QUK7X3LH&BI6/
M1<JE,@J)&[A(XE%-0A]B'*<IA$#%.41 2F#8Q3;?6#8-?T.WZA2JII%*Y!5L
M C(*D8(\0/+V>.-]?A:_/#*'4E)(G'*ZD\RNC QMD$'KL3MDY&=:#/:)X#_%
MSXGKY6HUL*%+MC@,@4!4I=FQZS:557Q&*!P^J?Z%D!?0J@%$>46)1$H <-<]
M5,3TL\U/("&A<H,^*'=",XV*D>6X.NM^%+NM]L=!< V93$(JA<G*U,0"2Y\?
M6(Y@-AAAL=]0 <KB.^^^XCY>73]>H]Q^6H1)W)R?8-_HUDXPHR<Y.VV01U^^
M_O&<:HBZO-TWZ!W'U'^/X]._P -4&<[YV '3V_KSY_KUY))Z^&W\_P!_LU25
ME=QWZ!MT#?R#?OV_3Y_=J%+)@9\_N/@<=?+SSJLBD>W.^,>.VV<]!XX^K5)6
M4WZ=OD.^_GYAMW^P/F&VK9,^Q .<]>F^?<??X8R-5U&!OUZ[YZG[_;O@Z^AO
M^Q,AW]GKEKX<4]Q /_9QB\?TB.M?\2$&NCQX4ZC_ .Y+K*+4"*4Y_OKGZEUV
MCM8]JY::::::::::::::::::::::::::::::::::::::::::::::::::::::
M::::::::::::::::::::::::::::::::::::::::::::::::::::::::::UF
M^V3-R>R\XUC>F%I8?\J1.KUPZ<7NVGRJ5^QM1*_^TJK_ "$G^R=?+607 0 0
M'?80WVZ?;U'RV'?KU#XB&M[J<8(_I^_WZ:P ['('JGJ/M/E]F??JKHK@.WK\
M^_7Y=![!Z]PU61NA'7Q'Z/=Y?KUX*[9&X^S[^/B-59!QV 3;=0Y1]/4!^'PZ
M;^7J-=6SC!W^OVX_FUY)!Z]1X^?O^'3W;^&JPDOU[[#ZAY[=_7?TZAY>8==2
M$?<9V/GX=1X>?L^CPQ29/+Z#Y'?;/3S^.JD@XWVZ[&].@[[AY=.^WP]-2D?;
M;;?<9SY??/7J/#5%U*GU?#V8S\.A\=5))?ML.WJ4=^^_EY==^^_GU#SU7# ^
MP^7L]_Z,;:\X!VV5A]&?A_2-<]-8#;" ["(=0$!Z^@_KUZ[?.HK$==Q]GN^_
MVZILI&QR/:/OOKE%4V\_L'M\PZ]/EO\ ?WU61R-P?AGI[NA'C^K5,KM[?IZ^
M[&,;^&-_H[PO"^._#9@ ?7#&,Q^^FPPZ_GZ[7O\ VK=I?_\ /O%O_;U?[OLU
M^IG!'_ OA'_^6;%_V72ZRG;8-S9ZK9*VSL$W4G<_ RT*UM-:5:-[%7'$FP79
M(SL"N_9R#%&8B5%BOHU5VQ>-DWB")UFRR93)FPNTUT=LNEMN4UOHKM#;Z^DK
M9;7<DFDMUQCI:B.9Z&O2GFIYWHZM4,%2D4\,C0R.J2(Q#"_UE.]71U5*E344
M;U--/ E92E%JJ5IHVC6HIVD26-9X2PDB9XW02*I9& (.DKB(Q!<.!_*>#N+J
M3R_;>*1)+(U<PX\K/$$+:QVVJQ>0Q?-WTYAJ7A_H:*K]D!NR<$6:HUDZKU)0
MZB[M1J5XBIVQV><7V?MOX6XW[(Z7A"T]ESOPY<>,8;GV?]Y;K3=*KA[N)(*'
MC*CK!65=PMO>31LDK7-4@<!8X5E,,BZ!XGL==V?7CA_C:6]UO& %UI+$])Q-
MR55;1PW0R))/8IX!3PTU7RHP9%HRTBDEG9 ZG>MKA?70^H>93PC>LC9JD9YD
MI$0U52H6*645;WCQXM/14S7[9F.3ND+5HIHN9-NC;H*>JE;NKU^2-2?5J1!N
MT5G'$>HRCMQ<*\;V+AO@NFH)UK*VZM?^*IZJSPP0)05=%<+3P=36:MNM7-&'
M=[174%UN5EAIS4O!<J;O)5H8ZA9ZG$;I9:ZX7F2=###2BAM:15;NYGBFIZJ\
M25L-+$C$*M7!/24U9)((Q)32%4,[1E(['1X5LE(O73A:UTJ1CB0-,A5JX>-&
M)@[ZQI]DQM,H0M[&+KQ)9W'KPM1L-5.[GI.^A[M8UU6\2SKKV5I+F]OVJ\-O
M#$B6F]4U2U?>JV.Y"I%776">\6[B2DDK;$*FX&DBJ$K;O;KJ(:"FL/Y6W(LE
M7-<8:2]QPAPO<@[LU5121"GHX&IC'W4%>E'46V98:[NZ?O7C:&DJ*4O42U_J
M5+%84IGEHFK9>%BRO)RR/)FRQ[B.GIFB/#MVSU=!@M5X/(V)KE-8_D(1"N-9
M*4A&$'CR6IE2>3MVGD&E?LC^-)7XAM+V,9:$>U2VPT-MAHK;41U-!17V%9)8
M4DJ$N==P[Q99J*_TU:]QEIJ6MJ*[B&DO-WAH;)0R2W"VP5)N%7)26X4M8<+U
M#SU+S5$31SS4+D(Y6,TT%PM-9+;Y(%IDDD@CAMTM'2//6SJE/4R1BGB6:H[V
MWY'A$M2,;9HZ!D,<BK:H&JP$A-RD U=3A8NJN;\VAXANO-5FU,RLH2+GZ4M%
M.G+%VZ0)2_H"-3@E741;J[<:?M>M+U5LJ:ZGXC"6NONMPIZ&EN$L5"U5=8K#
M+65DB45TM<QGK:J@O:544<T,3F]>GU+5Z15=HN$>3A*J6*IC@DMQ:JIZ6"2>
M:G1Y^[I6KUAA#3TU4@2"*HHFB=D=E%%Z/&("\-739(O'#Y:[79L36 D]7UG]
M'J]2KTI894)I2RL'\#=Z7;Y:T55PB8Z2DM.,:K)UA<LFHV.9E:'B[MZ[C4Y6
MN6/&K)V@VJU6WBRW^@7".GOEUN]QI;?2FC6VST]?9;U:*2UW6-P&%)0S72FN
M:&F64">UP)%!%4-2W&W7&ML%5555JJ._IVDHJ6DII:B43&ICD@K:.KEJJ5@2
M#-.E+)3,)"IY*EV=WB$M-46A1>&?(];D(^4LT]0K>FG<UK(]J:\<K$4]M)/*
MM3():_0<9 U^*;-+A&2M5E9Z!8N6#AT@6XRK22O,E-LPMLC>+[VF\.7*GJ*6
MVT-^M#-94ML%VCJ$K+Q)30W2\URV"NJ:^X5<LUGJJ2Z4M!7SQU,<<AL]++3V
M.FH9?DFGB4/#=QII(I:FHH:L"M-3)2-&8:1)'I:. U\$<$$2K6134LM1 CQL
MR^F2I)6RSH*N2[\9<.]MH&((W&#F[MI=]%W'#5D1M8IR2,DXBL>36-Y:9K#P
M 6\,T>1I2Y*LU/W--BW0JCR&CIIB\DV,S.S]GXF[0[1?^+ZCB>*R2TD%59^,
MK:]JS3-31U7$-%Q)245SA/)S"H:6]4USNW?-/(]UBK:BBGBIIZ.AH)=LX?JZ
M"T16QZU9GBK+/4K58D$C16^:W334S[X,86CDIJ3D$:K2-!'-&\L<T]18+?@\
MEF#3'A&=@KAI*GMJ$[=2SE@\6D$[U%8MRQC>Y9.A73M-\JA;WCR\TVW1;I;D
M7>O<<PL:_?QX)1LG&7Z3MAI*B;B$S4%Q%-=Y;]%%21SPI ]CJN*.$^([-PS6
MQ0O3J]HAAL5YM-5$A:."#B.MJ*>GJ"U1354%>$)8UMW)44_>4:4+/*R.T@KH
MK7=K;67.!W$A6K=ZZBJXV/*SO;88Y)(^6*6*\V?#;*+X=R+CN91H?-<)BJ3<
M94VK:2D<?1[RGL*643."2[11YXUSG:BO8;"Z1BCF9/IM5R="Q3+>1G;!9YNT
MFE3C'AWB*B>_%;11W:AJKM-)34_$-3#>*B]-A#23+!R6:AN\=OMT3U2B:"A6
M,/;Z.2GH;?+7AR1K1<;?*M!_7<U+/%2*DDEOC>CCHAZPE4OFLGI&J*AUB)C>
M<L143))/46O*\)<^$=*_@Q8X*O/K!/7>PVR/8M@3B;B2<S_%Y:KE9FQDH2>C
MEH>'J2=@HHJ2%6FF*!9]ZN-=DXIY*1#^YTO:U0>DTORG;J^XT]OH+);[345$
MG/66=J'@"KX3N-SH?1ZZ@J4K*R[M;[[R4]UHIG-!"@N%-50TM9!'EX4G$4OH
MM1!3O45%=45<:+B&M$]_BNU+33]Y#/&88:05% 2]+,BBHD;T>6)Y89+OR!PS
M.[I2\:PK2=9Q=DQSCVTU.*LDFF2RS#%]8H2"BS^XSCN)9K"R72B%HJ4=%BF2
MKR(=FY8Q,0]S"T\/]IL%EO7$U;-0355MXCXAM=VJK=3$VVDF@MU;7U0[ZACJ
MYD$\;5<=521&KG2"LA&:EA^6,JX<--6T=MA2=(JBW6^JI(JB0"IF1ZF"")N2
M=HD/(PA,4K]TC/"Y_)CYFK7C^%RQP2R<[ 'IS6S##8Y3]]?/5EG\>XQOQ#2F
M;@J$=8H2E5P$:-;XV:5ICAM&UF#85*,AH1I&U.:B4$HYE<JCM1MM>CT->+Q+
M;/3.(V[F"!$@J(^(^SVEX)^5ZBW5U[N1:^6FIHDO*2U%TKI[M4UE;+4W6BJG
M>HGCQ\,U$!$\'H:U/<VT<\CEI(FMO$$M[]#CJ(:.GQ0U<<[416.F@CHXH*=8
MZ2>)1&F0L2X3N5&N1;%8YV FVSNA/JW8%4DW#Y]+S#JP-99DI%&F(Q28J\!&
MM0E6SJ%0MDM#3J[YA('@8B8C9"7L-@XMXWLU]LIMUMH;A120WZ"Y6]&:.""D
MHXK?+1S+5"CJEH[I7U,OHLL5;)::2MH$@GIQ7U='4T]';YUILM905@J*B>"9
M6H'IIV ,DDLS5"S1F(S1&:F@C3O4> 5<L$[/')Z/%-')-48;BN#F]BD\C;;E
M<;977+"O(#"2 3JC=66J5IIT+"V)4RTBL9*1=8.H%?J\XBVY&SV\2=IM9 3/
M*\P9E5=L=A#05-HX4^2;A%47&05M.:!9%I+M:[Q65MN4)3J'IXN.+_7W2A>3
M,D%DIK9:FYA2X-HBX0KL/'5W7TJG:.G7N9._*F:DJJ.&"H.9#B1K);Z>EG"^
MK)72U56,&7.JHZX3+E]-/EF5Z13A?H#(D%4635V:(+CII8;1FJ3K4=!()UJ3
MD7, A6<EU2K2<%$V:FQ[9K0(KF1L3)G78^OQ(>UFSBBA2>QR-6FOX>KKO-+$
M*P\136^V<%TURJ:^1KE2T\5>]SX:NMTI:ZJMEYJ));_58>W337"HKZS\*U9F
M<I6J(/1[A!2(K=U\GI45-YEIXX%%-+(U.*:Y4M)+!%4T<:I01>K4(E/'!DFD
M</3ZDY8;7%I+HJ59C'L4X:-:NT8YU!@E2FU6DZR9N%9=RT]69B>+)9%<IO;T
MRCANDNYFG=5D)U!&P&QN^=H<%[X3EL\U)(MUGJ)VK*F6%ZB*MY[U)=*6YB3Y
M3AI*"YT= :?AV-H;%/4BRTD=%#=:>@=K>MPH>'WHKHM6DP-*D<8AC5Q&T 6B
M6EEI>7T9Y:BEFG$EQ8/7)'Z=,T[TLE0HJ#*G6JM91J-_%\IX/#-FA7_>4F0-
MWV[*M_/6_P#\%<X_"'[)3Y<74G_45'NUJ?MT /9!VA ]/W-5W_X:T&8AM*D;
M(LSD5$H"=,0$##^440'O\=A'TV /0-?T>,!+"0=R!C!_>D#K\=O'Q\#M^&]U
M@$<[''JOY],YRIQY X'CCF)/765_:BXK2SIPA5G-L,V!S<,"R*:4V=$G.Y<X
M^LZK=F_\0P )S(P\V$8^3#J1%%W(J] YQUHWCBVFFJDK%&%<F*3&VQ8]VY&W
M1LJ3X!AYZV1V17OT>XU=DF8".L0U%,I("BJA'+,@'G)'Z^=R2NPZZZN[A4=Q
M !^L/GOML #^G^+MMK G;P'QV!^T:Z"8[GV$C[_?IC8:I*RH;<H#T\]O,>O3
M]?SAJ')(-_$ [ ^[.<=<?7[M>D7Q^CKMX:I2RH;#U'<?T?#S#Y^OKUU;9I>I
M\>GMQN,CH,_H\]2%7?/A["#\#[QU\-_#IJF'/W$!ZB([]=_7]'3OJ!(QZY.2
M.IP/?X]/:/YS71<[^1&/U?9KZ(/[$N'?V>F6^N__ &U-Q#_W;XMZ:P;B'^W(
MO\W7_K)=9-;?[6W_ +XW7W+]_9TUVD=6'4_3333333333333333333333333
M333333333333333333333333333333333333333333333333333333333333
M333333333333333333333333336LCVS/3V6_&R/IA27_ ,ZQ&KSP]_=JV_YR
MGV'[-1:[^TZG_(R?[)U\K]NX$-NOQ$ '\^WD/P^[<-]]XJW*?8>NL%=?$#W_
M *_U_P!.JV@ON " ^GZ]^^WV#OMUU6!\0?OY???5#!4Y7YI\.I'Z_OMTU54%
M^P;^>V_E]H=.W?\ 1JLK ].H/3;8>SV#^;RU\*@Y*[^SW>7ZO'Z-55%P)>XC
MMO\ :'^WU\M5U8'KMU^CZO;\!OKQG.Q\2-_$>?M.WAJJ)+[@'UO0>8-@Z_';
MKYAL  (?;JNLA'4^6#]^H^WVZ^%?$C(/0^'P\C]!U4TG'D8?J^1O, ]1\]AW
M].FI*R9QD^P$'^?I] ^O$=TZ'?FQ\,G)\/+Z\[=-5!-?L(CS!VW#X#Y_+[]5
MU?/49VSD>7V:I^L,\PR/AX>/AX9WZZYZ;C<!$1YNFWH(#\0_4?CJH&ST/T;'
MX^/AKYR@C*^S(_I^_7?7>5X6QWX:>'T?7"V,1^^EPPZ_ /M=_P#:MVE>'_\
M'G%G7VWVN.OU%X(_X&<)?_RS8A]%LI=5'.N#*AQ!4I&DV^3N5?3CYV.M-?L^
M/K5)4RY5BRQ2+ULPFX&=C3"=N\0:R+]OR.F[QFHFZ4%1J=0J*B=MX%XYN_9_
M>WO=HIK-7M44-1:Z^V<06JFO-GN=MJWADGHJ^AJ0!)#)+3P2<T4D,RM$O+*%
M+JTOB+AZAXEH%M]=-7TPBJ(JRFJ[962T%=25<*R)'44U3"<K(J2R+AUDC(<\
MR$@$1KI_L]L>QE^IN1,HYDXC.)"7QQ)ISF/8G/62D+=5JA/MQ(+.R,*_&0$
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M!L!KV?M7WG_ ?^4X?^D->?Q?\7?P1_K]L_;=??W66#_#_P#5:W]FT_:OO/\
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MZ?NLL'^'_P"JUO[-I^U?>?\  ?\ E.'_ *0T_%_Q=_!'^OVS]MT_=98/\/\
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CIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g99471g31l69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g31l69.jpg
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MHK3!P]35U]CA_\0 ' $!  (# 0$!              $# @0%!@<(_\0 81$
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M(A*37_QI7ML&/,Q3D(-=(>'A1HE9A\J0&R9$&N91VK":2*XBF#)"\FF/1J&
M"&)8Z2GGI).=AN#C&:^1K>*>TGM]$EQ'$7F$NDAB0R *NM93MI#@#SP"#6#?
M97U-^T.KXOUMBJH=16GNB$OTY!T$HZH-FX"9W<:$'>,VM*ST8LJW$.N.12GL
M#8CW5?9+S>$M)V(K.%SPX$-_*1/S<-UY9.G3MW?7SK2GXC<QCC&DI_(C:<C*
M9QSCA]>_>].F*V*:F[57VP=L[EK*^;0ZUA:JK'3S7.^C::$QL.'WG4YN>5!O
M6*[7F<FPVM1AZI0,1-883'3[U@C_ '09$@P,(B2*>U'A40*ZI+K:=X]7<,3
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M6ZE&7,(4O"DIRA6-I$LUS#$^=+N V#@XP3L?#I6=_,]O9W$\>-<<>I=0R,Y
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MFF/B8Q02SDB)"Y49.X  /3)8@#/AOOX5G<75O:A3/*(PY(0$,S,0,D*JAF;
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MB:$IM?@P8Z4EY*QK3\X$%#D!S!)VCDM+(B:,/;,XDB9B)"'F4J5&""%7<Y(
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M:-\!3S%>197SD'278'7I]X,>A (C.]%Z^-8&KC7]I76 N =S9O4=-)BZG,,
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M/4_'./PV^ZF>I]%<_P"N=D=GB?U\=L.Q8'G^Z(V5'8Q_X.$^/X>.!Q&8=(;
M?'AUBW^M;M3 ]?ZS?O\ 3^,FN,]1M7*_KW'L^O/\<X[J]Q&O/W\_D/O1G&/[
M,8QC&/MC&,9SC+\XW']'8?\ 1?##^-H33 ]?ZS?OICJ)JG'C_P!%G9_[9QG'
MGN[W0S^7GQY\[]SYQ]_OC/G&?MYQGQCC\Y7']'8?]%<+_P#DZC2/\;^LWA]O
M_CXUQ_HA:ERGVYLO99>//N_?[I]R',XSX\?;*]\JSC'C^&,XQ_+C\Y7']'8C
MX<+X8/PM*G ]?F?WUQ_H@:CQ_P#A%V3_ /EH=Q?_ /._'YRN?J67_1G#?_E*
M8'K\S^^NV>HFJ,Y5G%I[.)RKQY]G=GN:W^6?/V^'OM/MQ_)/C&?XXX_.5Q_1
MV'_17"__ ).F!Z_UF_?3_1$U5_"V]G\9^_W_ --ON=G\_/\ !6^U)_C]OMYQ
MXQC'VQC''YRN/Z.P_P"BN%__ "=1I'FW]9OWUS_HDZU3]V+QV>8S^O\ IE=L
MROX^?ZLAN<Q'V_FG\OMGSCC\XS^,5@?_ /%\-'WBT!_;4X'K\S^^G^BI5&_^
MM-L=GA/'Y9_TFMSR/C_]-6^4PK_P\*X_.$AZV]@?_P !:KY_4B7S_#RI@>O]
M9OWUQ_HQ_"_ZQ["=GP/']7_TV/JWM_\ C% 37N\?^Z>_^?GCM_G96#?_ (?3
MG^HZ?=C\:C3_ (S?/]]<_P"CO=6?^Q_;KL]'>/R_UW7^9\?R_P#1/H">]WZ?
MO^[.?'G.<Y\YR[;%^EPVP;U_EJ_]7>H/NJ<'ZQ^[]H_LKC]@^W6?WA^Z_8QY
M>/ZJ)2E]0BA_Y84B-ZNPQ*L8_D8E6<>?*LYSYP[7;'KPNR _Q9>) _-N(,/N
MI@_6/^C_ +M<YU1V.$SYC>UY9OC^KBW:1US*XS^GQ?PJNB95_/X>6?/W\>W[
M>':+(^]PX#UBNIU_ZSG#[J8/G\Q^[&WW^OA7&:?W('SX%W_UV-:3]\)F>JNP
ME%N8Q^25&Q';B+%;SG^*TQ"\8_/#?V]N7-X8>MG>@^.GB$&/L#<-8_#O?;3O
M>8_JG_>I_P"K/C/X=8+K[?X>[:VL/C9Q_#W>W;OR_N_7VE>S]%^/N_\ -C?X
M?#_S>XQ_^5S]WW[.]Z?>/W_+[ZX_'?;B._?F.N.GY9A.?ZM![-SDO(K3C\\I
M#O/7?6T>A:L?=+2IQ2,9_=41X_>XY/#6V6]NE/G-8(JC[8KV=C_4^SPIEO(?
M/^RG^D%L.,^]JZB=BH<9O[$2T&7H6^QF,_\ &4+'TW=TM>"D8QYSC/X*9=5C
MQA+65Y]G'8X6QR^)63$]%<7D+?:TMHL0_P Z1ZTR?JG_ $?WT3W'Z_@J2B[6
MBQZ?SE26\D[XUILS1<-\=6<)^"/:-L5&H5.15ES.&D.Q4Z>,\Y^XP^ZK.,9?
MFR\/\U&ESZ6D\%V^/,QV\DDB^?>12/$"FH?#X@C\0*R0BI:+G8T*9A)*/F8B
M2';,CI6*,&D(T\1Y.%,E!'"./"E#NISA3;[#KC3B<XRE6<??FBRLC%64JRDA
ME8%64CJ"#@@CQ!&:FO0Y%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*^>?N;VMVEZ3>^2;7$Z4H6]-/=EY>V7M5WGGWZ9
MNF-NSTZ[)6?7$SMB-A;*U8:=5P92$SJV*L54=.@JA\&GA2A494F7&?KOL;[#
MP?E#X7<+:\8_-W%N#F&![":-I+&2U>/%O>Q*KZXY)729+O0I7G#GMAK@*.9>
M7W89$YD1>&4$AT(U!P>\I!P"!D$'/0D =VHE"_I&G56:;89V)IC?5"/<PGXY
M$,)1;W7A\_DK_A[-OKEA>3C/W3EJHY4I/G.4(SX3F^^_(;[:VQ8VR\.OT&<-
M#=B)S\(YE0[^08G-8IQFQ?J[(?)T;\1D??66=4];KTV+3AI#N^).J&.X3Y"M
MVIMNQ7P<J_@]*CT<^O)]N?LK.)E2<?GA64_O<\M=?DR]NK0GF>SE_(H."]NL
M<Z_9RG8X]<??6TM_9/[MS#]KA3\FP?[=NM9#5WU)^@-HPWF-[B]=Q5.^/AM6
M+:55J!"LY_)/RULD(0C"\_E[%-87Y^WM\\X%Q[,^T5J2+C@?%8L=<V-P0 /'
M*QD8]<XJY9H6]V6-O@ZGT\ZOC =D^NEKPWFK;]TK9<.^/A9@-IT:8PYY_+X?
MTZ=)]_G^'M\^?X<YKV-]'_.6=U'^O;S+_K(/(U9D>8^8J[<?*Q<LS@B*D@)-
MC.,9P_'F#FLYQG\LX<&<<1G&?X9PKQS6*LIPRE3Y$$'Y&IJ?Y%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*?E^?%*I";V#0JRE:K)=ZA7TMXSE:I
MNRPT2E&,?GE>3S1\)QC^.<^,8Y8D,TFR12.?)(V;KTZ TR/.K+6#NGTZJ?OQ
M9^U_6VOK;\^]J8WCK*/?\I_-*1RK.V^M?\/8AM2\Y^V$YSS<BX3Q68@0\-OY
M2=@([.X?.?U8S6)= ,EE '4E@ /F:L19O5D].>J8<S(]LM92.&_/N_""K#?L
MJ\?]J318*Q*>\^/M\'#GN^WM\^<<[%M[$^UUWCL_L[Q:3/3^1RIG^N%JIKJV
M3WIXE^,BC]O_ (^%8TW'U\_3RK27<U^R[9V4IO"O:W3M262)4_E/_%:5LU6N
MVL95_P 7+SK2,_GE6,??GHK3\D?M[=D?^9&ML^-W<008VSOEV/ITZUKOQ2Q3
MK<(?U,O_ *H/[OLK"?:']))J*1BQ-,]5[1,N/MN,CR>W+W!55@?"TJ3AXNM4
ML"_?4F\X\8<"1:HSWI4K'SJ?'A7L>&_D!]H9V1N)<4X=8ID%TAYMU+C.^@JJ
M1YQODMCPK3DX[:KG0DLA\,*%'VZB#\@:W)=!-;7FNZC7MG:4)6:)LOL+]&V=
M;M3:XKB*3J_6SIP#F8:*@:>E\PD>XGP94>7L^R3,C(SUAM:7&"R&XZ%B0Q?D
MWM1V*'BUQP[AUU+Q"RX7))90\1G.J>],3:9IM09@+;G"06:(="P:7]Z1ZZL#
M.\222((WD4,8P<Z =U4Y [P7&O8=[(\*SKYYVKJ<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*P5]1SJ<)W(ZH[#U6**.Y?
M(P;%YU08]\-"@]B5@8IZ(#20[G"!A[.$_)5"0(<]R!@)\@S"%/#,Y3[;\GWM
M2_LC[46'$V9A8R-V+BB#)#V%RRK*^D;LULZQW<:C=G@5,X8UIW]L+NVDBQWP
M-<9\I%R1_6W4^C9K\\$P,N/+* /%(".!)?#-#+9<'*$+&=4R2*2.ZE#K!##R
M%M/,NH2XTXA2%I2I.<8_?".DB+)&RNCJKHZD,KHP#*RL,AE8$$$$@@@C:O!D
M$$@[$'!'D14OS*E.*5 <&&=_VH[#G_?&FU_^4G/*GMX)/YR"&3]>-&\OK*?(
M?(5F)'7W7<?!B/P-=& 0AG</C"##OISC*7V&&F7DYQGSC*76T)7C.,_?SA6/
MOS3DX/PB7(EX7PZ3/7796S9SU]Z(UF+FX'2>88Z8E?'RU57,9L/84+A.(78%
M[A<(\>S$/<K)%X1X\>/9@"3']OCQC&/;X\8^V.:$GLG[,RYU\ X2V>O\@MP?
MF(Q5@O;Q>ES-_78_B3X;?#:J] [,]F(G"<1/9/L/%83C&$XC-Y[4CO;C'Y83
M\G;&?;X_AX\<T9/8'V,E.7]FN$D__P!JJ_ZN*S'$KX=+F3[2#\L@X^RJQ"[M
M]TH_VX%[A=J4I3X]J'NQ&X"V\>,>/]D9<7V\X\?PRG[^,>?RYJ/^3/V#?.KV
M8X:,^*I*A_T9168XK?C_ -(8_%(_]RJI%]0WO<%X^!V_[#*]OY?-;0LTC_C]
M1-+]W]JO.?USGFJWY*O8%O\ [.VR_JRW*_\ ;9^^LOSO?_TP/QCC_8HKWQ_4
MT]00;Q\+MWN?/C\OF)T$S_'YV+(]W]_G^?*&_)'[ M_Q&J_JW-R/^U/\?960
MXQ?C^^J?C&O[OXQ7LL^JEZBH^,8;[;[.SX_+XPM)*S_#\\E5)[.?R_CY_CC\
MLYY4?R/>P)_XH<?"\N1_M_VU(XS?#]-#\8P:]!OU9O4@:\>SMK?OM_VRM:M?
M_AX^_P >@.>?M^OW\_?/W^_*C^1CV"/_ !;<CX7UP/\ :J?SU?;=Z/;_ -GG
M/QR:F,>KAZDV,8QCMI=O&/UINH%9_ORK7&<Y_OSS$_D7]@C_ ,7W8^%_/^^G
MYZONN8_ZA_#5BNV?5R]2?/G_ -5I=/OGSGQ2M.8^_P!_R\:VQXQ]_P"KCPG\
MOM]L>(_\BWL%_P"K[O\ Y_/^^GYZOO./S]P_[WW=*Z+]6[U)%_UNVEWQ]O'[
ME0U&W]OU_P!7KI/C/W_/'C/\_MCDC\B_L$/^+KH_&_G_ 'T_/5]]:/\ J9/W
MDU)N>J_ZCCOGW]MMAX\^?]G":X8_/]/@4=KQ_+QX\?P\<L'Y&O8$?\5S']:]
MN3_MBAXU??7C'_NQ\]R?ET]*\I_U1O4.)\_%[<[8QY\XS\!VL"?G^GRE<8\?
MRSCQGEJ_D@]@5_XF+?K75P>G_O!]M8_GF_\ Z1/\VO\ '[/2O$)]27OX7CP]
MV\WGC&?S^6N+P.?Y_<!@;./_  <X\?P\<N7\DOL"O_$,3?K3W)_[7^/A4?GB
M_P#Z4#_(3]H-4X9WZ[R'>?F.X/99/N_/Y/=.P(W_  ^FSP?M_P#!\?Q\<V%_
M);[!+_\ 9NR;]9KAOQFJ#Q:_/]_Q\$C'^S^-4F=W"[?R?NQ(=M^TYJ5>?<@K
ML9N5YK/G\\?"7=5-^/X>/;^7V_+[<V4_)Q[#1^[[,<+'QA9C\V<FL#Q2_/\
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MC0A/TH69Q#/S3[6 8=!T@\.*[WKSV6XW86CWEQ:J(8P#-RYX97A!(&9$C=B
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M-SZFLMGH=]C=>J@<ZUMMDAJUN:B8772 ZMMK9T$]"#6RW8:+%L\6#71PX@7
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M"MV#.K2)UR'2=^PY*W(U&X$#:Y3-_)(>72GW=GYAT20Z=</R8['40+JXTZR
M>QIG1VC0&QVOWNS9GTYQS<6^K2>>&_D.GF>N/ATSX^6^/"I@VU]C6L&?(:7U
MB6IO\0_(X)WI-!X*^311LUGYC*-+%_)_7%RFPTROLP7^'TTZM+8^NYNYB*;
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M:!%&1KYI$3?R'S_LJRO[4/4'_P#:?=;O_ELW#_\ T[YL\C@__K*^_P"BHO\
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M> JUUR[==9*"AY5EW?KQIUC"LO P\^-:)5OV^?*51%7^LRF%Y\?NHR)[E?\
M%QGG5L_9'VFOR!;<$XB0>CS6[6L1^$UUR8L>NO K5EXE80_SEW"#Y*XD;[5C
MU,/E51Z.WO3.P=:E;GKT:?74@)XJO SDY%_1VK 6 .,^<9#!/OKD51@ZC&A/
MFI 4!UPYHP=(W_!%K5K\<X%>^S]S%9<0:W%W);I</!!+SC;I(S*B3.JB/FMH
M9],;R (48MWP!G:7<5[&TL(?EAR@=UTARH!)4$ZM(R!E@ISD8VJ]/.+6U3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI6CKU?M+^Y&O=]1(GW1E6NKBXTC[Y0K)<Q43WL(Q^25?7HTD
MIWSG.7(83"_&&4<^W_DAXU@\0X#*_7_SC9@GQ&B&[C&?,=GD5!Y3/CJ:\I[2
MVNT-XHZ?0RGT.6C)\?K*3^J*T:<^XUY*JQ@MB; JV$8K-ZN-<PWX^'B"L\W$
M8;\?E[,1YP_M\>,>/;X\>.:<_#N'W6>U6-G<YZ\^VAFS\>8C9ZGK5J3SQ_S<
MTJ?J2.O^J15VXCM[VB@\(2#OW:JTM^/8B3N4S.(3C'Y)PB:)D$^W'Y83G'MQ
MC[>/'VYR9O9'V7GSS. <*!/4Q64,!/KF!8SGU\]^N];*\3X@N,7EQM]:1F_U
MB<_;5QXWU$.Y$7[<,;ID2$I\8]LE5:%*^[&/X*<D:L2]GS_%6',+_P"ZYS9?
MR>>QTN=7!8U)\8KN_BQ\!'=*OW8J]>-\37I=$^C1PM^,9/R-5T#ZHG;T3V_,
M6ZK2GC\\G4:NM^[_ )WTP6.QCS_'VX3_ "\<T9/R7^R+YTV=U%_R=]<G'^=>
M3[\U:./\2'62-OC"G^R!56">K/VE&\?& U4?X_/)=2F$>[^>?D;4%C_Q<8Q_
M+FH_Y)_99O=DXK'^I=PG_K+5ZM'M'Q =5MC\8W_9**J,;U?NQC>,8*HFEB/'
MYY;@KN.K/\\Y_'[R?.?X^$8Q^F,?ES7;\D/LX?=O^-+\9[%A_P#\]3]YK,>T
MM[XPVI^"RC_MC7M,^L/NQ/CYC5^K7<_Q^#^+6//]F%V CQ_CGE#?D?X(?=XI
MQ0?K=D;\+=*R_NFNO&WM_G(/]LUZ+?K%[6QC'Q=0Z]7G^/PY2R-XS_9A1+OC
M_'/*S^1[A7AQ?B'VQ6Q_V167]TUQ_@T/]9_WU-)]8[9&/'OTS2%?K[;#/)_L
M\>65^/\ I\_RYC_Y'>&^'&;[_F\!_:*?W33^-K#_ %W'[Z[Y]8_8OC[:7I6,
M_P ,YL<YG'^'RV//^..1_P"1WAW_ *YO?^;P?[U3_=//_@L7]=_W5!7ZQNS,
M_P"STY1$_P#/G+ O_P G#?,A^1WAGCQB_(](+<??O^%1_=-<?X-#_6>I)WUB
MMNY\_!U-KAO]/BFV=WQ^GGV2+/G_ *//\N9C\CW"/TN+<2/P2U'XQM3^Z:X_
MP:'^L_[Z\I_UA-\*\_+:VU&S^GQQ+D1X_M^';1?/]WCEB_D@X%^EQ+BQ_5>S
M7\;1JQ_NFN_\'M__ (O_ 'E>"5ZN_9A_SABIZ8#Q_#+-9N+B\?SSDF_O(SG_
M -[QC[?E^?-A/R1^S2^]=\:?T:YLP/\ 1X>I^_[:P/M)?'I%:K_D2D_?-C[J
MIDWU6NUQ6,X8(UW'>?RR%35.93_9]0EC\?\ C85S93\E7LHOO+Q&3]>\ _ZN
M*.JS[1<1/3D+\(C_ +3FJ.D/4S[CFX5AC9<9%85YQXCZ%0U9QC/_ "52-=D%
MX_M]WG'Z\W(_R9^QR>]PV67_ )2_OQ\^5<1C]E5-Q[B9Z3JOZL,1_P!9&J@9
M3OCV[E\*P7O.UM>_SY^EC0$)G'G_ ).86'C\H_E[,I\?P\<Z$7L)[(PXT<#M
M#C^E:XG^?.FDS]N:I;C'$FZW<@_5")_J(M6PFNR786PX6F:WEMN1:7YPH9_8
M=K^4\9_/& T2J!4XS_'"6<><>,9^V,<Z</LW[/6^#!P/A,;#])>'6FO^N8B_
M^E5#W]Z_OW=R1Y<Z0#Y!@/NJTTE+RTR_DJ8E)&5*SY\DR1I)S^?.?.?+Q3KK
MF?.?OG][[Y_/G6CABA71#%'$GU8T6-?ZJ@#[JUF=WW9F8^;,3^)-=8J+D)N3
MC86)%=.E)<\.+C06$^]\R0/(;$#%93YQ[G2"'6V6T^<>5K3CS]^)98X(I)I7
M$<4,;RRR-LJ1QJ7=V/@%4$GT%%5G94499V"J!U+,< ?:3BOLDT+JN/TGI[7V
MKX[#2L5.NAAR)+*?:W(3Q/OD+')IQXQG&)*=+D#4I5Y4A#Z6\YSA&,\_'7'N
M*R<;XQQ#BDF?Y7<.\:MUCMUQ';1?^Z@2-#CJ5)\:^FVENMK;0VZ_WM "?-SN
M[?Y3EC]M7=YR*V:<4IQ2G%*<4JP=1[6=7=@;"-U'0^R.A+MM:.^<^H:RJ.X=
M>V380/TY"W)#!E,AK$;8QL@(;<6;AZ-1\HA"U/\ P\)SG&W)87T,(N);*[B@
M.,3R6TR0G/3$C($.?##;^%8AT)TAU+>08$_('-3NR>S?6W3,Z-5]P=@]'ZIL
MQL6Q.!UW9.V*'19TN$**-!&F!HBT3\7(/Q9!L=(!L2#0ZQ'B@#1VWE.BOH1$
M-E>7*&2WM+J= Q4O#;RRH& !*ED1@& 8$C.0"#C!%"Z*<,RJ>N"P!QY[FO;I
M&]-);,J<[?-;[BU7L&C59TYBS7.D;"J5KJ=<>BXYF8DV9VQ0,N?#Q#L=$$CR
MAS<@8.L2.(9.(PV,ZVZK"6UN8)%BFMYX97 *1RPR1R.&8JI5'4,P+ J, Y8$
M#<4#*02&4@=2""!MG<CIMO\ "IO6.Y=/[LKA%QTSM;6VVZB)(%1)5JUC>JO?
M:X-*@MM.FQA$Y5926C&9 1I]ATH)PI)([;S2W6T)<1G,3VUQ;.([F":WD*AA
M'/$\3E3D!@DBJQ4D'!Q@X.*E65AE6##IE2",^614_K?:&MMQU"/V!J2_TS9U
M$EB94.*N= LT-;ZK)E04J;!3+$?/P!A\4:Y%S,<?%G)&*=R,>&2*[[7F5IQ$
MT$UM(T-Q#+!*H4M%,C1R*'4.I9' 8:E8,,@9!!Z&BLK#4I# YP000<$@[C;8
M@BJZY54TXI7BJLE=3845)4_"IM3D3F>;K*I4'%A7!I*R"J91"Y?^I*B<&XR'
MF12-D/!6,CY>^+C*.3@XU8.G.,X.,^6>F?2HU+JTZAJQJTY&K3G&<=<9VSC&
M:\HG8-"#9LQ!EWJ H]*='8N3Y-EAF&:D\7A*A6;,ZZ:E$"Z2E:%#MRJA%O84
MG+>%85CS.EMNZW>SIV/>QUQMOCQQTJ"Z#42Z@)@,2P&DGH&WVSX9Q54CD,%L
M,%"OLDBDLMD#$CN(>8(8>0EQE]AYM2FW676U)<;<;4I#B%)4E64YQGF-9=>E
M>#7KE4+=F435+56[/F$/<BYK%>G(R:S$2;658=CI3$:43D ]O*%8<$+^$0C*
M584WCVY\259<:E(R,C((R/,9ZCUK%71LZ65L'!TL#@^1P3@^AKO9;=4Z6 U*
M7&SUZIQCY2 69&RS4;! /&NM//M!M&2A(H[A3C(Q#R!T.9>6TP\XE&4-+RD%
M9CA06/7 !)QY[49E09=E49QEB%&?+)(&:C5^S5NVQR9>JV"#LT2MQ;*)2ORP
M$S'+>;\?$:2;'$$C*<;]R?>C#N5(]V/=C'G'!!4X8$'R((/R-2K*PRK!AYJ0
M1\QD53T1M36%@F?P[ ['H<W8/>0U]"B+A7I*9^()[_FF_I@<B\;[QOAN?,(^
M![F?8OXF$^U7B2C@9*,!YE2!\\8K$2QEM(D0MN-(=2V1U& <[>-=YS9^M*Q+
MH@++L.C5Z=<0.XW"3EM@(F76V5G*15HC3Y <Q2"<XS@=26<I>SC.&\JSC/ 1
MR,A6(\PI(^8%&EC4Z6D16\F=0=^FQ(.]>G:[K3:)".V6\6VLTVN,+:;?G[7/
M15=A&7'_ #\!#LK+EA@MK>\9^$E;^%.>,^S"O&>0JLQPJECY*"3\A4LZ(NIV
M5%'5F8*N_3<D#>H\=:ZO,04=:(BR0,M6I? >8FP1<N!(0LK]1+; C\1DH&0\
M$?D\YYD()(C[V2S'6AA\./N(1D002""".H(((QN<CJ,#>@92 P92K8PP((.3
M@8.<')V&.IVJF=7;;UMNND0&Q]67"'NE*M$2/.P4]$NNX'/ARWBQQ9' Y;0Q
MPXQ+P!J!W"Q6/C_*O*:PI*,JYD\;QL5=2K X(/@=CCR\1FL8Y8Y462-PZ, R
ML.A4YP=]\'!ZUZ%/V5KG8:I9- O]*O"H$I(4XFGVJ"LRH4U>7<($EL0IYN8X
MI>67L)',^"ZK+3N,(S\-7B&1UQJ5ESN-2D9'F,@9J4DCDSHD1])PVAE;2?(X
M)P?C7L"VBLG3TI50K%!&6>$&$-F:X++QY$]$!R"<+ +E(=HA<@ ,:C.%B/EC
MM-$ISA3*UXSC/(P<!L'23@'!P2.H!Z9%2&4L5#*64 E01J /0D=0#X9ZUZIA
M@D>(4>>4.""$.\6::8^T,(((,VIX@HHEY2&1QV&4+=>>=6AMIM"EK4E*<YQ
M!)P!DG8 =2?*I) !)(  R2=@ .I)\ *IFF[ H>QHQZ:U[=JC>X<<MP!^6IMD
MAK1&,',I0MX)X^$-.%:+:0XVIP9;J7D)6A2D8PI.<RRLIPRE3UPP(.//!K%)
M$D&J-T=<XRC!AGRRI(S7HQ5HK,\?-Q<'8H*9DZR8W'62.BI>/D3Z_(.H4XT#
M-B!D/$11CC:%N-C'MCO+0A2THRE.<X%6 !((#;@D$ CS!\?LJ0RL2 RDJ<,
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MV;XM><=N9)AQ:)K;A=O.%UN[Q2H\\48"B. &1)!I55 A#( 9(B^@T<9GB2$
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MN(/KBLY)#S-)':%&"8P,]T G3D9&,XR,UAQ0W?9C'<-'R[CB,4*<G4#V1B[
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M1%M/Q[95TDHQY4_!1Y9! \6M)>4EM#-+''F75)P]9;</(TA1QJ81C(R5T@X
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MJF2(;Z]F?0_QC]_W'RJ*UM_#I@P?[+]PM?,RHT5\T]2%(#'^8V+(Z\^I$O\
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M#,4S[D?.6V LT+A3>8G)#\BUR5':;0:BHR9L!=4KQ98Z=@NCF.=\1.C_ *6
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M^'L21BZS\3.2_G&\C:88CM-H<,5R)MCB=8-0.G=3JYP/] K2>&*9]#\O3/\
M9\=J]3]K>/\ V,MN_P#Q*S__ ''F'9__ &]O_G?_ --35W>:]*<4IQ2G%*<4
MJFY&X5:(F X"6GXJ+F) ;YR/ DC&079!C#RV%9!44IIHQUMQ&<.CC..D-)RA
MQQI#;C:U;,=G=30O<0V\LL,;:))(T:01M@,.9H!* @[,P"DY )((&)90=)8
MD9 )QGX9ZU3%KTSJ"^_$7=-7:]MCC^,Y63/TZORQ6<J^_P 1!AD>\2VY]_*7
M6GDN8SGRE>,_?FS:<9XO88%EQ3B%H%Z+;WEQ$GP*)($(\P00?$55);6TO\[;
MPR9\7B1C\V4FL=K'Z>/3ZRY<<(T['Q1"_.4D5RP6V PUG/YY;"C)UB,_L2X"
MXC'\$XYZ*V_*%[7VV O&))5&.[<V]I<9QYO+ TOQ(<$^)K2?@O#).MJJGS1Y
M$^Y7"_=5D)STD^L<G[UQ<UM:MKSYRVB/LT&:*G.?RPMN:JTD2M&/T28VK/\
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M3\TUE64X5C"_$^V]YRK""S4X:[FUN,]8;?#$$>LS1$$[=PX!(R-FU7+EOJC
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MV>^=P%5_J,1IQG:N8.(WLEM?F:WF:..>:-IH9X(7M532>4I"EG://\X%;7G
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MF3OL,9C ]U3'D@OLK8VSFLHKV\;BEQ;- 3 @3'TD/T2'.)R0-;B4 $1Y+)D
M@'(K7%Z:WJD[8ZO=4M8KVQUBV[L;KQ8>W5WU%;^W4OM2OJ9K-KV)L.4=A8Z
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M[D\4M26&JK) 6%:TQ!@YC@6MR2 +><DD* (9"2QD:(*.[N3*K1 #<R*R>\"
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MF!Y#Y#RQ^&WPVJ*_J35)*'VR=9:](;)Q(I)0_2ZVZ@A,P+ @RR7TN1JDNXE
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M_OY2UA:M_>@/@SC[@V*SYL@_2^8'[OPKT6]C6-'CW*">_P"^"^//]OPG&O\
MH\<J/#;8].8/@_[P:GG/Z?+K]_X8J<1LZ;Q_7"BU?S2T6C/_ $EJQ_T<P/"X
M/"24?$H?]@5//;R7[_M\?_#UJ83M"1Q_6C L_P#-<?3_ )J5S'\U1_TK_P!5
M:GGGZH^9J)C:)G\8D;^XEW'_ /+SR/S4G],W]0?[U.>?JCY_V5S^U$O_ /%
M_P#\*=_^RX_-2?TS?U!_O4YY^J/F:ZYVB=_"*%Q_:^]G_)*>/S4GC,W]4#]I
MISS]4?/^RH*MGRN?ZL='X_3W9)5_D\CS_P!',APJ+QED/PTC]AISS]4?,U+.
M;+GU>?8/&-_S2P0K./[UEJQ_^SS(<+MQU>4^FI /]3/WU'/?R7Y']]2+NP+.
MYY]I;#/G_M08^?']GQD.\L'#K4=58_%V_9BHYS^8^0KRW[99"//Q)@Q/G_M*
M\#?_ +NEKQ_=RU;.U7I"A_6RW^L36/,?ZQ_#\*\5XDDE7O(??(7G/]9YUQU7
MG/\ W2U*SYS_ &\O5$08550>2J%&/L K$DGJ2?B<UDQ7@/ID+&A93[5M"H4]
MCQ^1#WEXCS_8\XO&//\ #&.>7N).;/+)X,QQ^J.ZO^B!6Z@TJH\A\/C_ &U[
M/*:RIQ2G%*<4IQ2G%*<4IQ2I8TT.-#+D9$L8"/ &?-..-?:%#"#%:6^2662^
MMM@<8=AM;S[[RT-,M(6XXM*$YSB0"2  220  ,DD[  #<DG8 =:5@'J'U6?3
MIWWMX?0VG^WFG[WM<\PR/AJK$31;>+,>"V\\0%4)T^/#K5Q+^7'()8&JTQ+O
M%BL/$B(?8:6XGK7' >,6EL;NXX=<Q6X +2,@[@; !D0$O&,D EU4 D D$@54
ML\3-I612QV W&3Y D8/V'?PJ]?9SN9U:Z9UF(MW:#>-#TS"V$PD"N?BR2<Q+
MV0L)#+A[5<K<8/(V2?\ IK9(KDFY#Q)K48@L19ZQTE,9<U;'AM]Q*1H[&UEN
M70!GY:]U =@7=B$3.#IU,-6#C.#63R)&,NP4'IGJ?@.I]<#:N*_W.ZL6CK8[
MW"A=YT$CK(Q$RDT1N4B55&4\8&%G2*O)8*(E& C!CQ[,*]74Q+X;<L3.?!B1
M0GCR1QW9?AM_'>_FY[687VI4%L%U2%G02+@*2""A#Z@=(7O$@ D!(A3F!AHZ
MZN@V./'UVQUS4QJSN'UAW7IZW;^UANRC6G3VOEVAJ_WEJ2<BXRAD4J.3,6P6
M[#S;$9)U(R AW&9>1#L $<4Q%$B266<A%C/NQ/PZ^MKF.TGMI8[F;E\F+3J:
M42MIC,10LL@=LJI0L"P*YR"*+(C*75@5&03T (Z@YQC'K5S]2;7H6]-:4K<&
MKII^QZZV+ AVBEV$B"L-;S.UV23ER-F1X>U14)/#@28^$&QCYL6,F0CGQ9(/
MXX!8I#U%Q;RVL\MM.H2:%S'*@9'T.OO*6C9D)4[, QP00<$$#)6#*&4Y!&0<
M$9'P.#5Q.4U-.*51B]CZ\;O[.J'+Y3&]I$595X8UJNT0:;^_2D22X9=P9IJC
ML6)RK)EVG(I5@1'*B4R3:P<EX*0IK&6EM.O2VC5IUX.G5C.G5C&K&^,YQO6'
M,CYG*YB<W3KY>I>9HSC7HSJTYVU8QG;.:IHS?6C(]C9!1^Z-3@BZ;)!"V\29
ML6GC,:K,D\>8T39#STPANCDR&/N"Q9U1;I>/NPAS')Y<G<^C?Z3)3N-WP.I3
M;O8\<9Q6)GA D)FB A($I,B 1$]!)OW"? -C-==9;]T3NO,DG36ZM2[;5#):
M7,)UEL>G7W,4A]64,+DL569E<@I>7C*6E%?"PXK&4HSG.,XX>.2/&N-TSTUH
MRY^&0,TCGAFSR9HI<=>7(CX^.DG'VUZ*MRZ@3LQ&EE;6ULG<;D3F>1J95YK&
M-F+@\#J+S,HHF93\4JB<"H63F1Q%9#^70I[XWPTY5ARWT<S0_+SC7I.C/EJQ
MISZ9S4\Z+F<GFQ\[&KE:UYFGZVC.K'KC%7)YA5E4"-M;5QNQC]/![)H)>VXJ
MO)MTIJT:XUU_8T;5%D!"(LY](:D5V8.O++DHX5,T1&-QJB#PF<$Y<*82YEH?
M0)-#:"=(?2=!;!.D-C&< G&<X!JL2Q&0PB2,RA=9B#KS F0-13.H+D@:L8R0
M,U7W,:LIQ2G%*<4IQ2K4:IWKIW><39I[3^R:CL:%IEWF];6J3JDP-*!05\K>
M 53=6D7V590S+Q[<G&O.CYSGWL'AD,J<9)9<7F\<D942(R%E#J&&,H<X8>8.
M#OZ&JHIXIPS12+($<QL5.0KKC*GU&1MZBHA^\-0Q6X(+K_([&J86Z[/3C-@U
M_6),N,U<9BE1YID<9908=2L$/Q3)L=(CY(3C]]4;(J;2M !BF0CD*&4(QC5@
MI?!TAB,A<],X\/4>8H9HA,L!D43,AD6//?* D%@/+((SZ'R-73YA5M.*5;7<
M&XM8:!UO:MO;ENL)KS6M)"9D+/;K"^MB,BQR31HT-"L,MOE%&2$F:%&1D<".
M3(2<D8)'@"DF$LLKSCC>5Q'&I=VV"CJ?$_(;DG857++'!&TLSK'&@RSL< 9(
M ^))(  R22  2:E=);NU9V.U=5-TZ4N -]UA>&)(FK6R.$E !)9J'FI*NRGL
M"F@8R5%= G(>3C26#@!7VR0WDJ;\82I22-XG,<BE77&5.,C(!'3(W!!^VHAF
MBN(EFA<21/G2XR =+%3U .S C<>%714XA"D)6M"5.*REM*E82IQ6$Y7E*,9S
MC*E82E2LX3YSA*<J\>,9SS"K:[\4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2J3NT?]0KAV$I]SHF$G-?RR-YR
M[G^?_!E/8QC'\<XYMV,G+N8SG <F,_Y73_2TU7*,H?3?Y?V9_P#"L<^>EK3I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*]ZL ?4YZ,%RGW-Y)2\]C./ME@;R^ZG/
MZ86AO*/[58YKW<G*MY6S@Z2J_K-W01\"<_96<8U.H]<GX#<UDUSR];M.*4XI
M3BE.*4XI3BE.*4XI6*G>E>J_]"WM@-O&XRFOM/2O7;<4#LJ[03#AD_6*;8J%
M.P4[+U\!E#CLE8! 9%U<'%MM.N2<K\G'H9=43AM6_P +[1^<N'FUC6:Y6\MG
M@B8X1Y4F1T5R=E0E1K;;2N3D8S6$FGEOJ.%*,"?($$''F?(>)VKXE^K3FZ("
MQ>A?_ITZA8U+T5H.ZL272GL'KV@5")V5N"^6JR1T_P!>V.Q 47L:R&:SKEI4
M'$6Z05&@G*M4*ITZ3<L2&I6ZP?TR^%LZ^U7YJN#<<4FMBO$[.:61H+:&-&2\
M[&S0()WC):-=17EMLH3*QMSDU#LW-73&&^C90-1).4U=XE03@G .1Y[L-F7:
M5OMCMK^D.W6O=====7MI;'T/T'K<KJ:.[C2%V:U)KV&F[A6C;=L"M0E#CCYV
M4V&?,W4FEA&#Y";&BY@Y^0D$M1 2&.+8_F^W]CXWO)K^""[XLZW!X:L1N)F6
M*01PR-,RH(0L0D8')+* %.HU=)S&NB$",RQ9429TC<9(P"<[X'QWZ"LH=03E
MO]<KTB]L:]#J6M^JV[ZCV#?HD[$U^-+E-)?MFT%LV@;F?+;B(Y[$H_1[T06$
M+/9;-FI*.FCY67;+LCH+29#0N4C]E_:"WF,DU_:R68F1G*K=&VO+>:VQJ8%1
M+$-13*JK*JJ0@8XS4FY@8;(P;&P.G4I#=,YP=L[G!WWK5CM20ND+MGL]JK<[
MX6X]3[5[^ZNL'=JG]55GQE$WKVIV&S5JKUW]-C5=TV;(UA!L<*]7<[2[97V<
M?@TQL:R!0G!X>P"LMV;NP"-[>QN+8&VN+?A,Z<,DO\&6UL(>9)><;GC@5R#A
M^1P^) Y9M4V60YCH.K4ZL=0,J\T1C9W(PD*EB#_C.=L# &_7ZQNCW;.D=O-3
M6>QU+7EDU!,Z9VYL+K7M'4-J16U2>K]J::.$A+32FC:=)2]4E8J,9*BWH>3K
MQSD:1&EC);;&<:=&9\#Q3A\O#KB-))DN%N;>&]@N(]>F>WN07CEQ(JR*S88,
MKC(8'<C!.]&XD4X&DJQ1EV[K+L1D;''IM69'.=5E.*5\T/;RU]EZ=Z]]#ENJ
M6IZ'N79R_3%&#)J.Q;ZK7, S57NP]_<E9ENP("/RY(AFLQ(X\=\#&"6C27?B
M)^6\*ZUNL+<-D$[M&G;!WD76=7*7 QD;'??TKSMRUPG' ;:))I/S:H*2/RUT
M=HDR=6#N#I&,;Y-:U+++[1GNJ_\ 22IC==0K]!VM(;+ZR$7FFU6P9M==KTXJ
MZO8?CHBQ*8&S+B-M)96@S+#65J6I/LQ[>;@"";A C8L@672S#22/,C)P?MK0
M8R-;^T!E14D+VY=%;6JMK.0&P,CUQ6>/0WK9?;GW8ZC=PJ#TQ=Z&]>M"]2)6
ML;CM<\SK?7Y/9ZQ6G7AL9'R3E(U])$).A@C9*.V J[V=AM^1;@QLS!C<@!"!
MIU;F95MYX'N!<RRSAHPNMN2%<D]YP.\1E-(SC)QL<UNV5O(UY:W26G8K>"U*
MRLW+0W+-&0"40^Z"5DYC==.YV%:>9OO/H;/9,+U40MI'O]FQ_4;+/<U<W6-A
M-O9]/=%+'U&&!FQKK6*)FQN4^/>"5'-3N2LM3:RLB?.-N@JWUMY.4;$I]$;0
M=[*__P UJ,I.G5JZG&<?HCP.W):\@-P.)"4]I[?GEE9=K'0(@-6G1JT#!&K.
M_3/=/VDE=V(IOL;"]>8OK7W LP,^Y6LQO8RL:+-F.J[H-HJ0-O#F5;G9G$QV
M(8(:0;AY4]$8ML.Q,DQ7AU37QE<#LYY1E,L (SF(R 39#%2.7C.=LC?<;UZX
MW@[0(!;W;!M.)U@)ML,H<'G9Q@ X)QLV16I?KCU[U9UM_I!%^I>IX,^(B[%Z
M9\UL.TG3-BL%LL-KO=M[,U9^R6RQV*SR4K+R<Q++%$0ZXZ7@<<804($84(9@
M=O?ED>7A2LY!(O J@ *%41-A550  /AN22<DDUS(((K?CCI$I ;A[2,2S.S.
M]PI9F9B22<#QP    !6/?J">I#V0T79^P&Y.NW<?9^U83KSV B*!:M0UCI%
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MM23&<\]I@@8!H<Z0KDX"@ XP0<D8JMK[B,_9[E!/(LMQIE@%LG9D@YC(62<
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M/7IJ%N*H[O9/5*R;^2-<9 =Z1E:26DZ!<J[N&U9K33)B<D$,C)>02I:FW,?
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MMK:>:XB0B6<L7)8D#6^M@H/N@MO@>0'05;+7/I-=7]0;'C;OJVS]D*!48?9
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M>I/[AM2WLY%O;F\G9&:0".!5+'EPCP.I5 9M*DA00#JW.HUC5N#H#W=I._\
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M[MR$S($)_P!80O.1N)R"#*Y!!!!8[AD2-OFD:*?-54= *8'D/E4JUI34K [
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MET@P^TQ-W,)=7[?*GB;=!0]B>7G[KEHT0S/^M93G$"XG  $L@  4#4=E$;1
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M.;D64^$DN8S)N;@DDS29;43WCN79'8_Y31HQ\RBGP%,#R'R_CS/SKJ]I34I
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54XI3BE.*4XI3BE.*4XI3BE.*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g99471g35h67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g35h67.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2':4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (;Z^AC@X0DE-! 0      % < 5H  QLE1QP"   ".HT< E  "')R,C V
M,#,T' (% "]-:6-R;W-O9G0@4&]W97)0;VEN=" M(%)A;&QY8FEO(%,M,2!)
M;6%G97,N<'!T>#A"24T$)0      $,9Q=]Z,[ 9OJZ'>) #&J%TX0DE-!#H
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q 8VA1X         IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M/X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          (X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$'@      !      X0DE-!!H      S4    &              +?
M   #TP         !                          $              ],
M  +?                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  +?     %)G:'1L;VYG   #TP    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   "WP    !29VAT;&]N
M9P   ],    #=7)L5$585     $       !N=6QL5$585     $       !-
M<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q497AT
M27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG
M;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L
M:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O
M;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET
M;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T
M=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-
M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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MR2E\/^?S?^/'_GFA6E4P7%UV:2TM_6(AT3I50-VA=[7?2:K:2FAU3H?3.K,
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MO4_])@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MNI!73FLU'S[9+;<;QX>E5X[EUMAFF"+79*ZQF J*W=ND )HV8YAETR?@D=@
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MEL=",FH5O<C3T<DWF6Z:<3,G9#74&P18E;E4)X:JJIQ*-:W]OO\ X4R"\<]
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M-]-9UYI_9-5V A6I1:'G1KLFB]4C7R)A*)7")1!8K=82F\E>@F+-X!#BU75
MAA#K5<C0O%PIW*]HL9'(\02MD<UDS2Z)Q:TDALC02QVM. .B=%6CEG .:<%D
MIQ\OXWE< [(1OEIG(5G1,G;&0)6,E!='YT+B!/7+Q/ 7-\V-G4%N7.WOX>_F
MJ@G7_P O8/\ 7[?9C?OU_/Y?BB9*)A$PB81,(F$3")[,(O43% .HCT#H(_#[
M ]H_H#X\C8'Y;_!-[_FM+[ZV79-4ZWF+94=<6O:MC*JUC8:H4Y%):4=R,HL#
M1DX6,N/AMHYJY524D'1B'!LV ZHD$"CF+S-^?&X^:U6HVLC8: V&K4:'2R22
M'H9O9 #&N<'/=WZ6@NUV5X\.N*XOF/*J6%S?*<-P[%/;/:O9O./>RG!5IQ^?
M/&P1_6EM31,D;6B!:9)2UG4"52QH#17.=SOZA6'8]$@J.5A>2VVT3K.'07EP
MAW+EQ+2AI7::3Y=Q9U9E)^,&>I =S'LT6Z*)&4<FV*<VJ<)A^8NS-.;(TX*3
M67!9GEBBZI1&7&5QER D_P"H=*'&N:P+XV@-+@SX^\O$KQ$_1ZA\-N28OBO(
MLCR%UGCKL+B,=8OOBI&[%%%2IBEQ!U:-F(91?7&0;FNF&S.^620V+3I7-;;Q
MM?EQHO1U]KVOML6U:CR-GC/.<5.SD/*MJ:H47*K0C)>W T/",Y)15!0P,G#M
M)4J0IJJ>&50@FV9D^38?#7*]/)VC2?:9U0S312-J.^MT]+K73Y+)-]^A[VG7
M?6EXHX;X+^(GB#QW)\DX;A6<AJXBW]$O8_'WJ<N=81$R9T\6%$S<A/5:R1H-
MB*!S"\.:W;FOZ=_P%CK]IC&LU6)R)L4.]("K.5A)%K*QSI,WK!1N^8JKMEB#
MU_WDU3!^?,U#/#8C;+7EBGB> 620R-DC<#Z%KV$M(/S!6NLCC,EA[DV/RV/N
MXR]7<63T\A5GIVH7M.BV6O89'+&[?P<P%9K.5=%,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PBPT_8H"J1+Z>LTU%U^$C4#NI"6F7S:-CF3=,.IUG+QVHB
MW13*'_VE%"@(B !U$0#.*:>&O&^6>6.&)C2Y\LKVQQL:!LESW$-:!\22N[CL
M;D<O=KXW%4+F2R%N1L-6E0KRVK5B5QTUD,$#'R2./R:TG0)] JO:[S3MM_KE
MOWW0]@:_F-:5'<W]ER6GD(!52TVB--/L*\TE86ZGEDUG,]-HR)+1"QL?7GD<
MO%)%;G<E4\H50U]7Y7/?@LYFC>HSX^ME6X]N-$#G3V&_28Z[9(;7F-ZII6R>
M?$&QOA=$!W)ZBWUKE? ;#\:RF$\..1<:Y-1Y7G.#'E\G.),DUF(P]K]6V<G+
M2O8%M-S(L;0?5.'O6K.3@MQW'F5L1;Y3)+4FSINZ2!1NX1<$[QB>(BJ58G?(
M82G+WR"8.\4P"4Q>O>*("!N@@.;$#@0"TAP/H00X$;UO8)V/MVO'[V21.Z)8
MWQ/T#T2,<QVG#J:2UP!TYO<'6B.X)'=?3GTOE,(F$3")A$PB81,(F$3")A$P
MB810 [3ZQSU3X5;>GJW/SE9EV8TPJ$S6Y%Y%331%S>*^V>>0OF"R#M)19HLL
MW$$5 %1-4Z9@,4PE&E^(,\];B65FKSS5I6-K 35WOCF:UUN!CQ&]CFO:YS'.
M:"T@C97H_P#1+Q>.S7CWPC'93'8_+4I_UZ9*&5JP7*$[XN/Y26#Z37L,DA>R
M.=D<@+VD,<QKAH@$5N\?Y"9](C11N+EPYIV^!<O'X[[)R'96DNOF-*/$B;RJ
M/>6=DS3)+'?]X(P60*+'.5($U  PE/0L&Z89_"GCUKE]JL\R?KMV<;9--E41
M$CRG6HF 2F0[:6.<2-'OI>I/$JO0_P#AAXB#Q>PG@)A<E#!6'AN[PQGQ!Y)8
MSXN@"&U!B+$[S4;7U]+\\M8T%Y<TZVW;6G.6VU-.<24K<T@2[5LDYR0WA6QL
M.SMCMJG3ZE"1-SD/)#62WV%RJLS:%1$K&#CFQ%>^<AT4R))IE(;)XKDV2Q?&
M!;9#^M)Y>09JK](R60;6K5((KLA8;5N8O#&!@\N&-G8EH:WIV%2^<^"_#^<^
M-+\)-DCPW%8_PK\/<M^J^)<7FS.;S60O8*N)ABL'BX8V3SF3=C(VYGL(:6O<
M7N)+=H5?M/9"Y<>Z[?ZSJ1O/;DN.['?'^HZ[B;:BYJL_>6+9C(N)1G<_)2 %
M7&*?I/$GQFH&4]7=$$!%<,A6\0W7,'7O5\8)\K<R[L'5H166.JS7FM9(9&V^
MD'Z+Y;Q()"P=33L=NXJ>8_1)KX+Q,RG&\KS27'<$P7 (?$K-\GNX:2'-8WC]
MB6S5CJ6,$)3_ /-_IE9T+J[9B&=P6B3ZAYY=N=NS-(\<+;M7D)H576FR8;8K
M36U:IRMH3>5&X24J1%:.GH^X)ME 2JZ+4L@O(R0LU>Z$<L1N5519,"]N[S3(
M8? 6\GF\(:&0@O-H04_I(?6MOD(,<\=H,);6#"YTLAC/3Y;FM!<0%7./_H[<
M5Y_XIX7AWAEXD-Y7Q7(<8FY5E<ZW$O@S>#JU'.CM8VSA'2LZ\N^7Z*RI5\^/
M?TIKI7,#'$PMW5V@,]R$X97JT5-LM3=H:MWMIZ"L#+6MR?2,//,)BTM5HX*U
M;6J48X>QUA2;NXMTV71*0%DE4ERJHG*8U5R_-Y\UQ6]8JM-3(XW-8JO.W&77
M2PSQRV6N8:]MK83)%.&NB<T@?6[/:6^N^.!?HU8[PT\=^.XC,RLSW$.7^'?.
M<CC;'*\#!6NXZS1Q$C+)RV&FDN1U[>,DEAMPRQR%W0]CXRR1K@V=6O.<5XBK
MQL/7?*73']A]CJ^J)/>=?"(M"%W8SFN(<SA.5,X=,VZ)&L_%K-E$'3-$5$A6
M353 2"0HJ7&CRZY'<O4>18G]46*V,?F8!#:9<CGH1]39.I[&- L1.!;(QO4T
M'OV"\\\F_1^X_<X]QGE'@_ST^(&+S',ZGAYDOI^(EX_9QW*KPC=3$<%B1[I<
M;;9*V2&=_0\1N:X@@Z9QC3_/K:%HO6G4MM\>U=8:BY)/'4?HV^IVUO/RDD_,
MT7E8-E;H)!JF>#6GXMN=RQ$%3E[ITC@"B(G5+UL7S6_9N8H9/!NQ^,Y ]S,-
M>%EDTDCRQTL++5=H)@=/"PO9IQ[$$CN0,OS;]''B.(X]SA_"O$YO+^:^%4,-
MCQ"XX_"R8ZI5KB>.GD9\+DI)G#(,Q=R006-L!ZFO:2UX#3:5FQ5Y&3")A%"G
M57O\>8WZC>&'\8Y4X18G@%^(7(;Z=G.#[26P,(IV81,(F$3"*M61XNVZ3NO:
M5Q<)6(FGU3DIHW7M#UM+1Y8F/CY.S#K#;-<M3Y9A&&(NS59S]NCEW[MZV14D
M%G2CE-1<2**%)[]^_P":B4?0G);8D;9-M2&B;=2+!K:I\(:S7=63ENI#BS[.
M>\3=O%VG;'E;D8BP/:^P96MMWH:MJV&1C7#MP4JL@W8)&$"QWT?M!'S^[MZ=
M_7^?HGR^S^WW?V5@/%#76PB4G?UHO]=LFH)[D+N"][&CJH[EH9[=-?1,[ 0=
M4B@>R-??2\$A82IU_P ^IDC9"0;,U7B"9EU5$U.LJ/7Y_#^__*B9MW0$YJ7D
M]V>\S)[[W5M5)[R.MK D-LFRH344T4-Q_P!L*>7M6Z3-N*;P@$$A51$P%(H<
M.@"(#A3[]/N]_DKD<(F$3")A%"WM#:7LS9/#C>.O-/UN5M6P[I6VE?K\5#2\
M=!OA5=3L4=VY+)2;EHU12;,$G2JR9E@.X3*9N4A_%$,^H\75S4C,?<OT\=6?
M)'/)/D:\]JA*:4L=QE&[7K SR4\@^ 4;?E@EM>>5P#M=+KMX<\MK\%YI@^56
MJER[!B9K+I(L=)7AR,8N4+6/;=Q\MICZ[;V-=;&1J>: TV*L3>N-SFR-ZN%&
MX(]J'QZD[/:>/>HMM:O:J1B;R0-%;9I)+',-VZ#51ZQ<IP,HJVGCF>E<N6,>
M2,(9)N1%N0B[@#KJYBY@\EROE]KF,_B#Q;B5UV.AP6.X_8P$G+,$R%L\DODP
M%V.P;,5BF.97%:6:#(WF.EM/<^%C_*7JBQXX> F#\.>.^%N:X!G_ !?H?K2?
MD&<Y9'D+/#\ZR]8B9#]/L3WLAF;V3Y%8B!&5%2[B\7)Y,(A=(1]774=VKG:2
M:^L3JEVK=LG4Y*.>K-7K':>NX%Q)1(I!U\"8*ZJ+N<(MWB 0W=:"<>\!S=T.
M\IGIWBWA3@K/%<99Y3CL/E>0FN]V0M\1MVZ^*M2><_RY*,;[,48#H#$9 0UO
MFEX8.G07A+Q+Y3Q6QSS,CPQK9? \(EGK_J6ARP";*U&.KP_2&VK#9K;W,^E&
M;R"^>9WD]!>_JV!N:H]N9SS8'24>N-)W]L01\0CBLJQJZHE[H&*/F=6,.3_[
MPB)$SEZ@ IE >@>5LWXD>%.!S&0Q/*_#WQ0X>:MF:&&S(R"PVQ#'*Z.*VV*\
M*NFS!O6P,EG9H@-E?\/=.+_0/YORCC^.SW /&'PMYFR]3@GDCA=>KUX)WQ-?
M/6;>H3Y=DGD/=Y9>^O7>[6S#'O2D\CVZ?+^DILWVU^(,>RCGC1)^V4497ZH
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M815_<PO?!=G1])^V?9ZVYA%8#A$PB81,(F$3"*'W)_@IQLY<PJS';VOHMU8
M;F0C;]!H-X:]Q ]T_A"UL2#<SERV2.<5 C9,KZ-.81%1J8W0P6SC/-^2<3F$
MF)R$C8.H.DH3E\M&7TZNJ!S^EKCKL^(QR#TZNYWT+V,I9!A99A:\Z^K(!J5G
M8@=+Q]8>OIO2ZMO+[L2>17'<7]WTBY=;XU^T%9RL$"Q".V)7V93&.'G"N)N7
M!YQ)%,0!5Y *.%#]PRR\6T2$>[Z/P/BOPWFD P_+<=0IS3 -=6RL$-_#VGGZ
MIZ9+,+HHG$D:98:T#?2V1Q"K]2'EW#[8RG#>0YO$V8]AEC"Y.[BLC&PZ)#9J
M-B![VZ&G-:07#MTD'2U30.U.Y905&F]$;+>L]BU:0B'%17C[0B2H;*K[0R"$
M>BSKES(U#S<Y:  I)MY6)D3@0RQ%!(01$O)RWP1X7R+&6H<;+>XR+E8Q-N<?
ME9]'BC<UVWQUM/8UO0- PN8SI(: =Z7=X9XG9_B_+,5RBQ6QW),GBLHS*FIR
M&.61EVY'+YO_ %QZV?2'/E)E)>1(9 ']8<-G8FE++Q:MULIM?VG9:;1X,\HQ
M)8*OR/TR5,%X(CQ(DL-9V]J\8WSF[62\H28NK*TCV:A^Z==4Q2F*;R)D?T5.
M:\;R=/)<;R6'Y;C:=JO*]_T..IFJT44C906"M+"^6=K6]FO#VEY!='KL?T&'
MZ>V$S^#S=7-\=YCPOE-O'78:%OC_ "R6]@K%V6!T5?Z5B>1U;U*O2=,X><RB
MXO\ +#BP@D$6Y<B>!W!6#U&.Y./U5VN[$LS'(I3?$;8DG.R,6T<F.LXGRQK6
M>>L'4?$ID3\K;,SHNQ!=)(GA@<QRV7G'BAXB8[C^1QV2?E#+98RHZ2+#5'YF
M@R1QZK59EB",DQ!G226O+@[;?K?6'FOP!XE@,SXE8ATTG!:[*D-V_%7YY>M5
M>+YFS'&&0XJP^N\QB:P^4OKNDU#$^(O=U=#6&,NA=1VC9=U9Z_T'VG.X8RPN
M".W3[7'(#5MAD[<E'M$C+./ B;\_F6$DFV3Z%6.V?QH=T5%"%]0%'6W"O$_(
M6LY1JY+*XODE*(DW<+E.-?Z:SCZ\;' NJ9#%_1-2L?T/<^:.PQP:1Y?J1Z<\
M</#7 8'@V9S5[P%@XC9DC9%BN>^'GB'1Y1Q-F1LRM$+LC2LPRR,BDT]K*T/E
MN#7!OG@Z(WKM?BAS^US&-7X:RX-\RF2,CX;AC8^/56@+VNS\-147*BJ@,6!N
M\8@(*> X>NDS+E.1)8A3=-V<@\2<+C\<RUQG!\]?D'SQQ/QV/YF*=>&NYKW2
MV&26FRF5T9:UL=<MB\SJ),C-$GQYX9\*XQRO.V<=X@<_QG"<4S'R35,Q/QFS
ME6V,@V2..&C.VM8/T2%\;I)I+0:YW[/HZ=DZJFYFCL!U6:I V+LOM=\<[C(W
M.*;,;/38&1:QMR<F2=E2I[=HT:P""82BIBO5E(Z37=>$P420_!.<P=_PY\8Y
MLIGHL$'<^AR.1KVHZ4/,?HL.&J_1X'6K%Z;+UIL@YYKP02B&NVJZ2Q(\!H;L
MENTN0_HS\4Q>!S7,1XI\#Y=Q3C=1N0R\7 (I+G+9(I+,%&E5APU\4&5Q9NW:
M[+-V>?Z/4AW))YA#8W[B[(+;G+'9U9O_  WU#LZF:SBH=X:[R-HG&;F3NM0@
M95<L=8F.OHE1X";ARX?JH.C*K]U.&=@HN91-5^90N'_2$Q_-,IF:4N.I8[!L
MCA;1Y!R.K9??CL23Q"QC64*TE>I)'.:;9S)),7D/Z&#;&QOD[/AIC_T=^#<7
MQ_.N33<O\09\S/>FX=X>WZ-?!11_JF=M6_-R;(UY[T%B@S(NC9#'3=&+$+G#
MRWOBL,C[1?''CW"\=:0YJL9;[O?)*9F'%CLUMO\ 8'<].3<\\323>/.\X,9%
M@W4%(!29-2@FD'K.HNH)E1U#@L)%@JCJS+=V])+*Z>Q:O6'SRS3N&GO =]6)
MIUH1L&F@ $DC:H?BAXE9#Q0S\.9N83C_ !RK1I18O$X3C>-AQV/Q^-KN<Z"#
M48#[,K>L]=B4]3S^ZV-@#!(01 /;_73,VM;KT$X  B'KZ?%_G\/Q![?BQ_%1
MO[OS]_#NM,Q?(G2LU>C:VB]A03RYE>NXTL2D=SW%Y)@4QGT8TE#-@B'LDS B
M@.8]H_6=HF3.51$IB& ,7'FL7+;-&.["^T'NC\IO6=O9^\P/Z/++V_[F->7#
MY*]V_#/GE#CS>57.,9*# N@@M&\]L/5'4M$"M;GIME-ZO4G+F^59GK1P/#FN
M;(0X$[H[P?!Z_;\(? /0?A^#V_\ 'H.93W\??OLJ)OOKU]?B/4?#U]4 0$.O
MP?H'^OZZ^S(W]_Y'^WO[U*_)5))PF=-8A%$C )3D5(0Z9RCU 2G(<#%,0WL$
M!#H/L'V8T"-$;!&B".Q!^!']%]-<YCFO8YS'M(<US26N:X>A:X$$$? @@J&/
M)/5UDDI6*OU0=5<@MJ%:=8R,5/V8:&I&15M<,5T['2;:FV<IUVTL73))KXPM
M?^DQJJK=%0JO<(>KYS'3OD9<K.KC5&SCY&36#3\MEGI=])JV&L<(;+'M#=Z
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MN90*BK3.^-%4CD/0'VN[Z663B7+EK),I&!E74+.0LU'* O%S,3(M3 =!\P7
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M?7-N6Q!0E?U_1:_FEU6K(]CW!YBCTU^GN:=ZV2-KS[RCQ4O\9\2)>6>&>?\
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MKS62]+NL/T_3MC:3'C*X#2L=JNQ;?V5<[)#V)&X1&VK0^82-XC[0PF2SD.]
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ME(Q[A\T:R2B?BIG(I4K?&W'*6LGCYJ=2?(UVUKLLM%D]@,Z1&XUI1)$6%\8
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M(\]=<_2HB8X.K?0'.98?4?H]1'T9Q[C:Z.0$V1QT=V-OEY3#RN\YH[.#XO\
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MVP''J;U9RRK>]->H.8IUMUDRN%8EF0+D38;WU(F@_1;]3.4F@/;;7FB/DY3
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M$PB81,(F$3")A$PB81,(F$3")A$PB@%VENA'N^>*=W;UE @[&U@9OM_6KLI
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M/H\Y[-V&/.]$V3#9@76M@L$-M!I+': ;98P?6>P']U["-2QCZS';_P!O<W7
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M(UK,0,K&S<0^(91E*1#YM)1SQ,BAT3G:OF:JS9P0BR:B1C)*'*51,Y!$#%,
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M!?B%R&^G9S@^TEL#"*3FWMQT+1=.5OFQW\M&UI*18Q1W,+5[/;WP/9$RA6A
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M]#U_3M>/4U=?GV!IJ$A7.U=CP)8)@E349->2A$8U<SA\H3T'?T]?R^WU_O\
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MU5+()HG>5_CV?R7'[7^AN:27L4ZO,/U)G&R%MK 6G'4+XY@7"SB)W!HDC/7
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M2[#DL7;EIW*[@^.6)Q;L [<R1H[21/'U7QN!:\=B%Q300V(W131MDC>-.8X
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MEJZ@N!23E#$UKRSA\.1IY# B.-M3,F7*<?E9_P!O&\CC:9[=1I.PVIF6CSH
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M.)K*\9#Y-W650[I[M;MWH%,B/\H\A9^6 4KL&K<'12F[Y0< D4%@*?H'? %
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M4+*\_P >FN--_2FT'_XN#^O_ #]F%"G9A$PB81,(F$3")A$PB@AO?WZG"O\
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M;I+<FGF4')UV$3E)=A7W-P3N\"\"TNA.ZF%&<KY8BV3;DC[/?=1[_N/S'?\
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M"V2O& #!.PW00 0_]*,O8/K 0_O_ %@/P#F,^CV/_0F__BD_^U<Z\^Z.O?\
MX[#?_F;+_P#7Q]'L?^A-_P#Q2?\ VHGNCKW_ ..PW_YFR_\ U\?1['_H3?\
M\3__ +47J>RUQ,ICGGX4A"%,<YC2C$I2E*'4QC"*X    "(B(@   C[ P*]@
MZ KSDGL!Y,G<GT'[J>GJM>Z8WIJ_D#6).XZFM#.V5Z'M5AID@_9]0(A/UEZ+
M*3:B4?6*8]47C)P']T^CG;1\W,=NY2.;OY?"Y/!68JF5JR5+$U2O=CCD'=U>
MTSKB=]_8M>WU9(US':<T@<,%B&RUSX)&R,9(^)SFG8#XSIS=_85MW,4N9,(@
MB >WU83W_+?\U7^ZY=^Y7GA-\:KW9J1"4B2T_7;;1'#MVV82KJ[OIY2/>UUZ
M]<.BI'>N6"2CQA'B1-8Z14CIE.90N4IW)VUN9S<>N6*D-67%06Z1<YL<C[CI
MW,EA<]SM.>8F];(P 2 7#9V%Z/A\%3F/T=:/BMQS$Y_(9^GSC*87D44,$UFG
M%Q^OC668,G!7BA+Q7BLO9!8M O8V0O:]S0U3_ 0,'4!Z@/L'X^H=?ZZY=5YO
M!V-^_P"B\X4IA%"G57O\>8WZC>&'\8Y4X18G@%^(7(;Z=G.#[26P,(IV81,(
MF$3")A%X$0* F,(  !U$1$   #VB(CZ@ /C'"(4Q3 !BF Q1#J!BB @(?& A
MU 0_1A-@^A5?_,+WP79T?2?M?V>MN_\ EA2/C]W]1[[K*\_O\.=-_2ET%U__
M ,O+[/Z]8=0R#Z'7R4*=F2B81,(F$3")A$PB8100WO[]/A9_[NWI_P"&H+"*
M=^$3")A$PB81,(F$3")A$PB81,(F$3")A$PB815G=KS;;31^!FV[)3;-8:A/
MLI.@)M9ZK3$A!3;-%W>8%J[*TDXMPU>H>4-554%2I+I@LDH=(_>(<Q1V1X35
M*M[G.)KW*M>Y ^.^706H8YX7N91G<POBE#F.Z7 .&VG1&P-]UA\_+)#B;4D4
MDD3V^3J2)SFR-!GB#NAS2""6DCM\U2G5=GQ<MN32%8X+[\YZ7W>?]H-8>7&D
M[TEIIU1":W\1,UMD+!'V*0*F1D@W52.58S%TD+90Z@*(JE;J#N2WC9(L1F[/
M.,%P2C@10M,J7L'%"V^<CHBI'7=7BV7N(UH2-/4-:=L@8&&P'VJT6,N9::WY
MT;IX+AD,/T8EOFN>VP!H $=):-[(T=':N>[.RY6ZU;&[0%I:;38K&VJ_,"VP
M5;;3DS(RS>O0B$4Q,A#PB3YPNG%Q:)Q$R3!D5!HF(B8B0"(CFG?$"I3J8W@+
MZU:O6?:XC4GLNABBB=8F=+(#+,6-:993\9'[<?FL_C)9))\L'R/D;'D9(X@]
MSG"-@BB=T,V2&LV[8:T@#?H">^HN66VMJ=GOOB?Y'$/?=M\>-^P@U20USYYD
M)8FNM\LF!@HKFNMY!RZ2B*Q=_)%HV2919&2*+Q19R1N[<$9-E,GQ3$XOG^"K
M\=U1Q/(,%.;4>1$,</ZQP,LO_7,L.C:UTUJB'"6-\I>XM#6ES6F0CAO69\99
M=;/G3T[#&QF$.+_)M-[0^6UQ(9'/^X\-  ?IW<NTJ\.3L-M71J7#%QR<W[R6
MCY;D!:]T;'WXAIJYW'W05\SV(JSRL42E5Z+DS-21]1!RU8JM&;)-N116872;
M$(4#AL+C,^+SAYBWC6!XV^' 5,+CL"_,4Z?T>P&36H[-Z[9DCZC);Z72!SWD
MD>2"\DK$WS/6.,%R[>:;<UJ6V*DDW6WJC#V0PLCV1'$3T#3=?5+]:TMF<)]M
M[%O&X.56@N-7(7;ZD#.:):36EWG+=Q(NKW"[+.NQCI2?B&<NF[FEH*,:N7JP
ME01,@1P+)TXCU@;@JKC.:8K'4L1Q;/\ )./X@6(,X^'-1\2#&T9\:&O?%7F=
M$8X!-*]L8^L0==;&R#JTN?&V)I;%^K4MV2PU6NK')AYG98=UM,C&O:V1T+1T
MD@C74 /CI;5T1!;0TMSKUEIK57)W;O)F:9:WN,QS)B[K:'MDUO59[S(U=U(L
M.^>*/6]7DY*T.E&Z<0V.,DQ8)HD<";Q7C1OC,Y8QF:X/D\QE.,XGC<,F1IQ<
M.EI5F5LC:K^>YMKSF-##:BBJM#G3$=+WEQ:T$,>[GK-G@R<%>'(6KNHI'Y)L
M[_,BB<6CR>CL1 ^1^^F('70-^@V=O<1K'RL+VCNZJKR6O;63EG_&JMWEAK>H
MRLD;7&ODI6Z),XN$BFBQRLI&98,45"25G!H1W(JO%BF642(3,5RRMQ8^'>&M
M<:HNBB9R2Q1DR-N*,9*_Y--SY9Y7@>9'#*]P,=;J+&!@T 2=<M)]X9>U';F#
M@:,4[8(RXPPETSFAK0==;P&Z,FAU;([#2Q6EK3RU3[59G7N1%T9M(VT\;KU;
MJ]J&DSLD[H5-A6=Y:P]?(\3$[>/L%H5:-#R4A8%6)7)%)$6")DT&Y$B\N8J<
M4_\ A<ZQQ^D]\E7D=&I8R]R")EZY.^B^:P6'1DKU@]PCCKA_21'UN!))45Y+
MPSACM2CRY*$DL=:)SO*B LM8TN) $DO3V+^D:V6CL.]X.:65A3")A%IK?VC:
M!R-U-<M/[*B$92K6^*5:+G$A!=Q;Y,?'C9J,5$/$;2<2](B]9KIB4042%,_>
M244(?+8+-W^.Y6IE\;(8K525KQHCHF9W$D,H[A\4K-QO:1V#BX?6 (X+->*W
M!+7G:'Q2M+7-/\'#Y.:>[2.X(V%_.LNM/DM2;:MM35*N[3I-^L%2(\EF<Q M
M)I&"F5XP57R22S&28MI!F1)XZ;$=).D6SHH J'>(<WZ#TK<>6Q-6V"UINT(+
M19"Z&=T)GB;+TL):^.1T;RYC7%I:7-^\#3DD,E&[(S3M0V9( ^5LL4<C62%I
MZ]%I <W3G:(/0?31VIFUC<.G]=*)M+SQ$XV[P<&  3D:YNK9B!SB42CWU2!<
M)9#\(.H"11FEUZ^L@B'0*;:Q.7R&W4N6<CPC?_3L87'. !V- FI$?Q#NWKL=
MEGVSP0@=6*Q=UW8_L+[R1\R62%Y!^T]SZ*5FN.T"[/.JF4"]=F%2&,@02BCY
MBLD?=VQ^@=#BJE<(Q/N" ]1#NJ+ /3U^L<JV0X#X@6R#1\3;SXCV<)ZTE)P^
M +75)-_+UT/DNVS-X>+3;&"9&X]OJ,K3C[07.#2/L!]5,JA=IQV0;DA L7#2
M*H*X@8!*GI'6MB2* =!#^^CC(KB)A 0__AN@=T>HCU#K3KWAGXML/_3\PEOL
M'^XYG(UC_P#3)U-'P)^M]Q[E=Z'D/' /_P **Y'^TT8SZZ'8Q!P[]O>U$/M!
M-O=F=O\ IU=N/'16L:VM.OD9APZU[&Z1>TU_M%U-*1S1BP=3D(G'1[%.%*FZ
MD!7>J.0$HJ)H@!U0*-MX#B/$K V[%/D+;.0JWS"UN0DS3+C,8R$2/?(V&7KD
M>9B1'I@;W().@NGE+?'K<+9HG0B2 O>(&UC&ZP2WI:QS@&::T_6&]@:!&ES/
MB?1NQBJ&K&P\DMC5;:%\LCPMC35(QW%6G-/C9&/8F"EOV<')),73N#?%>D4D
M2]XSSQ .4PIE3'.IRF]XQ6\F[_3N.M8NA69]&+>O$66VY(Y)/^MC?-$Y[63,
M+"(^W00=C9*^Z4/%8X1Y\U6=[R9&ND+VEC7@:CZ>O>V'8)/PT?BI NI#_9WF
MIE@\P-7'A"/K:K[X4!7N^OJB/GL@G#I[.O='IF!;'^D"[1^D.:#\',P0(^_]
M@=?E_==DCAW<%M3M\C.?L]0[N/N['U7&7EN_V>%L4#!0I]QWA$.XR#?!CE]7
M41,'NJ2 "^SV&$>H^S.PRI^D"XZ%^%OVO_4?<_(?]*?Y_P EQE_#  0V#U]6
M-M;^T_5^?H3^"U]=[QV"KZHVB-HNO=@1%N>0$NUK$VHAO1S'1,^X8+IQ$@\;
MGNZGE#1F_,W<N$/)E@413.3PE.O='(4Z/CLRW4EO9&C+499A?:@ZL&))J[9&
M&:)CA2'2Z2,.8UW4""0=CX\<DW$>AXC9IY:>ES67B X@@..B3II[GX]M?%5+
M\>&W&U3=,*RWC,23K4M>>OTYIQ0X+8"MMVDS61=)M1C&K1VDZA731WY([3!T
M$:4S8IT54UE>H9M7D#^1C#3OPL,;,K89&8&WY\>VIBWL+"[S7N86SL>SJ8>C
MS2':<T@*OT#CS;:VP0Z&+J#G0QW727>L'1Z6'KC+7:=MP;L;!5HC]AV+HIB+
M*L\V4E##T C&&N9#E >O=$!D)(Q! G4!*'X1A'_> P9K)DOC'OZ]GA9 _P#4
MFIDGY_N1#7W>GKZ;6?<SC7H*V2'<]FQ9#>R-?'?^#\/EJR9G.QLCG2C<KCG*
MS43]0E\J:,C$. "!TQ0D)$JQ3@?H!^^4 [P>KU .92*#Q@D:'='"'@_'I+P0
M1L=XX]'MW_ALGL>"27BT?U2<I%\-%]MI'KOLYPUOU.P/CVV1KAJUR[)XY@)$
MO.>ZS@3 1))K/U@#GZFZ%$H"[5-WB^KH0"]1Z].H>O.V*?BH.\T?!0T>KGP6
M-#[-]#1K?J?0>N_1<7G\<<=13Y@[UV;+,?YN<3^6OEW4%N2SW6RU^:-M*L=Z
MLJ&E$QSQFVW8_P#*K0M*G5< \?LT6C=-JVCU.ZBV9*I"NHH=NJJ*@"8$27GC
M;,B*#GYE^#?>=+(Q[L,SIJB(!I9&]SG%SI -O>'=(:' $$:)PN2=$Z9C*@R+
MH6M:X"T^4R%W407-:6[:/W0"-:/;[5SJH3FA34N =W^7Y>,;4HV5--.JH[K[
MNI.E074*BM"+2[QF]!MX )^*"PJ]U;Q"E.8A"F-T;<&=%RPVA#Q)]4/ A9:9
M8;;8WI&VS-A8]G5U$Z(T" .PV==N&>EY$;IWYT2= ZG12 Q%VNY:YSP2T]B.
MP(!^/JOL5L_$PRAO#V3S%:E$ Z$5:TER9,>@]1,<+>W X /K  (7K[.H>T/D
M5>5 =\;Q!Y'_ )776 ^O;1IO/V;W^"&SBC__ %F=8=#L9&'1[>O[0'[P=_'O
MWTOB/-<7U"F*ENOEDW.(@)%%*G471>GPE%(NSVQA'I[!!4 Z^ONB'7/H0\F&
MMX3BKA\0+=MI_ G&N _(KX=/C-'61S8_^EW;_P#;,/C\>WR7#KQ):E0K#][K
MW<O(B:LJ9FY6D5;*=&0L"Y25=)).S.YR+V?-N&0HM3*J(%+#O"NER)MS"W(H
M*Q.W2CRSK4<>0PW'H:YZB^2K<DGL,(9U,#8),; U^W !Q\YO2TEP!(7%/)!Y
M#G5K^7DD ! GC+(BTD [>R4Z&M]]'OH'[+N_]G@OM\-?=XZY15*;6AJE"6Y^
MT6> *C*Z%E/-3.18,SJ@JF66B =-Y8Z29DCGBH[QSE4% HZ6_2"HT?H.$R+]
MC(_2YZD;PPCKIF+SGQR2 :)AF#7Q[=U 2R #7459>'32N^E0Z @$<;]=8),W
M46EP8>XZVCZQ';; 3\-=K,/8'Z/Z^+/+RO*81>#!U#I\'P_G#U^K]OLPG]%4
MQMK@[:K?MB[VMC2*989FY2DPI7-OR]I=L7U&@;2T@VTTPG*>5HLK:9.O^9%3
M4M^TD$$V82"95"M#L_%/KG)\1EM9.W:;3JV)K+Y?H^3DL/CEIP6&P,DBEKZ?
M])? (7.JO:YK6"30Z"T$^R>%?I XG"<-X_AK&?SV*H8.I2;E>$4L/!:K<AR.
M'FR$U&SCLZ;#&8>KDSD&C/5[%61]AU9Y:9VSEK;6HUH=BQ9LCKJN3-&C9L+E
M<W>6<&01*D994>H]5%1)XB@]1ZG.;UCFPXV%D;&%Q>6M:TO=KJ>6M#>HZ[;=
MK97CRQ*)[$\XC9$)II91%&-1Q"1[GB-@^#6;Z6^G8#L%]V?:X4PBA3JKW^/,
M;]1O##^,<J<(L3P"_$+D-].SG!]I+8&$4[,(F$3")A$PB@]VA+UPWX]-(X[]
MS&UJT[IX^TK8KMM*.8,":ON&Y:77MBD>331=JO%1JU2D)5&2?D=-O)V1UCF<
M(E 5"OG[]_Q4'7;?S[??H^_O7#^#8+P- Y+T_6:B$[3=<\@-F5C1C63L[^9@
M30#2!KTDPA6UH75F79J^TMK^9C?&15?^;D4EFZ1#F:^%CY_9[[*5H#;UAY3R
MW)[L]4-ZZVU+3:\3D=;5&$A0-BS=OD5Y4./VV2IM7,?*U&OIH-3)F5,9RFZ5
M,4Q"E\$>^ @12CY__P"'&F_I3:#_ -;<']?#A%.W")A$PB81,(F$3")A%!#>
M_OT^%@] _P#Y=O7V_GK4$&$4[\(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPBB7S?XV2/+;CC<]%Q5L:4E[:G]7=I6)]%+S35F%>LD9/*)J1[=['K+"Y3CS
M-R&*Z)X1U"J"!BE$HVKA?(X^)\AIYR6J^ZRK':8:\<K87R&Q6E@&I',D Z2\
M./U#L @:]5T<C3^GU)*HD\KS#&>LMZ]>7*R373MOJ&ZWL:WOOZ'3O*O@JMNF
MX:9W5J.\QNG>0NEIF)<1VPPKAY1G:ZTU3(1]5K7'1\A%.Y-@N8I1;"L]6!%N
MJ]8G(=%UU1RG%^<MPU/,X;+4I,QQ_,PS-DQPL>7)5LO=MEJK))'*V%[03UAL
M?UG!CP0YNG<-S&BQ)6L0R_1[59[2)VLZO,C[!\,K6N87,>!O75H$+1,-P7YP
M:QV1O:WZ"YA:YU[7=X[3FMIS%=EM'-+6X:S,P0B1D0D9:6=+=QLW23;E!$4D
M5 3!442JG4S/2\WX5D\;@Z>=XCD;\^$Q<.+ALPYMU5CX8B2#Y<,+!MSB7$G9
M!/2"0U=88W(PSVY:F0@ACM6#8=')2\XM>6L:=/,S1H!GP:-[[J4?)OBI?.3'
M';6VI+/L^&;WNK7;5=YME[+4SDC+-+4-V5Y-'85MG)M B G'!U5&J1':R+#J
M1(4S$Z"2K\:Y30XUR'(Y:MC)GTK-+*TJM#Z7U2U8KXZ80^P^)_FF ::\EK7/
M WL=UW;E)]RK' ^8->V6M*^41]GN@D9([3.KZG66=@'$-W_NTN+<S>(6WM_;
M$XZ[7TIN:O:?O7']U>'<5)V.C>[=L^7N,9$12BA(]:0:LP!LTCW1#)NV[DJ@
MNR*)BFH@ CV.&\MQ& QW(<5F</8R]'D#:3)(Z]TTG,;3DGE'[1L3W'J=(P@L
M+=!I!V"%Q9&A/;FJ3UK3*TM1TKFE\'GAWFL#' CS(]: ^WU^"T7'=GUREG=@
MV+>^UN74#:M[1NH;;JS3EEKNIFE.@:$:X(JM7]DDF$1+HKS<@S:N7OFPH&;&
M:/547AEE0;)MS9Q_/N,0T*V#Q7$IZN$ERU3*9>M8RS[<UX4B'1UXGS0%L,;W
M-C\SZK@]G4W0+B5PLQEPRNM6+[);3:TU:"1E5L3(O.[N>Y@E<Z1P(!;N1H;K
ML.^U]7"3@9RFXD66,;.^2NM+=K%Y-S,]L:#9:39L+WL"2DT)!5)W-;)>2CNQ
M/';24>IN4'#]V\\%NFJT12!-42C\\UYYQCE=:5S.-Y*IDV0PP8^=^9=)CZ$<
M1CZF0X]L3*[&R0L+2(VLZG%KW$D:$8W&7J!#'7H9H"7/E;]":R::1VSUOG\Y
MSW.#B""X.[#IT.Q4PX/C3(1'-&]<K36UFO&6_2-9U*E2RQ*Q'S)U V \PK-'
MF?+CMUF[D@E0(S)'IJIFZG%<P  #4I^2LFX;0XM]#>V6IF[.6-PRM+)&3UC"
M(1!T!S7,/<O,A;ZG0'IWFU"W(2WO,&I*L=?RNGN.B1TG7U]7?9<1KI';XKYG
MW&.3?\W:[RW]U[).+@]$RVGE*2,0L+]=Y)64)XLV6:!^+=-NDF MC,18"J)^
MB@..Z/=SZCY,QG"K'%/HCS--G(<P+GFM$;61U1 8##T;Z]GJZA*1KMI#3WD6
MW_,_=INJ^5T_%THEZ^K?H .GIZ2=G>]#2F%E47>3")A$PBK8LG9:\>[=-3,O
M8K?N^6;SVRW6V9*OR&Q2OZ\K<7<DWDE7(1[^$='!GU:-&(,A<&3&,:-F1Q.D
MBGW=B5O$WD%2&&&O4PD3H,<S%1V(\<8[ J,B,36^9'.P=>G/>7](/FN<\#;B
ML:_%UY'.+WSN#IC.6NE);UEW5H#6PS>AT;UT@#T4D['PWXGVT3FL7'+2TFHH
M7NG64UQ5$5S!T OK7:Q:"O7H !U[_7]N5VOR[E-30K\AS,8'H!D;3@/P?*X?
MP79=3J/WUU:[B?4NAC)/WDMV?ELGT[+34SV7? >;(J5SQFUVU,L4Q3*Q3-[$
MJD$P"'>3-'O4.X8.O4HE#H @ ]/;US$'B9SN#73R7(O (T)GLF';X:D8[L?C
M_#2ZKL-BG[+L?5V?BV%C#^; T[^WU^U:(G>Q"[/N;546+KJVPIE#";NP=_GV
MB9.H=.A$EU'1"E^'IW1Z#^SIG8/&GGT T<A4GT-?MZ$#S]Y+0T[^U=23C6&D
M]:@;_P#IR2L_@UX'Y#^JK-YA=@T\82M-6X:L).8BETI@;RUV%L",059K%.W&
M&3A5585%0Y3D.Z!T=450+X:70H&,81V-Q'QT:^*Z.8/BAF:Z(47X^A*YL@(=
MYWG 3D#1UT@ $DD=P/K8>_Q&![X/U>"P N\[S9W:((TTL)C?H@^NP>Q)7S<<
M_P#9]92R5&:><E;]/:VN*5A60@XJ@.ZW:XQW6@9M3HO'KITS3.C(F>J/$5$D
MS"GX*2*@% 3F#/OD'CY%7MPLXW0KY&F:[73RWV6:LK;)<X%C&,>0Z+H#'!QT
M[9(/IV^*O#8_+)N3R,E#W= KO:Y@C[=&RZ($O^9 U\@%O%Y_LZ&I# ;S?R1V
M.W-U#N^5TVLNR@ ?[W>%&09"81]8%$ * =0ZE$.N89GZ0V6&NOCF.=\RR[99
M\?\ W,?Z?'U79_T=3/I<M@;'PB)T/O8/O]._Q7"'_P#LYK,H",/RLD$#E$XD
M%_JYNJ  '04NIFUQ0'J A^'TZ=>G4H!T]?<9^D*__P ;BT3A\>C)$>O9Q^O4
M/P/S7R.'Q-T69"PT^O>*,Z.]_!P]/Q'Q[>BU[?/]GYV96*?:9^N\H$+._A*]
M+RL?6&^LY-J\L+UA'N'2$*V4;W)WX;B452*R;J U7[JBY3"BH'X ]ZEX]XVQ
M<J06.,.KQSV889+)R,3F5V22!KIWAU-NV1 E[@7-V 0' ZW\R\5G;'(8\K,2
M&.+6&( .(:2&DB4:ZCVW\-[^:KQXR]F1RNM^[M70%HINU]-0%@EG!)K9#:K3
M;=[1&J,<]= [7.L$:DW7=*($8)&*^*0BCHAE#"4#%'8/)?$KBM3"Y.>M<Q>8
MGKP@PX]UF%S+SS(UA:.GS'%K6DR';">EIZ0/087'\<R;;=9TIEK,<7&22)S1
M+!INP=^FW=AVWHE7PONPQJ\Z0I;+S&Y*SJ@$("AG4G'BF8Q Z%$B:ZKH2%*(
M )0$Z@@'J[P^L<T<SQMLPD_1N'\;A&R=-CDWW[]W!K>^CWT #\@K4[COF#]I
ME<F_[Y@.Q!&B ._K\UKY_P#[.]I1XJ9QZ1FWE'1C&/X\A#5>0-XAC"(J*>*5
M,RO7U]X!. F'U]>@],[S/T@LS&T-_P!.XCH].F.>U$ W6M-T2 ?EV_+LNL[B
M%-QZC<NN<"#U/?&_T(/?J9W]/4E;&JO8R7'6C8C;5W-:\U9)(Q#(@KJ:BNU4
M^@]1,+H'J3DR@&]:1_% 2 'J]8=,Q]GQAIY)Q=D^%TK))/5TY:\P'?I]4-+0
M"/4$'?W:7>BPDL#0V')V& >FX*KOAV&C&WXZ.]_9K2KMY==EERGL6ZG3ZRW;
M=7(=,NOX\S':5?UE6'@K3#-5TA&TQS'O-I0)F$>P;)I.74JEXO\ ?NS^#'+G
M*HL?8'$O%#B];#-CJTL+@#]/D\S%SY.RT,A>&NDN->W&SB225Q(;&==F_6E
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MWW^2R.$3"+T44313.JJH1)),AE%%%#%(FF0@"8QSG,(%(0I0$3&,(   (B(
M&$4/M<<Y=$[3VREJBJ2%B54F49T*%?7M=?L=:[2DJFX\GM\/KFWN"%86=_7
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MD5XU,H]^_8U\5-_"E,(F$4*=5>_QYC?J-X8?QCE3A%B> 7XA<AOIV<X/M);
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MG8)U.;7:HR[>2BF4].2+Y],M:XN]^_Z^]%V!DA4%),52E*J*9!5*01,0J@E
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MNN5WI1T34@\NX>0H+>DU/7#V\TO7]AX]RS;O#-6'7DC>Y*.JCJ+V,B<B%P7
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MQ23E60!$6Q0='LK]]#CMO^R2E)[T-#*[6;1JK.W/($I$HV3=LGSMHSF$VZ0
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ME,K7*3I#6S[-Y;W72%D>!74I]NS18>;XWSPP<-&1)U)19-B^DY)BS;($*?\
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MH!R+$US@AQ/J=OMMZ@-1M&-DO?NF&V+FME]>1<TK< ,%B<N*X_M+JMHO) 1
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M4B#=ZL4@$*P%+\!1"(1A&J1$6C1J#95%TS4: DFHT>M'"+]JY3([0=)NB%6
MBUM-<.N,UAJVO*5+:BKCBKZJ4*>AQ*2\RR2A0\=-TN@LNQE&SN;9OW21'<LP
ML#B593#KO.95N\7444,1<Q-QZTH>V)WD=<5SW5I7%AL!*9*@N1PG<HNAJZPC
MYXB95RMBNVE 65JJ)"H V+%G%/P!4 %0(N+UWB/QPJB>RDH/5%>;I;?:+1VP
MTG2\Q*IST6N*ISQ"2<M)/B0<,11919O#UX(F,:..XX:M$5TDE"$7X1'#WC/
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MF?N84:'R"S9-&:E3U*_T5[AXE34TK79"J2M+<'>N6$K RJ"C>492;MP[5E)
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D9N]Y/+/("?5EQN4?&LD?=_ HMB2;MJZ='.X,BB=-!0Q2+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g99471g78e05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g78e05.jpg
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M 0$! 0$! 0$! 0$!_\  $0@ EP)+ P$1  (1 0,1 ?_$ !\  0 !!0$  P$
M           *!08'" D$ 0(#"__$ &$0   % P$"!PP$!@P*!PD   (#! 4&
M  $'" D4$1(3%U18U!48&1I6DY66E]+6UPH6(9(Q.7>DT=,B(R0X.E=XE+6V
MM]4E-#4V-T%14U6X)C)Q=':&M#-&4G.!A9&QL__$ !T! 0 !!0$! 0
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MOJ/I:;SY7OTV<G-OT6[*;:+G8^FO;4<#;F7M;9OQHJ][6-4ZX9>8G+O?@,/
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M"(:BV^%$$F3RK:Y)SF)E8;KP;@SD+YPH ))S)>)/1&<!WN\=! 6+R;RR U8
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M8O223N,I60=<='B\8ELYTK>FQ25N:BR '4R,BNPDS.Z4S.J1G-M0Y@*,@NL
MVN3J@UY>V>!RAES$+1(80BG. 6\;23;AM!JL7.L6*'5V>KK'.J7$\^:R'J+,
M3"_HQPS*ZW*D<Q_+FV5P9M:AQJ":D(^VR>'Y7CB-*C=4+XHT\S-LR'A^/-3D
MJ(:LD-L.5R.>W+>E2,=ZF. $D'6349ER8[VB)#1G/>-JI5R1F4UO)\FBSW94
M*PU)3*L;!D *I<*&250 0=@XDB4'<X77D&=;=:JLO*L:8WEZP;],<2J$H69O
M@^1T1^&>Y4PG<@LI21V#(3,AG2Q$Q$G.UTPY7(IO#(_'&2/IG-WM*$*)&K=$
MF&% SJ,E<'/60[0%5'*QU=7/=\D*Q).0U2=QVKJ4QQN<WB(R"2#8Y.Y^2@VA
M8+F?E,ZJH4$ZP S&"\!Y_P O3/5G*,;RJ8L<G@J."/*I"3$B(D8Q&/3-%]/2
MTB2H6I,@#DJ,1A[=I;D=1%)7+9%(XGDUI6-JF+)H\2SMXY%DEC18%8*0Q<#,
MZP.1,FXDG4) "9JH#(<]8G/=A@GE>Y:-G#($/R NKK*L!ULLMHJL6D*,[,D@
M(U,@ 6Z3UJ5Z%*4I2E*4I2E*4KE_,,H9!PWFY^@;7E4D5FZ4X3E$?PX)@B:E
M+.8EGS4AE51G*3*+#9#LE!!BK&BBTE42AEE2"(1,R)B=Y2T+6E:L0J=M45XP
MQ3E60&3-AJM%$@C7//4\M]V1!8ZV0((%>:TDD4S1B4>2866(JN3K-/)MF.[:
M?%QY-K*X1=7-AD35C,>J'5@^P>8/:5B/89LIR3BF48UBF0X$&.(%>$M6+FKQ
M#BMA>%"(I2O4O6!\IN35-LCO"2Z=P=8<RC9'!&A429O<DUQBA#J,\U"LKLA)
M.TA&NY&9 RD0%4&>08YC/5(-BW-TR.=75?:1-&LB:JF&Z)BC!W9YP2D/(=Q*
M#5(\H-6Y61LEO./LX:6X JRFPEM\^62R-2F-/"6+(I',5"#'LB<FB3C/N).H
M1"42YH9FY"AC+6TMY[J[*FTRZ[?&IO;\"(&CF;4.:ZI4C,A06 (^8^2223GN
M .[>3N22%)K9#*N3EE92%#/E&Q#?./+"@!0!F<M^8 VOK#6S2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I7(MXT^ZN+Y0>
M2&XZ1J,7*YNZX$"6/([8G2F::,M9/>L\Y$RZV(OK$%S0R2#QY?&],$11*T@I
MR0*..DB:T(HJXD/"G=$L(09Y:X7:_(.8F11&B9Y9$,<YF/R=X!.L,J\IH+K:
M,!K;(N8!\8N7@\LAGDF'E:P9%*VR@C7\DL!JG6JVB=/NH(N-09&[89?WI<TZ
MJYO.<B$"2X7=!37&[G$]0R"+.*JSGJ<9D\X(;G>50<1!DF6PQ^837-L6(X2X
M68'$3=4RQZS$2 #8JJ_I!JOK1%N2(ZNY6Y,P<N7?OMV$^JN<+$BY=Y!E"=>,
MK.$)SN5#Y%T^4489@A#JG+:_3=C3-4*G><%^7F^02!IETNS<]8K>2)HWF!A4
M ?-0>4I&S8W"RD26PT3S*6!^C.06.<MXPK1LB]#C67"A9F(HBF?<,KQLD80@
M%5C#@J<V81(I?/5Y%(*E3YQK+K:[$;5O',CS&4,RLTS1'7'D(T\K"/5#<K*R
MR!^7(B-M79+GJ<=A'5(Y@T_ 0XTRE'4>-,SYJ?U+=*<E8UE"\R)2/6)$,IP(
MQ[DQ6:WMXCQI&%V]9'C)LR+,DS(,>4Y"QRXP_D9(UK7K-M(1M,W4EXXQFJN!
MK"!D;)=F WQA!U3J+K!6#;MVJ8;D['**5!'+,<GDC8ZK72RIFPG8J=D,@X,C
M@:\90:P)ZV9!C)LU@,WAI"LM =+8A)8R2N-*$>4B-?F5:U%JS" #+&<6F&KL
M<,H)@!&!!< 1AO>PK::G596Y=5@<OU'.O4D77C= <M=&7/YM92,_ZLZN^K:O
MI2E*4I2E0@_&-==_D3IG]0,@_-JOH#Q7:.^D8MUFU_!5\F>/+3#T/ .I7WYG
M3QC77?Y$Z9_4#(/S:IXKM'?2,6ZS:_@J>/+3#T/ .I7WYG3QC77?Y$Z9_4#(
M/S:IXKM'?2,6ZS:_@J>/+3#T/ .I7WYG3QC77?Y$Z9_4#(/S:IXKM'?2,6ZS
M:_@J>/+3#T/ .I7WYG7S?Z1IKQ#?@%"--%K\%K\%\?Y"M?@%:P@W^W+7X!!O
M85K_ (+VO:]OLO3Q7:.>D8MUFU_!4\>6F'H> =2OOS.OCQC77?Y$Z9_4#(/S
M:IXKM'?2,6ZS:_@J>/+3#T/ .I7WYG3QC77?Y$Z9_4#(/S:IXKM'?2,6ZS:_
M@J>/+3#T/ .I7WYG3QC77?Y$Z9_4#(/S:IXKM'?2,6ZS:_@J>/+3#T/ .I7W
MYG3QC77?Y$Z9_4#(/S:IXKM'?2,6ZS:_@J>/+3#T/ .I7WYG3QC77?Y$Z9_4
M#(/S:IXKM'?2,6ZS:_@J>/+3#T/ .I7WYG3QC77?Y$Z9_4#(/S:IXKM'?2,6
MZS:_@J>/+3#T/ .I7WYG3QC77?Y$Z9_4#(/S:IXKM'?2,6ZS:_@J>/+3#T/
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M&G'J#VM(:<<<8.]QF&FF"$,P8KW$,8KB%>][WO4?3@">8   2R  #( !V
MW  ;@!R5+=HS-:VS,2S-;PLS$DEF,:DDD[R23F2=Y-7-6*MBE*5'GV[^>LV8
M2>M$1.'LLY#Q@5,I[D=#+2X'+GR+ DJ-O5XE A2O@69:DLYIT875R"F*5V-
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M+.]EL[,Q6ZI"\5YAD4;"1(EF;5CGF4"21@=<D@D*1WBJ.ZF&E*4I2H^.S'U
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MR=($Y(W)XC[<XKAE)PVXI!0E2DT19(?V)8;V!;[ VJY_A(TH5V43VF09@/\
M0XN0$BL<7P-Z#O%&QM+_ #:-&/\ K&?E903_ ,35^> %V<_D9DSVJ2+]%6^,
MG2CG[3J<59/$SH-Z)?\ WC/3P NSG\C,F>U21?HIXR=*.?M.IQ4\3.@WHE_]
MXST\ +LY_(S)GM4D7Z*>,G2CG[3J<5/$SH-Z)?\ WC/3P NSG\C,F>U21?HI
MXR=*.?M.IQ4\3.@WHE_]XST\ +LY_(S)GM4D7Z*>,G2CG[3J<5/$SH-Z)?\
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M6!RU9&!&1S!) [+#\2M(<.PR*1;G73#,-#:D<17?8VY&1:92=Q&>:C?G^NK
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M$\7Q:RL;^PM;7@.YGGM9(&F(O(;OP5XI'$A(7R+=0P0G5D,B:Q*5)PT0ZO\
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M=>F6)KBW$,2E\_ULY'>]]CCP\OB9C@X9ED-SR(^.9"IO(&O6-$52+'%6N.4
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MM2)L)^9E]F_93<EG1%/F#?<IM(^<3I+VTV$_,R^S?LKF#M-MGVMULPS&0HL
MEER- YXS)@OJHBX+7QK+75N;)^09<5B[*S6!*%),FU,8:(PT3$XM3<7=8^\
M^CT=T@CP>:YVCA[>>!R4# _Z1$K- 1OW!V)B8C=DZLQR3=Q^E^B<^D-O:;&-
MX[NUN8P)6C;]R3NB72\@UC&H6X0$YG9/&GE2[^B,!QTS8RA$2QW#6,UIBD(C
MK/%H\W%D&7LE:&1"0WHBS!V+#<X^Y! !J5([7-5*!&J#A"--&*_@SW7A,TMQ
M-,CRS2/+(Q9=[NQ9CR[AF=PY ,@-PKJ;;#S9V\%K;VTB06T4<,2"-_)CC4(H
M)U=YR&;,=[,2QS))J[=R6=$4^8-]RL6TCYQ.DO;6?83\S+[-^RFY+.B*?,&^
MY3:1\XG27MIL)^9E]F_97*?:.;-P.M.58!EK0#N*]Q"9M\7R6Z<2Z98X82<5
M1SL]A1FC (2A\CS@2?\ 5E)8-BKG2EW./%<!8+6Z;1_2-<'BOHF=72:%I+==
M8$+>* J9C/<DBD;0_-$@'+7%Z5Z'2Z0389/'%)')!<+#=R:C!FPYR7DU21Y4
ML+@[!-P)GD)\PKJ(QQ=)&61GCC R=R6*/M;>R,K4B2&$HVQI:DA*!M;TA5@\
M!29$C3DIB"[?8 HL ;?9:N;>=9'>1Y59Y&9W8NI+.Q+,Q.>\DDD_6:[&.T>*
M..**WD2*)$CC18W"I&BA411EN55 4#S "JIN2SHBGS!ON5;M(^<3I+VU?L)^
M9E]F_97Q="K%:X1(U%PWM>U[73F7M>U[<%[7M<'!>U[?9>U_LO:FTCYQ.FO;
M383\S+[-^RN'^E[95!PGM"\O9Q51\(</1<BTIP @LGL,@B29( Y >$0$H0F!
M((Q>06^LK80I#RPD[W%'H@_>TAMB^RQ+2E;S ;2R$R^%RG9WS:P!,=N5U#GF
M,S<DH[$;LTE0C(C..\&T&DP[2B_Q$VKBPA&VPM!&Q ENPXD4+D<A9*)8D#;R
M)()5;64Y=P=R6=$4^8-]RN-VD?.)TE[:D383\S+[-^RFY+.B*?,&^Y3:1\XG
M27MIL)^9E]F_97T,;E!Q8RC4)QI1H!%F%F)AC+,+&&X1@& 0+A& 8;W"((K7
M"(-[VO:]KTVL8Y)$Z:]M#;S$$&&4@[B#&^1'S'R:Y%Z*-F"WZ7-5NHK-@VTD
MZ+KW$;-IY0 +Y8Z-Q.6D)Y!+AF$\!@T:AG5*"L?L9XQ@6GLK6]*3[73O15Q=
M5C&DW">&6%GM )%77OVUE DEB)CAR.>9#*#/(/DAW0#>E<-H]H4V#8UBN(;!
MS"SF/"UV;$Q03A99R1D=4QL1:Q$^48TD8[I!77?<EG1%/F#?<KE=I'SB=)>V
MNYV$_,R^S?LIN2SHBGS!ON4VD?.)TE[:;"?F9?9OV4W)9T13Y@WW*;2/G$Z2
M]M-A/S,OLW[*Y(X&V8+/A_: YBU0@:THH$O;K2'#K"21PBCL\R'W3)R29=&$
ML&Y$Q\!3@3&RRR;( M$\+2I;V51\0@=1>Z3>%X':8;M1MU;9W;EA\9!!JFV&
MMF=8OFIDS\K7@S.Y\CQ&&Z%&PTGO\9V#&V=-K81"-LX;JZUQ=G5"C5$63B$
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M&7Z D O)9W"1H"<BSNT85$7E9F("J"2<A5KZ3:/*C,,<PF0JK,(XL1LY99"
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M7[TL>_IWV&EGK*X ]LF.OB.G V,>JL2ZC==U3C)H[Z_P7[TL>_IWV&EGK*X
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ML$;-[G"L-O+ARSSW5U86DT]Q*[%I)99'A9BSN2<L]5 0B!455'Z]ZGI=ZMN
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M#&2MXBALE;;O$?*?T!+"-0UFO+5;NDW%K %#5HKA4DA$2(([VG%L8 5CB>)
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,E)523YMY(SY-U?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g99471g87q67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g87q67.jpg
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M7)E^6\3-OD6UAB$*_ /X1BZD$W?5IJ&DD !K#%8D!V)T@I'0M+KN( #G$#"
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M-(:3I&Z,G.K 7$8R"7C"&1G T/@LZ/:W<_-NF+6N+PYS6C#<$.N_7TWQ$O\
M=S>,FG5S#5#<K,\*XN-%0CWMSI:NLVSH\_8#5_5</'4W8Z>UEGK-U'25YK!
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M[YWL0/W'/W(@;FR1DJB:0[ _:Z>Z.[V]<VOO7T;ZQ=J@RG(TL,D5G"W<6_\
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M3O[YCK)2<)4<>/HDV4UW 4G$FZ=8Y\6=O?6/A^O\-(,V ,WGT5[\*!72:O\
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M(R[G.)<YQT[I))/UKL./)U1#''%%15#(XF-CC8VGE#6,8T-8QHP:&M:  .\
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M<F#Z30>QW?GRMQL U7>2#Z]DWXQ.RUK?><'LK+?RU/+><F#Z30>QW?GRMQL
MU7>2#Z]DWXQ.RUK?><'LK+?RU/+><F#Z30>QW?GRMQL U7>2#Z]DWXQ.RUK?
M><'LK+?RU/+><F#Z30>QW?GRMQL U7>2#Z]DWXQ.RUK?><'LK+?RU/+><F#Z
M30>QW?GRMQL U7>2#Z]DWXQ.RUK?><'LK+?RU/+><F#Z30>QW?GRMQL U7>2
M#Z]DWXQ.RUK?><'LK+?RU/+><F#Z30>QW?GRMQL U7>2#Z]DWXQ.RUK?><'L
MK+?RU/+><F#Z30>QW?GRMQL U7>2#Z]DWXQ.RUK?><'LK+?RU/+><F#Z30>Q
MW?GRMQL U7>2#Z]DWXQ.RUK?><'LK+?RU95\.7$=K3B[6?;@T9<92U:<K+9[
M1HR8- 7*H,+->7B\=+6I92%N4+7W\DVJ,6UK4?"3"4>+/PA8KBP*LJLQYTN'
MRIDJKR(&T648&0UTQ;4/CSD$[X:=H>R$"2"25K#.\RND878L,4#K .T_19"R
M[0:IB_*>2*J2IR73M=1QRYBJI65%6YS):DF*KA@D>VFC;3LBD$>''/4L#B6Z
M,3+#RM_ 1K#<FX*SM'B,) V2H61/6Q:NSH6W[-&QA:4+HLW(&?5:B3U=5FI&
MV2L_'O'$7*NB*P<!64W!6SY!XW)S,6HO5)5T-#+1Y*,L4\1JL\:BAB>XSVS;
M,,U1%*&,A9&X![!:224B[2TKYN;7*U&Y/RIE2GRCES,5%+/U *=M%E2HCC%(
M7"5^.FHIX#+)4R3,>8Y77AAIP["]KFCL>6\Y,'TF@]CN_/E;D; -5WD@^O9-
M^,679:UOO.#V5EOY:GEO.3!])H/8[OSY6XV :KO)!]>R;\8G9:UOO.#V5EOY
M:GEO.3!])H/8[OSY6XV :KO)!]>R;\8G9:UOO.#V5EOY:GEO.3!])H/8[OSY
M6XV :KO)!]>R;\8G9:UOO.#V5EOY:GEO.3!])H/8[OSY6XV :KO)!]>R;\8G
M9:UOO.#V5EOY:GEO.3!])H/8[OSY6XV :KO)!]>R;\8G9:UOO.#V5EOY:GEO
M.3!])H/8[OSY6XV :KO)!]>R;\8G9:UOO.#V5EOY:GEO.3!])H/8[OSY6XV
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M)/,\[C8XF%[W?79K38=\Z MFCI*BOJZ6AI(S+4UE1#34\0W9)IY&Q1M^J[W
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MQBHIE,'/L>H /,(% 0YP$0'Z_P" 1#+H"<ZS2?[W?_Y7+5K&M%-(0UH.TT@
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8IID*',4A"$ "E*4/J I0  #Z@#(4K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g99471g89t00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g89t00.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X8 G:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z8W)E
M871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^4F]P97(L($YI8VAO;&%S/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z
M=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \
M<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/G!R:6YT;6=R(&9I;&4\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I
M=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR
M9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E
M<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @(" @(&<X.70P,"YA:28C>$$[
M57-E<FYA;64Z(" @(" @(" @(" @("!R<C$W-C,V,B8C>$$[3&]C86P@5&EM
M93H@(" @(" @(" @(" @,C8M07!R+3(P,C$@,3 Z-#8Z-34F(WA!.T535"!4
M:6UE.B @(" @(" @(" @(" @,C8M07!R+3(P,C$@,#$Z,38Z-34F(WA!.U-C
M<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R
M<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($QI
M;F4@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C
M;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP
M;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @($-A;&EB<FDF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E
M('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($--64LF
M(WA!.R @(" @(" @("!";&%C:R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I
M<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM
M;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+VEM
M9R\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP-"TR-E0Q,#HT
M-SHP,2LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E
M871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP
M.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(Q
M+3 T+3(V5#$P.C0W.C Q*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @
M(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TP-"TR-E0Q,#HT-SHP,2LP-3HS
M,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*
M(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @
M(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ.# \+WAM<$=);6<Z:&5I9VAT/@H@
M(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM
M9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y
M:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-
M=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!
M0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'
M0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/
M1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E'
M:%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!=$%%04%W
M15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!
M449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%1
M04-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!
M1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2
M>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=:
M:$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR
M:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K
M0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!
M04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:
M17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S
M4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K
M4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D
M;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM
M<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!
M-F0K6B]M8E8Q.'EZ85!P5W%A:%HF(WA!.T=(5%=L;'0W4WEU6D=K=4MS.75S
M37-58C=Y4'=6,C)52T-V2W!90UE$0U)4+W=!-EAE<W=X*U5,:4-85E1+3#8S
M9E4T8DLR;EI8="LF(WA!.TDY9')T3%I*95!%;BLW3#!.5',S2%E"2EED9C-8
M;4=A-'9:<F50>DYB-DI.<6M9;G-),#%5,W-D<D9B,T,K<D1.24]80V4U35I-
M8TPF(WA!.VM+;U=T2VM95TAZ97 K4V8P,R]H1%)V,#=Y+U1(,4](-CEZ*S,V
M=D%C=68K6"].-S5%.#)Y4$QD361/=FQV8F0U;%%O16UN9V]46&4F(WA!.S-M
M945N-E1(6$%L131Q-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ;&QN
M-6PP83AU:W1B95IM:VQ$;4(R:6Q32U52+V$Y1UHF(WA!.S!72U=N6#1'3S(O
M5$13,FUE0E5L,51Z;C5:,')56DY.,4,K5T,Y:710,&<X2E-2:CE7.5%X8W=6
M56AV:D@R4CA896Q-3DET3G)M-%,F(WA!.S-T-6)I44\P8TM.239X;SAR:TM+
M:TI(1T=D,C(R5E%393)"2UAE6'9-*VHK66)2<GI3;FUK=&Q9<#9S,71C5W=:
M;$I6=4@Q:4],;G@F(WA!.UI31'AR43=94T5!,FUU0DQS5F1I<G-69&ER<U9D
M:7)S5F1I<G<O.$%/1S8Q:3@X>C)4,F-/;U=W=%DW<3%62EEU34UI=$9):S%X
M8D8F(WA!.UHQ.50Y,TQY87%J6E)U3CAN1FA*-U)P<V)X-F1A>'E02DI):TUA
M=3@S.39X0V=%>6)N-&HS,S8U0FUI359D:7%695=F*T]D3B]W07@F(WA!.S)O
M9CE2,#)%;T-A-$5U>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+<58Q6C)T,&E*
M8U),2VE34GI)1T9A4U)/2DDR2'5R2T--5E%-6&PF(WA!.VY1;VEH:G,P57AM
M37 Q,DU,4U!(,R]:860O=G<R=$I2<'9K0WET6DQD2C5H8S)6:W9#,&<Y34DS
M1EE(=%DO5VM"4'%'2S-L84Y/2W(F(WA!.W-A='EA:'AT1DIQ+VQB>2LV3VI7
M4T9:1EI(1E<S5C1&=&U(6'9$1W%9,FUM4&5D4'EY="]-,3E096TK3FYC3F)7
M,71B3VM18WAE:$HF(WA!.T]:0V9J6&MS<U8P>49D<6).531185EM3G)F2E U
M6F8T63$R-C%8.4ER9$<T:&QG-')B*VI*2C9T>3%Z-G0S3#9K;G)Y<'DY3E@T
M<E(F(WA!.V1Q66U6<4DP5D<R+TMR,$QJ>2].*VMK8CE!>7IZ0F9Q,RLY2#%I
M-DYY5FPO96YA3W8W<BM6+VHS*WIJ>$QW<RMY3$HR2W5X5C)+=7@F(WA!.U8R
M2W5X5C)+=7A6-#$K8DU(;'I64$YY45,S3W R*W(V9%E.5T\P,"M3.&IN:FY7
M4D)$15%P-'E-<WI$;G9(5V=/-C!Y8U=U5E<Y8C F(WA!.W%+2TA3-T]+2T]3
M2TM/0TY)-'!V-WA65D%!<CEF:4$V-4)S4E=+=7A62W9,4"](3VTO-6IT42\V
M:G!S2E%%,7=*9&ER<U9D:7%7;GHF(WA!.TIO<3-V,4DS2#<S,69Q+U!H2C9)
M;E!317HX9E-%;2\R3UA,,G<P='!L9U8R2W5X5C)+=7A6,DMO4%8Y6'-D27-*
M3"LK36DR,%A%3UDF(WA!.UE:8FAX>5E+2U)W<DDU,U!:8U5%<V,O-5=V-4LO
M=T(K,S,O8TLQ4"]!3$IS4$-58UE387<O3S-22G)M,DXQ83-%1FIE0FI"3$AA
M-FHF(WA!.TQ+=$9,<#9I9E9&43AK0B]U;F5H.%(X45!#:FI4;B]L82]K<B]F
M,3DO=T)W=E4O*WEB0G=L4$5%2C5N+T%$3&9Y.35Q8E1*9$YU=%,F(WA!.W1P
M3$LQ;71,8E1B8WHS>C-&>$ID8W@V8D]G2TQ&86-U;%)V.4)%54=61D(V1BM:
M1W$V;C5M4S%U1G0Y3G-P9%%M,#)(4S=I,G57=F4F(WA!.U5&=5I(36PQ0S!L
M<DA*>49217<S4W!$;G4X2VE7-DIV4%!8;4)B;3!E,W0W5#9H4#5J8E$U5$HV
M:&U%2T528VQ!255U,&E32&M304(F(WA!.WA(1G1Z:E-B4F9M3#AZ.4\P5%9:
M.4YK,&Y58GE3,V%.2&UT571Z2#9K<T0S0V]$3%!%,693:&1J.$Y.=79404EQ
M6E5H62]Z93!U-6@F(WA!.S%+87DP:E5P3%A4-V8Q:'%-:TM2,F-S<DEH:G0T
M-6952F%6,VQ63TE862LR*TAH6&E5;B]!1&1T3E!95VUQ851F=F17>&5'*W9,
M84\F(WA!.T0V<C8Q=#936%1X:#=J,694:F4T5'%+,$\Q5%A(:%AI5CE!."MA
M=&975VI8;#-&8G)(<4]S6'5K>G)%:F=Q251C0S-D0UAB971S03DF(WA!.V$Q
M-59&2UEK2TI--GE,2C)+=7A6,DMU>%8T9BMA,2]Q;75E86TP;E-8,5=+.3 K
M0FPO4CEU4V=E<%I48VA93&A*0W1(5FQ::S9Q0C F(WA!.UDU3TQ83&1M9FY,
M>DAE*UA)4$IY2%=9<DIB;3ET<EA563=S4D-A-&A+9U-U5VQD=4%4+V1H5W!Q
M=RM)9G1!0FM45'IU,R].4'IB2TPF(WA!.UE84&U,-G!:,TQ1;E=D42MQ,G@O
M4E4W;3DO,%1E27%/6#%E269V9WIE*RM3-%=(1C5V4612,6)Z5'%(-5%796]H
M;G-D979R5WAE96$F(WA!.TTK;3AB5%-2:5-1055+,55K.&4Q8WAD4T1W:U(U
M+W1D:C)B;7A9.&]N;4A&0TEK4T\K;VUH.#).84IQ9FTW4TY::FLP:4]85V)A
M94DF(WA!.W=Z5T8Q9%1,1VLP,'E5=651:G531UHS*TTX86)L;4DS3U)X-&I'
M9DUM4$0Y<FI993 T-3E02TUO>$=56D])14%$,$53<V)D>'(U<W0F(WA!.W1D
M4R].5%5956YS4#A.1S-K54UK<V1Z95A3:T=V>$%R1D-#3G-Y=&UO5VE&,"\X
M04YM-&]*.6$P87=!,W)B869C5'18<W Y5S9153DF(WA!.S993FPS5VIY="M9
M:D@Y-S4T6E)T6#!.371%3D\O=T1E971V:EE7:C-R:C5!,6%C8W(S>FYR:VMP
M3E=-1#)D<VQE9V]S5G-+8F1Q-#(F(WA!.W9$-7-D;2]+8GI-:&MT8D1Z3&92
M5WI4=$MT,6,S8C-3;%=K37A%;&A*1C944#9N*S="37!**TQR=&@T:V-+9&YZ
M1BM95VA(:G(R:'(F(WA!.W)L:W8O4WHP2W!M<'5!6DQ'66@V.7HV8G1J451:
M0V1E6'902&Q8>D$W4F%8<4UC=#-(6#%B2BM53GEL3W9/0U5*2W10.5A!46M%
M1E F(WA!.V-#6%EQ-T9867$W1EA9<6PY;C5E,%=Y=DAV3%<P4TLU8FU/67%E
M26MB;$E)=U-21TAB-&TT9V-J=6-.<E-96499,35Y+TPW45!.:U4F(WA!.U$Q
M0E1&4$5W4#%Q2TLR:VM:5E-61FIF-GI$8TEY3#E99&Q"6#174$IA2&9#1%1'
M55%59%EE55!,3FQ083-C3VU7>#%#>FAJ=#1D4V4F(WA!.T=.<G9H1D=);')/
M5CE1+T%+9&-B5%%50C5&.'%V2D\Y-7 P1V]#83=L=F\Q=EE9<F=15%1H4%8Y
M1&UP2T(R:C5N9C=2.$M!3G)W:$TF(WA!.W Y1S!E-&QE865X=#5:6%E/.&IX
M27I->7AT14-34E5K4GE-;BMQ4T]H=TIP:D9H*U5V;$MY.'A3-C1I4TY-.&YR
M4E=T25DT63-%:U4F(WA!.VE5.4=/2U8Q:F%"1$=K<G-Q9G-G6DQI63A)=3)3
M5&58.4)M3&UB5&)747E'47EC-$DR-4=9<3!P3E8S-6U.0S-J>$9E;5)T;%-#
M5'DF(WA!.U0U86@Q3S,Q1WIS64Q'94-D<G515W--34EN;DU5:U-Y5&Q51%-&
M1FYK-"]&,5EN1&%/14HU9U,W1EA9<3=&6%EQ.&TX,#96;T=M960F(WA!.U@Q
M0U1Z=$9O;7!3,TIV-#=E5T-#5F]N;'1284AN2R]22&I8-%9K,CA..3AM3U1!
M9UAZ96YA4F5W,S)L5V0W1$DP,$YZ0DA.2$LV1TXF(WA!.VY6,$1";5%H94I)
M3F%5>41-279&5G-S555S8E)Y;W-K8F)-:D%-<$AU1&=)=FUK16IK.#(P=W=E
M6'9-.7)E;TAJ<TY4;#%#>&MH:E8F(WA!.V92:F5,55I&42]A:E=/=DY"6&9:
M4TMD.'<X<#A02T0P27(X9'IS.4]";3 X;V5N:FI+>"]0;'-D=5(T9T%$=#=T
M-EHU8S9.<&0R-74F(WA!.U)'23=M4VHO049Y02MN2U-);FE2:395-3A5;6)J
M>7%"5W5:;TQQ>49*<F)88E5(-G!C4C-K64(T45AL565V1TY%6#$T=S)W-'E/
M>&$F(WA!.TYM67-"54%954PO,#-(2$U)8GDR;G179&=K8D]N3TYI.'I1>$%0
M15A7<C!$,')52U)Y<'9J4U5D8C-%1GI"2&-7.&E445-Q2&EL:EDF(WA!.TUJ
M2W=Q1U9H545%9'AG5F9I<G-64V)Z1#5..'(K66Q187IP<TXS2DA1>%A"0E-D
M2T=O.4]A37!+;BMX65E1545!<$0O04E7.#DV1TLF(WA!.RM7+TU(-E-T9V8X
M06IM95E!,"MX-CA,,DE#9&5M=V18=S)%55)Y6$PK6G-E;75)9D]':UAF;'1Y
M84,X8V97.5!*2C)P9'=!<71F.$$F(WA!.VEX57@T935E3'9:9%DV:%E8.7-L
M,5E8358S87EF,V,X1')*1S-Y6D-18VEY5CA65U1.3T9":%)88FMO64]X44)#
M=T1K14LQ4T9Q44\F(WA!.R]3;S8T1&92;$5$<6@P;#%1;&5D=$-O4$1L>&U9
M,'%7-3E9:%AJ4F%E3E0P<'9!1UAC4&XK>'--8V91;C5F3"M,,RLW>G9B;"]K
M5'HF(WA!.T(K8D8Q-31V3&)78E=4.4A+2F9R154P66EG:$MG*VHV56]89FLQ
M0G17<2]&=C%Z03 K5$U:,&9I.5@R<F\K>F]A4TUS56AX-U92<VXF(WA!.W9S
M6"MQ:G,Y4&%B5G5,1F)707-!94E--T-P.4U%5E!P1VXW,G$O-G9X9C5/6CEY
M-V@X+S)02VE/4"MC9CE,-2\Q=3=F,S=E8GI8.'<F(WA!.S1F4%(X*U=T>G!(
M-E)84TQE,'-J8TY:>5A*:35Y5#-+4W%,95 Y,4UX1%)E;W@K2TYA3E1,;SAN
M1FQF13=Y.%!.,F]195-18FI6-$$F(WA!.SA#5VYM;&)Q2SAH6EIB2D9U,6-T
M37-:0FUK0FAE559%9U!'<'!40V%21S9$15!,9'@U*VDX<#9J839X1#5K;G9B
M>&).3$LY23%I3C<F(WA!.T\W9%IL;&MD54UL>$I(171(9FA73C(T<G=(6$-A
M=&E,<F4R5C-L,W)W=2].:U5D-S5I;&AL,&$Q3VTS2S).-T=294HV9VM7,E%7
M-%8F(WA!.T=F;$9Z-&IL=51Y*T5L47EV8V]N>E1Q9FUT+TDO;'%,5$=V2617
M=3=A6EI/66YG=6YV3&93-3-J:6-38TI/5%1X.'%..6]Q3V\V9V,F(WA!.S!K
M;6MS9W903FMF:S=6-V%"3F9-52MO5WIA8S%X1F9.<6=S62]Q;C91-'E-1$EH
M2F%8,&=Z0FU(3&A7;7@R=$<Y26)4:C5Y1C-O:W,F(WA!.VMM=4=%5%AY6$9T
M3$9Q,W%R<')'-BMR5%A5;E P2&M24%0O9$MO=4-E3DAR45DW249S:CAQ6%AN
M5WDX;&%G645U8G)5+W="37)B-F(F(WA!.TYQ<TXX=V%Z=4QM0TUZ+U8W;50V
M-&M-56-J=%-356MC4WAB:F=.5WE&,&QE<&9M2BMA3VYA9$-B<7=S64PR.&5-
M45-Z5T=P0T=-1#8F(WA!.S9:,65+0G)M9#(Y3WE34W%,.$MV.%$T+TAH;TE-
M:45E;FU8>G)Q35HQ,WDK.$XY1E!+;6Y135E,<5-Z2U=T;%!C,U8P;'5K<4UV
M<E@F(WA!.V%R8F]886]O1C9N0E%46C9+9'(U:S@Y=C5L.'981W4R5C-"6E)0
M8TQE+V\V>79V45E83FAB4W=R4$-V,6=K=WIY>5(X,C)Q<#)88UDF(WA!.S!&
M<SE7669L,V589#4U3W-*<G5:-VE5971%3&E1;&YK:FAN:VEI9&UA<%ET1VEK
M:S=N05=1648U>#%(54Q$5B].1VPV64)0;RMR,&(F(WA!.WI(<5179'AC9F\P
M>E=I47E694YG2D%S0W),>' X1F0Y<VM'2C9V5TY/:&=G,"LQ9W0U1$YB>%%X
M<$1+5T1L,%911EES3FI58C%Y1$XF(WA!.T59<3=&5T5A=G!N,3-Y6&1Y<$=K
M;'IP,F\S,2]A:5=N05,R.3E/=TQ!-T@T83=(8DUF5G<T;V59,V,S<S=/8V58
M;5%*96LP3$Y(;4(F(WA!.S<K5S(O8VYF:S=6;3%,4F)A5U(P;&Q-36-J4$,U
M;%-S:2]%=G%"5E1K<G%Y.$%35D9+.6-D3E!I:5!X*U!C>3=1=T1(;$Y!9U=E
M66\F(WA!.R]+-S56=C%.,7E4>DUH=TA9<6PP=6<V8WI.2F)Q,6QC34MF5TQ5
M*VLQ4D4P2T9L2'=396UR;F=*1EI184=L4FAT1E!05W0S:3 U-"\F(WA!.U1H
M=2]/8DY)1CE72F]D4T8W5D)&2DA-0DE7=&Q+>5!Z4#=S<'A8-%9Q34M(;U$Q
M5S52*T9Z<#%X2%9W9VMJ0WI)961W6550=TAM2V\F(WA!.T)+>$LP5E1U83=9
M1U,V,#$W4C=S;W-&,&YQ4T-.;&EE<V-L2F5::G)'+T9X>D54:T%J8T$T2U9(
M-'$P>7%Y;%=!2VM524\T24]+<U(F(WA!.W9F>78X=4<V92\P4G O3&5P=G4Q
M,7!,+T%&9%A);U(V='92<F515D<O2DXX4$5X-%%S='!V>D\P935H9W998E1Z
M3G!R37%09E<U1FHF(WA!.V5X<50X56MK1&QO2D])-U)S<%!H:G-U-TUS1$HR
M2V]31%8Y2G5*:$1B,W-%,'AR4TM/5D=B8G(X24I/5GAY=TIO14XP.5!K:4QL
M1U$F(WA!.TAU2TQY>'!3*S<X>&58-TQ523E/=DY4=$QB54IK.5-'>FUN:FIM
M9%!I*TY9,EE-5BM"='=/>'<P:7<R;FU$45A22D4Q2S%A3U-/2V$F(WA!.TYX
M4$=1,%9W+W!W=7!$8G))+W=O96I(65E+5S!'=FYJ>54Q;SDT=FU$5%=S-#5&
M:&4U1C5!63%L8T9L:DPX*TE:9W!)2%AB1%)8:4,F(WA!.T]F6$Y&:F$U5U15
M3%I'<V\Q;G9&86%-1T=*=U-S:W14.$-S05-'8F)"4S)T=F)V45=T8F$X=G!R
M53)H9$IR3S1N84UX;5%G=$<X5',F(WA!.V503&I5<59X4S-:-CEO5CEP,&UP
M,E=O,G0Q<#!18WDS<TTP8VM#:4U69FQ)<D9">$<U,S)X<$%+2W0W:3-U8F5+
M-71P56UT-6M74T<F(WA!.V%.9S9/:FEQ<W)#;TE)3E%2:6Q5>%9,=%$P-WDW
M<G%35T]O,G1N<6E7<VDK=&$S0U)806EL2T)L-4DT8FDS0C9I;W)1*RM&0D%+
M<$PF(WA!.W%M:E=,4&)46&1T871A=T-E4T8U231Z1F(Q2TQ)>6MJ:DA64V]B
M<'1G5&%.>%94=')A,G1B94\R=&]K9W0T5D5C34UA:$521D9&5E8F(WA!.U=G
M04$V05EQ.&<X-W)O=C9D.'<V4'!Y95E*3F)V66UU6G1/,"MD4F%44$IB<$=*
M2&A755-'3F=Q<35P-UI-34,Y5C!'1U=$43E/:&PF(WA!.VDY0U=+,6A34T56
M25)L:D%+-VQJ<V1U=5%,3C1B82]M=#5M;F%E3S8X=VUY<S)V:VIU3E5%1G!)
M='!#>'9I;S1I26E)>4<S:%0P-7<F(WA!.WIJ<E@T:%-Z:&%U3'IE>F539%,Q
M4%902T=J86IQ:V9P86ID,F--,3!L3U W>#!"2C0O<SAU=$\S5$E(;3)23WEP
M-6)!8E1*=U)51RLF(WA!.S%!14AP5#8Y3F=+45=(*U5)+S!4<G5P95AR3WE,
M4S9C.&QY2C1W95!'5&=);U1Z+T%(8UIL9U9+1E1U5F)V;71W9WAM66=C="]W
M0FXF(WA!.V1U2&]D651L=WAY>FMA;#9F56)*-FU7,W%01$EY1DAC06IP5#!/
M0V5'-&=J;F=C4U%Z2TI)<$9.5EI71E992'=)>EEG9VEW-D-C1$4F(WA!.VM(
M66AF:%EU>%8R2W5X5E1N=')E-%%*4$5K<4-T1F11=S-"53=(+TI9:D95=5!L
M<E1K56EY86)4>59+<CE6;&%.1B]C0S-1:4EL;W8F(WA!.S-C87)W0E-G27)3
M=4<P579E,C$R3G!'9W99<'=X8W!&8U)5<'EE4&E/8UI86D56*W%K:W-.>%-H
M571I+S%73U%,8V%A>%%S1CE7,FPF(WA!.U-64GIN36%K:"]28C19=4UJ+T1T
M=4)Y<'5O870O34]L5%!&13!J5S@X,T%2=S--8G=/5VM74C%53$M&<3-'1GIX
M-FEM3DIT1F%H85,F(WA!.S-D;SEV1F145U1V4VQZ8BMN-FDP25!W*W%K<6(Y
M4',U0U5B1EA48FAY0T5H27A%=DDS6#)%2#=51VUI,U,S1G!+9%EV;E<R44DX
M3&8F(WA!.U8K135&9FIL<$-'-4=V-TI58EI$=VI9.5(R+TAC,TA64DU:1'<T
M97)R-G1V9#9V=G0U6#5/+TI4>E9P2&U34%5B;E998F5"4DE';7,F(WA!.TI#
M8FMC,4E&0E!B;5!E=2M91TQ1>FI)16XU9C)05SEP93 K;GI91$--1$DW8E-(
M<"]W0FI/,W%P,&$V*W1Y6$@V6'91<VM8<$,S+S F(WA!.V8P,&)G1CE69C-0
M3&Y58W0R27(R<'1M9C1:=2M)+UHK<#5,.'I(:$5F1&AZ=2]69E!L.5A,<#,Q
M,71H;FYF.$%,6%=D93@R4F$S8E@F(WA!.V-!=#=E,G-O;'1*>7EI5U<S;G5(
M9#5#:V)-=D),;FQ(>&%H655:86(U94118TM58DYT840K6%=S>'@K5% P=$A:
M2DHU6%)R935.=&,F(WA!.U13:35I4T9F<3=K3D1"=6QY9VM#3E5,4V]9:VM9
M:V]J2&MX>GDW*U5V-6<V2C5E=CE*:&TP,6]T56AT8DQ522]R9'E42F)20U54
M;4\F(WA!.V53,6MA1G!%:T5A;T5:5DA):C1S2FM'26E113EU4'DK,3DW;GI%
M64Y),&%',#%N4W)E=V=T9G)5>DMS.75826UK<EIF1G@Y5W%T=3$F(WA!.U58
M>'%O=&QW;7EU.#$K5"]!1$)F*U5F3%=H4VA9-319<#E/=3-T5$QC47AV3'!K
M.7!$3W@Y3TXO5#5-07A+1&IY.$XX460Q27-5<38F(WA!.UHU23@P,C)H-B]A
M6%9N<%4X*W9->G9A3&-43&%13DAB=U<X2E%.87573&5K,&IT>$9#1G!8<45L
M44-R6%!K;GIB8RM4+TQU:DIQ03 F(WA!.S(V,&TP93)V1W-B,C9H5U(T-U)O
M3%9X3$5K3'-O;$-337),='50:3=T-W)W;6U+87IO4&YV4V19,&EZ;75T83%/
M=U=9>FXY2%@Q*T\F(WA!.V9-5VMB4EA&=TE*-G%(4V512DDX86A4=$E0<V=G
M:$)"=%!*=GDX.#18;&Y&8W!Q8W5M86AD>'DS96]25SDW8S(T1V]83C%&2S-,
M-G4F(WA!.U-J<D9A<3!#;7 V1"]707100V]8;FMZ>FAP;C96=C521G)6=E!O
M9#-P5'$Q>&-Z6'!8-C%D>C(V;W)14W1/,V]Z>%)N:S1.461Z,4HF(WA!.W-)
M;W93.4AT-VTR,&UY=#=P=61Z1&)X4GIV5W185D%'3F4K-'E$66DX5F5'*V-R
M:3!S9E P-3!(5C=Y8GI'9%%J:U-Y:',W9&MG=7(F(WA!.W4Q4S!62DQQ-31$
M9SA62TM/45AW<G9K>'EA>GIE,C)G;D9R0TQJ969G=G)(62](46-U9T$V*T%Y
M1%EQ-'$W1E5Q.',O.&,V8B]M3S$F(WA!.T0O<4]M=VQ!63<U,G1&=$YE,'96
M=S%Y;UIH1U)A<4=*;6AR3D=R0V]Q6FM6-&0O15IR.59'<$-7+W=!3R]W1&)Y
M9'@R9$U'13161&,F(WA!.V,U1VI2,C(O<6LX8DI.23%',W5O-&)I,V-Y5T]O
M4FDV<S5'3$UF,V<U;%-Z<S(K.5924CA)0CA->6-C-SEX,T@T+U$T96]W;4)-
M6D,F(WA!.W!W4$-F:'0P2#(Y4VUE6$])-T9867$W1EA9<3=&6%EQ-T9814%I
M:#-">%9:3DY$0D<P<S!I>%),.7 S259253 S2C)W16=#>7EJ17DF(WA!.TY!
M5U9I6&QN2D%B:$HT,W0Q<5=M5C%+041R5F=A8EE"345897E4:FM$=VM'*S5I
M6&QZ.#)02W9M1%=5,&EW1G@Y86-/=TUK87%L27<F(WA!.U=B-&=X-T1-8D9R
M651K26=(9#-/=#EN.5)P<UAI>C1E2&)K92]W0T1,3&$K<W)R:TQA-&EN-%4U
M*VTV=E-V4W9%;DUM331Y-4<S5'HF(WA!.WA4:#E123DT63$U:B]-;E)F3"]M
M0T123#(Q=35*6F\T6F9R54MX3D-N,6PU631L8FQ)<VY*;70R*WEH03)Q8VU!
M,&U7.4Y19FU:;U4F(WA!.W%A37=T-W17.'=7.$9Z<%5B2DAY;$4X:7AS9W!)
M4GIH16EY4S<P0V)G;G!J=W%*2EIO,S5Z-D)R4&PO571C,#=43E%N=$Y*5EIB
M-4(F(WA!.SE41'!#,&)Y1U1E-31F07-:-4IY.51C9D1V:$U50UE)=$Y*4'I+
M,%)F,'A3>G8S1VI78T8O4%,R64=71S4U8U!25FE'86Y!.&U)0VHF(WA!.W)Y
M;T-13T9016ED5S@K84IP5V=73W584WIF5F11:3EE1TY1:&Q%671N=3-:;$QG
M9D)&1S%A13<W0W!)>'!*3DM.:"M95VPS96@V;G$F(WA!.W!T3&TP8E-(160Y
M65AJ5W1V3VA:16Q1;#5*,71W<DI+<D%T2T(Y3S).231K3G!8-7 V2'%6+V]D
M;D1A6&%395E)5W5,278X059I>6\F(WA!.V]K2F%72DHS;E90,TIP24EZ1V1Q
M3F@T5D5K-FXX-F54;TPQ-T=F6&1/:7958U)0879D=TQ+<VA.06A1=GE$13EQ
M64M+94E+1G@U-S@F(WA!.W%P85A-.6YQ14=Q4U=S:TU%=')95%$S12]Q,T5O
M:&EJ-$LK>DY)841K4FI3.%%A9CAW4$I8<'EM,S%Y=W9*;V\U6D)A,C$Q0DQ-
M+V\F(WA!.V]:2%9%1#%:9V\V63!6-&=R85@U<C W55I.2U-+2V%0.4TV9BML
M3$IP46=":4AP8VM01FUP26]U14I(5&99;6U.2T-N5T),>6(X>"\F(WA!.TUT
M:4Y6=61/,3=Y:%HS=C%/,FMV<E,Y;78T<F5:<F5*>4$P1&Q&;%)Y=RMW:C%Y
M641#4F5O85A-:RMM5VLV2WEP3$1'-G$W33=!36<F(WA!.TE$32]X369%='9K
M1V%*>%8R2W!6-5HO-#4P,R]!1$AA:"\Q2%194V=+9FY$4S,Q2'DY9%)22U=U
M;V5.>F%"5TM.-C!$0U)!1T93=DPF(WA!.VIX<C<U4G%)8U5$.#--,%=B=SAO
M3C!$<U16,$1T9&1A-7!F-68Q06%H1DY(.61J=4HU1T]O-E9'2T(T64=007A&
M>D=Y9D)+2DEI5D(F(WA!.U!!*RM5-'!C5FDY*UDX=GAU4&,U3V]G26E-:$5I
M3F--=64U-3-69S=X-%I583E42DQA9%HT1FQ!<'EQ0TM-3G=A1VY)2V%61WAP
M=FTF(WA!.U9'5FDS6%1H=VUL6$I-2%EQ-T9867$W1EA9<3=&6%EQ<%A6<&$S
M8TIG=6]5=4E7<'EI;%5/<&]A:7%S0TUJ2TEK2TET;D1*2T)U2DDF(WA!.U!K
M<%(V6'!K5F\Y;DA:=TIA4U8U,C9X;TDR<C%Q9TA%-$)J:4)60VU5<RM1>31J
M23A89F4O=T$R2F57+WEH.')E6#E95%9B2U,V930F(WA!.U):13E/6C0R:DMY
M<5991E)'=EDK3UDR4%)1:$LW4#0K1'5D8C=286I5679$;4DQ='E"=F(T<W1S
M.4HP<7A:;7-R3T,Q6GA2,FAI4TTF(WA!.VM$<V5)1F-Y630T>#5!0C K5%5:
M36XQ>6Q,,VML:B]M2#AT+TPK=38V=7588GIX-FQ&0D1B,C@X3%)Q66MH;&MK
M4$%S:D5E<4HR4U,F(WA!.W!O5C=!-S590S0U:4QT=E)0>3DP-U-O.41J*W8S
M;#103'!L1VQM-2MR,5-/5S,K<BMK,V]W>&-L5F1W5#A65'533G-35D5A4T\P
M+TDF(WA!.R]W078R;&M,5T16.5564CE754]Z5V)6:',R9#196%)R67A34F@U
M3UI$;S%30G9T:#1K8T-B,T@U9'!C6&5Q6&,R=F%K,"MR,E-A9&0F(WA!.W13
M=T@W:4UK:F="83!$2#%(0E K569"94ET4$-P83$K6&-.+V\R:6%/8F@W<7HP
M=U,R='<Q>7EP3$I:,T9P3&%/03!-87(V:4Q)<%$F(WA!.SA".6YF<EA#0W!I
M:71).&A,<$9T8W@R1W5A:VQZ94]:8GDK9C9N3%!++T-+3TUS6DQ:,"]D4G<X
M54%50VA.45119T5Q27%';B]L:G F(WA!.TYK3D=I1V]8,#EL;U5Z6&1L6E-M
M,D5:=5A-:DY--U)W2DM35VY9.%$T5"]*<&IX3'=U,4@X<F9,;6]36$5K.&QW
M2'5:3'56,E9O<6@F(WA!.W(Q-$AK-&MX;C=0,591=G-45W9:-&LX2U)E42]Y
M=C$S4C=M0G18=4Q,-FQA5$QD>#)L<$9'>E0S4W!,1THU<&QT-TYY1D5T5E-4
M,5<F(WA!.S5#=G%95$IJ1TY*<78U4"M6;'15=&QL=6=S8V1V1TA$46AY3%9B
M:%9*4'!D5RMT=GDX84PW,65*4$-J3D8X:WHV5G%E:E5V-6(S5&0F(WA!.T1S
M6C=3>F$V35@Q9T=B,$522U%1=TE9-#1R8S!*<7A,8CE-0DMG57EZ07EE3V9N
M:DYQ365S-EI01F0R;C%3>G0U2$YR4$I':VM5='<F(WA!.TAG4S0T=6IS=T1L
M1UAJ57)W63 W:6-713-R96Y'539F8D=A6F)M67A*-FQX2%1H23-%5F1A8E59
M-VEM45IV0S1V>E8X,7EI4U!53E@F(WA!.T]L2DIF:&(W56\Q='!O9$]H2G91
M;',P5#)Q;4M6;719=V96:VQQ<$)"0D]78TQ6>$8W1C5*,4Q5.54X;V%.<4]Q
M4BML<4XS6G=Z6%,F(WA!.U4T+W9(445N:BMZ>38P-V1-9V5B6D4W2W9L;B]!
M234P,R]-9'%(+U5D3FE60V$T17-#<UDQ,&96<G%Y<V)A,F$V,#8W1G=K6F]J
M2G F(WA!.TXX>6UC>&PR4E(V8W$X;3-P.%!I8S$X4G=324971"]S4S=W:S5O
M8U5Z4&AN1W(U9S5),W=J8F9L<TYR,S=M6&PP=$PS,4-W1G9E;&$F(WA!.W-3
M9T%N;T989&TU35I&0W%Q<4\S=FU89D1,>6PY+S=85F='8TLO:6HY,WDV8FLS
M,V\W3%A(9&ER<U9D:7)S5F1I<G-69&EQ2#%#.48F(WA!.VQA4&-M1V$T0U4O
M9%<V1U-1,4E(=W%.>C%Y134X275I9F,R-&-82$QH<T0S;6=K+RM-678K<E!Q
M=B]32$IL2#5R*VI0-4]:+TIP+S$F(WA!.U1&+W!W.#<X;V9N9'(R<BM9-#E/
M=F1.:F$R65-&;'-O<'!,:C1&2D9&3'0T8C=::5ET9$UY1FEX-41F-S-P93!F
M6F9$:'='8UIN:3(F(WA!.RMO9U(K-39:<"]M5T\Y=3!T:' R;U<U978W,C1T
M;FIJ1D%4.%1(<#!Z3VAN-&I81$EE.%!,6G1%65)-=5!'9F1)17-/.#@O;5(U
M9S F(WA!.TAZ>%HV2%EW,C!T;$YB5S P=G)25$8K53AL>6I(-G=S:7A2.%)B
M<592;'$U<49Z2D$R9&5:8C!R5W9N>GI68S9B-5!U27)3,F54>E8F(WA!.V)2
M1&MQ4V-)3'%I>GEL9UI+;4PV<4IM559R>5563D1S,&]L<U!.:EAL=CA!3TAZ
M9G%V;'4O=7)K869A87I(1F$S1VLR9C%795@V-3DF(WA!.V%%<7!"1VE84E!+
M4U=-0E@U,4$U1F\V0W5%>$-"36M-=6)Z9C5V5%5F361J3%HR36,K;#968F%J
M6E(X-5=(3UE40U%4=4)U1DU"258F(WA!.T9(:'DS<4)42WIA2G,O3BMS,VQN
M-5-%149U8C=Z0G P;"]C0GDV4D)O-U)*3T-%1C)11V5D3GE';V]/>$\K0VQ"
M571'+TU'-6)Y4' F(WA!.T=V86Y9=F1A:'%D>#E45WHP,59(2UIP<$DP-$,T
M;%%"9C-E-5HX3F)R97E!:B]/-U$U;TE7='1$,7$V=6)L;R]Q.6IB,C!-='<X
M53 F(WA!.U)L4UE):WA(<#A6,TI.4C-&365&2$=I3E(O3D]05&)Y*V4U,#(U
M=4Y09V%31T57:7A.34I,2S,K<U@W>6U384]0:$5(0T%*53AK86XF(WA!.TMO
M>#15;51T22]-:34Q,WI60F\K;C)H<V]P3$\Y95IB*TU'94LV=%AH5D%21$UY
M1TUR4%5G1W9U36%8:3-:4C54,7!T8SAS-EIQ-V\F(WA!.TDU8C(R:FUM:E=V
M1EI'56,Q5W1D9S%134)30VUU0DQS5F569FUZ9F%F2'%C57%185IE,SA&;E!&
M2&(S3G9F5%A$;5984F]697HK06,F(WA!.S%B:6]F9%-X27!82E)94V5M85E8
M3VTR:&5!5WHK:DAY=&Q52TEZ=T950VET3U!3;5):;VY&6%EQ;%AL;B]J;E1F
M.'@R;V8X055D3F@F(WA!.TM!;75"3$8O3D9T8E%A>G!U<#-*<%EZ<DIP;6]X
M,'%R>#-#:W@K;V5O4E<U5BME66UC05-%:GE/>"](8S=$4U1K65-J141J1E-"
M=7$F(WA!.W)N435'4CE0-#)),U%1<VUM,T=J;4LT=&PP>'I92DDX:D=34TI%
M57A43$M!:%!+3FAU3VAQ36YI,VE9-VIH,E)Q.7!J3&-:8V9Q-6(F(WA!.T$S
M=4LS-4@W13!S-7!:25(V=W!/:#1Y9TM66&M/<%5.=G@X1#-Y,D)*1R].>$US
M441T>2](,G$K5&$S67$W1EA9<3=&6%EQ-T9867$F(WA!.S=&579T4$PR9U=D
M=TQM,#!Y,'0W:&$X6F]O23!C5D9$4FQ52&9+-#1903)!069C-4]45UIP>#1:
M5&Q+4&-:17!H;&IJ24\W,%A2<GDF(WA!.U8U8GEW=#=M5U)9-#5*2F]K9&U3
M1GI,17!,06MH2D1Z561M,T<K3F]P4C O>7HU8S Q26\Y3S!Q>G-K:&QA-&A7
M,W0T;V=K>G@K:S F(WA!.W%H1D9(85 T0W<S-#=D34YQ045*+V=,>4M,6G)5
M95A.3"MR3S1L940V;&(X1$EO2W$U6&A4:T%X05!V:EI2=VIU6$1Y4#5+0FQ9
M95@F(WA!.SE.0FYJ14TU*W!W5F5)8V%)+W=F16\T3'-D=&@T63)5.$ED3#5-
M.'50*VHP:G-O<F4Q,#!816-.:D)(1VQS,%8S1WE4=WE1:&5"4BLF(WA!.UA)
M9T%F15!#;TQA,&DW3'DU-65S8F%/,7-T3'1,5S%I;$9Z1D)$0D9(1W-W-E-Q
M<7%!2"]!36]B-#)O1$@O3E U5F55=DU-3G1$3$$F(WA!.TQ"3%93:6EZ:'16
M1$E9+U-65T5S37EJ,#$O=3)50FLO6DEX16M'24MF4F57=$)J<S!S+W%-371U
M;G(X5FY8,7HO<%I:<FER4S@R4'$F(WA!.VPR-3%0>%8S>'1.2U8S-5$X<UA-
M<3-$-E9:<F5X3UIB93E&=$%:-%IJ5#DY1S=O,T=11E9)8GA!>'1A0TTP:E,W
M5%-D2W,Y3'1!4F$F(WA!.S)-361V04=.5S122T9(26EL5%%B;D%K279&6%EQ
M.%@O041).&Q83VTK6C,Q9E$Y4FHP56%T0DLP,#<V;DQ:13--8DY--G%N<E$X
M:$\F(WA!.WA29&IX56MS44YJ:W=7=558<T=N8R\P9F$K;WEU+W!*>F5.,FM1
M;FE+;%AC;&U"-T9J535"<U)'2W5X5DMV3% O2$]M+W=#63=54"LF(WA!.V\V
M8D-50DYC0U5T.'DV475S841F86%X24YZ17EO5F)G430S43AH,"M)1$MS,E!J
M9U$U1VQZ949K:E!B63E262M34V%F<3A*5%)D9G4F(WA!.TQY5D5V25ET374W
M4F='45AC:$)2<$-#06I++TI#869&>4=54GE$,'IV;C9F:35P=VU1>5EO9T5X
M2FU*8W933FI894]V;%):1&-+;'0F(WA!.V1,94%"56MP1F150VEO3S!B:VA$
M27A6<4E">4%!66YT;5),,&TO;31-0UIX-&4W8V9P2$]H,SAU:4UY>&]D:7)S
M5F1I<G-69&ER<U8F(WA!.U=3*W1X2&\X95A*95A/=$].9FEP5'94<&EG,S!5
M>6(P8FMX:T-1:V=":693<#!'+S(V+U)I>#E8-#=M2S9$<75T>2M96D=U24IL
M=&(F(WA!.W=M<75J.%EW<6MP4W5W.$1G9&9P.'51-61W84Q+-&AE,6DY57@P
M-&XQ=4%B-V4Q3TY4,#8Y8TQS4GAB5SAV.$%Z16@X.&YZ-V)83VHF(WA!.R]P
M2F1(=#=3>CED<D]3-3E,;DIC6$M32TQE4#DQ2WA$4F5O>"M+3F%.,'E9<6U*
M=3(Y15AZ9'%7;&539TQJ5F)E5U)%,#=Z44QQ3SDF(WA!.V=K53(X4S-H;$Q3
M:4UH;F%%=T=95D1E<'@U5D=Y855845EF-6)U4% P6&Q056)85TEF36LY-V5,
M6G!:6'!'<U)V6C-B<DUS<VIQ:&LF(WA!.W5*231L;S<X2WAU,T9E038T5%9S
M4F1B,GI!-G)Q5G)Q,VU2-VQ0365S-F,R;#),5VM35S)O5VI08V\W<DML<S!5
M8TAP365C5%!X4$LF(WA!.VY+=DQI44%Y=F-R<C8T.#%7+VMR>7A:5W0W950V
M<F-,97$Q>DMT>F(S170S0EE8571V031U4D9->2MS9W V:3%K0T%N631/<65I
M2#@F(WA!.W,V<G$Y:C5B,7=A;EIE63<K>F192#!Y,6M456AQ1'EP8E%#-U9:
M=T)C4DMB:"]H<7=Q3UI114)S2E%$=#%4;3,X>6%X-6,X;"M6+U<F(WA!.TXQ
M<70U951Y5V0R.#%P979D<S1T3'%D47-%:7!D2&I,06DX,U-P:G%X-C%!<7EM
M-D%9-6)F;7(U,79R<31T1VIS-TM784=+>C K>F4F(WA!.WIV-')X=%5M:&=6
M>#9K,RMI<6M%,7IY6E-X8TEU-"]A=SA)44I',#%U9DU(-7%A5S=7,6Q94EAU
M;C),5'=1=%!:,W,Q,4Y$6D<S:E(F(WA!.S-M13%(:W5233="=5 W1$@T=#9#
M9VYD6F]'<RM927)(4C1,,3E2:C%74'I(4$)/;#=(9'AR3F%83#-:4E9E6E93
M6D5H54]V171W-'(F(WA!.S R=VM+0SE4>41.,DMV1W9Z;C%3>#!V>E1:6&9+
M63-P<T-K:4QA,E9Z14EG.&MQ;70V=T%C*VLY3TDY=7!!>6-716I4,793<#!U
M3DPF(WA!.W,W:$-3:S!%8VEL;%9725I!4E96*T5(,D<R45IV1C<S.#!V3DPS
M.3E(95@Q>#5D<UAV-V148U0R2'!M=W189W585E=.>D)X6C5N:&DF(WA!.W%7
M<G5313(S>69#,4=4,6IY5'%7<#9P-5$P8E5D56HY3%5B=7IH;75K<'@O94]G
M2E!(.6YL,7 R-EI%.#)Y2C)69DQ0+TA/;2]W0UDF(WA!.S=54"MO-F)%<44Q
M=TID:7)%3DTP*T=Y,698.41I94\S8E5'+U-E;F=H6'!*3"]E5&5M.5%3:WEG
M9V1.:&U(1TY3;$196'50,2]0-VXF(WA!.V$U33!P>'@U5'A316943&]+2$M)
M26\W>"M/+TY0.4AU6'9D2E)B=5-+5SA29G$K;VDS66Q&=45(1UI184M24G-V
M>'DT;S<X*U(Y-V@F(WA!.S9M07@U1'=G:5!/3B]W03-O>#(Q+TUV>7I&-6PO
M=T%*>7IY2%59-79Q>51#3VM$3U)627<S3U)U47)W2F)Q=T]5>#%54DQG-CAV
M>#DF(WA!.WIS<VY9;6,T4'I)031#3'$Y+V9Y03@Y=6I-<WDS4T]X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5E-N=$Q7-#E0-GA#:S,F(WA!.V]U
M<W-0<4M'-%-,.6PQ<412:%A9:D966$963U<R=#5N:&ML:5-34S-C>5<W=6]9
M>'5584UU:% R5S1/>3%(66MD.%91<T]G-DA"<6,F(WA!.W5Q=S9D87AA<$]/
M33DK:TUA,T1J8EHU44]B1#12,4].;W!(67!5-6)7,FQL:&UL:%-383-*83-K
M6E%7:EIL2TU52C-5;%=)3D\R2W$F(WA!.VU+=7A6-4@U<#%B5$Y5.#%A;#9U
M;S-7;'IA65)P8W1U;6Q3-G9B,T-)23=P2FE"0DQ&1S1E57)X*S%T6'5-;4="
M3S<Q:3%9=&)1<U<F(WA!.UIY555L,U%X<WA)-G-H0VQ3931P=&M'87!I<G-6
M4W)Y>B]X>G!V.$%M3S%$+W%/;7=L051806PR2W-9.#11+U9B-U)D9$5G:%=X
M=3$F(WA!.VAV2#1"<3(Y,2LV3E<V<4$W3&U,<4)2:E!U3'-.165+33AD8U)L
M1W@V<3-'-5!C9&=F,$DK,VEE>3AW4U)7.6M&<V13:F$V;G9%2B\F(WA!.S-R
M5&A'431*;T]C6$5J:5 R5%A*9V--.6AT3&8T<TIY1U1#1$M8<F=E140K:6)0
M,D@W=VQ,+VQB-51F>EHO:61O<%1F*W%,:C!U9C<F(WA!.VXQ:#!K-# U5C5F
M1CEQ;&-H*U5H>#A8>&-W9'9A:V%F.'99-$MR;'988WE*9$MT63%664=L9T-G
M2V=34BM+:%EZ16]#:VQA0E17;$\F(WA!.W1$,7DW=V=/5S,T<#%P,45J>F\O
M060Y+VIY,F,Y<&9Q:FE#*V)M43-P*W1':VEQ>%)64V]8,&U92WDX:CA65%4W
M,'!2-$ID0V]Y44HF(WA!.S-J.&E2,2M0=35F0F-Z86]R2&EK17$Q86<U3D=1
M0S9H061P3VEC:7@X855'4'(X:T%9>C-J-V5M+V0Q<6UH95A164-3>6M!3$%C
M,&$F(WA!.TYH=DM50BLP1RMZ4GIT<U!F2&I0569I+W=6.$]04U$K,W5V.6IK
M,5,P67%'3'A-+TAI2EDS:C-F:U%+<V]&9C-:<C1D*V]X1U5+8T4F(WA!.W9)
M*S1G.3,V,5<S=F)/-5)8=#4T-6M92U9:1T1!:#$U<61J*S!P-40R>5%M1'E,
M0V5+55159U(K2RLY5WE40C)+=7A6,DMU>%8R2W4F(WA!.WA6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W9+=&(X-V5:=DIV;6I53&4W,#=42CE.,4)P3"M#5TM7
M84=8:4-S6'$S4&\R.7E6-'AO<7,F(WA!.S=Q1DY.;C(T:617=TI)3#%',VM-
M='9&2V5&6%)74'!T>E1C5BM&-DQY2&=A0W516G%M2W5X5DMV3% X07AZ<'8K
M63=54"MO-F)#54(F(WA!.TYC0UA9<6A.6# U3E,P=39S2%EO3&U*;W<T,DMS
M=RM&=V9&5'5-:&MJ>%))8DU5>$=9:U%#0652-4AY4&M73C988698+TID9W,O
M<G8F(WA!.V9A37EU:4E61G@V.6EX0WAM;TMK=7$X1'1U1WI':$AI>$,W=5!Z
M,F1I8R]$<4I5659K<TAN=RMR;C4W2&9Y<&LR;#9H0G%7;E=T+T(F(WA!.U51
M,U535%)H:%)G2%5-05%E:$9C>5E416]G:G$V+U!H3TMC;TAN13!I8VTQ3WA6
M,DMU>%8R2W%%.6I:5#$Y84-/4W1A;&Q"4'A)67HF(WA!.W52,U)I=GDR>4IH
M13AW,E)Y>FIY2D@T=C<Y,4XY3'1I2$5B4W=C=S(X56IO05=657%&0C0W0D)X
M,C(W6D4T:# R6D103')2.31(-#8F(WA!.W1M,75W4UDW>#DR2C1Y2VI#:E-"
M<4-G43=+0V<S-S<Q27@T5#!+*TI(<D@W*S<X1G<O4VES2VU#5F%R56=01U%$
M2652+W=",F1)*TXF(WA!.T(S879162MV>5@Y,F8U=RM2-F9$<CEN9717.'9&
M0V5T675#479)>$]K:7%3<DTS56]X0VQ1=E1C:V)D8V5-.5%K-&\Y2D0T,D\W
M,R\F(WA!.T%)1&IQ,6]I1G!V56=645-X;&ID04%):$MX3$5C84MV53$V9VIR
M:C1O-C=F,E=V-6523S%(,T5D.69F*W184S=T6DA+4GI2=39K:&PF(WA!.U9G
M4T-O0DY11#)$1#=X:VA-2'$Q;DA)0WE#<35*9S=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T970BME-V9Y1F13;2\Q5%8W:3%M06938G,F(WA!.V%:3$DX:W-:0FQK
M=%HT;T9M8FE&-4TS=V=Q3S1Y471I85IT6DQA2EIW3%HX9G%I>&],8C!Y0VYP
M:%)W-&M6<4]05$ES;FI&+RM:5CDF(WA!.SE9=F9Q6&TU53!--G!(84162D5S
M6DQQ,&E3,W5';5IO:VE#<D1*8U)X>'A02VY),%!7;T]4-%=R:3@S<69K;E5T
M5#%4>6AO,F\V<$@F(WA!.S97;S-D;D1.9$I4:BLX9$%395 W4$QR5'0P>4HU
M=&M4<W$K5V8K3V1.+WI(86@O,4A466Q1;75"3'-69&ER1F1+=$)P9FYV5EE5
M-'@F(WA!.S(K<G=*9E)P>4I,5%)N,#5Q2U1T4W%S,T5F=$1-6$A$:'EY-W!B
M=7EZ-51K,#!,<VU"3657=TA-8C$Q-E=F-%1413=(.#):8DAZ>F4F(WA!.V56
M-VTQ93539E940F(S56LQ4%)J:UI526]63E96<7-O<4M$8G1836%'<DU:;4HS
M2$8S.'0S935F6CA:3DI(55)L=S%I<VEU6DAX+T@F(WA!.TXV3F%E661!=EE0
M<D9P<59R8U%C>$8V<U4P8G(V:$91;%%4.%9/,UA-.%I92&5W.'IK,&5A0C1:
M46M$>C-"-60V65I9-'IS5F1I<G,F(WA!.U9D:7)S5F1I<G-69&ER<U956G)/
M>FY"13A%8V]91E-(4E="1%5*1S0W.%(Y,E)-06596GAY4VIY2D-M9$UT3UA*
M03A23$9J-F-J;T,F(WA!.U=L17)B2U%0:6-B*S%2,$]2.$UF:C5S+TAL,6\K
M.$1U<C=M:W,W;$=8:&53;$)X<6IH1W%!>DTS>&-1,WA"9W9864%5-S1I0DA6
M5&PF(WA!.VEE8U(Y=C0R-2]&<%8Q:4Y%0F%#-%E"4DEE3'<X:45B:U)V3%1L
M2GAO3W=R,7@Y63=J.6E38U)**W%0,CEF:#!V-'5A.'9),5EY5U0F(WA!.W1X
M0F(Y>3906&I'1V]!>&I.4SE56&(S3DLT.%I(34E'3THU4RMD.2]X-F)R;C%/
M,FI:;&Q%:V9(;#A44G9X259L56YK0G@S36=P=G8F(WA!.W94;V-4:T$U<4U%
M:GEO+T5E9C9L.%8Y6E-K:4ME3GE#45%R06UQ=5EM-SEP1DLO4&)*0UE05FI,
M1DUC=V9W3"LW9C-+*U-A,FUD1DLF(WA!.W%Z049T;$).0V9L9W1)0F)W;V1I
M<GI$6"]W07!T5C$O>FIE871Q5C=A;7=+9S)+=$)&3CA38V934V4S84I&:U)"
M>D),5$U46#1F5'DF(WA!.U%K=TUB3#!Q,%-73S%H4U5)2E525FM%44MX.&=!
M1'=5:VM,6&]-:7I68U9D:7%695=F.$%J;E1F.'@R;V8Y4C R16]#831%=7A6
M,DLF(WA!.W-6+TU#,%IB2WDQ<48P:&XP935J;F%:,3559UHQ17DK,TMI,5!H
M6$U45FI94R]M;#)86G,W:V-D4VQX:C9187,P879V<7EA4%=U<70F(WA!.THU
M3#AJ1%=X<3<R54$Q8C%H8VDT36I"+U9R>40P-54V*S)4+T%#,E!I-'$S-3E7
M4#AS86=9+T(T+U)65G1Y5&TV,&I38GE!=UAD;&(F(WA!.S--1$YZ355S4T]H
M86Q/6$9G4E=H>3 T-&YM031U4%4U24<T>6M$-45H1'8U6C!*<G$T=7AA3$9D
M6%5::&YN:%IO;EI#;U=N2TUQ464F(WA!.TE!<4XX:#1%3'5T,C!A-TU):5!&
M8UEM=T1V.$%E<'(U6G0T;S=32S)V8C8S:G1(6C!68FU35&U'64YX:TUX;$QQ
M2U5&96=W2$%.<4TF(WA!.VA8;7E/=6M427EJ06U8.45#=F1W,51J<$]T24QW
M=S8S35=U1S57=VYH=#-3,TA0:U9526M43TM(:CAB1VU%-#4W,4PW078U:D5E
M1S@F(WA!.UDR-3!:1&DK6DYD*W=8>'AE6C0W:3%$6$YN8U=Q>&=8:D='4TM6
M<$)7<E(P:VM25D\R>$)P-#0Q:T)'-$DV<U1,5&U-='!I5C=B9VDF(WA!.W90
M64925RLX,GA75%-81VQ7,#DR2E%Q=S)T,F%'3&I8;GEM:6DS0C(T+VIG33AG
M2#!G;GE0-C)W-'1-6E9'8VA'=6-O.64W,'E+<S(F(WA!.W184UA5.$UU:S-G
M:6AI.5584T-'4TXV2T=-84):1$E8<5-T3TAB2DA+4GII5W-A84II0TUK3$IQ
M='=2-6YA<2M+;5!.5VQR1&)36$,F(WA!.UA6<6)T,FII:FYT8FA7-4M1<$15
M46AA,3)*3D0R>5 U:4E!2G-8-49L*U%Y16M235IC3RLP;R]R,R]2,59O+TTS
M;#)34S=I5%5R8C$F(WA!.TQ&=4XT<&Q11TDX=5!X,4DT+T9T:W9(:'9U3FU%
M=$1N06E40U94-6)C+V-J-' T6E9$4E-,27)$:W)+47=)4&-5-UI92D$X;DAL
M16HF(WA!.VU+6#173'-69&ER<U9D:7)S5F1I<7E30T-59WE2<35"56=S;T\V
M3GE5-R]Y<TMJ,W='24Q)5$DU1D1P<%9H1U%9;WI%1C0P5TIN:E@F(WA!.S1#
M>%5C54E&2WE.."]U>4%X4DA*<T]O;65:=C,W.3,V;FU0-6EF;%0U;C$W>DQ9
M,RMM-FE$87A1>%$X<FU2=E5G35A6,6]P-6-V=%8F(WA!.W)8;%A-1%5A4V-P
M5T19.#-Q*W@K,SE0<#A%;UI)96]K;EEB4W8W=3<S4%=&0D-G13AI0E%S92]V
M=&UZ1'@U8GA1-T9867$W1EA9<6PF(WA!.UAL;B]!234P,R]-9'%(+U5D3FA+
M06UU0DQS5F1I<5(V:S%X<70W2G!%1"ML85)O1'%%=T%,14].;VQR='5/=4%I
M,T=N2U4U.$U444@F(WA!.TTO;UEL-58Q6'EF0EE,<"MV6$9S3E9&>DYB07I$
M:3AP4U5X9W)4-&%C=&PT;G!3=3EC=SA/<$%&5$\W=712,D9X4TIW-#=G04-A
M.58F(WA!.U=,,W9E-F]M*W9,86U5,T9V3#5F2S-6;S=V<%A)0S9T1TIF,'=4
M5&Y'5'9T,T@K67I84E-I8T\T*VIQ3S<S36="1$%%1V]/-$DV57@F(WA!.V-X
M,DMU>%8R2W5X5C)+=7A66DYB=U1X=$A.1W-S8F=",&11>6M!,4918T)I1'I:
M4FU9;7=A2T)B>3,U9F$W=')W-F1B9E=R3F5&<DTF(WA!.TEK1%)R=CA!0VA!
M,DAX2&))941#=V%'>FM$5S5U17@T-6--=5EV;6AV.$IA5VQM,7!A>3-D;D<X
M;VY,5SDS8TLO3E%6-FPR*T5G-W(F(WA!.S!05VQC:"M8:4)1<V4T;',O;$1)
M6F-5:$=7,6)X:BMR-V5A<S)J,VDS8VQX1'$Q,FEV0UEK=%<Y1U-&2#1"5FQ(
M2U Q0W=)-6)V46XF(WA!.T0T4G5X27-"<5DX26EC8V5D,W5$-W5D95A*5$YL
M-7%I9W1K:#%/,FYL4C(K=%,S3G$Q6DEZ5&E&155S659L,S-O83$V0VTT16-G
M2$TF(WA!.T4K-6PT=6Y*2DU*059T5752*TU483939GI413$T>3)L;F-O=3EH
M1W,X:U1U3V1+4VQO;E9F9S,R<G9T-S1B>4,Y9V4U06IP>G<K<6,F(WA!.V8U
M,W!"*U<T=F1C;7%A=4HW3TMB4C5E339G,TTX53!$>'=-4U)X8FLX8G0P0G%Q
M;D54;'1C9G118T=+<$5:0G1Y0D5R;#EH02M*550F(WA!.S5Q=%DW3U,V=3='
M+W19-#5&:5I8=%I:2'%W2D1"64)+4W4R-T1!3E%+<VE1*T10.&A)>459>6A)
M:U@Y44@K-G)D168T;#!,-C(Q;3DF(WA!.S1K5GES6')T1DQ736E,9TI#>#5H
M8555,5!H,W<O;4E85C=T9C5,3G<X46E41S8R,S-U=6YM:4QB5F1,=6]5;71B
M>4-E1U4P:FMI:U(F(WA!.S%9:6XR5U5K2'%-;4UK5'E)834V9DI!:U-J245D
M-$M+>6)39W)V6$Y&<S5J1&0V:&)7.'=!2FIL;6I29T0P3D=)3U9Y>7=I84I!
M*TPF(WA!.V9J,'57675-6D5E44I2;TE)0D)Q1#!/5TY$<U9D:7)S5EET-2LX
M>39N;VM';'AA63%R1F0V<&5F5E)D6#9U,71%<3(X<S=--%(T;4HF(WA!.U!O
M.%(X6&9#07AK57@X;C8U3'(S;%A39&%M:"MR>39H87A816M)<E)7:U%%.&$W
M.&$O6CES4T5X3FDP4'!L>G%U;G=Z,GHV3F1Z9C8F(WA!.UAE4W!,13EN=UI*
M<G%35D=(3S12=#%C9%9'2V]V.4TV:B\Q66(W+V<W2"]S<'A6,S9:,4@O<7<S
M,R]",E O6E1I<G8P>G%0+T%&66(F(WA!.S<O9S=(+W-P>%9,3D@Q4SAI=4Y3
M5F1)=35P6'5M:VM#4&%!;T=58U5B;D]M-' K>E5E*T)X.5!Z;"]795(S34=J
M3S!L<SDQ2"MK:&4F(WA!.W9C<D@V,%%N1GE::2]P:F1Q2&ME1V%O-'-F:#=K
M8UA0;BM0-UAO:'$K,%!Z;FE2>%I":#101#-H27@T2W)I3E50-E8S>3AN;TAM
M0S8F(WA!.S@Y,VET3$YP='IP;&EI,&UJ:74W2C1J1V9T*W%'5C5(<C(T1F9K
M8WE4-'-I3G$O>F@K<'A-<# X34]16$=D:F$T4W9L-51!.3)X5DPF(WA!.VTV
M+TUA97=T66)(5&)I,45!2$,V9W5,1W,P65%+3V%82WI5<CEQ=3-Y=S5$;% P
M:79I4#%,,F5-14E23U%X;%E&9WAN='0P35IX,W8F(WA!.S1+=#%F+VU:3' P
M5G1&<%4Y=F-X,#4S>5A';D=34V=P4FQD6&E7=E5L52M16$))-6E+03,Y-"]5
M,UEH<&AK-'!%4VE39E1W>F]$<%(F(WA!.S0W*UHK83ET5"]-<CE':3)84G!2
M9&I9,S5U3$AM5'ER6&A8,'A29FAP>#DX4V,S1%9B.3EJ.51'3610-&=K6D1H
M,W501$PT8CA6*UHF(WA!.S-8,FUP+VU*1EIY=WHV4%!C5'-'.4\V85=W5FM*
M-DAI:V]1,"M735I:9TM)=GHR5&MX64-14D]).5!+<VQC6'8U,#-P*W)F;4Q"
M1$LF(WA!.W0U;W-L-4MX+V1397!:4D)0;7%Z9D8K1T]/5UE$,4,O:W5O>&%E
M4G5%-'A&1"ME8E!8<'0U3&1.,68X04UU1W8V4C!8-C-50VYP3F$F(WA!.W=5
M4$QF<F-Y9%8R*V4O=&I#5UEF54PK6#8R5V]X85=8.3-0:#-(4&E/,U@K06(X
M-EA7=70O;5ET,WEU=$%J;',K2B]D4E!"2$IY<G0F(WA!.SAB6&-I,' O:UE9
M>GID62]J-6]Y64Y+62MM9%,T=79%4G<Q,V-!.58K9%5V:3$O.'=H9FMZ95=M
M3FA5,%-/5S Y5VQ$5#0R=2M06"\F(WA!.T%#8U)K>3,Y3S,T.#!J4S99=T@W
M,E!&=F8Q,35B94@X.3)M.'<O;4HY87%V;&AJ86-L<6AM=%!5-"]T:TXY830O
M3#1C5&MY,W1(8C0F(WA!.V9R5T=K,#-#3'I2-'%.+UA6+W<O-5!L,W%L,35G
M."\K<D8Y53AR=4EQ<4HO5G5,4W98-&U1<F-D4$%%65I:370W4C(K2#8R1U!3
M-F8F(WA!.VA01FQJ>&-/,4-F,60S.3-Y."]S6%AF;5!Z,39K47,O2V-V<$=V
M<DY.9#)96F%$8FE&;4E.5'0Q1T=75$HP:CEO+U=S9$IG<58U;S,F(WA!.W1W
M,$HW.3DK:F%U;D\S5"MA+TXP56%G955,<'!I=DER.5IT4V=O=C)E84\K-5E5
M-F1.+V)!8SAX+T%5:E$T:50K*VAW,DLR;F1B5V$F(WA!.S1E;F0Q8W9M-WI0
M.51$;GEL96DX;T,P2')7+W Y3G=*961395@K4E-N=G1J*UEL6#!3=&9Y1U!J
M<GAS9D)X8R]69&0Y8U R6#A6+RLF(WA!.TQF35AO0G8X2U@S<C!Q.%EK='5/
M-#)#=#9L4U(S<6\Y<31F2&Q8,%-T:4Y"1&E&-7-F1%HO;F-T-DYC4%@S-U=U
M5'I:<BLT:SAR6#0F(WA!.TEQ055E,EE%,"M%-WE+861E5S%F04A%6C5F>DI-
M9GE-9'8S=5!L=CE84'4K;&\K8F190TU*+TLK;T-O2W%&.4=112LO1GI21#0P
M<B\F(WA!.T%*3U U9SE9>5%D1E@P-4U:3EAZ23,W=#0O86PP=7$R;#5(2$AE
M95)R<'A#>&MT,6MT;TA62$I(2C8Q4$5M9S-7<#AA6E8T:U1S8UHF(WA!.R]W
M0DLU4G@U<UI*:&YJ=4)Y;5)F;'DV969W56UV8DM35SE:4$MM<S(X;"]8-GA.
M1GEH63!F:U1Y:FU(1GEW<4]06'52,'E.=W,K:5DF(WA!.W8S+W)::UIO9V9V
M8TUH06IH0DE/,65C95$W:CA'0F5:=DQ&=G%E<#9J4&-2,TU5<VM554YK;"MZ
M4&-1:4]-54UJ;&Y:>7IB-W-D=',F(WA!.V=.3'@X4C,X<C5S8W9T5&LP;51&
M:FIW.$U*135/0W%K2DAK3FA64C9D-S%Z>7)Q,G%83VLV5W0U<&QZ1DI*87=M
M93=:<F(P=69P06PF(WA!.V=Q5$Y*4FTV9D(X-EIN-&9O2'5$<G18=RM.4&<K
M;FEL6'5V6E X<V-D,DMU>%9#86YP1VLV=&$O5DY5<V],*S$U0B]Q.3%%:S!F
M2F4F(WA!.V@T4T)L<4U515=R13)T;&%%+T)B,FQT2#=*2$A(1U!O0W%Q:D9+
M5RM89DYM9V59;W!P9$EU5VY71# O5E8T<&](06U14U).=VU33FDF(WA!.W-I
M34=69TM-3VAW:TE"=$XX0UA9<3=&56\Q0WIV8F$K3W%A8VYQ=39H3'DQ<E0Q
M1E@W3$MF-6QX8V)*0U5:8V-D*SAD-GA03C)J2&LF(WA!.VMR4W<S164P;'4X
M5#@Q66ET0T9$04AF>'A8.#-$<EE0=4ML24PS6%I%:F%&-UA315E02C9O-'E4
M;%153'@W2FEW4$9L3E954'94+W F(WA!.VDU:G-69&EQ4V%L-3$X<F%:<44K
M;E@R;U)W6&QT85-A:&-214]E1G1&5&TW37%L4CEO55=V23EH:'!"25)79RM9
M9$DQ-GIE-S!U6G F(WA!.UE9<%=G;45K57-%:5-P47-J>%1,2$EP05E(9&-3
M1D)T36-#6%EQ-T95=#$O>DIO;FPK,6EU=%AU;'192G!K=&]72W4U85=5,%)6
M5D$F(WA!.WI'=GDR-FY#06=M;710.$%-;6QA:'%6,W Q;S X;'A9<S!D>35T
M<FA)1F1#07E#-&5.64A98V@X2W54:E,R;65"3'-69&EQ,F%666\F(WA!.VYL
M8TU6:E5S=U)79'%+2VYI:4)M62MW1E1I<D9P9GI3.&I24E)Y>39G.%%E4U=&
M:V4Q=6QK:6%",%-8,30R:41W2VI3;T,P;U9D>'8F(WA!.V@T4W@T9WEV07ED
M:7)S5E%&,35E,$,W;F4T=71.=&)I-&5N3V%70TXS86=!1E=:4U110VU6>7=W
M2G-G12LU=FAQ8W-255I303DU4WDF(WA!.SDX-BM5.45N:S!Y-6MK<VYS;U$V
M5S1S-VM),$MT2$5"8F-9=44S1G!56&I$>7!83$)(8EIO;FM*2DI.;$\W1SEH
M=F)33S9H5U9)<%(F(WA!.U96;FAL=#5"43 K2TM:635&-F9T2TU65CA69&ER
M<U91,G%7165O-EIE869+>%-+.&=K=#-:96]75D-H27(S;V-663DU1SAK,TAL
M<S,F(WA!.VLQ,W%!,4<W=31R3S--:5%F5C!71W=G.4-)8U!5;7%X1E=:=5<U
M3W=!,G=K<U%+6E9G6D]X5C)+=7A6:3%X-4HK<V5E-U1Z4S Q<D0F(WA!.SE3
M5U)6:G0W5# W<6(Q6692-#-6,S9R97)';C)K6#!X43 S,G<S<W@T9#=:5&=:
M3WA6,DMU>%9G+VYF.'5B-WI6<514=G%S5G!9;7<F(WA!.W5.4%<S5S%:-5%,
M:WAU6E!7339R5EI)14E(<#E+:G954T)P:DM.<'8U6#!"+TQD:G%K*W!A:DAD
M6$8O9'DV;G%&-399=%E63%)O:&\F(WA!.VI03'=22312,6,K3T%M,&=5;CA5
M<U4P4U11=7-K56EH-#5%25I75FA537!'>$)'0DLW1EA9<7AN>GAO,&YM6%1*
M4$QT;G%L=%E85$XF(WA!.V(S9'=K<U)U6F92:6U%:V)#2EIO1U5.3$14:V%J
M66IR=4-'36AA:G!F:V%3,3@V4RMA2G)I,5=A4S-E,V5#=W-Z865S6D=2:DID
M3UHF(WA!.W!Z3WDX4&@R1DUB,E52,W1L;4)K-T9867%O,W-6,4Q:6$56<$],
M839K:F1B935+0U%2>49316-O4W9,:3(O1W4K2W9.2B]Y6'8W;7@F(WA!.T9V
M3G)S46UU3&4T<W15=5DW2G<Y,4)D5'A817)S6DQM56DT85=*<7E62S!)05%C
M4FMU2FAW4%5C:7ID:7)S5F1I<D,Y4CAI87AF83<F(WA!.W%E<#-.+W Q.4)E
M=VDQ=&),561.939J=#1!>7599T)D>$DT9# U=5-L4V%B,%5$2E=X354W.&YE
M5S$X=&57-TQ25G5$9$,P1"]V=5 F(WA!.W!G*W!),&Y&17$S0D8U.%57<&]O
M07)G2G1)1D)/8T-867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ;U@K;C)'
M;S)K;&YQ1G1&95<F(WA!.V-W06QT<FA&;&EC06AH>5)W5DY#2S<T<3A0,#-3
M4$YF;'9Y>G!%;FQV4E<P+U9P3DMU+W)T>$1P:V)84#%G,SES23%L6F]42E5W
M.'HF(WA!.W=*,T%R5#114EIZ839R:VUM;V%J*V,R;E!D;7EU3#-65VIU9%-T
M3&%+87AT,%9O64Q4,6)A-4Q247@Q6G!4>%=H-$U2>&]49S)89%@F(WA!.W4W
M+WID969L5#5N9E@U6EIQ8U%P:V=N=#4Q<WE):F-R2C9T;'!G8T)052M*26%5
M,G%A63E60DYB<5=Q840U=&M/=71B4D0Y1GIE8DPF(WA!.T,V5WHK<%108U-X
M23%J5S1I;E=653E&94<O-VQH.$QF1C1)25%19G11.%AM:C@R;&IH=694,5-A
M4D976%A,3CE-4D5T>75O>$E9<D8F(WA!.VA#1W51.6]:2SA3-6]/45E(64Y"
M3FQ',D]T9FUB<65O-G9+.3%Q3VLV6D1B,SEX<%IK,'-%<W=U5U-Z4U--,C!K
M-S!I6E=+24]:<#@F(WA!.S9T0DYL1BM4<C=83#-Z9F]5,F],9$154G!M<5(V
M;3DV:7A34U%*9%=W='!&45<Y:7EO,&Y->&@T5F%L82M/03AL1C)(<4]26G5X
M5C(F(WA!.TMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMQ3C<Y5"MP>B]89E0K<&4F(WA!.VTO
M,6XQ=5!P96QX4% Q3UAW.&5.83$R<&EQ-C(K<F96;W9Q=D0V='=8,%!3<#9F
M<# K2&AX,C0P-E5X5E5X5C)+;U)F,%0K;'!/4&\F(WA!.V9P9C!%.5=N1#9Z
M.5<U='<U9G0K;GHU.&4Q831Q:3A69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<B\Y:ST\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H
M=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP
M9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \
M<&1F.E!R;V1U8V5R/E1O;VQK:70@:'1T<#HO+W=W=RYA8W1I=F5P9&8N8V]M
M/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS
M.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N
M9&ED.D)#-C<U-C4T-#!!-D5",3$X.#<U.$$P-$0Q,C<W,D,T/"]X;7!-33I$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED
M.D)#-C<U-C4T-#!!-D5",3$X.#<U.$$P-$0Q,C<W,D,T/"]X;7!-33I);G-T
M86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z830S83(V,3$M,S4S."TT8S S+6)C968M9F,W-S(S8C,X8S<T/"]X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I$97)I=F5D
M1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS
M=%)E9CII;G-T86YC94E$/GAM<"YI:60Z0D(V-S4V-30T,$$V14(Q,3@X-S4X
M03 T1#$R-S<R0S0\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS
M=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z0D(V-S4V-30T,$$V14(Q,3@X-S4X
M03 T1#$R-S<R0S0\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#IA-#-A,C8Q,2TS-3,X+31C
M,#,M8F-E9BUF8S<W,C-B,SAC-S0\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\
M+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV
M961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z0D$V-S4V-30T,$$V14(Q,3@X-S4X03 T
M1#$R-S<R0S0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C$M,#0M,C94,3 Z-#8Z-3 K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.D)#-C<U-C4T-#!!-D5",3$X.#<U.$$P-$0Q,C<W,D,T/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(Q+3 T+3(V5#$P.C0W.C Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R
M871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-
M33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S
M<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9G@](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&1F>"\Q+C,O(CX*(" @(" @(" @/'!D9G@Z
M05!42U9%4CXU+C4N,"XQ-3 R."!0<F\@4')O9'5C=&EO;BTS,CPO<&1F>#I!
M4%1+5D52/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @
M(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @
M(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXY-C N
M,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XU-# N,# P
M,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\
M+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@
M(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @
M(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G
M.DAA<U9I<VEB;&5/=F5R<')I;G0^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE
M3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @
M(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M3F%M93Y#86QI8G)I/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1&86UI;'D^0V%L:6)R:3PO<W1&;G0Z9F]N=$9A;6EL
M>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\
M+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B V+C(S/"]S=$9N
M=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M
M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1FEL94YA;64^8V%L:6)R:2YT=&8\+W-T1FYT.F9O
M;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @
M(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'
M<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!)@&F P$1  (1 0,1
M ?_$ !X  0 " P # 0$            '" 4&"0$#! H"_\0 2A   04  P
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M,CENV0  0NB=^:LO[AP'6/3^%6?#<UT/.\X&:"/D!;N:O.>V6_3_ -*ZEC2
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M7"_0KY+%;39JO(*9_,OTRL:QCX;K811.JV4$UJ5U&QJY<3]V"$H?=9<)2U/
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M2G%*<4IQ2G%*<4IQ2J7S?8DHR6L[>*^:]]]#4RD'C57M&F9OWC8*F.V.L3Y
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M=1;7<S(+>0=MX]?#Q"9I DADV6YJI#A25 1@1E<ZK>(9$%\);65R;2MTL_H
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MRE@BJ"I4J-#DW('Z&JL5]<\()Y1"8[FRFN5B160QM"D<@4R,[!U=7/(E$X$
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M1(R5_+OKKO\ O?SZZ[_EU!.@2>9![)+(@_@KD#_<*NVDC36MM*_XI;>&1O\
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MQID5Y++$" ZUW)=TMY4AD61T9RI!4*X0;_X6T?8U^7$_K4E[!+<PM#%+'$)
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M%M!/KCWH8Y2OY%T#$#] 20*BGXBG]!GL7_3=L/\ L<SS>U_>8/YJ?U"H[_\
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MG7I%3GZ1C5JWC1\XU+5M!QK1K-3;Q:[/E[E=: MK+N2RL<0$(A:S!K%D"@8
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M?M.!1T9P;*2G)#$^R3EF:\*(EX_V&X[7Y98XG[0$P5F#F0NI"1E2>(##?+D
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M1Y=SOREJ1&Y9:/U$G<JAECES72+_ %!46ZY_ SS4J\UH]Y@"Y\@?=:)&%DA
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MPGAA4*>:RRRL3H1PQ*!S_+;2/&HY$#CS8;XFMIE>E?.<&#9B<W?L4AC:66%
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MX6^N24)A9,2!/6:F2932TPX.^MKZ/,].+:R8LX.0XE8(KJ1YACI("EA>P7#
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M'BE6C4VS3Z39E56Q&!'0 P?TDM6C$A,D;-$5YJA8D*Y 1^14*0Q*^ >0Y+R
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M=7%6"\^?]Z%[F3M-7S?NH!KY*"5S3:J,KC-4D7>S.5-EL/H,5,HFFQ6%<F6
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M:_8+"62#2==+!JA50PG/>C[*Q&(^-DLLG'FY]F<<#OB/"CEH#>M%F)U-K/\
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M8*#QYCJG&+D:L @:52Y$7.ERFG>^F9;W7<\-S+"4XL>".).'CB2""=^-CD
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M%T#[%VW[$\AO8UKE3W)6\EMY+>6Y@^&MY!'' DH5VEN S/R(/S!$X@D@%"0
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M[Z[[^7??7.X0#HD D'8)&]'VV/R.O'BODRNZAE5F4. KA6(#J"&"L =, P#
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MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*52DIZ
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MDYK.U#9"T#K<!IF[P\@,NV&L,9N.B>@S=D'UV]W&Q:-*O%*K!FP:)4K#V>E
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M^TS+1&;BHCYR6&Z@N+^2\QO5<V-A?MZL),79WUNG!%5PC2O&X[A4R$D,P9B
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M/@&O\O+D+[TYO%>683-D%ZEM>\TJA>W+)8Q9&."/152_:EDXA>2I(WRG[O\
M^$OJ[HO[/^.Z%Z3^WYT.<AA,/-:9'I^Z] \O]QRX0M?W&4Q%AU-DN@[W+7CS
M6L_8@ER.%L%O6+V\\^-AE-Q%>(/\0W6?*Y@?2ZS@^IZU3(:I)Z?!JE?F]@[!
M+L,5V&]&7;HM2L4T-+ .#A\UEH;'FM2W'Y4:8F)VKI??MLCD<U:.T>.Z;NLL
MG"-HYXK_ !]I"S,T@FC<W$PGC:(*C*5@D60R%>2<03^&?LS^FW2?4^!P^7ZL
M^T%TEZ983[XZE@S'365Z-ZMZBSSK#9X\8?(XY\1BY,7<VE[>/<1W$4N=QD]@
M+%Y/ALB+P1P<Z.]%R]DE82O7B3V^RZ9=G3 L,3INZ0%5"8[,FOQOOF':P:EW
M9"$/Q%./R(M5E+7$4CZW%R%2V_G$O34FH'BZ%ZA28EVN>/5<*A6,FUX2&\F:
M?Y?](QVC _*1(?V@_IS@_6'.19'K>/.?;*] <C@I_@X>@89?LXWTTUK;QXZ2
M"<9>SAZ7PR8T-="!F@7)=4QS*)9XY<?&5QU7SN7Q<=1NV/%L;.>6/5S#IN!(
M"%=4"4F]AK9* O=.*[CQA &K#7!11YKMD2^8@W+\I4-+\Y:7)<AUKGLKC)9N
MY6:QFZ-S@Q\L30M<0Y3'1WQ0QZT$BOT9&+?(72_+<-R$DDQU^3L/Z68C =.X
M?J+$?:X]#9?5O&Y6#)BWROI_U;?=#<H\J\C(\N1Z(NK>[2/'%)4AN.@H[=KI
M?A(XH0L63%4\Q]9-97H%-T$%A'Q-B"J>4#F'JE;KWLMJ!V25!?<7+AR.XU$K
MD"($EM*2W,$F %N:(L?7$4[$;6ZZ[Y?&X[)XYVNO[,]:2W,,L$EK%-U+;W%N
M_!R9$F"3VZ"-ET'22VO%E'R P^7/Z3]1NI,;UO>8'"6?VA?LCXSHJ_QF<L.O
M)[#T(RN'ZD=[RR2/&7>"DGQ&<NA=VMV&EM[JQZBZ6EQTFKF89D".TBLAM_Q4
MM#W2O&:S/P?W[EX@@8&' 3F%A;AF%SJ\@,Q,BMC)-^:S<O+M5>.]3E3C8J2(
M$]IG0AW<.4RW&[Z=[.9OL]E;"&V7IGJS'RF82S28O)6%E-'V^2I&MT&F,\4J
MOSD1H(-.B %M<J^9^D?0?0_IWZC=5]09/[0?V8.M^E6Q,>-Z1Q77G0?5_5%L
M\UY%#)D+[)X":UP\6,O;*XMQ#97<.<S7?M[BX8167-H*C/'_ 'WIF068K8X-
M=^)O=YY(*H##@:K'T;1\V"-27P\M\Y&H=MKA8H]9&OTZ5!C3UW+N-';*37F8
M';/:(7*V/;+8W+-<IA^N[FQ>#L]B_P E;W\$;%$)E6UGNI9#('3B&^-TH>1E
M4*1$)>L,1!UMZ('IV]]6_L2X3U8MLX^4M^H>C>A,QTA/>V$>1N(X<5=9_$=-
M8VP2W;%W+2=K^QA$DUK80W,TEPDV3:4M\^*#I&WQJHNNY1[]PB;7!#\4MWE]
M1M(UJS$B$H2J03_'_;#;*'H34*6F#&-K+PF(TUYMEMJ7VN2_-DLAFLG%+KI_
MK/%S11%;0XZ>U19'=U)>91*%Y*J@ 2=Y.+.$"OIFQTCZ?]+]"9WHTVGK9]DG
MK_I^\R2S>HT77>)ZDN+F&RM[ K':]-R28^6>."XNYKIR]J^)O!<QXV2\FN;%
M9[6/-^</BF:)B3!N)>\H]X^@!YOM*XG>CYR7<L@"5$6G[+L0G' ,0>A\V-(D
M,R8#;+BW'HD.3]V.O[R9+%97-XNQ59\!UCEKJ21S,U\MJQB52>WVF20#BRL
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M>A&FT]=)0TWO=]2VVCK^26VT_G=_2A">NDI3\_Y)ZZZYY$=%XX  9+J)0/
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M%;L(F;!E?IY0H)G,ICE Q0F(G02$E)&T3<6(/A6#*=JRL RLI\>""#Y (]B
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C.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
